methadone has been researched along with Addiction, Opioid in 3732 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methadone use for the management of opioid dependency during pregnancy is commonplace." | 9.41 | Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study. ( Badhan, RKS; Gittins, R, 2021) |
| "Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse." | 9.41 | A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2021) |
| " While methadone-maintenance currently is the standard of care for opioid dependence during pregnancy, research suggests that buprenorphine-maintenance may be associated with shorter infant hospital lengths of stay (LOS) relative to methadone-maintenance." | 9.19 | Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. ( Hall, ES; Lewis, D; Marcotte, M; Theobald, J; Van Hook, J; Wexelblatt, SL; Wilder, C; Winhusen, T, 2014) |
| "This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT)." | 9.17 | Epidemiology of pain among outpatients in methadone maintenance treatment programs. ( Dhingra, L; Homel, P; Jordan, AE; Katz, J; Masson, C; McKnight, C; Perlman, DC; Portenoy, RK; Seewald, RM; Wald, E; Young, C, 2013) |
| "Hepatitis C virus (HCV) is a prevalent chronic blood-borne infection among opioid-dependent patients on methadone maintenance treatment (MMT)." | 9.16 | Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. ( Acosta, A; Altice, FL; Bruce, RD; Eiserman, J; Gote, C; Lim, JK, 2012) |
| "To compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants." | 9.16 | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. ( Arria, AM; Badger, GJ; Coyle, MG; Gaalema, DE; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Scott, TL; Stine, SM, 2012) |
| "Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy." | 9.14 | Neonatal abstinence syndrome after methadone or buprenorphine exposure. ( Arria, AM; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Selby, P; Stine, SM, 2010) |
| " Infants born to buprenorphine maintained women are not exposed to a greater proportion of the maternal dose compared with methadone and may be exposed to relatively less of the maternal dose compared with infants born to women maintained on methadone during pregnancy." | 9.14 | (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. ( Foster, DJ; Gordon, AL; Lopatko, OV; Somogyi, AA; White, JM, 2010) |
| " Smoking cessation rates in methadone-maintained smokers are low, with men having greater success." | 9.12 | A smoking cessation intervention for the methadone-maintained. ( Anderson, BJ; Anthony, JL; Herman, DS; Niaura, R; Stein, MD; Weinstock, MC, 2006) |
| "Though methadone pharmacotherapy is the treatment of choice for opiate-dependence during pregnancy in the USA, most methadone-exposed neonates develop neonatal abstinence syndrome (NAS)." | 9.12 | Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. ( Dipietro, JA; Elko, A; Jansson, LM; Velez, M, 2007) |
| "This 13-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy of desipramine hydrochloride (0 or 150 mg/d) plus buprenorphine hydrochloride (12 mg/d) or methadone hydrochloride (65 mg/d) in 180 opioid-dependent cocaine abusers (124 men, 56 women)." | 9.09 | Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. ( Feingold, A; Jatlow, P; Kosten, TR; Oliveto, AH; Schottenfeld, R, 1999) |
| "Patients receiving methadone hydrochloride maintenance treatment were selected if they met the criteria for a DSM-III-R depressive disorder that was chronologically primary, had persisted during a past abstinent period or was long-standing, and persisted during at least 1 month of stable methadone treatment." | 9.08 | Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. ( Brady, R; Deliyannides, D; Donovan, SJ; Koenig, T; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Woody, G, 1998) |
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 9.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| " There have been several preliminary studies examining the effect of methadone on depression among addicts, however, these studies have reported inconsistent and even contradictory results." | 9.05 | The effect of methadone on depression among addicts: a systematic review and meta-analysis. ( Abdoli, N; Hosseinian-Far, M; Kazeminia, M; Khaledipaveh, B; Mohammadi, M; Salari, N; Shohaimi, S, 2020) |
| "This research evaluated the efficacy of an Anxiety Reduction program designed to reduce anxiety early in methadone detoxification and thereby facilitate dose reduction." | 9.05 | Methadone dose decreases and anxiety reduction. ( Hall, SM; Kushner, M; Loeb, PC, 1984) |
| "The effect of alcoholism on indices of productive activity was determined in a prospective, randomized, and controlled study of alcoholism in narcotic addicts undergoing methadone maintenance (MM) therapy." | 9.05 | The effect of alcoholism in methadone-maintained persons on productive activity: a randomized control trial. ( Cohen, M; Hanbury, R; Jackson, G; Korts, D; Stimmel, B; Sturiano, V, 1982) |
| "To systematically review and meta-analyse studies of neurodevelopmental outcome of children born to mothers prescribed methadone in pregnancy." | 9.01 | Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis. ( Boardman, JP; Chappell, FM; Hamilton, R; Mactier, H; Monnelly, VJ, 2019) |
| "To compare the effects of morphine and methadone on length of hospital stay (LOS) or treatment (LOT) and adverse effects in infants with neonatal abstinence syndrome (NAS)." | 8.98 | Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review. ( Gregory, PJ; Hein, DJ; Risoldi Cochrane, Z; Slowiczek, L, 2018) |
| "A literature search of PubMed (1966 to March 2016) and EMBASE (1973 to March 2016) was completed using the search terms buprenorphine, methadone, pregnancy, opioid, and neonatal abstinence syndrome Priority was given to randomized controlled trials and trials directly comparing buprenorphine and methadone during pregnancy." | 8.93 | Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy. ( Campbell, K; Crannage, E; Forinash, A; Noormohammadi, A; Shyken, J; Yancey, A, 2016) |
| "Opioids increase the risk for sleep disordered breathing (SDB), but there are few studies examining the prevalence and risk factors for SDB, specifically central sleep apnea (CSA), and obstructive sleep apnea (OSA) in chronic pain patients on opioids as well as methadone maintained patients (MMPs)." | 8.93 | A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. ( Hassamal, S; Miotto, K; Saxon, AJ; Wang, T, 2016) |
| "This systematic review synthesizes the evidence related to methadone use and risk for overdose and cardiac arrhythmia." | 8.90 | Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( Chou, R; Dana, T; Weimer, MB, 2014) |
| "Buprenorphine and methadone are opioid-receptor agonists used as opioid substitution therapy during pregnancy to limit exposure of the fetus to cycles of opioid withdrawal and reduce the risk of infectious comorbidities of illicit opioid use." | 8.90 | Buprenorphine and methadone for opioid addiction during pregnancy. ( Mozurkewich, EL; Rayburn, WF, 2014) |
| "Many individuals receiving methadone maintenance treatment (MMT) for opioid addiction also require treatment for acute or chronic pain, and the presence of pain is known to have a negative impact on patient health and function." | 8.89 | Chronic and acute pain and pain management for patients in methadone maintenance treatment. ( Eyler, EC, 2013) |
| "This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy." | 8.88 | Methadone and buprenorphine for the management of opioid dependence in pregnancy. ( Finnegan, LP; Jones, HE; Kaltenbach, K, 2012) |
| " Therefore, the aim of this study was to examine the efficacy of antidepressants in patients with unipolar major depressive disorder (MDD) and/or dysthymic disorder (DD) with comorbid opiate-use disorders currently in methadone maintenance treatment (MMT)." | 8.87 | Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. ( Bentley, KH; Iovieno, N; Papakostas, GI; Pedrelli, P; Tedeschini, E; Vitali, M, 2011) |
| "Individuals in methadone maintenance treatment are motivated to quit smoking and are interested in smoking cessation treatment." | 8.86 | Smoking cessation interventions among individuals in methadone maintenance: a brief review. ( Barr, AM; Greaves, L; Johnson, JL; Khara, M; Okoli, CT; Procyshyn, RM, 2010) |
| "Methadone is highly effective in treating opioid dependence, and it is also used as an analgesic for second-line management of chronic pain." | 8.86 | Methadone deaths: risk factors in pain and addicted populations. ( Brooks, D; Modesto-Lowe, V; Petry, N, 2010) |
| "To determine if there is a relationship between maternal methadone dose in pregnancy and the diagnosis or medical treatment of neonatal abstinence syndrome (NAS)." | 8.86 | Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. ( Clarke, M; Cleary, BJ; Donnelly, J; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, J, 2010) |
| "This article reviews the unique pharmacological properties of methadone and outlines its appropriate clinical application, with focus upon its use in the treatment of chronic pain." | 8.82 | Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. ( Brown, R; Fleming, M; Kraus, C; Reddy, S, 2004) |
| "Results showed mean reduction in birth weight associated with heroin use: 489 g (95% CI 284-693 g), compared with methadone: 279 g (229-328 g)." | 8.79 | The relationship between maternal use of heroin and methadone and infant birth weight. ( English, DR; Holman, CD; Hulse, GK; Milne, E, 1997) |
| " Illicit drug use during the pregnancy was common in all groups, but in the methadone group it was most common (p = 0." | 8.31 | Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. ( Kahila, HK; Kanervo, MM; Nikkola, EM; Rantakari, KM; Tupola, SJ, 2023) |
| "The preterm birth rate among individuals using buprenorphine for opioid use disorder (22." | 8.12 | Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. ( Abdelwahab, M; Cleary, EM; Petrich, M; Rood, KM; Walker, E; Wang, H, 2022) |
| " In early pregnancy, 10,704 pregnant persons were exposed to buprenorphine and 4387 to methadone." | 8.12 | Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. ( Bateman, BT; Connery, HS; Davis, JM; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Jones, HE; Lester, B; Mogun, H; Straub, L; Suarez, EA; Terplan, M, 2022) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 8.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| " While these agents have clinical utility supported by robust literature, we the authors posit that buprenorphine is a superior therapy for both opioid use disorder (OUD) as well as pain." | 8.02 | A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain. ( Komrowski, MD; Sekhri, NK, 2021) |
| "As CRH-binding protein (CRHBP) SNP rs1500 was associated with reduced cocaine abuse after 1 year in methadone maintenance treatment (MMT) for heroin addiction, we evaluated the association of additional 28 selected SNPs, in 17 stress-related genes, with MMT outcome." | 8.02 | Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder. ( Adelson, M; Kreek, MJ; Levran, O; Ott, J; Peles, E; Randesi, M, 2021) |
| "Preference for sweet-tasting foods, weight gain, and constipation characterize patients receiving methadone maintenance treatment (MMT)." | 8.02 | The prevalence of constipation and its relation to sweet taste preference among patients receiving methadone maintenance treatment. ( Adelson, M; Peles, E; Sason, A; Schreiber, S, 2021) |
| "This study examined the cross-sectional associations among pain intensity, pain catastrophizing, and sleep disturbance among patients receiving methadone maintenance treatment (MMT) for opioid use disorder (OUD) and reporting co-occurring chronic pain." | 7.96 | Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain. ( Barry, DT; Beitel, M; Edwards, KA; Eller, A; Ponce Martinez, C; Roos, CR, 2020) |
| "The aim of this study was to evaluate the prevalence and clinical correlates of impaired sleep quality and excessive daytime sleepiness among patients receiving methadone for opioid use disorder (OUD)." | 7.96 | Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment. ( Baldassarri, SR; Barry, DT; Bastian, LA; Beitel, M; Carrasco, D; Chen, K; Fiellin, DA; Lipkind, N; Madden, LM; Oberleitner, DE; Oberleitner, LMS; Redeker, NS; Yaggi, HK; Zinchuk, A, 2020) |
| "The mainstay of the management of opioid use disorder in pregnancy is with methadone or buprenorphine medication-assisted treatment." | 7.96 | Use of naltrexone in treating opioid use disorder in pregnancy. ( Katz, E; Towers, CV; Visconti, K; Weitz, B, 2020) |
| "To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy." | 7.88 | Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. ( Johnson, S; Martin, PR, 2018) |
| "Antenatal exposure to methadone or buprenorphine often causes neonatal abstinence syndrome (NAS) in newborns." | 7.88 | Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Miller, ES; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Our objective was to estimate the association between methadone and neonatal abstinence syndrome compared with buprenorphine using a probabilistic bias analysis to account for unmeasured confounding by severity of addiction." | 7.88 | Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome. ( Bodnar, LM; Caritis, SN; Lemon, LS; Platt, RW; Venkataramanan, R, 2018) |
| " Factors influencing adherence to buprenorphine during pregnancy have not been identified." | 7.88 | Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. ( Catlin, D; Coker, JL; Knight, B; Ray-Griffith, S; Stowe, ZN, 2018) |
| "Through retrospective chart review, this study described characteristics and length of stay for a cohort of newborns discharged on methadone following an inpatient weaning for neonatal abstinence syndrome (NAS)." | 7.85 | An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome. ( Boucher, J; Lai, A; Meyer, A; Philpot, P, 2017) |
| "This study examined gambling behavior in the context of a newly opening casino, comparing disordered gamblers to non-disordered gamblers, in a population of individuals involved in methadone maintenance treatment." | 7.85 | Impact of a Casino Opening on Gambling Behaviors of People Engaged in Methadone Maintenance. ( Himelhoch, S; Medoff, D; Miles-McLean, H; Palmer-Bacon, J; Potts, W; Rugle, L; Welsh, C, 2017) |
| " Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series Drug Alcohol Rev 2017;36:311-316]." | 7.85 | Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. ( Bruno, R; Degenhardt, L; Demirkol, A; Lintzeris, N; Nielsen, S, 2017) |
| "Club drugs and alcohol abuse are prevalent among methadone maintenance treatment (MMT) patients." | 7.85 | Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. ( Andrew, B; Gu, J; Hao, C; Hao, Y; Jiao, M; Liu, D; Xu, H; Zhang, X; Zhao, Y, 2017) |
| "The aim of this study was to characterize the epidemiology and disease related to hepatitis C in a population attending a low-threshold methadone program." | 7.85 | Hepatitis C in a Mobile Low-Threshold Methadone Program. ( Água-Doce, I; Balsa, C; Belo, E; Coutinho, R; Lopes, P; Loureiro, R; Martins, HC; Pádua, E; Pereira, C; Silva, MJ, 2017) |
| " Addressing these barriers in drug counselor training and in methadone maintenance treatment programs may benefit both methadone-maintained patients with chronic pain and their providers." | 7.85 | Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment. ( Barry, DT; Beitel, M; Ginn, J; Kahn, M; Kerns, RD; Liong, C; Madden, LM; Oberleitner, L, 2017) |
| "To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol." | 7.83 | A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. ( Akinbi, HT; Hall, ES; Harvey, S; Isemann, BT; Meinzen-Derr, J; Wexelblatt, SL; Wiles, JR, 2016) |
| "Five unique SNPs in four genes showed nominally significant associations with non-dependent opioid use and heroin dependence." | 7.83 | Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( Blanken, P; Butelman, ER; da Rosa, JC; Kreek, MJ; Levran, O; Ott, J; Randesi, M; van den Brink, W; van Ree, JM; Yuferov, V, 2016) |
| "Methadone maintenance treatment patients in Wuhan, China show a high prevalence of hepatitis C virus at admission (72." | 7.81 | Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. ( Chawarski, MC; Desrosiers, A; Liu, M; Liu, P; Luo, L; Peng, J; Schottenfeld, R; Wang, X; Xie, N; Zhou, S; Zhou, W, 2015) |
| "To estimate the prevalence of, and identify factors associated with, depression and anxiety among community-based methadone maintenance treatment (MMT) clients in China." | 7.81 | Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. ( Cao, X; Li, J; Li, Z; Liu, M; McGoogan, JM; Pang, L; Rou, K; Yin, W; Zhang, C, 2015) |
| "Over 80% of people in methadone treatment smoke cigarettes, and existing smoking cessation interventions have been minimally effective." | 7.81 | Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment. ( Bernstein, SL; Cooperman, NA; Richter, KP; Steinberg, ML; Williams, JM, 2015) |
| "To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy." | 7.81 | Buprenorphine and naloxone compared with methadone treatment in pregnancy. ( Jones, H; Seashore, C; Stringer, EM; Stuebe, AM; Thorp, J; Wiegand, SL, 2015) |
| "Urine samples from 921 patients prescribed opioids for chronic pain were analyzed for promethazine." | 7.81 | Promethazine use among chronic pain patients. ( Coffa, D; Kral, AH; Lynch, KL; Novak, SP; Shapiro, BJ, 2015) |
| "This article aims to describe neonatal outcomes, clinical correlates, and the rate for neonatal abstinence syndrome (NAS) for women on methadone maintenance therapy." | 7.81 | Maternal methadone treatment and neonatal abstinence syndrome. ( Faisal, M; Li, S; Liu, WF; Singh, K, 2015) |
| "To identify and describe infant deaths presenting suddenly and unexpectedly in whom there was a history of maternal methadone consumption or misuse of drugs during pregnancy." | 7.81 | Maternal use of methadone and risk of sudden neonatal death. ( Cohen, MC; Coombs, RC; Morley, SR, 2015) |
| "The primary objective was to determine whether oral morphine sulfate contributed to decreased length of stay, both in the hospital and neonatal intensive care unit (NICU), when compared to oral methadone for the treatment of neonatal abstinence syndrome (NAS)." | 7.81 | Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. ( Hager, SJ; Spurlock, D; Young, ME, 2015) |
| "Patients with opioid use disorder maintained on methadone report more chronic pain than the general population." | 7.80 | Severity and interference of chronic pain in methadone-maintained outpatients. ( Brooner, RK; Clark, MR; Dunn, KE, 2014) |
| "To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users." | 7.80 | The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. ( Dias Lima, V; Fairbairn, N; Grebely, J; Kerr, T; Montaner, J; Nolan, S; Wood, E, 2014) |
| "While methadone effectively treats opiate dependence, the side effect of erectile dysfunction (ED) may interfere with treatment adherence and benefits." | 7.79 | Risk factors of erectile dysfunction in patients receiving methadone maintenance therapy. ( Abdul Aziz, S; Baharudin, A; Das, S; Ibrahim, N; Midin, M; Mislan, N; Nik Jaafar, NR; Sidi, H, 2013) |
| "Depression and hepatitis C virus (HCV) infection are two common conditions among heroin users in methadone maintenance treatment (MMT)." | 7.79 | Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. ( Du, J; Mandel, JS; Page, K; Wang, Z; Xiao, Z; Zhao, M, 2013) |
| "The aim was to investigate hepatitis C virus (HCV) knowledge and alcohol consumption among patients (n = 114) in a methadone maintenance treatment (MMT) clinic in Shanghai." | 7.78 | Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China. ( Du, J; Wang, Z; Xie, B; Zhao, M, 2012) |
| " The group on methadone had a strong depression in all three measurements." | 7.78 | [Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification]. ( Jovanović, T; Lazarević, D; Nikolić, G, 2012) |
| "The success of rehabilitation is not influenced solely by drug abstinence, but also by the state of general health and well-being, which for patients in methadone maintenance treatment (MMT) frequently is compromised by experiencing pain, depression and sleep disorders." | 7.78 | Pain depression and sleep disorders among methadone maintenance treatment patients. ( Lawental, E; Pud, D; Zlotnick, C, 2012) |
| "Methadone, used both to treat opioid addiction and to manage chronic pain, is commonly prescribed as an opioid of choice for patients with chronic pain and comorbid substance use disorders." | 7.78 | Methadone in the chronic pain patient with a substance use disorder. ( Friedman, CK; Reisfield, GM, 2012) |
| "To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome." | 7.77 | Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. ( Akinbi, H; Isemann, B; Meinzen-Derr, J, 2011) |
| "Differences in lifetime trauma exposure and screened symptoms of posttraumatic stress disorder (PTSD) were examined in methadone maintenance treatment (MMT) patients with a variety of pain experiences." | 7.77 | Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients. ( Barry, DT; Beitel, M; Cutter, CJ; Garnet, B; Joshi, D; Rosenblum, A; Schottenfeld, RS, 2011) |
| "Determine whether infants exposed to chronic maternal methadone with abnormal intrapartum fetal heart rate (FHR) patterns are more likely to require treatment for neonatal abstinence syndrome (NAS)." | 7.77 | Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. ( Albright, B; Brown, SA; Hsi, A; Leeman, LM; Rayburn, WF; Skipper, B, 2011) |
| "05), birth weight, and neonatal morbidities were similar regardless of the maternal methadone dose." | 7.77 | Higher maternal doses of methadone does not increase neonatal abstinence syndrome. ( Bombrys, A; Grier, M; Habli, M; Livingston, J; Pizarro, D; Sibai, B, 2011) |
| "To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group." | 7.77 | Low risk for hepatitis C seroconversion in methadone maintenance treatment. ( Adelson, M; Peles, E; Rados, V; Schreiber, S, 2011) |
| "To estimate the relationship between maternal methadone dose and the incidence of neonatal abstinence syndrome (NAS)." | 7.76 | Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Hayes, EJ; Seligman, NS, 2010) |
| "Methadone is standard pharmacotherapy for opioid-dependent pregnant women, yet the relationship between maternal methadone dose and neonatal abstinence syndrome (NAS) severity is still unclear." | 7.76 | Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. ( Choo, RE; Concheiro, M; Elko, A; Gray, TR; Huestis, MA; Jansson, LM; Jones, HE; Williams, E, 2010) |
| " This study aims to determine the infant mortality rate of infants born to women on a methadone program during pregnancy and to identify any modifiable risk factors." | 7.76 | Infant mortality among women on a methadone program during pregnancy. ( Burns, L; Conroy, E; Mattick, RP, 2010) |
| "Tobacco use and depression are highly prevalent among methadone maintenance (MM) treatment programme participants." | 7.76 | Nicotine dependence and depression among women smokers on methadone maintenance. ( Arnold, S; Gandhi, D; Joshi, A; Khanna, N; Sadaphal, S; Stewart, D, 2010) |
| " In this study, we examined the link between resting rCBF in the PFC and current depressive symptoms in methadone-maintained opiate-dependent (MM) patients with or without major depression." | 7.75 | Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. ( Busch, SI; Childress, AR; Ehrman, RN; Hakun, JG; Langleben, DD; Li, Y; O'Brien, CP; Suh, JJ; Wang, Z, 2009) |
| " These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C." | 7.75 | Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. ( Arnsten, JH; Gourevitch, MN; Harris, KA; Kaswan, D; Litwin, AH; Nahvi, S; Soloway, IJ; Tenore, PL; Zamor, PJ, 2009) |
| "Following the findings of perceived poor sleep and of chronic pain among former heroin addicts, current methadone maintenance treatment (MMT) patients, and its possible relation to methadone dose, we studied these patients' objective sleep parameters." | 7.75 | Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. ( Adelson, M; Peles, E; Schreiber, S, 2009) |
| "Empirical evidence is needed to guide adequate postpartum pain relief of methadone and buprenorphine stabilized patients." | 7.75 | Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. ( Dahne, J; Johnson, R; Jones, HE; Lemoine, L; Milio, L; O'Grady, K; Ordean, A; Selby, P, 2009) |
| "Differences in psychiatric distress and substance use (licit and illicit) were examined in methadone maintenance treatment (MMT) patients with a variety of pain experiences." | 7.75 | Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. ( Barry, DT; Beitel, M; Garnet, B; Joshi, D; Rosenblum, A; Schottenfeld, RS, 2009) |
| "Prior studies noted elevated preterm birth (PTB) rates among opiate-addicted women treated with methadone." | 7.75 | Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Seligman, NS, 2009) |
| "To describe the patterns of screening for hepatitis C virus (HCV) infection in methadone-maintained pregnant women and their infants." | 7.75 | Screening for hepatitis C virus infection in methadone-maintained mothers and their infants. ( An, EI; Leroi, MJ; Liu, AJ; Murray, HG; Nanan, RK; Tetstall, E, 2009) |
| "Methadone-maintained pregnant patients with mood disorders have compromised treatment outcomes ( [1] )." | 7.75 | The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. ( Chisolm, MS; Fitzsimons, H; Heil, SH; Jones, HE; O'Grady, KE; Tuten, M, 2009) |
| "To examine the association between retention in methadone treatment during pregnancy and key neonatal outcomes." | 7.74 | Methadone in pregnancy: treatment retention and neonatal outcomes. ( Burns, L; Lim, K; Mattick, RP; Wallace, C, 2007) |
| "Data from this non-randomized comparison suggest that buprenorphine may offer advantages for treatment of opiate dependence during pregnancy." | 7.74 | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. ( Heilig, M; Kakko, J; Sarman, I, 2008) |
| "The aim of the study was to analyze the neonatal impact of a methadone maintenance program in pregnancy, and the social resources of the families involved." | 7.73 | Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. ( Arlettaz, R; Bucher, HU; Das-Kundu, S; Fauchère, JC; Kashiwagi, M; Lang, A, 2005) |
| "Iatrogenic opioid addiction among chronic pain patients was the initiative for starting a methadone programme for pain patients at the University Hospital of Uppsala." | 7.73 | Methadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-up. ( Gordh, T; Grönbladh, L; Nilsson, LH; Rhodin, A, 2006) |
| "This study assesses the effect of higher doses of methadone during pregnancy on maternal and fetal outcomes." | 7.73 | High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. ( Anania, B; Leamon, MH; McCarthy, JJ; Parr, MS, 2005) |
| "Both clinicians and researchers have expressed doubt that opiate dependent patients with significant pain can be effectively treated in methadone maintenance treatment (MMT) programs; however, little research exists on this topic." | 7.73 | Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. ( Humphreys, K; Ilgen, MA; Trafton, JA, 2006) |
| "This study compared methadone maintenance patients with and without pathological gambling (n = 167)." | 7.73 | Health correlates of pathological gambling in a methadone maintenance clinic. ( Blanco, C; Petry, NM; Weinstock, J, 2006) |
| "The safety, efficacy, and tolerability of nelfinavir (NFV)-containing antiretroviral therapy were evaluated in patients coinfected with HIV and hepatitis C undergoing methadone maintenance at an urban outpatient opioid treatment program serving a minority adult population." | 7.73 | Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. ( Brown, LS; Chu, M; Kritz, S; Madray, C, 2006) |
| "To investigate the relationship between the daily dose of the synthetic opioid methadone and the corrected QT (QTc) interval in a series of methadone-treated patients who developed torsade de pointes." | 7.72 | Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. ( Krantz, MJ; Kutinsky, IB; Mehler, PS; Robertson, AD, 2003) |
| "The objectives of this medico-legal case report were the following: 1) To present an example of a medico-legal problem that developed as a result of a decision to rotate a chronic pain patient (CPP) to methadone in order to taper the CPP from oxycodone; 2) To present both the plaintiff's and defendant's expert witnesses' opinions as to if and where the care of that patient fell below the "standard of medical care;" and 3) Based on these opinions, to develop some recommendations on how, in the future, pain medicine physicians and other physicians should proceed, in order to avoid allegations of breach of "standards of care" when using methadone." | 7.72 | Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Rosomoff, RS, 2003) |
| " In the 30 days before the survey, respondents reported that their clinics provided the following services to at least one patient: 73 percent provided brief advice to quit, 18 percent offered individual or group smoking cessation counseling, and 12 percent prescribed nicotine replacement therapy." | 7.72 | Smoking cessation services in U.S. methadone maintenance facilities. ( Ahluwalia, JS; Choi, WS; Harris, KJ; McCool, RM; Richter, KP, 2004) |
| "The usefulness of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) activity in urine as markers of chronic alcohol abuse was examined in male methadone programme participants." | 7.71 | The activity of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) in urine as non-invasive markers of chronic alcohol abuse: II. Opiate-dependent subjects receiving methadone substitution. ( Baran, H; Chmielewska, K; Habrat, B; Szukalski, B; Taracha, E; Walkowiak, J, 2002) |
| "This study measured the extent and examined implications of hepatitis C (HCV) infection in a methadone maintenance treatment (MMT) population." | 7.71 | Hepatitis C in methadone maintenance patients: prevalence and public policy implications. ( Flynn, N; McCarthy, JJ, 2001) |
| "The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection." | 7.71 | Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001) |
| "In a patient on methadone maintenance treatment, admitted for lung cancer suspicion, a slight decrease in pain dose response to morphine have necessitated adjustments of methadone treatment founded on clinical check-up and methadone assay." | 7.71 | Slow metabolism and long half life of methadone in a patient with lung cancer and cirrhosis. ( Beauverie, P; Edel, YA; Furlan, V, 2001) |
| "The purpose of this study is to evaluate women receiving methadone maintenance during pregnancy." | 7.70 | Methadone maintenance in pregnancy: a reappraisal. ( Britton, KA; Brizendine, E; Brown, HL; Hiett, AK; Mahaffey, D; Turnquest, MA, 1998) |
| "The volume of feeds, changes in infant body weight, as well as occurrence of adverse clinical effects in infants withdrawing from methadone were studied during the first month of life." | 7.70 | Hyperphagia in neonates withdrawing from methadone. ( Kastner, B; Martinez, A; Taeusch, HW, 1999) |
| "To evaluate an approach to enhancing compliance with tuberculosis chemoprophylaxis in drug users enrolled on methadone maintenance utilizing an isoniazid (INH)-methadone admixture." | 7.70 | Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. ( Durante, AJ; Friedman, L; Henry, S; O'Connor, PG; Selwyn, PA; Shi, JM, 1999) |
| " Because a history of depression has been shown in other populations to complicate cessation efforts, the relationship between depression and nicotine dependence was tested in 726 methadone patients." | 7.69 | Nicotine dependence and depression among methadone maintenance patients. ( Brown, LS; Lin, MM; Meyer, TJ, 1996) |
| "Alcoholism is a prevalent problem encountered during the methadone treatment of opioid dependence." | 7.68 | The relationship of mean daily blood alcohol levels to admission MAST, clinic absenteeism and depression in alcoholic methadone patients. ( Amass, L; Bickel, WK, 1993) |
| "The incidence of panic attacks methadone-maintained patients has increased over a 10-year period from 1 to 6-13%." | 7.68 | Cocaine-associated panic attacks in methadone-maintained patients. ( Kosten, T; Rosen, MI, 1992) |
| "The authors describe their experience with methadone treatment in pregnancy." | 7.67 | Methadone in pregnancy: clinical-toxicological aspects. ( Chiarotti, M; De Giovanni, N; Falasconi, AM; Offidani, C, 1986) |
| "There was no difference in prevalence of current alcoholism between new admissions to a methadone-maintenance treatment program (MMTP) and patients already in MMTP at least one year, by previous treatment for drug misuse, or between MMTP patients and the population of the surrounding community." | 7.66 | Alcoholism among narcotic addicts and patients on methadone maintenance. ( Cohen, M; Hanbury, R; Jackson, G; Korts, D; Stimmel, B; Sturiano, V, 1983) |
| "To investigate the relationship between methadone and alcohol abuse, 60 male veteran narcotic addicts entering a methadone maintenance program were divided into either a problem drinker group (N = 21) or a normal drinker group (N = 39) based on their drinking histories and Breathalyzer tests at admission." | 7.66 | Risk for alcoholism and methadone treatment. A longitudinal study. ( Marcovici, M; McLellan, AT; O'Brien, CP; Rosenzweig, J, 1980) |
| " Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen." | 7.11 | Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. ( Dahan, A; Ellerbroek, H; Kramers, C; Schellekens, AFA; Timmerman, H; van den Heuvel, SAS, 2022) |
| "The intensity of postoperative pain can range from mild to severe." | 7.01 | Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review. ( Cornett, EM; Edinoff, AN; Flanagan, CJ; Jackson, ED; Kaye, AD; Kaye, AM; Pearl, NZ; Sinnathamby, ES; Wenger, DM, 2023) |
| "Methadone maintenance treatment (MMT) patients are often under-nourished and overweight." | 6.87 | Knowledge about nutrition, eating habits and weight reduction intervention among methadone maintenance treatment patients. ( Adelson, M; Herzman-Harari, S; Peles, E; Sason, A, 2018) |
| " Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3." | 6.82 | Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016) |
| "Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone." | 6.78 | A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. ( Azadfard, M; Blondell, RD; Giambrone, AK; Homish, GG; Jaanimägi, U; Kowalik, U; Lozano, JR; Neumann, AM, 2013) |
| "Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production." | 6.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA; Shorter, D, 2013) |
| "Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine." | 6.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Lappalainen, J; Nielsen, DA; Wu, G, 2013) |
| "Methadone patients had lower baseline MHPG levels." | 6.70 | Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. ( Charney, DS; Kosten, TR; Krystal, JH; Petrakis, IL; Southwick, SM; Stine, SM, 2002) |
| "Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements." | 6.69 | Pain responses in methadone-maintained opioid abusers. ( Charuvastra, VC; Compton, P; Kintaudi, K; Ling, W, 2000) |
| "A retrospective, inception cohort, nonrandomized control design was employed to evaluate the effects of daily vs twice daily dosing of methadone on opiate/cocaine use, and noncompliance with urine toxicology requests in methadone-maintained pregnant women, n = 45." | 6.68 | Methadone dosing and pregnancy: impact on program compliance. ( DePetrillo, PB; Rice, JM, 1995) |
| "Methadone maintenance treatment (MMT) is an important treatment tool for the opioid epidemic." | 6.58 | Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. ( Antoine, DG; Huhn, AS; Schlienz, NJ; Speed, TJ; Sweeney, MM, 2018) |
| "Individuals with opioid use disorders, including those on medication-assisted therapy such as methadone or buprenorphine, are a key demographic group that can benefit from HCV treatment given their high HCV prevalence; however, pharmacokinetic and pharmacodynamic drug interactions could blunt their utility." | 6.53 | Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. ( Bruce, RD; Friedland, G; Ogbuagu, O, 2016) |
| "Methadone maintenance treatment (MMT) clinics have been implemented in China since 2004." | 6.50 | Epidemiology of syphilis infection among drug users at methadone maintenance treatment clinics in China: systematic review and meta-analysis. ( Peng, WJ; Wan, YN; Wang, BX; Wang, J; Wang, YJ; Yan, JW; Zhang, L, 2014) |
| "Methadone maintenance treatment (MMT) for opioid dependency has consistently shown important heath, social and legal benefits." | 6.43 | Methadone death, dosage and torsade de pointes: risk-benefit policy implications. ( Latowsky, M, 2006) |
| " These recommendations address: antepartum issues including treatment, dosage and pharmacological considerations, medical conditions and lab tests, intrapartum issues, postpartum concerns including breastfeeding, neonatal withdrawal, and developmental effects associated with methadone." | 6.41 | Clinical management of methadone dependence during pregnancy. ( Curet, LB; Dorato, V; Wallerstedt, C; Wilbourne, P, 2001) |
| " Contrary to the expectation that methadone patients who consumed excessive amounts of alcohol would require higher dosages of methadone, it was found that nonalcohol-abusing methadone patients requested the higher dosage levels." | 6.40 | Methadone patients and alcohol abuse. ( Ottomanelli, G, 1999) |
| "Methadone use was associated with 21." | 5.91 | Opioid and Methadone Use for Infants With Surgically Treated Necrotizing Enterocolitis. ( Keane, OA; Kelley-Quon, LI; Kim, E; Kim, ES; Lakshmanan, A; Mahdi, EM; Ourshalimian, S; Song, AY; Zamora, AK, 2023) |
| "Methadone use for opioid use disorder and chronic pain has increased since the start of the century with about 4." | 5.72 | Insulinoma mimic: methadone-induced hypoglycaemia. ( Balaji, A; Chae, K; Kanbour, S; Mathioudakis, N, 2022) |
| "Postoperatively, he developed OIC and Ogilvie syndrome, then following treatment with methylnaltrexone experienced an acute bowel perforation." | 5.51 | Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report. ( Blackney, KA; Edwards, DA; Kamdar, NV; Liu, CA, 2019) |
| "Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module." | 5.48 | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. ( Cooper, C; Cox, J; Hamelin, AM; Harper, S; Klein, MB; McLinden, T; Moodie, EEM; Rossi, C; Rourke, SB; Walmsley, SL, 2018) |
| "Patients with opioid use disorders on opioid agonist therapy (OAT) have lower pain tolerance compared to controls." | 5.42 | Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Mao, J; Samet, JH; Tsui, JI; Winter, MR, 2015) |
| "Per oral methadone maintenance therapy [MMT] was introduced as part of harm reduction strategy to manage rising numbers of HIV infections caused by intravenous use of illicit drugs." | 5.41 | Side Effects of Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements. ( Ang, WC; Anuar, A; Jamaluddin, R; Khalid, K, 2023) |
| "To assess studies examining the prevalence of chronic pain (CP) in patients treated with Opioid Substitution Treatment (OST - buprenorphine or methadone) for Opioid Used Disorder (OUD), we conducted a systematic review and meta-analysis of the literature between the years 2000 and 2020." | 5.41 | Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy. ( Authier, N; Bertin, C; Chenaf, C; Delorme, J; Kerckhove, N; Pereira, B, 2023) |
| "Methadone use for the management of opioid dependency during pregnancy is commonplace." | 5.41 | Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study. ( Badhan, RKS; Gittins, R, 2021) |
| "Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse." | 5.41 | A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2021) |
| "Weight loss was less in small for gestational age compared to appropriately grown infants (p<0." | 5.38 | Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding. ( Campbell, N; Dryden, C; Mactier, H; Young, D, 2012) |
| "Methadone maintenance treatment (MMT) is the standard treatment of choice for pregnant opiate addicts; however, data on newborn outcomes are contradictory." | 5.38 | Duration of methadone maintenance treatment during pregnancy and pregnancy outcome parameters in women with opiate addiction. ( Adelson, M; Bloch, M; Dollberg, S; Peles, E; Schreiber, S, 2012) |
| "Hypogonadism was found in 68 % of the participants, and about 68." | 5.38 | Depression, Testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV Infection. ( Amini Lari, M; Faramarzi, H; Marzban, M; Parsa, N; Shams, M, 2012) |
| "Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form)." | 5.37 | Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. ( Applebaum, A; Batchelder, A; Gonzalez, JS; Newville, H; Psaros, C; Safren, SA, 2011) |
| "Takotsubo cardiomyopathy is a syndrome characterized by transient apical ballooning or reversible midventricular systolic dysfunction." | 5.37 | Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. ( Bhat, T; Duvvuri, S; Jun, CH; Khattri, S; Lafferty, J; Saiful, FB; Teli, S, 2011) |
| " Maternal opiate dosing has been investigated with conflicting results." | 5.36 | Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. ( Cook, CM; Jones, MP; Liu, AJ; Murray, H; Nanan, R, 2010) |
| "Lifetime potential and probable pathological gambling (PG) were assessed using the South Oaks Gambling Screen (SOGS) questionnaire." | 5.36 | Pathological gambling in methadone maintenance clinics where gambling is legal versus illegal. ( Adelson, M; Linzy, S; Peles, E; Schreiber, S, 2010) |
| "Methadone maintenance therapy for the treatment of opioid dependence continues to carry a social stigma." | 5.34 | Liver transplant and hepatitis C in methadone maintenance therapy: a case report. ( Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L, 2007) |
| "Menopause is a natural process that occurs in women's lives as part of normal aging." | 5.34 | Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. ( Tuchman, E, 2007) |
| "Methadone maintenance treatment reduces drug-related-harm." | 5.32 | [Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment]. ( Aragonés, A; Barril, J; Esteban, J; Gimeno, C; Pellín, Mde L, 2003) |
| "Methadone levels were kept blinded from clinicians." | 5.31 | Methadone trough levels in pregnancy. ( Berghella, V; Drozdick, J; Hill, M; Kaltenbach, K, 2002) |
| "Age, and the duration of opioid dependence showed a significant influence on cocaine positive urinalysis." | 5.31 | [Cocaine abuse in maintenance therapy with methadone in narcotic dependent patients]. ( Fischer, G; Kraigher, D; Ortner, R; Peternell, A; Schindler, S; Topitz, A, 2001) |
| "Traditionally, methadone maintenance therapy has been a once-daily dosing schedule." | 5.30 | Alterations in methadone metabolism during late pregnancy. ( Jarvis, MA; Kniseley, JS; Schnoll, SH; Wu-Pong, S, 1999) |
| "Methadone dosing was not contingent upon ingestion of antituberculous medication(s)." | 5.29 | Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. ( Gourevitch, MN; Panero, MS; Selwyn, PA; Wasserman, W, 1996) |
| "Over 85% of opioid-dependent individuals in methadone treatment smoke cigarettes; however, smoking cessation interventions are minimally effective in this population." | 5.27 | Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence. ( Bernstein, SL; Cooperman, NA; Lu, SE; Richter, KP; Williams, JM, 2018) |
| "Newborns who are prenatally exposed to methadone are at risk for neonatal abstinence syndrome and the associated excess weight loss and poor weight gain." | 5.27 | Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study. ( Baker, R; Bogen, DL; Cohlan, B; Hanusa, BH; Medoff-Cooper, B, 2018) |
| "Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy." | 5.27 | Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. ( Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Salisbury, AL; Stine, S, 2018) |
| "These analyses corroborate evidence of weight gain with methadone treatment but did not observe a sex-based disparity in weight gain with methadone or buprenorphine treatment for OUD." | 5.22 | Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data. ( Dennis, E; Hu, L; Johnson, A; Kroll, D; Manza, P; McPherson, KL; Tai, B; Volkow, ND, 2022) |
| "Tobacco cessation medication adherence is one of the few factors shown to improve smoking cessation rates among methadone-maintained smokers, but interventions to improve adherence to smoking cessation medications have not yet been tested among methadone treatment patients." | 5.19 | Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics. ( Arnsten, JH; Litwin, AH; Nahvi, S; Segal, KS, 2014) |
| " While methadone-maintenance currently is the standard of care for opioid dependence during pregnancy, research suggests that buprenorphine-maintenance may be associated with shorter infant hospital lengths of stay (LOS) relative to methadone-maintenance." | 5.19 | Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. ( Hall, ES; Lewis, D; Marcotte, M; Theobald, J; Van Hook, J; Wexelblatt, SL; Wilder, C; Winhusen, T, 2014) |
| "This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT)." | 5.17 | Epidemiology of pain among outpatients in methadone maintenance treatment programs. ( Dhingra, L; Homel, P; Jordan, AE; Katz, J; Masson, C; McKnight, C; Perlman, DC; Portenoy, RK; Seewald, RM; Wald, E; Young, C, 2013) |
| " The objective of this study is to examine the extent to which cigarette smoking profiles differentially changed during the course of pregnancy in opioid-dependent patients receiving either double-blind methadone or buprenorphine." | 5.17 | A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. ( Acquavita, SP; Chisolm, MS; Fitzsimons, H; Heil, SH; Jansson, LM; Jones, HE; Kaltenbach, K; Leoutsakos, JM; Martin, PR; Tuten, M; Wilson-Murphy, M; Winklbaur, B, 2013) |
| "Hepatitis C virus (HCV) is a prevalent chronic blood-borne infection among opioid-dependent patients on methadone maintenance treatment (MMT)." | 5.16 | Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. ( Acosta, A; Altice, FL; Bruce, RD; Eiserman, J; Gote, C; Lim, JK, 2012) |
| "To identify factors that predict the expression of neonatal abstinence syndrome (NAS) in infants exposed to methadone or buprenorphine in utero." | 5.16 | Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. ( Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; Salisbury, AL; Stine, SM, 2012) |
| "To compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone- versus buprenorphine-exposed infants." | 5.16 | Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. ( Arria, AM; Badger, GJ; Coyle, MG; Gaalema, DE; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Scott, TL; Stine, SM, 2012) |
| "Buprenorphine appears to have an acceptable safety profile for use during pregnancy." | 5.16 | Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. ( Baxter, JK; Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; Stine, SM, 2012) |
| "To examine hepatic enzyme test results throughout the course of pregnancy in women maintained on methadone or buprenorphine." | 5.16 | Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. ( Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; McNicholas, LF; O'Grady, KE; Stine, SM, 2012) |
| "Opioid detoxification is not an effective stand-alone treatment for heroin dependence but is nevertheless an essential step in the path to recovery." | 5.15 | Outpatient versus inpatient opioid detoxification: a randomized controlled trial. ( Day, E; Strang, J, 2011) |
| " Methadone maintenance yielded to a significantly higher neonatal birth weight." | 5.15 | Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. ( Arria, A; Aschauer, C; Bäwert, A; Fischer, G; Jagsch, R; Jones, H; Leitich, H; Rohrmeister, K; Unger, A; Winklbaur, B, 2011) |
| "In order to investigate the effects of exposure to buprenorphine compared with methadone during pregnancy, a prospective multicenter study was conducted in collaboration with maternity hospitals, maintenance therapy centers, and general practitioners involved in addiction care." | 5.15 | Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. ( Berrebi, A; Chaumerliac, C; Damase-Michel, C; Garipuy, D; Hammou, Y; Lacroix, I; Lapeyre-Mestre, M; Montastruc, JL; Schmitt, L, 2011) |
| "One hundred and fourteen subjects were included in the analysis, with 77 in SP (n = 51 methadone, n = 26 buprenorphine), and 37 in CT (n = 19 methadone, n = 18 buprenorphine), comparing maternal concomitant consumption during third trimester, demographic birth data, duration of treatment for neonatal abstinence syndrome (NAS), morphine dose for NAS treatment and length of hospital stay (LOS)." | 5.15 | Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. ( Aschauer, C; Ebner, N; Fischer, G; Jagsch, R; Metz, V; Pribasnig, A; Würzl, J, 2011) |
| "This was a secondary analysis of data collected in a prospective randomized, double-blind, double-dummy, multicenter trial (MOTHER study) that examined the comparative safety and efficacy of methadone and buprenorphine during pregnancy." | 5.15 | Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates? ( Bäwert, A; Coyle, M; Fischer, G; Jagsch, R; Martin, PR; Rohrmeister, K; Unger, A; Winklbaur, B, 2011) |
| "Daily methadone maintenance is the standard of care for opiate dependency during pregnancy." | 5.14 | Maternal methadone dosing schedule and fetal neurobehaviour. ( Dipietro, JA; Elko, A; Jansson, LM; Kivlighan, KT; Knauer, H; Velez, M, 2009) |
| "Methadone, a full mu-opioid agonist, is the recommended treatment for opioid dependence during pregnancy." | 5.14 | Neonatal abstinence syndrome after methadone or buprenorphine exposure. ( Arria, AM; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Selby, P; Stine, SM, 2010) |
| " Infants born to buprenorphine maintained women are not exposed to a greater proportion of the maternal dose compared with methadone and may be exposed to relatively less of the maternal dose compared with infants born to women maintained on methadone during pregnancy." | 5.14 | (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. ( Foster, DJ; Gordon, AL; Lopatko, OV; Somogyi, AA; White, JM, 2010) |
| " Free and total buprenorphine and norbuprenorphine, nicotine, opiates, cocaine, benzodiazepines, and metabolites were quantified in meconium from 10 infants born to women who had received buprenorphine during pregnancy." | 5.13 | Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. ( Choo, RE; Huestis, MA; Johnson, RE; Jones, HE; Kacinko, SL, 2008) |
| "Methadone-maintained cocaine abusers (N = 78) were randomly assigned to 1 of the following 52-week interventions: (a) usual care only (UC), (b) take-home methadone doses contingent on cocaine- and opiate-negative results (THM), or (c) take-home methadone doses for cocaine- and opiate-negative results and monetary-based vouchers contingent on cocaine-negative urinalysis results (THM + V)." | 5.13 | Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers. ( Badger, GJ; Bigelow, G; Higgins, ST; Rogers, RE; Silverman, K; Stitzer, M; Thomas, CS, 2008) |
| "This study evaluated the efficacy of a contingency management (CM) intervention to promote smoking cessation in methadone-maintained patients." | 5.13 | Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study. ( Dunn, KE; Heil, SH; Higgins, ST; Sigmon, SC; Thomas, CS, 2008) |
| "The treatment of acute pain in patients maintained on methadone is difficult due to increased pain sensitivity (hyperalgesia) and cross-tolerance to other opioids." | 5.13 | Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients. ( Bochner, F; Hay, JL; Somogyi, AA; White, JM, 2008) |
| "Eighteen women were assigned randomly to receive either methadone (n = 9) or buprenorphine (n = 9) during weeks 24-29 of pregnancy." | 5.12 | Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. ( Aschauer, H; Baewert, A; Fischer, G; Jagsch, R; Langer, M; Ortner, R; Rohrmeister, K, 2006) |
| " Smoking cessation rates in methadone-maintained smokers are low, with men having greater success." | 5.12 | A smoking cessation intervention for the methadone-maintained. ( Anderson, BJ; Anthony, JL; Herman, DS; Niaura, R; Stein, MD; Weinstock, MC, 2006) |
| " The mothers received methadone (n=22), slow-release oral morphine (n=17) or buprenorphine (n=14) throughout pregnancy." | 5.12 | Management of neonatal abstinence syndrome in neonates born to opioid maintained women. ( Baewert, A; Ebner, N; Fischer, G; Jagsch, R; Peternell, A; Rohrmeister, K; Thau, K; Winklbaur, B, 2007) |
| "Though methadone pharmacotherapy is the treatment of choice for opiate-dependence during pregnancy in the USA, most methadone-exposed neonates develop neonatal abstinence syndrome (NAS)." | 5.12 | Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. ( Dipietro, JA; Elko, A; Jansson, LM; Velez, M, 2007) |
| " The Beck Depression Inventory was completed at baseline and 3 months by heroin dependent subjects receiving either buprenorphine or methadone maintenance as part of a larger, pre-existing, double blind trial conducted by NDARC (Australia)." | 5.11 | Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. ( Bell, J; Christie, MJ; Dean, AJ; Mattick, RP, 2004) |
| "Methadone maintenance has been an effective pharmacotherapy for the treatment of heroin dependence for nearly four decades." | 5.11 | Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. ( Bigelow, GE; Brasser, SM; Donny, EC; Stitzer, ML; Walsh, SL, 2005) |
| " To explore the treatment implications of these findings, ketoconazole's (600-900 mg daily) ability to reduce heroin and cocaine use was compared with placebo in 39 methadone maintained patients with a history of cocaine abuse or dependence during a 12-week double blind trial." | 5.10 | Ketoconazole increases cocaine and opioid use in methadone maintained patients. ( Feingold, A; Gonsai, K; Kosten, TR; Oliveto, A; Sevarino, KA, 2002) |
| "This 13-week, randomized, double-blind, placebo-controlled trial evaluated the efficacy of desipramine hydrochloride (0 or 150 mg/d) plus buprenorphine hydrochloride (12 mg/d) or methadone hydrochloride (65 mg/d) in 180 opioid-dependent cocaine abusers (124 men, 56 women)." | 5.09 | Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. ( Feingold, A; Jatlow, P; Kosten, TR; Oliveto, AH; Schottenfeld, R, 1999) |
| " Recent studies have evaluated disulfiram as a treatment for individuals with comorbid alcohol and cocaine abuse." | 5.09 | Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. ( Carroll, KM; Frankforter, T; Gordon, LT; McCance-Katz, EF; Nich, C; Petrakis, IL; Rounsaville, BJ, 2000) |
| "Patients receiving methadone hydrochloride maintenance treatment were selected if they met the criteria for a DSM-III-R depressive disorder that was chronologically primary, had persisted during a past abstinent period or was long-standing, and persisted during at least 1 month of stable methadone treatment." | 5.08 | Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. ( Brady, R; Deliyannides, D; Donovan, SJ; Koenig, T; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Woody, G, 1998) |
| "This study tested the effectiveness of fluoxetine as a treatment for depression in a population of methadone-maintained opioid addicts." | 5.08 | Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. ( Carroll, KM; Gordon, L; Kosten, T; Nich, C; Petrakis, I; Rounsaville, B, 1998) |
| " During general anesthesia lasting about six hours with methohexital or propofol, naloxone was administered with doubling of the dose every 15 minutes with a starting bolus dose of 0." | 5.08 | Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. ( Gastpar, M; Kaube, H; Kienbaum, P; Klein, S; Peters, J; Scherbaum, N, 1998) |
| "A literature search was conducted using scientific databases (PubMed, Scopus, Web of Science, and reports from international institutions) to review published articles on buprenorphine and methadone monitoring during pregnancy." | 5.05 | Monitoring Prenatal Exposure to Buprenorphine and Methadone. ( Busardò, FP; Carlier, J; Di Trana, A; Huestis, MA; La Maida, N; Pichini, S; Tittarelli, R, 2020) |
| " Methadone is a medication-assisted treatment used to treat opioid dependence and chronic pain." | 5.05 | The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: A systematic review. ( Ortman, HA; Siegel, JA, 2020) |
| "Methadone has unique characteristics that make it an attractive agent for the treatment of chronic pain and opioid drug dependence." | 5.05 | Levorphanol versus methadone use: safety considerations. ( Haider, A; Reddy, A, 2020) |
| " There have been several preliminary studies examining the effect of methadone on depression among addicts, however, these studies have reported inconsistent and even contradictory results." | 5.05 | The effect of methadone on depression among addicts: a systematic review and meta-analysis. ( Abdoli, N; Hosseinian-Far, M; Kazeminia, M; Khaledipaveh, B; Mohammadi, M; Salari, N; Shohaimi, S, 2020) |
| "Mean red cell volume, mean red cell hemoglobin, and mean red cell hemoglobin concentration were measured in a prospective, longitudinal, single-bind study of alcoholism and its treatment in 625 patients receiving methadone." | 5.05 | Failure of mean red cell volume to serve as a biologic marker for alcoholism in narcotic dependence. A randomized control trial. ( Gilbert, HS; Jackson, G; Korts, D; Stimmel, B, 1983) |
| "This research evaluated the efficacy of an Anxiety Reduction program designed to reduce anxiety early in methadone detoxification and thereby facilitate dose reduction." | 5.05 | Methadone dose decreases and anxiety reduction. ( Hall, SM; Kushner, M; Loeb, PC, 1984) |
| "The effect of alcoholism on indices of productive activity was determined in a prospective, randomized, and controlled study of alcoholism in narcotic addicts undergoing methadone maintenance (MM) therapy." | 5.05 | The effect of alcoholism in methadone-maintained persons on productive activity: a randomized control trial. ( Cohen, M; Hanbury, R; Jackson, G; Korts, D; Stimmel, B; Sturiano, V, 1982) |
| "To systematically review and meta-analyse studies of neurodevelopmental outcome of children born to mothers prescribed methadone in pregnancy." | 5.01 | Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis. ( Boardman, JP; Chappell, FM; Hamilton, R; Mactier, H; Monnelly, VJ, 2019) |
| "To compare the effects of morphine and methadone on length of hospital stay (LOS) or treatment (LOT) and adverse effects in infants with neonatal abstinence syndrome (NAS)." | 4.98 | Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review. ( Gregory, PJ; Hein, DJ; Risoldi Cochrane, Z; Slowiczek, L, 2018) |
| "This study examined the obstetric health of opioid-dependent women who were treated with implant naltrexone during pregnancy, and compared them with women treated with methadone and/or buprenorphine and a cohort of non-opioid-dependent controls." | 4.95 | A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls. ( Hulse, G; Kelty, E, 2017) |
| "While chronic pain has been said to impact patient's response to methadone maintenance treatment for opioid dependence, the reported findings are inconsistent." | 4.93 | Pain and Opioid Addiction: A Systematic Review and Evaluation of Pain Measurement in Patients with Opioid Dependence on Methadone Maintenance Treatment. ( Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Paul, J; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A, 2016) |
| "A literature search of PubMed (1966 to March 2016) and EMBASE (1973 to March 2016) was completed using the search terms buprenorphine, methadone, pregnancy, opioid, and neonatal abstinence syndrome Priority was given to randomized controlled trials and trials directly comparing buprenorphine and methadone during pregnancy." | 4.93 | Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy. ( Campbell, K; Crannage, E; Forinash, A; Noormohammadi, A; Shyken, J; Yancey, A, 2016) |
| "Moderately strong evidence indicates lower risk of preterm birth, greater birth weight and larger head circumference with buprenorphine treatment of maternal opioid use disorder during pregnancy compared with methadone treatment, and no greater harms." | 4.93 | Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. ( Amick, HR; Jones, HE; Joyce, AR; Kim, MM; Mann, AL; Murrelle, EL; Zedler, BK, 2016) |
| " In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine)." | 4.93 | Pharmacotherapy for Substance Use Disorders. ( Klein, JW, 2016) |
| "Opioids increase the risk for sleep disordered breathing (SDB), but there are few studies examining the prevalence and risk factors for SDB, specifically central sleep apnea (CSA), and obstructive sleep apnea (OSA) in chronic pain patients on opioids as well as methadone maintained patients (MMPs)." | 4.93 | A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. ( Hassamal, S; Miotto, K; Saxon, AJ; Wang, T, 2016) |
| "Parents of infants with neonatal abstinence syndrome (NAS) in the NICU may have questions about the long-term consequences of prenatal exposure to methadone, both asked and unasked." | 4.93 | Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome. ( Armstrong, K; Brooks, SS; Clark, L; Cline, GJ; Germain, AM; Maguire, DJ; Shaffer-Hudkins, E; Taylor, S, 2016) |
| " This review summarizes existing knowledge about smoking cessation treatments for pregnant women on buprenorphine or methadone, the two forms of medication-assisted treatment for opioid use disorder indicated for prenatal use." | 4.91 | Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. ( Akerman, SC; Blunt, HB; Brunette, MF; Goodman, DJ; Green, AI; Heil, SH, 2015) |
| " In this commentary, we briefly summarize the extant literature on pharmacotherapies in opioid-maintained smokers and contribute new data investigating the contribution of bupropion on smoking outcomes in 81 methadone- and buprenorphine-maintained participants from two randomized trials of financial incentives for smoking cessation." | 4.91 | Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions. ( Miller, ME; Sigmon, SC, 2015) |
| "This systematic review synthesizes the evidence related to methadone use and risk for overdose and cardiac arrhythmia." | 4.90 | Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline. ( Chou, R; Dana, T; Weimer, MB, 2014) |
| "Buprenorphine and methadone are opioid-receptor agonists used as opioid substitution therapy during pregnancy to limit exposure of the fetus to cycles of opioid withdrawal and reduce the risk of infectious comorbidities of illicit opioid use." | 4.90 | Buprenorphine and methadone for opioid addiction during pregnancy. ( Mozurkewich, EL; Rayburn, WF, 2014) |
| "Methadone and buprenorphine are maintenance replacement therapies for opioid dependence; they are also used for pain management." | 4.89 | Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. ( Moody, DE, 2013) |
| "The present paper considers naltrexone to treat opioid dependence during pregnancy." | 4.89 | Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. ( Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M, 2013) |
| "Many individuals receiving methadone maintenance treatment (MMT) for opioid addiction also require treatment for acute or chronic pain, and the presence of pain is known to have a negative impact on patient health and function." | 4.89 | Chronic and acute pain and pain management for patients in methadone maintenance treatment. ( Eyler, EC, 2013) |
| "Nearly 20 studies showed a prolonged QT interval secondary to methadone in patients exhibiting the following features: (1) patients with cardiac pathologies, notably bradycardia, congenital long QT interval, myocardial pathologies related to AIDS and electrolyte disturbances; (2) patients receiving concomitant treatment with substances known to prolong QT interval, such as psychoactive stimulants, narcoleptics, tricyclic antidepressants, antiarrhythmic agents, macrolids, quinolones, non diuretic hypokalemiants and certain corticoids; (3) patients receiving treatments that inhibit methadone's metabolism, particularly those that act on the cytochrome P450 3A4 such as SSRI, antifungal agents, some macrolids and some retroviral agents." | 4.88 | [Review of cases of prolonged QTC and wave burst arrhythmia in patients treated with methadone]. ( Berleur, MP; Kerbage, H; Laqueille, X; Richa, S; Scart-Gres, C, 2012) |
| "This article provides an overview and discussion of the collective maternal, fetal and neonatal outcome research on women maintained on methadone or buprenorphine during pregnancy." | 4.88 | Methadone and buprenorphine for the management of opioid dependence in pregnancy. ( Finnegan, LP; Jones, HE; Kaltenbach, K, 2012) |
| "While buprenorphine produces a less severe neonatal abstinence syndrome than methadone, both methadone and buprenorphine are important parts of a complete comprehensive treatment approach for opioid-dependent pregnant women." | 4.88 | Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. ( Arria, AM; Baewert, A; Coyle, MG; Fischer, G; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; Selby, P; Stine, SM, 2012) |
| "After completing this CME activity, physicians should be better able to assess the treatment options available to patients with opioid addiction during pregnancy, compare the risk/safety profiles of methadone and buprenorphine, and evaluate the recommendations and current data surrounding breast-feeding while on opioid maintenance treatment." | 4.88 | Opioid addiction in pregnancy. ( Lee-Parritz, A; Saia, K; Shainker, SA, 2012) |
| " Therefore, the aim of this study was to examine the efficacy of antidepressants in patients with unipolar major depressive disorder (MDD) and/or dysthymic disorder (DD) with comorbid opiate-use disorders currently in methadone maintenance treatment (MMT)." | 4.87 | Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. ( Bentley, KH; Iovieno, N; Papakostas, GI; Pedrelli, P; Tedeschini, E; Vitali, M, 2011) |
| "Individuals in methadone maintenance treatment are motivated to quit smoking and are interested in smoking cessation treatment." | 4.86 | Smoking cessation interventions among individuals in methadone maintenance: a brief review. ( Barr, AM; Greaves, L; Johnson, JL; Khara, M; Okoli, CT; Procyshyn, RM, 2010) |
| "Methadone is highly effective in treating opioid dependence, and it is also used as an analgesic for second-line management of chronic pain." | 4.86 | Methadone deaths: risk factors in pain and addicted populations. ( Brooks, D; Modesto-Lowe, V; Petry, N, 2010) |
| "To determine if there is a relationship between maternal methadone dose in pregnancy and the diagnosis or medical treatment of neonatal abstinence syndrome (NAS)." | 4.86 | Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. ( Clarke, M; Cleary, BJ; Donnelly, J; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, J, 2010) |
| "Methadone, an opioid analgesic, is used clinically in pain therapy as well as for substitution therapy in opioid addiction." | 4.84 | Interindividual variability of methadone response: impact of genetic polymorphism. ( Davani, S; Gerritsen-van Schieveen, P; Kantelip, JP; Li, Y, 2008) |
| "This article reviews the unique pharmacological properties of methadone and outlines its appropriate clinical application, with focus upon its use in the treatment of chronic pain." | 4.82 | Methadone: applied pharmacology and use as adjunctive treatment in chronic pain. ( Brown, R; Fleming, M; Kraus, C; Reddy, S, 2004) |
| "Methadone hydrochloride is a mu-opioid agonist that has been used for the treatment of pain and for the management and maintenance of opioid withdrawal for over 50 years." | 4.81 | Clinical use of methadone. ( Goode, JV; Layson-Wolf, C; Small, RE, 2002) |
| " First, women who continued to use illicit heroin throughout pregnancy; secondly, women stabilized on methadone at the time of conception or shortly after and thirdly, women who use heroin well into pregnancy with late entry into methadone treatment, or who continued to use illicit heroin during pregnancy while receiving methadone." | 4.80 | Assessing the relationship between maternal opiate use and neonatal mortality. ( English, DR; Holman, CD; Hulse, GK; Milne, E, 1998) |
| "Results showed mean reduction in birth weight associated with heroin use: 489 g (95% CI 284-693 g), compared with methadone: 279 g (229-328 g)." | 4.79 | The relationship between maternal use of heroin and methadone and infant birth weight. ( English, DR; Holman, CD; Hulse, GK; Milne, E, 1997) |
| "Alcoholism is a major problem among methadone maintenance patients." | 4.77 | The treatment of alcoholic methadone patients: a review. ( Bickel, WK; Lowinson, JH; Marion, I, 1987) |
| "We orally induced morphine dependence in NMRI male mice, and then performed detoxification programs using either methadone or buprenorphine." | 4.31 | Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction. ( Abedini, M; Amirinejad, M; Haghpanah, T; Moinaddini, F; Nematollahi-Mahani, SN; Yoosefi, F, 2023) |
| " Illicit drug use during the pregnancy was common in all groups, but in the methadone group it was most common (p = 0." | 4.31 | Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. ( Kahila, HK; Kanervo, MM; Nikkola, EM; Rantakari, KM; Tupola, SJ, 2023) |
| "Of 400 eligible pregnancies, 85 and 137 individuals received buprenorphine and methadone, respectively, during early pregnancy." | 4.31 | Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study. ( Brothers, TN; Hartzema, A; Lewkowitz, AK; Meador, KJ; Pawasauskas, J; Quilliam, BJ; Wang, S; Ward, KE; Wen, X, 2023) |
| "From August 2021 to March 2022, a pharmacist guided implementation of a pilot sOAT protocol consisting of escalating doses of oxycodone or oral hydromorphone scheduled every four hours, intravenous hydromorphone as needed, and non-opioid adjuvants for withdrawal and pain." | 4.31 | Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. ( Caputo, A; Christopher, C; Compton, P; Delgado, MK; Lowenstein, M; McFadden, R; Olenik, JM; Perrone, J; Ronning, K; Sigueza, AL; Thakrar, AP; Uritsky, TJ; Winston, A, 2023) |
| " In adjusted analyses assessing likelihood of initiation for individual MOUD, pregnancy status was associated with an increase in buprenorphine (adjusted odds ratio [aOR] 1." | 4.31 | Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People. ( Bierut, LJ; Carter, EB; Grucza, RA; Jones, HE; Kelly, JC; Martin, CE; Schiff, DM; Xu, KY, 2023) |
| " buprenorphine) or pregnancy status." | 4.31 | Treatment access for opioid use disorder among women with medicaid in Florida. ( Elmore, AL; Fryer, K; Marshall, J; McNeer, E; Mehra, S; Patrick, SW; Reid, CN; Salemi, JL; Sappenfield, WM, 2023) |
| " Key indicators for this analysis include pregnancy testing at intake, number of county jails offering methadone or buprenorphine to pregnant incarcerated persons for detoxification on admission, continuation of pre-incarceration treatment, or linkage to post-incarceration treatment." | 4.31 | United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder. ( Beckwith, C; Benck, KN; Jones, AK; Nowotny, KM; Omori, M; Rubinstein, LB; Seide, K, 2023) |
| " Among those on methadone or buprenorphine (N = 108), multivariable logistic regression models examined the association between socio-demographics, MOUD type; and past-30-day use of heroin/fentanyl; crack; benzodiazepines; and pain medications." | 4.31 | Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs. ( Case, P; Green, TC; Hughto, JMW; Moyo, P; Palacios, WR; Rapisarda, SS; Silcox, J; Stopka, TJ; Tapper, A, 2023) |
| "Slow-release oral morphine (SROM) is used to manage pain, and as opioid agonist treatment (OAT)." | 4.31 | Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada: A population-based time series analysis. ( Besharah, J; Campbell, T; Gomes, T; Kleinman, RA; Kolla, G; Ledlie, S; Leece, P; McCormack, D; Smoke, A; Sproule, B; Tadrous, M, 2023) |
| "Prior studies indicate that subjects undergoing methadone maintenance therapy (MMT) may experience anxiety, depression and cravings." | 4.31 | Impact of combination of intermittent theta burst stimulation and methadone maintenance treatment in individuals with opioid use disorder: A comparative study. ( Cai, Z; Gong, H; Huang, J; Huang, Y; Jin, Y; Lu, W; Sun, X; Zhu, N; Zhu, X, 2023) |
| "To compare the risks of cardiac arrythmias, long QT syndrome and overall mortality between patients with opioid use disorders (OUD) who were prescribed methadone, buprenorphine or naltrexone." | 4.31 | Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. ( Berger, NA; Davis, PB; Kaelber, DC; Volkow, ND; Wang, L; Xu, R, 2023) |
| " However, data suggest the potential for significant weight gain during methadone treatment and little is known about weight change during buprenorphine treatment." | 4.31 | Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder. ( Carr, MM; Cave, S; Martino, S; Masheb, R; Midboe, AM; Wolkowicz, NR, 2023) |
| " Research consistently demonstrates the efficacy of medications for OUD (MOUD); however, researchers have called for additional studies evaluating the safety of MOUD during pregnancy, particularly the relative safety of two commonly used MOUD medications-methadone and buprenorphine." | 4.12 | A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome. ( Aujla, R; Boyars, L; Cleary, E; Douglas, E; Guille, C; Smith, C; Sujan, A, 2022) |
| "The full potential of methadone maintenance treatment (MMT) is often limited by the large inter-individual variability in both pharmacokinetics (PK) and pharmacodynamics (PD), and by the risk of torsade de pointes, a severe adverse effect caused by QTc prolongation." | 4.12 | A genetic-based population PK/PD modeling of methadone in Chinese opiate dependence patients. ( Guo, D; Lou, X; Shi, S; Shu, Y; Tan, Z; Yang, H; Yu, L; Zhou, H, 2022) |
| "The preterm birth rate among individuals using buprenorphine for opioid use disorder (22." | 4.12 | Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder. ( Abdelwahab, M; Cleary, EM; Petrich, M; Rood, KM; Walker, E; Wang, H, 2022) |
| " Four unique themes emerged as barriers to medication utilization and adherence in the perinatal period: 1) Lack of agency and autonomy surrounding medication decisions because pregnancy or parenting status affected treatment adherence; 2) Hesitancy to use MOUD to minimize risk of newborn withdrawal; 3) Concern about increased scrutiny and potential loss of custody due to mandated child protective services reporting for opioid-exposure at delivery in Massachusetts; and 4) Perception that treatment environments, particularly methadone clinics, did not provide gender-responsive or equitable care, and standardized, inflexible visit regulations were particularly difficult to comply with in the early postpartum period." | 4.12 | "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period. ( Bernstein, J; Gray, JR; Greenfield, SF; Hoeppner, BB; Jones, HE; Kelly, JF; MacMillan, KDL; Muftu, S; Partridge, S; Schiff, DM; Terplan, M; Wilens, TE; Work, EC, 2022) |
| " Cases were categorized based on adherence to a dosing strategy and LDI indication, including OUD and acute pain, non-prescribed fentanyl exposure, and transition from methadone." | 4.12 | Development of an intravenous low-dose buprenorphine initiation protocol. ( Bodnar, AR; Jablonski, LA; Stewart, RW, 2022) |
| "The potential long-term developmental effects of prenatal methadone and buprenorphine exposure during pregnancy are still largely unknown." | 4.12 | Verbal and nonverbal memory in school-aged children born to opioid-dependent mothers. ( Konijnenberg, C; Melinder, A, 2022) |
| "To determine the prevalence of continued illicit drug use among people enrolled in methadone maintenance treatment (MMT), the association between hepatitis C status and methadone dosage, and the predictors for illicit drug abstinence during MMT." | 4.12 | Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study. ( Abdul Rashid, Q; Jamaluddin, R; Khalid, K; Mohammad Yusoff, MZA; Ooi, YT, 2022) |
| " In early pregnancy, 10,704 pregnant persons were exposed to buprenorphine and 4387 to methadone." | 4.12 | Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy. ( Bateman, BT; Connery, HS; Davis, JM; Gray, KJ; Hernández-Díaz, S; Huybrechts, KF; Jones, HE; Lester, B; Mogun, H; Straub, L; Suarez, EA; Terplan, M, 2022) |
| "To examine the evidence for emerging treatment options, buprenorphine or clonidine, as monotherapy for the treatment of neonatal abstinence syndrome (NAS) against standards of care, morphine or methadone." | 4.12 | Emerging therapies for the treatment of neonatal abstinence syndrome. ( Bobby, LE; Frazier, LM; Gawronski, KM, 2022) |
| "The aim of the study is to assess the correlation between maternal methadone dose and severity of neonatal abstinence syndrome (NAS) in infants that required pharmacological treatment for NAS." | 4.12 | Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome? ( Adeniyi-Jones, S; Aghai, ZH; Boelig, RC; Carola, D; Greenspan, JS; Kraft, WK; Lafferty, M; Smith, J, 2022) |
| "In our theoretical cohort, treatment of OUD with buprenorphine during pregnancy resulted in 2413 fewer cases of neonatal opioid withdrawal syndrome, 1089 fewer preterm births, 299 fewer cases of fetal growth restriction, 32 fewer stillbirths, and 13 fewer cases of cerebral palsy compared to methadone treatment." | 4.12 | Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder. ( Caughey, AB; Hersh, AR; John, C; Robin, AM, 2022) |
| "Methadone is an evidence-based treatment for opioid use disorder (OUD) and pain management." | 4.12 | Pronounced Regional Disparities in United States Methadone Distribution. ( Furst, JA; McCall, KL; Mynarski, NJ; Piper, BJ, 2022) |
| " Treatment with buprenorphine-naloxone (compared with methadone) reduced odds of each outcome including neonatal abstinence syndrome (adjusted odds ratio: 0." | 4.02 | Opioid Use Disorder and Perinatal Outcomes. ( Homayra, F; Marchand, C; Mead, A; Min, JE; Ng, J; Nosyk, B; Piske, M; Woolner, M; Zhou, H, 2021) |
| " While these agents have clinical utility supported by robust literature, we the authors posit that buprenorphine is a superior therapy for both opioid use disorder (OUD) as well as pain." | 4.02 | A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain. ( Komrowski, MD; Sekhri, NK, 2021) |
| "As CRH-binding protein (CRHBP) SNP rs1500 was associated with reduced cocaine abuse after 1 year in methadone maintenance treatment (MMT) for heroin addiction, we evaluated the association of additional 28 selected SNPs, in 17 stress-related genes, with MMT outcome." | 4.02 | Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder. ( Adelson, M; Kreek, MJ; Levran, O; Ott, J; Peles, E; Randesi, M, 2021) |
| "Over half reported chronic pain, and rates were highest among women and patients receiving methadone." | 4.02 | Chronic Pain Among Patients With an Opioid Use Disorder. ( Latif, ZH; Skjaervø, I; Solli, KK; Tanum, L, 2021) |
| "Medications for opioid use disorder, including methadone, combined with comprehensive wraparound services, are the gold standard for treatment in pregnancy." | 4.02 | Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder. ( Abatemarco, DJ; Barber, C; Baxter, JK; Cruz, Y; Hand, DJ; Roman, AR; Rosenthal, EW; Short, VL, 2021) |
| "Preference for sweet-tasting foods, weight gain, and constipation characterize patients receiving methadone maintenance treatment (MMT)." | 4.02 | The prevalence of constipation and its relation to sweet taste preference among patients receiving methadone maintenance treatment. ( Adelson, M; Peles, E; Sason, A; Schreiber, S, 2021) |
| "The number of pregnant women with OUD admitted and treated with methadone, buprenorphine or withdrawal; policies on provision of MOUD and withdrawal in pregnancy." | 3.96 | Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study. ( Beal, L; Clarke, JG; Latkin, C; Sufrin, C; Sutherland, L; Terplan, M, 2020) |
| "Pregnant smokers recruited to participate in a placebo-controlled trial of bupropion for smoking cessation provided a blood sample for measurement of NMR." | 3.96 | Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study. ( Hand, D; Kranzler, HR; Lynch, KG; Oncken, C; Schnoll, R; Tyndale, RF; Washio, Y; Zindel, LR, 2020) |
| "This study examined the cross-sectional associations among pain intensity, pain catastrophizing, and sleep disturbance among patients receiving methadone maintenance treatment (MMT) for opioid use disorder (OUD) and reporting co-occurring chronic pain." | 3.96 | Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain. ( Barry, DT; Beitel, M; Edwards, KA; Eller, A; Ponce Martinez, C; Roos, CR, 2020) |
| "The aim of this study was to evaluate the prevalence and clinical correlates of impaired sleep quality and excessive daytime sleepiness among patients receiving methadone for opioid use disorder (OUD)." | 3.96 | Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment. ( Baldassarri, SR; Barry, DT; Bastian, LA; Beitel, M; Carrasco, D; Chen, K; Fiellin, DA; Lipkind, N; Madden, LM; Oberleitner, DE; Oberleitner, LMS; Redeker, NS; Yaggi, HK; Zinchuk, A, 2020) |
| " Furthermore, buprenorphine is associated with milder symptoms of neonatal abstinence syndrome (NAS) compared with methadone." | 3.96 | Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine. ( Culhane, J; Meisel, ZF; Nguemeni Tiako, MJ; South, E; Srinivas, SK, 2020) |
| "Methadone is a vital treatment for women with opioid use disorder in pregnancy." | 3.96 | Methadone, Pierre Robin sequence and other congenital anomalies: case-control study. ( Addor, MC; Barisic, I; Cleary, B; de Walle, HEK; Dolk, H; Gatt, M; Klungsoyr, K; Loane, M; Matias Dias, C; McDonnell, B; Neville, A; Pierini, A; Rissmann, A; Tucker, DF; Zurriaga, O, 2020) |
| "The mainstay of the management of opioid use disorder in pregnancy is with methadone or buprenorphine medication-assisted treatment." | 3.96 | Use of naltrexone in treating opioid use disorder in pregnancy. ( Katz, E; Towers, CV; Visconti, K; Weitz, B, 2020) |
| "There is lack of knowledge about the safety of treatment with methadone and buprenorphine as part of opioid maintenance treatment (OMT) during pregnancy." | 3.91 | Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway. ( Engeland, A; Gabrhelík, R; Handal, M; Lund, IO; Mravčík, V; Nechanská, B; Skurtveit, S, 2019) |
| "To estimate whether methadone, buprenorphine, or detoxification treatment is the most cost-effective approach to the management of opioid use disorder (OUD) during pregnancy." | 3.91 | Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis. ( Grobman, WA; Miller, ES; Premkumar, A; Terplan, M, 2019) |
| " Thus, in the current study, we aimed to investigate the effects of metformin on the development of morphine and/or methadone-induced tolerance in human glioblastoma (T98G) cell line." | 3.91 | In vitro evaluation of effects of metformin on morphine and methadone tolerance through mammalian target of rapamycin signaling pathway. ( Dehpour, AR; Esmaeili, J; Sahebgharani, M; Shirooie, S, 2019) |
| " We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl." | 3.91 | Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019) |
| "Using the data linkage between the Methadone Maintenance Treatment (MMT) register with national health insurance, national birth notification system, and birth registration system, we identified 1712 pregnancies with 20 or more gestational weeks from women enrolled in the MMT (heroin-exposed: receiving no methadone treatment during pregnancy, n = 1053 by 882 women; methadone-treated: receiving methadone for at least one day during pregnancy, n = 659 by 574 women) and their 1:10 matched pregnancies from 17,060 women without substance use disorder in the period of 2004-2013." | 3.91 | Inadequate prenatal care utilization among women with and without methadone-treated opioid use disorders in Taiwan. ( Chang, SH; Chen, CY; Fang, SY; Huang, N; Tsay, JH; Wang, IA, 2019) |
| "The current study investigated whether a previously reported beneficial effect of methadone maintenance therapy (MMT) on antiretroviral adherence is also present in relation to antipsychotic treatment for schizophrenia." | 3.91 | Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: A 17-year Canadian Cohort Study. ( Moniruzzaman, A; Rezansoff, SN; Somers, JM, 2019) |
| "To assess safety and effectiveness of transitioning from methadone to buprenorphine when necessary during pregnancy." | 3.88 | Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. ( Johnson, S; Martin, PR, 2018) |
| "Antenatal exposure to methadone or buprenorphine often causes neonatal abstinence syndrome (NAS) in newborns." | 3.88 | Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome. ( Benjamin, DK; Bennett, MM; Clark, RH; Miller, ES; Murthy, K; Smith, PB; Tolia, VN, 2018) |
| "Our objective was to estimate the association between methadone and neonatal abstinence syndrome compared with buprenorphine using a probabilistic bias analysis to account for unmeasured confounding by severity of addiction." | 3.88 | Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome. ( Bodnar, LM; Caritis, SN; Lemon, LS; Platt, RW; Venkataramanan, R, 2018) |
| "Two national cohorts of women receiving opioid maintenance treatment during pregnancy showed small but not statistically significant differences in neonatal outcomes in favour of buprenorphine compared with methadone." | 3.88 | Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. ( Engeland, A; Gabrhelík, R; Handal, M; Lund, IO; Mravčík, V; Nechanská, B; Skurtveit, S, 2018) |
| " When medically indicated, limiting use of multiple psychiatric medications, particularly benzodiazepines and gabapentin, during pregnancy should be considered to improve NAS outcomes." | 3.88 | Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. ( Nikita, FNU; Saia, K; Schiff, DM; Shaw, D; Shrestha, H; Thomas, Z; Thomas-Lewis, JA; Wachman, EM; Warden, AH, 2018) |
| " Factors influencing adherence to buprenorphine during pregnancy have not been identified." | 3.88 | Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. ( Catlin, D; Coker, JL; Knight, B; Ray-Griffith, S; Stowe, ZN, 2018) |
| "Opioid use disorder, chronic pain relief, methadone maintenance treatment, prescriptions, male, female." | 3.88 | Association Between Socio-Demographic and Health Functioning Variables Among Patients with Opioid Use Disorder Introduced by Prescription: A Prospective Cohort Study. ( Bhatt, M; de Souza, R; Luo, C; Samaan, MC; Samaan, Z; Sanger, N; Shahid, H; Shams, I; Tam, SL; Thabane, L, 2018) |
| "Through retrospective chart review, this study described characteristics and length of stay for a cohort of newborns discharged on methadone following an inpatient weaning for neonatal abstinence syndrome (NAS)." | 3.85 | An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome. ( Boucher, J; Lai, A; Meyer, A; Philpot, P, 2017) |
| "The use of implant naltrexone during pregnancy was not associated with higher rates of negative birth outcomes compared with methadone- and buprenorphine-exposed neonates." | 3.85 | A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates. ( Hulse, G; Kelty, E, 2017) |
| "To report the presentation and characteristics of strabismus in children with prenatal methadone exposure." | 3.85 | Sensorimotor outcomes in children with prenatal exposure to methadone. ( Jansson, LM; Park, HJ; Yoo, SH, 2017) |
| "In this cohort, women taking ≥60mg of methadone during pregnancy were more likely to remain in treatment and to provide urine samples negative for illicit drugs." | 3.85 | Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder. ( Hosta, D; Wilder, CM; Winhusen, T, 2017) |
| "Maternal buprenorphine maintenance predisposes the infant to exhibit neonatal abstinence syndrome (NAS), but there is insufficient published information regarding the nature of NAS and factors that contribute to its severity in buprenorphine-exposed infants." | 3.85 | Maternal buprenorphine treatment and infant outcome. ( DiPietro, JA; Gandotra, N; Jansson, LM; Jones, H; King, VL; McConnell, K; Millio, L; Rios, R; Spencer, N; Tuten, M; Velez, ML, 2017) |
| "This study examined gambling behavior in the context of a newly opening casino, comparing disordered gamblers to non-disordered gamblers, in a population of individuals involved in methadone maintenance treatment." | 3.85 | Impact of a Casino Opening on Gambling Behaviors of People Engaged in Methadone Maintenance. ( Himelhoch, S; Medoff, D; Miles-McLean, H; Palmer-Bacon, J; Potts, W; Rugle, L; Welsh, C, 2017) |
| " Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series Drug Alcohol Rev 2017;36:311-316]." | 3.85 | Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. ( Bruno, R; Degenhardt, L; Demirkol, A; Lintzeris, N; Nielsen, S, 2017) |
| "Club drugs and alcohol abuse are prevalent among methadone maintenance treatment (MMT) patients." | 3.85 | Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China. ( Andrew, B; Gu, J; Hao, C; Hao, Y; Jiao, M; Liu, D; Xu, H; Zhang, X; Zhao, Y, 2017) |
| " The standard of care for pregnant women with opioid use disorder is opioid maintenance therapy including either methadone or buprenorphine, which can be initiated at any time during pregnancy." | 3.85 | Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study. ( Caritis, SN; Catov, JM; Lemon, LS; Mokhtari, NB; Parks, WT; Serra, AE; Venkataramanan, R, 2017) |
| "Methadone is effective for the treatment of chronic pain, but its unique pharmacology requires additional considerations with dosing and monitoring." | 3.85 | Methadone Inpatient and Discharge Prescribing Patterns for Pain at an Academic Health System. ( Atayee, RS; Edmonds, KP; Hollenbach, KA; Hur, GH; Karimian, P, 2017) |
| "The aim of this study was to characterize the epidemiology and disease related to hepatitis C in a population attending a low-threshold methadone program." | 3.85 | Hepatitis C in a Mobile Low-Threshold Methadone Program. ( Água-Doce, I; Balsa, C; Belo, E; Coutinho, R; Lopes, P; Loureiro, R; Martins, HC; Pádua, E; Pereira, C; Silva, MJ, 2017) |
| " Addressing these barriers in drug counselor training and in methadone maintenance treatment programs may benefit both methadone-maintained patients with chronic pain and their providers." | 3.85 | Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment. ( Barry, DT; Beitel, M; Ginn, J; Kahn, M; Kerns, RD; Liong, C; Madden, LM; Oberleitner, L, 2017) |
| " The objective of this study was to identify risk factors and determine awareness of risk for opioid overdose in veterans treated with opioids for chronic pain, using veterans treated with methadone or buprenorphine for opioid use disorder as a high-risk comparator group." | 3.83 | Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain. ( Miller, SC; Stein, MD; Tiffany, E; Wilder, CM; Winhusen, T; Winstanley, EL, 2016) |
| "To compare the duration of opioid treatment and length of stay among infants treated for neonatal abstinence syndrome (NAS) by using a pilot buprenorphine vs conventional methadone treatment protocol." | 3.83 | A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. ( Akinbi, HT; Hall, ES; Harvey, S; Isemann, BT; Meinzen-Derr, J; Wexelblatt, SL; Wiles, JR, 2016) |
| "Chronic pain is implicated as a risk factor for illicit opioid use among patients with opioid addiction treated with methadone." | 3.83 | Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment. ( Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Paul, J; Plater, C; Roshanov, PS; Samaan, Z; Thabane, L; Varenbut, M; Worster, A, 2016) |
| "The present study shows that patients affected by opioid-dependence in OST with methadone and buprenorphine have a high prevalence of constipation and reduced QoL." | 3.83 | High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments. ( Addolorato, G; Casari, R; Cossari, A; Faccini, M; Gasbarrini, A; Lugoboni, F; Mirijello, A; Zamboni, L, 2016) |
| "Five unique SNPs in four genes showed nominally significant associations with non-dependent opioid use and heroin dependence." | 3.83 | Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( Blanken, P; Butelman, ER; da Rosa, JC; Kreek, MJ; Levran, O; Ott, J; Randesi, M; van den Brink, W; van Ree, JM; Yuferov, V, 2016) |
| "Despite the clear efficacy of methadone for opioid dependence, one less desirable phenomenon associated with methadone may be weight gain." | 3.81 | Increases in body mass index following initiation of methadone treatment. ( Fenn, JM; Laurent, JS; Sigmon, SC, 2015) |
| "Methadone maintenance treatment patients in Wuhan, China show a high prevalence of hepatitis C virus at admission (72." | 3.81 | Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. ( Chawarski, MC; Desrosiers, A; Liu, M; Liu, P; Luo, L; Peng, J; Schottenfeld, R; Wang, X; Xie, N; Zhou, S; Zhou, W, 2015) |
| "Routinely collected data included: demographic information; drug use, sexual and criminal behaviours; status of infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis; random urine-opiate test results; and the daily methadone dose received." | 3.81 | Who uses methadone services in China? Monitoring the world's largest methadone programme. ( Cao, X; Liu, E; Luo, W; Mi, G; Pang, L; Rou, K; Sullivan, SG; Wang, C; Wu, Z; Yin, W, 2015) |
| "To estimate the prevalence of, and identify factors associated with, depression and anxiety among community-based methadone maintenance treatment (MMT) clients in China." | 3.81 | Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China. ( Cao, X; Li, J; Li, Z; Liu, M; McGoogan, JM; Pang, L; Rou, K; Yin, W; Zhang, C, 2015) |
| "Over 80% of people in methadone treatment smoke cigarettes, and existing smoking cessation interventions have been minimally effective." | 3.81 | Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment. ( Bernstein, SL; Cooperman, NA; Richter, KP; Steinberg, ML; Williams, JM, 2015) |
| "To compare neonatal abstinence syndrome prevalence and characteristics among neonates born to women prescribed buprenorphine and naloxone compared with methadone during pregnancy." | 3.81 | Buprenorphine and naloxone compared with methadone treatment in pregnancy. ( Jones, H; Seashore, C; Stringer, EM; Stuebe, AM; Thorp, J; Wiegand, SL, 2015) |
| "Urine samples from 921 patients prescribed opioids for chronic pain were analyzed for promethazine." | 3.81 | Promethazine use among chronic pain patients. ( Coffa, D; Kral, AH; Lynch, KL; Novak, SP; Shapiro, BJ, 2015) |
| "This article aims to describe neonatal outcomes, clinical correlates, and the rate for neonatal abstinence syndrome (NAS) for women on methadone maintenance therapy." | 3.81 | Maternal methadone treatment and neonatal abstinence syndrome. ( Faisal, M; Li, S; Liu, WF; Singh, K, 2015) |
| "Pregnant women filling at least one prescription for an opioid analgesic at any time during pregnancy for whom opioid exposure characteristics including duration of therapy: short term (<30 days) or long term (≥ 30 days); timing of use: early use (only in the first two trimesters) or late use (extending into the third trimester); and cumulative dose (in morphine equivalent milligrams) were assessed." | 3.81 | Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. ( Bateman, BT; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Kaltenbach, K; Kerzner, LS; Mogun, H; Patorno, E, 2015) |
| "To describe obstetrical and neonatal outcomes including neonatal abstinence syndrome (NAS) in a Canadian cohort of methadone-maintained pregnant women." | 3.81 | Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study. ( Abrahams, R; Graves, L; Kahan, M; Kim, T; Ordean, A, 2015) |
| "To identify and describe infant deaths presenting suddenly and unexpectedly in whom there was a history of maternal methadone consumption or misuse of drugs during pregnancy." | 3.81 | Maternal use of methadone and risk of sudden neonatal death. ( Cohen, MC; Coombs, RC; Morley, SR, 2015) |
| "The primary objective was to determine whether oral morphine sulfate contributed to decreased length of stay, both in the hospital and neonatal intensive care unit (NICU), when compared to oral methadone for the treatment of neonatal abstinence syndrome (NAS)." | 3.81 | Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome. ( Hager, SJ; Spurlock, D; Young, ME, 2015) |
| "The aim of this qualitative study was to examine the narratives of people who experience chronic pain (lasting 6 months or more) and were receiving methadone for the treatment of their opiate addiction through a major methadone clinic." | 3.80 | Coexisting addiction and pain in people receiving methadone for addiction. ( St Marie, B, 2014) |
| "In infants of methadone-prescribed opioid-dependent mothers mean birth weight was 259 g [95% confidence interval (CI) 214-303 g; P<0." | 3.80 | Reduced fetal growth in methadone-maintained pregnancies is not fully explained by smoking or socio-economic deprivation. ( Dryden, C; Mactier, H; Shipton, D; Tappin, DM, 2014) |
| "Patients with opioid use disorder maintained on methadone report more chronic pain than the general population." | 3.80 | Severity and interference of chronic pain in methadone-maintained outpatients. ( Brooner, RK; Clark, MR; Dunn, KE, 2014) |
| "Following our finding of high rates of obsessive compulsive disorder (OCD) among methadone maintained (MMT) former opiate addict women with a history of childhood sexual abuse, we compared 68 MMT sexually abused women to 48 women from a Sexual Abuse Treatment Center (SATC) without a history of opiate addiction, for clinical-OCD (Yale-Brown Obsessive Compulsive Scale), dissociation (Dissociative Experiences Scale (DES), complex-post-traumatic stress disorder (PTSD) (Structured Interview for Disorders of Extreme Stress - Non-Other Specify), sexual PTSD (the Clinician-Administered PTSD Scale) and trauma events history (Life Event Inventory)." | 3.80 | Psychiatric comorbidity differences between women with history of childhood sexual abuse who are methadone-maintained former opiate addicts and non-addicts. ( Adelson, M; Bloch, M; Peles, E; Potik, D; Schreiber, S; Seligman, Z, 2014) |
| " Three hundred ninety women were treated between 1994 and 2009 with buprenorphine (n = 77), methadone (n = 184), or slow-release oral morphine (SROM) (n = 129) on an outpatient basis throughout their pregnancy and postpartum period." | 3.80 | Characteristics and quality of life of opioid-dependent pregnant women in Austria. ( Comer, SD; Fischer, G; Metz, VE; Pribasnig, A; Wuerzl, J, 2014) |
| "To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users." | 3.80 | The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. ( Dias Lima, V; Fairbairn, N; Grebely, J; Kerr, T; Montaner, J; Nolan, S; Wood, E, 2014) |
| "While methadone effectively treats opiate dependence, the side effect of erectile dysfunction (ED) may interfere with treatment adherence and benefits." | 3.79 | Risk factors of erectile dysfunction in patients receiving methadone maintenance therapy. ( Abdul Aziz, S; Baharudin, A; Das, S; Ibrahim, N; Midin, M; Mislan, N; Nik Jaafar, NR; Sidi, H, 2013) |
| "Depression and hepatitis C virus (HCV) infection are two common conditions among heroin users in methadone maintenance treatment (MMT)." | 3.79 | Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. ( Du, J; Mandel, JS; Page, K; Wang, Z; Xiao, Z; Zhao, M, 2013) |
| "In Norway, most opioid-dependent women are in opioid maintenance treatment (OMT) with either methadone or buprenorphine throughout pregnancy." | 3.79 | Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. ( Bakstad, B; Bjarkø, L; Jones, HE; Ravndal, E; Skurtveit, S; Waal, H; Welle-Strand, GK, 2013) |
| "Limited pharmacological data are available to guide methadone treatment during pregnancy and postpartum." | 3.79 | Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. ( Bogen, DL; Friedman, CR; Hanusa, BH; Helsel, JC; Nukui, T; Perel, JM; Romkes, M; Wisner, KL, 2013) |
| "This study aimed to (i) describe methadone dosing before, during and after pregnancy, (ii) to compare the incidence of neonatal abstinence syndrome (NAS) between those with dose decreases and those with steady or increasing doses and (iii) to describe prescribed medication use among opioid-dependent pregnant women." | 3.79 | Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women. ( Carmody, D; Clarke, T; Cleary, BJ; Eogan, M; Fahey, T; Gallagher, PJ; Gleeson, J; McDermott, C; Murphy, DJ; O'Connell, MP; O'Sullivan, A; Reynolds, K; White, MJ, 2013) |
| "The responses pertaining to opioid agreements, urine drug testing, acetaminophen, and treatment for neuropathic pain are reassuring in that they prevent misuse and abuse of opioids, prevent acetaminophen-induced hepatotoxicity, and reflect evidence-based treatments." | 3.79 | Prescription patterns of pain medicine physicians. ( Avram, MJ; Benzon, HA; Benzon, HT; Cox, P; Dean, K; Katz, JA; Kendall, MC; Malik, K, 2013) |
| " Methadone patients will likely experience little harm and a great deal of benefit from treatment with varenicline for smoking cessation." | 3.79 | Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness. ( Arnsten, JH; Bernstein, SL; Nahvi, S; Richter, KP; Wu, B, 2013) |
| " For opiate-addicted pregnant women, methadone is the treatment of choice and should be maintained throughout pregnancy, despite the manageable problem of neonatal opiate withdrawal." | 3.79 | Management of the pregnant substance abusing woman. ( Sheehan, M; Sheehan, MG, 2013) |
| " This study explores the correlates of depression among a sample of methadone maintained treatment (MMT) adults in the Los Angeles area, and is part of a larger study on hepatitis health promotion among MMT clients who use alcohol." | 3.78 | Correlates of depressive symptoms among alcohol-using methadone maintained adults. ( Albarrán, CR; Branson, C; Khalilifard, F; Leake, B; Marfisee, M; Nyamathi, A, 2012) |
| "Pregnant women in methadone maintenance therapy may have poor nutrition during pregnancy." | 3.78 | A pilot study of the nutritional status of opiate-using pregnant women on methadone maintenance therapy. ( Bodnar, LM; Bogen, DL; Hanusa, BH; Tomedi, LE; Wisner, KL, 2012) |
| "The aim was to investigate hepatitis C virus (HCV) knowledge and alcohol consumption among patients (n = 114) in a methadone maintenance treatment (MMT) clinic in Shanghai." | 3.78 | Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China. ( Du, J; Wang, Z; Xie, B; Zhao, M, 2012) |
| " Methadone use in pregnancy has been associated with adverse perinatal outcomes and neonatal abstinence syndrome (NAS)." | 3.78 | Methadone and perinatal outcomes: a prospective cohort study. ( Carmody, D; Clarke, T; Cleary, BJ; Eogan, M; Fahey, T; Gallagher, PJ; Gleeson, J; McDermott, C; Murphy, DJ; O'Connell, MP; O'Sullivan, A; White, MJ, 2012) |
| "One hundred fifty-two opioid-dependent pregnant women on methadone maintenance therapy (MMT) (n = 136) or buprenorphine maintenance therapy (BMT) (n = 16) during pregnancy and their neonates." | 3.78 | Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. ( Hayes, MJ; Paul, JA; Pritham, UA, 2012) |
| " The group on methadone had a strong depression in all three measurements." | 3.78 | [Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification]. ( Jovanović, T; Lazarević, D; Nikolić, G, 2012) |
| "The success of rehabilitation is not influenced solely by drug abstinence, but also by the state of general health and well-being, which for patients in methadone maintenance treatment (MMT) frequently is compromised by experiencing pain, depression and sleep disorders." | 3.78 | Pain depression and sleep disorders among methadone maintenance treatment patients. ( Lawental, E; Pud, D; Zlotnick, C, 2012) |
| "Methadone, used both to treat opioid addiction and to manage chronic pain, is commonly prescribed as an opioid of choice for patients with chronic pain and comorbid substance use disorders." | 3.78 | Methadone in the chronic pain patient with a substance use disorder. ( Friedman, CK; Reisfield, GM, 2012) |
| "To identify maternal and neonatal factors that impact response to methadone therapy for neonatal abstinence syndrome." | 3.77 | Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome. ( Akinbi, H; Isemann, B; Meinzen-Derr, J, 2011) |
| "Differences in lifetime trauma exposure and screened symptoms of posttraumatic stress disorder (PTSD) were examined in methadone maintenance treatment (MMT) patients with a variety of pain experiences." | 3.77 | Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients. ( Barry, DT; Beitel, M; Cutter, CJ; Garnet, B; Joshi, D; Rosenblum, A; Schottenfeld, RS, 2011) |
| "Illicit drugs such as cocaine, and methadone can induce acquired long QT syndrome." | 3.77 | Cardiovascular-associated disease in an addicted population: an observation study. ( Bignamini, E; Cappa, C; Compostino, R; De Vivo, E; Demarie, D; Ferro, S; Imazio, M; Marletta, G; Trinchero, R, 2011) |
| "Determine whether infants exposed to chronic maternal methadone with abnormal intrapartum fetal heart rate (FHR) patterns are more likely to require treatment for neonatal abstinence syndrome (NAS)." | 3.77 | Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates. ( Albright, B; Brown, SA; Hsi, A; Leeman, LM; Rayburn, WF; Skipper, B, 2011) |
| "The purpose of this study was to examine the relationship among methadone maintenance treatment, perinatal outcomes, and neonatal abstinence syndrome." | 3.77 | Methadone and perinatal outcomes: a retrospective cohort study. ( Cleary, BJ; Donnelly, JM; Fahey, T; Gallagher, PJ; Murphy, DJ; Strawbridge, JD; White, MJ, 2011) |
| "05), birth weight, and neonatal morbidities were similar regardless of the maternal methadone dose." | 3.77 | Higher maternal doses of methadone does not increase neonatal abstinence syndrome. ( Bombrys, A; Grier, M; Habli, M; Livingston, J; Pizarro, D; Sibai, B, 2011) |
| "We have demonstrated previously that former opiate-dependent subjects treated and detoxified from methadone maintenance therapy suffer deficits in neuropsychological performance and have abnormal pain thresholds." | 3.77 | The effect of pain on stroop performance in patients with opiate dependence in sustained remission. ( Aniskin, DB; Boda, N; Cohen, LJ; Fink, E; Galynker, II; Prosser, J; Steinfeld, M, 2011) |
| "To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group." | 3.77 | Low risk for hepatitis C seroconversion in methadone maintenance treatment. ( Adelson, M; Peles, E; Rados, V; Schreiber, S, 2011) |
| "Twenty-eight term infants that were exposed to methadone in utero and exhibited symptoms of neonatal abstinence syndrome (NAS) prior to hospital discharge were included into the study." | 3.77 | The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. ( Gerlach, K; McQueen, KA; Montelpare, W; Murphy-Oikonen, J, 2011) |
| " Growth restriction was independent of the last maternal methadone dose and the cumulative methadone dose during pregnancy." | 3.76 | Growth restriction in pregnancies of opioid-dependent mothers. ( Cook, CM; Jones, MP; Liu, AJ; Nanan, R; Sithamparanathan, S, 2010) |
| "To estimate the relationship between maternal methadone dose and the incidence of neonatal abstinence syndrome (NAS)." | 3.76 | Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Hayes, EJ; Seligman, NS, 2010) |
| "Comorbid medical illness is common in patients with chronic hepatitis C (HCV) infection and in methadone treatment (MMT) patients, yet little is known about the impact of medical illness on HCV treatment eligibility." | 3.76 | Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study. ( Batki, SL; Canfield, KM; Levine, RA; Ploutz-Snyder, R; Smyth, E, 2010) |
| "Methadone is standard pharmacotherapy for opioid-dependent pregnant women, yet the relationship between maternal methadone dose and neonatal abstinence syndrome (NAS) severity is still unclear." | 3.76 | Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. ( Choo, RE; Concheiro, M; Elko, A; Gray, TR; Huestis, MA; Jansson, LM; Jones, HE; Williams, E, 2010) |
| " This study aims to determine the infant mortality rate of infants born to women on a methadone program during pregnancy and to identify any modifiable risk factors." | 3.76 | Infant mortality among women on a methadone program during pregnancy. ( Burns, L; Conroy, E; Mattick, RP, 2010) |
| "Tobacco use and depression are highly prevalent among methadone maintenance (MM) treatment programme participants." | 3.76 | Nicotine dependence and depression among women smokers on methadone maintenance. ( Arnold, S; Gandhi, D; Joshi, A; Khanna, N; Sadaphal, S; Stewart, D, 2010) |
| " In this study, we examined the link between resting rCBF in the PFC and current depressive symptoms in methadone-maintained opiate-dependent (MM) patients with or without major depression." | 3.75 | Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. ( Busch, SI; Childress, AR; Ehrman, RN; Hakun, JG; Langleben, DD; Li, Y; O'Brien, CP; Suh, JJ; Wang, Z, 2009) |
| " These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C." | 3.75 | Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. ( Arnsten, JH; Gourevitch, MN; Harris, KA; Kaswan, D; Litwin, AH; Nahvi, S; Soloway, IJ; Tenore, PL; Zamor, PJ, 2009) |
| "This observational study aimed to determine whether pain sensitivity in patients with noncancer chronic pain, taking either methadone or morphine, is similar to patients maintained on methadone for dependence therapy, compared with a control group." | 3.75 | Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. ( Bochner, F; Hay, JL; Rounsefell, B; Semple, TJ; Somogyi, AA; White, JM, 2009) |
| " We sought first to explore providers' perceptions of ambiguity, and then to examine their strategies for making diagnostic and treatment decisions to manage chronic pain among patients on methadone maintenance therapy." | 3.75 | Providers' experiences treating chronic pain among opioid-dependent drug users. ( Arnsten, JH; Berg, KM; Karasz, A; Sacajiu, G, 2009) |
| " This study investigated whether maternal methadone/buprenorphine dose and nicotine use in pregnancy affects the occurrence and duration of neonatal abstinence syndrome (NAS) in the infant." | 3.75 | Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. ( Bakstad, B; Ravndal, E; Sarfi, M; Welle-Strand, GK, 2009) |
| "Following the findings of perceived poor sleep and of chronic pain among former heroin addicts, current methadone maintenance treatment (MMT) patients, and its possible relation to methadone dose, we studied these patients' objective sleep parameters." | 3.75 | Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. ( Adelson, M; Peles, E; Schreiber, S, 2009) |
| "Empirical evidence is needed to guide adequate postpartum pain relief of methadone and buprenorphine stabilized patients." | 3.75 | Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. ( Dahne, J; Johnson, R; Jones, HE; Lemoine, L; Milio, L; O'Grady, K; Ordean, A; Selby, P, 2009) |
| "Differences in psychiatric distress and substance use (licit and illicit) were examined in methadone maintenance treatment (MMT) patients with a variety of pain experiences." | 3.75 | Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. ( Barry, DT; Beitel, M; Garnet, B; Joshi, D; Rosenblum, A; Schottenfeld, RS, 2009) |
| "Prior studies noted elevated preterm birth (PTB) rates among opiate-addicted women treated with methadone." | 3.75 | Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. ( Almario, CV; Baxter, JK; Berghella, V; Dysart, KC; Seligman, NS, 2009) |
| "To describe the patterns of screening for hepatitis C virus (HCV) infection in methadone-maintained pregnant women and their infants." | 3.75 | Screening for hepatitis C virus infection in methadone-maintained mothers and their infants. ( An, EI; Leroi, MJ; Liu, AJ; Murray, HG; Nanan, RK; Tetstall, E, 2009) |
| "Methadone-maintained pregnant patients with mood disorders have compromised treatment outcomes ( [1] )." | 3.75 | The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. ( Chisolm, MS; Fitzsimons, H; Heil, SH; Jones, HE; O'Grady, KE; Tuten, M, 2009) |
| "Majority of neonates born to mothers on methadone exhibit neonatal abstinence syndrome and require pharmacological treatment." | 3.74 | Neonatal abstinence syndrome. ( Kurian, O; Serane, VT, 2008) |
| "To examine the association between retention in methadone treatment during pregnancy and key neonatal outcomes." | 3.74 | Methadone in pregnancy: treatment retention and neonatal outcomes. ( Burns, L; Lim, K; Mattick, RP; Wallace, C, 2007) |
| "Fifteen opiate-abstinent and 12 methadone-maintained, opiate-dependent subjects, who lacked other Axis I pathology, and 13 control subjects were compared on the Cornell Dysthymia Rating Scale (CDRS) and regional cerebral glucose metabolism (rCMRglc) using [(18)F]fluorodeoxyglucose positron emission tomography." | 3.74 | Cerebral metabolism and mood in remitted opiate dependence. ( Cohen, L; Contoreggi, C; Eisenberg, D; Ernst, M; Galynker, II; Gertmenian-King, E; Kimes, AS; Kurian, V; London, ED; Matochik, JA; Prosser, J; Rosenthal, RN, 2007) |
| "The objective of this study was to determine the population prevalence and correlates of neonatal abstinence syndrome among neonates born to women on methadone, using a cross-sectional analysis of linked population health data." | 3.74 | Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. ( Burns, L; Mattick, RP, 2007) |
| "We selected 32 women in the city of Vancouver known to have used heroin or methadone during pregnancy between October 2001 and December 2002." | 3.74 | Rooming-in compared with standard care for newborns of mothers using methadone or heroin. ( Abrahams, RR; Janssen, PA; Kelly, SA; Mackintosh, J; Payne, S; Thiessen, PN, 2007) |
| "To assess potential risks related to the duration or total amount of fetal methadone exposure during gestation, we compared babies of women who conceived and maintained on methadone throughout pregnancy with babies of women who began methadone treatment during the second or third trimester." | 3.74 | Outcomes of neonates conceived on methadone maintenance therapy. ( Biles, LA; Leamon, MH; McCarthy, JJ; Stenson, G, 2008) |
| "To assess the ability of methadone maintenance treatment (MMT) patients to use two standardized health assessment tools to value health states related to chronic hepatitis C virus (HCV) infection and HCV treatment-associated side effects." | 3.74 | Can urban methadone patients complete health utility assessments? ( Schackman, BR; Teixeira, PA, 2008) |
| "Data from this non-randomized comparison suggest that buprenorphine may offer advantages for treatment of opiate dependence during pregnancy." | 3.74 | Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. ( Heilig, M; Kakko, J; Sarman, I, 2008) |
| "Although methadone maintenance is the standard treatment of opiate addiction in pregnancy, opinion as to its utility is divided." | 3.73 | Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. ( Arlettaz, R; Hebisch, G; Kashiwagi, M; Lauper, U; Zimmermann, R, 2005) |
| "The aim of the study was to analyze the neonatal impact of a methadone maintenance program in pregnancy, and the social resources of the families involved." | 3.73 | Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. ( Arlettaz, R; Bucher, HU; Das-Kundu, S; Fauchère, JC; Kashiwagi, M; Lang, A, 2005) |
| "Iatrogenic opioid addiction among chronic pain patients was the initiative for starting a methadone programme for pain patients at the University Hospital of Uppsala." | 3.73 | Methadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-up. ( Gordh, T; Grönbladh, L; Nilsson, LH; Rhodin, A, 2006) |
| "This study assesses the effect of higher doses of methadone during pregnancy on maternal and fetal outcomes." | 3.73 | High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. ( Anania, B; Leamon, MH; McCarthy, JJ; Parr, MS, 2005) |
| " Women who took heroin in later pregnancy were significantly more likely than women who were stabilised on methadone to have a baby who needed morphine (40% versus 19%), had higher mean maximum neonatal abstinence scores (NAS) (5." | 3.73 | Pregnancy outcome in women who use opiates. ( Armstrong, D; Fajemirokun-Odudeyi, O; Lindow, SW; Pairaudeau, P; Phillips, T; Sinha, C; Tutty, S, 2006) |
| "Both clinicians and researchers have expressed doubt that opiate dependent patients with significant pain can be effectively treated in methadone maintenance treatment (MMT) programs; however, little research exists on this topic." | 3.73 | Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. ( Humphreys, K; Ilgen, MA; Trafton, JA, 2006) |
| " In the present paper, we compared the decision-making ability using the Iowa gambling task of methadone- and buprenorphine-maintained individuals to non opiate-dependent drug-free controls." | 3.73 | Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. ( Bini, V; Diana, M; Fais, R; Falconieri, D; Messina, M; Pirastu, R; Spiga, S, 2006) |
| "This study compared methadone maintenance patients with and without pathological gambling (n = 167)." | 3.73 | Health correlates of pathological gambling in a methadone maintenance clinic. ( Blanco, C; Petry, NM; Weinstock, J, 2006) |
| "The safety, efficacy, and tolerability of nelfinavir (NFV)-containing antiretroviral therapy were evaluated in patients coinfected with HIV and hepatitis C undergoing methadone maintenance at an urban outpatient opioid treatment program serving a minority adult population." | 3.73 | Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. ( Brown, LS; Chu, M; Kritz, S; Madray, C, 2006) |
| "To investigate the relationship between the daily dose of the synthetic opioid methadone and the corrected QT (QTc) interval in a series of methadone-treated patients who developed torsade de pointes." | 3.72 | Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. ( Krantz, MJ; Kutinsky, IB; Mehler, PS; Robertson, AD, 2003) |
| "The objectives of this medico-legal case report were the following: 1) To present an example of a medico-legal problem that developed as a result of a decision to rotate a chronic pain patient (CPP) to methadone in order to taper the CPP from oxycodone; 2) To present both the plaintiff's and defendant's expert witnesses' opinions as to if and where the care of that patient fell below the "standard of medical care;" and 3) Based on these opinions, to develop some recommendations on how, in the future, pain medicine physicians and other physicians should proceed, in order to avoid allegations of breach of "standards of care" when using methadone." | 3.72 | Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. ( Cole, B; Cutler, RB; Fishbain, DA; Lewis, J; Rosomoff, HL; Rosomoff, RS, 2003) |
| "Approximately 85% of patients receiving methadone maintenance therapy (MMT) for opiate dependence in the United States are infected with hepatitis C virus (HCV)." | 3.72 | A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. ( Atanda, A; Barnett, R; DePiano, M; Lynch, KG; Olthoff, KM; Weinrieb, RM, 2004) |
| " In the 30 days before the survey, respondents reported that their clinics provided the following services to at least one patient: 73 percent provided brief advice to quit, 18 percent offered individual or group smoking cessation counseling, and 12 percent prescribed nicotine replacement therapy." | 3.72 | Smoking cessation services in U.S. methadone maintenance facilities. ( Ahluwalia, JS; Choi, WS; Harris, KJ; McCool, RM; Richter, KP, 2004) |
| "We describe an opioid-tolerant patient with severe acute pain which was unrelieved by morphine and ketamine via intravenous patient-controlled analgesia, but almost totally relieved by methadone." | 3.71 | Successful use of oral methadone after failure of intravenous morphine and ketamine. ( Mitchell, SJ; Sartain, JB, 2002) |
| "The usefulness of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) activity in urine as markers of chronic alcohol abuse was examined in male methadone programme participants." | 3.71 | The activity of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) in urine as non-invasive markers of chronic alcohol abuse: II. Opiate-dependent subjects receiving methadone substitution. ( Baran, H; Chmielewska, K; Habrat, B; Szukalski, B; Taracha, E; Walkowiak, J, 2002) |
| "This study measured the extent and examined implications of hepatitis C (HCV) infection in a methadone maintenance treatment (MMT) population." | 3.71 | Hepatitis C in methadone maintenance patients: prevalence and public policy implications. ( Flynn, N; McCarthy, JJ, 2001) |
| "The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection." | 3.71 | Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001) |
| "In a patient on methadone maintenance treatment, admitted for lung cancer suspicion, a slight decrease in pain dose response to morphine have necessitated adjustments of methadone treatment founded on clinical check-up and methadone assay." | 3.71 | Slow metabolism and long half life of methadone in a patient with lung cancer and cirrhosis. ( Beauverie, P; Edel, YA; Furlan, V, 2001) |
| "The purpose of this study is to evaluate women receiving methadone maintenance during pregnancy." | 3.70 | Methadone maintenance in pregnancy: a reappraisal. ( Britton, KA; Brizendine, E; Brown, HL; Hiett, AK; Mahaffey, D; Turnquest, MA, 1998) |
| " She developed post-dural puncture headache (PDPH) on the third postpartum day which was managed by palliative measures: bed rest (patient's position of choice), increased hydration (water: 3 litres po per day), lysine acetyl salicylate (5." | 3.70 | Unilateral trigeminal and facial nerve palsies associated with epidural analgesia in labour. ( Agustí, M; Carrero, EJ; Fábregas, N; Fernández, C; Valldeoriola, F, 1998) |
| "The volume of feeds, changes in infant body weight, as well as occurrence of adverse clinical effects in infants withdrawing from methadone were studied during the first month of life." | 3.70 | Hyperphagia in neonates withdrawing from methadone. ( Kastner, B; Martinez, A; Taeusch, HW, 1999) |
| "To evaluate an approach to enhancing compliance with tuberculosis chemoprophylaxis in drug users enrolled on methadone maintenance utilizing an isoniazid (INH)-methadone admixture." | 3.70 | Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. ( Durante, AJ; Friedman, L; Henry, S; O'Connor, PG; Selwyn, PA; Shi, JM, 1999) |
| " Compared to patients with pre-existing heroin, codeine, or morphine abuse respectively, patients from the methadone maintenance programme had significantly higher (P<0." | 3.70 | Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. ( Hensel, M; Kox, WJ, 2000) |
| "Drug-related fatal poisonings were analysed in Hamburg from 1990 to 30th June 1999 with special attention to the role of methadone." | 3.70 | Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment? ( Heinemann, A; Iwersen-Bergmann, S; Püschel, K; Schmoldt, A; Stein, S, 2000) |
| " Because a history of depression has been shown in other populations to complicate cessation efforts, the relationship between depression and nicotine dependence was tested in 726 methadone patients." | 3.69 | Nicotine dependence and depression among methadone maintenance patients. ( Brown, LS; Lin, MM; Meyer, TJ, 1996) |
| "This study examines the predictors of alcoholism among 201 patients from three methadone maintenance treatment programs (MMTPs) in New York City." | 3.68 | Correlates of alcohol use among methadone patients. ( el-Bassel, N; Schilling, RF; Su, KH; Turnbull, JE, 1993) |
| "Alcoholism is a prevalent problem encountered during the methadone treatment of opioid dependence." | 3.68 | The relationship of mean daily blood alcohol levels to admission MAST, clinic absenteeism and depression in alcoholic methadone patients. ( Amass, L; Bickel, WK, 1993) |
| "The incidence of panic attacks methadone-maintained patients has increased over a 10-year period from 1 to 6-13%." | 3.68 | Cocaine-associated panic attacks in methadone-maintained patients. ( Kosten, T; Rosen, MI, 1992) |
| "Self-reported depressive symptoms of opiate addicts were assessed at admission to a methadone treatment program and weekly during the first 4 treatment weeks using the Beck Depression Inventory." | 3.68 | Early treatment time course of depressive symptoms in opiate addicts. ( Bigelow, GE; Stitzer, ML; Strain, EC, 1991) |
| " A new program is described that provides methadone maintenance treatment to opiate addicts who are "AIDS affected"--heroin addicts diagnosed with AIDS, AIDS-related complex (ARC), or other significant symptoms of HIV infection." | 3.67 | Methadone maintenance program for AIDS-affected opiate addicts. ( Batki, SL; Good, P; Sorensen, JL; Wilkinson, K, 1989) |
| "The authors describe their experience with methadone treatment in pregnancy." | 3.67 | Methadone in pregnancy: clinical-toxicological aspects. ( Chiarotti, M; De Giovanni, N; Falasconi, AM; Offidani, C, 1986) |
| "This study compares the first year's health, neurodevelopmental status, and environment of infants of drug-dependent mothers attending methadone programs during pregnancy with those of drug-dependent mothers not enrolled in treatment programs (untreated)." | 3.66 | Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. ( Desmond, MM; Wait, RB; Wilson, GS, 1981) |
| "There was no difference in prevalence of current alcoholism between new admissions to a methadone-maintenance treatment program (MMTP) and patients already in MMTP at least one year, by previous treatment for drug misuse, or between MMTP patients and the population of the surrounding community." | 3.66 | Alcoholism among narcotic addicts and patients on methadone maintenance. ( Cohen, M; Hanbury, R; Jackson, G; Korts, D; Stimmel, B; Sturiano, V, 1983) |
| "To investigate the relationship between methadone and alcohol abuse, 60 male veteran narcotic addicts entering a methadone maintenance program were divided into either a problem drinker group (N = 21) or a normal drinker group (N = 39) based on their drinking histories and Breathalyzer tests at admission." | 3.66 | Risk for alcoholism and methadone treatment. A longitudinal study. ( Marcovici, M; McLellan, AT; O'Brien, CP; Rosenzweig, J, 1980) |
| "Participants were assigned to either OT (102) or methadone (102) using a patient-centred flexible dosing strategy." | 3.30 | Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial. ( Akhondzadeh, S; Choi, F; Gholami, A; Givaki, R; Jang, K; Javidanbardan, S; Jazani, M; Kazemi, A; Kianpoor, K; Krausz, M; Moazen-Zadeh, E; Moghaddam, NM; Mohammadian, F; Nikoo, M; Nikoo, N; Schütz, C; Tavakoli, S; Vogel, M; Wong, JSH, 2023) |
| "This study aimed to evaluate the effectiveness of flexible take-home dosing of buprenorphine/naloxone (BUP/NX) and methadone standard model of care in reducing depressive symptoms in people with prescription-type opioid use disorder (POUD)." | 3.30 | Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial. ( Bastien, G; Brissette, S; Hassan, AN; Jutras-Aswad, D; Le Foll, B; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Socias, ME; Talbot, A, 2023) |
| " In this exploratory analysis, we examined the effect of recent cannabis use on opioid use, craving, and withdrawal symptoms, in individuals participating in a trial comparing flexible buprenorphine/naloxone (BUP/NX) take-home dosing model to witnessed ingestion of methadone." | 3.30 | Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study. ( Bakouni, H; Bastien, G; Brissette, S; Elkrief, L; Hébert, FO; Jutras-Aswad, D; Le Foll, B; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Socias, ME, 2023) |
| " Using an attentional bias (AB) task with both pain and opioid cues, we evaluated a cognitive bias modification (CBM) task administered during regularly scheduled medications for OUD (mOUD) dosing visits." | 3.30 | Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. ( Heapy, AA; MacLean, RR; Meyerovich, J; Sofuoglu, M; Szollosy, SK; Waters, AJ; Wolkowicz, N, 2023) |
| "Methadone treatment is the most effective evidence-based treatment for opioid use disorder (OUD), but challenges related to dosing and premature treatment dropout argue for adjunct interventions to improve outcomes." | 3.30 | Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial. ( Belcher, AM; Billing, AS; Cole, TO; Colloca, L; Epstein, DH; Greenblatt, AD; Hoag, SW; Kaptchuk, TJ; Magder, L; Massey, E; Rotrosen, J; Wagner, M; Weintraub, E; Wickwire, EM; Wish, ED; Wooten, W, 2023) |
| "Regulatory changes made during the COVID-19 public health emergency (PHE) that relaxed criteria for take-home dosing (THD) of methadone offer an opportunity to improve quality of care with a lifesaving treatment." | 3.30 | Clinics Optimizing MEthadone Take-homes for opioid use disorder (COMET): Protocol for a stepped-wedge randomized trial to facilitate clinic level changes. ( Bao, Y; Choi, S; Cleland, CM; D'Aunno, T; Hong, S; Knopf, E; Neighbors, CJ; O'Grady, MA; Ramsey, KS, 2023) |
| "Methadone dose was associated with higher retention in treatment (odds ratio [OR]: 1." | 3.30 | Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study. ( Ahamad, K; Bakouni, H; Foll, BL; Jutras-Aswad, D; Lim, R; McAnulty, C; Socias, ME; Tatar, O, 2023) |
| "Opioid abuse is one of the most obvious problems in today's world and directly affects individuals' quality of life." | 3.30 | Effects of Roy's Adaptation Model on Quality of Life in People with Opioid Abuse under Methadone Maintenance Treatment: A Randomized Trial. ( Hosseini, SA; Musarezaie, A; Rezazadeh, M, 2023) |
| " All MOUD doses were directly observed and abstracted from dosing logs." | 3.11 | Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam. ( Bart, G; Blazes, CK; Button, D; Cook, R; Giang, LM; Khuyen, TT; King, C; Korthuis, PT; Kunkel, L; Nguyen, DB; Thuy, DT, 2022) |
| "Participants with opioid use disorder (n = 204) were randomised to receive opium tincture or methadone." | 3.11 | Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran. ( Akhondzadeh, S; Gholami, A; Jang, K; Kazemi, A; Kianpoor, K; Krausz, M; Nikoo, M; Schuetz, C; Song, MJ; Westenberg, JN, 2022) |
| "Pain, drug cravings, and opioid withdrawal symptoms can interfere with substance use disorder or opioid tapering treatment goals." | 3.11 | Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal, and Related Symptoms: A Pilot Randomized Controlled Trial. ( Bindler, RJ; Layton, ME; Quock, RM; Stanek, K; Wilson, M, 2022) |
| "Flexible take-home dosing buprenorphine/naloxone or supervised methadone models of care for 24 weeks." | 3.11 | Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. ( Bozinoff, N; Bruneau, J; Choi, JC; Hassan, A; Jutras-Aswad, D; Le Foll, B; Lim, R; Mok, WY; Rehm, J; Socias, ME; Wild, TC; Wood, E, 2022) |
| "People with opioid use disorder experience high burden of disease from medical comorbidities and are increasingly hospitalized with medical complications." | 3.11 | The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use ( Chan Osilla, K; Danovitch, I; Friedmann, PD; Huerta, S; Leamon, I; Mazer, MW; Messineo, G; Murray-Krezan, C; Nuckols, T; Ober, AJ; Page, K; Ryzewicz, S; Watkins, KE, 2022) |
| "We analyzed data from a multicentric, pragmatic, 24-week open-label randomized controlled trial conducted in participants with POUD (N = 272) who were randomly assigned to BUP/NX model of care with flexible take-home dosing (n = 138) or the standard model of care with closely supervised methadone (n = 134)." | 3.11 | Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial. ( Bastien, G; Brissette, S; Bruneau, J; Eugenia Socias, M; Foll, BL; Jutras-Aswad, D; Ledjiar, O; Lim, R; Marsan, S; McAnulty, C; Talbot, A, 2022) |
| " Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen." | 3.11 | Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. ( Dahan, A; Ellerbroek, H; Kramers, C; Schellekens, AFA; Timmerman, H; van den Heuvel, SAS, 2022) |
| "People with opioid use disorder are less likely than others to have a primary care physician." | 3.11 | Examining Access to Primary Care for People With Opioid Use Disorder in Ontario, Canada: A Randomized Clinical Trial. ( Hum, S; Kiran, T; Meaney, C; Mogic, L; Moineddin, R; Spithoff, S, 2022) |
| "Study outcomes will determine what dose of baclofen is safe to prescribe to those receiving methadone, to inform a subsequent proof-of-concept trial of the efficacy baclofen to facilitate opiate detoxification." | 3.11 | FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study. ( Barker, D; Cro, S; Lingford-Hughes, AR; Mozgunov, P; Nahar, L; Paterson, LM; Paterson, S; Phillips, R; Smith, C, 2022) |
| " The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET)." | 3.11 | Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation. ( Cowden, F; Day, E; Gilvarry, E; Johnstone, S; Kelleher, M; Lowry, N; Marsden, J; Mitcheson, L; Murray, R, 2022) |
| "We will enroll 100 participants with opioid use disorders receiving methadone maintenance treatment at an addiction treatment center and randomly allocate them to an experimental or control group." | 3.11 | Effect of light needle in the treatment of opioid use disorder: A protocol for a randomized controlled trial. ( Hu, WL; Hung, YC; Kuo, CE; Lu, TC; Tsai, MC; Tsai, YH; Wu, SY, 2022) |
| "Among adults with comorbid opioid use disorder and mental disorders, treatment with buprenorphine-naloxone produced greater reductions in opioid use than treatment with methadone." | 3.11 | Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. ( Evans, EA; Fei, Z; Hser, YI; Kelleghan, A; Matthews, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y, 2022) |
| "Individuals treated for opioid use disorder (OUD) have high rates of psychiatric disorders potentially diminishing treatment outcomes." | 3.01 | Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. ( Curtis, ME; Evans, EA; Hser, YI; Kelleghan, A; Mooney, LJ; Saxon, AJ; Yoo, C; Zhu, Y, 2021) |
| "The coexistence of opioid use disorder (OUD) in patients with chronic pain represents a complex challenge due to the need for managing both pain and OUD." | 3.01 | Systematic review on the clinical management of chronic pain and comorbid opioid use disorder. ( Calomarde-Gómez, C; Gual, A; Jiménez-Fernández, B; Lligoña, A; López-Lazcano, A; López-Pelayo, H, 2023) |
| "Buprenorphine is an effective MOUD that may suppress craving; however, treatment discontinuation and resumed opioid use is common during the early phases of treatment." | 3.01 | Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. ( Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K, 2023) |
| "The intensity of postoperative pain can range from mild to severe." | 3.01 | Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review. ( Cornett, EM; Edinoff, AN; Flanagan, CJ; Jackson, ED; Kaye, AD; Kaye, AM; Pearl, NZ; Sinnathamby, ES; Wenger, DM, 2023) |
| " Primary outcomes were retention in treatment at 1, 3, 6, 12, and 24 months, treatment adherence (measured through doses taken as prescribed, dosing visits attended, and biological measures), or extra-medical opioid use (measured by urinalysis and self-report)." | 3.01 | Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. ( Clark, B; Degenhardt, L; Farrell, M; Hickman, M; Kimber, J; Larance, B; Leppan, O; Macpherson, G; Martino-Burke, D; Nielsen, S; Zahra, E, 2023) |
| "Pharmacotherapeutic options for the treatment of opioid withdrawal are limited by abuse potential, adverse effects, and lack of availability of existing drugs." | 3.01 | Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials. ( Maiti, R; Mishra, BR; Mohapatra, D; Padhan, M, 2023) |
| " Less than 1% of pillbox alerts were for medication being consumed outside the dosing window and we observed no evidence of actual or attempted methadone diversion." | 3.01 | Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. ( Brooner, RK; Dunn, KE; Stoller, KB, 2021) |
| "Strategies for treating opioid use disorder can be divided into those that target the opioid receptor system and those that target non-opioid receptor systems, including the dopamine and glutamate receptor systems." | 3.01 | Insights into the mechanisms underlying opioid use disorder and potential treatment strategies. ( Cao, DN; Li, F; Li, J; Wu, N, 2023) |
| "Acute pain management in patients with opioid use disorder who are maintained on methadone presents unique challenges due to high levels of opioid tolerance in this population." | 3.01 | Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. ( Agin-Liebes, G; Bigelow, GE; Edwards, RR; Gruber, VA; Huhn, AS; Smith, MT; Strain, EC; Tompkins, DA, 2021) |
| "Opioid use disorder is common among detainees in US jails, yet methadone treatment is rarely initiated." | 2.94 | Methadone treatment of arrestees: A randomized clinical trial. ( Jaffe, JH; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A, 2020) |
| "Although the treatment of opioid use disorder (OUD) is a key element in the response to the opioid overdose epidemic, currently available pharmacotherapies (e." | 2.94 | Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. ( Bach, P; Brar, R; Dong, H; Fairbairn, N; Murphy, SM; Socias, ME; Wood, E, 2020) |
| " Blood samples were collected for pharmacokinetic analysis, and rectal temperature and sedation were assessed to evaluate opioid effects at predetermined times up to 24 hours after treatment." | 2.94 | Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ( Joo, H; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC, 2020) |
| "Individuals with opioid use disorder (OUD) who are released from pre-trial detention in jail have a high risk of opioid relapse." | 2.94 | Cost and cost-effectiveness of interim methadone treatment and patient navigation initiated in jail. ( Dunlap, LJ; Kelly, SM; Mitchell, SG; O'Grady, KE; Orme, S; Schwartz, RP; Zarkin, GA, 2020) |
| "Doravirine is a novel nonnucleoside reverse transcriptase inhibitor indicated for the treatment of HIV type 1 infection." | 2.94 | Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone. ( Bouhajib, M; Fan, L; Iwamoto, M; Khalilieh, S; Sanchez, RI; Searle, S; Vaynshteyn, K; Yee, KL, 2020) |
| "Participants with OUD and chronic pain (N = 30) were randomized to 8 weeks of MORE or treatment as usual (TAU)." | 2.90 | Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial. ( Cooperman, NA; Garland, EL; Hanley, AW; Kline, A, 2019) |
| "Fifteen men with opioid use disorder on methadone maintenance treatment have been enrolled from an addiction treatment center as an experimental group in this case-controlled study." | 2.90 | Adjuvant laser meridian massage in men with opioid use disorder on methadone maintenance treatment: Protocol for a case-controlled study. ( Hu, WL; Hung, YC; Kuo, CE; Liu, CT; Tsai, MC; Wu, SY; Wu, TC, 2019) |
| "Methadone maintenance treatment (MMT) is an important approach to address opioid dependence." | 2.90 | Effectiveness of a Psycho-Social Intervention Aimed at Reducing Attrition at Methadone Maintenance Treatment Clinics: A Propensity Score Matching Analysis. ( Fan, X; Gu, J; Hao, C; Hao, Y; Lau, JTF; Li, J; Xu, H; Yang, F; Zhang, X; Zhao, Y, 2019) |
| " They were randomized to receive either OT or methadone with an allocation ratio of 1:1 using a patient-centered flexible dosing strategy." | 2.90 | Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. ( Akhondzadeh, S; Choi, F; Gholami, A; Givaki, R; Goudarzi, N; Jang, K; Javidanbardan, S; Jazani, M; Kazemi, A; Krausz, M; Markazi Moghaddam, N; Moazen-Zadeh, E; Mohammadian, F; Nikoo, M; Nikoo, N; Schutz, C; Tavakoli, S; Vogel, M, 2019) |
| "In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment." | 2.90 | Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. ( Evans, EA; Hser, YI; Huang, D; Yoo, C; Zhu, Y, 2019) |
| "Study 206216 (NCT02666001) was a Phase I, open-label study, assessing the effect of FTR 600 mg (extended-release formulation) twice daily on pharmacokinetics of MET or BUP and norBUP, in non-HIV-infected participants on stable maintenance therapy with MET (40-120 mg; n = 16) or BUP plus naloxone (8-24 mg plus 2-6 mg; n = 16); pharmacodynamic response was assessed using standard opioid rating scales." | 2.90 | Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants. ( Ackerman, P; Chang, M; Llamoso, C; Lubin, S; Magee, M; Moore, K; Myers, E; Sevinsky, H, 2019) |
| "Methadone maintenance treatment is the gold standard of medication-based treatment for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory complications, among other side effects." | 2.90 | Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment. ( Belcher, AM; Billing, AS; Cole, TO; Colloca, L; Epstein, DH; Greenblatt, AD; Hamilton, KR; Hoag, SW; Kaptchuk, TJ; Kozak, ZK; Massey, E; Wagner, M; Weintraub, E; Welsh, CJ; Wickwire, EM; Wish, ED, 2019) |
| "Methadone maintenance treatment (MMT) is an effective way to address opioid use disorder and prevent overdose; however, few jails and prisons in the United States initiate or continue people who are incarcerated on MMT." | 2.87 | A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. ( Brinkley-Rubinstein, L; Dauria, E; Larney, S; Macmadu, A; McKenzie, M; Rich, J; Zaller, N, 2018) |
| "Methadone maintenance treatment (MMT) patients are often under-nourished and overweight." | 2.87 | Knowledge about nutrition, eating habits and weight reduction intervention among methadone maintenance treatment patients. ( Adelson, M; Herzman-Harari, S; Peles, E; Sason, A, 2018) |
| "Methadone maintenance treatment (MMT) programs have expanded rapidly in China during the last decade." | 2.87 | Service providers' adherence to methadone maintenance treatment protocol in China. ( Lan, CW; Li, L; Lin, C; Rou, K, 2018) |
| "Methadone maintenance treatment (MMT) may prevent overdose and death among homeless people with opioid dependence, but suboptimal medication adherence is a common limitation." | 2.87 | The effect of Housing First on adherence to methadone maintenance treatment. ( Moniruzzaman, A; Parpouchi, M; Rezansoff, SN; Russolillo, A; Somers, JM, 2018) |
| " Most studies to date have been conducted among heroin users, in controlled settings, and using similar strict dosing schedules (i." | 2.87 | The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. ( Ahamad, K; Bruneau, J; Fischer, B; Jutras-Aswad, D; Le Foll, B; Lim, R; Socias, ME; Wild, TC; Wood, E, 2018) |
| " SCI participants received standard methadone dosing and adaptive counseling." | 2.87 | Treatment initiation strategies for syringe exchange referrals to methadone maintenance: A randomized clinical trial. ( Brooner, RK; Kidorf, M; Leoutsakos, JM; Peirce, J, 2018) |
| "While the best way to rid society of drug addiction is to prevent it from occurring in the first place, this is highly unlikely in the near future given the many ways that individuals can be first exposed to some potentially addicting substance." | 2.87 | Relapse prevention: Using sound to reduce the probability of recidivism and suffering following detoxification. ( Sewak, R; Spielholz, NI, 2018) |
| "Methadone maintenance treatment (MMT) is used to detoxify users of illicit opiates, but drug relapse is common and associated with poor quality of life (QoL)." | 2.87 | Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population. ( Chen, HJ; Huang, CL; Hung, CC; Lee, HY; Lee, TE; Wang, JY; Wang, RY, 2018) |
| "Methadone maintenance treatment has proven effectiveness in the treatment of opioid use disorder, but significant barriers remain to treatment retention." | 2.87 | Re-engineering methadone-Cost-effectiveness analysis of a patient-centered approach to methadone treatment. ( Dunlap, LJ; Gryczynski, J; Kelly, SM; Meinhofer, A; Mitchell, SG; O'Grady, KE; Orme, S; Schwartz, RP; Zarkin, GA, 2018) |
| "Each client had a severe Opioid Use Disorder (OUD) and clients had spent on average 7." | 2.87 | Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services. ( Elmusharaf, K; Keenan, E; Moran, L, 2018) |
| "During induction/stabilisation, withdrawal symptoms subsided more slowly for buprenorphine/naloxone than for methadone, and craving was significantly higher in the buprenorphine/naloxone group ( p<0." | 2.84 | Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals. ( Coulton, S; Diaper, AM; Law, FD; Melichar, JK; Myles, JS; Nutt, DJ, 2017) |
| " Subjects received methadone (arm 1) or buprenorphine-naloxone (arm 2) once daily (QD) per their existing individual prescriptions alone (days 1 to 9) and then in combination with glecaprevir at 300 mg QD and pibrentasvir at 120 mg QD (days 10 to 16) each morning." | 2.84 | No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir. ( Asatryan, A; Geoffroy, P; Kort, J; Kosloski, MP; Liu, W; Zhao, W, 2017) |
| "Methadone maintenance treatment (MMT) is the gold standard for pregnant women with opioid use disorders." | 2.84 | Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: A national contingency management approach trial. ( Adelson, M; Peles, E; Sason, A; Schreiber, S, 2017) |
| "There is mounting evidence that opioid use disorder is experienced differently by people of different genders and race/ethnicity groups." | 2.82 | Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States. ( Hochheimer, M; Unick, GJ, 2022) |
| "Methadone was responsible for 10." | 2.82 | Public health risks associated with methadone in Iran: A systematic review and meta-analysis. ( Ansari, M; Baheshmat, S; Ekhtiari, H; Ghadirzadeh, MR; Gholami, J; Hamzehzadeh, M; Mojtabai, R; Noroozi, A; Rahimi-Movaghar, A; Rostam-Abadi, Y; Vahdani, B, 2022) |
| "Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and naltrexone, have the potential to reduce opioid use and associated harms; however, there are concerns that AYAs lack access to these potentially life-saving medications." | 2.82 | Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review. ( Bromberg, DJ; Karamouzian, M; Pilarinos, A, 2022) |
| "Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges." | 2.82 | Interim opioid agonist treatment for opioid addiction: a systematic review. ( Puig, T; Samsó Jofra, L; Solà, I; Trujols, J, 2022) |
| "Rates of at-risk opioid use, opioid use disorder, and opioid overdose remain alarmingly high." | 2.82 | An overview of buprenorphine prescribing for the advanced practice psychiatric nurse. ( Fradkin, D; Kameg, B; Lepore, M, 2022) |
| "Opioid use disorder is a significant global issue and the rate of opioid use in women of childbearing age and pregnant women is on the rise." | 2.82 | Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis. ( Baldacchino, A; Conti, AA; Hemmati, Z, 2022) |
| "Methadone was the highest ranked intervention (Surface Under the Cumulative Ranking [SUCRA] = 0." | 2.82 | Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. ( Douros, A; Farhat, I; Lim, J; Panagiotoglou, D, 2022) |
| "Besides simply managing withdrawal symptoms, clinicians can further improve the care of patients with OUD through initiating maintenance treatment with MOUD, ideally with opioids used in the initial management of withdrawal." | 2.82 | Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. ( Angermaier, G; Carswell, N; Castaneda, C; Delgado, F, 2022) |
| "Novel buprenorphine dosing strategies have emerged with an aim to transition patients from opioid agonists to buprenorphine without prerequisite opioid withdrawal." | 2.82 | Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis. ( D M, S; E J, M; K K, A, 2022) |
| " Specific areas of focus elaborated by the authors include: better characterization of opioid selection and dosing in managing labor analgesia, effectiveness of different regional anesthetic techniques, non-pharmacologic management, and psycho-social support for these patients." | 2.82 | Opioid Use Disorder in Pregnant Patients. ( Nathan, N, 2022) |
| "Successful MMT in patients with opioid use disorder in Vietnam may additionally require methamphetamine-focused screening and intervention." | 2.82 | Correlates of methamphetamine use severity among patients receiving methadone maintenance treatment for opioid use disorder in Vietnam. ( Diep, NB; Giang, LM; Li, MJ; Okafor, CN; Shoptaw, SJ, 2022) |
| "Sequalae of opioid misuse constitute a public health emergency in the United States." | 2.82 | Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review. ( Adam, GP; Balk, EM; Becker, SJ; Danko, KJ; Helseth, SA; Saldanha, IJ; Scott, K; Steele, DW, 2022) |
| "Methadone maintenance treatment (MMT) has been used as a treatment for opiate dependence since the mid-1960s." | 2.82 | Quantitative EEG and Low-Resolution Electromagnetic Tomography (LORETA) Imaging of Patients Undergoing Methadone Treatment for Opiate Addiction. ( Kydd, RR; Russell, BR; Wang, GY, 2016) |
| " The most frequent treatment-emergent non-OWS adverse events were headache, nausea, constipation, and neck pain." | 2.82 | Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. ( Cape, G; Devane, J; Friedhoff, L; Glue, P; Gray, A; Harland, S; Howes, J; Hung, CT; Hung, N; Lam, F; Lockhart, M; Tunnicliff, D; Weis, H, 2016) |
| "Methadone maintenance is an effective treatment for opioid dependence but is rarely initiated in US jails." | 2.82 | Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial. ( Dunlap, L; Jaffe, JH; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A; Zarkin, GA, 2016) |
| " Pain and pain interference were assessed with the Brief Pain Inventory, with side effects evaluated according to the Common Terminology Criteria for Adverse Events version 3." | 2.82 | Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. ( Garzón-Rodríguez, C; González-Barboteo, J; Llorens-Torromé, S; Porta-Sales, J; Villavicencio-Chávez, C, 2016) |
| "Other outcomes included SVR24, viral recurrence or reinfection, and adverse events." | 2.82 | Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. ( Altice, F; Barr, E; Chen, E; Conway, B; Dalgard, O; Dore, GJ; Dutko, FJ; Gane, EJ; Gendrano, IN; Grebely, J; Howe, AY; Huang, HC; Litwin, AH; Luetkemeyer, A; Nahass, R; Nguyen, BY; Nickle, DC; Peng, CY; Platt, HL; Robertson, MN; Shibolet, O; Wahl, J, 2016) |
| "Opioid dependence has devastating and increasingly widespread consequences and costs, and the most common outcome of treatment is early relapse." | 2.82 | The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. ( Alagoz, E; Gustafson, DH; Johnson, RA; Kornfield, R; Landucci, G; Mares, ML; McTavish, F; Pe-Romashko, K; Quanbeck, A; Shah, D; Thomas, C; Westergaard, RP, 2016) |
| " Cognitive testing took place at 2 time points: study weeks 4 through 5 to assess baseline performance and 10 to 13 weeks later to assess performance during stable dosing (300 mg topiramate or placebo)." | 2.80 | Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. ( Bigelow, GE; Johnson, MW; Mintzer, MZ; Rass, O; Strain, EC; Umbricht, A, 2015) |
| "Methadone is an effective treatment for opioid dependence." | 2.80 | Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. ( Clarke, J; Larney, S; McKenzie, M; Noska, A; Reddy, M; Rich, JD; Tran, L; Wong, JB; Zaller, N, 2015) |
| "Methadone maintenance treatment (MMT) is widely available in China; but, high rates of illicit opiate use and dropout are problematic." | 2.80 | Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial. ( Chen, H; Du, J; Jiang, H; Li, Z; Ling, W; Pan, S; Zhao, M, 2015) |
| " Rilpivirine decreased methadone minimum and maximum plasma concentrations (Cmin ; Cmax ) and area under the plasma concentration-time curve versus methadone alone (least-square mean ratio; 90% confidence interval) by 22% (0." | 2.79 | The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. ( Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP; Vandevoorde, A, 2014) |
| "Methadone treatment was switched to SROM with flexible dosing and vice versa according to period and sequence of treatment." | 2.79 | Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. ( Backmund, M; Beck, T; Haasen, C; Reimer, J; Ruckes, C; Schuler, C; Verthein, U; Walcher, S, 2014) |
| "Referral of patients with co-occurring psychiatric disorders receiving methadone maintenance to a community psychiatry program is often ineffective, even after reducing common barriers to care." | 2.79 | Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment. ( Brooner, RK; Kidorf, M; King, VL; Kolodner, K; Peirce, J, 2014) |
| "Opioid substitution treatment (OST) for opioid dependence may be limited by adverse events (AEs)." | 2.79 | Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. ( Babic-Hohnjec, L; Berthel, T; Bonorden-Kleij, K; Gholami, N; Haasen, C; Hämmig, R; Höpner, D; Köhler, W; Lebentrau, K; Reimer, J; Ruckes, C; Verthein, U; Vollmert, C; Weber, B, 2014) |
| "Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone." | 2.78 | A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. ( Azadfard, M; Blondell, RD; Giambrone, AK; Homish, GG; Jaanimägi, U; Kowalik, U; Lozano, JR; Neumann, AM, 2013) |
| "Methadone has been the most commonly used pharmacotherapy for the treatment of opioid dependence in U." | 2.78 | Retention in methadone and buprenorphine treatment among African Americans. ( Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, SG; Myers, CP; O'Grady, KE; Olsen, YK; Schwartz, RP, 2013) |
| "Methadone maintenance treatment (MMT) has been successfully scaled up nationally in China." | 2.78 | Effectiveness of prize-based contingency management in a methadone maintenance program in China. ( Chen, W; Hong, Y; Ling, L; McLaughlin, MM; Xia, Y; Zou, X, 2013) |
| "Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production." | 2.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Nielsen, DA; Shorter, D, 2013) |
| "Dolutegravir (DTG) is an investigational integrase inhibitor for treatment of HIV infection." | 2.78 | Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. ( Bala, U; Chen, S; Geoffroy, P; Mark, S; Peppercorn, A; Piscitelli, S; Savina, P; Song, I; Wajima, T, 2013) |
| "Gabapentin is a potentially useful drug in alleviating the hyperexcitatory painful states in the control of opiate dependence in acute detoxification and the stabilization phase." | 2.78 | The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial. ( Alavinia, M; Moghadam, MS, 2013) |
| "Methadone and Suboxone were highly and equally effective for preventing relapse to regular heroin use, with all but 3 of 37 (91." | 2.78 | Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. ( Cockayne, L; McKeganey, N; Russell, C, 2013) |
| "Disulfiram has been an effective cocaine addiction pharmacotherapy, and one of its possible mechanisms of efficacy is through copper chelation and inhibition of an enzyme involved in catecholamine metabolism, dopamine β-hydroxylase (DβH), which converts dopamine to norepinephrine." | 2.78 | Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. ( Hamon, SC; Harding, MJ; Huang, W; Kosten, TR; Lappalainen, J; Nielsen, DA; Wu, G, 2013) |
| "Lessons learned in research and treatment of opioid dependence demonstrate the need to include pregnant women in clinical trials." | 2.78 | Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. ( Baewert, A; Fischer, G; Graf-Rohrmeister, K; Jagsch, R; Langer, M; Thau, K; Unger, A; Winklbaur-Hausknost, B, 2013) |
| "How best to measure the occurrence of adverse events during a randomized clinical trial is an issue that has not been adequately examined in the research literature." | 2.77 | Nonserious adverse events in randomized trials with opioid-dependent pregnant women: direct versus indirect measurement. ( Arria, AM; Coyle, MG; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Selby, P; Stine, SM, 2012) |
| "Buprenorphine compared with methadone appears to result in less suppression of mean fetal heart rate, fetal heart rate reactivity and the biophysical profile score after medication dosing and these findings provide support for the relative safety of buprenorphine when fetal indices are considered as part of the complete risk-benefit ratio." | 2.77 | Fetal assessment before and after dosing with buprenorphine or methadone. ( Coyle, MG; Heil, SH; Jones, HE; Kaltenbach, K; Martin, PR; O'Grady, KE; Salisbury, AL; Stine, SM; Weninger, M, 2012) |
| "HRQOL in opioid dependence improved significantly (p < ." | 2.76 | Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. ( Haasen, C; Karow, A; Krausz, M; Pukrop, R; Reimer, J; Schäfer, I; Verthein, U, 2011) |
| "Fluoxetine was not efficacious in reducing cocaine use in patients dually dependent on cocaine and opioids." | 2.76 | A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. ( Bigelow, GE; Johnson, RE; Silverman, K; Strain, EC; Winstanley, EL, 2011) |
| "The influence of alcohol use on opioid dependence is a major problem that warrants a search for more effective treatment strategies." | 2.76 | Problem drinking and low-dose naltrexone-assisted opioid detoxification. ( Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT, 2011) |
| "Methadone maintenance treatment has been made available in China in response to the rapid spread of human immunodeficiency virus (HIV), but high rates of dropout and relapse are problematic." | 2.76 | Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. ( Chang, YJ; Du, J; Evans, E; Hser, YI; Huang, D; Jiang, H; Li, J; Peng, C; Roll, J; Stitzer, ML; Wu, F; Zhang, B; Zhang, C; Zhang, R; Zhao, M, 2011) |
| "The buprenorphine treatment was switched to buprenorphine/naloxone (4:1), and the patients were followed for about 1 year." | 2.76 | Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey. ( Baldassarre, C; Curcio, F; Franco, T; Topa, M, 2011) |
| "methadone-treated patients." | 2.76 | Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. ( Alho, H; Fabritius, C; Kalska, H; Rapeli, P, 2011) |
| "Interestingly, opioids induce hyperalgesia via many of the same neuro-inflammatory and central sensitization processes that occur with the development of neuropathic pain." | 2.75 | Gabapentin improves cold-pressor pain responses in methadone-maintained patients. ( Compton, P; Kehoe, P; Ling, W; Sinha, K; Torrington, MA, 2010) |
| "Methadone maintenance treatment has been shown to reduce heroin use, criminality and mortality." | 2.75 | Naltrexone implants compared to methadone: outcomes six months after prison release. ( Gossop, M; Katevoll, T; Kunøe, N; Lobmaier, PP; Waal, H, 2010) |
| " A total of 361 opiate-dependent individuals (89% of those eligible, presenting for treatment over 2 years at a drug service in England) received rapid titration then flexible dosing with methadone or buprenorphine; 227 patients chose methadone (63%) and 134 buprenorphine (37%)." | 2.75 | The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. ( Holland, R; Maskrey, V; Pinto, H; Rumball, D; Swift, L; Wagle, A, 2010) |
| "Buprenorphine patients were also less likely than methadone patients to withdraw voluntarily from medication while in jail (3% vs." | 2.74 | Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. ( Hershberger, J; Joseph, H; Lee, JD; Magura, S; Marsch, L; Rosenblum, A; Shropshire, C, 2009) |
| "CM appears to be an efficacious treatment for cocaine dependence among methadone maintenance clients, regardless of ethnicity." | 2.74 | Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients. ( Barry, D; Petry, NM; Sullivan, B, 2009) |
| "The intensity of withdrawal in opiate dependence shows a high inter-individual variability." | 2.74 | Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene. ( Augener, S; Bachmann, HS; Bonnet, U; Lieb, B; Scherbaum, N; Siffert, W; Specka, M, 2009) |
| "Opioid-substitution treatment (OST) for opioid dependence (OD) has proven effective in retaining patients in treatment and reducing illegal opiate abuse and crime." | 2.74 | Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. ( Alho, H; Fabritius, C; Kalska, H; Rapeli, P, 2009) |
| "Methadone has been shown to increase cigarette smoking in a dose-dependent manner, whereas smoking/nicotine has been shown to increase methadone self-administration and reinforcing properties." | 2.74 | Methadone-nicotine interactions in methadone maintenance treatment patients. ( Brands, B; Elkader, AK; Selby, P; Sproule, BA, 2009) |
| ", and questions relating to appropriate dosing of methadone remain an important issue." | 2.73 | Personality factors associated with methadone maintenance dose. ( Behar, E; McHugh, RK; Murray, H; Otto, M; Pratt, E, 2008) |
| "But, number and severity of withdrawal symptoms in methadone+TENS group were significantly lower than methadone group during tenth and fourteenth days." | 2.73 | A randomized effectiveness trial of methadone, TENS and methadone plus TENS in management of opiate withdrawal symptoms. ( Bakhshani, NM; Lashkaripour, K; Sadjadi, SA, 2008) |
| "This trial was aimed to estimate the pharmacokinetic interaction between voriconazole and methadone at steady state in male patients on methadone therapy and to characterize the safety and tolerability profile during the coadministration." | 2.73 | Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. ( Foster, G; Labadie, R; Liu, P; Sharma, A; Somoza, E, 2007) |
| "Steady-state plasma concentrations of (R)- (ie, the active form), (S)-, and (R,S)-methadone were measured in 14 addict patients in methadone maintenance treatment, before and after introduction of quetiapine, administered at a mean dosage of 138 mg/d (SD, 87 mg/d; median, 125 mg/d; range, 50-300 mg/d) during a mean period of 30 days (SD, 8 days; median, 30 days; range, 20-48 days)." | 2.73 | Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. ( Brawand-Amey, M; Brocard, M; Chassot, P; Crettol, S; Eap, CB; Koeb, L; Uehlinger, C, 2007) |
| "5mg) may be an effective mechanism for safely dosing this medication in persons with higher levels of physical dependence." | 2.73 | Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. ( Bigelow, GE; Rosado, J; Strain, EC; Walsh, SL, 2007) |
| "Heroin-assisted treatment has been found to be effective for people with severe opioid dependence who are not interested in or do poorly on methadone maintenance." | 2.73 | Heroin-assisted treatment for opioid dependence: randomised controlled trial. ( Berger, J; Degkwitz, P; Haasen, C; Krausz, M; Naber, D; Verthein, U, 2007) |
| " High dose opioid administration (150% normal dose) was associated with reductions in overall SpO2 levels and performance (reaction time, DSST) in the methadone patients, but had virtually no impact on pharmacodynamic responses in the buprenorphine group." | 2.73 | Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. ( Bond, AJ; Lintzeris, N; Mitchell, TB; Nestor, L; Strang, J, 2007) |
| " The major aims were to compare the efficacy of Bup and Meth in a flexible dosing regimen and to identify possible predictors of outcome." | 2.73 | Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. ( Koller, G; Kuefner, H; Soyka, M; Zingg, C, 2008) |
| "The registration of combination buprenorphine/naloxone, a formulation designed to reduce risk of diversion, has led some Australian jurisdictional authorities to allow treatment without direct observation of dosing for stable, opioid-dependent patients." | 2.73 | Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial. ( Batey, R; Bell, JR; Mutch, C; Rea, F; Ryan, A, 2008) |
| "Medications for opioid use disorder (MOUD) are evidence-based treatments, yet can be controversial among some populations." | 2.72 | Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. ( Light, T; Madden, EF; Prevedel, S; Sulzer, SH, 2021) |
| "Treating acute pain among persons with opioid use disorder (OUD) on opioid agonist therapy (OAT) is complex, and the therapeutic benefits of opioids remain unclear when weighted against their abuse potential and respiratory depressant effects." | 2.72 | Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. ( Avila-Quintero, VJ; Compton, P; De Aquino, JP; Flores, J; Gómez, O; Hickey, T; Parida, S; Sofuoglu, M, 2021) |
| "Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD)." | 2.72 | A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. ( Abdullah, A; Bansal, N; Chawar, C; D'Elia, A; Guan, L; Hillmer, A; Kapczinski, F; Panesar, B; Pare, G; Samaan, Z; Sanger, S; Thabane, L; Xie, DX, 2021) |
| " Pregnant women (and parents with children) were forced to negotiate dosing in dangerous conditions." | 2.72 | Changing Outdated Methadone Regulations That Harm Pregnant Patients. ( Jones, HE; McCarthy, JJ; Rudolf, VP; Terplan, M; von Klimo, MC, 2021) |
| "Methadone has a wide pharmacokinetic interindividual variability, resulting in unpredicted treatment response." | 2.72 | Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use. ( Ramli, FF, 2021) |
| " We systematically searched for studies of acute toxicity of quetiapine or other antipsychotics combined with morphine or methadone." | 2.72 | Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome? ( Andersen, CU; Andersen, FD; Simonsen, U, 2021) |
| " This review discusses the utility of pharmacometric techniques for enhancing precision dosing in infants requiring opioid treatment for NOWS." | 2.72 | Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. ( Akinbi, H; Butler, D; Emoto, C; Fukuda, T; McPhail, BT; Vinks, AA, 2021) |
| "The rapid increase in opioid overdose and opioid use disorder (OUD) over the past 20 years is a complex problem associated with significant economic costs for healthcare systems and society." | 2.72 | Economic Evaluation in Opioid Modeling: Systematic Review. ( Beaulieu, E; Cerdá, M; Connolly, A; DiGennaro, C; Hamilton, A; Hyder, A; Jalali, MS; Keyes, KM; Stringfellow, E, 2021) |
| " A scoping review was performed to evaluate whether existing literature on methadone bioavailability in human subjects support the current recommendation that an equivalent enteral dose is twice the intravenous dose." | 2.72 | Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review. ( Craig, WY; Fraser, GL; Kemp, HD; Liu, J; McKelvy, DJ; Nichols, SD; Riker, RR; Smith, KE, 2021) |
| "Opioid treatment programs (OTPs) may provide interim methadone services - up to 120 days of methadone dosing without counseling." | 2.72 | Interim methadone - Effective but underutilized: A scoping review. ( Bougatsos, C; Chan, B; Chou, R; Grusing, S; McCarty, D, 2021) |
| "Pharmacological treatments for opioid use disorders (OUDs) may have mixed efficacy across diverse groups, i." | 2.72 | Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review. ( Nalven, T; Schick, MR; Spillane, NS; Weyandt, LL, 2021) |
| "Methadone participants were hyperalgesic to cold pressor pain." | 2.72 | Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. ( Athanasos, P; Bochner, F; Ling, W; Smith, CS; Somogyi, AA; White, JM, 2006) |
| "Heroin was rapidly cleared from plasma." | 2.72 | Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. ( Beijnen, JH; Hendriks, VM; Hillebrand, MJ; Huitema, AD; Rook, EJ; van den Brink, W; van Ree, JM, 2006) |
| " Individually optimized flexible dosing was used for each group, with weekly possible doses of 255-391 mg of LAAM, 56-112 mg of BUP, and 420-700 mg of METH." | 2.72 | HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. ( Bigelow, GE; Brooner, RK; Johnson, RE; Lott, DC; Strain, EC, 2006) |
| " The average DAM dosage was 274." | 2.72 | Controlled trial of prescribed heroin in the treatment of opioid addiction. ( Carrasco, F; March, JC; Oviedo-Joekes, E; Perea-Milla, E, 2006) |
| "Severity of opioid dependence, and performance on two successive runs of the Wisconsin Card Sorting Test (WCST), were assessed in 39 right-handed male and female methadone patients who had been randomly assigned to either a recently dosed (n=21) or 24 hr abstinent (n=18) condition." | 2.71 | Neuropsychological correlates of opioid dependence and withdrawal. ( Lyvers, M; Yakimoff, M, 2003) |
| "Methadone was superior to buprenorphine in time to termination over the 13-week period (Wald chi 2 = 4." | 2.71 | Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. ( Ali, R; Danz, C; Mattick, RP; O'Brien, S; White, JM; Wolk, S, 2003) |
| "Methadone group was significantly better than 1mg buprenorphine dose group (p=." | 2.71 | Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. ( Ahmadi, J, 2003) |
| " Both dose-response and temporal associations of noncontingent voucher receipt with drug-positive urines were assessed." | 2.71 | Do noncontingent vouchers increase drug use? ( Epstein, DH; Gupman, AE; Preston, KL; Schroeder, JR; Umbricht, A, 2003) |
| "Opioid effects were of a similar overall magnitude following dosing for each drug and showed an inverse association with plasma drug concentrations, which peaked later for morphine compared to (R)-methadone (6." | 2.71 | Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. ( Bochner, F; Mitchell, TB; Somogyi, AA; White, JM, 2003) |
| "To construct a population pharmacokinetic model for methadone enantiomers in the setting of methadone maintenance treatment for opioid dependence." | 2.71 | Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. ( Bochner, F; Foster, DJ; Somogyi, AA; White, JM, 2004) |
| " In comparison to (R)-methadone, plasma nor- and dinor-LAAM concentrations fluctuated little over the dosing interval." | 2.71 | Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. ( Bochner, F; Newcombe, DA; Somogyi, AA; White, JM, 2004) |
| "No methadone dosage was changed in any subject." | 2.71 | Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. ( Bigelow, GE; Christopher, J; Fuchs, EJ; Hendrix, CW; Lou, Y; Martinez, E; Snidow, JW; Wakeford, J; Wire, MB, 2004) |
| "Intensive treatment for nicotine dependence, environmental interventions, and innovative harm reduction strategies are recommended to address the barriers to quitting observed in this population of pregnant women." | 2.71 | Motivational enhancement therapy for nicotine dependence in methadone-maintained pregnant women. ( Diclemente, C; Haug, NA; Svikis, DS, 2004) |
| " Withdrawal scores at the time of dosing were higher in the TOP patients (9." | 2.71 | Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. ( Ali, R; Bochner, F; Foster, DJ; Jittiwutikarn, J; Somogyi, AA; White, JM, 2004) |
| "Methadone-assisted treatment was approved in Norway in 1998, buprenorphine in 2000." | 2.71 | [Buprenorphine and methadone to opiate addicts--a randomized trial]. ( Asland, R; Espegren, O; Jakobsen, E; Kristensen, Ø; Lie, Ø; Seiler, S, 2005) |
| "Methadone-treated subjects remained in treatment significantly longer and achieved significantly longer periods of sustained abstinence and a greater proportion drug-free tests, compared with subjects who received buprenorphine." | 2.71 | Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. ( Carroll, KM; Chawarski, MC; Kosten, TR; Pakes, JR; Pantalon, MV; Schottenfeld, RS, 2005) |
| "Methadone was first given to all patients within 24h of treatment admission." | 2.71 | Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. ( Jasinski, DR; Johnson, RE; Jones, HE; Milio, L, 2005) |
| "Buprenorphine appears to be an effective and safe drug in opioid-addicted patient detoxification." | 2.70 | Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. ( Borsutzky, M; Emrich, HM; Metzner, C; Paetzold, W; Passie, T; Rollnik, J; Schneider, U; Seifert, J; Wiese, B, 2002) |
| "This study compared the safety and efficacy of sublingual buprenorphine tablets with oral methadone in a population of opioid-dependent individuals in a double-blind, randomized, 6-week trial using a flexible dosing procedure." | 2.70 | Double-blind randomized trial of buprenorphine and methadone in opiate dependence. ( Déglon, JJ; Ladewig, D; Livoti, S; Petitjean, S; Stohler, R; Uehlinger, C; Waldvogel, D, 2001) |
| "Methadone treatment had no effect on craving or mood." | 2.70 | Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. ( Bearn, J; Curran, HV; Kleckham, J; Strang, J; Wanigaratne, S, 2001) |
| "Treatment with buprenorphine has been started in Poland in Toxicological Department in Kraków." | 2.70 | [Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report]. ( Chrostek Maj, J; Pach, J; Radomska, M, 2001) |
| "Diazepam pretreatment significantly decreased the amount of methadone consumed." | 2.70 | Human methadone self-administration: effects of diazepam pretreatment. ( Grabowski, J; Huang, DB; Meisch, RA; Spiga, R, 2001) |
| "Methadone maintenance is an effective treatment for opioid dependence, yet its use is restricted to federally licensed narcotic treatment programs (NTPs)." | 2.70 | Methadone maintenance in primary care: a randomized controlled trial. ( Chawarski, M; Fiellin, DA; O'Connor, PG; Pakes, JP; Pantalon, MV; Schottenfeld, RS, 2001) |
| "Methadone patients had lower baseline MHPG levels." | 2.70 | Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. ( Charney, DS; Kosten, TR; Krystal, JH; Petrakis, IL; Southwick, SM; Stine, SM, 2002) |
| " Participants in the DM group reported many more adverse events than did subjects on placebo (173 vs." | 2.70 | A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients. ( Bead, V; Caruso, FS; Childress, AR; Cornish, JW; Ehrman, RN; Esmonde, CA; Herman, BH; Martz, K; O'Brien, CP; Poole, S; Robbins, SJ, 2002) |
| "Significant differences in levels of withdrawal symptoms were found on days 11, 13-15 and 17-20, symptoms resolving most rapidly in the 5-day lofexidine treatment group, whilst withdrawal responses in the 10-day lofexidine treatment group were intermediate between the 5-day lofexidine and standard methadone treatment conditions." | 2.69 | Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. ( Bearn, J; Gossop, M; Strang, J, 1998) |
| " A free dosing schedule was used with no upper limit for methadone dosing but with a maximum buprenorphine dose of 8 mg." | 2.69 | Comparison of buprenorphine and methadone maintenance in opiate addicts. ( Eder, H; Fischer, G; Gombas, W; Jagsch, R; Kasper, S; Stühlinger, G, 1998) |
| "Objective and subjective withdrawal symptoms were measured until urine was free of drugs and patients had no withdrawal symptoms." | 2.69 | Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. ( Hirtl, C; Pfab, R; Zilker, T, 1999) |
| "Methadone hydrochloride treatment is the most common pharmacological intervention for opioid dependence, and recent interest has focused on expanding methadone treatment availability beyond traditional specially licensed clinics." | 2.69 | Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. ( Bigelow, GE; Liebson, IA; Stitzer, ML; Strain, EC, 1999) |
| " Therefore, we have developed a population-based pharmacokinetic (POP-PK) model that characterises adaptive changes in methadone kinetics." | 2.69 | Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. ( Calvert, R; Hay, AW; Raistrick, D; Rostami-Hodjegan, A; Tucker, GT; Wolff, K, 1999) |
| "06) could be found in the retention rate of investigated patients being maintained on a mean dosage of 63 mg oral applicable methadone (racemat of L- and D-methadone) in comparison to the group on a mean dosage of 7." | 2.69 | [Buprenorphine vs. methadone as maintenance treatment for opioid dependence]. ( Aschauer, HN; Eder, H; Fischer, G; Gombas, W; Jagsch, R; Kasper, S; Stühlinger, G, 1999) |
| " Subjective symptoms and pharmacodynamic measures were assessed throughout the study period." | 2.69 | Three oral formulations of methadone. A clinical and pharmacodynamic comparison. ( Freeman, K; Gourevitch, MN; Hartel, D; Hecht, J; Lowinson, J; Marion, I; Tenore, P, 1999) |
| "To compare outcomes of patients with opioid dependence treated with MMT vs an alternative treatment, psychosocially enriched 180-day methadone-assisted detoxification." | 2.69 | Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. ( Banys, P; Clark, HW; Delucchi, KL; Hall, SM; Masson, C; Robillard, H; Rosen, A; Sees, KL, 2000) |
| "Illicit substance use, measured through urine toxicology, was found to increase in a stepwise fashion from nonsmokers, to chippers, to heavy smokers." | 2.69 | Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. ( Frosch, DL; Jarvik, ME; Nahom, D; Shoptaw, S, 2000) |
| "Naloxone treatment, in opioid-addicted patients, induced a marked increase in catecholamine plasma concentrations, metabolism, and cardiovascular stimulation during anesthesia with both propofol and methohexital." | 2.69 | Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns. ( Gastpar, M; Kienbaum, P; Michel, MC; Peters, J; Scherbaum, N; Thürauf, N, 2000) |
| "Trazodone is a non-tricyclic antidepressant drug with specific antagonistic activities at 5-HT(2) and alpha-1 adrenoceptors." | 2.69 | Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study. ( Conte, G; De Risio, S; Pozzi, G, 2000) |
| "Clinical trials carried out to compare methadone and buprenorphine in the treatment of opioid dependence have generally employed an alcoholic solution of buprenorphine, which has a bioavailability superior to that of the tablets." | 2.69 | Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. ( Gessa, GL; Maremmani, I; Pani, PP; Pirastu, R; Tagliamonte, A, 2000) |
| "Withdrawal symptoms were significantly less severe on days 4-7, and 9-13, in the naltrexone/lofexidine combination group." | 2.69 | Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. ( Bearn, J; Buntwal, N; Gossop, M; Strang, J, 2000) |
| "Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements." | 2.69 | Pain responses in methadone-maintained opioid abusers. ( Charuvastra, VC; Compton, P; Kintaudi, K; Ling, W, 2000) |
| "Methadone was administered daily." | 2.69 | A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. ( Bigelow, GE; Chutuape, MA; Johnson, RE; Stitzer, ML; Strain, EC; Walsh, SL, 2000) |
| "Fluoxetine was examined as a candidate in two randomized, double-blind, placebo-controlled trials, one with cocaine-dependent patients (study 1) and the other with patients both cocaine and opiate dependent (study 2)." | 2.68 | Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. ( Creson, D; Davis, C; Elk, R; Grabowski, J; Kirby, K; Rhoades, H; Schmitz, J, 1995) |
| "A retrospective, inception cohort, nonrandomized control design was employed to evaluate the effects of daily vs twice daily dosing of methadone on opiate/cocaine use, and noncompliance with urine toxicology requests in methadone-maintained pregnant women, n = 45." | 2.68 | Methadone dosing and pregnancy: impact on program compliance. ( DePetrillo, PB; Rice, JM, 1995) |
| "Buprenorphine is a partial agonist at the mu-opioid receptor that has been proposed as an alternative to traditional full agonist maintenance therapy for the treatment of opioid addiction." | 2.68 | A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. ( Charuvastra, C; Klett, CJ; Ling, W; Wesson, DR, 1996) |
| " Testing consisted of three daily sessions of fixed cocaine dosing (four injections; 0, 16 and 48 mg/70 kg) and three daily sessions of cocaine self-administration with a choice procedure (16, 32 and 48 mg/70 kg vs." | 2.68 | Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. ( Fischman, MW; Foltin, RW, 1996) |
| " In a follow-up period of nine weeks after replacement of l-methadone with racemic methadone, there was also no significant increase in complaints about withdrawal symptoms, although six patients needed an elevation of their daily dosage by at least 20 mg racemic methadone." | 2.68 | The efficacy of L-methadone and racemic methadone in substitution treatment for opiate addicts--a double-blind comparison. ( Finkbeiner, T; Gastpar, M; Leifert, K; Scherbaum, N, 1996) |
| "Buprenorphine (BUP) is an alternative to methadone (METH) maintenance." | 2.68 | A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. ( Connerney, I; Fischman, MW; Foltin, RW; Levin, FR, 1997) |
| "15 l kg-1 day-1 and a bioavailability of 100% was 17." | 2.68 | Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. ( Dusci, LJ; Hackett, LP; Ilett, KF; Kristensen, JH; Wojnar-Horton, RE; Yapp, P, 1997) |
| "Buprenorphine and methadone were equally effective on measures of treatment retention, urine results for opioids, and compliance with attendance and counseling." | 2.67 | Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. ( Bigelow, GE; Liebson, IA; Stitzer, ML; Strain, EC, 1994) |
| "This study examines the prevalence of psychiatric disorders in an opioid dependent population maintained on methadone." | 2.67 | Psychiatric disorders of opioid addicts entering treatment: preliminary data. ( Abbott, PJ; Walker, SR; Weller, SB, 1994) |
| "Clonidine was more effective than lefetamine in suppressing withdrawal in the first 3 days of treatment (day 3: F = 4." | 2.67 | Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. ( Janiri, L; Mannelli, P; Persico, AM; Serretti, A; Tempesta, E, 1994) |
| " Dosing was double-blind and double-dummy." | 2.67 | Comparison of buprenorphine and methadone in the treatment of opioid dependence. ( Bigelow, GE; Liebson, IA; Stitzer, ML; Strain, EC, 1994) |
| "Consensus on the optimal dosing of methadone in the treatment of opioid dependence has not yet been achieved, with some programs committed to low dose regimens." | 2.67 | Methadone dose and treatment outcome. ( Bigelow, GE; Liebson, IA; Stitzer, ML; Strain, EC, 1993) |
| "A methadone treatment research clinic." | 2.67 | Dose-response effects of methadone in the treatment of opioid dependence. ( Bigelow, GE; Liebson, IA; Stitzer, ML; Strain, EC, 1993) |
| " As hypothesized, 6 mg of buprenorphine were superior to 2 mg of buprenorphine in reducing illicit opioid use, but higher dosage did not improve treatment retention." | 2.67 | Buprenorphine versus methadone maintenance for opioid dependence. ( Falcioni, J; Kosten, TR; Schottenfeld, R; Ziedonis, D, 1993) |
| "No methadone-treated patient required modification of the therapeutic regimen, whereas eight of eleven placebo-treated patients needed treatment with methadone." | 2.67 | Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects. ( Camí, J; Fernández, T; Ollé, JM; Peri, JM; San, L; Torrens, M, 1992) |
| "Buprenorphine was as effective as methadone, 60 mg/d, and both were superior to methadone, 20 mg/d, in reducing illicit opioid use and maintaining patients in treatment for 25 weeks." | 2.67 | A controlled trial of buprenorphine treatment for opioid dependence. ( Fudala, PJ; Jaffe, JH; Johnson, RE, 1992) |
| "Methadone pretreatments may provide a convenient mechanism for the production and examination of long-term mu-opiate receptor physical dependence." | 2.67 | Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans. ( Bigelow, GE; Felch, LJ; June, HL; Stitzer, ML; Wright, C, 1991) |
| " Laboratory measurements of phenobarbital and methadone helped to identify the use of illicit methadone, as well as incorrect self-administration, such as the consumption of several days' dosage at one time." | 2.67 | Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to "estimate" methadone plasma levels. ( Calvert, R; Feely, M; Hay, A; Raistrick, D; Wolff, K, 1991) |
| "Treatment with methadone and buprenorphine has the additional risk of diversion and misuse of medication." | 2.66 | Medication Treatment of Opioid Use Disorder. ( Bell, J; Strang, J, 2020) |
| "Demand for treatments for severe opioid use disorder is increasing worldwide." | 2.66 | Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review. ( Fluyau, D; Pierre, CG; Revadigar, N, 2020) |
| "In order to successfully treat opioid use disorder and overdose in emergency rooms, they must have waivered providers and they must be equipped with the necessary resources." | 2.66 | Buprenorphine initiation to treat opioid use disorder in emergency rooms. ( Fuehrlein, B; Jaeger, S, 2020) |
| " Understanding these pharmacologically driven patterns then guides the judicious choice of drug and dosing schedule and the proactive risk management that is crucial to minimising the risk of death in treatment." | 2.66 | Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality. ( Hulse, G; Joyce, D; Kelty, E; Preen, DB, 2020) |
| " Several factors at the individual, interpersonal, and institutional levels, such as concurrent substance use, MOUD adherence, family conflict, and MOUD dosage and flexibility, appeared to have roles in MOUD retention among adolescents and young adults." | 2.66 | Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. ( Altice, FL; Bromberg, DJ; Nyhan, K; Refsland, BM; Stanojlović, M; Viera, A; Whittaker, S, 2020) |
| " The aims of this review were to summarize eligibility criteria for entry to OAT, doses in routine clinical practice, access to and eligibility for unsupervised dosing and urine drug screening practices in OAT programs globally." | 2.66 | Global opioid agonist treatment: a review of clinical practices by country. ( Ali, R; Bruneau, J; Degenhardt, L; Fiellin, DA; Hickman, M; Jin, H; Larney, S; Marshall, BDL; Strang, J, 2020) |
| "The diagnosis of opioid use disorder (OUD) is often overlooked or inadequately managed during the inpatient admission." | 2.66 | Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients. ( Fine, M; Herscher, M; Hirt, L; Navalurkar, R; Wang, L, 2020) |
| "Co-occurring stimulant/opioid use disorder is an important problem for targeting future research." | 2.66 | A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. ( Ayers, C; Chan, B; Freeman, M; Kansagara, D; Kondo, K; Korthuis, PT; Paynter, R, 2020) |
| "Medications for opioid use disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release naltrexone (XR-NTX)." | 2.66 | A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. ( Biondi, BE; Cioe, K; Easly, R; Simard, A; Springer, SA; Zheng, X, 2020) |
| "Opioid use during pregnancy has serious consequences for mother and baby." | 2.66 | Management and monitoring of opioid use in pregnancy. ( Ibsen, IO; Jørgensen, JS; Lamont, RF; Rausgaard, NLK; Ravn, P, 2020) |
| " Physiologic measures and subject- and observer-rated behavioral responses were measured before dosing and for 2 hr after drug administration." | 2.66 | Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. ( Bigelow, GE; Liebson, IA; Preston, KL, 1988) |
| "Clonidine appears to be a safe and efficacious outpatient treatment for opiate withdrawal, although the results were less favorable than those obtained in open or inpatient studies." | 2.66 | Clonidine in outpatient detoxification from methadone maintenance. ( Charney, D; Gaspari, J; Hogan, I; Kleber, HD; Kosten, T; O'Connor, C; Riordan, CE; Rounsaville, B, 1985) |
| "Those with opiate dependence plus antisocial personality disorder alone improved only on ratings of drug use." | 2.66 | Sociopathy and psychotherapy outcome. ( Luborsky, L; McLellan, AT; O'Brien, CP; Woody, GE, 1985) |
| "Disulfiram was administered at a dosage of 125 mg/day for seven days and 250 mg/day thereafter for 36 weeks." | 2.65 | Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. ( Charuvastra, VC; Ling, W; O'Brien, CP; Weiss, DG, 1983) |
| "Lofexidine might prove to be a safer and more effective nonopiate treatment for opiate withdrawal, especially for ambulatory outpatients; controlled studies are required to confirm this possibility." | 2.65 | Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. ( Geyer, G; Resnick, RB; Washton, AM, 1983) |
| " Dosage for both groups was reduced to 0 mg during weeks 11-13." | 2.65 | Chronic opiate use during methadone detoxification: effects of a dose increase treatment. ( Bigelow, GE; Liebson, IA; McCaul, ME; Stitzer, ML, 1984) |
| "5% of tests) rates of opiate-positive urine test results during two weeks of dosage stabilization." | 2.65 | Treatment outcome in methadone detoxification: relationship to initial levels of illicit opiate use. ( Bigelow, GE; Liebson, I; McCaul, ME; Stitzer, ML, 1983) |
| " These studies showed that short-term effects of oral methadone can be readily detected during a 24-hr dosing regimen." | 2.65 | Short-term effects of oral methadone in methadone maintenance subjects. ( Bigelow, GE; Liebson, I; McCaul, ME; Stitzer, ML, 1982) |
| " Under controlled inpatient conditions established to assess dosage guidelines and to examine specific signs and symptoms of withdrawal, ten (91%) of 11 patients were able to withdraw completely from methadone therapy by the end of a six-day period." | 2.65 | Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy. ( Braverman, P; Charney, DS; Heninger, GR; Kleber, HD; Murburg, M; Redmond, DE; Riordan, CE; Sternberg, DE, 1982) |
| "Doxepin was superior to placebo on Clinical Global Impressions and several factors of the Hamilton Rating Scale for Depression and the Profile of Mood States." | 2.65 | Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. ( Barranco, M; Kyle, EM; Seco, G; Titievsky, J, 1982) |
| "Methadone was investigated to see if it induced an insomnia comparable to that after single doses of morphine." | 2.65 | Morphinelike arousal by methadone during sleep. ( Kay, DC; Neidert, GL; Pickworth, WB, 1981) |
| "Medication-assisted treatment for opioid use disorder with methadone or buprenorphine may ameliorate some of this risk; however, there is presently limited research in humans, including in non-HIV populations, describing changes in immune activation on these treatments which is of paramount importance for those with HIV infection." | 2.61 | The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV. ( Hileman, CO; McComsey, GA, 2019) |
| "Many patients with opioid use disorder are treated in primary care, where effective addiction treatment can be provided." | 2.61 | Opioid Use Disorder: Medical Treatment Options. ( Coffa, D; Snyder, H, 2019) |
| "Treatment with buprenorphine or methadone is associated with NOWS, but neither medication appears to have significant adverse effects on early childhood development." | 2.61 | Opioid Use in Pregnancy. ( Forray, A; Habecker, E; Tobon, AL, 2019) |
| "Memantine was well tolerated with similar rates of adverse effects between treatment groups." | 2.61 | Adjunctive memantine for opioid use disorder treatment: A systematic review. ( Brown, JN; Elias, AM; Pepin, MJ, 2019) |
| "The current epidemic of opioid addiction has arguably been the most recalcitrant in the nation's history and the first to involve substantial numbers of adolescents." | 2.61 | Youth and the Opioid Epidemic. ( Levy, S, 2019) |
| "Effective and widely available opioid addiction treatment resources are needed to ensure successful resolution of the "opioid epidemic"." | 2.61 | Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction. ( James, DL; Jowza, M, 2019) |
| "Providing medications for opioid use disorder (MOUD) with methadone, buprenorphine, and extended-release naltrexone is essential to achieving optimal HIV treatment outcomes including viral suppression and retention in treatment." | 2.61 | Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. ( Fanucchi, L; Korthuis, PT; Springer, SA, 2019) |
| "Medications to treat opioid use disorder, including methadone and buprenorphine, are highly effective in reducing the morbidity and mortality related to illicit opioid use." | 2.61 | Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. ( Bach, P; Calcaterra, SL; Chadi, A; Chadi, N; Kimmel, SD; Morford, KL; Roy, P; Samet, JH, 2019) |
| "Women with opioid use disorder who become pregnant are a particularly vulnerable population and require a comprehensive treatment approach for mother and fetus." | 2.61 | Opioid use disorder during pregnancy: An overview. ( Carter, LC; Nicholas, JS; Read, L; Read, MA; Schmidt, E, 2019) |
| "Methadone is a long-acting mu-opioid receptor agonist that has been shown to increase retention in treatment programs and attendance at prenatal care while decreasing pregnancy complications." | 2.61 | Pharmacological treatment of opioid use disorder in pregnancy. ( Klie, KA; Rodriguez, CE, 2019) |
| "Despite increasing prevalence of opioid use disorder among females, little is known about sex considerations in relation to treatment with buprenorphine." | 2.61 | A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions. ( Cleverley, K; Ling, S; Mangaoil, R; Puts, M; Sproule, B, 2019) |
| "The efficacy of MMT for patients with opioid dependence in China is confirmed by the present review." | 2.61 | Meeting the challenges of opioid dependence in China: experience of opioid agonist treatment. ( Chen, T; Zhao, M, 2019) |
| "When opioid misuse rises in the United States, pregnant women and their neonates are affected." | 2.61 | Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019) |
| "Chronic pain affects millions of adults in the USA." | 2.61 | Comprehensive Perioperative Management Considerations in Patients Taking Methadone. ( Anyama, BC; Cornett, EM; Gennuso, SA; Green, JB; Kaye, AD; Kline, RJ; Okereke, EC; Robichaux, SL, 2019) |
| "Buprenorphine has logistical advantages over methadone, such as greater flexibility of treatment setting and less risk of adverse effects." | 2.61 | Medications for management of opioid use disorder. ( Bridgeman, PJ; Koehl, JL; Zimmerman, DE, 2019) |
| "Available evidence indicated that methamphetamine dependence increased from 3." | 2.58 | Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern. ( Alammehrjerdi, Z; Dolan, K; Ezard, N, 2018) |
| "Methadone is a synthetic, long-acting opioid with a single chiral center forming two enantiomers, (R)-methadone and (S)-methadone, each having specific pharmacological actions." | 2.58 | Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. ( Ahmad, T; Rankin, GO; Valentovic, MA, 2018) |
| "Methadone is a long-acting opioid receptor agonist." | 2.58 | The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review. ( Ghachem, R; Moula, O; Oueslati, B, 2018) |
| "Buprenorphine was superior to clonidine in controlling severe withdrawal symptoms in an outpatient setting (RR 0." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| ": Medication-assisted treatment for opioid use disorder (OUD), which incorporates methadone, buprenorphine, or naltrexone, has been shown to reduce all-cause mortality rates in patients with this disease-and the numbers of patients receiving such treatment is substantial." | 2.58 | CE: Acute Pain Management for People with Opioid Use Disorder. ( Broglio, K; Matzo, M, 2018) |
| " This review provides information on the pharmacology and the toxic effects of pharmacologic agents that are used to treat opioid use disorder." | 2.58 | Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. ( Boyer, EW; Burns, MM; Chai, PR; Toce, MS, 2018) |
| "Methadone maintenance treatment (MMT) is an important treatment tool for the opioid epidemic." | 2.58 | Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. ( Antoine, DG; Huhn, AS; Schlienz, NJ; Speed, TJ; Sweeney, MM, 2018) |
| "Pharmacotherapy for opioid addiction with methadone, buprenorphine, and naltrexone has proven efficacy in reducing illicit opioid use." | 2.58 | Pharmacotherapy for opioid addiction in community corrections. ( Gordon, MS; Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, MM; Mitchell, SG; O'Grady, KE; Schwartz, RP, 2018) |
| "Options for treatment of opioid dependence, acute pain management, and perioperative multimodal analgesia are discussed." | 2.55 | Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient. ( Pan, A; Zakowski, M, 2017) |
| "The objective of this systematic review is to compare the effectiveness of OST with supervised dosing relative to dispensing of medication for off-site consumption." | 2.55 | Supervised dosing with a long-acting opioid medication in the management of opioid dependence. ( Gowing, L; Saulle, R; Vecchi, S, 2017) |
| "The recent heroin and prescription opioid misuse epidemic has led to a sharp increase in the number of opioid overdose deaths in the USA." | 2.55 | Update on Barriers to Pharmacotherapy for Opioid Use Disorders. ( Gryczynski, J; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A, 2017) |
| "Pregnant women with opioid use disorder can be treated with methadone, buprenorphine, or naltrexone to reduce opioid use and improve retention to treatment." | 2.55 | Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. ( Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM, 2017) |
| " However, frequent dosing requirements and potential for misuse and drug diversion contribute to significant complications with treatment adherence for available formulations." | 2.55 | Buprenorphine implants in medical treatment of opioid addiction. ( Chavoustie, S; Dammerman, R; Darwish, M; Frost, M; Owen, J; Sanjurjo, V; Snyder, O, 2017) |
| "Our study of the available oral treatments for opioid dependence has revealed that no current treatment can actually claim to be fully effective." | 2.55 | Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption. ( Benéitez, MC; Gil-Alegre, ME, 2017) |
| "Current treatments of opioid addiction include primarily maintenance medications such as methadone." | 2.55 | Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives. ( Bellivier, F; Bloch, V; Jourdaine, C; Lépine, JP; Marie-Claire, C; Vorspan, F, 2017) |
| "Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan." | 2.55 | Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. ( Alam, F; Alho, H; Auriacombe, M; Benyamina, A; Bobes, J; D'Agnone, O; Daulouede, JP; Dematteis, M; Leonardi, C; Littlewood, R; Maremmani, I; Somaini, L; Soyka, M; Szerman, N; Torrens, M; Walcher, S, 2017) |
| " Recommendations are made for further research into physician/patient interactions and into optimal dosing of methadone and buprenorphine to minimize maternal/fetal withdrawal." | 2.55 | Opioid dependence and pregnancy: minimizing stress on the fetal brain. ( Fassbender, C; Finnegan, LP; Leamon, MH; McCarthy, JJ, 2017) |
| "Methadone has higher treatment retention rates than buprenorphine-naloxone does, while buprenorphine-naloxone has a lower risk of overdose." | 2.55 | Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone? ( Kahan, M; Nader, M; Srivastava, A, 2017) |
| "And, heroin-assisted treatment was associated with better retention than methadone among treatment-refractory patients." | 2.53 | Retention in medication-assisted treatment for opiate dependence: A systematic review. ( Cucciare, MA; Garrison-Diehn, C; Schultz, NR; Timko, C; Vittorio, L, 2016) |
| "Recommendations and options for treating postoperative pain in patients on methadone and buprenorphine are outlined below." | 2.53 | New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine. ( Arulkumar, S; Cornett, EM; Flower, RR; Fox, CJ; Gayle, JA; Kaye, AD; Sen, S, 2016) |
| "The economic costs associated with opioid misuse are immense." | 2.53 | Economic Evaluations of Opioid Use Disorder Interventions. ( Murphy, SM; Polsky, D, 2016) |
| "Individuals with opioid use disorders, including those on medication-assisted therapy such as methadone or buprenorphine, are a key demographic group that can benefit from HCV treatment given their high HCV prevalence; however, pharmacokinetic and pharmacodynamic drug interactions could blunt their utility." | 2.53 | Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. ( Bruce, RD; Friedland, G; Ogbuagu, O, 2016) |
| "Methadone maintenance treatment (MMT) has been implemented in China since 2004 and has expanded into a nationwide programme." | 2.52 | Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis. ( Chow, EP; Li, T; Li, XY; Lu, YH; Sun, HM; Tian, T; Xian, Y; Zhang, L; Zhuang, X, 2015) |
| "Methadone has been used to treat opiate dependence since the mid-1960s." | 2.52 | Resting EEG and ERPs findings in methadone-substituted opiate users: a review. ( Kydd, R; Russell, BR; Wang, GY, 2015) |
| "Methadone has been the mainstay of maintenance treatment for nearly 50 years, but recent research has found that both methadone and buprenorphine maintenance treatments significantly improve maternal, fetal and neonatal outcomes." | 2.52 | Pharmacological Management of Opioid Use Disorder in Pregnant Women. ( Wilder, CM; Winhusen, T, 2015) |
| "Opioid dependence is associated with high levels of morbidity, yet sparse data exists regarding the health-related quality of life (HRQoL) of individuals with opioid dependence, particularly following treatment initiation." | 2.52 | Short term health-related quality of life improvement during opioid agonist treatment. ( Aden, B; Ang, A; Bray, JW; Eggman, AA; Hser, YI; Ling, W; Nosyk, B; Potter, J; Schackman, BR; Weiss, RD; Wittenberg, E, 2015) |
| " Among programs using methadone there was no statistically significant difference in average retention by dosage level, and the 10 highest and lowest dosage programs obtained similar average retention levels after 12 months." | 2.50 | Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. ( Abdul-Quader, AS; Arasteh, K; Des Jarlais, D; Feelemyer, J; Hagan, H, 2014) |
| "Methadone maintenance treatment (MMT) was implemented in mainland China since 2004." | 2.50 | Retention in methadone maintenance treatment in mainland China, 2004-2012: a literature review. ( Zhou, K; Zhuang, G, 2014) |
| "Methadone maintenance treatment (MMT) helps individuals with an opioid use disorder abstain from or decrease use of illegal or nonmedical opiates." | 2.50 | Medication-assisted treatment with methadone: assessing the evidence. ( Daniels, AS; Delphin-Rittmon, ME; Dougherty, RH; Fullerton, CA; Ghose, SS; Kim, M; Lyman, DR; Montejano, LB; Thomas, CP, 2014) |
| "Methadone maintenance treatment (MMT) clinics have been implemented in China since 2004." | 2.50 | Epidemiology of syphilis infection among drug users at methadone maintenance treatment clinics in China: systematic review and meta-analysis. ( Peng, WJ; Wan, YN; Wang, BX; Wang, J; Wang, YJ; Yan, JW; Zhang, L, 2014) |
| "Buprenorphine maintenance treatment has been evaluated in randomised controlled trials against placebo medication, and separately as an alternative to methadone for management of opioid dependence." | 2.50 | Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2014) |
| "The field of opioid dependence treatment is poised to undergo a process of reinforcement and transformation." | 2.50 | Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack? ( Bascaran, MT; Bobes, J; Bobes-Bascaran, MT; Garcia-Portilla, MP; Saiz, PA, 2014) |
| "Methadone treatment has been 'programmatic', with a one-size-fits-all approach that in part reflects the perceived need to impose discipline on deviant individuals." | 2.50 | Pharmacological maintenance treatments of opiate addiction. ( Bell, J, 2014) |
| "Methadone maintenance treatment (MMT) is an effective therapy for opioid-dependence; its use is based on a harm reduction philosophy and represents one of a range of treatment approaches for opioid-dependent individuals." | 2.49 | Problem based review: The patient taking methadone. ( Arora, A; Williams, K, 2013) |
| "Methadone has been used as a pharmacotherapy for the treatment of opiate dependence since the mid-1960s." | 2.49 | Methadone maintenance treatment and cognitive function: a systematic review. ( Russell, BR; Wang, GY; Wouldes, TA, 2013) |
| "Managing opioid dependence in pregnant women is a complex and potentially challenging task." | 2.49 | Managing opioid dependence in pregnancy -- a general practice perspective. ( Arunogiri, S; Foo, L; Frei, M; Lubman, DI, 2013) |
| "Birth weight was higher in the buprenorphine group in the two trials that could be pooled (mean difference (MD) -365." | 2.49 | Maintenance agonist treatments for opiate-dependent pregnant women. ( Amato, L; Bellisario, C; Davoli, M; Ferri, M; Minozzi, S, 2013) |
| "Neonatal abstinence syndrome has become a growing concern in infants born to substance-abusing mothers in the State of Florida." | 2.49 | Pharmacologic management of neonatal abstinence syndrome in a community hospital. ( Calhoun, DA; Napolitano, A; Seng, SK; Theophilopoulos, D, 2013) |
| "Constant refinement of opioid dependence (OD) therapies is a condition to promote treatment access and delivery." | 2.48 | Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. ( Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT, 2012) |
| "Opioid dependence is a significant public health problem associated with high risk for relapse if treatment is not ongoing." | 2.48 | Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. ( Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G, 2012) |
| "Methadone maintenance treatment (MMT) has rapidly expanded in China, from 8 pilot sites to 696 clinics covering 27 provinces, during 2004-2010." | 2.48 | Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis. ( Chow, EP; Liang, Y; Wang, Y; Wilson, DP; Zhang, L; Zhuang, X, 2012) |
| "Treatment for opiate addiction requires long-term management." | 2.48 | Maintenance medication for opiate addiction: the foundation of recovery. ( Bart, G, 2012) |
| "Opioid dependence is becoming a more common problem in the United States that gives rise to many negative health and social consequences for both individuals and society as a whole." | 2.47 | Opioid dependence. ( Benich, JJ, 2011) |
| "There are three stages to treating opioid dependence." | 2.47 | Opioid dependence. ( Law, F; Melichar, J; O'Shea, J; Praveen, KT, 2011) |
| "Pharmacological approaches incorporate the continuation of usual medications (or equivalent), short-term use of sometimes much higher than average doses of additional opioid, and prescription of non-opioid and adjuvant drugs, aiming to improve pain relief and attenuate opioid tolerance and/or opioid-induced hyperalgesia." | 2.47 | Acute pain management in opioid-tolerant patients: a growing challenge. ( Huxtable, CA; MacIntyre, PE; Roberts, LJ; Somogyi, AA, 2011) |
| " With respect to the particular consumed drug substances other than opioids during pregnancy variable forms of teratogenic and toxic effects can be assigned to the baby." | 2.47 | [Pregnant opioid addicted patients and additional drug intake. Part I. Toxic effects and therapeutic consequences]. ( Havemann-Reinecke, U; Hoell, I, 2011) |
| "Buprenorphine and methadone were ranked as the most effective methods of opioid detoxification followed by lofexidine and clonidine respectively." | 2.46 | A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. ( Meader, N, 2010) |
| "Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions." | 2.46 | The pharmacological treatment of opioid addiction--a clinical perspective. ( Bramness, J; Gossop, M; Lobmaier, P; Waal, H, 2010) |
| "To date, methadone dosing is still an issue of debate and controversy among clinicians who are involved in methadone maintenance programs." | 2.46 | Methadone maintenance dosing guideline for opioid dependence, a literature review. ( Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S, 2010) |
| "Methadone has been the standard medication for the management of heroin craving." | 2.46 | Heroin anticraving medications: a systematic review. ( Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S, 2010) |
| "This review extends a prior meta-analysis of acupuncture's utility for treating opioid detoxification, addressing the efficacy of acupuncture when combined with allopathic therapies." | 2.45 | A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms. ( Bao, YP; Epstein, DH; Liu, TT; Lu, L; Shi, J, 2009) |
| "Buprenorphine/naloxone is an effective maintenance therapy for opioid dependence and has generally similar efficacy to methadone, although more data are needed." | 2.45 | Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. ( Keating, GM; Orman, JS, 2009) |
| "The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease." | 2.45 | Opioid dependence treatment: options in pharmacotherapy. ( Dodrill, CL; Kosten, TR; Stotts, AL, 2009) |
| "Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy." | 2.45 | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2009) |
| "There are three approaches to treating opioid dependence." | 2.45 | Opioid dependence. ( Law, F; Melichar, J; O'Shea, J, 2009) |
| "While drug abuse abated following the establishment of People's Republic of China, modernization and Westernization in the 1980s led to the reemergence of this problem." | 2.44 | Drug addiction in China. ( Lu, L; Wang, X, 2008) |
| "Women using methadone for treatment of opioid dependence should not be discouraged from breastfeeding." | 2.44 | Methadone exposure during lactation. ( Finkelstein, Y; Garcia-Bournissen, F; Glatstein, MM; Koren, G, 2008) |
| "We conclude that methadone maintenance treatment in opioid dependence shows positive effects on retention, opioid abuse and criminality compared with non-active controlled conditions." | 2.44 | Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study. ( Berglund, M; Johansson, BA; Lindgren, A, 2007) |
| "The most effective intervention for opioid dependence remains maintenance with methadone, a full mu-opioid receptor agonist, or buprenorphine, a partial mu-opioid receptor agonist." | 2.44 | Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? ( Fiellin, DA; Gunderson, EW, 2008) |
| "While opioid dependence has more treatment agents available than other abused drugs, none are curative." | 2.44 | Pharmacologic treatments for opioid dependence: detoxification and maintenance options. ( Kleber, HD, 2007) |
| "The management of opioid dependence during pregnancy has received considerable attention over the past three decades." | 2.44 | Opioid dependence and pregnancy. ( Fischer, G; Jung, E; Winklbaur, B, 2008) |
| "Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is less effective than methadone delivered at adequate dosages." | 2.44 | Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2008) |
| "Buprenorphine is a partial opioid agonist that can be prescribed by trained physicians and dispensed at pharmacies." | 2.44 | Narrative review: buprenorphine for opioid-dependent patients in office practice. ( Fiellin, DA; Sullivan, LE, 2008) |
| "Methadone maintenance treatment (MMT) has been the 'gold standard' pharmacotherapy treatment for illicit opioid dependence for over 30 years." | 2.43 | Eyes wide shut?--A conceptual and empirical critique of methadone maintenance treatment. ( Fischer, B; Kim, G; Kirst, M; Rehm, J, 2005) |
| "Opiate dependence is a major health and social issue in many countries." | 2.43 | The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. ( Bond, C; Inkster, K; Ludbrook, A; Matheson, C; Simoens, S, 2005) |
| "Methadone maintenance is an effective and most widely used treatment for opiate addiction, allowing normalization of many physiological abnormalities caused by chronic use of short-acting opiates." | 2.43 | Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. ( Bart, G; Kreek, MJ; LaForge, KS; Lilly, C; Nielsen, DA, 2005) |
| "Methadone is an opioid with complex properties, and a patient that is taking methadone can represent a unique challenge to the anesthesiologist." | 2.43 | Review article: perioperative pain management of patients on methadone therapy. ( Gourlay, D; Peng, PW; Tumber, PS, 2005) |
| "Buprenorphine was used in only one of the studies, and then as a transition between methadone and abstinence." | 2.43 | From opioid maintenance to abstinence: a literature review. ( Kornør, H; Waal, H, 2005) |
| "Methadone maintenance treatment (MMT) has not been officially approved by the Chinese government for widespread implementation, but some pilot studies are currently underway." | 2.43 | Opiate addiction in China: current situation and treatments. ( Cubells, JF; Tang, YL; Zhao, C; Zhao, D, 2006) |
| "Treatment of opioid dependence often requires continued opioid administration in the form of substitution therapy, which means that opioid-using IDUs often continue receiving opioids even after cessation of illicit drug use." | 2.43 | Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. ( Fairbairn, N; Kerr, T; Maas, B; Montaner, J; Wood, E, 2006) |
| "Opioid dependence is a chronic and relapsing medical disorder with a well-established neurobiological basis." | 2.43 | Opioid dependence: rationale for and efficacy of existing and new treatments. ( Fiellin, DA; Friedland, GH; Gourevitch, MN, 2006) |
| "Methadone maintenance treatment (MMT) for opioid dependency has consistently shown important heath, social and legal benefits." | 2.43 | Methadone death, dosage and torsade de pointes: risk-benefit policy implications. ( Latowsky, M, 2006) |
| "Buprenorphine is a new and attractive medication option for many opioid-addicted adults and their physicians." | 2.42 | Practical considerations for the clinical use of buprenorphine. ( Jones, HE, 2004) |
| "Buprenorphine has been studied extensively since 1978 when it was initially proposed as an alternative to methadone for treatment of opioid dependence." | 2.42 | Clinical efficacy of buprenorphine: comparisons to methadone and placebo. ( Ling, W; Wesson, DR, 2003) |
| "Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is not more effective than methadone at adequate dosages." | 2.42 | Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2003) |
| "Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy." | 2.42 | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2003) |
| "Methadone maintenance treatment (MMT) is a long term opioid replacement therapy, recognised as effective in the management of opioid dependence." | 2.42 | Methadone maintenance at different dosages for opioid dependence. ( Faggiano, F; Lemma, P; Versino, E; Vigna-Taglianti, F, 2003) |
| "Cardiac arrhythmias have been reported with methadone and levomethadyl, but not with buprenorphine." | 2.42 | Treating opioid dependence. Growing implications for primary care. ( Krantz, MJ; Mehler, PS, 2004) |
| " Effectiveness of Methadone maintenance program affects methadone dosage policy, treatment duration and ancillary services." | 2.42 | [Economic efficiency of methadone maintenance and factors affecting it]. ( Padaiga, Z; Subata, E; Vanagas, G, 2004) |
| "Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is not more effective than methadone at adequate dosages." | 2.42 | Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2004) |
| "Methadone is a synthetic opioid, used both as an analgesic in severe pain relief and now mainly in the treatment of opiate dependence." | 2.42 | The effects of methadone and its role in fatalities. ( Corkery, JM; Ghodse, AH; Oyefeso, A; Schifano, F, 2004) |
| "This article reviews the literature on treatment of depressive disorders and symptoms among patients with opiate dependence." | 2.42 | Treatment of depression in patients with opiate dependence. ( Levin, FR; Nunes, EV; Sullivan, MA, 2004) |
| "A new service delivery system for the treatment of opioid dependence, called motivational stepped care, matches the intensity of counseling services to each patient's clinical progress." | 2.41 | Using behavioral reinforcement to improve methadone treatment participation. ( Brooner, RK; Kidorf, M, 2002) |
| "Opiate addiction is a chronic, relapsing disorder." | 2.41 | History and current status of opioid maintenance treatments: blending conference session. ( Kreek, MJ; Vocci, FJ, 2002) |
| "Methadone maintenance treatment is the most prominent form of pharmacotherapy treatment for illicit opiate dependence in several countries, and its application varies internationally with respect to treatment regulations and delivery modes." | 2.41 | Heroin-assisted treatment as a response to the public health problem of opiate dependence. ( Casas, M; Fischer, B; Hall, W; Kirst, M; Krausz, M; Metrebian, N; Reggers, J; Rehm, J; Uchtenhagen, A; van den Brink, W; van Ree, JM, 2002) |
| "Methadone has a mean bioavailability of around 75% (range 36-100%)." | 2.41 | Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. ( Baumann, P; Buclin, T; Eap, CB, 2002) |
| "Buprenorphine is an effective intervention for use in the maintenance treatment of heroin dependence, but it is not more effective than methadone at adequate dosages." | 2.41 | Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2002) |
| "Methadone is an effective maintenance therapy intervention for the treatment of heroin dependence as it retains patients in treatment and decreases heroin use better than treatments that do not utilise opioid replacement therapy." | 2.41 | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. ( Breen, C; Davoli, M; Kimber, J; Mattick, RP, 2002) |
| "Methadone maintenance is the premier pharmacological treatment for opioid addiction, but it is rarely informed by evidence-based practice guidelines for dosage monitoring and adjustment." | 2.41 | Therapeutic drug monitoring in methadone maintenance: choosing a matrix. ( Epstein, D; Moolchan, ET; Umbricht, A, 2001) |
| "The efficacy of methadone maintenance in opioid addiction was assessed in terms of programme retention rate and reduction of illicit opioid use by means of a meta-analysis of randomised, controlled and double blind clinical trials." | 2.41 | Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. ( Camí, J; Farré, M; Mas, A; Moreno, V; Torrens, M, 2002) |
| " These recommendations address: antepartum issues including treatment, dosage and pharmacological considerations, medical conditions and lab tests, intrapartum issues, postpartum concerns including breastfeeding, neonatal withdrawal, and developmental effects associated with methadone." | 2.41 | Clinical management of methadone dependence during pregnancy. ( Curet, LB; Dorato, V; Wallerstedt, C; Wilbourne, P, 2001) |
| "Methadone maintenance for the treatment of opioid dependence is described in this article." | 2.40 | Opioid dependence during pregnancy. Effects and management. ( Berghella, V; Finnegan, L; Kaltenbach, K, 1998) |
| "Opiate dependence is a brain-related medical disorder that can be effectively treated with significant benefits for the patient and society, and society must make a commitment to offer effective treatment for opiate dependence to all who need it." | 2.40 | Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. ( , 1998) |
| "Methadone maintenance treatment (MMT) involves the daily administration of the oral opioid agonist methadone as a treatment for opioid dependence-a persistent disorder with a substantial risk of premature death." | 2.40 | Role of maintenance treatment in opioid dependence. ( Hall, W; Mattick, RP; Ward, J, 1999) |
| " Contrary to the expectation that methadone patients who consumed excessive amounts of alcohol would require higher dosages of methadone, it was found that nonalcohol-abusing methadone patients requested the higher dosage levels." | 2.40 | Methadone patients and alcohol abuse. ( Ottomanelli, G, 1999) |
| "Lofexidine is an alpha-2 adrenergic agonist that is increasingly used in the management of opiate withdrawal--notably in the UK." | 2.40 | Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. ( Bearn, J; Gossop, M; Strang, J, 1999) |
| "This paper describes the mechanisms of opiate dependence and opiate withdrawal and reviews the available instruments for the measurement of withdrawal." | 2.39 | Opiate withdrawal. ( Farrell, M, 1994) |
| "Methadone maintenance treatment programs have been shown to decrease criminal behavior, improve psychosocial functioning, and decrease injecting narcotic use, thus reducing the spread of AIDS." | 2.39 | Methadone maintenance treatment. When and how to refer patients. ( DeMaria, PA; Weinstein, SP, 1995) |
| "Methadone treatment can reduce illicit drug use, needle sharing, and the social costs and health risks of heroin addiction." | 2.39 | Opiate-dependent patients receiving methadone. How physicians should manage therapy. ( Kahan, M; Sutton, N, 1996) |
| "Methadone has improved our understanding of these pathologies." | 2.39 | Treatment of depressive syndromes in detoxified drug addicts: use of methadone. ( Baylé, FJ; Jalfre, V; Laqueille, X; Lôo, H; Spadone, C, 1996) |
| "Many patients with alcohol or drug abuse also have anxiety disorders for whom effective pharmacotherapy may be needed." | 2.38 | Alprazolam and benzodiazepine dependence. ( Ciraulo, DA; DuPont, RL; Griffiths, RR; Kosten, TR; Romach, MK; Sellers, EM; Woody, GE, 1993) |
| "Methadone maintenance treatment has allowed for stabilization and normalization in the lives of hundreds of thousands of chronic opiate addicts." | 2.38 | Methadone maintenance treatment: dispelling myths and recovering truths. ( Neshin, SF, 1993) |
| "Also methadone has been shown to be very effective when appropriately used in programs which combine pharmacotherapy with the best elements of "drug free" treatment, that is, counseling and psychological support." | 2.38 | Rationale for maintenance pharmacotherapy of opiate dependence. ( Kreek, MJ, 1992) |
| "Methadone maintenance is an important component of the management of many pregnant opioid addicts." | 2.38 | Narcotic use in pregnancy. ( Hoegerman, G; Schnoll, S, 1991) |
| "New medications for the treatment of opiate dependence are being developed." | 2.38 | Drugs of abuse--opiates. ( Ling, W; Wesson, DR, 1990) |
| " Blood specimens were generally not collected from 0-15 minutes after intravenous dosing 6." | 2.38 | Clinical toxicology of drugs used in the treatment of opiate dependency. ( Fraser, AD, 1990) |
| " Chronic use of methadone, administered orally, can result in a steady state with respect to both drug levels and overall functioning." | 2.37 | Opioid interactions with alcohol. ( Kreek, MJ, 1984) |
| "The acquired immunodeficiency syndrome (AIDS) has recently emerged as a serious medical complication of parenteral substance abuse." | 2.37 | Major medical problems and detoxification treatment of parenteral drug-abusing alcoholics. ( Novick, DM, 1984) |
| "Buprenorphine is an opioid mixed agonist-antagonist that has potential usefulness as a pharmacotherapy for opiate addiction." | 2.37 | Behavioral pharmacology of buprenorphine. ( Mello, NK; Mendelson, JH, 1985) |
| " Narcotics are used for the euphoria they provide; however, chronic use results in physiological and psychological changes." | 2.37 | Narcotic withdrawal in the emergency department. ( Freitas, PM, 1985) |
| "Mortality from opioid use disorder (OUD) can be reduced for patients who receive opioid agonist treatment (OAT)." | 1.91 | A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder. ( Gottlieb, DJ; Hoyt, JE; Peltzman, T; Riblet, NB; Shiner, B; Teja, N; Watts, BV, 2023) |
| "Most people with co-occurring opioid use disorder (OUD) and mental illness do not receive effective medications for treating OUD." | 1.91 | Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness. ( Bromley, E; Hunter, SB; Leamon, I; Martinez, J; McCreary, M; Montero, A; Ober, AJ; Sheehe, J; Shih, KJ; Tarn, DM; Watkins, KE, 2023) |
| "To examine preferences of patients with opioid use disorder (OUD) concerning the terminology used by addiction counselors." | 1.91 | What's in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment. ( Barry, DT; Beitel, M; Bergman, E; Cammack, KM; Carmichael, ID; Eggert, KF; Gazzola, MG; Jegede, O; Maclean, E; Madden, LM; Roehrich, T; Zheng, X, 2023) |
| "Gabapentin exposure in treatment-seeking persons with OUD appears to be quite common, and use, both medically and nonmedically, frequently occurs alongside OAMs." | 1.91 | Understanding motivations and use typologies of gabapentin with opioid agonist medications. ( Buttram, ME; Ellis, MS; Qureshi, R, 2023) |
| "Patients with opioid use disorder (OUD) tend to get assigned to one of 3 medications based on the treatment program to which the patient presents (e." | 1.91 | Optimally Choosing Medication Type for Patients With Opioid Use Disorder. ( Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT, 2023) |
| "Methadone cost was the control." | 1.91 | The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment. ( Chiu, K; McGee, M; Moineddin, R; Sud, A, 2023) |
| "For patients with opioid use disorder (OUD), medications for OUD (MOUD) reduce morbidity, mortality, and return to use." | 1.91 | Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities. ( Carlson, KF; Gordon, AJ; Korthuis, PT; Liberto, JG; Lindner, S; Lovejoy, TI; Morasco, BJ; Ono, SS; Shull, S; Wyse, JJ, 2023) |
| "Medications for opioid use disorder (MOUDs) - including methadone, buprenorphine, and naltrexone - are the most effective treatments for opioid use disorder (OUD)." | 1.91 | Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. ( Andraka-Christou, B; Golan, O; Gordon, AJ; Ohama, M; Saloner, B; Stein, BD; Totaram, R, 2023) |
| " The restrictions on methadone availability including take-home dosing were loosened during the COVID-19 pandemic although there have been concerns about the high street value of diverted methadone." | 1.91 | Examination of methadone involved overdoses during the COVID-19 pandemic. ( Kaufman, DE; Kennalley, AL; McCall, KL; Piper, BJ, 2023) |
| " Many settings across North America relaxed restrictions for take-home dosing during the COVID-19 pandemic and have reported consistent or improved patient outcomes." | 1.91 | Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20. ( Dale, L; Guerra-Alejos, BC; Kurz, M; Min, JE; Nosyk, B; Piske, M, 2023) |
| "The introduction of depot buprenorphine for the treatment of opioid dependence allows for reduced dosing frequency compared with conventional treatments, such as oral methadone and sublingual buprenorphine-naloxone." | 1.91 | Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study. ( Allen, E; Altobelli, G; Holmwood, C; Johnson, J; Samadian, S, 2023) |
| "Access to medications for opioid use disorder (MOUD) is limited for individuals in drug courts - programs that leverage sanctions for mandatory substance use treatment." | 1.91 | Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. ( Boland, AK; Friedmann, PD; Lemon, SC; Pivovarova, E; Smelson, DA; Taxman, FS, 2023) |
| "Buprenorphine was associated with greater protection against overdose death than methadone for clients with circulatory (MSM aIRR = 0." | 1.91 | Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17. ( Ali, R; Degenhardt, L; Hickman, M; Jones, NR; Larney, S; Nielsen, S, 2023) |
| "Despite efficacy of medication for opioid use disorder, low-income, ethno-racial minoritized populations often experience poor opioid use disorder treatment outcomes." | 1.91 | "Sometimes you have to take the person and show them how": adapting behavioral activation for peer recovery specialist-delivery to improve methadone treatment retention. ( Anvari, MS; Belcher, AM; Bennett, M; Bradley, VD; Dean, D; Felton, JW; Greenblatt, AD; Kleinman, MB; Magidson, JF; Seitz-Brown, CJ, 2023) |
| "Policymakers should consider patients' perspectives to foster a more patient-centered approach to methadone dosing that is safe, flexible, and accommodating to a diverse array of patients' needs." | 1.91 | Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore. ( Abidogun, TM; Belcher, AM; Cole, TO; Greenblatt, AD; Kleinman, M; Magidson, JF; Massey, E; Seitz-Brown, CJ, 2023) |
| "Among patients with opioid use disorder seeking medication treatment, the risk of overdose events over the next 24 weeks is elevated among those who fail to initiate or discontinue medication and those who report benzodiazepine use at baseline." | 1.91 | Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. ( Balise, RR; Brandt, L; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Odom, GJ, 2023) |
| " The community-driven research (CDR) online survey collected information on how patient take-home methadone dosing and in-person drug testing, counseling, and clinic visit frequency changed prior to COVID-19 (before March 2020) to during COVID-19 (June and July 2020)." | 1.91 | Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey. ( Brothers, S; Coulter, A; Palayew, A; Simon, C; Strichartz, K; Vincent, L; Voyles, N, 2023) |
| "Medications for opioid use disorder (MOUD) are associated with positive health outcomes." | 1.91 | Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study. ( Kidorf, M; Knight, D; Latkin, C; Nkya, IH; Saleem, HT; West, NS; Yang, C, 2023) |
| "Heroin Assisted Treatment (HAT) is an alternative treatment modality for people for whom more traditional forms of opioid substitution therapy, such as methadone, have been ineffective." | 1.91 | More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment. ( Ahmed, D; Harris, M; Moore, HJ; Poulter, HL; Riley, F; Towl, G; Walker, T, 2023) |
| "We identified three themes related to patients' internal relationships to methadone: patients (1) viewed methadone as a bridge to opioid-free recovery, (2) believed that long-term methadone damages the body, and (3) felt that methadone increases craving for cocaine; and three themes related to their external relationships with opioid treatment programs and society at large: patients (4) viewed daily dosing as burdensome, (5) feared methadone inaccessibility could trigger relapse, and (6) experienced stigma from friends, family, and peers." | 1.91 | Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. ( Chander, G; Pytell, JD; Stoller, KB; Thakrar, AP; Walters, V; Weiss, RD, 2023) |
| "Buprenorphine availability has increased and relaxed regulations reduces barriers in general medical settings common in rural areas." | 1.91 | Augmenting project ECHO for opioid use disorder with data-informed quality improvement. ( Cox, KM; Doyle, M; Marsch, LA; McLeman, BM; Murray, OB; Ryer, J; Saunders, EC; Watts, D, 2023) |
| "Methadone medication treatment for opioid use disorder appears to remain an effective intervention for reducing illicit opioid use." | 1.91 | Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. ( Dawson, E; Gordon, AJ; Passik, S; Saloner, B; Stein, BD; Whitley, P, 2023) |
| "Management of patients with opioid use disorder during the acute postpartum period remains clinically challenging as obstetricians aim to mitigate postdelivery pain while optimizing recovery support." | 1.91 | A comparison of postpartum opioid consumption and opioid discharge prescriptions among opioid-naïve patients and those with opioid use disorder. ( Achu, R; Bateman, BT; Gibbs, L; Guang, Z; Holland, E; Saia, K; Spence, NZ; Wachman, EM; Werler, MM; Young, M, 2023) |
| ", i) the analgesic agent is identical to the OAT medication, and ii) the opioid agent is dosed above 1/6th morphine equivalent dose of the OAT medication." | 1.91 | Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment. ( Arnet, I; Dürsteler, KM; Grossmann, F; Hersberger, KE; Jaiteh, C, 2023) |
| "Methadone use was associated with 21." | 1.91 | Opioid and Methadone Use for Infants With Surgically Treated Necrotizing Enterocolitis. ( Keane, OA; Kelley-Quon, LI; Kim, E; Kim, ES; Lakshmanan, A; Mahdi, EM; Ourshalimian, S; Song, AY; Zamora, AK, 2023) |
| "Medication for opioid use disorder (MOUD) is an effective intervention to combat opioid use disorder and overdose, yet there is limited understanding of engagement in treatment over time in the community, contextualized by ongoing substance use." | 1.91 | Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019. ( Astemborski, J; Cepeda, JA; Genberg, BL; Kirk, GD; Mehta, SH; Rudolph, JE, 2023) |
| "Oral methadone is a feasible alternative to IV methadone for patients undergoing spine surgery regarding both pain scores and postoperative opioid consumption." | 1.91 | Comparison of oral versus intravenous methadone on postoperative pain and opioid use after adult spinal deformity surgery: A retrospective, non-inferiority analysis. ( Dunn, LK; Esfahani, K; Naik, BI; Tennant, W; Tsang, S, 2023) |
| " Hospitalization offers a monitored setting for methadone initiation, however dosing practices and safety are not well described." | 1.91 | Rapid Methadone Induction in a General Hospital Setting: A Retrospective, Observational Analysis. ( Adams, ZM; Casey, S; Gale, E; Lambert, E; Omede, FO; Regan, S; Wakeman, SE, 2023) |
| " Patients preferred dosing at the van over the clinic because they were able to "get in and out" faster." | 1.91 | "Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment. ( Castellanos, S; Joshi, N; Knight, KR; Lambdin, BH; Shapiro, B; Steiger, S; Suen, LW, 2023) |
| "Naloxone was prescribed in 16." | 1.91 | Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department. ( Ali, SA; Bedder, M; Harris, R; Shell, J, 2023) |
| "Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U." | 1.91 | Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. ( Bart, G; Bratberg, J; Burns, AL; Cochran, G; DiPaula, BA; Elmes, A; Ghitza, UE; Green, TC; Hill, LG; Homsted, F; Hsia, SL; Jarrett, JB; Legreid Dopp, A; Matthews, ML; Wu, LT, 2023) |
| "Methadone, an OUD treatment, has been shown to be effective in reducing the risk of overdose and improving overall health and quality of life." | 1.91 | Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic. ( Fanelli, JL; Furst, JA; Jarvis, MA; Kennalley, AL; McCall, KL; Mynarski, NJ; Nichols, SD; Piper, BJ, 2023) |
| "Buprenorphine dose hold was less likely for patients who had experienced homelessness/housing insecurity in the year prior to surgery (aOR = 0." | 1.72 | Perioperative Management of Buprenorphine/Naloxone in a Large, National Health Care System: a Retrospective Cohort Study. ( Dougherty, J; Englander, H; Herreid-O'Neill, A; Lovejoy, TI; Mackey, K; Priest, KC; Shull, S; Thoma, J; Wyse, JJ, 2022) |
| "Methadone was associated with a statistically significant increased probability of retention in outpatient treatment as compared to buprenorphine (P < 0." | 1.72 | Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder? ( Kessler, SH; Liss, DB; Schwarz, ES, 2022) |
| "As part of a broader study of opioid misuse, we examined proximity to evidence-based treatment as a potential barrier to treatment access." | 1.72 | Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California. ( Bowles, JM; Davidson, PJ; Faul, M; Gaines, TL, 2022) |
| "Medications for opioid use disorder (MOUD) reduce opioid overdose (OD) deaths; however, prevalence and misuse of MOUD in ED patients presenting with opioid overdose are unclear, as are any impacts of existing MOUD prescriptions on subsequent OD severity." | 1.72 | Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity. ( Allen, LR; Manini, AF; Nobel, I; Richardson, LD; Shastry, S; Vidal, K, 2022) |
| "0% for slow-release oral morphine) and half of all episodes that completed induction reached the minimum effective dosage (51." | 1.72 | Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. ( Dale, LM; Kurz, M; Min, JE; Nosyk, B, 2022) |
| "Relaxed restrictions on medications for opioid use disorder created opportunities for improved patient-centered care." | 1.72 | "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. ( Bagley, SM; Gunn, CM; Harris, MTH; Lambert, AM; Maschke, AD; Walley, AY, 2022) |
| "Medications for opioid use disorder (MOUDs), including methadone, buprenorphine and naltrexone, are associated with lower death rates and improved quality of life for people in recovery from opioid use disorder (OUD)." | 1.72 | Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data. ( Ashmead, R; Bailey, E; Bickert, T; Bonny, AE; Doogan, NJ; Mack, A; Schmidt, S; Tossone, K; Zhang, P, 2022) |
| "Hospitalizations related to opioid use disorder (OUD) are rising." | 1.72 | Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers. ( Binswanger, IA; Calcaterra, SL; Callister, C; Hoover, K; Lockhart, S, 2022) |
| "Of 10,513 individuals with incident opioid use disorder, 1202 (11%) initiated MOUD, 742 (7%) engaged, and 253 (2%) were retained in MOUD at 6 months." | 1.72 | Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. ( Chaisson, CE; Ciemins, E; LaRochelle, MR; Linas, BP; Morgan, JR; Quinn, EK; Stempniewicz, N; Walley, AY; White, LF, 2022) |
| " We aimed to assess the immediate effects of the methadone reformulation on missed doses, days off methadone, changes in medication dosing and dispensations of opioids for pain, and hospitalizations and mortality among all people receiving treatment at or near the time of the change." | 1.72 | The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. ( Dale, LM; Hongdilokkul, N; Krebs, E; Min, JE; Nosyk, B; Schnepel, KT; Shigeoka, H, 2022) |
| " However, evidence to guide appropriate dosing of pharmacotherapy for the treatment of opioid use disorder, such as methadone, based on self-reported opioid use during pregnancy is limited." | 1.72 | Does self-reported consumption of heroin correlate with dose of methadone among pregnant people with opioid use disorder? ( Arlandson, ME; Gonzalez, AM; Patel, A; Premkumar, A, 2022) |
| " It is important to evaluate the changes in unsupervised OAT dosing after the release of the Ontario COVID-19 OAT Guidance based on patients' and prescribers' reports." | 1.72 | Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing. ( Barrass, S; Corace, K; Cragg, S; Hutton, B; Konefal, S; Leece, P; Pana, P; Porath, A; Suschinsky, K; Wyman, J, 2022) |
| "Opioid agonist treatment (OAT) clients frequently bear costs associated with their treatment, including dosing fees." | 1.72 | Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. ( Ali, R; Byrne, J; Chen, R; Degenhardt, L; Farrell, M; Larance, B; Nielsen, S; Santo, T; Tran, AD; Zahra, E, 2022) |
| "Buprenorphine is a partial agonist at mu-opioid receptors and competes for these receptors with other opioids in vitro." | 1.72 | Comparison Between Preoperative Methadone and Buprenorphine Use on Postoperative Opioid Requirement: A Retrospective Cohort Study. ( Dale, RC; Delgado, C; Dinges, EM; Komatsu, R; Nash, M; Peperzak, KA; Terman, GW; Wu, J; Ziga, TM, 2022) |
| "The number of patients with opioid use disorder (OUD) has increased dramatically." | 1.72 | Understanding and co-managing medication treatment options for opioid use disorder. ( Beck, M; Kay, A; Shmuts, R, 2022) |
| "No data exist on comparative risk of cardiac arrhythmias among 3 Medication-Assisted Therapy (MAT) medications in patients with opioid use disorder." | 1.72 | Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders. ( Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X, 2022) |
| "The chapters on opioid dependence in the 26 editions of Cecil Textbook of Medicine published from 1927 through 2020." | 1.72 | Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine. ( Manu, P; Rogozea, LM; Shulman, M, 2022) |
| "Opioid misuse is common, as is opioid agonist treatment of opioid dependence." | 1.72 | Opioid use disorder in anaesthesia and intensive care: Prevention, diagnosis and management. ( Demirkol, A; Murnion, BP, 2022) |
| "Characterize severity of opioid use disorder during pregnancy over time." | 1.72 | Trends in the severity of opioid use disorder during pregnancy over time. ( Bailit, JL; Sadananda, GB; Sundaresh, S, 2022) |
| "Buprenorphine was initiated by 58% and 42% started methadone." | 1.72 | Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. ( Biondi, BE; Schlossberg, EF; Shaw, A; Springer, SA; Vander Wyk, B, 2022) |
| "The primary outcome was opioid overdose (fatal and non-fatal) while on treatment, with secondary outcomes including opioid overdose (first 30 days of treatment), treatment discontinuation, health-care interactions related to treatment of opioid use disorder, receiving a weekly supply of take-home doses and opioid overdose within 30 days of treatment discontinuation." | 1.72 | Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study. ( Antoniou, T; Bozinoff, N; Campbell, T; Gomes, T; Mamdani, M; McCormack, D; Munro, C; Paterson, JM; Sproule, B; Tadrous, M, 2022) |
| " However, given that changes were small, strategies to improve retention in OAT and ensure equitable access to take-home dosing should continue." | 1.72 | Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. ( Antoniou, T; Bozinoff, N; Campbell, TJ; Gomes, T; Kitchen, SA; Men, S; Munro, C; Tadrous, M; Werb, D; Wyman, J, 2022) |
| "Medications for opioid use disorder (MOUD) prescribed in the emergency department (ED) have the potential to save lives and help people start and maintain recovery." | 1.72 | "Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED. ( Beck, SA; Girardin, AL; Potee, BG; Schoenfeld, EM; Simon, C; Soares, WE; Tozloski, JM; Vysetty, S; Westafer, LM, 2022) |
| " We assessed the effects of COVID-19-related changes on take-home methadone dosing in two OTPs serving five rural Oregon counties." | 1.72 | Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. ( Cook, R; Foot, C; Hoffman, KA; Korthuis, PT; Levander, XA; McCarty, D; McIlveen, JW; Terashima, JP, 2022) |
| "The incidence of opioid use disorder (OUD) is increasing worldwide, and the opioid-related overdose crisis is currently a major global challenge." | 1.72 | Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment. ( Hu, WL; Hung, YC; Kuo, CE; Liu, CT; Tsai, MC; Wu, SY; Wu, TC, 2022) |
| "Methadone was administered during 150 episodes of care for 142 unique patients, the majority of whom were male (73%), white (67%), and used fentanyl (85%)." | 1.72 | Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. ( Christine, PJ; Evans, J; Farrell, NM; Kehoe, J; Kim, TW; Laks, J; Taylor, JL; Walley, AY; Weinstein, ZM; White, CS, 2022) |
| "Despite growing awareness of opioid use disorder (OUD), fatal overdoses and downstream health conditions (e." | 1.72 | Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey. ( Anselin, L; Kolak, M; Lin, Q; Pollack, H; Schneider, J; Taylor, B; Watts, B, 2022) |
| "Treatment for opioid use disorder (OUD), particularly medication for OUD, is highly effective; however, retention in OUD treatment is a significant challenge." | 1.72 | Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: A predictive modeling study. ( Jalali, MS; Lich, KH; Marrero, WJ; Naumann, RB; Stafford, C; Wakeman, S, 2022) |
| "Like buprenorphine, methadone is a life-saving medication that can be initiated in the emergency department (ED) to treat patients with an opioid use disorder (OUD)." | 1.72 | Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study. ( Baston, KE; Carroll, G; Ganetsky, VS; Haroz, R; Heil, J; Hunter, K; Ketcham, E; Salzman, MS, 2022) |
| "Among individuals with opioid use disorder (OUD), medications for OUD (MOUD) may lower suicide risk." | 1.72 | Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder. ( Blosnich, JR; Edelman, EJ; Frost, MC; Hawkins, EJ; Richards, JE; Tsui, JI; Williams, EC, 2022) |
| "Opioid misuse and opioid use disorder (OUD) are important comorbidities in people with advanced cancer and cancer-related pain, but there is a lack of consensus on treatment." | 1.72 | Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder. ( Arnold, R; Bulls, H; Dao, E; Fitzgerald Jones, K; Kapo, J; Khodyakov, D; Liebschutz, J; Meier, D; Merlin, J; Paice, J; Ritchie, C, 2022) |
| " Once young people initiated OAT, staying on it was difficult and complicated by daily witnessed dosing requirements and strict rules around repeated missed doses, especially for those receiving methadone." | 1.72 | Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada. ( Buxton, JA; DeBeck, K; Fast, D; Joe, R; Kwa, Y; Pilarinos, A; Thulien, M, 2022) |
| "As Medicaid is the largest payer for opioid use disorder (OUD) treatment services in the United States, information about Medicaid provider reimbursement is critical, and Medicaid payment policies influence the structure of OUD treatment services for everyone with OUD treatment needs." | 1.72 | Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021. ( Aarons, J; Clemans-Cope, L; Lynch, V; Payton, M, 2022) |
| "If methadone distribution was to expand to FQHCs, more counties and a larger area of Georgia would have greater access to methadone treatment." | 1.72 | Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis. ( Anwar, T; Duever, M; Jayawardhana, J, 2022) |
| "Surveys assessed demographics, opioid misuse, depression and anxiety symptoms, trauma history and symptoms, social support, and barriers to retention in treatment (e." | 1.72 | Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities. ( Agius, E; Broman, M; Brown, S; Kollin, R; Lee, G; Lister, JJ; Pasman, E; Resko, SM, 2022) |
| "Individuals with opioid use disorder (OUD) are highly represented among the incarcerated population and are frequent utilizers of the emergency department (ED)." | 1.72 | Emergency department utilization by individuals with opioid use disorder who were recently incarcerated. ( Abare, M; Chyorny, A; Olson, M; Wilhelm-Leen, E; Will, J, 2022) |
| " A need exists to adapt methadone dosing from opioid treatment programs (OTPs) in this era." | 1.72 | Adapting methadone inductions to the fentanyl era. ( Buresh, M; Nahvi, S; Steiger, S; Weinstein, ZM, 2022) |
| "Methadone treatment is proven to be highly successful in preventing opioid use disorder, reducing the use of illicit drugs, and preventing overdoses." | 1.72 | Improving geographic access to methadone clinics. ( Bonifonte, A; Garcia, E, 2022) |
| "Methadone and buprenorphine have pharmacologic properties that are concerning for a high risk of drug-drug interactions (DDIs)." | 1.72 | Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection. ( Acton, EK; Bilker, WB; Brensinger, CM; Dawwas, GK; Hennessy, S; Leonard, CE; Li, L; Miano, TA; Neuman, M; Nguyen, TPP; Soprano, SE; Wang, L; Woody, G; Yu, E, 2022) |
| "Methadone use for opioid use disorder and chronic pain has increased since the start of the century with about 4." | 1.72 | Insulinoma mimic: methadone-induced hypoglycaemia. ( Balaji, A; Chae, K; Kanbour, S; Mathioudakis, N, 2022) |
| " The effects of buprenorphine on sleep-like measures resulted in a biphasic dose-response function, with the highest doses not disrupting actigraphy-based sleep." | 1.72 | Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys. ( Berro, LF; Freeman, KB; Rowlett, JK; Talley, JT; Zamarripa, CA, 2022) |
| "Buprenorphine was generally perceived as more efficacious than both naltrexone and methadone." | 1.72 | Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants. ( Andraka-Christou, B; Buche, J; Haffajee, RL; Page, C; Schoebel, V, 2022) |
| "Adrenergic signaling is involved in opioid use disorder." | 1.72 | Hypermethylation in the promoter region of the ADRA1A gene is associated with opioid use disorder in Han Chinese. ( Cheng, C; Fu, X; Lu, Y; Wang, K; Xie, Q; Zhang, J; Zhu, Y, 2022) |
| "Methadone treatment (MT) for opioid use disorder is only available in opioid treatment programs (OTPs) in the United States, with retention predictive of positive health outcomes." | 1.72 | Comprehensive analysis of discharge reasons from methadone outpatient treatment programs. ( Andraka-Christou, B; Nguyen, TD; Totaram, R, 2022) |
| " We estimated the extent to which different dosing strategies would affect risk of relapse over 12 weeks of treatment, separately for BUP-NX and methadone." | 1.72 | Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. ( Díaz, I; Fishman, M; Goodwin, ATS; Luo, S; Nunes, EV; Rotrosen, J; Rudolph, KE; Shulman, M; Williams, NT, 2022) |
| "Participants enrolled in opiate abuse (n = 82) and control (n = 112) groups completed tasks that challenged selective attention and balance." | 1.72 | Inter-trial variability in postural control and brain activation: Effects of previous opiate abuse. ( Bauer, LO, 2022) |
| " Opioid agonist treatment (OAT) with oral methadone or daily sublingual buprenorphine hydrochloride, either administered separately or in combination with naloxone hydrochloride (SL-BPN, SL-BPN/NX), is supervised by a healthcare professional experienced in treating opioid use disorder to ensure proper dosing and prevent misuse." | 1.72 | Administration and patient-incurred costs associated with opioid agonist treatment in Norway. ( Danø, A; Gibbons, C; Jensen, R; Pedersen, MH, 2022) |
| " However, requirements for observing methadone dosing can impose barriers to patients and increase risk for respiratory illness transmission (e." | 1.72 | Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. ( Blalock, KL; Darnton, J; Grekin, P; Hallgren, KA; Michaels, A; Saxon, AJ; Soth, S; Tsui, JI; Woolworth, S, 2022) |
| "2%) of methadone patients indicated that some form of multi-day take home dosing was offered at their clinic, and 45." | 1.72 | Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID. ( Andres, HJ; Arredondo, C; Bentele, KG; Brady, BR; Coles, H; Downer, M; Garcia, RC; Garnett, I; Granillo, B; Lutz, R; Mahoney, A; Meyerson, BE; Russell, DM; Samorano, S, 2022) |
| "Methadone treatment allowed them to regain their lives from the adverse effects of opioid use disorder." | 1.72 | Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study. ( Kiburi, SK; Maina, G; Mwangi, J, 2022) |
| "Medication for opioid use disorder (MOUD) includes administering medications such as buprenorphine or methadone, often with mental health services." | 1.72 | Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care. ( Dekeseredy, P; Haggerty, T; Sedney, CL; Turiano, NA; Turner, T, 2022) |
| "Access to treatment for opioid use disorder (OUD) is poor." | 1.72 | ( Bates, AE; Martin-Misener, R, 2022) |
| "For those on medication to treat opioid use disorder (MOUD), incarceration in either setting may disrupt treatment." | 1.72 | Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam. ( Bart, G; Cook, R; Giang, LM; Hoffman, K; King, C; Korthuis, PT; Waddell, EN, 2022) |
| "Persons with HIV (PWH) and opioid use disorder (OUD) can have poor health outcomes." | 1.72 | Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. ( Bryant, K; Edelman, EJ; Fiellin, DA; Gordon, AJ; Justice, A; Kennedy, AJ; Korthuis, PT; Kraemer, KL; McGinnis, KA; Merlin, JS; Oldfield, B; Skanderson, M; Williams, EC; Wyse, J, 2022) |
| " In the final adjusted models, clients who reported using methamphetamine in the last 30 days experienced a significantly larger increase in take-home dosage (55." | 1.72 | Changes in methadone take-home dosing before and after COVID-19. ( Amiri, S; Amram, O; Joudrey, PJ; Lutz, R; Thorn, EL, 2022) |
| " OT was perceived to produce lower levels of physiological dependence than methadone, but the requirement for twice supervised dosing was restrictive." | 1.72 | Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran. ( Bastani, P; Charkhgard, N; Conigrave, KM; Kebriaeezadeh, A; Mirrahimi, B; Narenjiha, H; Noroozi, A; Salehi, M; Vaziri, A, 2022) |
| "Relaxation of federal regulations for methadone take-out dosing during the COVID-19 pandemic is unprecedented." | 1.72 | Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year. ( Bart, G; Hodges, JS; Rosenthal, R; Wastvedt, S, 2022) |
| "Buprenorphine (BPN), FDA approved for opioid use disorder (OUD), requires an induction protocol for the patient in mild to moderate withdrawal." | 1.62 | Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series". ( Betsch, B; Sethi, R; Singh, G; Sri Konakanchi, J; Thapa, A, 2021) |
| " The largest hazard ratios for earlier cessation from the deep learning model were observed for treatment factors, including private dosing points (HR=1." | 1.62 | Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment. ( Barbieri, S; Bharat, C; Degenhardt, L; Dobbins, T; Farrell, M; Larney, S, 2021) |
| "Medications for opioid use disorder such as opioid agonist treatment (OAT, including methadone, buprenorphine) are the gold standard intervention for opioid use disorder (OUD)." | 1.62 | Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs. ( Arias, F; Arnsten, J; Cunningham, CO; Olsen, JP; Rivera Mindt, M; Scott, TM, 2021) |
| "In the United States, methadone for opioid use disorder (OUD) is limited to highly regulated opioid treatment programs (OTPs), rendering it inaccessible to many patients." | 1.62 | Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. ( Farrell, NM; Kehoe, J; Kolodziej, J; Komaromy, M; Laks, J; Taylor, JL; Walley, AY, 2021) |
| "Mothers who screen positive for opioid abuse should be referred to a provider experienced in opioid maintenance therapy." | 1.62 | Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up. ( Schroeder, M; White, J, 2021) |
| "Methadone was reported as the most helpful aspect of the methadone maintenance therapy programs; however, participants also expressed negative views about the substance." | 1.62 | Experiences of Clients in Three Types of Methadone Maintenance Therapy in an Atlantic Canadian City: A Qualitative Study. ( Brunelle, C; DiTommaso, E; MacNeill, L; Skelding, B, 2021) |
| " Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively." | 1.62 | The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. ( Altice, FL; Bojko, MJ; Dvoriak, S; Farnum, SO; Islam, Z; Madden, L; Makarenko, I; Marcus, R; Mazhnaya, A; Prokhorova, T; Rozanova, J, 2021) |
| "To understand the role of comorbid substance use disorders (SUDs), or polysubstance use, in the treatment of opioid use disorder (OUD), this study compared patients with OUD only to those with additional SUDs and examined association with OUD treatment receipt." | 1.62 | Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. ( Blow, FC; Bohnert, ASB; Gordon, AJ; Ignacio, RV; Ilgen, MA; Kim, HM; Lin, LA, 2021) |
| "Methadone dosage was significant at a 6-month follow-up." | 1.62 | Pay for Performance and Treatment Outcome in Agonist Treatment for Opioid Use Disorder. ( Levit, A; Loscalzo, E; Sterling, RC; Weinstein, SP, 2021) |
| "On March 16, 2020, Ukraine's Ministry of Health issued nonspecific interim guidance to continue enrolling patients in opioid agonist therapies (OAT) and transition existing patients to take-home dosing to reduce community COVID-19 transmission." | 1.62 | Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. ( Altice, FL; Dvoryak, S; Farnum, SO; Filippovych, M; Fomenko, T; Galvez de Leon, SJ; Islam, ZM; Madden, LM; Meteliuk, A; Pykalo, I, 2021) |
| "Looking forward, to address both opioid use disorder and COVID-19, jails and prisons need to develop capacity to implement mitigation strategies, including universal and rapid COVID-19 testing of staff and incarcerated individuals, and be resourced to provide evidence-based addiction treatment." | 1.62 | COVID-19 and treating incarcerated populations for opioid use disorder. ( Donelan, CJ; Evans, EA; Hayes, E; Potee, RA; Schwartz, L, 2021) |
| "Medications used to treat opioid use disorder can potentially impact dissociative symptoms, but the existing literature has not explored this." | 1.62 | The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder. ( Crawford, TN; Fischer, KB; Gainer, DM; Wright, MD, 2021) |
| "Methadone maintenance treatment (MMT) is effective in decreasing opioid use or facilitating abstinence." | 1.62 | Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment. ( Du, J; Jiang, H; Li, J; Mandali, A; Ren, Q; Sun, B; Voon, V; Weidacker, K; Whiteford, S; Zhang, C; Zhang, Y; Zhou, H; Zhou, Z, 2021) |
| "Buprenorphine is a partial opioid agonist commonly used to treat opioid dependence." | 1.62 | Managing opioid withdrawal precipitated by buprenorphine with buprenorphine. ( Hayes, V; Lintzeris, N; Oakley, B; Wilson, H, 2021) |
| "366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019." | 1.62 | Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. ( Bachellier, J; Bendimerad, P; Brousse, G; Chappuy, M; Hjelmström, P; Kosim, M; Meroueh, F; Nourredine, M; Nubukpo, P; Rolland, B; Trojak, B, 2021) |
| "Hospitalized patients with opioid use disorder who present with acute pain are challenging to manage." | 1.62 | An anesthesiologist-led inpatient buprenorphine initiative. ( Baratta, JL; Ferd, P; Patel, N; Schwenk, ES; Torjman, MC; Viscusi, ER, 2021) |
| "Treatment with medications for opioid use disorder (MOUD) can significantly reduce overdose risk, but no national studies to date have reported on the extent to which AI/ANs access these treatments overall and in relation to other groups." | 1.62 | Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample. ( Ahmad, NJ; Garrett, B; Krawczyk, N; Patel, E; Saloner, B; Solomon, K; Stuart, EA, 2021) |
| "Past research suggests that people with opioid dependence show increased consumption of sweet food, but it is unclear if this is influenced by altered taste preference and/or taste perception." | 1.62 | Associations between opioid dependence and sweet taste preference. ( Garfield, JBB; Lubman, DI, 2021) |
| "(1) Background: Opioid use disorder (OUD) is a complex condition that can require long-term treatment." | 1.62 | What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report. ( Benoit Hardouin, J; Challet-Bouju, G; Dany, A; Grall-Bronnec, M; Guillou-Landreat, M; Laforgue, E; Leboucher, J; Victorri-Vigneau, C, 2021) |
| "Methadone maintenance treatment (MMT) in the United States, and particularly the clinic system of distribution, is often criticized as punitive, over-regulated, and misaligned to the needs of many patients." | 1.62 | A chance to do it better: Methadone maintenance treatment in the age of Covid-19. ( Frank, D, 2021) |
| "Methadone maintenance treatment is a life-saving treatment for people with opioid use disorders (OUD)." | 1.62 | Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. ( Dasgupta, N; Day, E; Figgatt, MC; Salazar, Z; Vincent, L, 2021) |
| "Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied and undertreated." | 1.62 | Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events. ( Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY, 2021) |
| "To assess the pharmacokinetics and opioid effects of methadone after administration of multiple doses by means of 2 dosing regimens of methadone-fluconazole-naltrexone." | 1.62 | Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs. ( Cho, P; Fitzgerald, AH; Komp, MS; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC, 2021) |
| "As the coronavirus disease 2019 (COVID-19) pandemic threatens to worsen the opioid crisis, payers must rapidly deploy policies to ensure care for individuals with opioid use disorder." | 1.62 | Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19. ( Bachireddy, C; Terplan, M, 2021) |
| "Methadone is an opioid drug commonly prescribed for treating opioid use disorder in pregnant women and was found to accumulate at high levels in the fetal brain of mice, which fell quickly after birth." | 1.62 | Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry. ( Allen, MR; Atwood, BK; Baucum, AJ; Engleman, EA; Gao, Y; Grecco, GG; Haggerty, DL; Hoffman, H; Huang, JY; Katner, SN; Kim, J; Lu, HC; Masters, AR; Metzger, CE; Mork, BE; Morris, CW; Newell, EA; Reeves, KC; Sheets, PL; Wu, YC; Yamamoto, BK, 2021) |
| " While some clinicians expressed support for the increased flexibility around dosing and use of telemedicine, others expressed concern about increased risk of medication diversion and overdose." | 1.62 | Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study. ( Dopp, AR; Hunter, SB; Ober, AJ; Uscher-Pines, L, 2021) |
| "Women with histories of opioid misuse face drug-related stigma, which can be amplified during pregnancy." | 1.62 | Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio. ( Clapp, J; Howard, H; Madden, D; Spadola, C; Syvertsen, JL; Toneff, H, 2021) |
| " Dosage adjustments were more frequent (p < 0." | 1.62 | Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients. ( Bohr, U; Enge, S; Guillery, SPE; Hellweg, R; Kronenberg, G; Kunte, H, 2021) |
| "Although opioid use disorder (OUD) is common in patients with cirrhosis, it is unclear how medication treatment for OUD (MOUD) is used in this population." | 1.62 | Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis. ( Agbalajobi, O; Belperio, P; Fine, MJ; Gellad, W; Good, CB; Kraemer, K; Morgan, T; Rogal, S; Youk, A; Zhang, H, 2021) |
| "Individuals receiving medications for opioid use disorder after delivery were included in the study." | 1.62 | Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. ( Bernson, D; Bernstein, J; Bharel, M; Greenfield, SF; Hadland, SE; Hoeppner, BB; Kelly, JF; Nielsen, TC; Reddy, J; Schiff, DM; Taveras, EM; Terplan, M; Wilens, TE, 2021) |
| " Opioid-related variables as seroprevalence rates, other previous lifetime maintenance program, the daily opioid dosage and the daily alcohol use are the most discriminative variables between both groups." | 1.62 | Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders. ( García-Marchena, N; Martinez Delgado, JM; Ruíz Ruíz, JJ, 2021) |
| "Buprenorphine is a semisynthetic opioid, a partial mu-opioid agonist with limited respiratory toxicity preferably used by these patients, as it is accompanied by significantly lower risk factors in the development of obstructive and central sleep apnea." | 1.62 | The effect of buprenorphine vs methadone on sleep breathing disorders. ( Adimi Naghan, P; Malekmohammad, M; Setareh, J, 2021) |
| "Methadone maintenance treatment is reported as cost-effective in treatment of opioid use disorder." | 1.62 | Estimate cost of providing methadone maintenance treatment at a methadone clinic in Nairobi Kenya: direct costs. ( Kendagor, M; Kiburi, SK; Mogaka, B; Mutinda, M, 2021) |
| " We used careful diagnostics, simultaneous psychosocial efforts were given, the outcome was continously evalutated and the dosage was administered according to the principle of lowest effective dose." | 1.62 | [Methadone and buprenorphine maintenance therapy of opioid dependence - 10 years of experience]. ( Hoffmann, O; Ljungberg, T, 2021) |
| "Methadone maintenance treatment (MMT) is reco-gnized as a reference treatment for opioid dependence." | 1.62 | Methadone overdose in patients following methadone mainte- nance treatment:A three years overview in the district of Bari (South-Italy). ( De Donno, A; Favia, M; Introna, F; Mita, Q; Santoiemma, I; Strisciullo, G, 2021) |
| "Standard of care for opioid use disorder (OUD) includes medication and counseling." | 1.62 | A Virtual Reality Meditative Intervention Modulates Pain and the Pain Neuromatrix in Patients with Opioid Use Disorder. ( Bluth, MH; Faraj, MM; Goldberg, E; Greenwald, MK; Lipanski, NM; Marusak, HA; Morales, A, 2021) |
| " Some systems deviated from evidence-based treatment by limiting OAT dosage to low levels, requiring counseling for participation and requiring detoxification before medication initiation." | 1.62 | Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters. ( Bandara, S; Barry, CL; Kennedy-Hendricks, A; Merritt, S; Saloner, B, 2021) |
| "Retaining people with opioid use disorder in treatment longer can increase these benefits." | 1.62 | Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. ( Ching, JH; Goldhaber-Fiebert, JD; Owens, DK; Salomon, JA; Trafton, JA, 2021) |
| "Longer duration of medication for opioid use disorder use during pregnancy appears to be associated with improved maternal and perinatal outcomes." | 1.62 | Outcomes associated with the use of medications for opioid use disorder during pregnancy. ( Chen, Q; James, AE; Jarlenski, MP; Kelley, D; Kim, JY; Krans, EE; Rothenberger, SD, 2021) |
| "He had a medical history of opiate dependence and was receiving 60 mg of methadone once daily." | 1.62 | Interaction between methadone and clarithromycin as the suspected cause of an opioid toxidrome. ( Edwardes, D; Murtaza, M; Subbe, C; Wallace, B, 2021) |
| "Most buprenorphine treated participants (67." | 1.62 | Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs. ( Bhatraju, E; Glick, SN; Hiser, JKD; Poorman, E; Tsui, JI, 2021) |
| "Medications for opioid use disorder (OUD) are the gold standard for treating OUD and preventing overdose but are underused among people with OUD, with disproportionately low treatment initiation and retention among people of color." | 1.62 | Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. ( Andraka-Christou, B, 2021) |
| " We also analyzed state-level data on confirmed accidental opioid-involved deaths to assess if relaxation of take-home dosing restrictions and in-person attendance requirements correlated with increased methadone-involved fatal overdose rates." | 1.62 | Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. ( Brothers, S; Heimer, R; Viera, A, 2021) |
| "Patients with opioid use disorder (OUD) often have complex health care needs." | 1.62 | Plausibility of patient-centred care in high-intensity methadone treatment: reflections of providers and patients. ( Maina, G; Marshall, K; Sherstobitoff, J, 2021) |
| "Buprenorphine and methadone were associated with highest retention prevalence regardless of OUD or AUD severity." | 1.62 | An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders. ( Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY, 2021) |
| "Codeine was detected in 29% of the samples." | 1.62 | Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol™ (morphine sulfate). ( Beck, O; Böttcher, M; Keller, T; Lierheimer, S; Monticelli, FC, 2021) |
| "Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids." | 1.62 | "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives. ( Curran, L; Frank, D; Guarino, H; Mateu-Gelabert, P; Perlman, DC; Walters, SM, 2021) |
| "Methadone maintenance treatment (MMT) remains the cornerstone for the management of opiate abuse." | 1.62 | Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment. ( Chang, WC; Cheng, WC; Chiang, YC; Ho, IK; Huang, CL; Lane, HY; Ma, WL; Su, YT; Yang, JC, 2021) |
| " Participants had histories of both heroin and prescription opioid use, and previous OAT including daily dosing of buprenorphine and methadone." | 1.62 | Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. ( Arunogiri, S; Barnett, A; Bathish, R; Dunlop, AJ; Graham, R; Haber, P; Hayes, V; Lintzeris, N; Lubman, DI; Savic, M, 2021) |
| "The Methadone Maintenance Treatment Stigma Mechanisms Scale appears to be a reliable measure of methadone maintenance treatment stigma with robust validity in a sample of people with opioid use disorders receiving methadone maintenance treatment." | 1.56 | Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). ( Copenhaver, MM; Cunningham, CO; Earnshaw, VA; Mittal, ML; Smith, LR; Wagner, K, 2020) |
| "Type of medication for opioid use disorder received appeared to be age associated." | 1.56 | Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. ( Bagley, SM; Bernson, D; Hadland, SE; Land, T; Larochelle, MR; Patel, A; Samet, JH; Silverstein, M; Walley, AY; Wang, N; Xuan, Z, 2020) |
| "Medication treatment for opioid use disorder (MOUD), methadone, buprenorphine, and naltrexone, is widely used to treat OUD in the community." | 1.56 | An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. ( Brezel, ER; Fox, AD; Powell, T, 2020) |
| "We estimated the cascade of care for opioid use disorder and identified factors associated with care engagement for people with opioid use disorder (PWOUD) provincially." | 1.56 | The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. ( Homayra, F; Hongdilokkul, N; McGowan, G; Min, JE; Nosyk, B; Pearce, LA; Piske, M; Socias, ME; Zhou, H, 2020) |
| "Methadone maintenance treatment (MMT) has been proven to be effective in treating opioid dependence." | 1.56 | Preferences for methadone clinics among drug users in Vietnam: a comparison between public and private models. ( Dang, AD; Ho, CSH; Ho, RCM; Latkin, CA; Le, TA; Nguyen, CT; Nguyen, TA; Nguyen, THT; Phan, HT; Tran, BX; Vu, GT; Ying, J; Zhang, MWB, 2020) |
| "The impact of medications for opioid use disorder (MOUD) on against medical advice (AMA) discharges among people who inject drugs (PWID) hospitalized for endocarditis is unknown." | 1.56 | Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis. ( Johnson, JA; Liebschutz, JW; Martin, B; Montgomery, MW; Mosquera, M; Price, CD; Robinson, D; Schnipper, JL; Solomon, DA; Suzuki, J; Weiss, RD, 2020) |
| "Methadone was an independent determinant of asthma, adjusting for smoking status (OR 3." | 1.56 | COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care. ( Ashworth, M; Durbaba, S; Jolley, CJ; Kelleher, M; Mehta, S; Parmar, N; White, P, 2020) |
| "The increasing prevalence of opioid use disorders among pregnant and postpartum women (PPW) has generated a need for greater availability of specialized programs offering evidence-based and comprehensive substance use disorder treatment services tailored to this population." | 1.56 | Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings. ( Ali, MM; Hinde, JM; Meinhofer, A, 2020) |
| "Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0." | 1.56 | Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. ( Ameli, O; Azocar, F; Chaisson, CE; Crown, WH; Larochelle, MR; McPheeters, JT; Sanghavi, DM; Wakeman, SE, 2020) |
| "While many individuals with opioid use disorder seek treatment at residential facilities to initiate long-term recovery, the availability and use of medications for opioid use disorder (MOUDs) in these facilities is unclear." | 1.56 | Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. ( Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A, 2020) |
| "55 347 people with opioid use disorder who received OAT between 1 January 1996 and 30 September 2018." | 1.56 | Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. ( Homayra, F; Irvine, M; McGowan, G; Min, JE; Nosyk, B; Pearce, LA; Piske, M; Slaunwhite, A; Zhou, H, 2020) |
| " Although the principal methadone metabolizing enzyme remains controversial, our results suggest that sex, CYP2B6 genotype, and BMI should be incorporated into multivariate models to create methadone dosing algorithms." | 1.56 | Toward precision prescribing for methadone: Determinants of methadone deposition. ( Brown, LS; Chakan, LM; Dharia, A; Ding, Y; Kharasch, ED; Markatou, M; McLeod, A; Morse, GD; Talal, AH; Venuto, CS, 2020) |
| "Treatment with methadone or buprenorphine is the current standard of care for opioid use disorder." | 1.56 | Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States. ( Cerdá, M; Goedel, WC; Hadland, SE; Marshall, BDL; Shapiro, A; Tsai, JW, 2020) |
| "A single poisoning was found in 62." | 1.56 | Non-Opioid Substances Acute Poisonings with Suicidal Intent in Patients with Opioid Use Disorder. ( Babulovska, A; Simonovska, NK; Stefanovska, VV, 2020) |
| "People with opioid use disorder are prevalent in criminal problem-solving courts and dependency courts, which have rehabilitative aims." | 1.56 | Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff. ( Andraka-Christou, B; Atkins, D; Madeira, J; Silverman, RD, 2020) |
| "counties, 1,889 (60." | 1.56 | Opioid Use Disorder Treatment Facilities With Programs for Special Populations. ( Alinsky, RH; Cerdá, M; Hadland, SE; Jent, VA; Marshall, BDL; Mauro, PM, 2020) |
| "344 methadone maintenance treatment (MMT) patients were recruited with records and measurements on methadone dose, plasma methadone concentrations, and treatment emergent symptom scales (TESS)." | 1.56 | Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use. ( Chen, ACH; Chung, RH; Fang, CP; Kuo, HW; Liu, CC; Liu, SC; Liu, TH; Liu, YL; Tsou, HH; Wang, SC, 2020) |
| " On the fourteenth day of SROM treatment patients switched from racemic methadone took an average dosage of 922." | 1.56 | Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care. ( Baschirotto, C; Kuhn, S; Lehmann, K; Reimer, J; Verthein, U, 2020) |
| "Fentanyl is a potent synthetic opioid that has contributed to increasing overdose deaths in the United States in recent years." | 1.56 | One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. ( Carroll, JJ; Green, TC; Rich, JD; Stone, AC, 2020) |
| "The methadone group had a lower mean newborn birthweight (2874±459 g) and a greater incidence of low birth weight (11." | 1.56 | Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. ( Davis, JA; Garretto, D; Garry, ET; Herrera, KM; Ly, V; Staszewski, CL, 2020) |
| "Medication for opioid use disorder (MOUD) improves both maternal and neonatal outcomes for pregnant women with opioid use disorder (OUD)." | 1.56 | Medications for opioid use disorder in pregnancy in a state women's prison facility. ( Amos, E; Jones, HE; Knittel, AK; Thorp, JM; Zarnick, S, 2020) |
| "The US is confronted with a rise in opioid use disorder (OUD), opioid misuse, and opioid-associated harms." | 1.56 | Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. ( Burden, J; Codell, NK; Drexler, K; Dungan, MT; Gordon, AJ; Hagedorn, H; Hawkins, EJ; Mhatre-Owens, A, 2020) |
| "Medications for opioid use disorder (MOUD), such as methadone and buprenorphine, are effective strategies for treatment of opioid use disorder (OUD) and reducing overdose risk." | 1.56 | Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. ( Bruneau, J; Cochran, G; Cox, N; Gordon, AJ, 2020) |
| "Most people with opioid use disorder (OUD) are not treated with FDA-approved medications methadone, buprenorphine, or naltrexone." | 1.56 | Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. ( Bachhuber, MA; Barry, CL; Kennedy-Hendricks, A; McGinty, EE; Stone, E, 2020) |
| "Patients with opioid use disorder (OUD) are frequently admitted for invasive infections." | 1.56 | A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections. ( Durkin, MJ; Liang, SY; Liss, DB; Marks, LR; Munigala, S; Schwarz, ES; Warren, DK, 2020) |
| "Although homelessness and opioid use disorder (OUD) are important public health issues, few studies have examined their cooccurrence." | 1.56 | Correlates of Homelessness Among Patients in Methadone Maintenance Treatment. ( Barry, DT; Beitel, M; Gaeta, M; Madden, LM; Oberleitner, DE; Oberleitner, LMS; Tamberelli, JF, 2020) |
| "Many people being treated for opioid use disorder continue to use drugs during treatment." | 1.56 | Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials. ( Bertz, JW; Burgess-Hull, AJ; Epstein, DH; Kowalczyk, WJ; Panlilio, LV; Phillips, KA; Preston, KL; Stull, SW, 2020) |
| "Opioid use during pregnancy is rising, with an estimated 14-22% of women obtaining an opioid prescription during pregnancy." | 1.56 | Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment. ( Haug, NA; Jancaitis, B; Kelpin, S; Masho, S; May, J; Svikis, D, 2020) |
| "The independent variable was chronic pain measured at study inception using the Brief Pain Inventory-Short Form." | 1.56 | Comparison of psychiatric comorbidity in treatment-seeking, opioid-dependent patients with versus without chronic pain. ( Higgins, C; Matthews, K; Smith, BH, 2020) |
| "Fewer than 20% of Americans with opioid use disorder receive empirically-supported treatment." | 1.51 | Innovations in efforts to expand treatment for opioid use disorder. ( Sigmon, SC, 2019) |
| "Fentanyl has become widespread in the illicit opioid supply, and is a major driver of overdose mortality." | 1.51 | Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. ( Gryczynski, J; Hill, P; Mitchell, SG; Nichols, H; Schwartz, RP; Wireman, K, 2019) |
| "Buprenorphine participants were referred from NYC jails to a public hospital office-based buprenorphine program and not enrolled in the parent trial." | 1.51 | Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. ( Badolato, R; Flannery, M; Garment, AR; Giftos, J; Lee, JD; McDonald, RD; Tofighi, B; Velasquez, M; Vittitow, A, 2019) |
| "Patients with opioid use disorder admitted to publicly funded residential treatment programs in the province of Ontario between January 1, 2013, and December 31, 2016." | 1.51 | Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes. ( Harrington, K; Kahan, M; Leece, P; Meaney, C; Que, B; Shehadeh, V; Spithoff, S; Sullivan, F; Urbanoski, K, 2019) |
| "Methadone maintenance is an effective treatment for opioid use disorder (OUD), yet many methadone-maintained patients (MMPs) struggle with cocaine use during OUD recovery." | 1.51 | Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients. ( Ayaz, H; Brooner, RK; Dunn, KE; Huhn, AS; Sweeney, MM; Yip, SW, 2019) |
| "Given rising rates of opioid use disorder (OUD) and related consequences, opioid treatment programs (OTPs) can play a pivotal role in the U." | 1.51 | Characteristics and current clinical practices of opioid treatment programs in the United States. ( Byrd, DJ; Campbell, TB; Clarke, TJ; Jones, CM; McCance-Katz, EF; Ohuoha, C, 2019) |
| "Opioid addiction is a serious public health concern with severe health and social implications; therefore, extensive therapeutic efforts are required to keep users drug free." | 1.51 | Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction. ( Baijnath, S; Gopal, ND; Govender, T; Kruger, HG; Naicker, T; Pamreddy, A; Teklezgi, BG, 2019) |
| "Methadone was preferred by those seeking sedation and wishing to continue using other opioids, and buprenorphine/naloxone was most effective for participants no longer wishing to experience sedation and seeing opioid abstinence as an end point in their recovery." | 1.51 | Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder. ( Bishop, B; Deering, D; Gilmour, J, 2019) |
| "Postoperatively, he developed OIC and Ogilvie syndrome, then following treatment with methylnaltrexone experienced an acute bowel perforation." | 1.51 | Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report. ( Blackney, KA; Edwards, DA; Kamdar, NV; Liu, CA, 2019) |
| " Data collected included demographic data, laboratory tests, antiretroviral treatment history, methadone dosing and drug abstinence." | 1.51 | Risk factors for kidney disease among HIV-1 positive persons in the methadone program. ( Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E, 2019) |
| "We compared the risk of serious infection among patients initiating long-acting opioid analgesics with and without previously reported immunosuppressive properties." | 1.51 | Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study. ( Greevy, RA; Griffin, MR; Grijalva, CG; Mitchel, EF; Schaffner, W; Stein, CM; Wiese, AD, 2019) |
| "Methadone maintenance is an effective treatment for opioid use disorder, yet many methadone-maintained patients (MMPs) continue to struggle with chronic relapse." | 1.51 | Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients. ( Ayaz, H; Brooner, RK; Dunn, KE; Huhn, AS; Kidorf, MS; Sweeney, MM; Tompkins, DA, 2019) |
| "Methadone maintenance treatment (MMT) is a harm reduction approach for persons who wish to stop using opioids and is rather effective if used for a minimum of 12 months." | 1.51 | Methadone maintenance treatment as social control: Analyzing patient experiences. ( Jeske Pearson, C; O'Byrne, P, 2019) |
| " Considerable evidence documents the treatment effectiveness of MMT and, in turn, the importance of adequate dosing to MMT's effectiveness." | 1.51 | Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017. ( D'Aunno, T; Park, SE; Pollack, HA, 2019) |
| "Purpose With the rise of opioid use disorder (OUD) among women of childbearing age, effective care models must address the complex needs of pregnant and postpartum women with OUD." | 1.51 | Coordinating Outpatient Care for Pregnant and Postpartum Women with Opioid Use Disorder: Implications from the COACHH Program. ( Connolly, KA; Hodgins, FE; Lang, JM; Malseptic, GG; Melby, LH, 2019) |
| "We recruited 3,620 patients in 27 addiction units in Italy and collected data on the self-reported rate of intravenous injection of methadone (MET), buprenorphine (BUP), BUP-naloxone (NLX), OMT dosage and type, experience of and reason for misuse, concurrent intravenous benzodiazepine misuse, pattern of -misuse in relation to admission to the addiction unit and ER -admissions because of misuse." | 1.51 | Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. ( Cibin, M; Lugoboni, F; Tamburin, S; Zamboni, L, 2019) |
| "Ever-increasing numbers of opioid use disorder (OUD) in Canada has created the recent opioid crisis." | 1.51 | Sociodemographic characteristics of patients with children in a methadone maintenance program: a cross-sectional study. ( Bhatt, M; Hudson, J; Luetam, S; Luo, C; Mouravska, N; Samaan, Z; Sanger, N; Shahid, H; Shams, I; Thabane, L; Zielinski, L, 2019) |
| "Methadone treatment was divided into medicated (methadone was dispensed) and nonmedicated (methadone was not dispensed) periods and analyzed as a time-varying exposure." | 1.51 | Association of Methadone Treatment With Substance-Related Hospital Admissions Among a Population in Canada With a History of Criminal Convictions. ( Moniruzzaman, A; Russolillo, A; Somers, JM, 2019) |
| "Our study aimed to evaluate the impacts of the cytochrome P450 (CYP) 2B6-G516T and CYP2D6 genetic polymorphisms on pharmacokinetic and clinical parameters in patients receiving methadone maintenance treatment." | 1.51 | Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. ( Bouquié, R; Challet-Bouju, G; Dano, C; Grall-Bronnec, M; Hardouin, JB; Laforgue, EJ; Le Geay, B; Leboucher, J; Verstuyft, C; Victorri-Vigneau, C, 2019) |
| "Opioid agonist treatment is considered important in preventing acquisition of hepatitis C virus (HCV) among people who inject drugs; however, the role of dosage in opioid agonist treatment is unclear." | 1.51 | Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. ( Artenie, AA; Bruneau, J; Gauvin, L; Høj, S; Jacka, B; Jutras-Aswad, D; Minoyan, N; Roy, É; Zang, G, 2019) |
| "Buprenorphine/naloxone has a lower abuse potential than buprenorphine and should therefore be prioritized as the prescribed drug." | 1.51 | Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. ( Johnson, B; Richert, T, 2019) |
| "An R-methadone model was developed and validated against 11 retrospective clinical studies prior to use in all subsequent studies." | 1.51 | The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study. ( Al Zabit, D; Badhan, RKS; Gittins, R, 2019) |
| "The buprenorphine dose was further increased based on clinical judgment." | 1.51 | Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. ( Calcaterra, SL; Smith, C; Terasaki, D, 2019) |
| "Personality is associated with substance use patterns and may be an appropriate target for intervention for those undergoing MMT to reduce opioid use, and potentially dangerous concurrent use of other drugs, while receiving methadone." | 1.51 | Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients. ( Barrett, SP; Chinneck, A; Conrod, PJ; Laroque, F; Lawrence, M; Mahu, IT; Morin, JF; Nogueira-Arjona, R; Sako, A; Stewart, SH; Swansburg, J, 2019) |
| "Perinatal opioid use disorder (OUD) is a life-threatening condition that significantly impacts women in rural areas." | 1.51 | Treating perinatal opioid use disorder in rural settings: Challenges and opportunities. ( Goodman, DJ; Higgins, TM; Meyer, MC, 2019) |
| "There has been a rise in opioid abuse and related injection drug use in the United States, and treatment for opioid use disorders may be underutilized." | 1.48 | Utilization of buprenorphine and methadone among opioid users who inject drugs. ( Burt, R; Glick, SN; Thiede, H; Tsui, JI, 2018) |
| "Methadone maintenance treatment is an effective way to reduce harms associated with opioid use disorder and, in several countries, is delivered in community-based primary care settings." | 1.48 | Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder. ( Adams, E; Hering, R; Jordan, M; Livingston, JD; MacMillan, Z, 2018) |
| "Methadone maintenance treatment was the primary independent variable and was treated as a time-varying exposure." | 1.48 | Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. ( McCandless, LC; Moniruzzaman, A; Patterson, M; Russolillo, A; Somers, JM, 2018) |
| "The prevalence of opioid use disorders (OUDs) is rising across the United States." | 1.48 | Expanding Treatment Opportunities for Hospitalized Patients with Opioid Use Disorders. ( Perrone, J; Weinrieb, RM; Winetsky, D, 2018) |
| "Methadone has a long history of pain relief and successful substitute for maintenance treatment in heroin and narcotic addiction." | 1.48 | Forensic Toxicology Perspectives of Methadone-associated Deaths in Tehran, Iran, a 7-year Overview. ( Akhgari, M; Amini-Shirazi, N; Iravani, FS, 2018) |
| " Lower methadone dosage was significantly associated with improvements in the physical, psychological, and environmental domains." | 1.48 | Evaluation of Methadone Treatment in Malaysia: Findings from the Malaysian Methadone Treatment Outcome Study (MyTOS). ( Abdullah, N; Ali, N; Aziz, SA; Danaee, M; Mahmud, M; Mi, NC; Nordin, S; Paranthaman, V; Yee, A, 2018) |
| "Opioid addiction in pregnancy is a growing concern that has recently received a great deal of attention." | 1.48 | Invited Commentary: A Novel Strategy for Addressing Unmeasured Confounding When Comparing Opioid Agonist Therapies in Pregnancy. ( Lemon, LS, 2018) |
| "The prevalence of risky opioid use, opioid use disorder, and related harms continue to rise among youth (adolescents and young adults age 15-25) in North America." | 1.48 | Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions. ( Chang, DC; Fairbairn, N; Klimas, J; Wood, E, 2018) |
| "Methadone treatment was developed by Drs." | 1.48 | From Narcotic to Normalizer: The Misperception of Methadone Treatment and the Persistence of Prejudice and Bias. ( Joseph, H; Woods, JS, 2018) |
| "Methadone has been recognized as an effective maintenance treatment for opioid dependence." | 1.48 | Plasma Testosterone and Sexual Function in Southeast Asian Men Receiving Methadone and Buprenorphine Maintenance Treatment. ( Danaee, M; Loh, HS; Ng, CG; Riahi, S; Sulaiman, AH; Yee, A, 2018) |
| "Adults with a diagnosis of opioid dependence who initiated treatment with XR-NTX, BUP, MET, or NPT between January 1, 2011 and December 31, 2014 were identified in the Truven Health MarketScan Commercial administrative claims database." | 1.48 | Healthcare utilization and costs associated with treatment for opioid dependence. ( Atreja, N; Duncan, M; Gore, M; Shah, A; Tai, KS, 2018) |
| "Methadone maintenance treatment (MMT) services may reduce the risk of HIV transmission if patients completely adhere to the treatment." | 1.48 | Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. ( Latkin, CA; Nguyen, LH; Tran, BX; Tran, TT, 2018) |
| "Methadone maintenance programs (MMP) for opioid dependence treatment have been widely used due to their effective therapeutic outcomes." | 1.48 | Harm reduction program use, psychopathology and medical severity in patients with methadone maintenance treatment. ( Esojo, A; Grau-López, L; Martínez-Luna, NG; Palma-Álvarez, RF; Perea, M; Robles-Martínez, M; Rodríguez-Cintas, L; Roncero, C, 2018) |
| "Methadone maintenance treatment center in Connecticut, USA." | 1.48 | An investigation of an open-access model for scaling up methadone maintenance treatment. ( Ball, SA; Barry, DT; Eggert, KF; Farnum, SO; Freeman, RM; Madden, LM; Quanbeck, AR; Savage, ME; Schottenfeld, RS; Shi, JM, 2018) |
| "Unfortunately, treatment of opioid dependence is difficult, particularly because of codependence - for example, on alcohol or other drugs of abuse." | 1.48 | Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. ( Bujalska-Zadrożny, M; de Cordé, A; Filip, M; Kleczkowska, P; Krząścik, P; Wolińska, R, 2018) |
| "8), lower OAT dosage (aOR = 1." | 1.48 | Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. ( Altice, FL; Dvoriak, S; Filippovich, S; Madden, L; Makarenko, I; Marcus, R; Mazhnaya, A; Pykalo, I, 2018) |
| "Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module." | 1.48 | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. ( Cooper, C; Cox, J; Hamelin, AM; Harper, S; Klein, MB; McLinden, T; Moodie, EEM; Rossi, C; Rourke, SB; Walmsley, SL, 2018) |
| "Methadone maintenance treatment (MMT) has been shown to be an effective therapeutic strategy for opioid users." | 1.48 | Factors affecting the dose of methadone among patients receiving methadone maintenance therapy in Taiwan. ( Chung, KS; Hsu, CY; Li, DJ; Wu, HC; Yen, CF, 2018) |
| "In patients with severe opioid use disorder enrolled into the SALOME trial, injectable hydromorphone provided similar outcomes to injectable diacetylmorphine." | 1.48 | Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. ( Anis, AH; Bansback, N; Brissette, S; Guh, D; Harrison, S; Janmohamed, A; Krausz, M; MacDonald, S; Marsh, DC; Oviedo-Joekes, E; Schechter, MT, 2018) |
| "Participants were recruited from an opioid dependence treatment center in an urban setting in the Southeastern United States." | 1.48 | Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy. ( Hicks, J; Morse, E; Wyant, DK, 2018) |
| " In Norway, there has been vocal patient resistance to the newest medication, buprenorphine-naloxone (BNX), and complaints have focused on the side effect profile." | 1.48 | Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. ( Bjørnestad, R; Clausen, T; Muller, AE, 2018) |
| "Methadone was found in 56 of those cases and was declared as the cause of death in 39 cases (70%)." | 1.48 | Methadone Maintenance Treatment: A 15-year Retrospective Study in Split-Dalmatia County, Croatia. ( Definis-Gojanovic, M; Kljucevic, Z; Sliskovic, L; Susnjar, H; Sutlovic, D; Viskovic, I, 2018) |
| "Treating patients with opioid use disorder (OUD) and traumatic brain injury illustrates 6 neurobiological principles about the actions of 2 contrasting opioid analgesics, morphine and fentanyl, as well as pharmacotherapies for OUD, methadone, naltrexone, and buprenorphine." | 1.48 | Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury. ( Graham, DP; Kosten, TR; Nielsen, DA, 2018) |
| "Drug overdoses are the leading cause of accidental death in the United States." | 1.48 | Medical, psychosocial, and treatment predictors of opioid overdose among high risk opioid users. ( Cropsey, KL; Dantzler, J; Galbraith, JW; Hodgin, K; Schiavon, S; Sellers, A; Word, M, 2018) |
| "Buprenorphine was associated with decreased all-cause mortality (AHR, 0." | 1.48 | Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. ( Bagley, SM; Bernson, D; Land, T; Larochelle, MR; Liebschutz, JM; Stopka, TJ; Walley, AY; Wang, N; Xuan, Z, 2018) |
| "Treatment for opioid dependence in Ireland is provided predominantly by general practitioners (GP) who have undergone additional training in opioid agonist treatment (OAT) and substance misuse." | 1.48 | Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland. ( Crowley, D; Delargy, I; McBride, A; Van Hout, MC, 2018) |
| "Methadone Maintenance Treatment (MMT) is utilized by an increasingly broad age-range of individuals with opioid use disorders." | 1.48 | Characteristics of Medicaid recipients in Methadone Maintenance Treatment: A comparison across the lifespan. ( Brooks, JM; Bruce, ML; Bryson, WC; Cotton, BP; Lohman, MC, 2018) |
| "Methadone maintenance treatment (MMT) is one of the best evidence-based opioid substitution treatments (OSTs), but there is uncertainty about whether methadone treatment reduces the risk of mortality among convicted offenders over extended follow-up periods." | 1.48 | Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada. ( Moniruzzaman, A; Russolillo, A; Somers, JM, 2018) |
| " The primary outcome was continuous retention in treatment as measured by opioid agonist dosing records between patients with clinic (onsite) pharmacy dosing versus community (offsite) pharmacy dosing." | 1.48 | Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies. ( Eibl, JK; Gauthier, G; Marsh, DC, 2018) |
| "For methadone, there were significant reductions in the rate of suicidal behaviors (hazard ratio=0." | 1.48 | Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. ( Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J, 2018) |
| "Patients with opioid use disorder (OUD) show memory deficiencies and impaired treatment outcomes." | 1.48 | Correlation of cytokines, BDNF levels, and memory function in patients with opioid use disorder undergoing methadone maintenance treatment. ( Chang, YH; Chen, KC; Chen, PS; Chen, SH; Chen, SL; Chu, CH; Hong, JS; Huang, SY; Lee, IH; Lee, SY; Lu, RB; Tzeng, NS; Wang, TY; Yang, YK, 2018) |
| " There is a need to better understand risk for adverse outcomes during and after OAT, and for innovative approaches to identifying people at greatest risk of adverse outcomes." | 1.48 | Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. ( Ali, R; Degenhardt, L; Dobbins, T; Fiellin, DA; Hickman, M; Jones, NR; Larney, S; Mattick, RP; Nielsen, S, 2018) |
| "Buprenorphine or methadone was initiated clinically." | 1.48 | Prenatal Treatment and Outcomes of Women With Opioid Use Disorder. ( Brogly, SB; Hernández-Díaz, S; Regan, E; Saia, KE; Werler, MM, 2018) |
| "008), dosage of methadone (HR=0." | 1.48 | Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. ( Amiri, S; Amram, O; Hirchak, K; Lutz, R; McDonell, MG; McPherson, SM; Roll, JM, 2018) |
| "Over 300,000 patients with an opioid use disorder (OUD) receive methadone maintenance therapy from opioid treatment programs (OTPs) in the United States." | 1.48 | Challenges to Opioid Treatment Programs After Hurricane Sandy: Patient and Provider Perspectives on Preparation, Impact, and Recovery. ( Benoit, E; Dunlap, E; Elliott, L; Matusow, H; Rosenblum, A, 2018) |
| "Methadone was most frequently used for prenatal opioid dependence; there was little buprenorphine or buprenorphine + naloxone use." | 1.46 | Infants Born to Opioid-Dependent Women in Ontario, 2002-2014. ( Brogly, SB; Davies, G; Dow, K; Johnson, A; Lajkosz, K; Newman, A; Turner, S, 2017) |
| "Methadone maintenance treatment (MMT) is the most common pharmacological treatment for opioid use disorder (OUD), and despite its documented effectiveness, a large number of patients respond poorly and experience relapse to illicit opioids." | 1.46 | Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. ( Bhatt, M; Daiter, J; Desai, D; MacKillop, J; Marsh, DC; McDermid Vaz, S; Pare, G; Plater, C; Samaan, Z; Sanger, N; Steiner, M; Thabane, L; Varenbut, M; Worster, A; Zielinski, L, 2017) |
| "Long-term opioid dependence in young women may lead to low bone quality." | 1.46 | A comparison of bone quality and its determinants in young opioid-dependent women with healthy control group. ( Chen, Y; Ding, Z; Jiang, M; Ma, Z; Sun, Y; Wang, X; Xu, Y; Zhou, X, 2017) |
| "Methadone maintenance treatment (MMT) has been proved worldwide by large bodies of research to be one of the most effective practices for illicit drug users." | 1.46 | Reliability and validity of the Treatment Outcome Profile among patients attending methadone maintenance treatment programs in Kunming, China. ( Deng, Y; Finch, E; Li, J; Liu, X; Shen, J; Wang, M; Wolff, K, 2017) |
| "Methadone is a widely used opioid agonist treatment associated with QT prolongation and torsades de pointes." | 1.46 | QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings. ( Brown, AL; Calver, L; Dunlop, AJ; Gill, A; Isbister, GK; Scott, AJ, 2017) |
| "This study aimed to evaluate the polydrug abuse among opioid-dependent patients receiving OMT with inadequate (Group IA) and adequate (Group A) doses of OMT medicine as experienced by the patients." | 1.46 | Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. ( Heikman, PK; Muhonen, LH; Ojanperä, IA, 2017) |
| "We examined self-reported nicotine dependence and associated factors in a large sample of opioid-dependent patients receiving methadone maintenance treatment (MMT) in northern Vietnam." | 1.46 | Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam. ( Do, HP; Dunne, MP; Latkin, CA; Le, GT; Le, HT; Ngo, C; Nguyen, CT; Nguyen, LH; Nguyen, LK; Phan, HTT; Thi Nguyen, HL; Thi Nguyen, NP; Tran, BX; Tran, TD; Vu, TMT, 2017) |
| "The rate of opioid addiction, in particular, has been rising steadily in recent years, which necessitates deeper understanding of risk factors in order to develop effective prevention and treatment methods." | 1.46 | Intolerance of uncertainty in opioid dependency - Relationship with trait anxiety and impulsivity. ( Allen, MT; Frydecka, D; Garami, J; Haber, P; Misiak, B; Moustafa, AA; Myers, CE, 2017) |
| " The results confirm the importance of adequate OAT dosing (≥60mg of methadone, ≥8mg of buprenorphine)." | 1.46 | Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic. ( Altice, FL; Chernova, O; Dumchev, K; Dvoryak, S; Morozova, O, 2017) |
| "Drug overdose is the leading cause of accidental death in Canada and the US, and the growing toll of opioid-related morbidity and mortality requires a diversity of novel therapeutic and harm reduction-based interventions." | 1.46 | Rationale for cannabis-based interventions in the opioid overdose crisis. ( Lucas, P, 2017) |
| " While previous research suggested low dosing of methadone and high rates of discontinuation of MMT among PWID in Thailand, little is known about patients' lived experiences with MMT in this setting." | 1.46 | Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study. ( Ayutthaya, PPN; Hayashi, K; Kaplan, K; Kerr, T; Small, W; Suwannawong, P; Ti, L, 2017) |
| "To evaluate the potential association of the genetic polymorphisms in ABCB1, ARRB2, DRD1 and OPRD1 genes with methadone dosage requirement among Han Chinese opioid-dependent patients." | 1.46 | Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients. ( Feng, X; Hu, P; Li, X; Liu, Z; Luo, R; Luo, X; Luo, Z; Qin, S, 2017) |
| "Inmates with untreated opioid addiction often relapse shortly after release into the community, thereby increasing the risk of overdose, serious illnesses (HIV, hepatitis C) and psychosocial problems (e." | 1.46 | Prescribing Opioid Replacement Therapy in U.S. Correctional Settings. ( Chaplin, MM; Farahmand, P; Modesto-Lowe, V, 2017) |
| "Three were prescribed methadone for opiate dependence (80, 90 and 125 mg daily), one also with hypokalemia; one prescribed escitalopram with hypokalaemia/hypomagnesaemia; three more with hypokalaemia alone." | 1.46 | The prevalence of QT prolongation in a population of patients with substance use disorders. ( Brown, A; Dunlop, AJ; Isbister, GK; Sadler, C; Scott, AJ, 2017) |
| " As part of the original study protocol, participants completed a comprehensive battery to assess satisfaction with MMT, psychological distress, opinion of methadone as a medication, participation in dosage decisions, and perception of dose adequacy." | 1.46 | Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions. ( Alcaraz, S; Batlle, F; Duran-Sindreu, S; González-Saiz, F; Manresa, MJ; Pérez de Los Cobos, J; Trujols, J, 2017) |
| "In methadone-treated OD subjects drawn from a case and control sample, we conducted a genome-wide association study of usual daily methadone dose." | 1.46 | Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. ( Cook-Sather, SD; Farrer, LA; Gelernter, J; Hakonarson, H; Jensen, KP; Kranzler, HR; Li, J; Nunez, Y; Smith, AH, 2017) |
| "Methadone maintenance treatment (MMT) of opiate addiction was introduced in Sweden 50years ago." | 1.46 | Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013. ( Ledberg, A, 2017) |
| "Methadone was reported to be most frequently associated with the occurrence of ADR (n=82/46." | 1.46 | Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. ( Cabanis, M; Connemann, BJ; Eller, J; Freudenmann, RW; Gahr, M; Hiemke, C; Lang, D; Schönfeldt-Lecuona, C, 2017) |
| " Consistent safe injection, however, was inversely associated with age (aOR=0." | 1.46 | Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. ( Altice, FL; Copenhaver, M; Huedo-Medina, TB; Karki, P; Madden, L; Meyer, JP; Shrestha, R, 2017) |
| "Fentanyl was commonly detected during this period with some clients having multiple fentanyl-positive UDS." | 1.46 | Characterizing fentanyl use in methadone-maintained clients. ( Arfken, CL; Greenwald, MK; Suchanek, J, 2017) |
| "Methadone maintenance was not associated with differences in therapeutic efficacy compared with buprenorphine maintenance treatment." | 1.46 | Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids. ( Larance, B; Lintzeris, N; Nielsen, S, 2017) |
| "Methadone was rated as the least acceptable among all other treatment approaches." | 1.43 | Counselor training and attitudes toward pharmacotherapies for opioid use disorder. ( Aletraris, L; Edmond, MB; Fields, D; Paino, M; Roman, PM, 2016) |
| "Adults treated for opioid dependence during April 2005 to March 2009: 151,983 individuals; 69% male; median age 32." | 1.43 | Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. ( Bird, SM; Dunn, G; Hickman, M; Jones, A; Marsden, J; Millar, T; Pierce, M, 2016) |
| " This is the first study to test the therapeutic effect of daily methadone dosing on the integrity of the cortico-subcortical brain functions as measured by the saccadometry." | 1.43 | Improvement of saccadic functions after dosing with methadone in opioid addicted individuals. ( Fareed, A; Feit, J; Gorzelańczyk, EJ; Kunc, M; Walecki, P, 2016) |
| "The syndemic of opioid addiction, HIV, hepatitis, tuberculosis, imprisonment, and overdose in Russia has been worsened by the illegality of opioid substitution therapy." | 1.43 | Emergence of methadone as a street drug in St. Petersburg, Russia. ( Barbour, R; Heimer, R; Levina, OS; Lyubimova, A, 2016) |
| "Co-occurring psychiatric disorders are among the difficulties faced by patients with opioid dependence on methadone maintenance therapy (MMT)." | 1.43 | Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life. ( Habil, MH; Teoh Bing Fei, J; Yee, A, 2016) |
| "Methadone was dispensed to 16,406 individuals and buprenorphine to 1777 individuals (increased from 12,400 and 192 respectively in 2006)." | 1.43 | Community pharmacy services for people with drug problems over two decades in Scotland: Implications for future development. ( Bond, C; Matheson, C; Robertson, H; Thiruvothiyur, M, 2016) |
| "At present, polydrug abuse comprises, besides traditional illicit drugs, new psychoactive substances (NPS) and non-prescribed psychotropic medicines (N-PPM)." | 1.43 | New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening. ( Heikman, P; Ojanperä, I; Pelander, A; Sundström, M, 2016) |
| "Adults with opioid dependence (n=283) were recruited from two integrated health systems to participate in interviews focused on prior experiences with treatment for opioid dependence, knowledge of medication options, preferences for treatment, and experiences with treatment for chronic pain in the context of problems with opioids." | 1.43 | Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. ( Green, CA; McCarty, D; Mertens, J; Stumbo, SP; Weisner, C; Yarborough, BJ, 2016) |
| " The mean current daily dosage of methadone was 77." | 1.43 | Report: Demographic profiles and sleep quality among patients on methadone maintenance therapy (MMT) in Malaysia. ( Choon, TS; Ismail, R; Mohamad, N; Mohd Yasin, MA; Musa, N; Siong, LC; Zahari, Z, 2016) |
| "To test if polysubstance use profiles and drug-related outcomes differ between those receiving and not receiving opioid substitution therapies (OST) among people who inject drugs (PWID)." | 1.43 | Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies. ( Alati, R; Betts, KS; Burns, L; Chan, G; Dietze, P; McIlwraith, F; Whittaker, E, 2016) |
| "A region-wide cross-sectional study was performed focusing on dosage and duration of treatment." | 1.43 | Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment. ( Bermpohl, F; Gutwinski, S; Riemer, TG; Schoofs, N; Stuke, H; Wiers, CE, 2016) |
| "A feared complication of opioid use disorder (OUD) is intravenous drug use related infective endocarditis (IDU-IE)." | 1.43 | Medication-assisted treatment for hospitalized patients with intravenous-drug-use related infective endocarditis. ( Suzuki, J, 2016) |
| " All opioid dependent patients were stabilized in treatment, defined as having been enrolled in the program for more than one month with no change of methadone dosage over the past one month." | 1.43 | Comparison of Pain Tolerance between Opioid Dependent Patients on Methadone Maintenance Therapy (MMT) and Opioid Naive Individuals. ( Ibrahim, MA; Ismail, R; Lee, CS; Lee, YY; Mohamad, N; Mohd Yasin, MA; Musa, N; Tan, SC; Zahari, Z, 2016) |
| "Methadone treatment decreased slightly in all social areas until 2011 and then increased bringing rates back to 2004 levels." | 1.43 | Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. ( DiRocco, D; Hansen, H; Siegel, C; Wanderling, J, 2016) |
| "Data analysis from observatory for pharmacodependency in ambulatory medicine survey (observation des pharmacodépendances en médecine ambulatoire [OPEMA]) program in 2013 of the subjects under high dosage buprenorphine (HDB) and methadone prescribed or obtained illegally reported by GPs in France." | 1.43 | [Characteristics of subjects under opiate maintenance treatment in primary care using the OPEMA data 2013]. ( Amaslidou, D; Frauger, E; Gentile, G; Giocanti, A; Micallef, J; Orleans, V; Pauly, V; Thirion, X, 2016) |
| "Methadone was detected in 130 overdose deaths (71." | 1.43 | Methadone-Related Overdose Deaths in a Liberal Opioid Maintenance Treatment Programme. ( Andersen, LV; Christoffersen, DJ; Clausen, T; Linnet, K; Skurtveit, S; Tjagvad, C, 2016) |
| "A sample of 1179 PWID with opioid use disorder not currently on OAT from five regions in Ukraine was assessed using multivariable logistic regression for independent factors related to willingness to initiate OAT, stratified by their past OAT experience." | 1.43 | Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. ( Altice, FL; Bojko, MJ; Dvoriak, S; Filippovych, S; Makarenko, I; Marcus, R; Mazhnaya, A; Polonsky, M; Springer, S, 2016) |
| " This case highlights that patients whose goal is not abstinence can be successfully treated for acute medical illnesses and comorbid substance use disorders using harm reduction approaches, including appropriate dosing of pharmacotherapy." | 1.43 | Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV. ( Ahamad, K; Fairgrieve, C; Joe, R; Voon, P, 2016) |
| "Chronic pain was present in 68% of the sample, 51% reported craving opioids in the past week, and 16% had a positive UDT." | 1.43 | Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Samet, JH; Tsui, JI; Winter, MR, 2016) |
| "Findings were inconclusive regarding bacterial vaginosis (± candidiasis) and trichomoniasis." | 1.43 | Evaluation of the vaginal flora in pregnant women receiving opioid maintenance therapy: a matched case-control study. ( Farr, A; Hagmann, M; Holzer, I; Husslein, PW; Kiss, H; Kueronya, V; Petricevic, L, 2016) |
| "Methadone dose/weight was moderately correlated with QTc, and independently associated with longer QTc at both 440 and 470 cut-offs." | 1.43 | Methadone maintenance dose/weight ratio, long QTc, and EKG screening. ( Adabag, S; Anand, V; Batres-Y-Carr, T; Thuras, P; Westermeyer, J; Yoon, G, 2016) |
| " Thus, monitoring plasma methadone levels is unlikely to be effective for guiding dosing decisions in situations where compliance with MMT is already very high or when the methadone dose is no longer the dominant factor in determining the clinical outcome." | 1.43 | Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China. ( Alfonso, A; Du, J; Hillhouse, M; Jiang, H; Ling, W; Pan, S; Wang, J; Yuan, W; Zhao, M; Zhou, Z, 2016) |
| " Data were collected from medical screening forms and jail databases and included demographic variables, dates of admission and release, number of doses and total dosage of methadone if applicable, reason for incarceration, and the date of rebooking and nature of offense, if it occurred." | 1.43 | Community-Based Methadone Maintenance in a Large Detention Center is Associated with Decreases in Inmate Recidivism. ( Guerin, P; McCrady, BS; Owens, M; Westerberg, VS, 2016) |
| " The aim of this study was to assess the trends in the prevalence of doctor shopping for high dosage buprenorphine (HDB) and methadone (MTD) from 2004 to 2014 by using the French Health Insurance claims." | 1.43 | [Trend in buprenorphine and methadone shopping behavior in France from 2004 to 2014]. ( Authier, N; Brousse, G; Chenaf, C; Delorme, J; Kabore, JL; Kernisant, M; Laporte, C; Zenut, M, 2016) |
| " Higher methadone dosage was associated with increased odds of treatment retention, whereas criminal charges and lower self-esteem decreased these odds." | 1.42 | Psychological predictors of retention in a low-threshold methadone maintenance treatment for opioid addicts: a 1-year follow-up study. ( Julien, D; Lauzon, P; Milton, D; Perreault, M; Rabouin, D; White, ND, 2015) |
| "Poly-drug exposed infants and those treated for neonatal abstinence syndrome performed significantly poorer (p=0." | 1.42 | Infants of opioid-dependent mothers: neurodevelopment at six months. ( Mactier, H; McGlone, L, 2015) |
| "5, 1, 2, and 24 hours after dosing in subjects with confirmed cocaine use and abstinence." | 1.42 | The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection. ( DInh, AT; Fiellin, DA; Fiellin, LE; Lruie, BS; McCance-Katz, EF; Moody, DE; Tetrault, JM, 2015) |
| "Buprenorphine retention was also poorer." | 1.42 | A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. ( Burns, L; Butler, T; Degenhardt, L; Dobbins, T; Gibson, A; Gisev, N; Kimber, J; Larance, B; Larney, S; Mattick, RP, 2015) |
| " An analysis of the responses pertaining to the most desired changes required at the center found dosing hours, waiting area and staff shortages to be common." | 1.42 | A satisfaction survey of opioid-dependent patients with methadone maintenance treatment. ( Aziz, Z; Chong, NJ, 2015) |
| "Gambling was statistically significant more commonly among males (79." | 1.42 | Past-year gambling behaviour among patients receiving opioid substitution treatment. ( Alho, H; Castrén, S; Lahti, T; Salonen, AH; Simojoki, K, 2015) |
| "Individuals being treated for opioid dependence had a more than fourfold increase of mortality risk compared with the general population [SMR = 4." | 1.42 | Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. ( Evans, E; Hser, YI; Huang, D; Li, L; Liu, L; Min, J; Nosyk, B; Urada, D, 2015) |
| "heroin) use disorder." | 1.42 | Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users. ( Bach, P; Hayashi, K; Kerr, T; Koehn, JD; Milloy, MJ; Nguyen, P; Rieb, L; Wood, E, 2015) |
| "While opioid dependence is a complex health condition, the treatment of HIV-infected individuals with opioid dependence presents additional challenges." | 1.42 | HIV-gp120 and physical dependence to buprenorphine. ( Abood, ME; Benamar, K; Palma, J, 2015) |
| "Pregnancy is an opportune time to identify opioid dependence, facilitate conversion to opioid maintenance treatment, and coordinate care with specialists in addiction medicine, behavioral health, and social services." | 1.42 | Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. ( Bogen, DL; Cochran, G; Krans, EE, 2015) |
| "2% among those with a methadone dosage ≥60 mg/day." | 1.42 | Relationship between plasma concentrations of the l-enantiomer of methadone and response to methadone maintenance treatment. ( Chericoni, S; Daini, L; Giarratana, T; Meini, M; Moncini, M; Rucci, P; Scaramelli, D; Stefanelli, F, 2015) |
| " Given that sub-optimal dosing of BNX increases the risk of diversion, more attention should be paid to providing patients with an optimal medical dose." | 1.42 | Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. ( Alho, H; Kotovirta, E; Launonen, E; Simojoki, K; Wallace, I, 2015) |
| " However, to our knowledge, the role of methadone dosing in adherence to antiretroviral therapy (ART) has not yet been investigated." | 1.42 | Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids. ( Ahamad, K; Dobrer, S; Dong, H; Kerr, T; Lappalainen, L; Milloy, MJ; Montaner, J; Nolan, S; Puscas, C; Wood, E, 2015) |
| "Scores on the Alcohol Use Disorders Identification Test (AUDIT) revealed the prevalence of hazardous, harmful, and dependent drinking to be 25% (n = 26), 6% (n = 6), and 16% (n = 17), respectively." | 1.42 | Psychosocial Interventions for Problem Alcohol Use in Primary Care Settings (PINTA): Baseline Feasibility Data. ( Anderson, R; Bury, G; Cullen, W; Dunne, C; Keenan, E; Klimas, J; Marie Henihan, A; McCombe, G; Saunders, J; Shorter, GW; Smyth, BP; Swan, D, 2015) |
| "Patients with opioid use disorders on opioid agonist therapy (OAT) have lower pain tolerance compared to controls." | 1.42 | Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Mao, J; Samet, JH; Tsui, JI; Winter, MR, 2015) |
| "Treatment with buprenorphine, methadone, or both is predominantly offered in methadone clinics, yet many people do not receive the treatment they need." | 1.42 | Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11. ( Burns, RM; Dick, AW; Gordon, AJ; Leslie, D; Pacula, RL; Sorbero, M; Stein, BD, 2015) |
| "Nationally, in 2012, the rate of opioid abuse or dependence was 891." | 1.42 | National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. ( Baldwin, G; Campopiano, M; Jones, CM; McCance-Katz, E, 2015) |
| "Drug overdose is now the leading cause of unintentional death nationwide, driven by increased prescription opioid overdoses." | 1.42 | Opioid Overdose Deaths in the City and County of San Francisco: Prevalence, Distribution, and Disparities. ( Burke, C; Coffin, PO; Lemos, NP; Santos, GM; Visconti, AJ, 2015) |
| " Clinical predictor variables included average methadone dosage (mg/d) and urinalysis drug screen (UDS) findings for opioids and various nonopioid substances at intake and 6 months." | 1.42 | Predictors of patient retention in methadone maintenance treatment. ( Copeland, AL; Herschman, PL; Hoffmann, NG; Kopak, AM; Polukhina, N; Proctor, SL, 2015) |
| "Opioid addiction is no longer a primarily urban problem." | 1.42 | Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas. ( Meyer, M; Phillips, J, 2015) |
| "The burden of opiate dependence not only relies on somatic complications such as infectious diseases or acute intoxication but also on frequent psychiatric events such as major depressive disorder (MDD) and suicidal behavior (SB)." | 1.42 | A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients. ( Bellivier, F; Bloch, V; Hajj, A; Icick, R; Karsinti, E; Ksouda, K; Laplanche, JL; Lépine, JP; Mouly, S; Peoc'h, K; Prince, N; Vorspan, F, 2015) |
| "The heritability of opioid use disorder has been widely investigated; however, the influence of specific genes on methadone treatment outcomes is not well understood." | 1.42 | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study. ( Anglin, R; Bawor, M; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Pare, G; Plater, C; Samaan, Z; Steiner, M; Tan, C; Thabane, L; Varenbut, M; Worster, A, 2015) |
| "Chronic pain is common among patients receiving opioid maintenance treatment (OMT) for opioid use disorder." | 1.42 | Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. ( Dunn, KE; Finan, PH; Fingerhood, M; Strain, EC; Tompkins, DA, 2015) |
| "Methadone maintenance treatment (MMT) reduces the harms of opioid use disorder and is being rapidly scaled-up in China." | 1.42 | Evaluation of an implementation of methadone maintenance treatment in China. ( Chawarski, MC; Liu, P; Marienfeld, C; Schottenfeld, R; Wang, X; Zhou, W, 2015) |
| "Methadone maintenance treatment is the most widely-used therapy in opioid dependence, but some patients relapse or drop out from treatment." | 1.40 | ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment. ( De Cid, R; Escaramís, G; Estivill, X; Farré, M; Fonseca, F; Gratacòs, M; Martín-Santos, R; Torrens, M, 2014) |
| "The aim of our survey was to assess the dosage and the frequency of side effects in patients with opioid dependency receiving opioid maintenance therapy (OMT)." | 1.40 | [Methadone and levomethadone - dosage and side effects]. ( Bald, LK; Bermpohl, F; Gallinat, J; Gutwinski, S; Heinz, A; Riemer, T; Schoofs, N, 2014) |
| "Methadone maintenance treatment and buprenorphine maintenance treatment are the two main therapeutic options considered for opioid replacement therapy." | 1.40 | Outcome evaluation of the opioid agonist maintenance treatment in Iran. ( Baneshi, MR; Esmaeili, HR; Nakhaee, N; Nikravesh, MR; Ziaddinni, H, 2014) |
| "Methadone maintenance was well accepted by HIV+ and HIV- opioid dependent individuals and has the potential for significant public health impact if made more widely available with sustained access and support." | 1.40 | Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response. ( Booth, R; Chhatre, S; Chychula, N; Dvoriak, S; Karachevsky, A; Metzger, D; Pecoraro, A; Schumacher, J; Woody, G, 2014) |
| " Medical and socio-demographic data were gathered and the instruments Opiate Dosage Adequacy Scale (ODAS), European Addiction Severity Index (EuropASI) and the Derogatis Interview for Sexual Functioning - Self Report (DISF-SR) were applied." | 1.40 | When higher doses in opioid replacement treatment are still inadequate - association to multidimensional illness severity: a cohort study. ( Bachner, C; Boniakowski, E; Reimer, J; Tietje, W; Verthein, U; Walcher, S; Weber, B, 2014) |
| "Methadone dose was not associated with continued drug use while in treatment." | 1.40 | Continued drug use during methadone treatment in China: a retrospective analysis of 19,026 service users. ( Cao, X; Detels, R; Liu, E; Sullivan, SG; Wu, Z, 2014) |
| "Methadone maintenance treatment (MMT) patients may achieve up to a 2-week privilege of methadone take-home doses (THD), which is associated with considerable responsibility." | 1.40 | Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients. ( Adelson, M; Domany, Y; Peles, E; Sason, A; Schreiber, S; Tene, O, 2014) |
| " Safe use of methadone requires clinical skills and knowledge in use of methadone to mitigate potential risks, including serious risks related to risk of overdose and cardiac arrhythmias." | 1.40 | Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. ( Chou, R; Compton, P; Cruciani, RA; Farrar, JT; Fiellin, DA; Haigney, MC; Inturrisi, C; Knight, JR; Marcus, SM; Mehta, D; Meyer, MC; Otis-Green, S; Portenoy, R; Savage, S; Strain, E; Walsh, S; Zeltzer, L, 2014) |
| "Methadone treatment appears to be associated with relatively intact cognitive control in opioid dependent individuals." | 1.40 | Cognitive control in opioid dependence and methadone maintenance treatment. ( Chen, PC; Chen, WT; Fang, SC; Hu, S; Huang, CY; Lee, TS; Li, CS; Liao, DL; Wu, CS, 2014) |
| "In this study we describe a renal lipidosis occurring in patients with a positive history of narcotic abuse who were enrolled in a methadone substitution program." | 1.40 | Renal lipidosis in patients enrolled in a methadone substitution program. ( Birk, HW; Floege, J; Gröne, HJ; Kuppe, C; Maier, T; Moeller, MJ; Porubsky, S; Wörnle, M, 2014) |
| "Buprenorphine patients were more likely to be male, have health insurance, be employed, abuse prescription opioids, and be human immunodeficiency virus (HIV) infected; they were less likely to abuse benzodiazepines." | 1.40 | A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment. ( Brooner, RK; Fingerhood, MI; King, VL; Rastegar, DA, 2014) |
| "Amid the global transition to treat opioid addiction as an illness, many people who inject drugs (PWID) face heterogeneous legal environments that include both punitive and harm reduction measures." | 1.40 | "In their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam. ( Binh, NT; Celentano, DD; Dat, do T; Go, VF; Huong, NM; Quan, VM; Tomori, C; Tuan, le N; Zelaya, CE, 2014) |
| "Use of methadone for the treatment of opioid addiction is an effective harm-reduction approach, although variability in treatment outcomes among individuals has been reported." | 1.40 | Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol. ( Anglin, R; Bawor, M; Dennis, BB; Samaan, Z; Steiner, M; Thabane, L, 2014) |
| "Methadone maintenance treatment (MMT) has been used to treat opiate dependence since the mid-1960s." | 1.40 | Neuropsychological performance of methadone-maintained opiate users. ( Jensen, M; Kydd, R; Russell, BR; Wang, GY; Wouldes, TA, 2014) |
| "The optimal approach to postpartum dosing among women treated with methadone maintenance is unclear." | 1.40 | Postpartum changes in methadone maintenance dose. ( Cheng, DM; Kaminetzky, LB; Pace, CA; Saia, K; Samet, JH; Walley, AY; Winter, M, 2014) |
| " Linear regression models examined predictors of unsupervised dosing in the past month." | 1.40 | A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses? ( Ali, R; Carragher, N; Degenhardt, L; Larance, B; Lintzeris, N; Mattick, RP, 2014) |
| " Patients were grouped into 1 of 3 medication categories based on their selection at intake (methadone [n = 2,738; M dosage = 64." | 1.40 | A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study. ( Copeland, AL; Herschman, PL; Kopak, AM; Polukhina, N; Proctor, SL, 2014) |
| "To characterize lifetime psychiatric diagnosis groups among methadone maintenance treatment (MMT) patients and associations of diagnosis to long-term (up to 20 years) retention and survival either during treatment or post discontinuation." | 1.40 | Impact of lifetime psychiatric diagnosis on long-term retention and survival of former opiate addicts in methadone maintenance treatment. ( Adelson, M; Domany, Y; Peles, E; Schreiber, S, 2014) |
| "Despite the effort, the prevalence of opioid use disorder continues to rise." | 1.40 | The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol. ( Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A, 2014) |
| " The retention rates for the 6-year by low (≤ 30 mg/day), medium (31-60 mg/day), and high (>60 mg/day) methadone dosage groups were 20." | 1.40 | Retention and its predictors among methadone maintenance treatment clients in China: a six-year cohort study. ( Cao, X; Li, J; Li, L; Lin, C; Luo, W; Pang, L; Rou, K; Wang, C; Wu, Z; Yin, W, 2014) |
| "Medication assisted treatment for opioid dependence alters the pain experience." | 1.40 | Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain. ( Gonzalez, G; Wachholtz, A, 2014) |
| " To identify potentially contributing covariates in methadone pharmacokinetics, we used population pharmacokinetic modeling to estimate clearance (CL/F) and volume of distribution (V/F) for each methadone enantiomer in an ethnically diverse methadone maintained population." | 1.40 | Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. ( Bart, G; Brundage, RC; Lenz, S; Straka, RJ, 2014) |
| " For analysis of the prescribed methadone dose distribution, the patient sample was split into three methadone dosage groups: a low dose group (LDG) (n = 200; < 60 mg/day), a medium dose group (MDG) (n = 273; 60 to 100 mg/day), and a high dose group (HDG) (n = 140; > 100 mg/day)." | 1.40 | Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study. ( Baumeister, M; Dürsteler-MacFarland, KM; Gerhard, U; Petitjean, SA; Strasser, J; Vogel, M; Walter, M; Wiesbeck, GA, 2014) |
| " Estimates of this model indicated that increase in average methadone dosage was associated with longer retention time." | 1.40 | Predictors of treatment retention in a major methadone maintenance treatment program in iran: a survival analysis. ( Heydari, H; Moeeni, M; Pashaei, T; Razaghi, EM; Roshanaei Moghdam, B; Turner, NE, 2014) |
| "A group of 287 patients with opioid dependence was monitored prospectively from 1995 to 2007." | 1.39 | Risk factors for fatal outcome in patients with opioid dependence treated with methadone in a family medicine setting in Croatia. ( Cerovečki, V; Kastelic, A; Križmarić, M; Ožvačić Adžić, Z; Pregelj, P; Tiljak, H, 2013) |
| "The historical and current contexts of opioid use disorders during pregnancy are reviewed." | 1.39 | Treating opioid use disorders during pregnancy: historical, current, and future directions. ( Jones, HE, 2013) |
| "The interindividual variability in the dose required for effective methadone maintenance treatment (MMT) for opioid addiction may be influenced in part by genetic variations in genes encoding pharmacodynamic factors of methadone." | 1.39 | Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. ( Adelson, M; Kreek, MJ; Levran, O; Ott, J; Peles, E; Randesi, M; Shen, PH; Shu, X, 2013) |
| "Optimal methadone dosage and service profile is challenging in treatment of opioid dependence." | 1.39 | Higher methadone doses are associated with lower mortality in patients of opioid dependence in Taiwan. ( Chen, CH; Chen, PC; Cheng, JJ; Hsieh, CJ; Huang, YF; Liao, DL; Shih, WY, 2013) |
| "Methadone maintenance treatment (MMT) in China was established in 2004." | 1.39 | Time to first treatment interruption in the Chinese methadone maintenance treatment programme. ( Detels, R; Sullivan, SG; Wu, Z, 2013) |
| "Being diagnosed with congestive heart failure and taking methadone were the only individual variables that showed a statistically significant association with a QTc prolongation > 500 ms." | 1.39 | Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. ( Blackinton Gale, R; Casarella, J; Drexler, K; Fareed, A; Patil, D; Scheinberg, K; Vayalapalli, S, 2013) |
| " Compared to baseline values, the R-methadone mean area under the concentration-time curve to the end of the dosing period (AUCtau) (5,550 versus 6,210 h · ng/ml) and mean maximum concentration of drug in serum (Cmax) (316 versus 337 ng/ml) did not significantly increase in the presence of EVG/COBI." | 1.39 | Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. ( Bruce, RD; Custodio, JM; Friedland, GH; Kearney, BP; Ramanathan, S; Rhee, MS; Wei, X; Winkle, P, 2013) |
| "Younger age, longer duration of the opioid abuse, and higher subjective opiate intoxication severity before treatment entry were all significantly associated with negative treatment outcome." | 1.39 | Treatment outcome predictors in flexible dose-duration methadone detoxification program. ( Dezfouli, A; Ekhtiari, H; Ghodousi, A; Mokri, A; Zamanian, B, 2013) |
| "Pregnant women meeting criteria for opioid dependence and attending an integrated care program between 1997 and 2009." | 1.39 | Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study. ( Abrahams, R; Boyajian, T; Graves, L; Kahan, M; Ordean, A, 2013) |
| "Methadone was the treatment of preference, with a prescribed mean dose of 41." | 1.39 | Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland. ( Baroudi, M; Barro, J; Broers, B; Casillas, A; Favrod-Coune, T; Gaspoz, JM; Gétaz, L; Rieder, JP; Wolff, H, 2013) |
| "Adequate methadone dosing in methadone maintenance treatment (MMT) for opioid addiction is critical for therapeutic success." | 1.39 | CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. ( Adelson, M; Hamon, S; Kreek, MJ; Levran, O; Peles, E; Randesi, M, 2013) |
| "Opioid dependence is growing at an alarming rate in the United States, and opioid dependent patients have substantial medical, as well as psychiatric, conditions that impact their ability to work." | 1.39 | Antisocial personality disorder is associated with receipt of physical disability benefits in substance abuse treatment patients. ( Byrne, SA; Cherniack, MG; Petry, NM, 2013) |
| "Oral methadone maintenance treatment was effective in improving the overall Quality of Life during the first three months of treatment in substance-dependent outpatients." | 1.38 | Quality of life in patients on methadone maintenance treatment: a three-month assessment. ( Bakhshani, NM; Lashkaripour, K; Sadjadi, SA, 2012) |
| "Weight loss was less in small for gestational age compared to appropriately grown infants (p<0." | 1.38 | Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding. ( Campbell, N; Dryden, C; Mactier, H; Young, D, 2012) |
| "Methadone maintenance treatment (MMT) is the standard treatment of choice for pregnant opiate addicts; however, data on newborn outcomes are contradictory." | 1.38 | Duration of methadone maintenance treatment during pregnancy and pregnancy outcome parameters in women with opiate addiction. ( Adelson, M; Bloch, M; Dollberg, S; Peles, E; Schreiber, S, 2012) |
| "Buprenorphine use has increased in recent years, with the greatest use in rural communities and in office based settings." | 1.38 | The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. ( Dick, AW; Farmer, C; Gordon, AJ; Schuster, J; Sorbero, M; Stein, BD, 2012) |
| "1%, depending on definition applied) in patients receiving relatively low daily doses of methadone therapy, with no evidence of a dose-response relationship." | 1.38 | Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. ( Keenan, E; Kiernan, G; Mahon, NG; McCarthy, C; McGorrian, C; Roy, AK; Sweeney, B, 2012) |
| "Buprenorphine and naloxone were misused at lower rates when compared with buprenorphine and methadone." | 1.38 | Use and misuse of opioid replacement therapies: a Queensland study. ( Kemp, R; Smirnov, A, 2012) |
| "Methadone maintenance treatment (MMT) is an intervention used to treat opioid (heroin) dependence." | 1.38 | Methadone as social control: institutionalized stigma and the prospect of recovery. ( Harris, J; McElrath, K, 2012) |
| "However, with the FrSBe, the opiate abusers reported overall higher levels of apathy." | 1.38 | Premorbid and current neuropsychological function in opiate abusers receiving treatment. ( Lagundoye, O; Lee, KH; Parks, RW; Pluck, G; Rele, R; Sarkar, S; Spence, SA, 2012) |
| " Further research to determine levels of tolerance and psychosocial and pharmacogenetic factors contributing to differences in methadone treatment outcome and dosing in Hmong may provide further insight into opiate addiction and its treatment." | 1.38 | Superior methadone treatment outcome in Hmong compared with non-Hmong patients. ( Bart, G; Carlson, G; Hodges, JS; Nolan, C; Wang, Q, 2012) |
| "Methadone treatment centers, in contrast to convenience stores, are not associated geographically with crime." | 1.38 | Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers. ( Boyd, SJ; Dixon, LB; Fang, LJ; Gorelick, DA; Medoff, DR, 2012) |
| "Methadone maintenance treatment is a chronic treatment for opiate addicts." | 1.38 | Long waiting period to enter methadone maintenance treatment: relation to patient characteristics and outcome. ( Adelson, M; Peles, E; Sason, A; Schreiber, S, 2012) |
| " Clinically significant MDIs included withdrawal symptoms, which were found among MMTP patients co-administered with buprenorphine or tramadol; severe QTc prolongation effect, which might be associated with use of haloperidol or droperidol; and additive CNS and respiratory depression, which could result from use of methadone in combination with chlorpromazine or thioridazine." | 1.38 | Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. ( Lee, HY; Li, JH; Tang, HP; Wu, JS; Wu, LT; Yen, CF, 2012) |
| "The cohort of women treated for opioid dependence during pregnancy with medication-assisted therapy and delivered at a single institution between 2000 and 2006 were retrospectively identified (n = 149 women; n = 151 neonates)." | 1.38 | Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome. ( Benvenuto, A; Howard, D; Johnston, A; Mandell, T; Metayer, J; Meyer, M; Plante, D, 2012) |
| "Neonatal abstinence syndrome is an expected and treatable condition that follows prenatal exposure to opioid agonists." | 1.38 | ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. ( , 2012) |
| "The prevalence of opioid abuse is increasing in North America." | 1.38 | Are infants exposed to methadone in utero at an increased risk for mortality? ( Bridgman-Acker, K; Kelly, LE; Koren, G; Lauwers, A; Madadi, P; Rieder, MJ, 2012) |
| "Buprenorphine as maintenance treatment of opioid dependence during pregnancy has promise and may offer some benefits, but more research is needed, especially regarding induction of actively addicted women during pregnancy." | 1.38 | Treatment of opioid dependence in the setting of pregnancy. ( Martin, PR; Young, JL, 2012) |
| "Methadone prescription is a controversial topic." | 1.38 | Methadone replacement therapy: tried, tested, effective? ( Daniels, AM; Robertson, JR, 2012) |
| "Among patients receiving methadone maintenance treatment (MMT) for opioid dependence, receipt of unobserved dosing privileges (take homes) and adequate doses (ie, ≥ 80 mg) are each associated with improved addiction treatment outcomes, but the association with acute care hospitalization is unknown." | 1.38 | Methadone dose, take home status, and hospital admission among methadone maintenance patients. ( Alford, DP; Chen, C; Cheng, DM; Filippell, T; Pierce, CE; Samet, JH; Walley, AY, 2012) |
| "Hypogonadism was found in 68 % of the participants, and about 68." | 1.38 | Depression, Testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV Infection. ( Amini Lari, M; Faramarzi, H; Marzban, M; Parsa, N; Shams, M, 2012) |
| "Methadone treatment by the primary care physician is a successful method of retaining opioid users in treatment." | 1.38 | A national study of the retention of Irish opiate users in methadone substitution treatment. ( Barry, J; Delargy, I; Grogan, L; Keenan, E; Long, J; Mulholland, D; Mullen, L, 2012) |
| "Implementation of MAT for opioid use disorders was low." | 1.38 | Financial factors and the implementation of medications for treating opioid use disorders. ( Knudsen, HK; Roman, PM, 2012) |
| "Lifetime prevalence of opioid dependence is about 0." | 1.38 | Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. ( Bühringer, G; Haberthür, A; Klotsche, J; Rehm, J; Soyka, M; Träder, A; Wittchen, HU, 2012) |
| "Methadone poisonings were associated with accidental overdoses with the drug concentration in blood remaining within a therapeutic range." | 1.38 | Comparison of fatal poisonings by prescription opioids. ( Häkkinen, M; Launiainen, T; Ojanperä, I; Vuori, E, 2012) |
| "Buprenorphine-treated patients performed statistically significantly better in a simple reaction time test than methadone-treated ones." | 1.38 | Do drug treatment variables predict cognitive performance in multidrug-treated opioid-dependent patients? A regression analysis study. ( Alho, H; Fabritius, C; Kalska, H; Rapeli, P, 2012) |
| "Patterns of symptom reports may have clinical implications for maternal and fetal health during pregnancy for OM women including optimization of opioid dosing regimens, education regarding maternal nutritional intake and preventing postnatal depression, thereby ensuring maternal health and fetal development during pregnancy and enhancing mother-infant bonding and healthy child development postnatally." | 1.38 | Patterns of symptom reporting during pregnancy comparing opioid maintained and control women. ( Fisk, A; Gordon, AL; Lopatko, OV; Pearson, V; Stacey, H; White, JM; Woods, A, 2012) |
| "Methadone was readily identified in oral fluid at concentrations greater than 20 ng/mL following daily 30-110 mg/day methadone pharmacotherapy." | 1.37 | Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence. ( Choo, RE; Dams, R; Gray, TR; Huestis, MA; Jones, HE, 2011) |
| "Hazardous drinking, alcohol abuse, and dependence were measured using a Chinese version of the Alcohol Use Disorders Identification Test (AUDIT) and by measuring breath alcohol concentration." | 1.37 | Alcohol use problem among patients in methadone maintenance treatment in Taiwan. ( Chen, IC; Chie, WC; Chou, SY; Hwu, HG; Tan, HK; Yeh, YC; Yu, CY, 2011) |
| "Depressive disorders among opiate abusers have detrimental effects on their well-being and ability to refrain from illegal drugs." | 1.37 | Adapting problem-solving therapy for depressed older adults in methadone maintenance treatment. ( Morse, JQ; Reynolds, CF; Rosen, D, 2011) |
| " The objective of this study is to elucidate the reason for the low methadone dosage prescribed in MMT clinics in China." | 1.37 | A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China. ( Detels, R; Lin, C, 2011) |
| "In addition to treatment for opioid dependence, addressing other substance use, social issues, particularly housing, and mental health may have important implications for reducing HIV transmission in HIV-infected opioid-dependent patients." | 1.37 | Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. ( Botsko, M; Chaudhry, AA; Egan, JE; Estrada, B; Fiellin, DA; Flanigan, TP; Lucas, GM; Mitty, J; Weiss, L; Woodson, T, 2011) |
| "R-Methadone concentration was 1." | 1.37 | Estimated infant exposure to enantiomer-specific methadone levels in breastmilk. ( Bogen, DL; Hanusa, BH; Helsel, JC; Perel, JM; Thompson, M; Wisner, KL, 2011) |
| "Methadone was indisputably identified by means of the MS technique in exhaled breath condensate from all 14 patients." | 1.37 | Determination of methadone in exhaled breath condensate by liquid chromatography-tandem mass spectrometry. ( Beck, O; Eriksen, P; Franck, J; Palmskog, G; Sandqvist, S, 2011) |
| "Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form)." | 1.37 | Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. ( Applebaum, A; Batchelder, A; Gonzalez, JS; Newville, H; Psaros, C; Safren, SA, 2011) |
| " The aim of this study is to analyze methadone dosage in responder and nonresponder patients considering pharmacogenetic and pharmacokinetic factors that may contribute to dosage adequacy." | 1.37 | Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. ( Cuyàs, E; de la Torre, R; Díaz, L; Farré, M; Fonseca, F; Khymenets, O; Pastor, A; Pizarro, N; Torrens, M, 2011) |
| "Takotsubo cardiomyopathy is a syndrome characterized by transient apical ballooning or reversible midventricular systolic dysfunction." | 1.37 | Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal. ( Bhat, T; Duvvuri, S; Jun, CH; Khattri, S; Lafferty, J; Saiful, FB; Teli, S, 2011) |
| "008), having a separate dosing area (P = 0." | 1.36 | Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. ( Lea, T; Sheridan, J; Winstock, AR, 2010) |
| "Our objectives were to: (1) characterize obstructive sleep apnea (OSA) and CSA in patients in methadone maintenance treatment (MMT) for opioid dependence; (2) examine factors associated with SDB in this population; and (3) investigate whether SDB was related to severity of subjective sleep complaints in MMT patients with subjective sleep disturbances." | 1.36 | Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. ( Anderson, BJ; Corso, RP; Kurth, ME; Millman, RP; Sharkey, KM; Stein, MD, 2010) |
| "Glutamate is critically involved in opioid addiction." | 1.36 | Expression of NR3B but not NR2D subunit of NMDA receptor in human blood lymphocytes can serve as a suitable peripheral marker for opioid addiction studies. ( Goodarzi, A; Mokri, A; Sedaghati, M; Vousooghi, N; Yaghmaei, P; Zarrindast, MR, 2010) |
| "Methadone dose was reduced in five patients with improvement of QT interval and resolution of arrhythmia." | 1.36 | Ventricular arrhythmias in patients treated with methadone for opioid dependence. ( Hanon, S; Rosman, J; Schweitzer, P; Seewald, RM; Yang, F, 2010) |
| " Of the 140 patients treated at the clinic between 2002 and 2009, 85 were excluded from the study because they had been treated as guests (had been in treatment in other clinics but received methadone dosing temporarily from our clinic), were treated in the clinic for less than 6 months, or dropped out of treatment." | 1.36 | Onsite QTc interval screening for patients in methadone maintenance treatment. ( Amar, R; Byrd-Sellers, J; Casarella, J; Drexler, K; Fareed, A; Lutchman, TS; Smith-Cox, J; Vayalapalli, S, 2010) |
| "Aspects of methadone maintenance treatment (MMT) delivery, particularly daily dosing practices, are associated with longer retention in treatment." | 1.36 | Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. ( Anis, AH; Marsh, DC; Nosyk, B; Schechter, MT; Sun, H, 2010) |
| "New methadone treatment admissions (N = 283) were assessed at 3 months post-admission for satisfaction with their counselors and programs." | 1.36 | The role of patient satisfaction in methadone treatment. ( Brown, BS; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP, 2010) |
| "The methadone maintenance treatment has significantly improved physical, psychological, and environmental components of quality of life during follow-up." | 1.36 | Cost-utility analysis of methadone maintenance treatment in Lithuania. ( Bagdonas, E; Padaiga, Z; Vanagas, G, 2010) |
| "Methadone was eluted from sweat patches with sodium acetate buffer, followed by solid-phase extraction and quantification by gas chromatography mass spectrometry (limit of quantification > or = 10 ng/patch)." | 1.36 | Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration. ( Barnes, AJ; Brunet, BR; Choo, RE; Huestis, MA; Johnson, RE; Jones, HE; Mura, P, 2010) |
| "01) but fewer dosing visits." | 1.36 | The cost of concordance with opiate substitution treatment guidelines. ( Barnett, PG; Humphreys, K; Trafton, JA, 2010) |
| " Maternal opiate dosing has been investigated with conflicting results." | 1.36 | Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. ( Cook, CM; Jones, MP; Liu, AJ; Murray, H; Nanan, R, 2010) |
| " Diversion for OST programmes using supervision of dosing is less than diversion of opioids prescribed for pain, which is now a growing public health problem." | 1.36 | The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective. ( Bell, J, 2010) |
| "Individuals with diagnoses of opioid dependence (two or more diagnoses per year) and at least 9 months of health plan eligibility each year were extracted from electronic health records for the years 2000 through 2004 (1,518 individuals and 2,523 observations across the study period-some individuals were in multiple years)." | 1.36 | Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. ( Green, CA; Leo, MC; Lynch, F; McCarty, D; Perrin, NA; Polen, MR, 2010) |
| "Lifetime potential and probable pathological gambling (PG) were assessed using the South Oaks Gambling Screen (SOGS) questionnaire." | 1.36 | Pathological gambling in methadone maintenance clinics where gambling is legal versus illegal. ( Adelson, M; Linzy, S; Peles, E; Schreiber, S, 2010) |
| "Five methadone clients were interviewed at the clinic and interviews taped for transcription with consent." | 1.36 | A special type of 'hard-to-reach' patient: experiences of pregnant women on methadone. ( Calvin, C; Moriarty, H, 2010) |
| "To evaluate the impact of introduction of supervision of methadone dosing on deaths related to overdose of methadone in Scotland and England between 1993 and 2008 while controlling for increased prescribing of methadone." | 1.36 | Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland. ( Bird, SM; Hall, W; Hickman, M; Strang, J, 2010) |
| "Addiction to opioids, or opioid dependence, encompasses the biopsychosocial dysfunction seen in illicit heroin injectors, as well as aberrant behaviours in patients prescribed opioids for chronic nonmalignant pain." | 1.36 | Opioid dependence - management in general practice. ( Frei, M, 2010) |
| " Use of these illicit substances have other consequences like compromising the dosing schedule or adherence / poor compliance to ARTs/ARVs among those enrolled." | 1.36 | Methadone maintenance therapy as evidence based drug abuse planning in developed countries: can developing countries afford and learn from this experience? ( Nsimba, SE, 2010) |
| "The treatment of heroin addiction as a chronic disease is reviewed, including social, medical, and cultural issues and pharmacologic treatment with methadone and the more experimental medication options of buprenorphine and naltrexone." | 1.35 | A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. ( O'Brien, CP, 2008) |
| "Buprenorphine should be used for opiate dependence and chronic pain in patients with methadone-induced QT prolongation and as first line therapy in patients with risk factors for torsades de pointes." | 1.35 | Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. ( Do, LT; Esses, JL; Hanon, S; Rosman, J; Schweitzer, P, 2008) |
| "The cost of providing and receiving treatment for opioid dependence can determine its adoption." | 1.35 | Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. ( Fiellin, DA; Jones, ES; Moore, BA; O'Connor, PG; Schottenfeld, RS; Sindelar, JL, 2009) |
| "Methadone subjects were significantly (odds ratio of 7." | 1.35 | Electrocardiogram characteristics of methadone and buprenorphine maintained subjects. ( Athanasos, P; Compton, P; Farquharson, AL; Hay, J; Psaltis, P, 2008) |
| "Buprenorphine was more likely to be prescribed for short-term detoxification and methadone for maintenance treatment." | 1.35 | Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. ( Gossop, M; Lintzeris, N; Ridge, G; Strang, J; Witton, J, 2009) |
| " Seventeen methadone patients (7 depressed and 10 not depressed) had pharmacokinetic and pharmacodynamic assessments (opioid withdrawal, drug effects, and mood) over one 24-hour dosing interval." | 1.35 | Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients. ( Brands, B; Dunn, E; Elkader, AK; Selby, P; Sproule, BA, 2009) |
| "Methadone was the only psychoactive drug detected in blood in only 10 cases." | 1.35 | Methadone and impairment in apprehended drivers. ( Bernard, JP; Khiabani, HZ; Krogh, M; Mørland, J, 2009) |
| "Methadone maintenance treatment and compulsory detoxification might he benefit to quality of life for drug addicts, and MMT contribute to it much more." | 1.35 | [Comparison of quality of life for drug addicts in methadone maintenance treatment clinics, community and compulsory detoxification institutions in Sichuan Province]. ( Chen, J; Wang, Y; Wu, Z; Xiao, L, 2009) |
| " Here, we comprehensively analyzed the DRD2 gene locus, and in addition, the ANKK1 rs1800497C>T single nucleotide polymorphism (SNP), formerly known as 'dopamine D2 receptor Taq1A C>T polymorphism', for associations with the risk of opiate addiction and the methadone dosage requirements." | 1.35 | Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. ( Doehring, A; Geisslinger, G; Graff, J; Harder, S; Hentig, Nv; Lötsch, J; Salamat, S; Schmidt, M, 2009) |
| " Participants were mainly satisfied with service provided by the clinic, although had concerns over the inflexibility associated with the clinic atmosphere, frequency of clinic attendance, dosing hours and lack of takeaway doses." | 1.35 | Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. ( Bath, N; Lea, T; Madden, A; Winstock, AR, 2008) |
| "In the present study, the effects of opioid addiction on mRNA expression of dopamine D(3), D(4) and D(5) receptors in human peripheral blood lymphocytes were investigated, using a real-time PCR method." | 1.35 | Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction. ( Goodarzi, A; Mokri, A; Sedaghati, M; Vousooghi, N; Zarrindast, MR, 2009) |
| "VHA methadone treatment costs were higher than reported by other providers." | 1.35 | Comparison of costs and utilization among buprenorphine and methadone patients. ( Barnett, PG, 2009) |
| " Geometric mean area under curve of the plasma concentration-time curve over 24 hour dosing interval (AUC(0-24 hour)) ratio of methadone with and without SQV/RTV was 0." | 1.35 | Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. ( Jamois, C; Morcos, PN; Morrison, R; Patel, A; Riek, M; Schmitt, C; Smith, P; Zhang, X, 2009) |
| "Buprenorphine was safer during induction." | 1.35 | Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. ( Bell, J; Butler, B; Randall, D; Rubin, G; Trinh, L, 2009) |
| "Methadone maintenance treatment (MMT) is typically provided separately from medical care." | 1.35 | Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue. ( Alford, DP; Cheng, DM; Farrar, D; Samet, JH; Walley, AY, 2009) |
| "Subjects with a history of opiate dependence have impairments in the functioning of sustained attention, and abnormalities in brain regions identified as important in attention processing." | 1.35 | Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results. ( Galynker, II; London, ED; Prosser, J, 2009) |
| "Methadone is a proven first-line treatment in opioid dependence but few studies have addressed the efficacy of different isoforms of methadone or the transfer from one form to the other." | 1.35 | Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. ( Soyka, M; Zingg, C, 2009) |
| "It has been shown that opioid dependence can be characterized as a disease of brain metastable balance, wherein local functional connectivity (synchronicity within neuronal assemblies) increased and remote functional connectivity (synchronicity between neuronal assemblies) decreased." | 1.35 | Methadone restores local and remote EEG functional connectivity in opioid-dependent patients. ( Autti, T; Borisov, S; Fingelkurts, AA; Jokela, O; Kähkönen, S; Kivisaari, R; Puuskari, V, 2009) |
| "They were also offered residential treatment before pregnancy and after the child was born." | 1.35 | Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine. ( Bakstad, B; Martinsen, H; Røislien, J; Sarfi, M; Waal, H, 2009) |
| "We assess the influence of co-occurring psychiatric disorders on retention in 189 opioid dependent patients in a methadone maintenance treatment (MMT) and determine the incidence of psychiatric co-morbidity during an 18-month follow-up period." | 1.35 | Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. ( Astals, M; Bulbena, A; Díaz, L; Domingo-Salvany, A; Martín-Santos, R; Torrens, M, 2009) |
| " There was wide variation between pharmacies in the level of supervision provided during supervised buprenorphine dosing and a lack of clarity between pharmacists regarding what behaviors are examples of buprenorphine diversion." | 1.35 | What is diversion of supervised buprenorphine and how common is it? ( Lea, T; Sheridan, J; Winstock, AR, 2009) |
| "Methadone dosing has been an issue of controversy among clinicians for a long time." | 1.35 | High dose versus moderate dose methadone maintenance: is there a better outcome? ( Amar, R; Casarella, J; Drexler, K; Fareed, A; Roberts, M; Sleboda, M; Vayalapalli, S, 2009) |
| " Nonetheless, the finding of a dose-response effect supports one of the basic principles of clinical practice during detoxification, namely the matching of the medication withdrawal schedule to the pre-admission opiate dose." | 1.35 | Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification. ( Bearn, J; de Wet, C; Glasper, A; Gossop, M; Reed, L, 2008) |
| " Metropolitan pharmacists dosed greater numbers of OST clients (median = 7) than rural pharmacists (median = 4)." | 1.35 | Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. ( Lawrinson, P; Le, PP; Roche, A; Terao, H, 2008) |
| "Methadone is an interesting analgesic for multiple reasons." | 1.35 | The safety of methadone hydrochloride. ( Swegle, JM; Wensel, DD, 2008) |
| " These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity." | 1.35 | BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. ( de Cid, R; Estivill, X; Fonseca, F; Gratacòs, M; Gutierrez, F; Martín-Santos, R; Torrens, M, 2008) |
| "Opioid dependence is a complex medical condition affecting neurocognitive and physical functioning." | 1.35 | Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. ( Bruce, RD; Schleifer, RA, 2008) |
| "Prevalence of prescription opioid abuse has increased dramatically in recent years in the United States generally, and a similar pattern of increasing prescription opioid use has also been noted among patients seeking treatment for opioid dependence." | 1.35 | Evaluation of ongoing oxycodone abuse among methadone-maintained patients. ( Dunn, KE; Heil, SH; Higgins, ST; McGee, MR; Sigmon, SC, 2008) |
| "Treatment with methadone, for both pain and opioid dependence, should be preceded by an abuse liability evaluation." | 1.35 | Methadone- and heroin-related deaths in Florida. ( Gold, MS; Goldberger, BA; Graham, NA; Merlo, LJ, 2008) |
| "Methadone maintenance therapy for the treatment of opioid dependence continues to carry a social stigma." | 1.34 | Liver transplant and hepatitis C in methadone maintenance therapy: a case report. ( Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L, 2007) |
| "Another approach to treat opiate dependence could be to target the endogenous opioid system by enhancing the effects of enkephalins by protecting them from enzymic degradation by the dual peptidase inhibitor RB101." | 1.34 | Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments. ( Cordonnier, L; Noble, F; Roques, BP; Sanchez, M, 2007) |
| "The SOWS measures withdrawal symptoms at the time of assessment." | 1.34 | Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS). ( De Jong, CA; Dijkstra, BA; Krabbe, PF; Riezebos, TG; van der Staak, CP, 2007) |
| "Methadone adherence was calculated as the fraction of days methadone was administered." | 1.34 | The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. ( Conway, B; DeVlaming, S; Duncan, F; Grebely, J; Khara, M; McLean, M; Mead, A; Petkau, AJ; Raffa, JD; Tossonian, H; Viljoen, M; Wong, T, 2007) |
| "Oral methadone therapy is an effective and increasingly popular treatment for opioid dependency and chronic pain." | 1.34 | QTc prolongation and torsades de pointes associated with methadone therapy. ( Brooks, DE; Katz, KD; Routhier, DD, 2007) |
| "Methadone maintenance treatment substantially reduces morbidity associated with opioid dependence and improves the quality of life of patients." | 1.34 | Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania. ( Padaiga, Z; Subata, E; Vanagas, G, 2007) |
| "Methadone maintenance treatment programs (MMTP) often provide onsite primary care." | 1.34 | Primary care affiliations of adults in a methadone program with onsite care. ( Arnsten, JH; Federman, AD, 2007) |
| "Amongst people on opioid maintenance treatment (OMT), chronic hepatitis C (HCV) is common but infrequently treated." | 1.34 | Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. ( Conigrave, KM; Haber, PS; Wallace, C; Watson, B; Whitfield, JB; Wurst, F, 2007) |
| " We initiated active surveillance for cases throughout Australia, a survey of dosing points in NSW, and a case control study of clients receiving methadone syrup (MS) at two clinics." | 1.34 | An epidemiological investigation into an outbreak of rash illness among methadone maintenance clients in Australia. ( Alam, NK; Armstrong, PK; Capon, AG; Hailstone, ST; Irvine, K; Jauncey, ME; Kaldor, JM; Mannes, TF; McAnulty, JM; Monger, CK, 2007) |
| "Methadone-treated patients, as a group, had significantly slower simple reaction time (RT) compared to buprenorphine/naloxone-treated patients." | 1.34 | Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. ( Alho, H; Fabritius, C; Kalska, H; Rapeli, P; Salaspuro, M; Wahlbeck, K, 2007) |
| "Buprenorphine may be used to treat opioid dependence in office-based settings, but treatment models are needed to ensure access to psychosocial services needed by many patients." | 1.34 | Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. ( Arnsten, JH; Gourevitch, MN; Kunins, HV; Whitley, SD, 2007) |
| "Although it is said that drug addiction is associated with poor dental health, there is little research in this area." | 1.34 | Dentition of addiction in Queensland: poor dental status and major contributing drugs. ( Reece, AS, 2007) |
| " In addition, methadone dosage requirements were not influenced by CYP2D6 genotypes in these subjects." | 1.34 | Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. ( Christrup, L; Coller, JK; Foster, DJ; Gillis, D; James, H; Joergensen, C; Somogyi, AA, 2007) |
| "Menopause is a natural process that occurs in women's lives as part of normal aging." | 1.34 | Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. ( Tuchman, E, 2007) |
| " In subjects whose dosage of levomethadyl or methadone remained fixed over at least 8 weeks, the QTc continued to increase progressively over time (P = ." | 1.34 | QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. ( Bigelow, GE; Haigney, MC; Johnson, RE; Nuzzo, PA; Wedam, EF, 2007) |
| " Naloxone, an opiate antagonist, is very poorly absorbed with sublingual administration, but if it is injected intravenously, it will antagonise the effects of buprenorphine." | 1.34 | Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection. ( , 2007) |
| " However, the pharmacology underpinning the effects of methadone is little studied despite controversies about dosing in relation to outcome." | 1.33 | Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. ( Ahmad, R; Brooks, DJ; Daglish, MR; Hume, SP; Lingford-Hughes, A; Malizia, AL; Melichar, JK; Myles, JS; Nutt, DJ; Taylor, LG; Williams, TM, 2005) |
| "Buprenorphine is a new drug for the pharmacotherapy of opioid dependence." | 1.33 | Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. ( Albrecht, S; Bliesener, N; Klingmüller, D; Lichtermann, D; Schwager, A; Weckbecker, K, 2005) |
| "When methadone and puffs were concurrently available, an increase in methadone's price decreased puff consumption, and demand for methadone was less elastic than when puffs were not concurrently available." | 1.33 | Methadone and nicotine self-administration in humans: a behavioral economic analysis. ( Cowan, K; Hursh, S; Martinetti, MP; Meisch, RA; Spiga, R, 2005) |
| "3mg; number of days/month dosed in the clinic was 13." | 1.33 | Deaths of clients in methadone treatment in Texas: 1994-2002. ( Maxwell, JC; Pullum, TW; Tannert, K, 2005) |
| "Methadone is effective treatment for opioid addiction, but regulations restrict its use." | 1.33 | Methadone medical maintenance in primary care. An implementation evaluation. ( Awan, A; Brumback, LC; Carney, M; Donovan, D; Jackson, TR; Kapitan, S; Merrill, JO; Saxon, AJ; Schulman, BA, 2005) |
| "Desired adjustment of methadone dose, perceived participation in dosage regulation, and satisfaction with methadone treatment centres were assessed in a sample of opioid-dependent patients from the Valencia Region (eastern Spain)." | 1.33 | Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction with treatment. ( Pérez de Los Cobos, J; Puig, T; Trujols, J; Valderrama, JC; Valero, S, 2005) |
| "(1) Methadone is an opiate used for replacement therapy of opiate addiction that causes dose-dependent QT prolongation." | 1.33 | Torsades de pointes with methadone. ( , 2005) |
| " The second part was a cross-sectional study (n = 223 doctors), which consisted of a target-week assessment of 2,694 consecutive patients to determine (a) the severity and problem profiles and treatment targets; (b) the choice and dosage scheme of the substitution drug; (c) past and current interventions, including treatment of comorbid hepatitis C; and (d) cross-sectional differences between the two drugs with regard to comorbidity, clinical course, acceptance/compliance and social integration." | 1.33 | Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. ( Apelt, SM; Backmund, M; Bühringer, G; Gastpar, M; Gölz, J; Klotsche, J; Kraus, MR; Pittrow, D; Siegert, J; Soyka, M; Tretter, F; Wittchen, HU, 2005) |
| "Methadone serum levels were available in 55 patients, assessed by Gas Chromatography Mass Spectroscopy." | 1.33 | Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. ( Adelson, M; Peles, E; Schreiber, S, 2006) |
| "To determine if atazanavir, a once-daily protease inhibitor and moderate inhibitor of P450 CYP3A4, exhibited pharmacokinetic interactions with (R)-methadone." | 1.33 | Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. ( Agarwala, S; Andrews, L; Child, M; Daley, L; Friedland, G; O'Mara, E; Schreibman, T; Shi, J; Wang, Y, 2005) |
| " The focus of this research is to estimate the percentage of outpatient methadone clients receiving this level of methadone and examine the association between treatment retention and level of methadone dosage as recommended by the NIH expert panel." | 1.33 | Methadone dosage and retention: an examination of the 60 mg/day threshold. ( Brady, TM; DeSale, S; Kyeyune, H; Male, A; Salvucci, S; Sikali, E; Sverdlov, LS; Yu, P, 2005) |
| "Methadone maintenance treatment of opiate addiction is highly effective at reducing drug use, drug-related criminal activity, and risk of HIV transmission." | 1.33 | Linkage with methadone treatment upon release from incarceration: a promising opportunity. ( Clarke, J; Key, RG; McKenzie, M; Poshkus, M; Rich, JD; Shield, DC; Wolf, FA, 2005) |
| " Blood samples and pharmacodynamic data were collected 10-12 times over a 24-h inter-dosing interval." | 1.33 | Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. ( Bochner, F; Foster, DJ; Hanna, J; Salter, A; Somogyi, AA; White, JM, 2005) |
| "Methadone is a synthetic opiate used in the treatment of opiate addiction." | 1.33 | Dental management of patients taking methadone. ( Graham, CH; Meechan, JG, 2005) |
| "To determine the monitoring and treatment of neonatal abstinence syndrome (NAS) in neonatal intensive care units (NICUs) following opiate or polydrug exposure in utero." | 1.33 | Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. ( Donn, SM; Sarkar, S, 2006) |
| "Treatment of maternal opioid dependence with methadone is associated with a delay in fetal heart rate (FHR) accelerations in nonstress tests." | 1.33 | Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. ( Flores, S; McKay, J; Ramirez-Cacho, WA; Rayburn, WF; Schrader, RM, 2006) |
| "7 g/70 kg of alcohol in two separate sessions, one 2-3 hours before opioid pharmacotherapy dosing and the other 1-2 hours after dosing." | 1.33 | Effect of opioid substitution therapy on alcohol metabolism. ( Clark, NC; Dietze, P; Lenné, MG; Redman, JR, 2006) |
| "Urine samples were analyzed for drug abuse after one month and after one year." | 1.33 | Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic. ( Adelson, M; Peles, E, 2006) |
| " This retrospective chart review provides an exploratory examination of newborns treated with either methadone or paregoric for opioid withdrawal and outlines dosage ranges and intervals, side effects, and clinical outcomes of the two regimens." | 1.33 | A chart review comparing paregoric to methadone in the treatment of neonatal opioid withdrawal. ( Wunsch, MJ, 2006) |
| "Methadone treatment for heroin addiction in the UK, the 'British system', is unique as it is largely provided by General Practitioners." | 1.33 | Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. ( Griffiths, C; Hickman, M; Morgan, O, 2006) |
| "Methadone medical maintenance (MMM) is a model for the treatment of opioid dependence in which a monthly supply of methadone is distributed in an office setting, in contrast to more highly regulated settings where daily observed dosing is the norm." | 1.33 | A 5-year evaluation of a methadone medical maintenance program. ( Arnsten, JH; Gourevitch, MN; Harris, KA; Hecht, J; Joseph, H; Juliana, P; Marion, I, 2006) |
| "Methadone is a substrate for the P-glycoprotein transporter, encoded by the ABCB1 gene, which regulates central nervous system exposure." | 1.33 | ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. ( Barratt, DT; Coller, JK; Dahlen, K; Loennechen, MH; Somogyi, AA, 2006) |
| "Buprenorphine has the potential to reduce the harm caused by drug abuse." | 1.32 | Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. ( Ertl, M; Giacomuzzi, SM; Hinterhuber, H; Kemmler, G; Kurz, M; Riemer, Y; Rössler, H, 2003) |
| "Methadone maintenance treatment reduces drug-related-harm." | 1.32 | [Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment]. ( Aragonés, A; Barril, J; Esteban, J; Gimeno, C; Pellín, Mde L, 2003) |
| "No miscarriages were observed in the second trimester (n = 54; incidence rate ratio = 0 compared to population norms (95% CI = 0-3." | 1.32 | Is opiate detoxification unsafe in pregnancy? ( Bearn, J; Luty, J; Nikolaou, V, 2003) |
| "Central to both pain responses and opioid addiction is activity at the micro -opioid receptor." | 1.32 | Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. ( Alarcón, M; Compton, P; Geschwind, DH, 2003) |
| "Lopinavir is a potent inducer of methadone metabolism, and treatment with L/R requires clinical monitoring and increased methadone doses in some patients, whereas ritonavir has no significant effect on methadone metabolism." | 1.32 | The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. ( Friedland, G; Jatlow, P; McCance-Katz, EF; Rainey, PM, 2003) |
| "Results in OM and OA indicate that opiate dependence is also associated with an impaired EFE decoding but less than in alcoholism." | 1.32 | Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls. ( Dan, B; Foisy, ML; Hess, U; Kornreich, C; Noël, X; Pelc, I; Philippot, P; Tecco, J; Verbanck, P, 2003) |
| "Pain was associated with an increased propensity for misuse of substances with analgesic effects, suggesting that ongoing pain contributes to an altered and more severe pattern of drug-seeking behavior." | 1.32 | Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. ( Horst, DA; Humphreys, K; Minkel, JD; Oliva, EM; Trafton, JA, 2004) |
| "The results indicate that opiate addiction in humans (tolerant state) is associated with down-regulation of brain micro-opioid receptors and regulatory GRK 2/6 and beta-arrestin-2 proteins." | 1.32 | Decreased immunodensities of micro-opioid receptors, receptor kinases GRK 2/6 and beta-arrestin-2 in postmortem brains of opiate addicts. ( Ferrer-Alcón, M; García-Sevilla, JA; La Harpe, R, 2004) |
| "Methadone serum levels were maintained around 200 ng/ml during 1 week and approximately 5 weeks with the optimised implants." | 1.32 | Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies. ( Delgado, A; Evora, C; Llabrés, M; Negrín, CM, 2004) |
| "The study estimated serious adverse event (SAE) rates among entrants to pharmacotherapies for opioid dependence, during treatment and after leaving treatment." | 1.32 | Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). ( Digiusto, E; Mattick, RP; O'Brien, S; Ritter, A; Shakeshaft, A, 2004) |
| "Methadone was tapered and discontinued prior to ROD and Naltrexone was administered in increasing daily doses." | 1.32 | Unexpected delirium during Rapid Opioid Detoxification (ROD). ( Golden, SA; Sakhrani, DL, 2004) |
| " Most reported that they determine dosing levels on an individual patient basis." | 1.32 | Physicians practicing in methadone treatment programs: who are they and what do they do? ( Crum, L; Diesenhaus, H; Dunlap, L; Flannery, B; Kasten, JJ; Murdoch, O; Roussel, AE; Suerken, C; Wechsberg, WM, 2004) |
| " MTD excretion was higher in men, decreased with increased urinary pH, and increased with daily dosage of MTD; these factors explain 32% of the total variance of urinary MTD." | 1.32 | Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening. ( Bézie, Y; Billaud, E; Boutouyrie, P; Illier, C; Lillo, A; Prognon, P; Talon, V, 2004) |
| " Daily supervised dosing by a pharmacist for the first six months resulted in significantly better treatment retention (80% vs 46%) and lower heroin use." | 1.32 | French field experience with buprenorphine. ( Auriacombe, M; Daulouède, JP; Dubernet, J; Fatséas, M; Tignol, J, 2004) |
| "Improving office-based treatment of opioid dependence requires an evaluation of processes of care." | 1.32 | Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. ( Chawarski, M; Fiellin, DA; O'Connor, PG; Schottenfeld, RS, 2004) |
| "The methadone patients were followed up to 1998 with respect to being expelled from treatment." | 1.32 | Leaving methadone maintenance treatment: the role of personality traits and psychiatric status. ( Brandt, L; Lettholm, L; Stenbacka, M, 2004) |
| "Rates of specific personality disorders are reported." | 1.32 | A psychometric study of the prevalence of DSM-IV personality disorders among office-based methadone maintenance patients. ( Daiter, J; O'Connell, T; Teplin, D; Varenbut, M, 2004) |
| "Providers of treatment for opioid addiction have entered a new era of accountability, as Federal and State regulators increasingly demand objective evidence of treatment effectiveness." | 1.31 | Treatment practice and research issues in improving opioid treatment outcomes. ( Jackson, TR, 2002) |
| "It has been shown repeatedly that opioid dependence is associated with increased consumption of refined sugars." | 1.31 | Taste function in methadone-maintained opioid-dependent men. ( Baran-Furga, H; Bienkowski, P; Bogucka-Bonikowska, A; Chmielewska, K; Habrat, B; Koros, E; Kostowski, W; Kukwa, A; Polanowska, E; Scinska, A, 2002) |
| "Methadone maintenance treatments (MMTs) are the commonest substitution treatments offered to opiate addiction in Switzerland, in order to reduce criminal behaviour, infectious disease transmission and overdose death." | 1.31 | Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983-1999. ( La Harpe, R; Niveau, G; Rougemont, AL, 2002) |
| "In methadone maintenance treatment, prognostic studies have failed to find robust predictors on the basis of single predictive variables." | 1.31 | A staging system to predict prognosis among methadone maintenance patients, based on admission characteristics. ( Favrat, B; O'Connor, PG; Rao, S; Schottenfeld, R, 2002) |
| "Methadone levels were kept blinded from clinicians." | 1.31 | Methadone trough levels in pregnancy. ( Berghella, V; Drozdick, J; Hill, M; Kaltenbach, K, 2002) |
| "Methadone dosage was also correlated with both duration of neonatal hospitalization and neonatal abstinence score (r(s) =." | 1.31 | Relationship between maternal methadone dosage and neonatal withdrawal. ( Dashe, JS; Jackson, GL; Olscher, DA; Sheffield, JS; Todd, SJ; Wendel, GD, 2002) |
| "Treatment of opiate dependence with naltrexone has been limited by poor compliance." | 1.31 | Behavioral naltrexone therapy: an integrated treatment for opiate dependence. ( Church, SH; Collins, E; Kleber, HD; Nunes, EV; Rothenberg, JL; Seracini, A; Sullivan, MA, 2002) |
| "Occurrence of trauma or PTSD did not predict drop-out rates." | 1.31 | Posttraumatic stress disorder and short-term outcome in early methadone treatment. ( Fraser, D; Hien, DA; Levin, FR; Nunes, E, 2000) |
| "Tramadol hydrochloride is a centrally acting analgesic with a partial affinity for the opiate receptor (mu), having an analgesic potency estimated to be one tenth that of morphine." | 1.31 | Methadone detoxification of tramadol dependence. ( DeGuiseppe, B; Leo, RJ; Narendran, R, 2000) |
| "Methadone is a 50:50 mixture of two enantiomers and (R)-methadone accounts for the majority of its opioid effect." | 1.31 | Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. ( Baumann, P; Bourquin, M; Déglon, J; Eap, CB; Livoti, S; Martin, J; Powell, K; Spagnoli, J, 2000) |
| "Methadone treatment had a beneficial effect on HIV risk behaviors, and though some risk behaviors improved signiticantly for both groups, comorbid subjects continued to have higher rates of HIV risk factors than noncomorbid subjects." | 1.31 | Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment. ( Brooner, RK; Kidorf, MS; King, VL; Stoller, KB, 2000) |
| "The methadone group was slower to process all sentences compared with family members." | 1.31 | The processing of automatic thoughts of drug use and craving in opiate-dependent individuals. ( Feldtkeller, BT; Law, F; Myles, J; Nutt, DJ; Weinstein, AM, 2000) |
| "Since many methadone maintenance treatment (MMT) clinics in the United States do not share with patients, information concerning their methadone dosage, we aimed to investigate the impact of patients being informed of their methadone dosage and the influence of ending blind dosing on treatment outcome." | 1.31 | A naturalistic study on ending blind dosing in a methadone maintenance clinic in Israel. ( Adelson, M; Bleich, A; Gelkopf, M; Hayward, R, 2001) |
| "Across substance use and psychosocial domains, participants showed significant and comparable levels of improvement regardless of comorbidity." | 1.31 | The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. ( Alterman, AI; Cacciola, JS; McKay, JR; Mulvaney, FD; Rutherford, MJ, 2001) |
| "The study was carried out on 44 opiate abusers (14 women aged from 21-33 years and 30 men aged from 21-46 years), who were classified to methadone maintenance treatment." | 1.31 | [Nutritional problems of persons qualified for the methadone treatment. Part I. Nutritional status of opiate addicts]. ( Janik, A; Kolarzyk, E; Kroch, S; Szpanowska-Wohn, A, 2000) |
| "Sufficient treatment facilities for opioid dependence should be provided when law enforcement activities against open drug scenes are planned." | 1.31 | Closure of an open drug scene--a case register-based analysis of the impact on the demand for methadone maintenance treatment. ( Dürsteler-Mac Farland, KM; Eich, D; Eichenberger, A; Falcato, L; Rössler, W; Stohler, R, 2001) |
| "Methadone treatment programme for 50 opiate addicts has been conducted at the Department of Clinical Toxicology for a one year." | 1.31 | [Evaluation of health status in participants from a methadone treatment program in Krakow after one year of maintenance treatment]. ( Foryś, Z; Kamenczak, A; Maj, JC; Pach, J, 2001) |
| " Although the current analysis did not rule out differences in pharmacological effects as a contributing factor, the results are consistent with an interpretation of a dose-response association between psychosocial/psychotherapeutic support and detoxification outcome." | 1.31 | Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. ( Backmund, M; Eichenlaub, D; Meyer, K; Schütz, CG, 2001) |
| "In 71% of the group who had a comorbid psychiatric illness, the onset of psychiatric symptomatology was reported to predate the use of heroin." | 1.31 | Prevalence of psychiatric disorder in a methadone maintenance population. ( Callaly, T; Munro, L; Trauer, T; Whelan, G, 2001) |
| "This study reports on the prevalence of alcohol dependence, patterns of alcohol consumption and preliminary findings about clients' beliefs that they will change their drinking behavior in the future." | 1.31 | Excessive alcohol consumption and drinking expectations among clients in methadone maintenance. ( Finch, E; Hillebrand, J; Marsden, J; Strang, J, 2001) |
| "Age, and the duration of opioid dependence showed a significant influence on cocaine positive urinalysis." | 1.31 | [Cocaine abuse in maintenance therapy with methadone in narcotic dependent patients]. ( Fischer, G; Kraigher, D; Ortner, R; Peternell, A; Schindler, S; Topitz, A, 2001) |
| " 5,510 +/- 237 microg/L), or terminal elimination half-life (t 1/2; 55." | 1.31 | The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. ( Andrews, L; Friedland, GH; Jatlow, P; Lane, B; McCance-Katz, EF; Mitchell, SM; Rainey, PM; Snidow, JW, 2002) |
| "Long-term opioid dependence seems to decrease prefrontal CBF in particular." | 1.31 | Opioid addiction changes cerebral blood flow symmetry. ( Brücke, T; Fischer, G; Jagsch, R; Kasper, S; Pezawas, L; Podreka, I; Schindler, S; Thurnher, M, 2002) |
| "Paroxetine is a strong CYP2D6 inhibitor, and these results confirm previous studies showing an involvement of CYP2D6 in methadone metabolism with a stereoselectivity toward the (R)-enantiomer." | 1.31 | Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. ( Baumann, P; Begré, S; Cosendai-Savary, L; Eap, CB; Golay, KP; Jaquet-Rochat, S; Kosel, M; Ladewig, D; von Bardeleben, U, 2002) |
| "Opioid agonist effects and opioid withdrawal symptoms were assessed prior to heroin challenge." | 1.31 | High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. ( Bigelow, GE; Donny, EC; Eissenberg, T; Stitzer, ML; Walsh, SL, 2002) |
| "Methadone treatment is often criticized by drug war supporters not because of its limitations, but because its very effectiveness highlights the meagre benefits of supply reduction." | 1.31 | Methadone and heroin prescription: babies and bath water. ( Wodak, A, 2002) |
| "Psychiatric and substance use comorbidity was assessed in 716 opioid abusers seeking methadone maintenance." | 1.30 | Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. ( Bigelow, GE; Brooner, RK; Kidorf, M; King, VL; Schmidt, CW, 1997) |
| "Methadone dosing was flexible, with patient participation in dose decisions." | 1.30 | The relationship of methadone dose and other variables to outcomes of methadone maintenance. ( Maddux, JF; Prihoda, TJ; Vogtsberger, KN, 1997) |
| "Women with ASPD were unlikely to have alcohol use disorder, but likely to have opioid use disorder." | 1.30 | Gender differences in psychiatric comorbidity among cocaine-using opiate addicts. ( Foote, J; Handelsman, L; Kang, SY; Magura, S; Rosenblum, A, 1998) |
| "Women with mild withdrawal symptoms were given clonidine initially, and methadone was substituted if symptoms persisted." | 1.30 | Opioid detoxification in pregnancy. ( Dashe, JS; Jackson, GL; Olscher, DA; Wendel, GD; Zane, EH, 1998) |
| "Codeine has a weaker pharmacological effects and our results suggest that codeine maintenance treatment deserves more attention and controlled trials to assess the benefits compared with methadone (or other opioids)." | 1.30 | Maintenance treatment of opiate addicts in Germany with medications containing codeine--results of a follow-up study. ( Degkwitz, P; Haasen, C; Krausz, M; Raschke, P; Verthein, U, 1998) |
| "Methadone treatment is most frequently used." | 1.30 | [Problems with maintenance therapy in opiate dependence and the clinical importance of methadone]. ( Wilczek, H, 1998) |
| "Naloxone's effects were usually greater during the descending dose series than during the ascending series." | 1.30 | Orally delivered methadone as a reinforcer: Effects of the opioid antagonist naloxone. ( Meisch, RA; Stewart, RB; Wang, NS, 1999) |
| "In the national Drug Abuse Treatment Outcome Studies (DATOS), many clients in outpatient methadone treatment (OMT) and outpatient drug-free (ODF) modalities were admitted with multiple sex and needle-risk behaviors, but they reduced these risks significantly during treatment." | 1.30 | HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences. ( Broome, KM; Joe, GW; Simpson, DD, 1999) |
| "Methadone has been effectively used in the treatment of opiate dependence." | 1.30 | A therapeutic use of the methadone fluvoxamine drug interaction. ( DeMaria, PA; Serota, RD, 1999) |
| "Traditionally, methadone maintenance therapy has been a once-daily dosing schedule." | 1.30 | Alterations in methadone metabolism during late pregnancy. ( Jarvis, MA; Kniseley, JS; Schnoll, SH; Wu-Pong, S, 1999) |
| "Methadone Transition Treatment (MTT) is an innovative treatment organized around this strategy." | 1.29 | Methadone transition treatment: a treatment model for 180-day methadone detoxification. ( Banys, P; Krumenaker, CL; Reilly, PM; Sees, KL; Shopshire, MS; Tusel, DJ, 1995) |
| "A 75 year-old man with a well known opioid abuse is described." | 1.29 | [Abuse--of hospital services too]. ( Eriksen, J; Højsted, J, 1995) |
| "To assess antisocial personality disorder in women it may be necessary to revise current, or develop new, diagnostic criteria." | 1.29 | Gender differences in diagnosing antisocial personality disorder in methadone patients. ( Alterman, AI; Cacciola, JS; Rutherford, MJ; Snider, EC, 1995) |
| "Methadone is a typical mu-opioid receptor agonist that is widely used for maintenance and detoxification treatment of opiate-dependent patients." | 1.29 | Methadone withdrawal psychosis. ( Galynker, II; Levinson, I; Rosenthal, RN, 1995) |
| "Buprenorphine is an opioid partial agonist being developed for possible use in the treatment of opioid dependence." | 1.29 | Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. ( Bigelow, GE; Liebson, IA; Preston, KL; Strain, EC, 1995) |
| "However, intravenous drug abusers (IVDAs) remain at higher risk for exposure to HIV-1 because they are likelier to have sexual contact with other IVDAs and former IVDAs." | 1.29 | Condom use rates for specific sexual behaviors among opioid abusers entering treatment. ( Bigelow, GE; Brooner, RK; Felch, LJ; Gazaway, PM; King, VL; Schmidt, CW, 1994) |
| " Relapse rates were related to dosage level, client monitoring with urinalyses, and methadone take-home privileges in some clinics, and hence, these time-varying treatment events were important factors in treatment outcomes." | 1.29 | Treatment process and relapse to opioid use during methadone maintenance. ( Joe, GW; Sells, SB; Simpson, DD, 1994) |
| "Methadone maintenance treatment was introduced in Austria in 1987." | 1.29 | [Methadone substitution treatment. Results of an evaluation of 3 years implementation in an Austrian province]. ( Rittmannsberger, H; Ruschak, M; Silberbauer, C, 1994) |
| "Methadone alone was found to be the cause of death in 50% more cases in 1989 than in 1981." | 1.29 | [Methadone and drug addicts]. ( Kringsholm, B; Steentoft, A; Worm, K, 1993) |
| "The impact of length of stay in drug abuse treatment on follow-up drug use and criminal behavior has important clinical and policy implications." | 1.29 | The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. ( French, MT; Hubbard, RL; Rachal, JV; Zarkin, GA, 1993) |
| " The disposition of methadone at steady-state was assessed on 8 occasions-in 5 opioid addicts prescribed wide ranging doses of methadone (10 mg to 60 mg per day)-providing unique pharmacokinetic data." | 1.29 | Steady-state pharmacokinetics of methadone in opioid addicts. ( Calvert, R; Hay, AW; Raistrick, D; Wolff, K, 1993) |
| "Methadone maintenance treatment for patients with opiate addiction, started in the Canton of Basel in 1980, today includes more than 600 patients, with a marked increase since 1987 due to a change in inclusion criteria following the spreading of HIV infections." | 1.29 | [Substitute drug treatments with methadone]. ( Ladewig, D; Petitjean, S; Stohler, R; von Bardeleben, U, 1993) |
| "Methadone was the opiate most commonly dispensed to misusers (96." | 1.29 | Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies in England and Wales. ( Barber, N; Sheridan, J; Strang, J, 1996) |
| "Methadone dosing was not contingent upon ingestion of antituberculous medication(s)." | 1.29 | Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. ( Gourevitch, MN; Panero, MS; Selwyn, PA; Wasserman, W, 1996) |
| "Methadone treatment for opioid dependence needs to be promoted and liberalized, especially because the oral route of administration eliminates the risks accompanying drug injection." | 1.29 | Inadequate treatment of opioid dependence due to society's attitudes and beliefs. ( Blansfield, HN, 1996) |
| "Axis I nonsubstance use disorder was associated with benzodiazepine use, while Axis II disorder was associated with both benzodiazepine and cocaine use early in treatment (P < 0." | 1.29 | Concurrent validity of cocaine and sedative dependence diagnoses in opioid-dependent outpatients. ( Brooner, RK; Chutuape, MA; Kidorf, M; King, VL; Stitzer, ML, 1996) |
| " The reactivity of the nonstress tests, biophysical profile scores and time needed to complete the biophysical profiled before and after methadone dosing were compared." | 1.29 | Effect of methadone on the biophysical profile. ( Cejtin, HE; Mills, A; Swift, EL, 1996) |
| " Three scoring systems to quantify dose-response relationships for withdrawal are described: (1) using the mean number of withdrawal behaviors per animal within each treatment group; (2) using the sum of the percentage of animals within a treatment group displaying each of the withdrawal behaviors; and (3) a modification of these, to further isolate the naloxone-induced component of the withdrawal score, that is, subtraction of data obtained from saline-challenged animals from those of naloxone-challenged rats." | 1.29 | The induction and quantitation of methadone dependence in the rat. ( Hope, W; Pierce, TL; Raper, C, 1996) |
| "Relapse is a central problem in the treatment of addictive behaviour, and a specific problem in the out-patient treatment of the opiate withdrawal syndrome." | 1.28 | Factors associated with relapse among opiate addicts in an out-patient detoxification programme. ( Gossop, M; Strang, J; Unnithan, S, 1992) |
| "An outcome evaluation of a voluntary AIDS prevention program for methadone patients in three clinics (two experimental, one control) is reported." | 1.28 | Outcomes of an AIDS prevention program for methadone patients. ( Amann, KR; Grossman, JI; Koger, J; Lipton, DS; Magura, S; Marion, IJ; Shapiro, J; Siddiqi, Q; Weisenfeld, L, 1991) |
| "Methadone treatment offers a first step toward social rehabilitation for drug addicts who have been living as criminals on the fringe of society." | 1.28 | [Nicotine--drug addiction--AIDS. Drug use habits of Vienna addicts]. ( Hollerer, E; Loimer, N; Pfersmann, V; Presslich, O; Schmid-Siegel, B; Vedovelli, H; Werner, E, 1991) |
| " Significant predictors included professional classifications of the diagnosing and treatment-planning staff members, measures of early treatment services, client attitudes and satisfaction, methadone dosage level, and frequency of urine monitoring." | 1.28 | Treatment predictors of tenure in methadone maintenance. ( Hubbard, RL; Joe, GW; Simpson, DD, 1991) |
| " drug abusers on levomethadon maintenance programs, adjustment of the levomethadon dosage may be necessary when specific therapy for HIV infection and associated diseases requires the use of drugs known to be potent inducers of the liver microsomal enzyme system." | 1.28 | Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. ( Brockmeyer, NH; Goos, M; Mertins, L, 1991) |
| "Methadone treatment and the use of needle exchanges were related in subsequent analysis to the sharing of injecting equipment." | 1.28 | The sharing of injecting equipment among drug users attending prescribing clinics and those using needle-exchanges. ( Faugier, J; Hayes, C; Klee, H; Morris, J, 1991) |
| "Multiple substance use disorders were found in these patients, and more substance use disorders were found in those patients with, versus without, a non-substance use psychiatric diagnosis." | 1.28 | Clustering of multiple substance use and psychiatric diagnoses in opiate addicts. ( Bigelow, GE; Brooner, RK; Strain, EC, 1991) |
| " It should also be emphasized that there is considerable variability among methadone programs in such vital areas as leadership, staffing patterns, organization, dosing procedures, location, physical plant, and availability of ancillary services." | 1.28 | Psychotherapy and counseling for methadone-maintained opiate addicts: results of research studies. ( Luborsky, L; McLellan, AT; O'Brien, CP; Woody, GE, 1990) |
| "The treatment with methadone was unstable and only 11% had received stable prolonged maintenance treatment." | 1.28 | The influence of prolonged stable methadone maintenance treatment on mortality and employment: an 8-year follow-up. ( Bay, H; Mygind, O; Segest, E, 1990) |
| "Amphetamine alone was rarely the cause of death but the drug was seen in an increasing number of deaths in recent years." | 1.28 | [Narcotic abuse in Jylland. A study based on narcotics and deaths of addicts examined at the Institute of Forensic Medicine, University of Aarhus during the period 1981-1988. 2. Deaths among addicts]. ( Kaa, E, 1990) |
| "Seventy-eight opiate abusers were followed up after successful in-patient detoxification in order to examine renewed opiate use." | 1.28 | Circumstances surrounding the initial lapse to opiate use following detoxification. ( Bradley, BP; Gossop, M; Green, L; Phillips, G, 1989) |
| "Patients reported mild opiate withdrawal symptoms after initiation of CBZ treatment." | 1.28 | Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. ( Halikas, JA; Kemp, KD; Kuhn, KL, 1989) |
| "Cyclizine was taken in large doses intravenously with methadone." | 1.28 | Cyclizine abuse among a group of opiate dependents receiving methadone. ( McLean, PC; Melville, J; Ruben, SM, 1989) |
| "Methadone maintenance was associated with significant decrements in food intake in four of five monkeys." | 1.27 | Comparison of buprenorphine and methadone effects on opiate self-administration in primates. ( Bree, MP; Mello, NK; Mendelson, JH, 1983) |
| "Innovative treatment techniques such as self-regulation of methadone dosage and client knowledge of dosage are not widely accepted by small community methadone maintenance programs." | 1.27 | Methadone maintenance in the small community drug abuse clinic. ( Hebert, SW; Lauterbach, EC, 1983) |
| "85% of the newborns had withdrawal symptoms and 12% had convulsions the severity of which was not correlated with the type of drug abuse." | 1.27 | Investigation of 89 children born by drug-dependent mothers. I. Neonatal course. ( Andersen, GE; Buckley, W; Friis-Hansen, B; Olofsson, M, 1983) |
| " The study was done in three phases: a training phase in which training drugs were identified to subjects by letter code before the session, a test of acquisition phase in which the subject's ability to identify the training drug by letter code was tested and a generalization phase in which dose-response curves for the two active training drugs were tested." | 1.27 | Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. ( Bickel, W; Bigelow, GE; Liebson, IA; Preston, KL, 1987) |
| "Methadone treatment alone was not associated with increased abnormal movements." | 1.27 | Prevalence of movement disorder in a methadone-maintained population. ( Gaspari, J; Kleber, H; Riordan, C; Santangelo, S; Swift, R, 1985) |
| "Of the 7 patients who developed AIDS or ARC, 4 were tested for both antibodies and T-cell ratios: all 4 were seropositive and had low ratios." | 1.27 | Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations. ( Bodner, AJ; Emeson, E; Friedland, G; Harris, C; Moll, B; Shine, D; Small, CB; Spigland, I; Weiss, SH, 1987) |
| " In particular, studies of retention, counselor characteristics, program policies and goals, the nature and extent of services received by clients, the context in which treatment is administered, methadone dosage levels, and other such variables are reviewed." | 1.27 | Drug abuse treatment process: a review of the literature. ( Allison, M; Hubbard, RL, 1985) |
| "This paper summarizes data for 106 male opioid addicts which give evidence that there are demographic and clinical differences between groups of patients maintained in three ranges of methadone dosage (less than 35 mg, 36-59 mg, greater than 60 mg)." | 1.27 | Methadone dosage: patient characteristics and clinical correlates. ( Calsyn, DA; Roszell, DK, 1986) |
| " Three times per week dosing of LAAM proved to be a safe and effective treatment agent for the majority of subjects." | 1.27 | Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM). ( Pumphrey, E; Rawson, RA; Seecof, R; Tennant, FS, 1986) |
| "Differences between the opioid addiction careers of 84 female and 91 male addicts were examined longitudinally." | 1.27 | Sex differences in opioid addiction careers. ( Marsh, KL; Simpson, DD, 1986) |
| "The goal of drug abuse treatment is to decrease the dominance of drug-related behaviors while enhancing the dominance of alternative socially acceptable behaviors." | 1.27 | Behavior therapy in drug abuse treatment: review and evaluation. ( Bigelow, GE; McCaul, ME; Stitzer, ML, 1985) |
| "For methadone addicts there was a close relationship between the two dose measures: for heroin addicts there was no relationship." | 1.27 | Prescribing methadone for the opiate addict: a problem of dosage conversion. ( Gossop, M; Johns, AR, 1985) |
| "Naloxone failed to produce a significant increase in ACTH in methadone addicts while opiate-naive normal volunteers demonstrated a significant naloxone-induced release of ACTH." | 1.26 | Evidence for an endorphin dysfunction in methadone addicts: lack of ACTH response to naloxone. ( Extein, I; Finn, LB; Gold, MS; Kleber, HD; Martin, DA; Pottash, AL; Sweeney, DR, 1981) |
| "Clonidine-treated patients had significantly fewer symptoms than a comparable group of opioid addicts abruptly withdrawn from methadone." | 1.26 | Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. ( Kleber, HD; Redmond, DE; Uhde, TW, 1980) |
| "The duration of opioid dependence was positively correlated with fraction I values." | 1.26 | Endorphin levels in opioid-dependent human subjects: a longitudinal study. ( Krivoy, W; McLellan, AT; O'Brien, CP; Terenius, L; Wahlström, A, 1982) |
| " The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4." | 1.26 | Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. ( Anggård, E; Gunne, LM; Holmstrand, J; Nilsson, MI, 1982) |
| "That naloxone's effect was an expression of opiate withdrawal and not due to antagonism of depressed motility is also supported by the observation that naloxone significantly reduced the hatchability of opiate-exposed chicks and not of control chicks." | 1.26 | Prenatal withdrawal from opiates interferes with hatching of otherwise viable chick fetuses. ( Kuwahara, MD; Sparber, SB, 1981) |
| " Patients were assigned to three dosage groups." | 1.26 | Extraneous drug use in methadone-supported patients. ( Chapman, C; Hartfield, M; Seow, SS; Swensen, G; Willis, D, 1980) |
| "Despite the vast literature on drug dependence, little has been written about patients who become addicted while taking medically prescribed drugs for organic pathology." | 1.26 | Treatment of iatrogenic drug dependence in the general hospital. ( Streltzer, J, 1980) |
| "The origin of the psychiatric illnesses observed in drug abusers is often unclear." | 1.26 | Development of psychiatric illness in drug abusers. Possible role of drug preference. ( Mc Lellan, AT; O'Brien, CP; Woody, GE, 1979) |
| "This incidence of SIDS was 5." | 1.26 | Sudden unexpected death in infants of narcotic-dependent mothers. ( Falciglia, H; Kandall, SR; Rajegowda, BK, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 374 (10.02) | 18.7374 |
| 1990's | 485 (13.00) | 18.2507 |
| 2000's | 884 (23.69) | 29.6817 |
| 2010's | 1321 (35.40) | 24.3611 |
| 2020's | 668 (17.90) | 2.80 |
| Authors | Studies |
|---|---|
| Piske, M | 7 |
| Homayra, F | 6 |
| Min, JE | 10 |
| Zhou, H | 7 |
| Marchand, C | 1 |
| Mead, A | 2 |
| Ng, J | 1 |
| Woolner, M | 1 |
| Nosyk, B | 29 |
| Dufort, A | 1 |
| Samaan, Z | 18 |
| Wyse, JJ | 3 |
| McGinnis, KA | 2 |
| Edelman, EJ | 9 |
| Gordon, AJ | 15 |
| Manhapra, A | 4 |
| Fiellin, DA | 26 |
| Moore, BA | 6 |
| Korthuis, PT | 17 |
| Kennedy, AJ | 2 |
| Oldfield, BJ | 1 |
| Gaither, JR | 1 |
| Gordon, KS | 1 |
| Skanderson, M | 2 |
| Barry, DT | 23 |
| Bryant, K | 2 |
| Crystal, S | 2 |
| Justice, AC | 1 |
| Kraemer, KL | 2 |
| Brousseau, NM | 1 |
| Farmer, H | 1 |
| Karpyn, A | 1 |
| Laurenceau, JP | 1 |
| Kelly, JF | 5 |
| Hill, EC | 1 |
| Earnshaw, VA | 2 |
| Komrowski, MD | 1 |
| Sekhri, NK | 1 |
| Singh, G | 1 |
| Sri Konakanchi, J | 1 |
| Betsch, B | 1 |
| Thapa, A | 1 |
| Sethi, R | 4 |
| Chan, B | 6 |
| Bougatsos, C | 4 |
| Priest, KC | 5 |
| McCarty, D | 15 |
| Grusing, S | 4 |
| Chou, R | 6 |
| Brown, AR | 1 |
| Sujan, A | 1 |
| Cleary, E | 1 |
| Douglas, E | 1 |
| Aujla, R | 1 |
| Boyars, L | 2 |
| Smith, C | 3 |
| Guille, C | 3 |
| Madden, EF | 4 |
| Prevedel, S | 1 |
| Light, T | 1 |
| Sulzer, SH | 2 |
| Hochheimer, M | 1 |
| Unick, GJ | 1 |
| Herreid-O'Neill, A | 1 |
| Dougherty, J | 1 |
| Shull, S | 2 |
| Mackey, K | 1 |
| Englander, H | 4 |
| Thoma, J | 1 |
| Lovejoy, TI | 3 |
| Edsall, A | 2 |
| Hoffman, KA | 6 |
| Thuy, DT | 5 |
| Mai, PP | 2 |
| Hang, NT | 1 |
| Khuyen, TT | 3 |
| Trang, NT | 3 |
| Kunkel, LE | 2 |
| Giang, LM | 8 |
| Kessler, SH | 1 |
| Schwarz, ES | 3 |
| Liss, DB | 2 |
| Zhu, Y | 7 |
| Mooney, LJ | 3 |
| Yoo, C | 5 |
| Evans, EA | 6 |
| Kelleghan, A | 3 |
| Saxon, AJ | 26 |
| Curtis, ME | 2 |
| Hser, YI | 15 |
| Devlin, LA | 1 |
| Young, LW | 1 |
| Kraft, WK | 4 |
| Wachman, EM | 7 |
| Czynski, A | 2 |
| Merhar, SL | 1 |
| Winhusen, T | 8 |
| Jones, HE | 52 |
| Poindexter, BB | 1 |
| Wakschlag, LS | 1 |
| Salisbury, AL | 5 |
| Matthews, AG | 2 |
| Davis, JM | 5 |
| Taylor, EN | 1 |
| Timko, C | 6 |
| Binswanger, IA | 5 |
| Harris, AHS | 3 |
| Stimmel, M | 1 |
| Smelson, D | 3 |
| Finlay, AK | 4 |
| Bharat, C | 1 |
| Degenhardt, L | 30 |
| Dobbins, T | 4 |
| Larney, S | 15 |
| Farrell, M | 18 |
| Barbieri, S | 1 |
| Sobel, HG | 1 |
| Warrington, JS | 1 |
| Francis-Fath, S | 1 |
| Crocker, AM | 1 |
| Berger, CA | 1 |
| Knypinski, J | 1 |
| Vorawandthanachai, T | 1 |
| Wolfe, DS | 1 |
| Christian, BT | 1 |
| Lagisetty, PA | 1 |
| Ray, BR | 1 |
| De Aquino, JP | 2 |
| Parida, S | 1 |
| Avila-Quintero, VJ | 1 |
| Flores, J | 1 |
| Compton, P | 11 |
| Hickey, T | 1 |
| Gómez, O | 1 |
| Sofuoglu, M | 6 |
| Joudrey, PJ | 8 |
| Bart, G | 14 |
| Brooner, RK | 34 |
| Brown, L | 1 |
| Dickson-Gomez, J | 1 |
| Gordon, A | 1 |
| Kawasaki, SS | 1 |
| Liebschutz, JM | 6 |
| Nunes, E | 4 |
| Schwartz, RP | 38 |
| Szapocnik, J | 1 |
| Trivedi, M | 1 |
| Tsui, JI | 12 |
| Williams, A | 1 |
| Wu, LT | 10 |
| Davidson, PJ | 1 |
| Bowles, JM | 1 |
| Faul, M | 1 |
| Gaines, TL | 1 |
| Frost, MC | 2 |
| Lampert, H | 1 |
| Iles-Shih, MD | 1 |
| Williams, EC | 3 |
| Tran, AD | 2 |
| Chen, R | 2 |
| Nielsen, S | 16 |
| Zahra, E | 3 |
| Santo, T | 3 |
| Larance, B | 10 |
| Farrell MacDonald, S | 1 |
| Russell, C | 4 |
| Beauchamp, T | 1 |
| Derkzen, D | 2 |
| Fischer, B | 19 |
| Levander, XA | 2 |
| Pytell, JD | 3 |
| Stoller, KB | 12 |
| Chander, G | 2 |
| Scott, TM | 2 |
| Arnsten, J | 1 |
| Olsen, JP | 2 |
| Arias, F | 2 |
| Cunningham, CO | 5 |
| Rivera Mindt, M | 1 |
| Tolomeo, S | 2 |
| Davey, F | 1 |
| Steele, JD | 3 |
| Baldacchino, A | 4 |
| Pascual, FS | 1 |
| Muñoz, A | 2 |
| Oraa, R | 1 |
| Flórez, G | 1 |
| Notario, P | 1 |
| Seijo, P | 2 |
| Gonzalvo, B | 1 |
| Assaf, C | 1 |
| Gómez, M | 1 |
| Casado, MÁ | 1 |
| Sud, A | 2 |
| Salamanca-Buentello, F | 1 |
| Buchman, DZ | 1 |
| Sabioni, P | 1 |
| Majid, U | 1 |
| Kurz, M | 4 |
| Dale, LM | 3 |
| Hongdilokkul, N | 5 |
| Greiner, L | 1 |
| Olley, M | 1 |
| McLeod, KE | 1 |
| Slaunwhite, A | 2 |
| Shastry, S | 2 |
| Nobel, I | 1 |
| Allen, LR | 1 |
| Richardson, LD | 2 |
| Vidal, K | 1 |
| Manini, AF | 3 |
| Lister, JJ | 7 |
| Lister, HH | 1 |
| Button, D | 1 |
| Cook, R | 3 |
| King, C | 5 |
| Kunkel, L | 2 |
| Nguyen, DB | 2 |
| Blazes, CK | 1 |
| Harris, MTH | 1 |
| Lambert, AM | 1 |
| Maschke, AD | 1 |
| Bagley, SM | 5 |
| Walley, AY | 17 |
| Gunn, CM | 1 |
| Smith, K | 1 |
| Wang, M | 4 |
| Abdukalikov, R | 1 |
| McAullife, A | 1 |
| Whitesell, D | 1 |
| Richard, J | 1 |
| Sauer, W | 1 |
| Quaye, A | 1 |
| Bodkin, C | 1 |
| Bondy, S | 1 |
| Regenstreif, L | 2 |
| Kiefer, L | 2 |
| Kouyoumdjian, F | 2 |
| Peterkin, A | 1 |
| Laks, J | 3 |
| Weinstein, ZM | 4 |
| Rostam-Abadi, Y | 1 |
| Gholami, J | 2 |
| Noroozi, A | 4 |
| Ansari, M | 1 |
| Baheshmat, S | 1 |
| Hamzehzadeh, M | 1 |
| Ghadirzadeh, MR | 1 |
| Vahdani, B | 1 |
| Ekhtiari, H | 4 |
| Mojtabai, R | 2 |
| Rahimi-Movaghar, A | 2 |
| Chawar, C | 3 |
| Hillmer, A | 3 |
| Sanger, S | 2 |
| D'Elia, A | 2 |
| Panesar, B | 2 |
| Guan, L | 1 |
| Xie, DX | 1 |
| Bansal, N | 1 |
| Abdullah, A | 1 |
| Kapczinski, F | 2 |
| Pare, G | 10 |
| Thabane, L | 16 |
| Struble, CA | 1 |
| Urbiel, J | 1 |
| Nyaku, AN | 1 |
| Arfken, CL | 2 |
| Mindt, MR | 1 |
| Coulehan, K | 1 |
| Aghvinian, M | 1 |
| Arnsten, JH | 14 |
| Pilarinos, A | 3 |
| Bromberg, DJ | 6 |
| Karamouzian, M | 2 |
| Harocopos, A | 1 |
| Nolan, ML | 1 |
| Goldstein, GP | 1 |
| Mantha, S | 1 |
| O'Neill, M | 2 |
| Paone, D | 1 |
| Lamri, A | 1 |
| Bachireddy, C | 4 |
| Shrestha, R | 5 |
| Azbel, L | 6 |
| Kurmanalieva, A | 3 |
| Wegman, M | 1 |
| Shumskaya, N | 2 |
| Rozanova, J | 5 |
| Meyer, JP | 3 |
| Altice, FL | 29 |
| Padmanathan, P | 1 |
| Forbes, H | 1 |
| Redaniel, MT | 1 |
| Gunnell, D | 1 |
| Lewer, D | 1 |
| Moran, P | 1 |
| Watson, B | 2 |
| Hickman, M | 16 |
| Zhang, P | 1 |
| Tossone, K | 1 |
| Ashmead, R | 1 |
| Bickert, T | 1 |
| Bailey, E | 1 |
| Doogan, NJ | 1 |
| Mack, A | 1 |
| Schmidt, S | 1 |
| Bonny, AE | 1 |
| Kehoe, J | 2 |
| Farrell, NM | 2 |
| Komaromy, M | 1 |
| Kolodziej, J | 1 |
| Taylor, JL | 2 |
| Merlin, JS | 2 |
| Khodyakov, D | 2 |
| Arnold, R | 2 |
| Bulls, HW | 1 |
| Dao, E | 2 |
| Kapo, J | 2 |
| Meier, D | 3 |
| Paice, J | 2 |
| Ritchie, C | 2 |
| Mitra, S | 1 |
| Grant, C | 3 |
| Nolan, S | 7 |
| Mohd Salleh, NA | 1 |
| Milloy, MJ | 19 |
| Richardson, L | 3 |
| Calcaterra, SL | 7 |
| Lockhart, S | 2 |
| Callister, C | 1 |
| Hoover, K | 1 |
| Guo, D | 1 |
| Tan, Z | 1 |
| Lou, X | 1 |
| Shi, S | 1 |
| Shu, Y | 1 |
| Yu, L | 1 |
| Yang, H | 1 |
| Schroeder, M | 2 |
| White, J | 3 |
| Gibbons, JB | 1 |
| Stuart, EA | 4 |
| Saloner, B | 14 |
| Morgan, JR | 4 |
| Quinn, EK | 1 |
| Chaisson, CE | 3 |
| Ciemins, E | 1 |
| Stempniewicz, N | 1 |
| White, LF | 1 |
| Linas, BP | 3 |
| LaRochelle, MR | 7 |
| Frank, CJ | 1 |
| Morrison, L | 1 |
| Heikkinen, M | 1 |
| Taipale, H | 1 |
| Tanskanen, A | 1 |
| Mittendorfer-Rutz, E | 1 |
| Lähteenvuo, M | 1 |
| Tiihonen, J | 1 |
| Beauchamp, GA | 2 |
| Hanisak, JL | 1 |
| Amaducci, AM | 1 |
| Koons, AL | 1 |
| Laskosky, J | 1 |
| Maron, BM | 1 |
| McLoughlin, TM | 1 |
| Samsó Jofra, L | 1 |
| Puig, T | 2 |
| Solà, I | 1 |
| Trujols, J | 10 |
| Kameg, B | 1 |
| Fradkin, D | 1 |
| Lepore, M | 1 |
| Krebs, E | 8 |
| Schnepel, KT | 1 |
| Shigeoka, H | 1 |
| Checkley, L | 1 |
| Steiger, S | 4 |
| Knight, KR | 6 |
| Abdelwahab, M | 1 |
| Petrich, M | 1 |
| Wang, H | 3 |
| Walker, E | 1 |
| Cleary, EM | 1 |
| Rood, KM | 1 |
| Gonzalez, AM | 1 |
| Arlandson, ME | 1 |
| Patel, A | 4 |
| Premkumar, A | 3 |
| Corace, K | 1 |
| Suschinsky, K | 1 |
| Wyman, J | 3 |
| Leece, P | 11 |
| Cragg, S | 1 |
| Konefal, S | 1 |
| Pana, P | 1 |
| Barrass, S | 1 |
| Porath, A | 1 |
| Hutton, B | 1 |
| Byrne, J | 1 |
| Ali, R | 21 |
| Komatsu, R | 1 |
| Nash, M | 1 |
| Peperzak, KA | 1 |
| Ziga, TM | 1 |
| Dinges, EM | 1 |
| Delgado, C | 1 |
| Wu, J | 1 |
| Terman, GW | 1 |
| Dale, RC | 1 |
| Kay, A | 1 |
| Shmuts, R | 1 |
| Beck, M | 1 |
| Raji, MA | 1 |
| Priyadarshni, S | 1 |
| Yu, X | 1 |
| Digbeu, B | 1 |
| Kuo, YF | 1 |
| Ngarachu, EW | 1 |
| Kiburi, SK | 4 |
| Owiti, FR | 1 |
| Kangethe, R | 1 |
| Song, MJ | 1 |
| Westenberg, JN | 2 |
| Kianpoor, K | 2 |
| Nikoo, M | 5 |
| Kazemi, A | 4 |
| Schuetz, C | 1 |
| Jang, K | 4 |
| Gholami, A | 4 |
| Akhondzadeh, S | 3 |
| Krausz, M | 14 |
| Ball, CM | 1 |
| Featherstone, PJ | 1 |
| Manu, P | 1 |
| Rogozea, LM | 1 |
| Shulman, M | 4 |
| Vallecillo, G | 2 |
| Pedro-Botet, J | 1 |
| Fernandez, S | 1 |
| Román, I | 1 |
| Elosua, R | 1 |
| Camps, A | 1 |
| Torrens, M | 18 |
| Marrugat, J | 1 |
| Alawa, J | 1 |
| Muhammad, M | 1 |
| Kazemitabar, M | 1 |
| Garcia, D | 1 |
| Khoshnood, K | 1 |
| Ghandour, L | 1 |
| Murnion, BP | 2 |
| Demirkol, A | 4 |
| Burgess-Hull, AJ | 3 |
| Panlilio, LV | 4 |
| Preston, KL | 29 |
| Epstein, DH | 20 |
| Sundaresh, S | 1 |
| Sadananda, GB | 1 |
| Bailit, JL | 2 |
| Pearce, LA | 4 |
| Wang, L | 6 |
| Gardner, G | 1 |
| O'Briain, W | 1 |
| Wood, E | 35 |
| Daly, P | 1 |
| Walsh, T | 1 |
| Henry, B | 1 |
| Ray, B | 1 |
| Victor, G | 1 |
| Cason, R | 1 |
| Hamameh, N | 1 |
| Kubiak, S | 1 |
| Zettner, C | 1 |
| Dunnigan, M | 1 |
| Comartin, E | 1 |
| Costello, M | 1 |
| Nafeh, F | 1 |
| Pang, M | 1 |
| MacDonald, SF | 2 |
| Rehm, J | 12 |
| Wood, CA | 1 |
| Duello, A | 2 |
| Miles, J | 1 |
| Lohmann, B | 1 |
| Gochez-Kerr, T | 1 |
| Richardson, K | 1 |
| Anderson-Harper, R | 1 |
| Winograd, RP | 2 |
| Biondi, BE | 2 |
| Vander Wyk, B | 2 |
| Schlossberg, EF | 1 |
| Shaw, A | 1 |
| Springer, SA | 4 |
| Gomes, T | 14 |
| McCormack, D | 2 |
| Bozinoff, N | 6 |
| Tadrous, M | 6 |
| Antoniou, T | 3 |
| Munro, C | 6 |
| Campbell, T | 2 |
| Paterson, JM | 1 |
| Mamdani, M | 1 |
| Sproule, B | 5 |
| Hemmati, Z | 1 |
| Conti, AA | 1 |
| Kitchen, SA | 2 |
| Campbell, TJ | 2 |
| Men, S | 2 |
| Werb, D | 3 |
| Ghanem, N | 1 |
| Dromgoole, D | 1 |
| Hussein, A | 1 |
| Jermyn, RT | 1 |
| Jasmine Silva, M | 1 |
| Coffee, Z | 1 |
| Goza, J | 1 |
| Rumrill, K | 1 |
| Ellis, MS | 4 |
| Buttram, ME | 4 |
| Kasper, ZA | 1 |
| Stalund, IV | 1 |
| Grønseth, H | 1 |
| Reinholt, FP | 1 |
| Svarstad, E | 1 |
| Marti, HP | 1 |
| Leh, S | 1 |
| Tas, B | 1 |
| Kalk, NJ | 2 |
| Lozano-García, M | 1 |
| Rafferty, GF | 1 |
| Cho, P | 2 |
| Kelleher, M | 6 |
| Moxham, J | 1 |
| Strang, J | 47 |
| Jolley, CJ | 2 |
| Schiff, DM | 7 |
| Work, EC | 1 |
| Muftu, S | 1 |
| Partridge, S | 1 |
| MacMillan, KDL | 2 |
| Gray, JR | 1 |
| Hoeppner, BB | 3 |
| Greenfield, SF | 2 |
| Wilens, TE | 6 |
| Terplan, M | 17 |
| Bernstein, J | 3 |
| Simon, C | 3 |
| Vincent, L | 3 |
| Coulter, A | 2 |
| Salazar, Z | 2 |
| Voyles, N | 2 |
| Roberts, L | 1 |
| Frank, D | 4 |
| Brothers, S | 3 |
| Wyatt, JP | 2 |
| Suen, LW | 4 |
| Coe, WH | 2 |
| Adams, ZM | 4 |
| Gandhi, M | 2 |
| Batchelor, HM | 2 |
| Castellanos, S | 4 |
| Joshi, N | 4 |
| Satterwhite, S | 3 |
| Pérez-Rodríguez, R | 2 |
| Rodríguez-Guerra, E | 2 |
| Albizu-Garcia, CE | 2 |
| Jordan, A | 2 |
| McIlveen, JW | 2 |
| Lim, J | 1 |
| Farhat, I | 1 |
| Douros, A | 1 |
| Panagiotoglou, D | 1 |
| Pang, B | 1 |
| Jiang, Y | 1 |
| Wilson, M | 1 |
| Bindler, RJ | 1 |
| Stanek, K | 1 |
| Layton, ME | 1 |
| Quock, RM | 1 |
| Alibrahim, A | 1 |
| Marsh, JC | 3 |
| Amaro, H | 3 |
| Kong, Y | 3 |
| Khachikian, T | 3 |
| Guerrero, E | 3 |
| Welsh, JW | 1 |
| Mataczynski, MJ | 1 |
| Passetti, LL | 1 |
| Hunter, BD | 1 |
| Godley, MD | 1 |
| Dorgay, CE | 1 |
| Doltu, S | 2 |
| Litz, T | 2 |
| Galvez, S | 2 |
| Polonsky, M | 4 |
| Dvoryak, S | 7 |
| Schoenfeld, EM | 1 |
| Westafer, LM | 1 |
| Beck, SA | 1 |
| Potee, BG | 1 |
| Vysetty, S | 1 |
| Tozloski, JM | 1 |
| Girardin, AL | 1 |
| Soares, WE | 1 |
| Brown, PCM | 1 |
| Dinh, TTT | 1 |
| Nguyen, TH | 1 |
| Hoffman, K | 2 |
| Le, MG | 1 |
| Kolak, M | 2 |
| Lin, Q | 2 |
| Paykin, S | 1 |
| Anguiano, V | 1 |
| Wang, EA | 5 |
| Jarlenski, M | 1 |
| Chen, Q | 2 |
| Gao, A | 1 |
| Rothenberger, SD | 2 |
| Krans, EE | 7 |
| O'Grady, MA | 2 |
| Neighbors, CJ | 6 |
| Randrianarivony, R | 1 |
| Shapiro-Luft, D | 1 |
| Tempchin, J | 1 |
| Perez-Cubillan, Y | 1 |
| Collymore, DC | 1 |
| Martin, K | 1 |
| Heyward, N | 1 |
| Wu, M | 2 |
| Beacham, A | 1 |
| Greenfield, B | 1 |
| Walters, SM | 2 |
| Perlman, DC | 6 |
| Guarino, H | 7 |
| Mateu-Gelabert, P | 2 |
| Bouck, Z | 1 |
| Scheim, AI | 1 |
| Ling, V | 1 |
| Caudarella, A | 1 |
| Matheson, C | 5 |
| Foster, R | 1 |
| Schofield, J | 1 |
| Browne, T | 1 |
| Diep, NB | 3 |
| Thuy, DTD | 1 |
| Hoe, HD | 1 |
| Van, HTH | 2 |
| Truc, TT | 2 |
| Nguyen, HH | 2 |
| Lai, NL | 1 |
| Linh, PTD | 1 |
| Vi, VTT | 1 |
| Reback, CJ | 2 |
| Leibowitz, A | 1 |
| Li, L | 10 |
| Lin, C | 12 |
| Li, M | 2 |
| Shoptaw, S | 7 |
| Jiménez-Fernández, B | 1 |
| Calomarde-Gómez, C | 1 |
| López-Lazcano, A | 1 |
| Lligoña, A | 2 |
| Gual, A | 1 |
| López-Pelayo, H | 1 |
| Garg, R | 1 |
| Presnall, NJ | 2 |
| Butler, GC | 1 |
| Grucza, RA | 5 |
| Clifton, D | 1 |
| Ivey, N | 1 |
| Poley, S | 1 |
| O'Regan, A | 1 |
| Raman, SR | 1 |
| Frascino, N | 1 |
| Hamilton, S | 1 |
| Setji, N | 1 |
| Khan, T | 1 |
| Ariyawansa, P | 1 |
| Quinn, J | 1 |
| Hayllar, J | 2 |
| Khalid, K | 2 |
| Anuar, A | 1 |
| Ang, WC | 1 |
| Jamaluddin, R | 2 |
| Tabatabaeepour, N | 1 |
| Jalali, A | 4 |
| Kapadia, SN | 1 |
| Meinhofer, A | 4 |
| Foot, C | 1 |
| Terashima, JP | 1 |
| Hu, WL | 3 |
| Tsai, MC | 3 |
| Kuo, CE | 3 |
| Liu, CT | 2 |
| Wu, SY | 3 |
| Wu, TC | 2 |
| Hung, YC | 3 |
| Corry, B | 1 |
| Underwood, N | 1 |
| Cremer, LJ | 1 |
| Rooks-Peck, CR | 1 |
| Jones, C | 1 |
| Christine, PJ | 1 |
| Evans, J | 1 |
| Kim, TW | 1 |
| White, CS | 1 |
| Nguemeni Tiako, MJ | 2 |
| Friedman, A | 1 |
| South, EC | 1 |
| Epstein, RL | 1 |
| Meisel, ZF | 2 |
| Watts, B | 1 |
| Anselin, L | 1 |
| Pollack, H | 2 |
| Schneider, J | 1 |
| Taylor, B | 1 |
| Stafford, C | 1 |
| Marrero, WJ | 1 |
| Naumann, RB | 1 |
| Lich, KH | 1 |
| Wakeman, S | 1 |
| Jalali, MS | 2 |
| Ellis, JD | 3 |
| Mun, CJ | 2 |
| Phillips, KA | 8 |
| Finan, PH | 4 |
| King, CA | 1 |
| Heil, J | 2 |
| Ganetsky, VS | 1 |
| Salzman, MS | 2 |
| Hunter, K | 1 |
| Baston, KE | 1 |
| Carroll, G | 2 |
| Ketcham, E | 1 |
| Haroz, R | 2 |
| Jutras-Aswad, D | 12 |
| Le Foll, B | 8 |
| Ahamad, K | 7 |
| Lim, R | 9 |
| Bruneau, J | 9 |
| Wild, TC | 3 |
| Brissette, S | 13 |
| Gagnon, L | 1 |
| Fikowski, J | 1 |
| Ledjiar, O | 5 |
| Masse, B | 1 |
| Socias, ME | 17 |
| Choi, JC | 2 |
| Mok, WY | 1 |
| Hassan, A | 1 |
| Richards, JE | 1 |
| Blosnich, JR | 1 |
| Hawkins, EJ | 2 |
| Jablonski, LA | 1 |
| Bodnar, AR | 1 |
| Stewart, RW | 1 |
| Kinsella, M | 1 |
| Halliday, LOE | 1 |
| Shaw, M | 1 |
| Capel, Y | 1 |
| Nelson, SM | 1 |
| Kearns, RJ | 1 |
| Xu, KY | 4 |
| Mintz, CM | 3 |
| Presnall, N | 3 |
| Bierut, LJ | 4 |
| Brandt, NJ | 1 |
| Fitzgerald Jones, K | 1 |
| Bulls, H | 1 |
| Liebschutz, J | 1 |
| Merlin, J | 2 |
| Andraka-Christou, B | 10 |
| Totaram, R | 4 |
| Randall-Kosich, O | 2 |
| Golan, M | 1 |
| Stein, BD | 8 |
| Konijnenberg, C | 4 |
| Melinder, A | 4 |
| Kwa, Y | 2 |
| Joe, R | 3 |
| Thulien, M | 1 |
| Buxton, JA | 3 |
| DeBeck, K | 8 |
| Fast, D | 2 |
| Clemans-Cope, L | 1 |
| Lynch, V | 1 |
| Payton, M | 1 |
| Aarons, J | 1 |
| Jones, CM | 5 |
| Compton, WM | 2 |
| Han, B | 2 |
| Baldwin, G | 2 |
| Volkow, ND | 4 |
| Carswell, N | 1 |
| Angermaier, G | 1 |
| Castaneda, C | 1 |
| Delgado, F | 1 |
| Gottlieb, DJ | 1 |
| Shiner, B | 1 |
| Hoyt, JE | 1 |
| Riblet, NB | 1 |
| Peltzman, T | 2 |
| Teja, N | 1 |
| Watts, BV | 1 |
| Anwar, T | 1 |
| Duever, M | 1 |
| Jayawardhana, J | 1 |
| Pasman, E | 2 |
| Kollin, R | 2 |
| Broman, M | 1 |
| Lee, G | 2 |
| Agius, E | 2 |
| Brown, S | 2 |
| Resko, SM | 2 |
| Will, J | 1 |
| Abare, M | 1 |
| Olson, M | 1 |
| Chyorny, A | 1 |
| Wilhelm-Leen, E | 1 |
| Manza, P | 1 |
| Kroll, D | 1 |
| McPherson, KL | 1 |
| Johnson, A | 2 |
| Dennis, E | 1 |
| Hu, L | 2 |
| Tai, B | 2 |
| Buresh, M | 2 |
| Nahvi, S | 5 |
| Bonifonte, A | 1 |
| Garcia, E | 1 |
| Bottner, R | 1 |
| Martin, M | 4 |
| Weimer, MB | 3 |
| Lambert, E | 2 |
| Ronan, MV | 1 |
| Huerta, S | 2 |
| Zaman, T | 1 |
| Ullal, M | 1 |
| Peterkin, AF | 1 |
| Torres-Lockhart, K | 1 |
| O'Brien, MT | 1 |
| Snyder, H | 3 |
| Herzig, SJ | 1 |
| Miano, TA | 1 |
| Leonard, CE | 1 |
| Brensinger, CM | 1 |
| Acton, EK | 1 |
| Dawwas, GK | 1 |
| Bilker, WB | 1 |
| Soprano, SE | 1 |
| Nguyen, TPP | 1 |
| Woody, G | 17 |
| Yu, E | 1 |
| Neuman, M | 1 |
| Hennessy, S | 1 |
| Kanbour, S | 1 |
| Balaji, A | 1 |
| Chae, K | 1 |
| Mathioudakis, N | 1 |
| Berro, LF | 1 |
| Zamarripa, CA | 1 |
| Talley, JT | 1 |
| Freeman, KB | 1 |
| Rowlett, JK | 1 |
| Ober, AJ | 3 |
| Murray-Krezan, C | 1 |
| Page, K | 5 |
| Friedmann, PD | 12 |
| Chan Osilla, K | 1 |
| Ryzewicz, S | 1 |
| Mazer, MW | 1 |
| Leamon, I | 2 |
| Messineo, G | 1 |
| Watkins, KE | 2 |
| Nuckols, T | 1 |
| Danovitch, I | 1 |
| Tarn, DM | 1 |
| Shih, KJ | 1 |
| Hunter, SB | 2 |
| Martinez, J | 1 |
| Montero, A | 1 |
| McCreary, M | 1 |
| Sheehe, J | 1 |
| Bromley, E | 1 |
| Townsend, EA | 2 |
| Blough, BE | 1 |
| Negus, SS | 4 |
| Shaham, Y | 1 |
| Banks, ML | 4 |
| Sadek, J | 1 |
| Saunders, J | 3 |
| Stöver, H | 5 |
| Keppler, K | 2 |
| Magidson, JF | 5 |
| Kleinman, MB | 3 |
| Bradley, V | 1 |
| Anvari, MS | 3 |
| Abidogun, TM | 2 |
| Belcher, AM | 8 |
| Greenblatt, AD | 8 |
| Dean, D | 2 |
| Hines, A | 1 |
| Seitz-Brown, CJ | 4 |
| Wagner, M | 4 |
| Bennett, M | 2 |
| Felton, JW | 3 |
| Page, C | 1 |
| Schoebel, V | 1 |
| Buche, J | 2 |
| Haffajee, RL | 3 |
| Lange, S | 1 |
| Butler, A | 1 |
| Ali, F | 1 |
| Zhang, J | 2 |
| Fu, X | 1 |
| Lu, Y | 2 |
| Cheng, C | 1 |
| Wang, K | 1 |
| Xie, Q | 1 |
| Nikoo, N | 3 |
| Javidanbardan, S | 3 |
| Choi, F | 3 |
| Vogel, M | 8 |
| Tavakoli, S | 3 |
| Wong, JSH | 1 |
| Moazen-Zadeh, E | 2 |
| Givaki, R | 2 |
| Jazani, M | 2 |
| Mohammadian, F | 2 |
| Moghaddam, NM | 1 |
| Schütz, C | 2 |
| Marsden, J | 17 |
| Hoare, Z | 1 |
| Hughes, D | 1 |
| Bisla, J | 1 |
| Cape, A | 1 |
| Cowden, F | 2 |
| Day, E | 9 |
| Dewhurst, J | 1 |
| Evans, R | 1 |
| Hearn, A | 1 |
| Kelly, J | 2 |
| Lowry, N | 3 |
| McCusker, M | 1 |
| Murphy, C | 2 |
| Murray, R | 2 |
| Myton, T | 1 |
| Quarshie, S | 1 |
| Scott, G | 2 |
| Turner, S | 3 |
| Vanderwaal, R | 1 |
| Wareham, A | 1 |
| Gilvarry, E | 2 |
| Mitcheson, L | 5 |
| Lier, AJ | 1 |
| Seval, N | 1 |
| Di Paola, A | 1 |
| Nguyen, TD | 1 |
| Wallace, B | 2 |
| Edwardes, D | 2 |
| Subbe, C | 2 |
| Murtaza, M | 2 |
| McAnulty, C | 5 |
| Bastien, G | 4 |
| Eugenia Socias, M | 3 |
| Foll, BL | 2 |
| Marsan, S | 4 |
| Talbot, A | 3 |
| Rodriguez, B | 1 |
| Shoff, C | 1 |
| Hodges, K | 1 |
| Blanco, C | 3 |
| Losby, JL | 1 |
| Ling, SM | 1 |
| Ellerbroek, H | 1 |
| van den Heuvel, SAS | 1 |
| Dahan, A | 1 |
| Timmerman, H | 1 |
| Kramers, C | 1 |
| Schellekens, AFA | 1 |
| Tse, WC | 1 |
| Rudolph, KE | 2 |
| Williams, NT | 2 |
| Goodwin, ATS | 1 |
| Fishman, M | 2 |
| Díaz, I | 2 |
| Luo, S | 3 |
| Rotrosen, J | 7 |
| Nunes, EV | 17 |
| Bauer, LO | 1 |
| Gazzola, MG | 1 |
| Maclean, E | 1 |
| Beitel, M | 16 |
| Carmichael, ID | 1 |
| Cammack, KM | 1 |
| Eggert, KF | 2 |
| Roehrich, T | 1 |
| Madden, LM | 10 |
| Jegede, O | 1 |
| Zheng, X | 2 |
| Bergman, E | 1 |
| Ooi, YT | 1 |
| Abdul Rashid, Q | 1 |
| Mohammad Yusoff, MZA | 1 |
| Pedersen, MH | 1 |
| Danø, A | 1 |
| Gibbons, C | 1 |
| Jensen, R | 1 |
| Spithoff, S | 7 |
| Mogic, L | 1 |
| Hum, S | 1 |
| Moineddin, R | 2 |
| Meaney, C | 2 |
| Kiran, T | 3 |
| Saunders, EC | 2 |
| Yue, JL | 1 |
| Yuan, K | 1 |
| Bao, YP | 4 |
| Meng, SQ | 1 |
| Shi, L | 1 |
| Fang, Q | 1 |
| Guo, XJ | 1 |
| Cao, L | 1 |
| Sun, YK | 1 |
| Lu, TS | 1 |
| Zeng, N | 1 |
| Yan, W | 1 |
| Han, Y | 1 |
| Sun, J | 2 |
| Shi, J | 5 |
| Kosten, TR | 51 |
| Xue, YX | 1 |
| Wu, P | 1 |
| Lu, L | 5 |
| K K, A | 1 |
| E J, M | 1 |
| D M, S | 1 |
| Tlali, M | 1 |
| Scheibe, A | 4 |
| Ruffieux, Y | 1 |
| Cornell, M | 1 |
| Wettstein, AE | 1 |
| Egger, M | 1 |
| Davies, MA | 1 |
| Maartens, G | 1 |
| Johnson, LF | 1 |
| Haas, AD | 1 |
| Hallgren, KA | 1 |
| Darnton, J | 1 |
| Soth, S | 1 |
| Blalock, KL | 1 |
| Michaels, A | 1 |
| Grekin, P | 2 |
| Woolworth, S | 2 |
| Tassey, TE | 1 |
| Ott, GE | 1 |
| Alvanzo, AAH | 1 |
| Peirce, JM | 4 |
| Antoine, D | 1 |
| Buresh, ME | 1 |
| Joshi, C | 1 |
| Ho Chui, KK | 1 |
| Skeer, MR | 1 |
| Stopka, TJ | 4 |
| Delorme, J | 3 |
| Kerckhove, N | 1 |
| Authier, N | 3 |
| Pereira, B | 1 |
| Bertin, C | 2 |
| Chenaf, C | 3 |
| Peterson, L | 2 |
| Murugesan, M | 1 |
| Nocon, R | 1 |
| Hoang, H | 1 |
| Bolton, J | 1 |
| Laiteerapong, N | 1 |
| Marsh, J | 1 |
| Paterson, LM | 1 |
| Barker, D | 1 |
| Cro, S | 1 |
| Mozgunov, P | 1 |
| Phillips, R | 1 |
| Nahar, L | 1 |
| Paterson, S | 2 |
| Lingford-Hughes, AR | 2 |
| Aldabergenov, D | 1 |
| Reynolds, L | 1 |
| Scott, J | 1 |
| Kelleher, MJ | 1 |
| Copeland, CS | 1 |
| Nathan, N | 1 |
| Johnstone, S | 1 |
| Leyrer-Jackson, JM | 1 |
| Acuña, AM | 1 |
| Olive, MF | 1 |
| Meyerson, BE | 1 |
| Bentele, KG | 1 |
| Russell, DM | 1 |
| Brady, BR | 1 |
| Downer, M | 1 |
| Garcia, RC | 1 |
| Garnett, I | 1 |
| Lutz, R | 4 |
| Mahoney, A | 1 |
| Samorano, S | 1 |
| Arredondo, C | 1 |
| Andres, HJ | 1 |
| Coles, H | 1 |
| Granillo, B | 1 |
| Liberman, AR | 1 |
| Lim, S | 1 |
| Cherian, T | 1 |
| Katyal, M | 1 |
| Goldfeld, KS | 1 |
| McDonald, R | 4 |
| Wiewel, E | 1 |
| Khan, M | 1 |
| Krawczyk, N | 9 |
| Braunstein, S | 1 |
| Murphy, SM | 6 |
| Jeng, PJ | 2 |
| MacDonald, R | 1 |
| Lee, JD | 10 |
| Sugarman, A | 1 |
| Vittitow, A | 2 |
| Cheng, A | 1 |
| Malone, M | 1 |
| Pace, N | 1 |
| Williams, O | 1 |
| Tofighi, B | 6 |
| McNeely, J | 2 |
| Schatz, D | 1 |
| Roberts, T | 1 |
| Hey, SP | 1 |
| Garrity, K | 1 |
| Lindquist, K | 1 |
| Ling, R | 2 |
| White, B | 3 |
| Roberts, J | 2 |
| Cretikos, M | 2 |
| Howard, MV | 2 |
| Haber, PS | 4 |
| Lintzeris, N | 21 |
| Reeves, P | 1 |
| Dunlop, AJ | 5 |
| Searles, A | 2 |
| Livingston, NA | 2 |
| Davenport, M | 1 |
| Head, M | 1 |
| Henke, R | 1 |
| LeBeau, LS | 1 |
| Gibson, TB | 1 |
| Banducci, AN | 2 |
| Sarpong, A | 1 |
| Jayanthi, S | 1 |
| Roth, C | 1 |
| Camacho-Cook, J | 1 |
| Meng, F | 1 |
| Hyde, J | 1 |
| Mulvaney-Day, N | 1 |
| White, M | 1 |
| Chen, DC | 1 |
| Stein, MD | 21 |
| Weisberg, R | 1 |
| Bazazi, AR | 2 |
| Culbert, GJ | 3 |
| Wegman, MP | 3 |
| Heimer, R | 6 |
| Kamarulzaman, A | 6 |
| Dong, H | 8 |
| Moinaddini, F | 3 |
| Amirinejad, M | 3 |
| Haghpanah, T | 3 |
| Abedini, M | 3 |
| Yoosefi, F | 3 |
| Nematollahi-Mahani, SN | 3 |
| Paul, LA | 3 |
| Bayoumi, AM | 4 |
| Chen, C | 5 |
| Kocovska, E | 3 |
| Smith, BT | 3 |
| Raboud, JM | 3 |
| Kendall, C | 3 |
| Rosella, LC | 3 |
| Bitonti-Bengert, L | 3 |
| Rush, B | 3 |
| Yu, M | 4 |
| Crichlow, F | 3 |
| Wright, A | 4 |
| Watford, J | 3 |
| Besharah, J | 4 |
| Taha, S | 3 |
| Strike, C | 3 |
| Manson, H | 3 |
| Kahan, M | 13 |
| Morford, KL | 4 |
| Tetrault, JM | 6 |
| Zhou, B | 4 |
| Li, F | 5 |
| Gleeson, B | 4 |
| Madden, L | 8 |
| Suarez, EA | 4 |
| Huybrechts, KF | 5 |
| Straub, L | 3 |
| Hernández-Díaz, S | 7 |
| Connery, HS | 3 |
| Gray, KJ | 3 |
| Lester, B | 4 |
| Mogun, H | 4 |
| Bateman, BT | 6 |
| Qureshi, R | 3 |
| Ciucă Anghel, DM | 2 |
| Ciobanu, AM | 3 |
| Guțu, CM | 2 |
| Stan, M | 2 |
| Tudor, G | 2 |
| Baconi, DL | 2 |
| Mwangi, J | 2 |
| Maina, G | 3 |
| Kleinman, RA | 3 |
| Sanches, M | 2 |
| Haggerty, T | 2 |
| Turiano, NA | 2 |
| Turner, T | 2 |
| Dekeseredy, P | 2 |
| Sedney, CL | 2 |
| Hassan, AN | 2 |
| Moallef, S | 2 |
| Fairbairn, N | 14 |
| Cui, Z | 3 |
| Brar, R | 5 |
| Wilson, D | 4 |
| Johnson, C | 3 |
| Hayashi, K | 19 |
| Tamburello, A | 1 |
| Luo, SX | 3 |
| Lu, TC | 1 |
| Tsai, YH | 1 |
| Kanervo, MM | 1 |
| Tupola, SJ | 1 |
| Nikkola, EM | 1 |
| Rantakari, KM | 1 |
| Kahila, HK | 1 |
| Baxley, C | 1 |
| Borsari, B | 1 |
| Reavis, JV | 1 |
| Manuel, JK | 1 |
| Herbst, E | 1 |
| Becker, W | 1 |
| Pennington, D | 1 |
| Batki, SL | 6 |
| Seal, K | 1 |
| Salapenka, I | 1 |
| Konakanchi, JS | 2 |
| Amini, Z | 1 |
| HeidariFarsani, E | 1 |
| Lin, YF | 1 |
| Chou, WH | 1 |
| Liu, TH | 3 |
| Fang, CP | 4 |
| Kuo, HW | 4 |
| Kuo, PH | 1 |
| Tsai, SJ | 1 |
| Wang, SC | 3 |
| Chung, RH | 2 |
| Tsou, HH | 2 |
| Chen, ACH | 4 |
| Liu, YL | 4 |
| Wohl, MJA | 1 |
| Greenwald, MK | 6 |
| Ledgerwood, DM | 6 |
| Wang, S | 2 |
| Meador, KJ | 1 |
| Pawasauskas, J | 1 |
| Lewkowitz, AK | 1 |
| Ward, KE | 1 |
| Brothers, TN | 1 |
| Hartzema, A | 2 |
| Quilliam, BJ | 1 |
| Wen, X | 1 |
| McGee, M | 1 |
| Chiu, K | 1 |
| Carlisle, VR | 1 |
| Maynard, OM | 1 |
| Bagnall, D | 1 |
| Shorrock, J | 1 |
| Thomas, K | 1 |
| Kesten, J | 1 |
| Lindner, S | 1 |
| Morasco, BJ | 1 |
| Carlson, KF | 1 |
| Ono, SS | 1 |
| Liberto, JG | 1 |
| Marom, A | 1 |
| Levy, I | 1 |
| Rosca, P | 2 |
| Golan, O | 1 |
| Ohama, M | 1 |
| Neven, A | 1 |
| Dumont, GJH | 1 |
| Kaufman, DE | 1 |
| Kennalley, AL | 2 |
| McCall, KL | 3 |
| Piper, BJ | 3 |
| Goeieman, DS | 1 |
| Nonyane, DS | 1 |
| Nzaumvila, DK | 1 |
| Anse van Rensburg, MNS | 1 |
| Lee, JJ | 1 |
| Saraiya, N | 1 |
| Kuzniewicz, MW | 1 |
| Guerra-Alejos, BC | 1 |
| Dale, L | 1 |
| Allen, E | 1 |
| Samadian, S | 1 |
| Altobelli, G | 1 |
| Johnson, J | 1 |
| Holmwood, C | 1 |
| Kozak, Z | 1 |
| Ciccarone, D | 1 |
| Thrul, J | 1 |
| Cole, TO | 4 |
| Pappas, AL | 1 |
| Welsh, C | 2 |
| Yoon, M | 1 |
| Gann, D | 1 |
| Artigiani, EE | 1 |
| Wish, ED | 3 |
| Pivovarova, E | 1 |
| Taxman, FS | 2 |
| Boland, AK | 1 |
| Smelson, DA | 1 |
| Lemon, SC | 1 |
| Sanjanwala, AR | 1 |
| Lim, G | 1 |
| Thakrar, AP | 2 |
| Uritsky, TJ | 1 |
| Christopher, C | 1 |
| Winston, A | 2 |
| Ronning, K | 1 |
| Sigueza, AL | 1 |
| Caputo, A | 1 |
| McFadden, R | 1 |
| Olenik, JM | 1 |
| Perrone, J | 4 |
| Delgado, MK | 1 |
| Lowenstein, M | 1 |
| Rivera, BD | 1 |
| Levin, E | 1 |
| Dooling, BCE | 1 |
| Jones, NR | 4 |
| Bradley, VD | 2 |
| Ryan, DA | 1 |
| Montoya, ID | 2 |
| Koutoujian, PJ | 1 |
| Siddiqi, K | 1 |
| Hayes, E | 2 |
| Cadet, T | 1 |
| McCollister, KE | 1 |
| Massey, E | 3 |
| Kleinman, M | 1 |
| McCarthy, JJ | 8 |
| Brandt, L | 3 |
| Hu, MC | 2 |
| Liu, Y | 6 |
| Castillo, F | 2 |
| Odom, GJ | 1 |
| Balise, RR | 2 |
| Feaster, DJ | 2 |
| Palayew, A | 1 |
| Strichartz, K | 1 |
| Martin, CE | 1 |
| Kelly, JC | 1 |
| Carter, EB | 1 |
| Busch, AB | 1 |
| Kennedy-Hendricks, A | 5 |
| Schilling, C | 1 |
| Hollander, M | 1 |
| Meiselbach, MK | 1 |
| Barry, CL | 6 |
| Huskamp, HA | 1 |
| Eisenberg, MD | 1 |
| Ware, OD | 1 |
| Sweeney, MM | 4 |
| Cunningham, C | 1 |
| Umbricht, A | 10 |
| Stitzer, M | 6 |
| Dunn, KE | 11 |
| Greiner, MG | 1 |
| Opara, O | 1 |
| Potter, K | 1 |
| Voronca, DC | 1 |
| Tafessu, HM | 1 |
| Hefner, K | 1 |
| Hamilton, A | 2 |
| Scheele, C | 1 |
| Ho, R | 1 |
| Dresser, L | 1 |
| Jelstrom, E | 2 |
| Ghitza, UE | 3 |
| Bisaga, A | 4 |
| Breland, H | 1 |
| Larkins, S | 1 |
| Antonini, V | 1 |
| Freese, T | 1 |
| McGovern, M | 1 |
| Dunn, J | 2 |
| Rawson, R | 2 |
| Tsai, TY | 2 |
| Tu, SY | 1 |
| Wu, CC | 1 |
| Ho, PS | 1 |
| Tung, CL | 1 |
| Tsai, JH | 1 |
| Yang, YH | 1 |
| Wu, KF | 1 |
| Chuang, HY | 1 |
| Alexander, K | 3 |
| Reed, MK | 1 |
| Sterling, RC | 3 |
| Hodge, A | 1 |
| Ashraf, W | 1 |
| McClean, K | 1 |
| Thompson, E | 1 |
| Gaeta Gazzola, M | 1 |
| Oberleitner, LMS | 5 |
| Eller, A | 2 |
| Marcus, R | 8 |
| Oberleitner, DE | 4 |
| Terasaki, D | 2 |
| Kulick, B | 1 |
| Calcaterra, S | 1 |
| Ray, L | 1 |
| Knight, D | 1 |
| Nkya, IH | 1 |
| West, NS | 1 |
| Yang, C | 2 |
| Kidorf, M | 15 |
| Latkin, C | 2 |
| Saleem, HT | 1 |
| Soto-Nevarez, A | 1 |
| Abo, M | 1 |
| Hudson, M | 1 |
| Bobak, T | 1 |
| Jason, LA | 3 |
| Elmore, AL | 1 |
| Patrick, SW | 4 |
| McNeer, E | 1 |
| Fryer, K | 1 |
| Reid, CN | 1 |
| Sappenfield, WM | 1 |
| Mehra, S | 1 |
| Salemi, JL | 1 |
| Marshall, J | 3 |
| Elkrief, L | 1 |
| Bakouni, H | 2 |
| Hébert, FO | 1 |
| Eisenbraun, A | 1 |
| Schroeder, D | 1 |
| Schaff, HV | 1 |
| Martin, E | 1 |
| Wittwer, ED | 1 |
| MacLean, RR | 1 |
| Heapy, AA | 1 |
| Waters, AJ | 1 |
| Wolkowicz, N | 1 |
| Szollosy, SK | 1 |
| Meyerovich, J | 2 |
| Huo, S | 1 |
| Fouladvand, S | 1 |
| Talbert, J | 2 |
| Dwoskin, LP | 1 |
| Bush, H | 1 |
| Meadows, AL | 1 |
| Peterson, LE | 1 |
| Mishra, YR | 1 |
| Roggenkamp, SK | 1 |
| Wang, F | 1 |
| Kavuluru, R | 1 |
| Chen, J | 2 |
| Billing, AS | 2 |
| Wooten, W | 1 |
| Hoag, SW | 2 |
| Wickwire, EM | 2 |
| Colloca, L | 2 |
| Magder, L | 1 |
| Weintraub, E | 4 |
| Kaptchuk, TJ | 2 |
| Bounthavong, M | 2 |
| Tralka, H | 1 |
| Poulter, HL | 1 |
| Walker, T | 1 |
| Ahmed, D | 1 |
| Moore, HJ | 1 |
| Riley, F | 1 |
| Towl, G | 1 |
| Harris, M | 1 |
| Benck, KN | 1 |
| Seide, K | 1 |
| Jones, AK | 1 |
| Omori, M | 1 |
| Rubinstein, LB | 1 |
| Beckwith, C | 1 |
| Nowotny, KM | 1 |
| Booty, MD | 1 |
| Harp, K | 1 |
| Batty, E | 1 |
| Knudsen, HK | 2 |
| Staton, M | 2 |
| Oser, CB | 1 |
| Walters, V | 1 |
| Weiss, RD | 5 |
| South, AM | 1 |
| Fanucchi, L | 2 |
| Lofwall, M | 1 |
| Anderson, PO | 1 |
| Murray, OB | 1 |
| Doyle, M | 1 |
| McLeman, BM | 1 |
| Marsch, LA | 7 |
| Cox, KM | 1 |
| Watts, D | 1 |
| Ryer, J | 1 |
| Edinoff, AN | 1 |
| Flanagan, CJ | 1 |
| Sinnathamby, ES | 1 |
| Pearl, NZ | 1 |
| Jackson, ED | 1 |
| Wenger, DM | 1 |
| Cornett, EM | 3 |
| Kaye, AM | 2 |
| Kaye, AD | 4 |
| Enns, B | 2 |
| Whitehurst, DGT | 1 |
| Dwivedi, I | 1 |
| Caldwell, AB | 1 |
| Zhou, D | 1 |
| Wu, W | 3 |
| Subramaniam, S | 2 |
| Haddad, GG | 2 |
| Bremer, W | 1 |
| Plaisance, K | 1 |
| Walker, D | 1 |
| Bonn, M | 1 |
| Love, JS | 2 |
| Sarker, A | 3 |
| Whitley, P | 1 |
| Dawson, E | 1 |
| Passik, S | 1 |
| Clark, B | 1 |
| Macpherson, G | 1 |
| Leppan, O | 1 |
| Kimber, J | 13 |
| Martino-Burke, D | 1 |
| Tierney, HR | 1 |
| Takimoto, SW | 1 |
| Azari, S | 1 |
| Taylor, EA | 1 |
| Cantor, JH | 1 |
| Bradford, AC | 1 |
| Simon, K | 1 |
| Holland, E | 1 |
| Gibbs, L | 1 |
| Spence, NZ | 1 |
| Young, M | 1 |
| Werler, MM | 3 |
| Guang, Z | 1 |
| Saia, K | 7 |
| Achu, R | 1 |
| Vella, A | 1 |
| Savona-Ventura, C | 1 |
| Mahmood, T | 1 |
| Hughto, JMW | 2 |
| Tapper, A | 1 |
| Rapisarda, SS | 1 |
| Palacios, WR | 1 |
| Case, P | 1 |
| Silcox, J | 1 |
| Moyo, P | 1 |
| Green, TC | 7 |
| Mocanu, V | 1 |
| Cheol Choi, J | 1 |
| Yin Mok, W | 1 |
| McInerney, K | 1 |
| Marchand, K | 4 |
| Buckley, J | 1 |
| Gao, C | 1 |
| Kestler, A | 1 |
| Mathias, S | 1 |
| Argyle, A | 1 |
| Barbic, S | 1 |
| Mortensen, JB | 1 |
| Andersen, CU | 2 |
| Eriksen, T | 1 |
| Lund, T | 1 |
| Pedersen, S | 1 |
| Møller, T | 1 |
| Sædder, EA | 1 |
| Panwala, V | 1 |
| Joudrey, P | 2 |
| Kowalski, M | 1 |
| Bach, P | 7 |
| Amram, O | 5 |
| Choi, S | 4 |
| Cleland, CM | 4 |
| Knopf, E | 1 |
| Hong, S | 1 |
| D'Aunno, T | 4 |
| Bao, Y | 1 |
| Ramsey, KS | 1 |
| Conway, A | 2 |
| Marshall, AD | 2 |
| Crawford, S | 2 |
| Grebely, J | 5 |
| Treloar, C | 4 |
| Jakubowski, A | 1 |
| Fowler, S | 1 |
| Fox, AD | 3 |
| Arnet, I | 1 |
| Dürsteler, KM | 4 |
| Jaiteh, C | 1 |
| Grossmann, F | 1 |
| Hersberger, KE | 1 |
| Tatar, O | 1 |
| Keane, OA | 1 |
| Zamora, AK | 1 |
| Ourshalimian, S | 1 |
| Mahdi, EM | 1 |
| Song, AY | 1 |
| Kim, E | 1 |
| Lakshmanan, A | 1 |
| Kim, ES | 1 |
| Kelley-Quon, LI | 1 |
| Kharasch, ED | 2 |
| Brunt, LM | 1 |
| Blood, J | 1 |
| Komen, H | 1 |
| Kelty, E | 6 |
| Havard, A | 1 |
| Preen, DB | 2 |
| Kim, JJ | 1 |
| Lafooraki, NY | 1 |
| Rezazadeh-Azar, P | 1 |
| Meyer, M | 3 |
| Cabanis, M | 3 |
| Aknondzadeh, S | 1 |
| Harris, SJ | 1 |
| Yarbrough, CR | 2 |
| Abraham, AJ | 3 |
| Rosic, T | 1 |
| Kolla, G | 2 |
| Kitchen, S | 1 |
| Marotta, P | 2 |
| Hass, A | 1 |
| Viera, A | 4 |
| Doernberg, M | 2 |
| Barbour, R | 3 |
| Grau, LE | 3 |
| Ledlie, S | 1 |
| Smoke, A | 1 |
| Rudolph, JE | 1 |
| Cepeda, JA | 2 |
| Astemborski, J | 1 |
| Kirk, GD | 1 |
| Mehta, SH | 1 |
| Genberg, BL | 1 |
| Rigg, KK | 1 |
| Weaver, R | 1 |
| Kusiak, E | 1 |
| Esfahani, K | 1 |
| Tennant, W | 1 |
| Tsang, S | 1 |
| Naik, BI | 1 |
| Dunn, LK | 1 |
| Vicent-Gil, M | 1 |
| Duran-Sindreu, S | 3 |
| Portella, MJ | 2 |
| Laptook, A | 1 |
| Das, A | 1 |
| Smith, B | 1 |
| Simon, A | 1 |
| Greenberg, R | 1 |
| Annett, R | 1 |
| Lee, J | 1 |
| Snowden, J | 1 |
| Pedroza, C | 1 |
| Eggleston, B | 1 |
| Bremer, D | 1 |
| McGowan, E | 1 |
| Rezazadeh, M | 1 |
| Hosseini, SA | 1 |
| Musarezaie, A | 1 |
| Padhan, M | 1 |
| Maiti, R | 1 |
| Mohapatra, D | 1 |
| Mishra, BR | 1 |
| Peles, E | 35 |
| Kim, Y | 1 |
| Sason, A | 13 |
| Adelson, M | 37 |
| Levran, O | 9 |
| John, WS | 3 |
| Mannelli, P | 9 |
| Morse, ED | 2 |
| Anderson, A | 2 |
| McGaffey, F | 1 |
| Doyle, S | 1 |
| Baaklini, V | 1 |
| Davis, CS | 2 |
| Colledge-Frisby, S | 1 |
| Cerdá, M | 4 |
| Yao, H | 1 |
| Hu, D | 2 |
| Wang, J | 5 |
| Zhao, HH | 1 |
| Gleeson, J | 3 |
| Whitney, BM | 1 |
| Pho, MT | 1 |
| Jenkins, WD | 1 |
| Young, AM | 1 |
| Cooper, HLF | 1 |
| de Gijsel, D | 1 |
| Miller, WC | 3 |
| Go, VF | 4 |
| Westergaard, R | 1 |
| Brown, R | 4 |
| Seal, DW | 1 |
| Zule, WA | 1 |
| Feinberg, J | 1 |
| Smith, GS | 1 |
| Mixson, LS | 1 |
| Fredericksen, R | 1 |
| Crane, HM | 1 |
| Delaney, JA | 1 |
| Lehmann, K | 3 |
| Kuhn, S | 3 |
| Schulte, B | 2 |
| Verthein, U | 16 |
| Jaffe, K | 1 |
| Gong, H | 1 |
| Huang, Y | 2 |
| Zhu, X | 1 |
| Lu, W | 1 |
| Cai, Z | 1 |
| Zhu, N | 1 |
| Huang, J | 2 |
| Jin, Y | 1 |
| Sun, X | 1 |
| Patel, K | 1 |
| Waldron, D | 1 |
| Graziane, N | 1 |
| Berger, NA | 1 |
| Davis, PB | 1 |
| Kaelber, DC | 1 |
| Xu, R | 1 |
| Kheirabadi, G | 1 |
| Asadi, M | 1 |
| Niroumand Sarvandani, M | 1 |
| Jamshidi, A | 1 |
| Mahdavi, F | 1 |
| Natvig, C | 1 |
| Mikulich, S | 1 |
| Van Dung, D | 1 |
| Xie, CZ | 1 |
| Ranganathan, M | 1 |
| Pittman, B | 1 |
| Rogan, M | 1 |
| Russoniello, K | 1 |
| Harrington, C | 1 |
| Beydoun, S | 1 |
| Borrego, L | 1 |
| Casey, S | 1 |
| Regan, S | 1 |
| Gale, E | 1 |
| Omede, FO | 1 |
| Wakeman, SE | 5 |
| Shapiro, B | 3 |
| Lambdin, BH | 2 |
| Ali, SA | 1 |
| Shell, J | 1 |
| Harris, R | 1 |
| Bedder, M | 1 |
| Gabrhelík, R | 4 |
| Hesse, M | 2 |
| Nechanská, B | 4 |
| Handal, M | 4 |
| Mravčík, V | 5 |
| Tjagvad, C | 2 |
| Thylstrup, B | 1 |
| Seid, AK | 1 |
| Bukten, A | 3 |
| Clausen, T | 13 |
| Skurtveit, S | 12 |
| Figgatt, MC | 2 |
| Hincapie-Castillo, JM | 1 |
| Schranz, AJ | 1 |
| Dasgupta, N | 3 |
| Edwards, JK | 1 |
| Jackson, BE | 1 |
| Marshall, SW | 1 |
| Golightly, YM | 1 |
| Carvalho, RM | 1 |
| de Magalhães-Barbosa, MC | 1 |
| Bianchi, LM | 1 |
| Rodrigues-Santos, G | 1 |
| da Cunha, AJLA | 1 |
| Bastos, FI | 1 |
| Prata-Barbosa, A | 1 |
| Mitchell, SG | 25 |
| Jester, J | 1 |
| Gryczynski, J | 13 |
| Whitter, M | 1 |
| Fuller, D | 1 |
| Halsted, C | 1 |
| Colzato, L | 1 |
| Elmers, J | 1 |
| Xu, X | 1 |
| Zhou, Q | 1 |
| Hommel, B | 1 |
| Beste, C | 1 |
| Jarrett, JB | 1 |
| Bratberg, J | 2 |
| Burns, AL | 1 |
| Cochran, G | 3 |
| DiPaula, BA | 1 |
| Legreid Dopp, A | 1 |
| Elmes, A | 1 |
| Hill, LG | 1 |
| Homsted, F | 1 |
| Hsia, SL | 1 |
| Matthews, ML | 1 |
| Carr, MM | 1 |
| Wolkowicz, NR | 1 |
| Cave, S | 1 |
| Martino, S | 1 |
| Masheb, R | 1 |
| Midboe, AM | 1 |
| Fanelli, JL | 1 |
| Furst, JA | 2 |
| Mynarski, NJ | 2 |
| Jarvis, MA | 2 |
| Nichols, SD | 2 |
| Jones, KF | 1 |
| Meghani, S | 1 |
| Lee, SJ | 2 |
| Pritchard, VE | 1 |
| Austin, NC | 1 |
| Henderson, JMT | 1 |
| Woodward, LJ | 3 |
| Stefanovics, E | 1 |
| Rosenheck, R | 5 |
| Garland, EL | 2 |
| Hanley, AW | 2 |
| Kline, A | 2 |
| Cooperman, NA | 5 |
| Lin, MP | 1 |
| Bahji, A | 1 |
| Cheng, B | 1 |
| Gray, S | 2 |
| Stuart, H | 1 |
| Bell, J | 11 |
| Di Trana, A | 1 |
| La Maida, N | 1 |
| Tittarelli, R | 1 |
| Huestis, MA | 9 |
| Pichini, S | 1 |
| Busardò, FP | 1 |
| Carlier, J | 1 |
| Lund, IO | 2 |
| Engeland, A | 3 |
| Williams, AR | 2 |
| Chemi, C | 1 |
| Suhail-Sindhu, S | 1 |
| Dickson, V | 1 |
| Uebelacker, LA | 2 |
| Van Noppen, D | 1 |
| Tremont, G | 1 |
| Bailey, G | 2 |
| Abrantes, A | 1 |
| Stein, M | 3 |
| Sigmon, SC | 12 |
| Hileman, CO | 1 |
| McComsey, GA | 1 |
| Smith, LR | 1 |
| Mittal, ML | 2 |
| Wagner, K | 1 |
| Copenhaver, MM | 5 |
| Camenga, DR | 1 |
| Colon-Rivera, HA | 1 |
| Muvvala, SB | 1 |
| May, T | 1 |
| Holloway, K | 2 |
| Bennett, T | 1 |
| Rivas, C | 1 |
| Hayes, V | 3 |
| Metpally, RP | 1 |
| Krishnamurthy, S | 1 |
| Moran, KM | 1 |
| Weller, AE | 1 |
| Crist, RC | 4 |
| Reiner, BC | 1 |
| Doyle, GA | 3 |
| Ferraro, TN | 1 |
| Radhakrishna, U | 1 |
| Bahado-Singh, R | 1 |
| Troiani, V | 1 |
| Berrettini, WH | 4 |
| Lu, RB | 6 |
| Wang, TY | 5 |
| Lee, SY | 6 |
| Chen, SL | 4 |
| Chang, YH | 5 |
| See Chen, P | 1 |
| Lin, SH | 2 |
| Chu, CH | 3 |
| Huang, SY | 4 |
| Tzeng, NS | 4 |
| Lee, IH | 5 |
| Chin Chen, K | 1 |
| Kuang Yang, Y | 1 |
| Chen, P | 1 |
| Chen, SH | 3 |
| Hong, JS | 4 |
| Nichols, H | 1 |
| Hill, P | 1 |
| Wireman, K | 1 |
| Alam, F | 2 |
| Wright, N | 2 |
| Roberts, P | 1 |
| Dhadley, S | 1 |
| Townley, J | 1 |
| Webster, R | 1 |
| Le, TA | 3 |
| Le, MQT | 1 |
| Dang, AD | 3 |
| Dang, AK | 1 |
| Nguyen, CT | 6 |
| Pham, HQ | 1 |
| Vu, GT | 2 |
| Hoang, CL | 1 |
| Tran, TT | 2 |
| Vuong, QH | 1 |
| Tran, TH | 2 |
| Tran, BX | 9 |
| Latkin, CA | 11 |
| Ho, CSH | 3 |
| Ho, RCM | 3 |
| Huang, D | 7 |
| Bertz, JW | 4 |
| Reamer, D | 1 |
| Kowalczyk, WJ | 6 |
| Kennedy, AP | 1 |
| Jobes, ML | 3 |
| Ward, G | 1 |
| Plitnick, BA | 1 |
| Figueiro, MG | 1 |
| Rea, MS | 1 |
| Oesterle, TS | 1 |
| Thusius, NJ | 1 |
| Rummans, TA | 1 |
| Gold, MS | 14 |
| Bergman, BG | 1 |
| Ashford, RD | 1 |
| Velasquez, M | 1 |
| Flannery, M | 2 |
| Badolato, R | 1 |
| McDonald, RD | 3 |
| Garment, AR | 1 |
| Giftos, J | 1 |
| Coffa, D | 2 |
| Adams, GB | 1 |
| Shanahan, M | 2 |
| Montebello, M | 1 |
| Gisev, N | 4 |
| Xuan, Z | 3 |
| Wang, N | 2 |
| Bernson, D | 6 |
| Silverstein, M | 2 |
| Hadland, SE | 7 |
| Land, T | 4 |
| Samet, JH | 9 |
| Grobman, WA | 2 |
| Miller, ES | 3 |
| Urbanoski, K | 3 |
| Harrington, K | 1 |
| Que, B | 1 |
| Shehadeh, V | 1 |
| Sullivan, F | 1 |
| Zhao, JK | 1 |
| Kral, AH | 3 |
| Wenger, LD | 1 |
| Bluthenthal, RN | 1 |
| Huhn, AS | 6 |
| Yip, SW | 2 |
| Ayaz, H | 2 |
| Byrd, DJ | 1 |
| Clarke, TJ | 1 |
| Campbell, TB | 1 |
| Ohuoha, C | 1 |
| McCance-Katz, EF | 11 |
| Ramli, FF | 3 |
| Shuid, AN | 1 |
| Pakri Mohamed, RM | 1 |
| Tg Abu Bakar Sidik, TMI | 1 |
| Naina Mohamed, I | 1 |
| Tran, AHT | 1 |
| Nguyen, LH | 7 |
| Nguyen, THT | 2 |
| Phan, HT | 4 |
| Fan, X | 1 |
| Zhang, X | 5 |
| Xu, H | 5 |
| Yang, F | 2 |
| Lau, JTF | 1 |
| Hao, C | 4 |
| Li, J | 12 |
| Zhao, Y | 6 |
| Hao, Y | 4 |
| Gu, J | 4 |
| Roxburgh, A | 1 |
| Hall, WD | 2 |
| Weicker, SA | 1 |
| Kerr, T | 25 |
| Shahkarami, K | 1 |
| Vousooghi, N | 4 |
| Golab, F | 1 |
| Mohsenzadeh, A | 1 |
| Baharvand, P | 1 |
| Sadat-Shirazi, MS | 1 |
| Babhadi-Ashar, N | 1 |
| Shakeri, A | 1 |
| Zarrindast, MR | 4 |
| Rosen, KD | 1 |
| Potter, JS | 2 |
| Tobon, AL | 1 |
| Habecker, E | 1 |
| Forray, A | 1 |
| Sharfstein, JM | 3 |
| Olsen, Y | 3 |
| Kelly, SM | 24 |
| O'Grady, KE | 37 |
| Sharma, A | 6 |
| Jaffe, JH | 19 |
| Elias, AM | 1 |
| Pepin, MJ | 1 |
| Brown, JN | 1 |
| Brezel, ER | 1 |
| Powell, T | 1 |
| Bivin, B | 1 |
| Waring, A | 1 |
| Alves, P | 2 |
| Valencia, E | 1 |
| Nasr, VG | 1 |
| Agage, D | 1 |
| Smith, MT | 2 |
| Polsky, D | 2 |
| Arsenault, S | 1 |
| Azocar, F | 3 |
| Felix, C | 1 |
| Reimer, J | 15 |
| Vogelmann, T | 1 |
| Trümper, D | 1 |
| Scherbaum, N | 17 |
| Tolami, HF | 1 |
| Sharafshah, A | 1 |
| Tolami, LF | 1 |
| Keshavarz, P | 1 |
| Jamin, D | 1 |
| Michels, II | 1 |
| Knorr, B | 1 |
| Deimel, D | 1 |
| McGowan, G | 2 |
| Ortman, HA | 1 |
| Siegel, JA | 1 |
| Nguyen, TA | 1 |
| Ying, J | 1 |
| Zhang, MWB | 1 |
| Andersson, L | 2 |
| Håkansson, A | 4 |
| Krantz, P | 1 |
| Johnson, B | 8 |
| Suzuki, J | 3 |
| Robinson, D | 1 |
| Mosquera, M | 1 |
| Solomon, DA | 1 |
| Montgomery, MW | 1 |
| Price, CD | 1 |
| Johnson, JA | 1 |
| Martin, B | 2 |
| Liebschutz, JW | 1 |
| Schnipper, JL | 1 |
| Mehta, S | 1 |
| Parmar, N | 1 |
| White, P | 1 |
| Durbaba, S | 1 |
| Ashworth, M | 1 |
| Yerneni, R | 2 |
| Healy, S | 3 |
| Goyal, M | 1 |
| Tsung, JH | 1 |
| Hinde, JM | 1 |
| Ali, MM | 1 |
| O'Connor, A | 3 |
| Bowling, N | 1 |
| Fluyau, D | 1 |
| Revadigar, N | 1 |
| Pierre, CG | 1 |
| Ameli, O | 2 |
| McPheeters, JT | 2 |
| Crown, WH | 2 |
| Sanghavi, DM | 2 |
| Ikegaki, J | 1 |
| Kizawa, Y | 1 |
| Hobelmann, JG | 1 |
| Strickland, JC | 1 |
| Oyler, GA | 1 |
| Bergeria, CL | 2 |
| Durand, L | 1 |
| O'Driscoll, D | 2 |
| Boland, F | 3 |
| Keenan, E | 12 |
| Ryan, BK | 1 |
| Barry, J | 9 |
| Bennett, K | 2 |
| Fahey, T | 8 |
| Cousins, G | 4 |
| Fleiz, C | 1 |
| Villatoro, J | 1 |
| Dominguez, M | 1 |
| Bustos, M | 1 |
| Medina-Mora, ME | 1 |
| Tripathi, R | 1 |
| Rao, R | 3 |
| Dhawan, A | 1 |
| Jain, R | 1 |
| Sinha, S | 1 |
| Shelly, S | 2 |
| Gerardy, T | 1 |
| von Homeyer, Z | 1 |
| Schneider, A | 1 |
| Padayachee, K | 1 |
| Naidoo, SB | 1 |
| Mtshweni, K | 1 |
| Matau, A | 1 |
| Hausler, H | 1 |
| Marks, M | 2 |
| Holtyn, AF | 4 |
| Toegel, F | 2 |
| Jarvis, BP | 1 |
| Leoutsakos, JM | 6 |
| Fingerhood, M | 4 |
| Silverman, K | 13 |
| Dennis, BB | 10 |
| Akhtar, D | 1 |
| Cholankeril, G | 1 |
| Kim, D | 1 |
| Sanger, N | 5 |
| Worster, A | 11 |
| Marsh, DC | 24 |
| Ahmed, A | 1 |
| Agus, D | 2 |
| Lyons, BC | 1 |
| Weiner, JP | 1 |
| Lodi, S | 1 |
| Li, Y | 4 |
| Babakhanlou-Chase, H | 1 |
| Jaeger, S | 1 |
| Fuehrlein, B | 1 |
| Ravishankar, DA | 1 |
| Calhoun, E | 1 |
| Din, A | 1 |
| Yang, JC | 2 |
| Roman-Urrestarazu, A | 1 |
| Brayne, C | 1 |
| Sufrin, C | 2 |
| Sutherland, L | 1 |
| Beal, L | 1 |
| Clarke, JG | 4 |
| Frazier, LM | 1 |
| Bobby, LE | 1 |
| Gawronski, KM | 1 |
| Haider, A | 1 |
| Reddy, A | 1 |
| Gertner, AK | 2 |
| Robertson, AG | 2 |
| Jones, H | 6 |
| Powell, BJ | 2 |
| Silberman, P | 2 |
| Domino, ME | 2 |
| Pro, G | 1 |
| Utter, J | 1 |
| Haberstroh, S | 1 |
| Baldwin, JA | 1 |
| Nelson, LF | 1 |
| Yocum, VK | 1 |
| Patel, KD | 1 |
| Qeadan, F | 1 |
| Hsi, A | 2 |
| Weitzen, S | 1 |
| McNeil, R | 4 |
| Puri, N | 1 |
| Boyd, J | 1 |
| Mayer, S | 1 |
| Small, W | 5 |
| Hulse, G | 5 |
| Joyce, D | 2 |
| Klie, KA | 2 |
| Irvine, M | 1 |
| Rodríguez Mega, E | 1 |
| Whittaker, S | 1 |
| Refsland, BM | 1 |
| Stanojlović, M | 1 |
| Nyhan, K | 1 |
| Andrews, L | 3 |
| Davies, TH | 2 |
| Haas, J | 1 |
| Loudin, S | 2 |
| Heyward, A | 1 |
| Werthammer, J | 1 |
| Jin, H | 1 |
| Marshall, BDL | 4 |
| Roos, CR | 2 |
| Kiluk, BD | 1 |
| McHugh, RK | 3 |
| Carroll, KM | 9 |
| Talal, AH | 3 |
| Ding, Y | 3 |
| Venuto, CS | 1 |
| Chakan, LM | 1 |
| McLeod, A | 2 |
| Dharia, A | 1 |
| Morse, GD | 1 |
| Brown, LS | 7 |
| Markatou, M | 3 |
| Kranzler, HR | 4 |
| Washio, Y | 1 |
| Zindel, LR | 1 |
| Lynch, KG | 2 |
| Hand, D | 1 |
| Tyndale, RF | 1 |
| Oncken, C | 2 |
| Schnoll, R | 1 |
| Jiang, H | 5 |
| Su, H | 1 |
| Zhang, C | 6 |
| Liu, X | 4 |
| Li, R | 6 |
| Zhong, N | 1 |
| Zhao, M | 7 |
| Kinasz, KR | 1 |
| Herbst, ED | 1 |
| Kalapatapu, RK | 1 |
| Finnell, DS | 1 |
| Goedel, WC | 1 |
| Shapiro, A | 1 |
| Tsai, JW | 1 |
| Simonovska, NK | 1 |
| Stefanovska, VV | 1 |
| Babulovska, A | 1 |
| Duren, T | 2 |
| Welle-Strand, GK | 5 |
| Abel, KF | 1 |
| Chalabianloo, F | 4 |
| Sarfi, M | 4 |
| Wen, H | 1 |
| Druss, BG | 1 |
| Galaj, E | 1 |
| Newman, AH | 2 |
| Xi, ZX | 2 |
| Atkins, D | 2 |
| Madeira, J | 1 |
| Silverman, RD | 1 |
| Duan, L | 1 |
| Li, X | 11 |
| Yan, J | 1 |
| Chen, Y | 6 |
| Luo, R | 3 |
| Zhang, Q | 3 |
| Feng, X | 2 |
| MacNeill, L | 1 |
| Brunelle, C | 1 |
| Skelding, B | 1 |
| DiTommaso, E | 1 |
| Farnum, SO | 4 |
| Makarenko, I | 3 |
| Mazhnaya, A | 5 |
| Prokhorova, T | 1 |
| Bojko, MJ | 4 |
| Dvoriak, S | 6 |
| Islam, Z | 1 |
| Lin, LA | 2 |
| Bohnert, ASB | 2 |
| Blow, FC | 2 |
| Ignacio, RV | 1 |
| Kim, HM | 2 |
| Ilgen, MA | 2 |
| Pena, E | 1 |
| Ahmed, S | 2 |
| Jent, VA | 1 |
| Alinsky, RH | 1 |
| Mauro, PM | 2 |
| Nielsen, T | 2 |
| Hansen, H | 2 |
| Diop, H | 2 |
| Bharel, M | 4 |
| Selk, S | 1 |
| Taveras, EM | 3 |
| Hoggatt, K | 1 |
| Kimmel, S | 1 |
| Wendling, AL | 1 |
| Garvan, C | 1 |
| Roussos-Ross, D | 1 |
| Zhang, L | 6 |
| Zeng, D | 1 |
| Ponce Martinez, C | 1 |
| Edwards, KA | 1 |
| Köck, P | 2 |
| Strasser, J | 4 |
| Herscher, M | 1 |
| Fine, M | 1 |
| Navalurkar, R | 1 |
| Hirt, L | 1 |
| Askari, MS | 1 |
| Martins, SS | 1 |
| Gao, L | 2 |
| Robertson, JR | 7 |
| Bird, SM | 5 |
| Fugelstad, A | 2 |
| Bremberg, S | 1 |
| Hjelmström, P | 2 |
| Thiblin, I | 2 |
| Malik, E | 1 |
| Altman, Y | 1 |
| Baharav, A | 1 |
| Schreiber, S | 22 |
| Liu, CC | 2 |
| Liu, SC | 2 |
| Baldassarri, SR | 2 |
| Zinchuk, A | 1 |
| Redeker, NS | 1 |
| Carrasco, D | 1 |
| Lipkind, N | 1 |
| Bastian, LA | 1 |
| Chen, K | 1 |
| Yaggi, HK | 1 |
| Geddes, L | 1 |
| Iversen, J | 1 |
| Wand, H | 1 |
| Maher, L | 4 |
| Baschirotto, C | 2 |
| Stone, AC | 1 |
| Carroll, JJ | 1 |
| Rich, JD | 12 |
| McDaniel, CE | 1 |
| Test, M | 1 |
| Deodhar, P | 1 |
| Jennings, R | 1 |
| Bove, J | 1 |
| Carlin, K | 1 |
| Schimmel, J | 1 |
| Fingerhood, MI | 2 |
| Staszewski, CL | 1 |
| Garretto, D | 1 |
| Garry, ET | 1 |
| Ly, V | 1 |
| Davis, JA | 1 |
| Herrera, KM | 1 |
| Salari, N | 3 |
| Abdam, B | 1 |
| Abdi, A | 1 |
| Daryoushi, H | 1 |
| Knittel, AK | 1 |
| Zarnick, S | 1 |
| Thorp, JM | 2 |
| Amos, E | 1 |
| Drexler, K | 7 |
| Burden, J | 1 |
| Codell, NK | 1 |
| Mhatre-Owens, A | 1 |
| Dungan, MT | 1 |
| Hagedorn, H | 1 |
| Cox, N | 1 |
| KuKanich, B | 2 |
| KuKanich, K | 2 |
| Rankin, DC | 2 |
| Locuson, CW | 2 |
| Joo, H | 1 |
| Packiasabapathy, S | 1 |
| Aruldhas, BW | 1 |
| Horn, N | 1 |
| Overholser, BR | 1 |
| Quinney, SK | 1 |
| Renschler, JS | 1 |
| Sadhasivam, S | 1 |
| Ma, J | 2 |
| Sahasranaman, V | 1 |
| Kirby, RS | 1 |
| Boaz, T | 1 |
| Brown, HL | 2 |
| Chalhoub, RM | 1 |
| Kalivas, PW | 1 |
| Flannery, T | 1 |
| Czynski, AJ | 1 |
| Dansereau, LM | 1 |
| Oliveira, EL | 1 |
| Camardo, SA | 1 |
| Lester, BM | 2 |
| Stone, E | 3 |
| Bachhuber, MA | 2 |
| McGinty, EE | 2 |
| Rudolf, VP | 1 |
| von Klimo, MC | 1 |
| Ortiz-Barrios, M | 1 |
| Gul, M | 1 |
| López-Meza, P | 1 |
| Yucesan, M | 1 |
| Navarro-Jiménez, E | 1 |
| Khuntia, HK | 1 |
| Chanakya, HN | 1 |
| D'Arienzo, M | 1 |
| Coniglio, A | 1 |
| Boag, AM | 1 |
| Short, A | 1 |
| Kennedy, LJ | 1 |
| Syme, H | 1 |
| Graham, PA | 1 |
| Catchpole, B | 1 |
| El Shahawy, O | 1 |
| Segoshi, A | 1 |
| Moreno, KP | 1 |
| Badiei, B | 1 |
| Zhou, Y | 3 |
| Guo, B | 1 |
| Zhang, H | 3 |
| Xia, S | 1 |
| Nielsen, CU | 1 |
| Pedersen, M | 1 |
| Müller, S | 1 |
| Kæstel, T | 1 |
| Bjerg, M | 1 |
| Ulaganathan, N | 1 |
| Carlsen, KL | 1 |
| Nøhr, MK | 1 |
| Holm, R | 1 |
| Dottino, JA | 1 |
| Loose, DS | 1 |
| Fellman, B | 1 |
| Melendez, BD | 1 |
| Borthwick, MS | 1 |
| McKenzie, LJ | 1 |
| Yuan, Y | 1 |
| Yang, RK | 1 |
| Broaddus, RR | 1 |
| Lu, KH | 1 |
| Soliman, PT | 1 |
| Yates, MS | 1 |
| Zhu, Z | 1 |
| Hasegawa, K | 1 |
| Ma, B | 1 |
| Fujiogi, M | 1 |
| Camargo, CA | 1 |
| Liang, L | 1 |
| Sangroula, S | 1 |
| Baez Vasquez, AY | 1 |
| Raut, P | 1 |
| Obeng, B | 1 |
| Shim, JK | 1 |
| Bagley, GD | 1 |
| West, BE | 1 |
| Burnell, JE | 1 |
| Kinney, MS | 1 |
| Potts, CM | 1 |
| Weller, SR | 1 |
| Kelley, JB | 1 |
| Hess, ST | 1 |
| Gosse, JA | 1 |
| Breves, JP | 1 |
| Springer-Miller, RH | 1 |
| Chenoweth, DA | 1 |
| Paskavitz, AL | 1 |
| Chang, AYH | 1 |
| Regish, AM | 1 |
| Einarsdottir, IE | 1 |
| Björnsson, BT | 1 |
| McCormick, SD | 1 |
| Villmones, HC | 1 |
| Halland, A | 1 |
| Stenstad, T | 1 |
| Ulvestad, E | 1 |
| Weedon-Fekjær, H | 1 |
| Kommedal, Ø | 1 |
| Nasri, A | 1 |
| Jaleh, B | 1 |
| Khazalpour, S | 1 |
| Nasrollahzadeh, M | 1 |
| Shokouhimehr, M | 1 |
| Ferrario, M | 1 |
| Fenoglio, D | 1 |
| Chantada, A | 1 |
| Guerrero, S | 1 |
| Odetayo, AA | 1 |
| Reible, DD | 1 |
| Acevedo-Mackey, D | 1 |
| Price, C | 1 |
| Thai, L | 1 |
| Li, S | 3 |
| Lin, Y | 1 |
| Wang, D | 2 |
| Wang, Z | 5 |
| Nie, E | 1 |
| Huang, L | 1 |
| Gao, X | 1 |
| Akhtar, K | 1 |
| Ye, Q | 1 |
| Yang, Y | 4 |
| Chen, W | 6 |
| Dai, Y | 2 |
| Guo, X | 1 |
| An, Y | 1 |
| Chai, C | 1 |
| Sang, J | 1 |
| Jiang, L | 1 |
| Lu, F | 1 |
| Liu, F | 1 |
| Pu, Y | 1 |
| Xiang, H | 1 |
| Yin, H | 1 |
| Yue, W | 1 |
| Yin, Y | 1 |
| Li, H | 3 |
| Shaw, L | 2 |
| Shaw, D | 2 |
| Hardisty, M | 1 |
| Britz-McKibbin, P | 1 |
| Verma, DK | 1 |
| Li, W | 2 |
| Wufuer, R | 1 |
| Duo, J | 1 |
| Luo, Y | 1 |
| Zhang, D | 1 |
| Pan, X | 1 |
| Jones, DL | 1 |
| Baluja, MQ | 1 |
| Graham, DW | 1 |
| Corbishley, A | 1 |
| McDonald, JE | 1 |
| Malham, SK | 1 |
| Hillary, LS | 1 |
| Connor, TR | 1 |
| Gaze, WH | 1 |
| Moura, IB | 1 |
| Wilcox, MH | 1 |
| Farkas, K | 1 |
| Shao, X | 1 |
| Liu, J | 2 |
| Ji, X | 1 |
| Tian, G | 1 |
| Zhang, Y | 4 |
| Sun, R | 1 |
| Tuyiringire, D | 1 |
| Li, K | 2 |
| Han, W | 1 |
| Wang, Y | 4 |
| Yan, L | 1 |
| El Hayany, B | 1 |
| El Fels, L | 1 |
| Quénéa, K | 1 |
| Dignac, MF | 1 |
| Rumpel, C | 1 |
| Gupta, VK | 1 |
| Hafidi, M | 1 |
| de Oliveira, BR | 1 |
| Bragança, MLBM | 1 |
| Batalha, MA | 1 |
| Coelho, CCNDS | 1 |
| Bettiol, H | 1 |
| Barbieri, MA | 1 |
| Saraiva, MDCP | 1 |
| Kac, G | 1 |
| da Silva, AAM | 1 |
| Rather, BA | 1 |
| Mir, IR | 1 |
| Sehar, Z | 1 |
| Anjum, NA | 1 |
| Masood, A | 1 |
| Khan, NA | 1 |
| Songsamoe, S | 1 |
| Koomhin, P | 1 |
| Matan, N | 1 |
| Flögel, F | 1 |
| Gärtner, S | 1 |
| Rahimi Khonakdari, M | 1 |
| Rezadoost, H | 1 |
| Heydari, R | 1 |
| Mirjalili, MH | 1 |
| Kebaili, I | 1 |
| Boukhris, I | 1 |
| Sayyed, MI | 1 |
| Tonguc, B | 1 |
| Al-Buriahi, MS | 1 |
| Ganson, KT | 1 |
| Nagata, JM | 1 |
| Cole, MA | 2 |
| Ozgen, C | 1 |
| Strobl, E | 1 |
| Coker, ES | 1 |
| Cavalli, L | 1 |
| Fabrizi, E | 1 |
| Guastella, G | 1 |
| Lippo, E | 1 |
| Parisi, ML | 1 |
| Pontarollo, N | 1 |
| Rizzati, M | 1 |
| Varacca, A | 1 |
| Vergalli, S | 1 |
| Elliott, RJR | 1 |
| Liu, B | 1 |
| Bajelan, S | 1 |
| Bahreini, MS | 1 |
| Asgari, Q | 1 |
| Mikaeili, F | 1 |
| Lakmal, MAC | 1 |
| Ekanayake, EMDNK | 1 |
| Kelum, SHP | 1 |
| Gamage, BD | 1 |
| Jayasundara, JASB | 1 |
| Gautam, S | 1 |
| Gautam, A | 1 |
| Chhetri, S | 1 |
| Bhattarai, U | 1 |
| Acharjee, N | 1 |
| Patel, AK | 1 |
| Lodha, D | 1 |
| Shekhawat, NS | 1 |
| Zeng, W | 1 |
| Dong, A | 1 |
| Chen, X | 1 |
| Cheng, ZL | 1 |
| Campo, M | 1 |
| Amandi, A | 1 |
| Biset, JC | 1 |
| Roviello, V | 1 |
| Roviello, GN | 1 |
| Freeman, M | 1 |
| Ayers, C | 1 |
| Paynter, R | 1 |
| Kondo, K | 1 |
| Kansagara, D | 1 |
| Day, CA | 1 |
| Reid, SE | 1 |
| Fowler, M | 1 |
| Black, KI | 1 |
| Marks, LR | 1 |
| Munigala, S | 1 |
| Warren, DK | 1 |
| Liang, SY | 1 |
| Durkin, MJ | 1 |
| Jordan, AE | 3 |
| Schackman, BR | 5 |
| Wyka, K | 2 |
| Nash, D | 2 |
| Thomson, T | 1 |
| Greenland, S | 1 |
| Gustafson, P | 1 |
| Karim, ME | 1 |
| McCandless, LC | 2 |
| Maclure, M | 1 |
| Platt, RW | 2 |
| Siebert, U | 1 |
| Kaplan, HC | 1 |
| Kuhnell, P | 1 |
| Walsh, MC | 2 |
| Crowley, M | 2 |
| McClead, R | 1 |
| Wexelblatt, S | 1 |
| Ford, S | 1 |
| Provost, LP | 1 |
| Lannon, C | 1 |
| Macaluso, M | 1 |
| Gaeta, M | 2 |
| Tamberelli, JF | 2 |
| Attermann, J | 1 |
| Cupito, A | 1 |
| Beck, AJ | 1 |
| Jia, L | 1 |
| Norman, WV | 1 |
| Stull, SW | 3 |
| Zarkin, GA | 6 |
| Orme, S | 2 |
| Dunlap, LJ | 4 |
| Kermode, M | 1 |
| Choudhurimayum, RS | 1 |
| Rajkumar, LS | 1 |
| Haregu, T | 1 |
| Armstrong, G | 1 |
| Kiriazova, T | 1 |
| Hershow, RB | 1 |
| Hamilton, EL | 1 |
| Sarasvita, R | 1 |
| Bui, Q | 1 |
| Lancaster, KE | 1 |
| Dumchev, K | 2 |
| Hoffman, IF | 1 |
| Loscalzo, E | 1 |
| Levit, A | 1 |
| Weinstein, SP | 3 |
| Gandhi, D | 2 |
| Larrabeiti, A | 1 |
| Sànchez, O | 1 |
| Madrid, M | 1 |
| De Andrés, S | 1 |
| Wouldes, TA | 4 |
| Elkana, O | 2 |
| Doniger, GM | 2 |
| Lake, S | 2 |
| St Pierre, M | 1 |
| Del Pozo, B | 2 |
| Cioe, K | 1 |
| Easly, R | 1 |
| Simard, A | 1 |
| Maricich, YA | 1 |
| Xiong, X | 1 |
| Gerwien, R | 1 |
| Kuo, A | 1 |
| Velez, F | 1 |
| Imbert, B | 1 |
| Boyer, K | 1 |
| Luderer, HF | 1 |
| Braun, S | 1 |
| Williams, K | 2 |
| Laubach, LT | 1 |
| Esposito, SB | 1 |
| Yazdanyar, A | 1 |
| Roth, P | 1 |
| Lauber, P | 1 |
| Allen, J | 1 |
| Boateng, N | 1 |
| Shaak, S | 1 |
| Burmeister, DB | 1 |
| Minozzi, S | 11 |
| Amato, L | 15 |
| Jahanfar, S | 1 |
| Bellisario, C | 3 |
| Ferri, M | 9 |
| Davoli, M | 23 |
| Meteliuk, A | 1 |
| Galvez de Leon, SJ | 1 |
| Pykalo, I | 3 |
| Fomenko, T | 2 |
| Filippovych, M | 1 |
| Islam, ZM | 1 |
| Mitchell, MM | 2 |
| Raski, M | 1 |
| Sutherland, C | 2 |
| Levin, FR | 8 |
| Reilly, MP | 1 |
| El-Bassel, N | 9 |
| Mohammadi, M | 1 |
| Kazeminia, M | 1 |
| Abdoli, N | 1 |
| Khaledipaveh, B | 1 |
| Shohaimi, S | 1 |
| Hosseinian-Far, M | 1 |
| Randesi, M | 5 |
| Ott, J | 4 |
| Kreek, MJ | 25 |
| Andersen, FD | 1 |
| Simonsen, U | 1 |
| Polenick, CA | 3 |
| Kaba, D | 1 |
| Zhou, AN | 1 |
| Han, BH | 2 |
| Cotton, BP | 5 |
| Snell-Rood, C | 1 |
| Willging, C | 1 |
| Showalter, D | 1 |
| Peters, H | 1 |
| Pollini, RA | 1 |
| Donelan, CJ | 1 |
| Potee, RA | 1 |
| Schwartz, L | 1 |
| Perry, NS | 1 |
| Donoyan, A | 1 |
| Mimiaga, MJ | 2 |
| Nelson, KM | 1 |
| Pantalone, DW | 1 |
| Ameral, V | 1 |
| Weisberg, RB | 1 |
| Culhane, J | 1 |
| South, E | 1 |
| Srinivas, SK | 1 |
| Smith, J | 1 |
| Lafferty, M | 1 |
| Boelig, RC | 1 |
| Carola, D | 1 |
| Adeniyi-Jones, S | 1 |
| Greenspan, JS | 1 |
| Aghai, ZH | 1 |
| Hatch-Maillette, MA | 1 |
| Peavy, KM | 1 |
| Banta-Green, CJ | 3 |
| Titus-Lay, EN | 2 |
| Jaynes, HA | 2 |
| Tomaselli Muensterman, E | 2 |
| Walroth, TA | 2 |
| Ott, CA | 2 |
| Desta, Z | 1 |
| Williams, G | 2 |
| Moe, PR | 2 |
| Wilbrandt, M | 2 |
| Tisdale, JE | 2 |
| Shapoval, L | 2 |
| Forthal, S | 1 |
| Muthulingam, D | 1 |
| Gainer, DM | 1 |
| Crawford, TN | 1 |
| Fischer, KB | 1 |
| Wright, MD | 1 |
| Gill, A | 2 |
| McPhail, BT | 1 |
| Emoto, C | 1 |
| Butler, D | 1 |
| Fukuda, T | 1 |
| Akinbi, H | 2 |
| Vinks, AA | 1 |
| Weidacker, K | 1 |
| Mandali, A | 1 |
| Whiteford, S | 1 |
| Ren, Q | 1 |
| Zhou, Z | 2 |
| Du, J | 6 |
| Sun, B | 2 |
| Voon, V | 1 |
| Syed Hashim, SA | 1 |
| Mohd Effendy, N | 1 |
| Gloeck, NR | 1 |
| Harris, BN | 1 |
| Webb, EM | 1 |
| Weaver, A | 1 |
| Molfenter, T | 1 |
| Himle, JA | 1 |
| Mariani, JJ | 1 |
| Pavlicova, M | 2 |
| Choi, CJ | 1 |
| Basaraba, C | 1 |
| Mahony, AL | 1 |
| Brooks, DJ | 4 |
| Naqvi, N | 1 |
| Liu, YC | 1 |
| Lee, PW | 1 |
| Chang, WH | 1 |
| Lu, TH | 1 |
| Tseng, HH | 1 |
| Chen, PS | 5 |
| Chen, KC | 5 |
| Yang, YK | 5 |
| Andenes, M | 1 |
| Sævold, E | 1 |
| Griffiths, ST | 1 |
| Sirnes, E | 1 |
| Rajput, K | 1 |
| Vadivelu, N | 1 |
| Krantz, MJ | 8 |
| Palmer, RB | 1 |
| Haigney, MCP | 1 |
| Finnegan, LP | 4 |
| Robin, AM | 1 |
| Hersh, AR | 1 |
| John, C | 1 |
| Caughey, AB | 1 |
| Levine, TA | 1 |
| Davie-Gray, A | 1 |
| Rozner, L | 1 |
| Oakley, B | 1 |
| Wilson, H | 1 |
| Rolland, B | 2 |
| Trojak, B | 1 |
| Nourredine, M | 1 |
| Bachellier, J | 1 |
| Chappuy, M | 1 |
| Bendimerad, P | 1 |
| Kosim, M | 1 |
| Meroueh, F | 2 |
| Nubukpo, P | 1 |
| Brousse, G | 3 |
| Patel, N | 1 |
| Schwenk, ES | 1 |
| Ferd, P | 1 |
| Torjman, MC | 1 |
| Baratta, JL | 1 |
| Viscusi, ER | 1 |
| Iloglu, S | 1 |
| Thornhill, TA | 1 |
| Gonsalves, G | 1 |
| Garrett, B | 1 |
| Ahmad, NJ | 1 |
| Patel, E | 1 |
| Solomon, K | 1 |
| Beaulieu, E | 1 |
| DiGennaro, C | 1 |
| Stringfellow, E | 2 |
| Connolly, A | 1 |
| Hyder, A | 1 |
| Keyes, KM | 1 |
| Garfield, JBB | 1 |
| Lubman, DI | 3 |
| Sabin, KM | 1 |
| Burke-Shyne, N | 1 |
| Chang, J | 1 |
| Daniels, C | 1 |
| Nguyen, VTT | 1 |
| Verster, A | 1 |
| Cook, RR | 1 |
| Nguyen, T | 1 |
| Bielavitz, S | 1 |
| Tam, NTM | 1 |
| Guillou-Landreat, M | 1 |
| Dany, A | 1 |
| Challet-Bouju, G | 2 |
| Laforgue, E | 1 |
| Leboucher, J | 2 |
| Benoit Hardouin, J | 1 |
| Victorri-Vigneau, C | 2 |
| Grall-Bronnec, M | 2 |
| Lanza, ST | 1 |
| Curtis, BL | 1 |
| Huang, CL | 3 |
| Tsai, IJ | 1 |
| Lin, WC | 1 |
| Ho, IK | 2 |
| Wang, RY | 2 |
| Lee, CW | 1 |
| Berge, J | 2 |
| O-Keefe-Markman, C | 1 |
| Daldegan-Bueno, D | 1 |
| Walters, C | 1 |
| Stringer, KL | 1 |
| Langdon, KJ | 1 |
| McKenzie, M | 9 |
| Brockmann, B | 1 |
| Petrosan, A | 1 |
| Zassman, S | 1 |
| Cohn, S | 1 |
| Guerra, M | 1 |
| Soares, K | 1 |
| Kennedy, J | 1 |
| Abdelghany, O | 1 |
| Gutman, E | 1 |
| Bates, AE | 1 |
| Martin-Misener, R | 1 |
| Nikraftar, NS | 1 |
| Feyzi, YF | 1 |
| Ramzani, F | 1 |
| Nikbakht-Zadeh, M | 1 |
| Amini, M | 1 |
| Arezoomandan, M | 1 |
| Shiehmorteza, M | 1 |
| Arezoomandan, R | 1 |
| Borodovsky, JT | 1 |
| Bhat, NR | 1 |
| Busch, M | 1 |
| Klein, C | 1 |
| Uhl, A | 1 |
| Haltmayer, H | 1 |
| Krausz, RM | 1 |
| Fitzgerald, AH | 1 |
| Komp, MS | 1 |
| Nayak, SM | 1 |
| Strain, EC | 27 |
| Benville, JR | 1 |
| Giordano, NA | 1 |
| Cheatle, MD | 1 |
| Mehtani, NJ | 1 |
| Ristau, JT | 1 |
| Surlyn, C | 1 |
| Eveland, J | 1 |
| Smith-Bernardin, S | 1 |
| Kuppalli, S | 1 |
| Seth, R | 1 |
| Orhurhu, V | 1 |
| Urits, I | 1 |
| Hunter, C | 1 |
| Gulati, A | 1 |
| Adekoya, P | 1 |
| Jones, MR | 1 |
| Grecco, GG | 1 |
| Mork, BE | 1 |
| Huang, JY | 1 |
| Metzger, CE | 1 |
| Haggerty, DL | 1 |
| Reeves, KC | 1 |
| Gao, Y | 1 |
| Hoffman, H | 1 |
| Katner, SN | 1 |
| Masters, AR | 1 |
| Morris, CW | 1 |
| Newell, EA | 1 |
| Engleman, EA | 1 |
| Baucum, AJ | 1 |
| Kim, J | 1 |
| Yamamoto, BK | 1 |
| Allen, MR | 1 |
| Wu, YC | 1 |
| Lu, HC | 1 |
| Sheets, PL | 1 |
| Atwood, BK | 1 |
| Latif, ZH | 1 |
| Skjaervø, I | 1 |
| Solli, KK | 1 |
| Tanum, L | 1 |
| Sohn, M | 1 |
| Talbert, JC | 1 |
| Huang, Z | 1 |
| Oser, C | 1 |
| Freeman, PR | 1 |
| Mohammadi, MR | 2 |
| Zandifar, A | 1 |
| Badrfam, R | 1 |
| Clark, SA | 1 |
| Davis, C | 2 |
| Wightman, RS | 1 |
| Wunsch, C | 1 |
| Keeler, LAJ | 1 |
| Reddy, N | 1 |
| Samuels, EA | 1 |
| Dopp, AR | 1 |
| Uscher-Pines, L | 1 |
| Choo, TH | 1 |
| Scodes, J | 1 |
| Wai, J | 1 |
| Haenlein, P | 1 |
| Campbell, ANC | 1 |
| Syvertsen, JL | 1 |
| Toneff, H | 1 |
| Howard, H | 1 |
| Spadola, C | 1 |
| Madden, D | 1 |
| Clapp, J | 1 |
| Guillery, SPE | 1 |
| Hellweg, R | 1 |
| Kronenberg, G | 1 |
| Bohr, U | 1 |
| Kunte, H | 1 |
| Enge, S | 1 |
| Fairley, M | 1 |
| Humphreys, K | 8 |
| Joyce, VR | 1 |
| Trafton, J | 1 |
| Combs, A | 1 |
| Oliva, EM | 5 |
| Goldhaber-Fiebert, JD | 2 |
| Asch, SM | 1 |
| Brandeau, ML | 1 |
| Owens, DK | 2 |
| McCauley, JL | 1 |
| Moreland, A | 1 |
| Rogal, S | 1 |
| Youk, A | 1 |
| Agbalajobi, O | 1 |
| Gellad, W | 1 |
| Fine, MJ | 1 |
| Belperio, P | 1 |
| Morgan, T | 1 |
| Good, CB | 1 |
| Kraemer, K | 1 |
| Chenworth, M | 1 |
| Graves, R | 1 |
| Hogg-Bremer, W | 1 |
| Nielsen, TC | 1 |
| Reddy, J | 1 |
| Ruíz Ruíz, JJ | 1 |
| Martinez Delgado, JM | 1 |
| García-Marchena, N | 1 |
| Adimi Naghan, P | 1 |
| Setareh, J | 1 |
| Malekmohammad, M | 1 |
| Smith, KE | 1 |
| Riker, RR | 1 |
| Craig, WY | 1 |
| McKelvy, DJ | 1 |
| Kemp, HD | 1 |
| Fraser, GL | 1 |
| Nys, H | 1 |
| Mogaka, B | 1 |
| Mutinda, M | 1 |
| Kendagor, M | 1 |
| Hoffmann, O | 1 |
| Ljungberg, T | 1 |
| Fadnes, LT | 1 |
| Høiseth, G | 2 |
| Ohldieck, C | 1 |
| Vold, JH | 1 |
| Aas, C | 1 |
| Løberg, EM | 1 |
| Johansson, KA | 1 |
| Bramness, JG | 6 |
| Thomas, PS | 1 |
| Nielsen, EM | 1 |
| Spellicy, CJ | 1 |
| Harding, MJ | 3 |
| Ye, A | 1 |
| Patriquin, M | 1 |
| Hamon, SC | 3 |
| Nielsen, DA | 6 |
| Favia, M | 1 |
| Santoiemma, I | 1 |
| Mita, Q | 1 |
| Strisciullo, G | 1 |
| Introna, F | 1 |
| De Donno, A | 1 |
| Faraj, MM | 1 |
| Lipanski, NM | 1 |
| Morales, A | 1 |
| Goldberg, E | 1 |
| Bluth, MH | 1 |
| Marusak, HA | 1 |
| Waddell, EN | 1 |
| Oliveira, C | 1 |
| Filipe, R | 1 |
| Meira, J | 1 |
| Sampaio, L | 1 |
| Teixeira, L | 1 |
| Rodrigues, J | 1 |
| Nunes, I | 1 |
| Tavares, J | 1 |
| Stanciu, C | 1 |
| Hybki, B | 1 |
| Penders, T | 1 |
| Galbis-Reig, D | 1 |
| McLaughlin, MF | 1 |
| Carrero, ND | 1 |
| Bain, PA | 1 |
| Chatterjee, A | 2 |
| Bandara, S | 2 |
| Merritt, S | 2 |
| Ching, JH | 1 |
| Trafton, JA | 9 |
| Salomon, JA | 1 |
| Arya, S | 1 |
| Aggarwal, N | 1 |
| Kumar, V | 1 |
| Rathee, S | 1 |
| Rani, M | 1 |
| Madaan, N | 1 |
| Malik, G | 1 |
| Gupta, R | 2 |
| Ndimbii, J | 1 |
| Guise, A | 1 |
| Igonya, EK | 1 |
| Owiti, F | 1 |
| Strathdee, S | 1 |
| Rhodes, T | 2 |
| Kim, JY | 3 |
| James, AE | 2 |
| Kelley, D | 3 |
| Jarlenski, MP | 4 |
| Flanagan, KE | 1 |
| Lal, K | 1 |
| Blankenship, K | 1 |
| Gorji, N | 1 |
| Rork, J | 1 |
| Wiss, K | 1 |
| Barocas, J | 1 |
| Assoumou, SA | 1 |
| Poorman, E | 1 |
| Glick, SN | 2 |
| Hiser, JKD | 1 |
| Bhatraju, E | 1 |
| Stewart, RE | 1 |
| Shen, L | 2 |
| Kwon, N | 1 |
| Vigderman, J | 1 |
| Kramer, S | 1 |
| Mandell, DS | 1 |
| Candon, M | 1 |
| Lamb, R | 1 |
| Rothbard, AB | 2 |
| Novak, MD | 1 |
| MacDonald, S | 2 |
| Gold, L | 1 |
| Carter, C | 1 |
| Li, MJ | 1 |
| Okafor, CN | 1 |
| Shoptaw, SJ | 1 |
| Becker, SJ | 1 |
| Scott, K | 1 |
| Helseth, SA | 1 |
| Danko, KJ | 1 |
| Balk, EM | 1 |
| Saldanha, IJ | 1 |
| Adam, GP | 1 |
| Steele, DW | 1 |
| Park, TW | 2 |
| Sikov, J | 1 |
| dellaBitta, V | 1 |
| Saitz, R | 3 |
| Drainoni, ML | 1 |
| Rosenthal, EW | 1 |
| Short, VL | 1 |
| Cruz, Y | 1 |
| Barber, C | 1 |
| Baxter, JK | 6 |
| Abatemarco, DJ | 1 |
| Roman, AR | 1 |
| Hand, DJ | 1 |
| Fei, Z | 1 |
| Matthews, A | 1 |
| Yadav, D | 1 |
| Bhad, R | 1 |
| Rajhans, P | 1 |
| Badhan, RKS | 2 |
| Gittins, R | 2 |
| Kebriaeezadeh, A | 2 |
| Mirrahimi, B | 2 |
| Armoon, B | 1 |
| Ahounbar, E | 1 |
| Narenjiha, H | 2 |
| Salehi, M | 3 |
| Cao, DN | 1 |
| Wu, N | 1 |
| Wyse, J | 1 |
| Oldfield, B | 1 |
| Justice, A | 1 |
| Harmon-Darrow, C | 1 |
| Lertch, E | 2 |
| Monico, LB | 3 |
| Sorensen, JL | 14 |
| Jacobsen, B | 1 |
| Walcher, S | 4 |
| Görne, H | 1 |
| Backmund, M | 6 |
| Mackay, L | 1 |
| Attalla, D | 1 |
| Mackson, J | 1 |
| Doyle, MF | 1 |
| McEntyre, E | 1 |
| Attia, J | 3 |
| Oldmeadow, C | 1 |
| Murrell, T | 1 |
| Marshall, K | 1 |
| Sherstobitoff, J | 1 |
| Agin-Liebes, G | 1 |
| Bigelow, GE | 63 |
| Edwards, RR | 3 |
| Gruber, VA | 3 |
| Tompkins, DA | 3 |
| Zankl, A | 1 |
| Martin, J | 4 |
| Davey, JG | 1 |
| Osborn, DA | 1 |
| Clark, MH | 1 |
| Atkins, DN | 1 |
| Nalven, T | 1 |
| Spillane, NS | 1 |
| Schick, MR | 1 |
| Weyandt, LL | 1 |
| Hartz, SM | 1 |
| Sahrmann, JM | 1 |
| Lierheimer, S | 1 |
| Beck, O | 4 |
| Keller, T | 1 |
| Monticelli, FC | 1 |
| Böttcher, M | 1 |
| Donohue, JM | 2 |
| Tang, L | 1 |
| Ahrens, K | 1 |
| Allen, L | 1 |
| Austin, A | 1 |
| Barnes, AJ | 2 |
| Burns, M | 2 |
| Chang, CH | 1 |
| Clark, S | 2 |
| Cole, E | 1 |
| Crane, D | 1 |
| Cunningham, P | 1 |
| Idala, D | 1 |
| Junker, S | 1 |
| Lanier, P | 1 |
| Mauk, R | 1 |
| McDuffie, MJ | 1 |
| Mohamoud, S | 1 |
| Pauly, N | 1 |
| Sheets, L | 1 |
| Zivin, K | 1 |
| Kennedy, S | 1 |
| Vogler, C | 1 |
| Arnold, S | 2 |
| Surbeck, E | 1 |
| Conklen, K | 1 |
| Deshpande, M | 1 |
| Adkins, S | 1 |
| Pippin, J | 1 |
| Van Buren, S | 1 |
| Chaiton, JA | 1 |
| Ehrenfeld, L | 1 |
| Guerra, ME | 1 |
| Kimmel, SD | 2 |
| Medley, A | 1 |
| Mekideche, W | 1 |
| Paquet, M | 1 |
| Sung, M | 1 |
| You Kheang, ROO | 1 |
| Amiri, S | 4 |
| Thorn, EL | 1 |
| Conigrave, KM | 2 |
| Bastani, P | 1 |
| Charkhgard, N | 1 |
| Vaziri, A | 1 |
| Kalbermatten, C | 1 |
| Binder, H | 1 |
| Walter, M | 4 |
| Falcato, L | 2 |
| Kormann, A | 1 |
| Philip, S | 1 |
| Griffin, B | 1 |
| Brothers, TD | 1 |
| Fraser, J | 1 |
| MacAdam, E | 1 |
| Morgan, B | 1 |
| Webster, D | 1 |
| Tun, S | 1 |
| Vicknasingam, B | 2 |
| Singh, D | 1 |
| Klimas, J | 7 |
| Hamilton, MA | 1 |
| Gorfinkel, L | 3 |
| Adam, A | 1 |
| Cullen, W | 3 |
| Haas, A | 1 |
| Tong, G | 1 |
| Pogorzelska-Maziarz, M | 1 |
| Gerolamo, A | 1 |
| Hassen, N | 1 |
| Kelly, EL | 1 |
| Rising, KL | 1 |
| Wastvedt, S | 1 |
| Hodges, JS | 2 |
| Rosenthal, R | 1 |
| Curran, L | 1 |
| Meyers, SN | 1 |
| Arnold, TD | 1 |
| Wei, LC | 1 |
| Chan, HY | 1 |
| Soyka, M | 20 |
| Groß, G | 1 |
| Hallowell, BD | 1 |
| Weidele, HR | 1 |
| Daly, M | 1 |
| Chambers, LC | 1 |
| Scagos, RP | 1 |
| Gargano, L | 1 |
| McDonald, J | 1 |
| Chiang, YC | 1 |
| Chang, WC | 1 |
| Su, YT | 1 |
| Cheng, WC | 1 |
| Lane, HY | 1 |
| Ma, WL | 1 |
| Barnett, A | 1 |
| Savic, M | 1 |
| Bathish, R | 1 |
| Arunogiri, S | 2 |
| Haber, P | 3 |
| Graham, R | 1 |
| Abrahamsson, T | 1 |
| Öjehagen, A | 1 |
| Mactier, H | 8 |
| McLaughlin, P | 5 |
| Gillis, C | 2 |
| Osselton, MD | 2 |
| Lee, CS | 3 |
| Anderson, BJ | 9 |
| Leone, B | 1 |
| Di Nicola, M | 1 |
| Moccia, L | 1 |
| Pettorruso, M | 1 |
| De Risio, L | 1 |
| Nucara, G | 1 |
| Zamboni, L | 5 |
| Callea, A | 1 |
| Janiri, L | 2 |
| Cibin, M | 2 |
| Lugoboni, F | 5 |
| Brogly, SB | 6 |
| Lajkosz, K | 1 |
| Davies, G | 2 |
| Newman, A | 2 |
| Dow, K | 2 |
| Naji, L | 2 |
| Bawor, M | 9 |
| Varenbut, M | 12 |
| Daiter, J | 11 |
| Plater, C | 8 |
| Desai, D | 7 |
| MacKillop, J | 3 |
| Duan, S | 2 |
| Jin, Z | 1 |
| Ye, R | 1 |
| Tang, R | 1 |
| Gao, M | 1 |
| He, N | 1 |
| Zielinski, L | 4 |
| Bhatt, M | 5 |
| Steiner, M | 6 |
| McDermid Vaz, S | 2 |
| Strehle, J | 1 |
| Bühringer, G | 4 |
| Wittchen, HU | 7 |
| Roncero, C | 4 |
| Fuster, D | 1 |
| Palma-Álvarez, RF | 2 |
| Rodriguez-Cintas, L | 3 |
| Martinez-Luna, N | 2 |
| Álvarez, FJ | 1 |
| Newcombe, DAL | 1 |
| Somogyi, AA | 17 |
| Bochner, F | 12 |
| White, JM | 22 |
| Luo, X | 4 |
| Gong, X | 2 |
| Zhao, P | 2 |
| Zou, X | 4 |
| Ling, L | 6 |
| Pan, A | 1 |
| Zakowski, M | 1 |
| Lai, A | 1 |
| Philpot, P | 1 |
| Boucher, J | 1 |
| Meyer, A | 1 |
| Sordo, L | 1 |
| Barrio, G | 1 |
| Bravo, MJ | 1 |
| Indave, BI | 1 |
| Wiessing, L | 1 |
| Pastor-Barriuso, R | 1 |
| Saulle, R | 1 |
| Vecchi, S | 6 |
| Gowing, L | 7 |
| Shoveller, J | 2 |
| Montaner, J | 10 |
| Ding, Z | 1 |
| Wang, X | 7 |
| Zhou, X | 1 |
| Xu, Y | 1 |
| Ma, Z | 1 |
| Sun, Y | 1 |
| Jiang, M | 1 |
| Hacohen, S | 1 |
| Lamberg, S | 1 |
| Schrieber, S | 1 |
| Pieri, MC | 1 |
| Manfredini, M | 2 |
| Somaini, L | 3 |
| Gerra, G | 6 |
| Shen, J | 2 |
| Deng, Y | 1 |
| Finch, E | 5 |
| Wolff, K | 12 |
| Isbister, GK | 2 |
| Brown, AL | 1 |
| Scott, AJ | 2 |
| Calver, L | 1 |
| Kenworthy, J | 1 |
| Yi, Y | 1 |
| Brown, J | 1 |
| Maria Madrigal, A | 1 |
| Dunlop, WCN | 1 |
| Modesto-Lowe, V | 5 |
| Swiezbin, K | 1 |
| Chaplin, M | 1 |
| Hoefer, G | 1 |
| Griffin, BL | 1 |
| Stone, RH | 1 |
| Vest, KM | 1 |
| Todd, TJ | 1 |
| Lind, JN | 1 |
| Interrante, JD | 1 |
| Ailes, EC | 1 |
| Gilboa, SM | 1 |
| Khan, S | 1 |
| Frey, MT | 1 |
| Dawson, AL | 1 |
| Honein, MA | 1 |
| Dowling, NF | 1 |
| Razzaghi, H | 1 |
| Creanga, AA | 2 |
| Broussard, CS | 1 |
| Chavoustie, S | 1 |
| Frost, M | 1 |
| Snyder, O | 1 |
| Owen, J | 1 |
| Darwish, M | 1 |
| Dammerman, R | 1 |
| Sanjurjo, V | 1 |
| Linzy, S | 3 |
| Vahabzadeh, M | 3 |
| Lin, JL | 3 |
| Mezghanni, M | 3 |
| Nosova, E | 4 |
| Benéitez, MC | 1 |
| Gil-Alegre, ME | 1 |
| Law, FD | 1 |
| Diaper, AM | 1 |
| Melichar, JK | 4 |
| Coulton, S | 1 |
| Nutt, DJ | 6 |
| Myles, JS | 3 |
| Ghaderi, A | 3 |
| Banafshe, HR | 3 |
| Motmaen, M | 2 |
| Rasouli-Azad, M | 2 |
| Bahmani, F | 2 |
| Asemi, Z | 3 |
| Rindom, H | 1 |
| Højsted, J | 2 |
| Brünés, N | 1 |
| Heikman, PK | 1 |
| Muhonen, LH | 1 |
| Ojanperä, IA | 1 |
| Michels, I | 1 |
| Leeman, L | 2 |
| Bishop, S | 3 |
| Cano, S | 1 |
| Bakhireva, LN | 2 |
| Yoo, SH | 1 |
| Jansson, LM | 14 |
| Park, HJ | 1 |
| Do, HP | 1 |
| Thi Nguyen, NP | 1 |
| Ngo, C | 1 |
| Thi Nguyen, HL | 2 |
| Le, GT | 1 |
| Nguyen, LK | 1 |
| Le, HT | 2 |
| Vu, TMT | 1 |
| Phan, HTT | 1 |
| Tran, TD | 2 |
| Dunne, MP | 1 |
| Kringen, MK | 1 |
| Bernard, JP | 2 |
| Molden, E | 1 |
| Guan, Q | 3 |
| Khuu, W | 2 |
| Martins, D | 3 |
| Andrew Tompkins, D | 1 |
| Aghakhani, N | 1 |
| Lopez, V | 1 |
| Cleary, M | 1 |
| Wilder, CM | 3 |
| Hosta, D | 1 |
| Garami, J | 1 |
| Myers, CE | 1 |
| Allen, MT | 1 |
| Misiak, B | 1 |
| Frydecka, D | 1 |
| Moustafa, AA | 1 |
| Burt, R | 1 |
| Thiede, H | 1 |
| Chernova, O | 1 |
| Morozova, O | 2 |
| Kosloski, MP | 1 |
| Zhao, W | 1 |
| Asatryan, A | 1 |
| Kort, J | 1 |
| Geoffroy, P | 2 |
| Liu, W | 2 |
| Lucas, P | 1 |
| Simeone, C | 1 |
| Lum, PJ | 3 |
| Johnson, S | 2 |
| Martin, PR | 20 |
| Marie-Claire, C | 1 |
| Jourdaine, C | 1 |
| Lépine, JP | 3 |
| Bellivier, F | 3 |
| Bloch, V | 3 |
| Vorspan, F | 3 |
| Livingston, JD | 1 |
| Adams, E | 1 |
| Jordan, M | 1 |
| MacMillan, Z | 1 |
| Hering, R | 1 |
| McElrath, K | 3 |
| Hickish, T | 1 |
| Parker, A | 1 |
| Liang, WJ | 1 |
| Velez, ML | 1 |
| McConnell, K | 1 |
| Spencer, N | 1 |
| Tuten, M | 5 |
| Rios, R | 1 |
| King, VL | 20 |
| Gandotra, N | 2 |
| Millio, L | 1 |
| DiPietro, JA | 4 |
| Christiansen, S | 1 |
| Adeniyi-Jones, SC | 1 |
| Ehrlich, ME | 1 |
| Whalen, B | 2 |
| MacMillan, K | 1 |
| Edwards, W | 1 |
| Grossman, MR | 2 |
| Berkwitt, AK | 1 |
| Osborn, RR | 1 |
| Ti, L | 2 |
| Ayutthaya, PPN | 1 |
| Suwannawong, P | 3 |
| Kaplan, K | 3 |
| Zheng, F | 1 |
| Zeljic, K | 1 |
| Pan, J | 1 |
| Farnia, V | 2 |
| Tatari, F | 1 |
| Alikhani, M | 2 |
| Yazdchi, K | 1 |
| Taghizadeh, M | 1 |
| Sadeghi Bahmani, D | 2 |
| Karbasizadeh, H | 1 |
| Holsboer-Trachsler, E | 2 |
| Brand, S | 2 |
| Mijatović, V | 2 |
| Samojlik, I | 2 |
| Petković, S | 2 |
| Vukmirović, S | 1 |
| Uvelin, A | 1 |
| Dickov, A | 1 |
| Ivers, JH | 2 |
| Zgaga, L | 1 |
| Sweeney, B | 3 |
| Darker, C | 2 |
| Smyth, BP | 7 |
| Lee, SS | 2 |
| Newman, R | 3 |
| Zhang, HS | 1 |
| Xu, YM | 1 |
| Zhu, JH | 1 |
| Zhong, BL | 1 |
| Farnum, S | 1 |
| Barry, D | 2 |
| Ivanchuk, I | 1 |
| Kolomiets, V | 1 |
| Filippovych, S | 2 |
| Russolillo, A | 4 |
| Moniruzzaman, A | 5 |
| Patterson, M | 2 |
| Somers, JM | 5 |
| Zhou, K | 3 |
| Jia, P | 1 |
| Bhargava, S | 1 |
| Reza, T | 1 |
| Peng, YB | 1 |
| Wang, GG | 1 |
| Lagisetty, P | 1 |
| Klasa, K | 1 |
| Bush, C | 1 |
| Heisler, M | 1 |
| Chopra, V | 1 |
| Bohnert, A | 1 |
| Tolia, VN | 1 |
| Murthy, K | 1 |
| Bennett, MM | 1 |
| Benjamin, DK | 1 |
| Smith, PB | 1 |
| Clark, RH | 1 |
| Elsayed, M | 2 |
| Espinoza, D | 2 |
| Veillard, AS | 2 |
| Hallinan, R | 8 |
| Lu, SE | 1 |
| Richter, KP | 5 |
| Bernstein, SL | 3 |
| Williams, JM | 2 |
| Winetsky, D | 1 |
| Weinrieb, RM | 2 |
| Akhgari, M | 1 |
| Amini-Shirazi, N | 1 |
| Iravani, FS | 1 |
| Bryson, WC | 3 |
| Bruce, ML | 2 |
| Lemon, LS | 3 |
| Caritis, SN | 2 |
| Venkataramanan, R | 2 |
| Bodnar, LM | 2 |
| Ali, N | 1 |
| Aziz, SA | 1 |
| Nordin, S | 1 |
| Mi, NC | 1 |
| Abdullah, N | 1 |
| Paranthaman, V | 1 |
| Mahmud, M | 1 |
| Yee, A | 6 |
| Danaee, M | 3 |
| Yu, KC | 1 |
| Wei, HT | 1 |
| Yeh, YH | 1 |
| Hsu, CH | 1 |
| Mehta, PK | 1 |
| Faherty, LJ | 1 |
| Regan, E | 2 |
| Fadli, E | 1 |
| Hahn, KA | 1 |
| Evans, E | 6 |
| Urada, D | 4 |
| Anglin, MD | 7 |
| Rawson, RA | 9 |
| Rezapour, T | 1 |
| Hatami, J | 1 |
| Farhoudian, A | 1 |
| Daneshmand, R | 1 |
| Samiei, A | 1 |
| Fonseca, F | 8 |
| Qin, S | 1 |
| Luo, Z | 1 |
| Hu, P | 2 |
| Liu, Z | 2 |
| Bogdanowicz, KM | 1 |
| Stewart, R | 1 |
| Chang, CK | 1 |
| Shetty, H | 1 |
| Khondoker, M | 1 |
| Hayes, RD | 1 |
| Dematteis, M | 1 |
| Auriacombe, M | 5 |
| D'Agnone, O | 1 |
| Szerman, N | 1 |
| Littlewood, R | 1 |
| Alho, H | 7 |
| Benyamina, A | 1 |
| Bobes, J | 4 |
| Daulouede, JP | 3 |
| Leonardi, C | 1 |
| Maremmani, I | 7 |
| Chang, DC | 1 |
| Federico, A | 1 |
| Tamburin, S | 2 |
| Picher, CE | 1 |
| Feder, KA | 2 |
| Joseph, H | 12 |
| Groh, A | 2 |
| Jahn, K | 1 |
| Burkert, A | 1 |
| Neyazi, A | 1 |
| Schares, L | 1 |
| Janke, E | 1 |
| Rehme, M | 1 |
| Schuster, R | 2 |
| Hillemacher, T | 3 |
| Bleich, S | 2 |
| Frieling, H | 2 |
| Heberlein, A | 2 |
| Woods, JS | 4 |
| Khosravi, N | 1 |
| Zamani, N | 1 |
| Hassanian-Moghaddam, H | 1 |
| Ostadi, A | 1 |
| Rahimi, M | 1 |
| Kabir, A | 1 |
| Kelly, MM | 1 |
| Reilly, E | 1 |
| Quiñones, T | 1 |
| Desai, N | 1 |
| Buono, FD | 1 |
| Printz, DMB | 1 |
| Lloyd, DP | 1 |
| Cutter, CJ | 9 |
| Schottenfeld, RS | 20 |
| Bogen, DL | 5 |
| Hanusa, BH | 4 |
| Baker, R | 2 |
| Medoff-Cooper, B | 1 |
| Cohlan, B | 1 |
| Loh, HS | 3 |
| Riahi, S | 1 |
| Ng, CG | 3 |
| Sulaiman, AH | 2 |
| Farahmand, P | 1 |
| Chaplin, MM | 1 |
| Reddon, H | 1 |
| Ho, J | 2 |
| Carney, BL | 1 |
| Majer, JM | 2 |
| Beasley, C | 1 |
| Stecker, E | 1 |
| Bobak, TJ | 1 |
| Norris, J | 1 |
| Nguyen, HM | 1 |
| Ogata, M | 1 |
| Siegel, J | 1 |
| Wiedbusch, E | 1 |
| Dovale, I | 1 |
| Gelfman, N | 1 |
| Callahan, S | 1 |
| Shah, A | 1 |
| Duncan, M | 1 |
| Atreja, N | 1 |
| Tai, KS | 1 |
| Gore, M | 1 |
| McGlothen, KS | 1 |
| Cleveland, LM | 1 |
| Gill, SL | 1 |
| Gilbert, A | 1 |
| Dechairo, BM | 1 |
| Martínez-Luna, NG | 1 |
| Esojo, A | 1 |
| Robles-Martínez, M | 1 |
| Grau-López, L | 2 |
| Perea, M | 1 |
| Neale, J | 2 |
| Tompkins, CNE | 2 |
| Fredheim, OMS | 1 |
| Shahid, H | 3 |
| Bantoto, B | 1 |
| Samaan, MC | 3 |
| de Souza, R | 2 |
| Streck, JM | 1 |
| Heil, SH | 21 |
| Higgins, ST | 8 |
| Bunn, JY | 1 |
| Mannaioni, G | 1 |
| Lanzi, C | 1 |
| Lotti, M | 1 |
| Galli, V | 1 |
| Totti, A | 1 |
| Pacileo, I | 1 |
| Sili, M | 1 |
| Pracucci, C | 1 |
| Dilaghi, A | 1 |
| Bertieri, L | 1 |
| Quaranta, M | 1 |
| Orsini, F | 1 |
| Occupati, B | 1 |
| Michahelles, A | 1 |
| Ciuti, R | 1 |
| Bianchini, E | 1 |
| Fabbro, G | 1 |
| Biggeri, A | 1 |
| Masini, E | 1 |
| Moroni, F | 1 |
| Brinkley-Rubinstein, L | 2 |
| Macmadu, A | 1 |
| Zaller, N | 3 |
| Dauria, E | 1 |
| Rich, J | 2 |
| Kaltenbach, K | 21 |
| Coyle, MG | 16 |
| Fischer, G | 30 |
| Stine, S | 2 |
| Alammehrjerdi, Z | 1 |
| Ezard, N | 1 |
| Dolan, K | 4 |
| Herzman-Harari, S | 1 |
| Teklezgi, BG | 1 |
| Pamreddy, A | 1 |
| Baijnath, S | 1 |
| Kruger, HG | 1 |
| Naicker, T | 1 |
| Gopal, ND | 1 |
| Govender, T | 1 |
| Kouyoumdjian, FG | 1 |
| To, MJ | 1 |
| Kurdyak, P | 3 |
| Jacob, B | 1 |
| Zaheer, J | 1 |
| Clarke, J | 5 |
| Alexander-Scott, N | 1 |
| Boss, R | 1 |
| Quanbeck, AR | 1 |
| Freeman, RM | 1 |
| Ball, SA | 5 |
| Shi, JM | 2 |
| Savage, ME | 2 |
| Ahmad, T | 2 |
| Valentovic, MA | 1 |
| Rankin, GO | 2 |
| de Cordé, A | 1 |
| Krząścik, P | 1 |
| Wolińska, R | 1 |
| Kleczkowska, P | 1 |
| Filip, M | 1 |
| Bujalska-Zadrożny, M | 1 |
| Filippovich, S | 1 |
| Nguyen, L | 1 |
| Lander, LR | 1 |
| Marshalek, PJ | 1 |
| Schmidt, A | 1 |
| Kelly, AK | 1 |
| Duan, LX | 1 |
| Li, XL | 3 |
| Hu, PW | 1 |
| Chen, YY | 1 |
| Haycraft, AL | 1 |
| Lan, CW | 1 |
| Rou, K | 11 |
| McLinden, T | 1 |
| Moodie, EEM | 1 |
| Hamelin, AM | 1 |
| Harper, S | 2 |
| Rossi, C | 1 |
| Walmsley, SL | 1 |
| Rourke, SB | 1 |
| Cooper, C | 1 |
| Klein, MB | 1 |
| Cox, J | 2 |
| Su, MK | 1 |
| Lopez, JH | 1 |
| Crossa, A | 1 |
| Hoffman, RS | 1 |
| Boggiano, VL | 1 |
| Nguyen, HV | 1 |
| Hoang, CD | 1 |
| Le, HQ | 1 |
| Thi Vu, TM | 1 |
| Zhang, MW | 1 |
| Ho, RC | 1 |
| Li, DJ | 1 |
| Chung, KS | 1 |
| Wu, HC | 1 |
| Hsu, CY | 1 |
| Yen, CF | 2 |
| Pierce, M | 2 |
| Millar, T | 3 |
| Brockbals, L | 1 |
| Staeheli, SN | 1 |
| Gascho, D | 1 |
| Ebert, LC | 1 |
| Kraemer, T | 1 |
| Steuer, AE | 1 |
| Holt, SR | 2 |
| Donroe, JH | 2 |
| Cavallo, DA | 1 |
| Nnoli, A | 1 |
| Seligman, NS | 4 |
| Dysart, K | 1 |
| Ballas, SK | 1 |
| Karki, P | 2 |
| Bansback, N | 1 |
| Guh, D | 4 |
| Oviedo-Joekes, E | 9 |
| Harrison, S | 2 |
| Janmohamed, A | 1 |
| Schechter, MT | 8 |
| Anis, AH | 6 |
| Hicks, J | 1 |
| Morse, E | 1 |
| Wyant, DK | 1 |
| Parpouchi, M | 1 |
| Rezansoff, SN | 2 |
| Muller, AE | 1 |
| Bjørnestad, R | 1 |
| Philipp, B | 1 |
| Joseph, K | 1 |
| Shrestha, H | 2 |
| Parker, MGK | 1 |
| Sutlovic, D | 2 |
| Kljucevic, Z | 2 |
| Sliskovic, L | 1 |
| Susnjar, H | 1 |
| Viskovic, I | 1 |
| Definis-Gojanovic, M | 1 |
| Steer, C | 1 |
| Tilling, K | 1 |
| Lim, AG | 1 |
| Telfer, M | 1 |
| Vickerman, P | 4 |
| Macleod, J | 6 |
| Ghaddar, A | 1 |
| Khandaqji, S | 1 |
| Abbass, Z | 1 |
| Peterson, BL | 1 |
| Fumo, N | 1 |
| Brooke Lerner, E | 1 |
| Maglione, MA | 1 |
| Raaen, L | 1 |
| Azhar, G | 1 |
| Shahidinia, N | 1 |
| Shen, M | 1 |
| Maksabedian, E | 1 |
| Shanman, RM | 1 |
| Newberry, S | 1 |
| Hempel, S | 1 |
| Peirce, J | 7 |
| Graham, DP | 1 |
| El Hage, C | 1 |
| Ghabrash, MF | 1 |
| Dubreucq, S | 1 |
| Lespérance, F | 1 |
| Lespérance, P | 1 |
| Ouellet-Plamondon, C | 1 |
| Behrouzi, MK | 1 |
| Bazrafshan, MR | 1 |
| Rahmati, M | 1 |
| Burnette, T | 1 |
| Chernicky, L | 1 |
| Towers, CV | 2 |
| Oueslati, B | 1 |
| Moula, O | 1 |
| Ghachem, R | 1 |
| Burgos, JL | 1 |
| Kahn, JG | 1 |
| Meza, E | 1 |
| Lazos, RRP | 1 |
| Vargas, PC | 1 |
| Strathdee, SA | 2 |
| Martin, NK | 1 |
| Aukštakalnis, R | 1 |
| Jurgelevičius, T | 1 |
| Ward, EN | 1 |
| Quaye, AN | 1 |
| Schiavon, S | 1 |
| Hodgin, K | 1 |
| Sellers, A | 1 |
| Word, M | 1 |
| Galbraith, JW | 1 |
| Dantzler, J | 2 |
| Cropsey, KL | 2 |
| Khazaee-Pool, M | 1 |
| Moeeni, M | 2 |
| Ponnet, K | 1 |
| Fallahi, A | 1 |
| Jahangiri, L | 1 |
| Pashaei, T | 2 |
| Metrebian, N | 2 |
| Weaver, T | 1 |
| Pilling, S | 1 |
| Hellier, J | 2 |
| Byford, S | 2 |
| Shearer, J | 3 |
| Astbury, M | 1 |
| Bijral, P | 1 |
| Bogdan, N | 1 |
| Bowden-Jones, O | 1 |
| Forshall, S | 1 |
| Glasper, A | 4 |
| Morse, G | 1 |
| Akhtar, S | 1 |
| Bajaria, J | 1 |
| Bennett, C | 1 |
| Bishop, E | 1 |
| Charles, V | 1 |
| Davey, C | 1 |
| Desai, R | 1 |
| Goodfellow, C | 1 |
| Haque, F | 1 |
| Little, N | 1 |
| McKechnie, H | 1 |
| Morris, J | 2 |
| Mosler, F | 1 |
| Mutz, J | 1 |
| Pauli, R | 1 |
| Poovendran, D | 1 |
| Slater, E | 1 |
| Pincus, HA | 1 |
| Johnson, KA | 1 |
| Campbell, AN | 1 |
| Remien, RH | 1 |
| Olfson, M | 1 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Dick, AW | 3 |
| Sorbero, M | 3 |
| Burns, RM | 3 |
| Leslie, DL | 2 |
| Pacula, RL | 3 |
| Wang, RJ | 1 |
| Su, MF | 1 |
| Liu, MX | 1 |
| Li, JQ | 1 |
| Ilgen, M | 1 |
| Mirhosseini, N | 1 |
| Mehrzad, F | 1 |
| Aghadavod, E | 1 |
| Mansournia, MA | 1 |
| Reiter, RJ | 1 |
| Karimi, MA | 1 |
| Buntin, MB | 1 |
| Scott, TA | 1 |
| Dupont, W | 1 |
| Richards, M | 1 |
| Cooper, WO | 1 |
| Streisel, SE | 1 |
| Van Hout, MC | 1 |
| Crowley, D | 1 |
| McBride, A | 1 |
| Delargy, I | 2 |
| Pirnia, B | 1 |
| Pirnia, K | 1 |
| Mohammadpour, S | 1 |
| Malekanmehr, P | 1 |
| Soleimani, A | 2 |
| Mahmoodi, Z | 1 |
| Soleimani, AA | 1 |
| Zahiroddin, A | 1 |
| Assanangkornchai, S | 3 |
| Cai, L | 1 |
| Tang, S | 1 |
| McNeil, EB | 1 |
| Chongsuvivatwong, V | 2 |
| Botticelli, M | 1 |
| Alexander, GC | 1 |
| Voon, P | 3 |
| Greer, AM | 1 |
| Amlani, A | 1 |
| Newman, C | 1 |
| Burmeister, C | 1 |
| Hood, M | 1 |
| LaRochelle, M | 1 |
| Bishop, B | 1 |
| Gilmour, J | 1 |
| Deering, D | 4 |
| Blackney, KA | 1 |
| Kamdar, NV | 1 |
| Liu, CA | 1 |
| Edwards, DA | 1 |
| Horn, BP | 1 |
| Mamun, S | 1 |
| McCrady, B | 1 |
| French, MT | 2 |
| Lohman, MC | 1 |
| Brooks, JM | 1 |
| Sewak, R | 1 |
| Spielholz, NI | 1 |
| Aschenbrenner, DS | 1 |
| Chen, HJ | 1 |
| Wang, JY | 1 |
| Lee, TE | 1 |
| Lee, HY | 2 |
| Hung, CC | 1 |
| Gauthier, G | 2 |
| Eibl, JK | 3 |
| Molero, Y | 1 |
| Zetterqvist, J | 1 |
| Hellner, C | 1 |
| Larsson, H | 1 |
| Fazel, S | 1 |
| Mattick, RP | 26 |
| Harrison, TK | 1 |
| Kornfeld, H | 1 |
| Aggarwal, AK | 1 |
| Lembke, A | 1 |
| Yang, YT | 1 |
| Gandotra, J | 1 |
| McDonell, MG | 3 |
| Roll, JM | 5 |
| Belackova, V | 1 |
| Shirooie, S | 1 |
| Sahebgharani, M | 1 |
| Esmaeili, J | 1 |
| Dehpour, AR | 1 |
| Johnson, Q | 1 |
| Mund, B | 1 |
| Saia, KE | 1 |
| Warden, AH | 1 |
| Thomas, Z | 1 |
| Thomas-Lewis, JA | 1 |
| Nikita, FNU | 1 |
| Martin, RA | 1 |
| Gresko, SA | 1 |
| Rodean, J | 1 |
| Levy, S | 2 |
| Zima, BT | 1 |
| Nordt, C | 3 |
| Dey, M | 1 |
| Moldovanyi, A | 2 |
| Beck, T | 4 |
| Berthel, T | 2 |
| Seifritz, E | 3 |
| Herdener, M | 3 |
| Broglio, K | 1 |
| Matzo, M | 1 |
| Matłosz, B | 1 |
| Pietraszkiewicz, E | 1 |
| Firląg-Burkacka, E | 1 |
| Grycner, E | 1 |
| Horban, A | 1 |
| Kowalska, JD | 1 |
| Wang, MJ | 1 |
| Kuper, SG | 1 |
| Sims, B | 1 |
| Paddock, CS | 1 |
| Muir, S | 1 |
| Harper, LM | 1 |
| Shulha, HP | 1 |
| Liu, S | 1 |
| Wiese, AD | 1 |
| Griffin, MR | 1 |
| Schaffner, W | 1 |
| Stein, CM | 1 |
| Greevy, RA | 1 |
| Mitchel, EF | 1 |
| Grijalva, CG | 1 |
| Lo, A | 1 |
| Coker, JL | 1 |
| Catlin, D | 1 |
| Ray-Griffith, S | 1 |
| Knight, B | 1 |
| Stowe, ZN | 1 |
| Meyer, J | 2 |
| Sproule, BA | 4 |
| Vigod, SN | 1 |
| Cadarette, SM | 1 |
| Greaves, S | 1 |
| Andrews, P | 1 |
| Nieves-McGrath, H | 1 |
| Reynolds, A | 1 |
| Sylvester, C | 1 |
| Dickerson, SS | 1 |
| Hirchak, K | 1 |
| McPherson, SM | 1 |
| Stimmel, MA | 1 |
| Bowe, T | 1 |
| Proctor, SL | 3 |
| Herschman, PL | 3 |
| Lee, R | 1 |
| Kopak, AM | 3 |
| Higgins, C | 2 |
| Smith, BH | 2 |
| Matthews, K | 4 |
| Kidorf, MS | 9 |
| Toce, MS | 1 |
| Chai, PR | 1 |
| Burns, MM | 1 |
| Boyer, EW | 1 |
| Azar, P | 1 |
| Miles, I | 1 |
| Schlienz, NJ | 1 |
| Speed, TJ | 1 |
| Antoine, DG | 1 |
| LaLiberte, B | 1 |
| Lundahl, LH | 2 |
| Nellhaus, EM | 1 |
| Murray, S | 1 |
| Hansen, Z | 1 |
| Rose-Jacobs, R | 1 |
| Trevino-Talbot, M | 1 |
| Lloyd-Travaglini, C | 1 |
| Cabral, HJ | 1 |
| Vibbert, M | 1 |
| Peters, L | 1 |
| O'Byrne, P | 1 |
| Jeske Pearson, C | 1 |
| Park, SE | 1 |
| Pollack, HA | 2 |
| Ahmed, MS | 1 |
| Moran, L | 1 |
| Elmusharaf, K | 1 |
| Kerns, RD | 3 |
| Oberleitner, L | 2 |
| Liong, C | 3 |
| Ginn, J | 2 |
| Shams, I | 2 |
| Luo, C | 2 |
| Tam, SL | 1 |
| Monnelly, VJ | 1 |
| Hamilton, R | 1 |
| Chappell, FM | 1 |
| Boardman, JP | 1 |
| Janíková, B | 1 |
| Drbohlavová, B | 1 |
| Popov, P | 2 |
| Pirona, A | 1 |
| Gordon, MS | 3 |
| Weiss, O | 1 |
| Levy-Gigi, E | 2 |
| Slowiczek, L | 1 |
| Hein, DJ | 1 |
| Risoldi Cochrane, Z | 1 |
| Gregory, PJ | 1 |
| Hou, JY | 1 |
| Cao, XB | 1 |
| Wong, JJ | 1 |
| Ellerbe, LS | 1 |
| Rubinsky, A | 1 |
| Gupta, S | 2 |
| Bowe, TR | 1 |
| Schmidt, EM | 1 |
| Burden, JL | 1 |
| Kaplan, L | 1 |
| Hodgins, FE | 1 |
| Lang, JM | 1 |
| Malseptic, GG | 1 |
| Melby, LH | 1 |
| Connolly, KA | 1 |
| Benzon, B | 1 |
| Ključević, N | 1 |
| Veršić Bratinčević, M | 1 |
| Rush, AJ | 2 |
| Volkow, N | 1 |
| James, DL | 1 |
| Jowza, M | 1 |
| Peeler, M | 1 |
| Fiscella, K | 2 |
| Barelli, R | 1 |
| Morelli Sbarra, G | 1 |
| Sbaraglia, F | 1 |
| Zappia, L | 1 |
| Rossi, M | 1 |
| Taremian, F | 1 |
| Nazari, S | 1 |
| Moradveisi, L | 1 |
| Moloodi, R | 1 |
| Hollander, MAG | 1 |
| Cole, ES | 1 |
| Markazi Moghaddam, N | 1 |
| Goudarzi, N | 1 |
| Mahic, M | 1 |
| Chang, KC | 1 |
| Lin, CY | 1 |
| Chang, CC | 1 |
| Ting, SY | 1 |
| Cheng, CM | 1 |
| Wang, JD | 1 |
| Chadi, A | 1 |
| Chadi, N | 1 |
| Roy, P | 1 |
| Carter, LC | 1 |
| Read, MA | 1 |
| Read, L | 1 |
| Nicholas, JS | 1 |
| Schmidt, E | 1 |
| Mouravska, N | 1 |
| Luetam, S | 1 |
| Hudson, J | 1 |
| Rodriguez, CE | 1 |
| Jones, AA | 1 |
| Dhingra, LK | 1 |
| Fucito, L | 1 |
| Camenga, D | 1 |
| Bollampally, P | 1 |
| Chen, CY | 1 |
| Wang, IA | 1 |
| Fang, SY | 1 |
| Huang, N | 1 |
| Tsay, JH | 1 |
| Chang, SH | 1 |
| Kunøe, N | 2 |
| Moore, KE | 1 |
| Roberts, W | 1 |
| Reid, HH | 1 |
| Smith, KMZ | 1 |
| McKee, SA | 1 |
| Schmith, VD | 1 |
| Curd, L | 1 |
| Lohmer, LRL | 1 |
| Laffont, CM | 1 |
| Andorn, A | 1 |
| Young, MA | 1 |
| Ling, S | 1 |
| Mangaoil, R | 1 |
| Cleverley, K | 1 |
| Puts, M | 1 |
| Witt, L | 1 |
| Butler, F | 1 |
| Ward, HB | 1 |
| Barnett, BS | 1 |
| Chen, T | 1 |
| O'Brien, L | 1 |
| Watson, L | 1 |
| Verstuyft, C | 1 |
| Bouquié, R | 1 |
| Laforgue, EJ | 1 |
| Hardouin, JB | 1 |
| Le Geay, B | 1 |
| Dano, C | 1 |
| Levin, J | 1 |
| Gollust, SE | 1 |
| Giacomuzzi, SM | 4 |
| Ruckes, C | 3 |
| Akiyama, MJ | 1 |
| Norton, BL | 1 |
| Agyemang, L | 1 |
| Heo, M | 2 |
| Litwin, AH | 6 |
| Moore, K | 2 |
| Magee, M | 1 |
| Sevinsky, H | 1 |
| Chang, M | 2 |
| Lubin, S | 1 |
| Myers, E | 1 |
| Ackerman, P | 1 |
| Llamoso, C | 1 |
| van den Brink, W | 9 |
| Blanken, P | 2 |
| van Ree, JM | 4 |
| Landau, R | 1 |
| Jordan, CJ | 1 |
| Cao, J | 1 |
| Artenie, AA | 1 |
| Minoyan, N | 1 |
| Jacka, B | 1 |
| Høj, S | 1 |
| Roy, É | 1 |
| Gauvin, L | 1 |
| Zang, G | 1 |
| Srivastava, A | 4 |
| McAndrew, A | 1 |
| Leshner, AI | 1 |
| Dzau, VJ | 1 |
| Richert, T | 6 |
| Gastberger, S | 1 |
| Baumgartner, MR | 1 |
| Quednow, BB | 1 |
| Hulka, LM | 1 |
| Mutschler, J | 1 |
| Jancaitis, B | 1 |
| Kelpin, S | 1 |
| Masho, S | 1 |
| May, J | 1 |
| Haug, NA | 5 |
| Svikis, D | 1 |
| Ebrahimi, A | 1 |
| Golshani, S | 1 |
| Wood, C | 1 |
| Horn, P | 1 |
| Green, L | 4 |
| Rudder, T | 1 |
| Korownyk, C | 1 |
| Perry, D | 1 |
| Ton, J | 1 |
| Kolber, MR | 1 |
| Garrison, S | 1 |
| Thomas, B | 1 |
| Allan, GM | 2 |
| Dugré, N | 1 |
| Finley, CR | 1 |
| Ting, R | 1 |
| Yang, PR | 1 |
| Vandermeer, B | 1 |
| Lindblad, AJ | 1 |
| Lei, S | 1 |
| Hong, L | 1 |
| Zhang, S | 1 |
| Huang, S | 1 |
| Xie, R | 1 |
| Ma, Q | 1 |
| Dervaux, A | 1 |
| Plancke, L | 1 |
| Amariei, A | 1 |
| Trouiller, P | 1 |
| Tahon, M | 1 |
| Martinetti, MP | 2 |
| Naassila, M | 1 |
| Cottencin, O | 3 |
| Danel, T | 1 |
| Khalilieh, S | 1 |
| Yee, KL | 1 |
| Sanchez, RI | 1 |
| Vaynshteyn, K | 1 |
| Fan, L | 2 |
| Searle, S | 1 |
| Bouhajib, M | 1 |
| Iwamoto, M | 2 |
| Al Zabit, D | 1 |
| McCarthy, JF | 1 |
| Morley, KC | 1 |
| Otuonye, IS | 1 |
| Banken, R | 1 |
| Kumar, VM | 1 |
| Pearson, SD | 1 |
| Westin, AA | 1 |
| Skogvoll, E | 2 |
| Spigset, O | 3 |
| Moeller, SJ | 1 |
| Abi-Dargham, A | 1 |
| DeVito, EE | 1 |
| Nich, C | 4 |
| Babu, KM | 1 |
| Brent, J | 1 |
| Juurlink, DN | 3 |
| Frauger, E | 3 |
| Fouilhé Sam-Laï, N | 1 |
| Mallaret, M | 1 |
| Micallef, J | 5 |
| Labuz, K | 1 |
| Adamowicz, P | 1 |
| Kała, M | 1 |
| Pyrc, K | 1 |
| Reszke, E | 1 |
| Mielczarek, P | 1 |
| Silberring, J | 1 |
| Smoluch, M | 1 |
| Rausgaard, NLK | 1 |
| Ibsen, IO | 1 |
| Jørgensen, JS | 1 |
| Lamont, RF | 1 |
| Ravn, P | 1 |
| Williams, N | 4 |
| Bossert, N | 1 |
| Jaanimägi, U | 2 |
| Kline, RJ | 1 |
| Robichaux, SL | 1 |
| Green, JB | 1 |
| Anyama, BC | 1 |
| Gennuso, SA | 1 |
| Okereke, EC | 1 |
| Cooney, H | 1 |
| Hodgson, K | 1 |
| Davis, P | 4 |
| Cleary, B | 1 |
| Loane, M | 1 |
| Addor, MC | 1 |
| Barisic, I | 1 |
| de Walle, HEK | 1 |
| Matias Dias, C | 1 |
| Gatt, M | 1 |
| Klungsoyr, K | 1 |
| McDonnell, B | 1 |
| Neville, A | 1 |
| Pierini, A | 1 |
| Rissmann, A | 1 |
| Tucker, DF | 1 |
| Zurriaga, O | 1 |
| Dolk, H | 1 |
| Hamilton, KR | 1 |
| Kozak, ZK | 1 |
| Welsh, CJ | 1 |
| Birditt, KS | 1 |
| Feng, N | 1 |
| Wu, Z | 17 |
| Lutz, RB | 1 |
| Roux, P | 10 |
| Morel, A | 8 |
| Wolfe, D | 1 |
| Carrieri, P | 1 |
| Sun, T | 1 |
| Wachholtz, A | 2 |
| Gonzalez, G | 2 |
| Ziedonis, D | 6 |
| Nagarajan, S | 1 |
| Wong, A | 1 |
| Greene, SL | 1 |
| Koutsogiannis, Z | 1 |
| Bech, AB | 1 |
| Waal, H | 18 |
| Šaltytė Benth, J | 1 |
| Skeie, I | 2 |
| Laes, JR | 1 |
| Wiegand, TJ | 1 |
| Chandra, DK | 1 |
| Nahaboo Solim, MA | 1 |
| Lancaster, K | 1 |
| Heydari, Z | 1 |
| Baneshi, MR | 2 |
| Sharifi, H | 1 |
| Zamanian, M | 1 |
| Haji-Maghsoudi, S | 1 |
| Zolala, F | 1 |
| Carr, DH | 1 |
| Nixon, LL | 1 |
| Marlinga, JC | 1 |
| Hayden, KA | 1 |
| Mrklas, KJ | 1 |
| Reichheld, AM | 1 |
| Hills-Evans, K | 1 |
| Sheehan, JK | 1 |
| Tocci, NX | 1 |
| Tandon, M | 1 |
| Hsu, D | 1 |
| O'Donoghue, S | 1 |
| Stevens, JP | 1 |
| Mahu, IT | 1 |
| Conrod, PJ | 1 |
| Barrett, SP | 2 |
| Sako, A | 1 |
| Swansburg, J | 1 |
| Lawrence, M | 1 |
| Laroque, F | 1 |
| Morin, JF | 1 |
| Chinneck, A | 1 |
| Nogueira-Arjona, R | 1 |
| Stewart, SH | 2 |
| Higgins, TM | 1 |
| Goodman, DJ | 2 |
| Meyer, MC | 2 |
| Schroeder, JR | 3 |
| Vahed, N | 1 |
| Omidi, A | 1 |
| Ghoreishi, FS | 2 |
| Spada, M | 1 |
| Kmiec, J | 1 |
| Glance, JB | 1 |
| Gopalan, P | 1 |
| Koehl, JL | 1 |
| Zimmerman, DE | 1 |
| Bridgeman, PJ | 1 |
| Dave, CV | 1 |
| Goodin, A | 1 |
| Winterstein, A | 1 |
| Alrwisan, A | 1 |
| Rieckmann, T | 2 |
| Cousins, S | 1 |
| McCann, M | 2 |
| Pearce, R | 1 |
| Kinsky, S | 1 |
| Houck, PR | 1 |
| Mayes, K | 1 |
| Loveland, D | 1 |
| Daley, D | 1 |
| Schuster, JM | 1 |
| Paterno, MT | 1 |
| Jablonski, L | 1 |
| Klepacki, A | 1 |
| Katz, E | 2 |
| Weitz, B | 1 |
| Visconti, K | 1 |
| Riquelme, M | 1 |
| Peyrière, H | 1 |
| Eschalier, A | 1 |
| Ardid, D | 1 |
| Wickersham, JA | 4 |
| Zahari, MM | 1 |
| Azar, MM | 1 |
| Pilgrim, JL | 1 |
| McDonough, M | 1 |
| Drummer, OH | 1 |
| Taplin, S | 1 |
| Cerovečki, V | 1 |
| Tiljak, H | 1 |
| Ožvačić Adžić, Z | 1 |
| Križmarić, M | 1 |
| Pregelj, P | 1 |
| Kastelic, A | 3 |
| Nik Jaafar, NR | 1 |
| Mislan, N | 1 |
| Abdul Aziz, S | 1 |
| Baharudin, A | 1 |
| Ibrahim, N | 1 |
| Midin, M | 1 |
| Das, S | 1 |
| Sidi, H | 1 |
| Ferroni, E | 1 |
| Reece, AS | 4 |
| Hulse, GK | 3 |
| Neumann, AM | 1 |
| Blondell, RD | 3 |
| Giambrone, AK | 1 |
| Homish, GG | 1 |
| Lozano, JR | 1 |
| Kowalik, U | 1 |
| Azadfard, M | 1 |
| Zirakzadeh, A | 1 |
| Shuman, C | 1 |
| Stauter, E | 1 |
| Hays, JT | 1 |
| Ebbert, JO | 1 |
| Serpelloni, G | 2 |
| Gomma, M | 2 |
| Genetti, B | 1 |
| Zermiani, M | 1 |
| Rimondo, C | 1 |
| Mollica, R | 1 |
| Moody, DE | 3 |
| Arora, A | 1 |
| Sullivan, S | 1 |
| Clark, N | 2 |
| Wang, C | 5 |
| McGoogan, JM | 3 |
| Bulterys, M | 1 |
| Busse, A | 2 |
| Gowing, LR | 3 |
| Myers, CP | 2 |
| Olsen, YK | 1 |
| Dehghani-Arani, F | 1 |
| Rostami, R | 1 |
| Nadali, H | 1 |
| Clarke, TK | 1 |
| Ang, A | 4 |
| Ambrose-Lanci, LM | 1 |
| Lohoff, FW | 1 |
| Ling, W | 28 |
| Hillhouse, MP | 2 |
| Bruce, RD | 11 |
| Meng, J | 1 |
| Burris, S | 1 |
| Malvini Redden, S | 1 |
| Tracy, SJ | 1 |
| Shafer, MS | 1 |
| Shu, X | 1 |
| Shen, PH | 1 |
| Uchtenhagen, A | 7 |
| Notley, C | 4 |
| Blyth, A | 2 |
| Maskrey, V | 6 |
| Craig, J | 1 |
| Holland, R | 6 |
| Siñol, N | 3 |
| Pérez De Los Cobos, J | 5 |
| Lindow, SW | 5 |
| Chandler, A | 1 |
| Whittaker, A | 1 |
| Cunningham-Burley, S | 1 |
| McGorm, K | 3 |
| Mathews, G | 1 |
| Hansen, HB | 1 |
| Siegel, CE | 1 |
| Case, BG | 1 |
| Bertollo, DN | 1 |
| DiRocco, D | 2 |
| Galanter, M | 4 |
| Stewart, RD | 2 |
| Nelson, DB | 1 |
| Adhikari, EH | 1 |
| McIntire, DD | 1 |
| Roberts, SW | 1 |
| Dashe, JS | 5 |
| Sheffield, JS | 4 |
| Jerry, JM | 1 |
| Collins, GB | 1 |
| Neufeld, K | 4 |
| Stoller, K | 3 |
| Kolodner, K | 7 |
| Marino, EN | 1 |
| Wiest, K | 5 |
| Canamar, CP | 1 |
| Martin, JA | 2 |
| McCabe, BE | 1 |
| Santisteban, DA | 1 |
| Mena, MP | 1 |
| Duchene, DM | 1 |
| McLean, C | 1 |
| Monroe, M | 1 |
| Sharif, B | 1 |
| Sun, H | 3 |
| Anis, A | 3 |
| Lua, PL | 2 |
| Talib, NS | 2 |
| Ismail, Z | 1 |
| Keane, H | 2 |
| Wang, GY | 8 |
| Russell, BR | 6 |
| Herskedal, A | 1 |
| Stine, SM | 17 |
| Arria, AM | 9 |
| Selby, P | 11 |
| Nyamathi, A | 2 |
| Albarrán, CR | 1 |
| Branson, C | 1 |
| Marfisee, M | 2 |
| Khalilifard, F | 1 |
| Leake, B | 2 |
| Savant, JD | 3 |
| Peters, S | 3 |
| Belisle, N | 1 |
| Pani, PP | 3 |
| Trogu, E | 1 |
| Pacini, M | 3 |
| Fareed, A | 7 |
| Vayalapalli, S | 6 |
| Scheinberg, K | 2 |
| Gale, R | 1 |
| Casarella, J | 6 |
| Katz, DF | 3 |
| Khatri, V | 1 |
| Kao, D | 1 |
| Bucher-Bartelson, B | 1 |
| Traut, C | 1 |
| Lundin-Martinez, J | 1 |
| Goodman, M | 1 |
| Mehler, PS | 3 |
| Watson, BJ | 1 |
| Taylor, LG | 2 |
| Reid, AG | 1 |
| Wilson, SJ | 1 |
| Stokes, PR | 1 |
| Myers, JF | 1 |
| Turkheimer, FE | 1 |
| Hong, Y | 2 |
| McLaughlin, MM | 1 |
| Xia, Y | 4 |
| Lee, IC | 1 |
| Baldwin, P | 1 |
| Gutwinski, S | 5 |
| Bald, LK | 4 |
| Heinz, A | 4 |
| Müller, CA | 2 |
| Schmidt, AK | 2 |
| Wiers, C | 2 |
| Bermpohl, F | 5 |
| Gallinat, J | 4 |
| Hall, MT | 1 |
| Leukefeld, CG | 1 |
| Havens, JR | 2 |
| Seewald, R | 1 |
| Elam, R | 1 |
| Tio, R | 1 |
| Lorenz, S | 1 |
| Friedmann, P | 1 |
| Rabin, D | 1 |
| Garger, YB | 1 |
| Bonilla, V | 1 |
| Shorter, D | 2 |
| Huang, W | 2 |
| Xiao, Z | 1 |
| Mandel, JS | 2 |
| St Marie, B | 1 |
| Feelemyer, J | 1 |
| Des Jarlais, D | 2 |
| Arasteh, K | 1 |
| Abdul-Quader, AS | 1 |
| Hagan, H | 3 |
| Lashkaripour, K | 2 |
| Bakhshani, NM | 2 |
| Sadjadi, SA | 2 |
| Liao, DL | 2 |
| Chen, PC | 2 |
| Chen, CH | 1 |
| Hsieh, CJ | 1 |
| Huang, YF | 1 |
| Shih, WY | 1 |
| Cheng, JJ | 1 |
| Isherwood, G | 1 |
| Nielsen, MK | 1 |
| Johansen, SS | 1 |
| Linnet, K | 3 |
| Sullivan, SG | 3 |
| Detels, R | 7 |
| Mojal, S | 1 |
| Roquer, A | 1 |
| Martinez, D | 1 |
| Rossi, P | 1 |
| Muga, R | 1 |
| Mason, JW | 1 |
| Bakstad, B | 4 |
| Bjarkø, L | 2 |
| Ravndal, E | 4 |
| Breivik, H | 1 |
| Otiashvili, D | 2 |
| Piralishvili, G | 2 |
| Sikharulidze, Z | 2 |
| Kamkamidze, G | 2 |
| Poole, S | 5 |
| Woody, GE | 32 |
| Montaner, JS | 1 |
| Valentine, K | 1 |
| Moskalewicz, J | 2 |
| Welbel, M | 1 |
| Malinowska-Sempruch, K | 1 |
| Hasson, A | 2 |
| Thomas, C | 3 |
| Hillhouse, M | 6 |
| Jacobs, P | 4 |
| Teruya, C | 1 |
| Cohen, A | 4 |
| Maas, J | 1 |
| Barton, G | 1 |
| Pinto, H | 3 |
| Stanhope, TJ | 1 |
| Gill, LA | 1 |
| Rose, C | 1 |
| Mehić-Basara, N | 2 |
| Oruč, L | 1 |
| Kapur-Pojskić, L | 1 |
| Ramić, J | 1 |
| Lions, C | 6 |
| Michel, L | 7 |
| Cohen, J | 6 |
| Mora, M | 7 |
| Marcellin, F | 4 |
| Spire, B | 9 |
| Carrieri, PM | 4 |
| Karila, L | 1 |
| Song, I | 1 |
| Mark, S | 1 |
| Chen, S | 1 |
| Savina, P | 1 |
| Wajima, T | 1 |
| Peppercorn, A | 1 |
| Bala, U | 1 |
| Piscitelli, S | 1 |
| Varosy, PD | 1 |
| Masoudi, FA | 1 |
| Moghadam, MS | 1 |
| Alavinia, M | 1 |
| Acosta, M | 1 |
| Aponte-Melendez, Y | 3 |
| Cleland, C | 1 |
| Grabinski, M | 1 |
| Brady, R | 4 |
| Edwards, J | 1 |
| Mueller, EA | 1 |
| Kirch, W | 1 |
| Patil, D | 1 |
| Blackinton Gale, R | 1 |
| Winkle, P | 1 |
| Custodio, JM | 1 |
| Wei, X | 2 |
| Rhee, MS | 1 |
| Kearney, BP | 1 |
| Ramanathan, S | 1 |
| Friedland, GH | 4 |
| Karlstad, Ø | 1 |
| Furu, K | 1 |
| Selmer, R | 1 |
| Zhuang, G | 2 |
| Richardson, RA | 1 |
| Dezfouli, A | 1 |
| Zamanian, B | 1 |
| Ghodousi, A | 1 |
| Mokri, A | 5 |
| Hall, BJ | 1 |
| Deppen, K | 1 |
| Hudak, ML | 1 |
| Leffert, L | 1 |
| McClelland, C | 1 |
| Sahin, L | 1 |
| Starer, J | 1 |
| Walsh, J | 2 |
| Anderson, BA | 1 |
| Faulkner, ML | 2 |
| Rilee, JJ | 1 |
| Yantis, S | 1 |
| Marvel, CL | 2 |
| Ordean, A | 3 |
| Graves, L | 2 |
| Abrahams, R | 2 |
| Boyajian, T | 1 |
| Foo, L | 1 |
| Frei, M | 2 |
| Havnes, IA | 2 |
| Middelthon, AL | 2 |
| Gradin, VB | 1 |
| Balfour, D | 1 |
| Favrod-Coune, T | 1 |
| Baroudi, M | 1 |
| Casillas, A | 1 |
| Rieder, JP | 1 |
| Gétaz, L | 1 |
| Barro, J | 1 |
| Gaspoz, JM | 1 |
| Broers, B | 5 |
| Wolff, H | 1 |
| Baird, CR | 1 |
| Fox, P | 1 |
| Colvin, LA | 1 |
| Piekoschowski, A | 1 |
| Böhm, M | 1 |
| Crauwels, HM | 1 |
| van Heeswijk, RP | 1 |
| Vandevoorde, A | 1 |
| Buelens, A | 1 |
| Stevens, M | 1 |
| Hoetelmans, RM | 1 |
| Lambdin, B | 1 |
| Chang, O | 1 |
| Masao, F | 1 |
| Mbwambo, J | 2 |
| Mteza, I | 1 |
| Nyandindi, C | 1 |
| Zamudio-Haas, S | 2 |
| Buma, D | 1 |
| Dunbar, MS | 1 |
| Kilonzo, G | 1 |
| Riksheim, M | 1 |
| Gossop, M | 41 |
| Gratacòs, M | 3 |
| Escaramís, G | 2 |
| De Cid, R | 3 |
| Martín-Santos, R | 4 |
| Farré, M | 6 |
| Estivill, X | 3 |
| Alexandre, PK | 1 |
| Fullerton, CA | 1 |
| Kim, M | 1 |
| Thomas, CP | 2 |
| Lyman, DR | 1 |
| Montejano, LB | 1 |
| Dougherty, RH | 1 |
| Daniels, AS | 1 |
| Ghose, SS | 1 |
| Delphin-Rittmon, ME | 1 |
| Schoofs, N | 2 |
| Riemer, T | 1 |
| Nagar, J | 2 |
| Kouimtsidis, C | 2 |
| Dertadian, GC | 1 |
| Johnson, PN | 1 |
| Miller, JL | 1 |
| Hagemann, TM | 1 |
| Castro, C | 1 |
| Harrison, D | 1 |
| Carrieri, MP | 7 |
| Swift, L | 2 |
| Robinson, A | 1 |
| Gale, T | 1 |
| Haasen, C | 13 |
| Schuler, C | 1 |
| Csete, J | 1 |
| Catania, H | 1 |
| Shipton, D | 1 |
| Dryden, C | 3 |
| Tappin, DM | 1 |
| Albright, K | 1 |
| Jaffray, M | 1 |
| Ryan, M | 1 |
| Bond, CM | 1 |
| Fraser, K | 1 |
| Kirk, M | 1 |
| Liddell, D | 1 |
| Hisham Hashim, HM | 1 |
| Wang, BX | 1 |
| Wang, YJ | 1 |
| Yan, JW | 1 |
| Wan, YN | 1 |
| Peng, WJ | 1 |
| Bohnert, AS | 2 |
| Austin, KL | 1 |
| Pizer, SD | 1 |
| Esmaeili, HR | 1 |
| Ziaddinni, H | 1 |
| Nikravesh, MR | 1 |
| Nakhaee, N | 1 |
| Obot, IS | 1 |
| Steineck, KJ | 1 |
| Skoglund, AK | 1 |
| Carlson, MK | 1 |
| Hall, G | 1 |
| Iheoma, J | 1 |
| Dauber, S | 1 |
| Adams, M | 2 |
| Culleton, R | 1 |
| Muench, F | 1 |
| Borys, S | 1 |
| Morgenstern, J | 1 |
| Sohani, Z | 1 |
| Breen, C | 8 |
| Ajduković, N | 1 |
| Đurendić-Brenesel, M | 1 |
| Farrell-MacDonald, S | 1 |
| MacSwain, MA | 1 |
| Cheverie, M | 2 |
| Tiesmaki, M | 1 |
| Bonnet, U | 3 |
| Stratmann, U | 1 |
| Isbruch, K | 1 |
| Friedman, CJ | 1 |
| Etesam, F | 1 |
| Assarian, F | 1 |
| Hosseini, H | 1 |
| Karachevsky, A | 1 |
| Chhatre, S | 3 |
| Booth, R | 1 |
| Metzger, D | 3 |
| Schumacher, J | 1 |
| Chychula, N | 1 |
| Pecoraro, A | 1 |
| Boniakowski, E | 1 |
| Bachner, C | 1 |
| Weber, B | 2 |
| Tietje, W | 1 |
| Koller, G | 4 |
| Koffarnus, MN | 2 |
| DeFulio, A | 2 |
| Sigurdsson, SO | 2 |
| Tobias, JD | 1 |
| Cao, X | 6 |
| Liu, E | 2 |
| Domany, Y | 3 |
| Tene, O | 3 |
| Rance, J | 1 |
| Farrell, MF | 2 |
| Cruciani, RA | 1 |
| Farrar, JT | 1 |
| Haigney, MC | 4 |
| Inturrisi, C | 1 |
| Knight, JR | 1 |
| Otis-Green, S | 1 |
| Marcus, SM | 1 |
| Mehta, D | 2 |
| Portenoy, R | 1 |
| Savage, S | 1 |
| Strain, E | 1 |
| Walsh, S | 1 |
| Zeltzer, L | 1 |
| Dana, T | 1 |
| Järvinen, M | 2 |
| Miller, G | 1 |
| Clark, MR | 1 |
| Besson, J | 8 |
| Wiesbeck, G | 1 |
| Hämmig, R | 6 |
| Kuntz, A | 1 |
| Abid, S | 1 |
| Stohler, R | 8 |
| Wright, NM | 5 |
| French, C | 1 |
| Allgar, V | 1 |
| Huang, CY | 1 |
| Hu, S | 1 |
| Fang, SC | 1 |
| Wu, CS | 1 |
| Chen, WT | 1 |
| Lee, TS | 1 |
| Li, CS | 1 |
| Wikner, BN | 1 |
| Öhman, I | 1 |
| Seldén, T | 1 |
| Druid, H | 1 |
| Kieler, H | 1 |
| Bruce, D | 2 |
| Sorensen, J | 2 |
| Porubsky, S | 1 |
| Kuppe, C | 1 |
| Maier, T | 1 |
| Birk, HW | 1 |
| Wörnle, M | 1 |
| Moeller, MJ | 1 |
| Floege, J | 1 |
| Gröne, HJ | 1 |
| Icick, R | 2 |
| Peoc'h, K | 2 |
| Ksouda, K | 2 |
| Laplanche, JL | 2 |
| Bruno, A | 1 |
| Romeo, VM | 1 |
| Pandolfo, G | 1 |
| Scimeca, G | 1 |
| Zoccali, RA | 1 |
| Muscatello, MR | 1 |
| Rastegar, DA | 2 |
| Doukas, N | 2 |
| Mozurkewich, EL | 1 |
| Rayburn, WF | 5 |
| Tomori, C | 1 |
| Tuan, le N | 1 |
| Huong, NM | 1 |
| Binh, NT | 1 |
| Zelaya, CE | 1 |
| Celentano, DD | 1 |
| Dat, do T | 1 |
| Quan, VM | 1 |
| Rezaee, S | 1 |
| Casati, A | 1 |
| Piontek, D | 1 |
| Pfeiffer-Gerschel, T | 1 |
| Anglin, R | 4 |
| Seligman, Z | 1 |
| Bloch, M | 3 |
| Potik, D | 4 |
| Kydd, R | 5 |
| Jensen, M | 2 |
| King, NB | 1 |
| Fraser, V | 1 |
| Boikos, C | 1 |
| Richardson, R | 1 |
| Segal, KS | 1 |
| Pace, CA | 1 |
| Kaminetzky, LB | 1 |
| Winter, M | 1 |
| Cheng, DM | 5 |
| Sellman, JD | 2 |
| Adamson, S | 2 |
| Frimpong, JA | 1 |
| Wutchiett, D | 1 |
| Stults-Kolehmainen, MA | 1 |
| Doucette, C | 1 |
| Carragher, N | 1 |
| Metz, VE | 1 |
| Comer, SD | 1 |
| Wuerzl, J | 1 |
| Pribasnig, A | 2 |
| Dias Lima, V | 1 |
| Köhler, W | 1 |
| Bonorden-Kleij, K | 1 |
| Lebentrau, K | 1 |
| Babic-Hohnjec, L | 1 |
| Vollmert, C | 1 |
| Höpner, D | 1 |
| Gholami, N | 1 |
| Copeland, AL | 3 |
| Polukhina, N | 2 |
| Clark, CB | 1 |
| Hendricks, PS | 1 |
| Lane, PS | 1 |
| Trent, L | 1 |
| Liebrenz, M | 1 |
| Saia, KA | 1 |
| Du, HM | 1 |
| Sebastiani, P | 2 |
| Coote, M | 2 |
| Wilder, C | 2 |
| Wexelblatt, SL | 3 |
| Theobald, J | 2 |
| Hall, ES | 3 |
| Lewis, D | 4 |
| Van Hook, J | 1 |
| Marcotte, M | 1 |
| Newman, RG | 15 |
| Kéri, S | 1 |
| Shapiro, AR | 1 |
| Bonner, A | 1 |
| Jaremko, KM | 1 |
| Van Bockstaele, EJ | 1 |
| Perreault, M | 1 |
| Julien, D | 1 |
| White, ND | 1 |
| Rabouin, D | 1 |
| Lauzon, P | 2 |
| Milton, D | 1 |
| Lock, K | 1 |
| Chettiar, J | 2 |
| Hall, W | 10 |
| Raina, S | 1 |
| Paydak, H | 1 |
| Al-Lahham, T | 1 |
| Shihabuddin, BS | 1 |
| Evans, JL | 1 |
| Hahn, JA | 1 |
| Matin, BK | 1 |
| Jalilian, F | 1 |
| Alavije, MM | 1 |
| Ashtarian, H | 1 |
| Mahboubi, M | 1 |
| Afsar, A | 1 |
| Rass, O | 2 |
| Johnson, MW | 2 |
| Mintzer, MZ | 4 |
| Vray, M | 1 |
| Fenn, JM | 1 |
| Laurent, JS | 1 |
| Luo, W | 5 |
| Pang, L | 5 |
| Yin, W | 4 |
| Lenz, S | 1 |
| Straka, RJ | 1 |
| Brundage, RC | 1 |
| McGlone, L | 1 |
| Ghazarian, S | 1 |
| Baumeister, M | 1 |
| Dürsteler-MacFarland, KM | 3 |
| Gerhard, U | 1 |
| Wiesbeck, GA | 3 |
| Petitjean, SA | 1 |
| Lruie, BS | 1 |
| DInh, AT | 1 |
| Fiellin, LE | 1 |
| Roshanaei Moghdam, B | 1 |
| Heydari, H | 1 |
| Turner, NE | 1 |
| Razaghi, EM | 1 |
| Burns, L | 9 |
| Gibson, A | 2 |
| Butler, T | 3 |
| Conroy, S | 1 |
| Hill, D | 1 |
| Zhou, W | 3 |
| Zhou, S | 1 |
| Xie, N | 1 |
| Liu, P | 3 |
| Luo, L | 1 |
| Peng, J | 1 |
| Liu, M | 2 |
| Desrosiers, A | 1 |
| Schottenfeld, R | 8 |
| Chawarski, MC | 5 |
| Mi, G | 1 |
| Shi, CX | 3 |
| Zhang, F | 2 |
| Li, Z | 2 |
| Bretteville-Jensen, AL | 1 |
| Lillehagen, M | 1 |
| Gjersing, L | 1 |
| Andreas, JB | 1 |
| Murnion, B | 1 |
| Dunlop, A | 2 |
| Muhleisen, P | 1 |
| Hendrikson, H | 2 |
| Hansen, M | 1 |
| Steinberg, ML | 1 |
| Wiegand, SL | 1 |
| Stringer, EM | 1 |
| Stuebe, AM | 1 |
| Seashore, C | 2 |
| Thorp, J | 1 |
| Sun, HM | 1 |
| Li, XY | 1 |
| Chow, EP | 2 |
| Li, T | 1 |
| Xian, Y | 1 |
| Lu, YH | 1 |
| Tian, T | 1 |
| Zhuang, X | 2 |
| Kleykamp, BA | 1 |
| Vandrey, RG | 1 |
| Akerman, SC | 1 |
| Brunette, MF | 1 |
| Green, AI | 1 |
| Blunt, HB | 1 |
| Aziz, Z | 1 |
| Chong, NJ | 1 |
| Blom Nilsson, M | 1 |
| Chassler, D | 1 |
| Lundgren, LM | 1 |
| Castrén, S | 1 |
| Salonen, AH | 1 |
| Lahti, T | 1 |
| Simojoki, K | 2 |
| Kotwas, A | 1 |
| Karakiewicz, B | 4 |
| Sein Anand, J | 1 |
| Min, J | 1 |
| Liu, L | 1 |
| Fogger, S | 1 |
| McGuinness, TM | 1 |
| McQueen, KA | 2 |
| Murphy-Oikonen, J | 3 |
| Desaulniers, L | 1 |
| Waluyo, A | 1 |
| Iriyanti, M | 1 |
| Muchransyah, AP | 1 |
| Bami, H | 1 |
| Wang, LJ | 2 |
| Koehn, JD | 1 |
| Nguyen, P | 2 |
| Rieb, L | 1 |
| Zinck, L | 1 |
| Sonne, NM | 1 |
| Madsen, SL | 1 |
| Nikolajsen, L | 1 |
| Lynch, KL | 1 |
| Shapiro, BJ | 1 |
| Novak, SP | 1 |
| Arends, MT | 1 |
| De Haan, HA | 1 |
| Van 't Hoff, GI | 1 |
| Kreitinger, C | 1 |
| Gutierrez, H | 1 |
| Hamidovic, A | 1 |
| Schmitt, C | 3 |
| Sarangarm, P | 1 |
| Palma, J | 1 |
| Abood, ME | 1 |
| Benamar, K | 1 |
| Jackson, H | 1 |
| Mandell, K | 1 |
| Johnson, K | 1 |
| Chatterjee, D | 1 |
| Vanness, DJ | 1 |
| Lefevere, J | 1 |
| Allegaert, K | 1 |
| Levine, AR | 1 |
| Lisieski, M | 1 |
| Rhodes, GL | 2 |
| Singh, PM | 1 |
| Shrestha, DM | 1 |
| Bhandari, GP | 1 |
| Salisbury-Afshar, E | 1 |
| Charles, M | 1 |
| Wellington, CE | 1 |
| Mokrysz, C | 1 |
| Freeman, TP | 1 |
| O'Ryan, D | 4 |
| Curran, HV | 5 |
| Cavaiola, AA | 1 |
| Fulmer, BA | 1 |
| Stout, D | 1 |
| Lalezari, J | 1 |
| Sullivan, JG | 1 |
| Varunok, P | 1 |
| Galen, E | 1 |
| Kowdley, KV | 1 |
| Rustgi, V | 1 |
| Aguilar, H | 1 |
| Felizarta, F | 1 |
| McGovern, B | 1 |
| King, M | 1 |
| Polepally, AR | 1 |
| Cohen, DE | 1 |
| Stevenson, E | 1 |
| Cole, J | 1 |
| Khampang, R | 1 |
| Teerawattananon, Y | 1 |
| Simpatico, TA | 1 |
| Popescu, G | 1 |
| Negrei, C | 1 |
| Bălălău, D | 1 |
| Baconi, D | 1 |
| Meini, M | 1 |
| Moncini, M | 1 |
| Daini, L | 1 |
| Giarratana, T | 1 |
| Scaramelli, D | 1 |
| Chericoni, S | 1 |
| Stefanelli, F | 1 |
| Rucci, P | 1 |
| Liu, WF | 1 |
| Singh, K | 1 |
| Faisal, M | 1 |
| Mark, TL | 1 |
| Lubran, R | 1 |
| Chalk, M | 1 |
| Richardson, J | 1 |
| Launonen, E | 1 |
| Kotovirta, E | 1 |
| Wallace, I | 1 |
| Lappalainen, L | 2 |
| Dobrer, S | 1 |
| Puscas, C | 1 |
| Mullins, ME | 1 |
| Hock, K | 1 |
| Scott, MG | 1 |
| Desai, RJ | 1 |
| Patorno, E | 1 |
| Kerzner, LS | 1 |
| Marie Henihan, A | 1 |
| McCombe, G | 2 |
| Swan, D | 2 |
| Anderson, R | 3 |
| Bury, G | 2 |
| Dunne, C | 1 |
| Shorter, GW | 2 |
| Clark, RE | 2 |
| Baxter, JD | 2 |
| Aweh, G | 1 |
| O'Connell, E | 1 |
| Fisher, WH | 1 |
| Barton, BA | 1 |
| Capecci, E | 1 |
| Kasabov, N | 1 |
| Kim, T | 1 |
| Kydd, RR | 1 |
| Cohen, MC | 1 |
| Morley, SR | 1 |
| Coombs, RC | 1 |
| Cavacuiti, C | 2 |
| Macdonald, EM | 1 |
| Steele, L | 1 |
| Luo, J | 1 |
| Mamdani, MM | 2 |
| Mjåland, K | 1 |
| Darker, CD | 2 |
| Kelly, G | 1 |
| Whiston, L | 2 |
| Wong, JB | 1 |
| Tran, L | 1 |
| Noska, A | 2 |
| Reddy, M | 1 |
| Oretti, R | 1 |
| Lira, MC | 2 |
| Winter, MR | 2 |
| Alford, DP | 4 |
| Mao, J | 1 |
| Donnerstag, N | 1 |
| Schneider, T | 1 |
| Lüthi, A | 1 |
| Taegtmeyer, A | 1 |
| Raetz Bravo, A | 1 |
| Mehlig, A | 1 |
| Leslie, D | 1 |
| Campopiano, M | 1 |
| McCance-Katz, E | 1 |
| Visconti, AJ | 1 |
| Santos, GM | 1 |
| Lemos, NP | 2 |
| Burke, C | 1 |
| Coffin, PO | 2 |
| Hoffmann, NG | 1 |
| Pan, S | 2 |
| Chen, H | 2 |
| Novick, DM | 4 |
| Salsitz, EA | 1 |
| Parrino, MW | 1 |
| Maremmani, AG | 2 |
| Samuels, PN | 1 |
| Maillard, C | 1 |
| Salles, N | 1 |
| Holbrook, AM | 4 |
| Aletraris, L | 1 |
| Edmond, MB | 1 |
| Paino, M | 1 |
| Fields, D | 1 |
| Roman, PM | 2 |
| Boucherie, Q | 1 |
| Pauly, V | 2 |
| Thirion, X | 4 |
| Pradel, V | 1 |
| Miller, ME | 1 |
| Finlayson, AJ | 1 |
| Weatherburn, DJ | 1 |
| Phillips, J | 1 |
| Courtney, B | 1 |
| Lyons, S | 2 |
| Torrents, R | 1 |
| Picot, C | 1 |
| Glaizal, M | 1 |
| Courne, MA | 1 |
| Richard, N | 1 |
| Simon, N | 1 |
| Cardona, F | 1 |
| de Haro, L | 1 |
| Mayet, A | 1 |
| Maradan, G | 3 |
| Marimoutou, C | 1 |
| Harris, JC | 1 |
| Karsinti, E | 1 |
| Hajj, A | 1 |
| Prince, N | 1 |
| Mouly, S | 1 |
| Vignali, C | 1 |
| Stramesi, C | 1 |
| Morini, L | 1 |
| Pozzi, F | 1 |
| Groppi, A | 1 |
| Grow, JL | 1 |
| Jasin, LR | 1 |
| Klebanoff, MA | 1 |
| McClead, RE | 1 |
| Meinzen-Derr, J | 3 |
| Mohan, VK | 1 |
| Stein, H | 1 |
| Granerud, A | 1 |
| Toft, H | 1 |
| Randall, D | 3 |
| Walton, G | 1 |
| Schacht, RL | 1 |
| Buckheit, K | 1 |
| Hearty, P | 1 |
| Kim, SJ | 2 |
| Acosta, MC | 3 |
| Domínguez-Hernández, R | 1 |
| Díaz, T | 1 |
| Fernández, JM | 1 |
| Forcada, R | 1 |
| Martínez, JM | 1 |
| Terán, A | 1 |
| Oyagüez, I | 1 |
| Tan, C | 1 |
| Dunn, G | 1 |
| Jones, A | 2 |
| Lima, VD | 1 |
| Brennan, F | 1 |
| Dahmke, H | 1 |
| Kupferschmidt, H | 1 |
| Kullak-Ublick, GA | 1 |
| Weiler, S | 1 |
| Weisberg, DF | 1 |
| Schultz, NR | 1 |
| Cucciare, MA | 1 |
| Vittorio, L | 1 |
| Garrison-Diehn, C | 1 |
| Gorzelańczyk, EJ | 1 |
| Walecki, P | 1 |
| Feit, J | 1 |
| Kunc, M | 1 |
| Bray, JW | 1 |
| Wittenberg, E | 1 |
| Aden, B | 1 |
| Eggman, AA | 1 |
| Potter, J | 1 |
| Humphreys, R | 1 |
| Minear, S | 1 |
| Combs, G | 1 |
| Philipp, BL | 2 |
| Bauhoff, S | 1 |
| Miller, SC | 1 |
| Tiffany, E | 1 |
| Winstanley, EL | 2 |
| Salsitz, E | 1 |
| Wiegand, T | 1 |
| Lyubimova, A | 1 |
| Levina, OS | 1 |
| Alam-Mehrjerdi, Z | 1 |
| Abdollahi, M | 1 |
| Young, ME | 1 |
| Hager, SJ | 1 |
| Spurlock, D | 1 |
| Dahlman, D | 1 |
| Björkman, P | 1 |
| Blomé, MA | 1 |
| Polydorou, S | 1 |
| Ferris, R | 1 |
| Blaum, CS | 1 |
| Ross, S | 2 |
| McKnight, S | 1 |
| Coo, H | 1 |
| Holmes, B | 1 |
| Newton, L | 1 |
| Weiss, R | 1 |
| Saxon, A | 1 |
| Liu, D | 4 |
| Wakim, P | 1 |
| Hatch-Maillette, M | 1 |
| Marienfeld, C | 1 |
| Courtwright, DT | 1 |
| Doborjeh, MG | 1 |
| Kasabov, NK | 1 |
| Russell, B | 1 |
| Searby, A | 1 |
| Maude, P | 1 |
| McGrath, I | 1 |
| Markwick, N | 1 |
| Anderson, S | 2 |
| Teoh Bing Fei, J | 2 |
| Habil, MH | 2 |
| Isemann, BT | 1 |
| Wiles, JR | 1 |
| Harvey, S | 1 |
| Akinbi, HT | 1 |
| Thiruvothiyur, M | 1 |
| Robertson, H | 1 |
| Bond, C | 3 |
| Maradiaga, JA | 1 |
| Sanchez, J | 1 |
| Roshanov, PS | 1 |
| Paul, J | 2 |
| Nordmann, S | 1 |
| Vilotitch, A | 2 |
| Glue, P | 2 |
| Cape, G | 3 |
| Tunnicliff, D | 2 |
| Lockhart, M | 2 |
| Lam, F | 2 |
| Gray, A | 1 |
| Hung, N | 2 |
| Hung, CT | 2 |
| Harland, S | 2 |
| Devane, J | 2 |
| Howes, J | 2 |
| Weis, H | 2 |
| Friedhoff, L | 2 |
| Heikman, P | 1 |
| Sundström, M | 1 |
| Pelander, A | 1 |
| Ojanperä, I | 2 |
| Yarborough, BJ | 1 |
| Stumbo, SP | 1 |
| Mertens, J | 1 |
| Weisner, C | 1 |
| Green, CA | 2 |
| Kleimann, A | 1 |
| Rehme, MK | 1 |
| Taschner, L | 1 |
| Glahn, A | 1 |
| Lichtinghagen, R | 1 |
| Quinones, L | 1 |
| Grishaev, E | 1 |
| Schmidt, CS | 1 |
| Strada, L | 1 |
| Götzke, C | 1 |
| Hiller, P | 1 |
| Zahari, Z | 4 |
| Siong, LC | 1 |
| Musa, N | 3 |
| Mohd Yasin, MA | 3 |
| Choon, TS | 1 |
| Mohamad, N | 4 |
| Ismail, R | 5 |
| Kourounis, G | 1 |
| Richards, BD | 1 |
| Kyprianou, E | 1 |
| Symeonidou, E | 1 |
| Malliori, MM | 1 |
| Samartzis, L | 1 |
| Harris, AH | 2 |
| Rosenthal, J | 1 |
| Blue-Howells, J | 1 |
| McGuire, J | 1 |
| Frayne, SM | 1 |
| Oliva, E | 1 |
| Binswanger, I | 1 |
| Nong, VM | 1 |
| Anghelescu, I | 1 |
| D'Hotman, D | 1 |
| Pugh, J | 1 |
| Douglas, T | 1 |
| Clark, J | 1 |
| Betts, KS | 1 |
| Chan, G | 1 |
| McIlwraith, F | 1 |
| Dietze, P | 6 |
| Whittaker, E | 1 |
| Alati, R | 1 |
| Lusetti, M | 1 |
| Licata, M | 1 |
| Silingardi, E | 1 |
| Reggiani Bonetti, L | 1 |
| Palmiere, C | 1 |
| Willet, J | 1 |
| James, A | 1 |
| Rudes, DS | 1 |
| Viglione, J | 1 |
| Stuke, H | 1 |
| Riemer, TG | 1 |
| Wiers, CE | 1 |
| Copenhaver, M | 3 |
| Weikum, D | 1 |
| Sen, S | 1 |
| Arulkumar, S | 1 |
| Gayle, JA | 1 |
| Flower, RR | 1 |
| Fox, CJ | 1 |
| Mahenge, B | 1 |
| Saleem, H | 1 |
| Zhang, B | 3 |
| Cai, T | 1 |
| Yan, Z | 1 |
| Mburu, G | 1 |
| Wang, B | 1 |
| Yang, L | 1 |
| Nguyen, AT | 1 |
| Le, TN | 1 |
| Goldner, E | 1 |
| Tyndall, M | 1 |
| King, JB | 1 |
| Sainski-Nguyen, AM | 1 |
| Bellows, BK | 1 |
| Frankland, L | 1 |
| Bradley, BP | 2 |
| Mogg, K | 1 |
| Tsai, LC | 1 |
| Doan, TJ | 1 |
| Ornoy, A | 1 |
| Finkel-Pekarsky, V | 1 |
| Ebstein, PR | 1 |
| Ibrahim, MA | 2 |
| Lee, YY | 2 |
| Tan, SC | 3 |
| Sharfstein Kawasaki, S | 1 |
| Harris, EE | 1 |
| Morales, GJ | 1 |
| Mai, NT | 1 |
| Brownson, RC | 1 |
| Ha, TV | 1 |
| Damon, W | 1 |
| Ogbuagu, O | 1 |
| Friedland, G | 5 |
| Stiefelhagen, P | 1 |
| Kehler, C | 1 |
| Laska, E | 2 |
| Goldfeld, K | 1 |
| Bonilla, W | 1 |
| Santana-Correa, N | 1 |
| Johnson, CW | 1 |
| Leibowitz, N | 1 |
| Gourevitch, MN | 11 |
| Siegel, C | 1 |
| Wanderling, J | 1 |
| Chandler, RK | 1 |
| Finger, MS | 1 |
| Farabee, D | 2 |
| Condon, T | 1 |
| McCollister, K | 1 |
| Bennett, D | 1 |
| Noormohammadi, A | 1 |
| Forinash, A | 1 |
| Yancey, A | 1 |
| Crannage, E | 1 |
| Campbell, K | 2 |
| Shyken, J | 1 |
| Messaadi, N | 2 |
| Favre, J | 1 |
| Calafiore, M | 1 |
| Stalnikiewicz, B | 1 |
| Berkhout, C | 1 |
| Mukherjee, TI | 1 |
| Desai, MM | 1 |
| Pillai, V | 1 |
| Herman, D | 1 |
| Anderson, B | 1 |
| Zedler, BK | 2 |
| Mann, AL | 1 |
| Kim, MM | 1 |
| Amick, HR | 2 |
| Joyce, AR | 2 |
| Murrelle, EL | 2 |
| Deng, L | 1 |
| Klein, JW | 1 |
| Gentile, G | 1 |
| Giocanti, A | 1 |
| Orleans, V | 1 |
| Amaslidou, D | 1 |
| Brown, A | 1 |
| Sadler, C | 1 |
| Andersen, LV | 1 |
| Christoffersen, DJ | 1 |
| Palmer-Bacon, J | 1 |
| Miles-McLean, H | 1 |
| Rugle, L | 1 |
| Medoff, D | 1 |
| Potts, W | 1 |
| Himelhoch, S | 1 |
| Bruno, R | 1 |
| Cataldo, M | 1 |
| Ziaee, SS | 1 |
| Fadardi, JS | 1 |
| Cox, WM | 1 |
| Yazdi, SA | 1 |
| Dunlap, L | 2 |
| Johnson, E | 1 |
| Horton, E | 1 |
| Andringa, K | 1 |
| Holmes, AV | 1 |
| Porta-Sales, J | 1 |
| Garzón-Rodríguez, C | 1 |
| Villavicencio-Chávez, C | 1 |
| Llorens-Torromé, S | 1 |
| González-Barboteo, J | 2 |
| Redmond, J | 1 |
| Springer, S | 1 |
| Barrio, P | 1 |
| Ezzeldin, M | 1 |
| Bruguera, P | 1 |
| Pérez, A | 1 |
| Mansilla, S | 1 |
| Fàbrega, M | 1 |
| Mondón, S | 1 |
| Balcells, M | 1 |
| Fairgrieve, C | 1 |
| Barral, C | 1 |
| Pérez-Pazos, J | 1 |
| Casas, M | 3 |
| Schuckit, MA | 1 |
| Farr, A | 1 |
| Kiss, H | 1 |
| Hagmann, M | 1 |
| Holzer, I | 1 |
| Kueronya, V | 1 |
| Husslein, PW | 1 |
| Petricevic, L | 1 |
| AlMeman, AA | 1 |
| Perola, M | 1 |
| Eisen, RB | 1 |
| Perera, S | 1 |
| Bhatnagar, N | 1 |
| Dore, GJ | 2 |
| Altice, F | 1 |
| Dalgard, O | 1 |
| Gane, EJ | 1 |
| Shibolet, O | 1 |
| Luetkemeyer, A | 1 |
| Nahass, R | 1 |
| Peng, CY | 1 |
| Conway, B | 2 |
| Howe, AY | 1 |
| Gendrano, IN | 1 |
| Chen, E | 1 |
| Huang, HC | 1 |
| Dutko, FJ | 1 |
| Nickle, DC | 1 |
| Nguyen, BY | 1 |
| Wahl, J | 1 |
| Barr, E | 1 |
| Robertson, MN | 1 |
| Platt, HL | 1 |
| Westermeyer, J | 2 |
| Adabag, S | 1 |
| Anand, V | 1 |
| Thuras, P | 1 |
| Yoon, G | 1 |
| Batres-Y-Carr, T | 1 |
| Hassamal, S | 1 |
| Miotto, K | 1 |
| Wang, T | 1 |
| Taveros, MC | 1 |
| Chuang, EJ | 1 |
| Zhang, N | 1 |
| Campbell, WA | 1 |
| Mirijello, A | 1 |
| Faccini, M | 1 |
| Casari, R | 1 |
| Cossari, A | 1 |
| Gasbarrini, A | 1 |
| Addolorato, G | 1 |
| Alfonso, A | 1 |
| Yuan, W | 1 |
| Maguire, DJ | 2 |
| Taylor, S | 2 |
| Armstrong, K | 2 |
| Shaffer-Hudkins, E | 2 |
| Germain, AM | 2 |
| Brooks, SS | 2 |
| Cline, GJ | 1 |
| Clark, L | 1 |
| DeBate, R | 1 |
| Morin-Taus, KA | 1 |
| Butelman, ER | 3 |
| Yuferov, V | 2 |
| da Rosa, JC | 1 |
| Westerberg, VS | 1 |
| McCrady, BS | 1 |
| Owens, M | 1 |
| Guerin, P | 1 |
| Mücke, S | 1 |
| Nagel, M | 1 |
| Siedentopf, J | 1 |
| Bührer, C | 1 |
| Hüseman, D | 1 |
| Leamon, MH | 3 |
| Fassbender, C | 1 |
| Ayanga, D | 1 |
| Garrido-Fernández, M | 1 |
| Marcos-Sierra, JA | 1 |
| López-Jiménez, A | 1 |
| Ochoa de Alda, I | 1 |
| Bates, DD | 1 |
| Tamayo-Murillo, D | 1 |
| Kussman, S | 1 |
| Luce, A | 1 |
| LeBedis, CA | 1 |
| Soto, JA | 1 |
| Anderson, SW | 1 |
| Alexandrescu, L | 1 |
| Henihan, AM | 1 |
| Leahy, D | 1 |
| Dunne, CP | 1 |
| Lambert, JS | 1 |
| Meagher, D | 1 |
| O'Gorman, C | 1 |
| O'Toole, TP | 1 |
| Kaner, E | 1 |
| Kernisant, M | 1 |
| Kabore, JL | 1 |
| Laporte, C | 1 |
| Zenut, M | 1 |
| Jiao, M | 2 |
| Lau, JT | 2 |
| Mo, P | 1 |
| Babbitt, A | 1 |
| George, P | 1 |
| Thurairajasingam, S | 1 |
| Ramasamy, P | 1 |
| Mohd Yusof, H | 1 |
| Yasin, MABM | 1 |
| Shah, ZUBS | 1 |
| Crockett, RS | 1 |
| Darpo, B | 1 |
| Zhou, M | 1 |
| Maguire, D | 1 |
| Gröer, M | 1 |
| Gibson, KS | 1 |
| Stark, S | 1 |
| Kumar, D | 1 |
| Andrew, B | 1 |
| Ruadze, E | 1 |
| Todadze, K | 1 |
| Stillwell, G | 2 |
| Brown, AM | 1 |
| Gustafson, DH | 1 |
| Landucci, G | 1 |
| McTavish, F | 1 |
| Kornfield, R | 1 |
| Johnson, RA | 1 |
| Mares, ML | 1 |
| Westergaard, RP | 1 |
| Quanbeck, A | 1 |
| Alagoz, E | 1 |
| Pe-Romashko, K | 1 |
| Shah, D | 1 |
| Nelson, EC | 1 |
| Martin, NG | 1 |
| Montgomery, GW | 1 |
| Kaur, S | 1 |
| Rajandaran, V | 1 |
| Osornprasop, S | 1 |
| Wilson, DP | 2 |
| Zhang, M | 1 |
| González-Saiz, F | 2 |
| Manresa, MJ | 1 |
| Alcaraz, S | 1 |
| Batlle, F | 1 |
| McQueen, K | 1 |
| Serra, AE | 1 |
| Mokhtari, NB | 1 |
| Parks, WT | 1 |
| Catov, JM | 1 |
| Royall, M | 1 |
| Garner, KK | 1 |
| Hill, SR | 1 |
| Barnes, M | 1 |
| Werler, M | 1 |
| Inrahim, MA | 1 |
| Atayee, RS | 1 |
| Hur, GH | 1 |
| Karimian, P | 1 |
| Hollenbach, KA | 1 |
| Edmonds, KP | 1 |
| Idrisov, B | 1 |
| Morrill, T | 1 |
| Saadoun, M | 1 |
| Lunze, K | 1 |
| Shepard, D | 1 |
| Smith, AH | 1 |
| Jensen, KP | 1 |
| Nunez, Y | 1 |
| Farrer, LA | 1 |
| Hakonarson, H | 1 |
| Cook-Sather, SD | 1 |
| Gelernter, J | 1 |
| Franklyn, AM | 1 |
| Pellegrini, D | 1 |
| Lightfoot, NE | 1 |
| Selin, J | 1 |
| Ledberg, A | 1 |
| Gahr, M | 1 |
| Eller, J | 1 |
| Hiemke, C | 1 |
| Freudenmann, RW | 1 |
| Connemann, BJ | 1 |
| Lang, D | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Silva, MJ | 1 |
| Pereira, C | 1 |
| Loureiro, R | 1 |
| Balsa, C | 1 |
| Lopes, P | 1 |
| Água-Doce, I | 1 |
| Belo, E | 1 |
| Martins, HC | 1 |
| Coutinho, R | 1 |
| Pádua, E | 1 |
| Brown, JL | 1 |
| Gause, NK | 1 |
| Kahn, M | 1 |
| Sabet, S | 1 |
| Primerano, DA | 1 |
| Richards-Waugh, LL | 1 |
| Lones, CE | 1 |
| Bond, GR | 1 |
| McGovern, MP | 1 |
| Carr, K | 1 |
| Leckron-Myers, T | 1 |
| Hartnett, T | 1 |
| Becker, DR | 1 |
| Huedo-Medina, TB | 1 |
| Mbewe, D | 1 |
| Suchanek, J | 1 |
| Comulada, WS | 1 |
| Hsieh, J | 1 |
| Yan, K | 1 |
| Nader, M | 1 |
| Matusow, H | 1 |
| Benoit, E | 2 |
| Elliott, L | 3 |
| Dunlap, E | 1 |
| Rosenblum, A | 11 |
| Rosen, D | 2 |
| Smith, ML | 1 |
| Reynolds, CF | 2 |
| Harvey-Dodds, L | 1 |
| Casadonte, PP | 1 |
| Kolodner, GF | 1 |
| Horton, T | 1 |
| McMurphy, SM | 1 |
| Bickel, WK | 5 |
| Gigelow, G | 1 |
| Kampman, K | 1 |
| Marion, IJ | 3 |
| Clair, J | 1 |
| Martin, L | 1 |
| Bond, AJ | 2 |
| Brewster, T | 2 |
| Farentinos, C | 2 |
| Collins, RL | 1 |
| Cornely, W | 1 |
| Grella, C | 1 |
| Jackson, TR | 5 |
| Serane, VT | 1 |
| Kurian, O | 1 |
| Winstock, AR | 10 |
| Lea, T | 9 |
| Sheridan, J | 10 |
| Chopra, MP | 2 |
| Feldman, Z | 2 |
| Mancino, MJ | 2 |
| Oliveto, A | 7 |
| O'Brien, CP | 40 |
| Lawrinson, P | 2 |
| Buavirat, A | 1 |
| Chiamwongpaet, S | 1 |
| Habrat, B | 5 |
| Jie, S | 1 |
| Mardiati, R | 1 |
| Newcombe, D | 2 |
| Poznyak, V | 1 |
| Subata, E | 4 |
| Utami, DS | 1 |
| Vial, R | 1 |
| Zhao, C | 2 |
| Collins, D | 1 |
| Ferri, MM | 2 |
| Mayet, S | 6 |
| Gaertner, J | 2 |
| Voltz, R | 2 |
| Ostgathe, C | 2 |
| Tan, HZ | 1 |
| Sun, ZQ | 1 |
| Suh, JJ | 1 |
| Langleben, DD | 1 |
| Ehrman, RN | 3 |
| Hakun, JG | 1 |
| Busch, SI | 1 |
| Childress, AR | 8 |
| Friesen, C | 1 |
| Roscher, M | 1 |
| Alt, A | 1 |
| Miltner, E | 1 |
| Roche, A | 2 |
| McCabe, S | 1 |
| Esses, JL | 1 |
| Rosman, J | 2 |
| Do, LT | 1 |
| Schweitzer, P | 2 |
| Hanon, S | 2 |
| Kacinko, SL | 1 |
| Johnson, RE | 20 |
| Choo, RE | 4 |
| Patkar, AA | 4 |
| Peindl, K | 3 |
| Gorelick, DA | 4 |
| Gottheil, E | 2 |
| Loeber, S | 1 |
| Kniest, A | 1 |
| Diehl, A | 1 |
| Mann, K | 2 |
| Croissant, B | 2 |
| Ross, D | 1 |
| Lo, F | 1 |
| McKim, R | 1 |
| Marti-Almor, J | 1 |
| Pastor, A | 2 |
| Cladellas, M | 1 |
| de la Torre, R | 2 |
| Okruhlica, L | 2 |
| Slezáková, S | 1 |
| Villes, V | 1 |
| Dellamonica, P | 2 |
| Poizot-Martin, I | 1 |
| Ravaux, I | 2 |
| Winklbaur, B | 9 |
| Kopf, N | 1 |
| Ebner, N | 5 |
| Jung, E | 2 |
| Thau, K | 5 |
| Jones, ES | 2 |
| Sindelar, JL | 3 |
| O'Connor, PG | 9 |
| Ochoa, E | 2 |
| Salvador, E | 1 |
| Madoz-Gúrpide, A | 1 |
| Lázaro, M | 1 |
| Murray, H | 2 |
| Behar, E | 1 |
| Pratt, E | 1 |
| Otto, M | 1 |
| Carpenter, KM | 1 |
| Smith, JL | 1 |
| Aharonovich, E | 1 |
| Iraurgi Castillo, I | 1 |
| Salva, N | 1 |
| Hayes, EJ | 2 |
| Dysart, KC | 3 |
| Pequignot, EC | 1 |
| Magura, S | 12 |
| Hershberger, J | 2 |
| Marsch, L | 1 |
| Shropshire, C | 1 |
| Athanasos, P | 2 |
| Farquharson, AL | 1 |
| Psaltis, P | 1 |
| Hay, J | 1 |
| Brands, B | 9 |
| Blake, J | 4 |
| Jeyapalan, R | 1 |
| Tenore, PL | 2 |
| Bearn, J | 10 |
| Swami, A | 1 |
| Stewart, D | 10 |
| Atnas, C | 1 |
| Giotto, L | 1 |
| Ridge, G | 2 |
| Witton, J | 1 |
| Lieb, M | 2 |
| Kagerer, S | 4 |
| Zingg, C | 3 |
| Lehnert, P | 1 |
| Limmer, C | 3 |
| Kuefner, H | 3 |
| Hennig-Fast, K | 1 |
| Andrews, S | 1 |
| Delucchi, KL | 4 |
| Greenberg, B | 2 |
| Guydish, J | 1 |
| Masson, CL | 3 |
| Shopshire, M | 1 |
| Prosser, JM | 1 |
| Eisenberg, D | 2 |
| Davey, EE | 1 |
| Steinfeld, M | 2 |
| Cohen, LJ | 3 |
| London, ED | 4 |
| Galynker, II | 5 |
| Dubajic, G | 1 |
| Strbad, E | 1 |
| Ashrafioun, L | 1 |
| Harris, KA | 2 |
| Zamor, PJ | 1 |
| Soloway, IJ | 1 |
| Kaswan, D | 1 |
| Hogan, B | 1 |
| Hershey, L | 1 |
| Ritchey, S | 1 |
| Eisenberg, E | 1 |
| Barnett, PG | 6 |
| Wong, W | 3 |
| Hall, SM | 8 |
| Nathwani, NS | 1 |
| Gallagher, JE | 1 |
| Rogers, RE | 1 |
| Thomas, CS | 2 |
| Badger, GJ | 2 |
| Bigelow, G | 4 |
| Glatstein, MM | 1 |
| Garcia-Bournissen, F | 1 |
| Finkelstein, Y | 1 |
| Koren, G | 3 |
| Greengold, B | 1 |
| de Castro, V | 1 |
| George, D | 1 |
| Velez, M | 4 |
| Elko, A | 6 |
| Knauer, H | 1 |
| Kivlighan, KT | 1 |
| Hay, JL | 2 |
| Semple, TJ | 1 |
| Rounsefell, B | 1 |
| Liu, TT | 1 |
| Teichtahl, H | 1 |
| Goodman, C | 1 |
| Drummer, O | 1 |
| Grunstein, RR | 1 |
| Kronborg, I | 1 |
| Ramani, A | 1 |
| Shiran, MR | 2 |
| Lennard, MS | 2 |
| Iqbal, MZ | 3 |
| Lagundoye, O | 3 |
| Seivewright, N | 3 |
| Tucker, GT | 3 |
| Rostami-Hodjegan, A | 3 |
| Elkader, AK | 3 |
| Dunn, E | 1 |
| Corsi, KF | 2 |
| Lehman, WK | 1 |
| Booth, RE | 3 |
| Aasland, OG | 1 |
| Spilhaug, G | 1 |
| Johannesen, A | 1 |
| Shaygani, S | 1 |
| Reisinger, HS | 4 |
| Peterson, JA | 4 |
| Agar, MH | 3 |
| Brown, BS | 14 |
| Wolstein, J | 1 |
| Gastpar, M | 11 |
| Finkbeiner, T | 6 |
| Heinrich, C | 1 |
| Heitkamp, R | 1 |
| Poehlke, T | 1 |
| Berg, KM | 5 |
| Sacajiu, G | 2 |
| Karasz, A | 1 |
| Davstad, I | 2 |
| Stenbacka, M | 6 |
| Leifman, A | 5 |
| Romelsjö, A | 5 |
| Kritz, S | 2 |
| Chu, M | 2 |
| John-Hull, C | 1 |
| Madray, C | 2 |
| Louie, B | 1 |
| Mørland, J | 2 |
| Krogh, M | 1 |
| Khiabani, HZ | 1 |
| Sandtorv, L | 1 |
| Reigstad, H | 1 |
| Bruarøy, S | 1 |
| Elgen, I | 1 |
| Laegreid, LM | 1 |
| Newville, H | 2 |
| Xiao, L | 2 |
| Goodarzi, A | 3 |
| Roushanzamir, F | 1 |
| Sedaghati, T | 1 |
| Noori-Daloii, MR | 1 |
| Sullivan, B | 1 |
| Petry, NM | 8 |
| Lieb, B | 1 |
| Specka, M | 6 |
| Augener, S | 1 |
| Bachmann, HS | 1 |
| Siffert, W | 1 |
| Deck, D | 1 |
| Wiitala, W | 1 |
| McFarland, B | 1 |
| Mullooly, J | 1 |
| Krupski, A | 1 |
| Bowman, SE | 1 |
| Jeronimo, A | 1 |
| Spiller, H | 1 |
| Lorenz, DJ | 1 |
| Bailey, EJ | 2 |
| Dart, RC | 2 |
| Maynard, C | 1 |
| Koepsell, TD | 1 |
| Wells, EA | 5 |
| Donovan, DM | 1 |
| Meise, M | 1 |
| Sauter, ML | 1 |
| Liu, ZM | 1 |
| Jacob, S | 1 |
| Jickells, S | 1 |
| Smith, N | 1 |
| Orman, JS | 1 |
| Keating, GM | 1 |
| Doehring, A | 1 |
| Hentig, Nv | 1 |
| Graff, J | 1 |
| Salamat, S | 1 |
| Schmidt, M | 1 |
| Geisslinger, G | 1 |
| Harder, S | 1 |
| Lötsch, J | 1 |
| Rapeli, P | 4 |
| Fabritius, C | 4 |
| Kalska, H | 4 |
| Madden, A | 1 |
| Bath, N | 1 |
| Anchersen, K | 2 |
| Hansteen, V | 3 |
| Zamani, S | 2 |
| Farnia, M | 2 |
| Gholizadeh, M | 1 |
| Nazari, M | 1 |
| Seddighi, AA | 1 |
| Setayesh, H | 1 |
| Afshar, P | 1 |
| Kihara, M | 1 |
| De Wulf, I | 1 |
| Duquet, N | 1 |
| Saevels, J | 1 |
| Puttemans, MK | 1 |
| Allard, L | 1 |
| Bogaert, J | 1 |
| Brohée, JP | 1 |
| Karadag, EN | 1 |
| Lagrain, J | 1 |
| Ledoux, MY | 1 |
| Remy, C | 1 |
| Verrando, R | 1 |
| Schmittner, J | 2 |
| Eid, NC | 1 |
| Alfò, M | 1 |
| Maruotti, A | 1 |
| Marzo, JN | 1 |
| Rotily, M | 1 |
| Varastet, M | 1 |
| Hunault, C | 1 |
| Obradovic, I | 1 |
| Zin, A | 1 |
| Bell, JR | 3 |
| Butler, B | 2 |
| Lawrance, A | 1 |
| Batey, R | 2 |
| Salmelainen, P | 1 |
| Anstice, S | 1 |
| Strike, CJ | 4 |
| Andersen, D | 1 |
| Sedaghati, M | 2 |
| Conner, KR | 2 |
| Ross, ME | 1 |
| Baciewicz, G | 1 |
| Sworts, LM | 1 |
| Meldrum, SC | 1 |
| O'Grady, K | 1 |
| Dahne, J | 1 |
| Johnson, R | 1 |
| Lemoine, L | 1 |
| Milio, L | 3 |
| Sharkey, KM | 4 |
| Kurth, ME | 4 |
| Corso, RP | 4 |
| Brower, KJ | 1 |
| Millman, RP | 4 |
| Wallner, C | 1 |
| Stöllberger, C | 1 |
| Hlavin, A | 1 |
| Finsterer, J | 1 |
| Hager, I | 1 |
| Hermann, P | 1 |
| Scott, GJ | 1 |
| Holding, S | 1 |
| Purcell, A | 3 |
| Tutty, S | 4 |
| Ignjatova, L | 1 |
| Raleva, M | 1 |
| Jamois, C | 1 |
| Smith, P | 1 |
| Morrison, R | 1 |
| Riek, M | 1 |
| Morcos, PN | 1 |
| Stotts, AL | 2 |
| Dodrill, CL | 1 |
| Trinh, L | 1 |
| Rubin, G | 1 |
| Chen, MS | 1 |
| Pei, DE | 1 |
| Peng, JS | 1 |
| Liu, MQ | 1 |
| Farrar, D | 1 |
| Sheard, L | 3 |
| Adams, CE | 3 |
| Bound, N | 2 |
| Rushforth, B | 1 |
| Hart, R | 2 |
| Tompkins, CN | 3 |
| Garnet, B | 2 |
| Joshi, D | 2 |
| Law, M | 1 |
| Prosser, J | 3 |
| George, S | 2 |
| Moreira, K | 1 |
| Fapohunda, M | 1 |
| Almario, CV | 2 |
| Berghella, V | 4 |
| Larance, BK | 1 |
| Ali, RL | 3 |
| Scheuer, N | 1 |
| Musshoff, F | 1 |
| Trafkowski, J | 1 |
| Lichtermann, D | 2 |
| Madea, B | 1 |
| Madlung-Kratzer, E | 1 |
| Spitzer, B | 2 |
| Brosch, R | 1 |
| Dunkel, D | 1 |
| Haring, C | 1 |
| Chast, F | 1 |
| Baud, FJ | 1 |
| Ruhf, A | 1 |
| Coviello, DM | 1 |
| Zanis, DA | 5 |
| Wesnoski, SA | 1 |
| Domis, SW | 1 |
| Callaghan, R | 1 |
| King, V | 1 |
| Clark, M | 3 |
| Darke, S | 6 |
| Duflou, J | 1 |
| Torok, M | 3 |
| Jiang, X | 1 |
| Patkar, A | 1 |
| Rozen, S | 1 |
| Matson, W | 1 |
| Krishnan, R | 1 |
| Kaddurah-Daouk, R | 1 |
| Martell, BA | 2 |
| Orson, FM | 1 |
| Poling, J | 3 |
| Mitchell, E | 1 |
| Rossen, RD | 1 |
| Gardner, T | 1 |
| Stapleton, RD | 1 |
| Comiskey, CM | 2 |
| Sharifa Ezat, WP | 1 |
| Noor Azimah, H | 1 |
| Rushidi, R | 1 |
| Raminder, K | 1 |
| Ruhani, I | 1 |
| Eide-Olsen, B | 1 |
| Liu, AJ | 3 |
| An, EI | 1 |
| Murray, HG | 1 |
| Tetstall, E | 1 |
| Leroi, MJ | 1 |
| Nanan, RK | 1 |
| Toskulkao, T | 1 |
| Pornchai, R | 1 |
| Akkarapatumwong, V | 1 |
| Vatanatunyakum, S | 1 |
| Govitrapong, P | 1 |
| Fingelkurts, AA | 4 |
| Kivisaari, R | 2 |
| Autti, T | 2 |
| Borisov, S | 2 |
| Puuskari, V | 2 |
| Jokela, O | 2 |
| Kähkönen, S | 2 |
| Schaub, M | 1 |
| Chtenguelov, V | 1 |
| Weiler, G | 1 |
| Martinsen, H | 1 |
| Røislien, J | 1 |
| Bakke, E | 1 |
| Bachs, L | 1 |
| Saldaña, C | 1 |
| Hart, CL | 1 |
| Abramsohn, Y | 1 |
| Marrari, EA | 1 |
| Guarino, HM | 1 |
| Campbell, WS | 1 |
| Gargano, SP | 1 |
| Haller, DL | 2 |
| Solhkhah, R | 1 |
| Schwarz, RK | 1 |
| Herme, M | 1 |
| Okoli, CT | 1 |
| Khara, M | 2 |
| Procyshyn, RM | 1 |
| Johnson, JL | 1 |
| Barr, AM | 1 |
| Greaves, L | 1 |
| Cohen-Moreno, R | 1 |
| Schiff, M | 1 |
| Levitt, S | 1 |
| Bar-Hamburger, R | 1 |
| Strauss, S | 1 |
| Neumark, Y | 1 |
| Heinz, AJ | 1 |
| Disney, ER | 1 |
| Glezen, LA | 1 |
| Clark, PI | 1 |
| Wu, E | 3 |
| Gilbert, L | 6 |
| Sanders, G | 2 |
| Müller, MC | 1 |
| Pichler, M | 1 |
| Martin, G | 2 |
| Plörer, D | 1 |
| Winter, C | 1 |
| Pogarell, O | 1 |
| Bogner, JR | 1 |
| Astals, M | 1 |
| Díaz, L | 2 |
| Domingo-Salvany, A | 2 |
| Bulbena, A | 1 |
| Epperson, MW | 1 |
| Khan, MR | 1 |
| Meader, N | 1 |
| de los Cobos, JP | 1 |
| Judson, G | 1 |
| Bird, R | 1 |
| O'Connor, P | 1 |
| Bevin, T | 1 |
| Loan, R | 1 |
| Schroder, M | 1 |
| McGrath, R | 1 |
| Weatherall, M | 1 |
| Moriarty, H | 2 |
| Robinson, G | 3 |
| Brooks, D | 1 |
| Petry, N | 1 |
| Yaghmaei, P | 1 |
| Roberts, M | 1 |
| Sleboda, M | 1 |
| Amar, R | 4 |
| Kehoe, P | 1 |
| Sinha, K | 1 |
| Torrington, MA | 1 |
| Lobmaier, P | 1 |
| Bramness, J | 1 |
| Constantinou, N | 2 |
| Morgan, CJ | 3 |
| Battistella, S | 2 |
| Anderson, MS | 1 |
| Mabalot Luk, JA | 1 |
| Hanley, WD | 1 |
| Jin, B | 1 |
| Riesenberg, RA | 1 |
| Wenning, LA | 1 |
| Chodakewitz, JA | 1 |
| Wagner, JA | 1 |
| Seewald, RM | 2 |
| Castells, X | 1 |
| Capellà, D | 1 |
| Vidal, X | 1 |
| Colom, J | 1 |
| Fitzsimons, H | 2 |
| Chisolm, MS | 3 |
| Proudnikov, D | 1 |
| Fischer, DA | 1 |
| Mueller, S | 1 |
| Schmid, O | 1 |
| Robertson, J | 2 |
| Roberts, K | 2 |
| Elton, R | 2 |
| Khachatrian, A | 1 |
| Abbott, PJ | 2 |
| Piekoszewski, W | 4 |
| Florek, E | 2 |
| Kobus, A | 2 |
| Lechowicz, W | 1 |
| Blanquart, T | 1 |
| Fischer, M | 1 |
| Schäfer, I | 6 |
| Fredheim, OM | 1 |
| Nøstdahl, T | 1 |
| Nordstrand, B | 2 |
| Høivik, T | 1 |
| Rygnestad, T | 1 |
| Borchgrevink, PC | 1 |
| Sithamparanathan, S | 1 |
| Jones, MP | 2 |
| Cook, CM | 2 |
| Nanan, R | 2 |
| Byrd-Sellers, J | 1 |
| Smith-Cox, J | 1 |
| Lutchman, TS | 1 |
| Wilson, ME | 1 |
| Bean, HK | 1 |
| Gannon, R | 1 |
| Ebrahimi, B | 1 |
| Shams, A | 1 |
| Eiroa-Orosa, FJ | 2 |
| Lobmaier, PP | 1 |
| Katevoll, T | 1 |
| Barjaud, M | 1 |
| Mammen, K | 1 |
| Adeniji, AA | 1 |
| Pearson, L | 1 |
| Antcliffe, JM | 1 |
| Sinha, C | 3 |
| Pairaudeau, PW | 1 |
| Moratti, E | 1 |
| Kashanpour, H | 1 |
| Lombardelli, T | 1 |
| Maisto, M | 1 |
| Mancino, M | 1 |
| Curran, G | 1 |
| Han, X | 1 |
| Allee, E | 1 |
| Booth, BM | 1 |
| Tang, YL | 2 |
| Smith, AK | 1 |
| Xiang, YT | 1 |
| Sheng, LX | 1 |
| Chi, Y | 1 |
| Du, WJ | 1 |
| Guo, S | 3 |
| Jiang, ZN | 1 |
| Zhang, GF | 1 |
| Luo, XN | 1 |
| Isemann, B | 1 |
| Marsh, D | 3 |
| Oneda, B | 2 |
| Crettol, S | 5 |
| Bochud, M | 1 |
| Croquette-Krokar, M | 3 |
| Monnat, M | 3 |
| Preisig, M | 2 |
| Eap, CB | 18 |
| Byrne, A | 11 |
| Plater-Zyberk, CJ | 1 |
| Cicero, T | 1 |
| Inciardi, J | 1 |
| Parrino, M | 2 |
| Fernández-Espejo, E | 1 |
| Weinstock, J | 2 |
| Rash, CJ | 1 |
| Che, Y | 1 |
| McNeil, E | 1 |
| Geater, A | 1 |
| You, J | 1 |
| Vanagas, G | 4 |
| Padaiga, Z | 4 |
| Bagdonas, E | 2 |
| Holbrook, A | 1 |
| Brunet, BR | 1 |
| Mura, P | 1 |
| Copeland, L | 1 |
| McKenzie, J | 1 |
| De Angelis, D | 1 |
| Winslow, M | 1 |
| Manning, V | 2 |
| Thane, KK | 1 |
| Holt, E | 1 |
| Engdahl, B | 1 |
| Perrin, NA | 1 |
| Polen, MR | 1 |
| Leo, MC | 1 |
| Lynch, F | 1 |
| Weich, L | 1 |
| Canfield, KM | 1 |
| Smyth, E | 1 |
| Ploutz-Snyder, R | 1 |
| Levine, RA | 1 |
| Borelli, JL | 1 |
| Luthar, SS | 3 |
| Suchman, NE | 2 |
| Naderi-Heiden, A | 1 |
| Gleiss, A | 1 |
| Bäcker, C | 1 |
| Bieber, D | 1 |
| Nassan-Agha, H | 1 |
| Kasper, S | 7 |
| Frey, R | 1 |
| Young, D | 1 |
| Campbell, N | 1 |
| Mayor, S | 1 |
| Byun, J | 1 |
| Hiltunen, AJ | 3 |
| Eklund, C | 3 |
| Borg, S | 4 |
| Gray, TR | 4 |
| Dams, R | 1 |
| Ducray, K | 1 |
| Pieper, B | 1 |
| Templin, TN | 1 |
| Kirsner, RS | 1 |
| Birk, TJ | 1 |
| Trelis-Navarro, J | 1 |
| Tuca-Rodríguez, A | 1 |
| Gómez-Batiste, X | 1 |
| Whitley, SD | 2 |
| Sohler, NL | 1 |
| Kunins, HV | 2 |
| Giovanniello, A | 1 |
| Simkin, DR | 1 |
| Grenoble, S | 1 |
| Calvin, C | 1 |
| Dilg, C | 1 |
| Karow, A | 3 |
| De Maeyer, J | 3 |
| Vanderplasschen, W | 3 |
| Lammertyn, J | 1 |
| van Nieuwenhuizen, C | 2 |
| Sabbe, B | 2 |
| Broekaert, E | 3 |
| Rumball, D | 1 |
| Wagle, A | 1 |
| Perrin-Terrin, A | 1 |
| Pathak, A | 1 |
| Lapeyre-Mestre, M | 2 |
| Cubells, JF | 2 |
| Pruzinsky, R | 1 |
| Gonsai, K | 3 |
| Cargile, C | 1 |
| Gonzalez-Haddad, G | 1 |
| Litwin, A | 1 |
| Protopopescu, C | 1 |
| Cleary, BJ | 4 |
| Donnelly, J | 1 |
| Strawbridge, J | 1 |
| Gallagher, PJ | 4 |
| Clarke, M | 1 |
| Murphy, DJ | 4 |
| Flassing, J | 1 |
| Concheiro, M | 1 |
| Williams, E | 1 |
| Carpentier, PJ | 1 |
| van Gogh, MT | 1 |
| Knapen, LJ | 1 |
| Buitelaar, JK | 1 |
| De Jong, CA | 3 |
| Conroy, E | 2 |
| Krupitsky, E | 1 |
| Zvartau, E | 1 |
| Felsen, UR | 1 |
| Fishbein, DA | 1 |
| Khanna, N | 1 |
| Sadaphal, S | 1 |
| Joshi, A | 1 |
| Grey, A | 1 |
| Rix-Trott, K | 2 |
| Horne, A | 1 |
| Gamble, G | 1 |
| Bolland, M | 1 |
| Reid, IR | 1 |
| Senbanjo, R | 2 |
| Hunt, N | 1 |
| Cornish, R | 1 |
| Chen, IC | 1 |
| Chie, WC | 1 |
| Hwu, HG | 1 |
| Chou, SY | 1 |
| Yeh, YC | 1 |
| Yu, CY | 1 |
| Tan, HK | 1 |
| Morse, JQ | 1 |
| Pukrop, R | 1 |
| Martin, TC | 1 |
| Rocque, MA | 1 |
| Wilson, P | 4 |
| Horyniak, D | 1 |
| Winstock, A | 2 |
| He, Q | 1 |
| Chen, A | 1 |
| Zhao, L | 1 |
| Han, L | 1 |
| Carver, HW | 1 |
| Kinzly, M | 1 |
| Demarie, D | 1 |
| Marletta, G | 1 |
| Imazio, M | 1 |
| Cappa, C | 1 |
| Ferro, S | 1 |
| Compostino, R | 1 |
| De Vivo, E | 1 |
| Trinchero, R | 1 |
| Bignamini, E | 1 |
| Leeman, LM | 1 |
| Brown, SA | 1 |
| Albright, B | 1 |
| Skipper, B | 1 |
| Donnelly, JM | 1 |
| Strawbridge, JD | 1 |
| White, MJ | 3 |
| Saenz, E | 1 |
| Ciccocioppo, R | 1 |
| Zaimovic, A | 2 |
| Gerra, ML | 1 |
| Amore, M | 1 |
| Donnini, C | 1 |
| Gordon, AL | 2 |
| Lopatko, OV | 2 |
| Foster, DJ | 6 |
| Lamanna, F | 1 |
| Dell'osso, L | 1 |
| Wilson, IB | 1 |
| Taracha, E | 3 |
| Dyr, W | 1 |
| Ćwiek, M | 1 |
| Turzyńska, D | 1 |
| Walkowiak, J | 2 |
| Wyszogrodzka, E | 1 |
| Kostowski, W | 2 |
| Płaźnik, A | 1 |
| Chrapusta, SJ | 1 |
| Skinner, ML | 1 |
| Haggerty, KP | 2 |
| Fleming, CB | 2 |
| Catalano, RF | 2 |
| Gainey, RR | 1 |
| Bryson, EO | 1 |
| de Castro, A | 2 |
| Shakleya, DM | 2 |
| Pizarro, D | 1 |
| Habli, M | 1 |
| Grier, M | 1 |
| Bombrys, A | 1 |
| Sibai, B | 1 |
| Livingston, J | 1 |
| Daoudal, P | 1 |
| Bein, C | 1 |
| Bazzi, N | 1 |
| Bourscheid, D | 1 |
| Floriot, C | 1 |
| Weil, M | 1 |
| Yu Tim, Y | 1 |
| Reichert, M | 1 |
| Trabelsi, C | 1 |
| Lang, JP | 1 |
| Ohl, J | 1 |
| Partisani, M | 1 |
| Habersetzer, F | 1 |
| Chaudhry, AA | 1 |
| Botsko, M | 2 |
| Weiss, L | 2 |
| Egan, JE | 2 |
| Mitty, J | 1 |
| Estrada, B | 1 |
| Lucas, GM | 3 |
| Woodson, T | 1 |
| Flanigan, TP | 1 |
| Netherland, J | 1 |
| Finkelstein, R | 2 |
| Perel, JM | 2 |
| Helsel, JC | 2 |
| Thompson, M | 1 |
| Wisner, KL | 3 |
| Longman, C | 1 |
| Temple-Smith, M | 1 |
| Gilchrist, G | 2 |
| Yang, J | 1 |
| Christian, KW | 1 |
| Louie, M | 1 |
| Schechter, M | 1 |
| Spittal, P | 1 |
| O'Brien, S | 4 |
| Benich, JJ | 1 |
| Kulza, M | 1 |
| Foryś, D | 1 |
| Seńczuk-Przybyłowska, M | 1 |
| Chuchracki, M | 1 |
| Roma, PG | 1 |
| Folk, JE | 1 |
| Rice, KC | 1 |
| Nsimba, SE | 1 |
| Unger, A | 5 |
| Jagsch, R | 17 |
| Arria, A | 1 |
| Leitich, H | 1 |
| Rohrmeister, K | 4 |
| Aschauer, C | 3 |
| Bäwert, A | 3 |
| Sandqvist, S | 1 |
| Eriksen, P | 1 |
| Franck, J | 1 |
| Palmskog, G | 1 |
| Samnaliev, M | 1 |
| Leung, GY | 1 |
| Hashemi, L | 1 |
| van Holst, RJ | 1 |
| Schilt, T | 1 |
| Camfield, L | 1 |
| Vanheule, S | 1 |
| Krystal, J | 1 |
| Möller, HJ | 1 |
| Naber, D | 3 |
| Buchholz, A | 1 |
| Kuhlmann, T | 1 |
| Rist, F | 1 |
| Gonzalez, JS | 1 |
| Psaros, C | 1 |
| Batchelder, A | 1 |
| Applebaum, A | 1 |
| Safren, SA | 2 |
| Tharwani, HM | 1 |
| Lacroix, I | 1 |
| Berrebi, A | 1 |
| Garipuy, D | 1 |
| Schmitt, L | 2 |
| Hammou, Y | 1 |
| Chaumerliac, C | 1 |
| Montastruc, JL | 1 |
| Damase-Michel, C | 1 |
| Lai, W | 1 |
| Cuyàs, E | 1 |
| Pizarro, N | 1 |
| Khymenets, O | 1 |
| O'Shea, J | 4 |
| Law, F | 4 |
| Melichar, J | 3 |
| Teljeur, C | 1 |
| Motterlini, N | 1 |
| McCowan, C | 1 |
| Dimitrov, BD | 1 |
| Gervasoni, JP | 1 |
| Balthasar, H | 1 |
| Huissoud, T | 2 |
| Jeannin, A | 1 |
| Dubois-Arber, F | 1 |
| Fehr, S | 1 |
| Prieto, L | 1 |
| Robles, E | 4 |
| Huang, BE | 1 |
| Simpson, PM | 1 |
| McMillan, DE | 2 |
| Aniskin, DB | 1 |
| Fink, E | 1 |
| Boda, N | 1 |
| Hamburger, RB | 1 |
| Hamon, S | 1 |
| Marchand, KI | 1 |
| Zhang, R | 1 |
| Wu, F | 1 |
| Chang, YJ | 1 |
| Peng, C | 1 |
| Stitzer, ML | 52 |
| Roll, J | 3 |
| Dollberg, S | 1 |
| Salkever, DS | 1 |
| Rieckmann, TR | 2 |
| Kovas, AE | 1 |
| McFarland, BH | 1 |
| Heilmann, M | 1 |
| Schifano, F | 2 |
| Metz, V | 2 |
| Würzl, J | 1 |
| Smith, L | 1 |
| Sundet, JM | 1 |
| Bornemann, R | 2 |
| Sullivan, LE | 3 |
| Breuer, T | 1 |
| Savant, J | 1 |
| Rounsaville, BJ | 23 |
| Karch, SB | 2 |
| Behonick, GS | 1 |
| Wunsch, MJ | 2 |
| Rados, V | 1 |
| Curcio, F | 1 |
| Franco, T | 1 |
| Topa, M | 1 |
| Baldassarre, C | 1 |
| Kenny, K | 1 |
| O'Carroll, A | 1 |
| Lehnert, R | 2 |
| Küfner, H | 1 |
| Haberthür, A | 2 |
| Toson, B | 1 |
| Backes, CH | 1 |
| Backes, CR | 1 |
| Gardner, D | 1 |
| Nankervis, CA | 1 |
| Giannone, PJ | 1 |
| Cordero, L | 1 |
| Metzger, DS | 4 |
| Kheirabadi, GR | 1 |
| Maracy, MR | 1 |
| Ranjkesh, M | 1 |
| Pedrelli, P | 1 |
| Iovieno, N | 1 |
| Vitali, M | 1 |
| Tedeschini, E | 1 |
| Bentley, KH | 1 |
| Papakostas, GI | 1 |
| Träder, A | 2 |
| Klotsche, J | 3 |
| Yeh, TL | 1 |
| Yao, WJ | 1 |
| Liao, MH | 1 |
| Chiu, NT | 1 |
| Savvas, SM | 1 |
| Stangeland, P | 1 |
| Havnes, I | 1 |
| Knoppert, D | 1 |
| Desmond, JE | 1 |
| Maricq, A | 1 |
| Jacques, D | 1 |
| Zdanowicz, N | 1 |
| Marchand, E | 1 |
| Evrard, P | 1 |
| Bulpa, P | 1 |
| Reynaert, C | 1 |
| Salimi, S | 1 |
| Nassirimanesh, B | 1 |
| Mohsenifar, S | 1 |
| Allsop, D | 1 |
| Sweeney, BP | 1 |
| El Hassan, HO | 1 |
| Barry, JM | 2 |
| Chekuri, V | 1 |
| Gerber, D | 1 |
| Brodie, A | 1 |
| Krishnadas, R | 1 |
| Praveen, KT | 2 |
| Domeque Valiente, N | 1 |
| Prieto Andrés, P | 1 |
| Lozano Ortiz, R | 1 |
| Andrés Arribas, I | 1 |
| Hedrich, D | 1 |
| Møller, L | 1 |
| Britton, PC | 1 |
| Wines, JD | 1 |
| Müller, MJ | 1 |
| Lange, M | 1 |
| Paul, T | 1 |
| Seeliger, S | 1 |
| Huxtable, CA | 1 |
| Roberts, LJ | 1 |
| MacIntyre, PE | 1 |
| Neukam, K | 1 |
| Mira, JA | 1 |
| Gilabert, I | 1 |
| Claro, E | 1 |
| Vázquez, MJ | 1 |
| Cifuentes, C | 1 |
| García-Rey, S | 1 |
| Merchante, N | 1 |
| Almeida, C | 1 |
| Macías, J | 1 |
| Pineda, JA | 1 |
| Hoell, I | 1 |
| Havemann-Reinecke, U | 1 |
| Stimmel, B | 14 |
| Campbell, A | 1 |
| Killip, T | 1 |
| Kotz, M | 1 |
| McCarroll, BA | 1 |
| Payte, JT | 2 |
| Taylor, T | 1 |
| Wilford, BB | 1 |
| Gevertz, SG | 1 |
| Di Pietro, JA | 1 |
| Williams, EL | 1 |
| Yao, Z | 1 |
| Hellings, C | 1 |
| Trautmann, S | 1 |
| Garijo, I | 1 |
| del Pozo, J | 1 |
| Saiful, FB | 1 |
| Lafferty, J | 1 |
| Jun, CH | 1 |
| Teli, S | 1 |
| Duvvuri, S | 1 |
| Khattri, S | 1 |
| Bhat, T | 1 |
| Coyle, M | 1 |
| Schuster, J | 1 |
| Farmer, C | 1 |
| Fulton, HG | 1 |
| Macisaac, C | 1 |
| Gerlach, K | 1 |
| Montelpare, W | 1 |
| Rushforth, BJ | 2 |
| Harrison, W | 1 |
| Qi, J | 1 |
| Roy, AK | 1 |
| McCarthy, C | 1 |
| Kiernan, G | 1 |
| McGorrian, C | 1 |
| Mahon, NG | 1 |
| Nejati, M | 1 |
| Nejati, V | 1 |
| Smirnov, A | 1 |
| Kemp, R | 1 |
| Tomedi, LE | 1 |
| Saint-Lèbes, J | 1 |
| Rodgers, R | 1 |
| Birmes, P | 1 |
| Harris, J | 1 |
| Katz, EC | 2 |
| King, S | 1 |
| Eiserman, J | 1 |
| Acosta, A | 1 |
| Gote, C | 1 |
| Lim, JK | 1 |
| Xie, B | 1 |
| Dickman, SL | 2 |
| Parihk, A | 1 |
| Kinlock, TW | 5 |
| Harris, A | 1 |
| Selling, D | 1 |
| Luther, C | 1 |
| Brittain, J | 1 |
| Dickman, S | 1 |
| Glick, A | 1 |
| Trigg, BG | 1 |
| Myrick, C | 1 |
| Peindl, KS | 1 |
| Lee, T | 1 |
| Bhatia, KS | 1 |
| Pluck, G | 1 |
| Lee, KH | 1 |
| Rele, R | 1 |
| Spence, SA | 1 |
| Sarkar, S | 3 |
| Parks, RW | 1 |
| Wang, Q | 1 |
| Nolan, C | 1 |
| Carlson, G | 1 |
| Zhang, G | 1 |
| Liu, H | 1 |
| Xue, H | 1 |
| Shan, D | 1 |
| Yang, YC | 1 |
| Sun, JP | 1 |
| Eogan, M | 2 |
| O'Connell, MP | 2 |
| Clarke, T | 2 |
| McDermott, C | 2 |
| O'Sullivan, A | 2 |
| Carmody, D | 2 |
| Vasić, G | 1 |
| Mihajlović, G | 1 |
| Jovanović-Mihajlović, N | 1 |
| Rafajlović, M | 1 |
| Barisić, J | 1 |
| Djukić-Dejanović, S | 1 |
| Janković, S | 1 |
| Radonjić, K | 1 |
| Baewert, A | 6 |
| Kaiser, G | 1 |
| Weninger, M | 2 |
| Zhong, Y | 1 |
| Dobbin, MD | 1 |
| McDonough, MA | 1 |
| Pritham, UA | 1 |
| Paul, JA | 1 |
| Hayes, MJ | 2 |
| Florian, J | 1 |
| Garnett, CE | 1 |
| Nallani, SC | 1 |
| Rappaport, BA | 1 |
| Throckmorton, DC | 1 |
| Laqueille, X | 6 |
| Richa, S | 1 |
| Kerbage, H | 1 |
| Scart-Gres, C | 1 |
| Berleur, MP | 1 |
| Boyd, SJ | 1 |
| Fang, LJ | 1 |
| Medoff, DR | 1 |
| Dixon, LB | 1 |
| Höflich, AS | 1 |
| Langer, M | 3 |
| Kosten, T | 10 |
| Guh, DP | 1 |
| Bansback, NJ | 1 |
| Meikleham, E | 1 |
| Green, C | 1 |
| Masuda, A | 1 |
| Grabowski, J | 10 |
| Wilson, K | 1 |
| Northrup, TF | 1 |
| Moeller, FG | 1 |
| Schmitz, JM | 3 |
| Golovanevskaya, M | 1 |
| Vlasenko, L | 1 |
| Saucier, R | 1 |
| Li, JH | 2 |
| Wu, JS | 1 |
| Tang, HP | 1 |
| Valga-Amado, F | 1 |
| Monzón-Vázquez, TR | 1 |
| Hadad, F | 1 |
| Torrente-Sierra, J | 1 |
| Pérez-Flores, I | 1 |
| Barrientos-Guzmán, A | 1 |
| Haklai, Z | 1 |
| Goldberger, N | 1 |
| Zohar, P | 1 |
| Margolis, A | 1 |
| Ponizovsky, AM | 1 |
| Himes, SK | 1 |
| Goodwin, RS | 1 |
| Rock, CM | 1 |
| Wilkins, DG | 1 |
| Benvenuto, A | 1 |
| Howard, D | 1 |
| Johnston, A | 1 |
| Plante, D | 1 |
| Metayer, J | 1 |
| Mandell, T | 1 |
| Bhupal, HK | 1 |
| Allard, R | 1 |
| Maurais, E | 1 |
| Haley, N | 1 |
| Small, C | 1 |
| Bracken, BK | 1 |
| Trksak, GH | 1 |
| Penetar, DM | 1 |
| Tartarini, WL | 1 |
| Maywalt, MA | 1 |
| Dorsey, CM | 1 |
| Lukas, SE | 4 |
| Kelly, LE | 1 |
| Rieder, MJ | 1 |
| Bridgman-Acker, K | 1 |
| Lauwers, A | 1 |
| Madadi, P | 1 |
| Jovanović, T | 1 |
| Lazarević, D | 1 |
| Nikolić, G | 1 |
| Chalmers, J | 1 |
| Ritter, A | 2 |
| Young, JL | 1 |
| Daniels, AM | 3 |
| Pierce, CE | 1 |
| Filippell, T | 1 |
| McKeganey, N | 1 |
| Cockayne, L | 1 |
| Ferrara, MM | 1 |
| Dedicoat, MJ | 1 |
| Amini Lari, M | 1 |
| Parsa, N | 1 |
| Marzban, M | 1 |
| Shams, M | 1 |
| Faramarzi, H | 1 |
| McDonald, S | 2 |
| Kaye, S | 3 |
| Liang, Y | 1 |
| Moshier, SJ | 2 |
| Calkins, AW | 1 |
| Hearon, BA | 1 |
| Rosellini, AJ | 1 |
| Weitzman, ML | 1 |
| Otto, MW | 3 |
| Aubertin, JF | 1 |
| Desenclos, JC | 1 |
| Pud, D | 1 |
| Zlotnick, C | 1 |
| Lawental, E | 1 |
| Mullen, L | 1 |
| Long, J | 1 |
| Mulholland, D | 1 |
| Grogan, L | 1 |
| Zaric, GS | 1 |
| Brennan, AW | 1 |
| Daiter, JM | 1 |
| Liang, LJ | 1 |
| Balhara, YP | 1 |
| Alvarado, MX | 1 |
| Rodriguez Morera, J | 1 |
| Martin Fernandez, X | 1 |
| Juanós Iborra, M | 1 |
| Caviness, CM | 1 |
| de Dios, MA | 1 |
| Kurth, M | 1 |
| Nunn, A | 1 |
| Bobes García, J | 1 |
| Bobes Bascarán, MT | 1 |
| White, WL | 1 |
| Appel, PW | 1 |
| Tsemberis, S | 1 |
| Stefancic, A | 1 |
| Lambert-Wacey, D | 1 |
| Chengappa, MN | 1 |
| Suresh Kumar, M | 1 |
| Häkkinen, M | 1 |
| Launiainen, T | 1 |
| Vuori, E | 1 |
| Wu, G | 1 |
| Lappalainen, J | 1 |
| Spence, D | 1 |
| Doraimani, G | 1 |
| Tasissa, G | 1 |
| Lokhnygina, Y | 1 |
| Leimberger, J | 1 |
| McCarthy, J | 1 |
| Bilangi, R | 1 |
| Ogle, A | 1 |
| Barrett, B | 1 |
| Young, MS | 1 |
| Pearson, J | 1 |
| Romkes, M | 1 |
| Nukui, T | 1 |
| Friedman, CR | 1 |
| Dhingra, L | 1 |
| Masson, C | 2 |
| Katz, J | 1 |
| McKnight, C | 1 |
| Homel, P | 1 |
| Wald, E | 1 |
| Young, C | 1 |
| Portenoy, RK | 2 |
| Doe-Simkins, M | 1 |
| Quinn, E | 1 |
| Pierce, C | 1 |
| Ozonoff, A | 1 |
| Larios, S | 1 |
| Tulsky, J | 1 |
| Powelson, E | 1 |
| Logan, DP | 1 |
| Gonzalez, A | 1 |
| Israel, J | 1 |
| Andres Bedoya, C | 1 |
| Reed, B | 1 |
| Schlussman, SD | 1 |
| Mooney, G | 1 |
| Devarajah, S | 1 |
| Sullivan, JV | 1 |
| Stallvik, M | 1 |
| Kristensen, Ø | 2 |
| Bathen, J | 2 |
| Bandstra, ES | 1 |
| Gaalema, DE | 1 |
| Scott, TL | 1 |
| Lin, H | 1 |
| Graf-Rohrmeister, K | 2 |
| Benningfield, MM | 1 |
| Dietrich, MS | 1 |
| McNicholas, LF | 1 |
| Cerić, I | 1 |
| Bongers, IL | 1 |
| Stacey, H | 1 |
| Pearson, V | 1 |
| Woods, A | 1 |
| Fisk, A | 1 |
| Garcia-Portilla, MP | 1 |
| Bobes-Bascaran, MT | 1 |
| Bascaran, MT | 3 |
| Saiz, PA | 1 |
| Winklbaur-Hausknost, B | 1 |
| Reisfield, GM | 1 |
| Friedman, CK | 1 |
| Reynolds, K | 1 |
| Benzon, HT | 1 |
| Kendall, MC | 1 |
| Katz, JA | 1 |
| Benzon, HA | 1 |
| Malik, K | 1 |
| Cox, P | 1 |
| Dean, K | 1 |
| Avram, MJ | 1 |
| Shainker, SA | 1 |
| Lee-Parritz, A | 1 |
| Dobrinas, M | 1 |
| Lahyani, R | 1 |
| Rotger, M | 1 |
| Choong, E | 1 |
| Lubomirov, R | 1 |
| Csajka, C | 1 |
| Ewen, M | 1 |
| Brekke, M | 1 |
| Lindbaek, M | 1 |
| Reinertsen, E | 1 |
| Thoresen, M | 1 |
| Acquavita, SP | 1 |
| Wilson-Murphy, M | 1 |
| Rotter, I | 1 |
| Król-Pakulska, E | 1 |
| Radlińska, I | 1 |
| Mroczek, B | 1 |
| Grochans, E | 1 |
| Pakulski, C | 1 |
| Napolitano, A | 1 |
| Theophilopoulos, D | 1 |
| Seng, SK | 1 |
| Calhoun, DA | 1 |
| Logan, BA | 1 |
| Brown, MS | 1 |
| Wu, B | 1 |
| Sheehan, M | 1 |
| Sheehan, MG | 1 |
| Green, A | 1 |
| Kaul, A | 1 |
| Sharma, E | 1 |
| Bennett, L | 1 |
| Mullings, EL | 1 |
| Munafò, MR | 1 |
| Donaldson, LF | 1 |
| Fazzino, T | 1 |
| Sulistio, M | 1 |
| Jackson, K | 1 |
| Byrne, SA | 1 |
| Cherniack, MG | 1 |
| Cecero, JJ | 2 |
| Eyler, EC | 1 |
| Bilban, M | 1 |
| Bilban Jakopin, C | 1 |
| Titsas, A | 1 |
| Ferguson, MM | 1 |
| Roozen, HG | 1 |
| de Kan, R | 1 |
| Kerkhof, BJ | 1 |
| Geerlings, PJ | 1 |
| Bogucka-Bonikowska, A | 1 |
| Baran-Furga, H | 3 |
| Chmielewska, K | 4 |
| Scinska, A | 1 |
| Kukwa, A | 1 |
| Koros, E | 1 |
| Polanowska, E | 1 |
| Bienkowski, P | 1 |
| Sartain, JB | 1 |
| Mitchell, SJ | 1 |
| Keszycka, B | 1 |
| Buster, MC | 1 |
| van Brussel, GH | 2 |
| Huber, A | 1 |
| Reiber, C | 1 |
| Vocci, FJ | 1 |
| Kellogg, SH | 2 |
| Ho, A | 2 |
| Bell, K | 1 |
| Schluger, RP | 1 |
| McHugh, PF | 1 |
| McClary, KA | 1 |
| Albert, PS | 1 |
| Follmann, DA | 1 |
| Wang, SA | 1 |
| Suh, EB | 1 |
| Niveau, G | 1 |
| Rougemont, AL | 1 |
| La Harpe, R | 3 |
| Kirst, M | 3 |
| Reggers, J | 1 |
| de los Cobos, J | 1 |
| Valero, S | 3 |
| Haro, G | 2 |
| Fidel, G | 2 |
| Escuder, G | 2 |
| Valderrama, JC | 3 |
| Seifert, J | 2 |
| Metzner, C | 2 |
| Paetzold, W | 2 |
| Borsutzky, M | 2 |
| Passie, T | 2 |
| Rollnik, J | 1 |
| Wiese, B | 2 |
| Emrich, HM | 1 |
| Schneider, U | 2 |
| Wilczek, H | 4 |
| Veselý, Z | 1 |
| Presl, J | 1 |
| Buclin, T | 1 |
| Baumann, P | 9 |
| Clark, DJ | 1 |
| Volfing, B | 1 |
| Sibbald, B | 2 |
| Lôo, H | 2 |
| Favrat, B | 3 |
| Rao, S | 1 |
| Drozdick, J | 1 |
| Hill, M | 1 |
| Olscher, DA | 2 |
| Todd, SJ | 1 |
| Jackson, GL | 2 |
| Wendel, GD | 3 |
| Baran, H | 1 |
| Szukalski, B | 1 |
| Prieto, IJ | 1 |
| Poyo-Guerrero, R | 1 |
| Fernández, R | 1 |
| Pollack, MH | 2 |
| Penava, SA | 1 |
| Bolton, E | 1 |
| Worthington, JJ | 1 |
| Allen, GL | 1 |
| Farach, FJ | 1 |
| Rothenberg, JL | 1 |
| Sullivan, MA | 2 |
| Church, SH | 1 |
| Seracini, A | 1 |
| Collins, E | 1 |
| Kleber, HD | 30 |
| Gilmore-Thomas, KK | 1 |
| Miller, FB | 1 |
| Ferner, RE | 1 |
| Cape, D | 1 |
| Daniel, N | 1 |
| Gliksman, L | 1 |
| Breitfeld, C | 1 |
| Eikermann, M | 1 |
| Kienbaum, P | 5 |
| Peters, J | 4 |
| Agar, M | 1 |
| Caflisch, C | 1 |
| Figner, B | 1 |
| Eich, D | 2 |
| Harding, C | 1 |
| Ritchie, J | 1 |
| Shinderman, M | 1 |
| Maxwell, S | 1 |
| Brawand-Amey, M | 2 |
| Golay, KP | 2 |
| Lyvers, M | 1 |
| Yakimoff, M | 1 |
| Wolk, S | 1 |
| Danz, C | 1 |
| Hawkins, WE | 1 |
| Covi, L | 1 |
| Ege, PP | 2 |
| Compton, M | 1 |
| Margolin, A | 5 |
| Kantak, K | 1 |
| Avants, SK | 5 |
| Buonanno, A | 1 |
| De Risio, S | 2 |
| Gill, AC | 1 |
| Oei, J | 1 |
| Lewis, NL | 1 |
| Younan, N | 1 |
| Kennedy, I | 1 |
| Lui, K | 1 |
| Taeron, C | 1 |
| Esteban, J | 2 |
| Gimeno, C | 2 |
| Barril, J | 2 |
| Aragonés, A | 2 |
| Climent, JM | 1 |
| de la Cruz Pellín, M | 1 |
| O'Keeffe, C | 1 |
| Wesson, DR | 3 |
| Fletcher, K | 1 |
| Riemer, Y | 5 |
| Ertl, M | 4 |
| Kemmler, G | 3 |
| Rössler, H | 1 |
| Hinterhuber, H | 1 |
| Pellín, Mde L | 1 |
| Ahmadi, J | 1 |
| Kutinsky, IB | 1 |
| Robertson, AD | 1 |
| Calsyn, DA | 11 |
| DeMarco, FJ | 1 |
| Sloan, KL | 1 |
| Gibbon, KE | 1 |
| Watson, R | 3 |
| Gilhooley, T | 1 |
| Wiggins, P | 1 |
| Barclay, C | 1 |
| Pardo López, MA | 1 |
| Cuadrado Pastor, JM | 1 |
| Pérez Hervás, MP | 1 |
| Fernández Villalba, E | 1 |
| Strauss, SM | 2 |
| Astone, J | 1 |
| Vassilev, ZP | 1 |
| Des Jarlais, DC | 6 |
| Browne, N | 1 |
| Luty, J | 2 |
| Nikolaou, V | 1 |
| Fishbain, DA | 2 |
| Cutler, RB | 1 |
| Cole, B | 1 |
| Lewis, J | 1 |
| Rosomoff, RS | 1 |
| Rosomoff, HL | 2 |
| Oliveto, AH | 2 |
| Feingold, A | 3 |
| Jatlow, P | 4 |
| Chowdry, J | 1 |
| Ellis, SW | 1 |
| Geschwind, DH | 1 |
| Alarcón, M | 1 |
| Rainey, PM | 2 |
| Ivani, A | 1 |
| Jacquiez, O | 1 |
| Kornreich, C | 1 |
| Foisy, ML | 1 |
| Philippot, P | 1 |
| Dan, B | 1 |
| Tecco, J | 1 |
| Noël, X | 1 |
| Hess, U | 1 |
| Pelc, I | 1 |
| Verbanck, P | 1 |
| Faggiano, F | 3 |
| Vigna-Taglianti, F | 1 |
| Versino, E | 1 |
| Lemma, P | 1 |
| Morse, GR | 2 |
| Kozielec, T | 2 |
| Stanaszek, R | 2 |
| Keen, J | 1 |
| Oliver, P | 1 |
| Rowse, G | 1 |
| Mathers, N | 1 |
| Gupman, AE | 1 |
| OSNOS, RJ | 1 |
| WEEKS, JR | 1 |
| ROSENTHAL, T | 1 |
| KRUG, DC | 1 |
| RICE, J | 1 |
| COHEN, L | 2 |
| Di Martini, A | 1 |
| Weinrieb, R | 1 |
| Ishøy, T | 1 |
| Iversen, C | 1 |
| Mitchell, TB | 4 |
| Wayte, C | 1 |
| Caplehorn, J | 1 |
| Funada, M | 1 |
| Lenné, MG | 2 |
| Rumbold, GR | 1 |
| Redman, JR | 2 |
| Triggs, TJ | 1 |
| Layson-Wolf, C | 1 |
| Goode, JV | 1 |
| Small, RE | 1 |
| Flynn, PM | 2 |
| Joe, GW | 21 |
| Broome, KM | 3 |
| Simpson, DD | 27 |
| Horst, DA | 1 |
| Minkel, JD | 1 |
| Becka, J | 1 |
| Carreño, JE | 2 |
| Alvarez, CE | 2 |
| Narciso, GI | 1 |
| Díaz, M | 1 |
| Scully, M | 1 |
| Geoghegan, N | 1 |
| Corcoran, P | 1 |
| Tiernan, M | 1 |
| Borisova, NN | 1 |
| Goodman, AC | 1 |
| Saules, KK | 1 |
| Helmus, TC | 1 |
| Beshears, RS | 1 |
| Schuster, CR | 3 |
| Schnoll, SH | 6 |
| Barthwell, AG | 2 |
| Gourlay, D | 2 |
| Busto, U | 1 |
| Palmer, NB | 2 |
| Salcedo, J | 2 |
| Miller, AL | 2 |
| Winiarski, M | 1 |
| Arno, P | 1 |
| Barnett, R | 1 |
| DePiano, M | 1 |
| Atanda, A | 1 |
| Olthoff, KM | 1 |
| Al-Adwani, A | 2 |
| Basu, N | 1 |
| Haarr, D | 1 |
| Lauritzen, G | 1 |
| Ferrer-Alcón, M | 1 |
| García-Sevilla, JA | 2 |
| Díaz-Flores Estévez, JF | 1 |
| Díaz-Flores Estévez, F | 1 |
| Hernández Calzadilla, C | 1 |
| Rodríguez Rodríguez, EM | 1 |
| Díaz Romero, C | 1 |
| Serra-Majem, L | 1 |
| Bassetti, S | 1 |
| Wolfisberg, L | 1 |
| Jaussi, B | 1 |
| Frei, R | 1 |
| Kuntze, MF | 1 |
| Battegay, M | 1 |
| Widmer, AF | 1 |
| Schindler, SD | 3 |
| Ortner, R | 3 |
| Peternell, A | 4 |
| Eder, H | 7 |
| Opgenoorth, E | 1 |
| Negrín, CM | 1 |
| Delgado, A | 1 |
| Llabrés, M | 1 |
| Evora, C | 1 |
| Perucci, CA | 3 |
| Sánchez, N | 1 |
| Pascual, C | 1 |
| Sell, L | 1 |
| Zador, D | 4 |
| Digiusto, E | 1 |
| Shakeshaft, A | 1 |
| Herman, DS | 3 |
| Lassor, JA | 2 |
| Weinstock, M | 2 |
| Anthony, J | 1 |
| Piff, J | 1 |
| Jofre-Bonet, M | 1 |
| Petrakis, IL | 3 |
| Frankforter, T | 2 |
| Golden, SA | 1 |
| Sakhrani, DL | 1 |
| Rao, SR | 1 |
| Mulder, R | 1 |
| Sheerin, I | 1 |
| Green, T | 1 |
| Sellman, D | 3 |
| Oldham, NS | 1 |
| Wechsberg, WM | 2 |
| Flannery, B | 1 |
| Kasten, JJ | 1 |
| Suerken, C | 1 |
| Roussel, AE | 1 |
| Crum, L | 1 |
| Murdoch, O | 1 |
| Diesenhaus, H | 1 |
| Sees, KL | 3 |
| Rosen, A | 2 |
| Bézie, Y | 1 |
| Talon, V | 1 |
| Lillo, A | 1 |
| Illier, C | 1 |
| Billaud, E | 1 |
| Prognon, P | 1 |
| Boutouyrie, P | 1 |
| Fatséas, M | 1 |
| Dubernet, J | 1 |
| Tignol, J | 3 |
| Chawarski, M | 2 |
| Borella, F | 1 |
| Moi, G | 1 |
| Bussandri, M | 1 |
| Bubici, C | 1 |
| Bertacca, S | 1 |
| Cumberbatch, Z | 1 |
| Copersino, M | 1 |
| Murillo, R | 1 |
| Crucilla, C | 1 |
| Hotchkiss, E | 1 |
| Pickworth, WB | 2 |
| Hume, SP | 1 |
| Williams, TM | 1 |
| Daglish, MR | 1 |
| Ahmad, R | 1 |
| Malizia, AL | 1 |
| Lingford-Hughes, A | 1 |
| Krenz, S | 2 |
| Dieckmann, S | 1 |
| Spagnoli, J | 2 |
| Leutwyler, J | 1 |
| Schnyder, C | 1 |
| Daeppen, JB | 1 |
| Lettholm, L | 1 |
| Corkery, JM | 1 |
| Ghodse, AH | 5 |
| Oyefeso, A | 2 |
| Newcombe, DA | 1 |
| Al-Shakarshi, JS | 1 |
| Bent-Hansen, L | 1 |
| Jensen, GB | 1 |
| Pons, D | 1 |
| Fremaux, D | 1 |
| Duvauchelle, B | 1 |
| Loas, G | 1 |
| Compagnon, M | 1 |
| Hendrix, CW | 1 |
| Wakeford, J | 1 |
| Wire, MB | 1 |
| Lou, Y | 1 |
| Martinez, E | 1 |
| Christopher, J | 1 |
| Fuchs, EJ | 1 |
| Snidow, JW | 2 |
| Greener, JM | 1 |
| Rowan-Szal, GA | 6 |
| Svikis, DS | 2 |
| Diclemente, C | 1 |
| Bliesener, N | 1 |
| Albrecht, S | 1 |
| Schwager, A | 1 |
| Weckbecker, K | 1 |
| Klingmüller, D | 1 |
| Cooper, G | 2 |
| Wilson, L | 2 |
| Reid, C | 2 |
| Baldwin, D | 2 |
| Hand, C | 2 |
| Spieher, V | 1 |
| Skowrońska, A | 1 |
| Groszek, B | 2 |
| Schmager, J | 3 |
| Szpanowska-Wohn, A | 6 |
| Kolarzyk, E | 8 |
| Pach, D | 9 |
| Targosz, D | 4 |
| Jittiwutikarn, J | 1 |
| Spiga, R | 2 |
| Meisch, RA | 3 |
| Cowan, K | 1 |
| Hursh, S | 1 |
| Choi, WS | 1 |
| McCool, RM | 1 |
| Harris, KJ | 1 |
| Ahluwalia, JS | 2 |
| Kraus, C | 1 |
| Fleming, M | 2 |
| Reddy, S | 1 |
| Teplin, D | 2 |
| O'Connell, T | 1 |
| Krook, AL | 4 |
| Ledoux, Y | 1 |
| Dyer, KR | 3 |
| Salter, A | 3 |
| Hrovatin, E | 1 |
| Zardo, F | 1 |
| Brieda, M | 1 |
| Dametto, E | 1 |
| Piazza, R | 1 |
| Antonini-Canterin, F | 1 |
| Cassin, M | 1 |
| Meneguzzo, N | 1 |
| Viel, E | 1 |
| Lestuzzi, C | 1 |
| Di Gennaro, G | 1 |
| Nicolosi, GL | 1 |
| Unglaub, W | 1 |
| Loncarek, E | 1 |
| Wismath, M | 1 |
| Johann, M | 1 |
| Wodarz, N | 1 |
| Klein, H | 1 |
| Ebner, R | 1 |
| Schreiber, W | 1 |
| Zierer, C | 1 |
| Townshend, PL | 1 |
| Coverdale, JH | 1 |
| Kermack, A | 1 |
| Wilson, HJ | 1 |
| Benton, D | 1 |
| Barron, P | 1 |
| Dean, AJ | 1 |
| Christie, MJ | 1 |
| Bogenschutz, MP | 1 |
| Blankertz, L | 2 |
| Staines, GL | 3 |
| Madison, EM | 2 |
| Spinelli, M | 2 |
| Horowitz, E | 2 |
| Bali, P | 2 |
| Grandy, A | 2 |
| Young, R | 2 |
| Fong, C | 2 |
| Gomez, A | 1 |
| Dimun, A | 1 |
| Friedman, E | 1 |
| Lidz, V | 3 |
| Sorrentino, DM | 1 |
| Robison, L | 2 |
| Bunce, S | 1 |
| Kim, G | 1 |
| Sanchez, M | 3 |
| Shadel, WG | 1 |
| Anthony, JL | 3 |
| Niaura, R | 2 |
| Astone, JM | 1 |
| Craig, RJ | 3 |
| Olson, RE | 1 |
| Melcher, M | 1 |
| Cicero, TJ | 2 |
| Inciardi, JA | 2 |
| Farrant, P | 1 |
| Creamer, D | 1 |
| Fuller, C | 1 |
| Espegren, O | 2 |
| Asland, R | 1 |
| Jakobsen, E | 1 |
| Lie, Ø | 1 |
| Seiler, S | 1 |
| Pakes, JR | 3 |
| Pantalon, MV | 3 |
| Kashiwagi, M | 2 |
| Arlettaz, R | 2 |
| Lauper, U | 1 |
| Zimmermann, R | 1 |
| Hebisch, G | 1 |
| Das-Kundu, S | 1 |
| Fauchère, JC | 1 |
| Lang, A | 2 |
| Bucher, HU | 1 |
| Simoens, S | 2 |
| Inkster, K | 1 |
| Ludbrook, A | 2 |
| Coleman, P | 1 |
| Wale, JB | 1 |
| Lilly, C | 1 |
| LaForge, KS | 1 |
| McMahon, TJ | 4 |
| Winkel, JD | 3 |
| Jasinski, DR | 5 |
| Maxwell, JC | 1 |
| Pullum, TW | 1 |
| Tannert, K | 1 |
| Millson, M | 2 |
| Moore, A | 1 |
| Engerman, J | 1 |
| Meldrum, S | 1 |
| Hayaki, J | 1 |
| White, MC | 1 |
| Kushel, MB | 1 |
| Song, YS | 1 |
| Tulsky, JP | 2 |
| Balousek, S | 1 |
| Mundt, M | 1 |
| Durst, P | 1 |
| Palazzolo, J | 1 |
| Peyrelong, JP | 1 |
| Berger, M | 1 |
| Chalabreysse, M | 1 |
| Billiard, M | 1 |
| Vialle, A | 1 |
| Ator, NA | 1 |
| Griffiths, RR | 5 |
| Weerts, EM | 1 |
| Ison, J | 1 |
| Merrill, JO | 2 |
| Schulman, BA | 1 |
| Awan, A | 1 |
| Kapitan, S | 1 |
| Carney, M | 1 |
| Brumback, LC | 1 |
| Donovan, D | 1 |
| Peng, PW | 1 |
| Tumber, PS | 1 |
| Gnam, W | 1 |
| Ullmann, R | 1 |
| Lachmann, A | 1 |
| Düring, A | 1 |
| Koch, B | 1 |
| Meyer-Thompson, HG | 1 |
| Schmidt, R | 1 |
| Boutwell, AE | 1 |
| Shield, DC | 2 |
| Key, RG | 2 |
| Pearson, EC | 1 |
| Woosley, RL | 1 |
| Vigl, A | 2 |
| Hearn, KD | 1 |
| O'Sullivan, LF | 1 |
| Günther, V | 1 |
| Kopp, M | 1 |
| Pilsz, W | 1 |
| Haaser, W | 1 |
| Ashwath, ML | 1 |
| Ajjan, M | 1 |
| Culclasure, T | 1 |
| Hunt, C | 1 |
| Kerr, B | 1 |
| Gerada, C | 3 |
| Pringle, M | 1 |
| Rhodin, A | 1 |
| Grönbladh, L | 2 |
| Nilsson, LH | 1 |
| Gordh, T | 1 |
| Gertmenian-King, E | 2 |
| Kunik, L | 1 |
| Weaver, C | 1 |
| Galynker, I | 1 |
| Bargagli, AM | 1 |
| Schifano, P | 1 |
| Wodak, A | 3 |
| Ray, J | 1 |
| Agho, K | 2 |
| Kraigher, D | 2 |
| Primorac, A | 1 |
| Kornør, H | 2 |
| Chevalley, AE | 1 |
| Davidson, C | 1 |
| Dubois, JA | 1 |
| Uehlinger, C | 5 |
| Apelt, SM | 3 |
| Gölz, J | 1 |
| Kraus, MR | 1 |
| Tretter, F | 2 |
| Siegert, J | 1 |
| Pittrow, D | 1 |
| Encrenaz, G | 1 |
| Rondeau, V | 1 |
| Messiah, A | 1 |
| Evans, SM | 1 |
| Kalbag, AS | 1 |
| Garawi, F | 1 |
| Willott, S | 1 |
| Kluwig, J | 2 |
| Krause, D | 1 |
| Merget, B | 1 |
| Kuehn, BM | 1 |
| Parr, MS | 1 |
| Anania, B | 1 |
| Dipietro, J | 1 |
| Hock, B | 1 |
| Bartholomew, NG | 3 |
| Courtney, K | 1 |
| Schreibman, T | 1 |
| Agarwala, S | 1 |
| Daley, L | 1 |
| Child, M | 1 |
| O'Mara, E | 1 |
| Donny, EC | 2 |
| Brasser, SM | 1 |
| Walsh, SL | 5 |
| Brady, TM | 1 |
| Salvucci, S | 1 |
| Sverdlov, LS | 1 |
| Male, A | 1 |
| Kyeyune, H | 1 |
| Sikali, E | 1 |
| DeSale, S | 1 |
| Yu, P | 1 |
| Wolf, FA | 1 |
| Poshkus, M | 1 |
| Hanna, J | 1 |
| Reed, LJ | 2 |
| de Wet, CJ | 2 |
| Ohlmeier, M | 1 |
| Hauser, U | 1 |
| Becker, H | 1 |
| Emrich, H | 1 |
| Hermann, D | 1 |
| Klages, E | 1 |
| Welzel, H | 1 |
| Lane, A | 1 |
| Cotter, M | 1 |
| Quinn, C | 1 |
| Fajemirokun-Odudeyi, O | 1 |
| Pairaudeau, P | 1 |
| Armstrong, D | 1 |
| Phillips, T | 1 |
| Olze, A | 1 |
| Geserick, G | 1 |
| Schmeling, A | 1 |
| Chrostek Maj, J | 4 |
| Janik, A | 2 |
| Kwiatkowski, J | 1 |
| Szurkowska, M | 3 |
| Wojtowicz, B | 1 |
| Jenner, B | 2 |
| Szczepańskai, L | 1 |
| Furtak, S | 1 |
| Piatek, P | 1 |
| Kamenczak, A | 2 |
| Lejeune, C | 1 |
| Simmat-Durand, L | 1 |
| Gourarier, L | 1 |
| Aubisson, S | 1 |
| Graham, CH | 1 |
| Meechan, JG | 1 |
| Cioe, P | 1 |
| Gombas, W | 5 |
| Winiarski, MG | 1 |
| Greene, LI | 1 |
| Villanueva, M | 1 |
| Déglon, JJ | 4 |
| Croquette-Krokkar, M | 1 |
| Gothuey, I | 2 |
| Hüttemann, H | 1 |
| O'Gara, C | 1 |
| Sessay, M | 1 |
| Pirastu, R | 2 |
| Fais, R | 1 |
| Messina, M | 1 |
| Bini, V | 1 |
| Spiga, S | 1 |
| Falconieri, D | 1 |
| Diana, M | 1 |
| Donn, SM | 1 |
| Ricketts, EP | 1 |
| Huettner, S | 1 |
| Cornelius, L | 1 |
| Bishai, D | 1 |
| Beilenson, P | 1 |
| Rapp, C | 1 |
| Lloyd, JJ | 1 |
| Stephens, MA | 1 |
| Mudric, T | 1 |
| Kolodner, KB | 1 |
| Hamilton, JA | 1 |
| Giacomuzzi, S | 1 |
| Bakker, A | 2 |
| Sibanda, V | 1 |
| Grella, CE | 1 |
| Huang, YC | 1 |
| Spiehler, V | 1 |
| Smith, CS | 1 |
| Rook, EJ | 1 |
| Hillebrand, MJ | 1 |
| Huitema, AD | 1 |
| Hendriks, VM | 1 |
| Beijnen, JH | 1 |
| Ramirez-Cacho, WA | 1 |
| Flores, S | 1 |
| Schrader, RM | 1 |
| McKay, J | 1 |
| Aschauer, H | 1 |
| Blaine, J | 3 |
| Kellogg, S | 1 |
| Satterfield, F | 1 |
| Schwartz, M | 1 |
| Krasnansky, J | 1 |
| Pencer, E | 1 |
| Silva-Vazquez, L | 1 |
| Kirby, KC | 1 |
| Royer-Malvestuto, C | 1 |
| Copersino, ML | 1 |
| Popova, S | 1 |
| Becker, WC | 1 |
| Critchlow, G | 1 |
| Nadeem, H | 1 |
| Millson, P | 1 |
| Challacombe, L | 1 |
| Villeneuve, PJ | 1 |
| Myers, T | 1 |
| Shore, R | 1 |
| Hopkins, S | 1 |
| Weinstock, MC | 2 |
| Minkel, J | 1 |
| Clark, NC | 1 |
| Mutch, C | 2 |
| Zhao, D | 1 |
| Perugi, G | 1 |
| Akiskal, HS | 1 |
| Fuller, BE | 2 |
| McCarty, DJ | 1 |
| Ringor-Carty, R | 1 |
| Kennard, S | 1 |
| Bennett, J | 1 |
| Whale, R | 1 |
| Guffens, JM | 1 |
| Johnson, BA | 1 |
| Blumenthal, D | 1 |
| Stoddard, R | 1 |
| Pfab, R | 3 |
| Eyer, F | 1 |
| Jetzinger, E | 1 |
| Zilker, T | 3 |
| Gruber, SA | 1 |
| Tzilos, GK | 1 |
| Silveri, MM | 1 |
| Pollack, M | 1 |
| Renshaw, PF | 2 |
| Kaufman, MJ | 2 |
| Yurgelun-Todd, DA | 1 |
| Maas, B | 1 |
| Gatherer, A | 1 |
| Matthews, AM | 1 |
| Fireman, M | 1 |
| Zucker, B | 1 |
| Sobel, M | 1 |
| Hauser, P | 1 |
| Peh, LH | 1 |
| Ng, BY | 1 |
| Lott, DC | 1 |
| March, JC | 1 |
| Perea-Milla, E | 1 |
| Carrasco, F | 1 |
| Ersche, KD | 1 |
| Fletcher, PC | 1 |
| Roiser, JP | 1 |
| Fryer, TD | 1 |
| London, M | 2 |
| Robbins, TW | 1 |
| Sahakian, BJ | 1 |
| Stoové, M | 1 |
| Finnerty, E | 1 |
| Selzer, J | 1 |
| Naumovsky, Y | 1 |
| Cho, E | 1 |
| Dermatis, H | 2 |
| McCambridge, J | 1 |
| Beswick, T | 1 |
| Best, D | 2 |
| Rees, S | 1 |
| Foster, G | 1 |
| Labadie, R | 1 |
| Somoza, E | 1 |
| Morgan, O | 1 |
| Griffiths, C | 1 |
| Schwartz, R | 2 |
| Hecht, J | 2 |
| Marion, I | 3 |
| Juliana, P | 1 |
| Haltiwanger, D | 1 |
| Eldred, L | 1 |
| Fazey, C | 1 |
| Skjervold, B | 1 |
| Sherman, J | 1 |
| Zador, DA | 1 |
| Raab, GM | 1 |
| Bruce, M | 1 |
| McKenzie, JS | 1 |
| Storkey, HR | 1 |
| Hall, S | 2 |
| Valentová, J | 1 |
| Horáková, R | 1 |
| Pechová, I | 1 |
| Devínsky, F | 1 |
| Fitzsimons, HE | 1 |
| Vaidya, V | 1 |
| Berkman, ND | 1 |
| Coller, JK | 2 |
| Barratt, DT | 1 |
| Dahlen, K | 1 |
| Loennechen, MH | 1 |
| Sergio, N | 1 |
| Salvatore, T | 1 |
| Gaetano, B | 1 |
| Davide, P | 1 |
| Claudio, I | 1 |
| Massimo, L | 1 |
| Barbara, M | 1 |
| Giuseppe, A | 1 |
| Stefano, C | 1 |
| Danila, C | 1 |
| Aikaterini, T | 1 |
| Luca, I | 1 |
| Daniela, C | 1 |
| Luciano, C | 1 |
| Andersen, HT | 2 |
| Ekgren, JS | 1 |
| Lim, K | 1 |
| Wallace, C | 2 |
| Neufeld, KJ | 2 |
| Hancock, MM | 1 |
| Prosser, CC | 1 |
| Ransibrahmanakul, K | 1 |
| Lester, L | 1 |
| Craemer, E | 1 |
| Bourgeois, JA | 1 |
| Rossaro, L | 1 |
| Tracy, SW | 1 |
| Lee, N | 2 |
| Taylor, D | 2 |
| Chatterji, P | 1 |
| Deb, N | 1 |
| Schoenbaum, EE | 3 |
| Turner, BJ | 1 |
| Daley, M | 1 |
| Cordonnier, L | 1 |
| Roques, BP | 1 |
| Noble, F | 1 |
| Dijkstra, BA | 2 |
| Krabbe, PF | 2 |
| Riezebos, TG | 1 |
| van der Staak, CP | 2 |
| Achsnick-Wetjen, C | 1 |
| Helander, A | 1 |
| Bannan, N | 1 |
| Rooney, S | 1 |
| O'connor, J | 2 |
| Najavits, LM | 1 |
| Rosier, M | 1 |
| Nolan, AL | 1 |
| Freeman, MC | 1 |
| Kwiatkowski, CF | 2 |
| Latowsky, M | 1 |
| Glickman, L | 1 |
| Dingle, S | 1 |
| Raffa, JD | 1 |
| Tossonian, H | 1 |
| Wong, T | 1 |
| Viljoen, M | 1 |
| McLean, M | 1 |
| Duncan, F | 1 |
| Petkau, AJ | 1 |
| DeVlaming, S | 1 |
| Maxwell, C | 1 |
| Haddox, JD | 1 |
| Fitzpatrick, M | 1 |
| Routhier, DD | 1 |
| Katz, KD | 1 |
| Brooks, DE | 1 |
| Mi, GD | 1 |
| Wang, CH | 1 |
| Rou, KM | 1 |
| Wu, ZY | 1 |
| Bodner, G | 2 |
| Federman, AD | 1 |
| Whitfield, JB | 1 |
| Wurst, F | 1 |
| McAnulty, JM | 1 |
| Jauncey, ME | 1 |
| Monger, CK | 1 |
| Hailstone, ST | 1 |
| Alam, NK | 1 |
| Mannes, TF | 1 |
| Capon, AG | 1 |
| Irvine, K | 1 |
| Armstrong, PK | 1 |
| Kaldor, JM | 1 |
| Al-Sardar, H | 1 |
| Brady, KT | 1 |
| Ehret, GB | 1 |
| Desmeules, JA | 1 |
| Dawe, S | 4 |
| Harnett, P | 1 |
| Kamal, F | 1 |
| Flavin, S | 1 |
| Campbell, F | 1 |
| Behan, C | 1 |
| Fagan, J | 1 |
| Smyth, R | 1 |
| Chassot, P | 1 |
| Brocard, M | 1 |
| Koeb, L | 1 |
| Bluschke, SM | 1 |
| Luke, JL | 1 |
| Rosado, J | 1 |
| Matochik, JA | 1 |
| Kimes, AS | 1 |
| Contoreggi, C | 1 |
| Kurian, V | 1 |
| Ernst, M | 1 |
| Rosenthal, RN | 2 |
| Crocetti, MT | 1 |
| Amin, DD | 1 |
| Oyemade, A | 1 |
| Dimsdale, JE | 1 |
| Norman, D | 1 |
| DeJardin, D | 1 |
| Wallace, MS | 1 |
| Gibson, AE | 1 |
| Degenhardt, LJ | 1 |
| Salaspuro, M | 1 |
| Wahlbeck, K | 1 |
| Peternell-Moelzer, A | 1 |
| Edwards, JW | 1 |
| Fisher, DG | 2 |
| Johnson, ME | 1 |
| Reynolds, GL | 1 |
| Redpath, DP | 1 |
| Smith, SJ | 1 |
| Servoss, TJ | 1 |
| DeVaul, SK | 1 |
| Simons, RL | 1 |
| Swaminathan, S | 1 |
| Klein, RS | 1 |
| Howard, AA | 1 |
| Lo, Y | 1 |
| Degkwitz, P | 3 |
| Berger, J | 1 |
| Patane', S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Chiribiri, A | 1 |
| Cofrancesco, J | 1 |
| Brown, TT | 1 |
| Luo, RF | 1 |
| John, M | 1 |
| Stewart, KJ | 1 |
| Dobs, AS | 1 |
| Nestor, L | 1 |
| Surratt, H | 1 |
| Firoozabadi, A | 1 |
| Mowla, A | 1 |
| Farashbandi, H | 1 |
| Gorman, JM | 1 |
| Gjersing, LR | 1 |
| Caplehorn, JR | 1 |
| Belcher, JM | 1 |
| Matthews, R | 1 |
| Joergensen, C | 1 |
| James, H | 1 |
| Gillis, D | 1 |
| Christrup, L | 1 |
| Johansson, BA | 1 |
| Berglund, M | 1 |
| Lindgren, A | 1 |
| Stokka, D | 1 |
| Heger, B | 1 |
| Nygaard, E | 1 |
| Gardner, TJ | 2 |
| Pelet, A | 1 |
| Doll, S | 1 |
| Resplendino, J | 1 |
| Nolan, LJ | 1 |
| Scagnelli, LM | 1 |
| Abrahams, RR | 1 |
| Kelly, SA | 1 |
| Payne, S | 1 |
| Thiessen, PN | 1 |
| Mackintosh, J | 1 |
| Janssen, PA | 1 |
| de Wet, C | 1 |
| Reed, L | 1 |
| Haraldsen, M | 2 |
| Tuchman, E | 1 |
| Nahata, R | 1 |
| Muller, FM | 1 |
| Arseculeratne, G | 1 |
| Evans, A | 1 |
| Fleming, C | 4 |
| Müller, BW | 1 |
| Steinchen, N | 1 |
| Zerbin, D | 1 |
| Lodemann, E | 2 |
| Mendez, IA | 1 |
| Trujillo, KA | 1 |
| Raz, B | 1 |
| Terao, H | 1 |
| Le, PP | 1 |
| Mettler, J | 1 |
| Battegay, E | 1 |
| Zimmerli, L | 1 |
| Stallwitz, A | 1 |
| Wedam, EF | 1 |
| Nuzzo, PA | 1 |
| Stenson, G | 1 |
| Biles, LA | 1 |
| Bethea, AR | 1 |
| McMahon, C | 1 |
| Tynan, P | 1 |
| Hall, DH | 1 |
| Nittis, M | 1 |
| Whitton, G | 1 |
| Swegle, JM | 1 |
| Wensel, DD | 1 |
| Gutierrez, F | 1 |
| Gunderson, EW | 1 |
| Nauck, F | 1 |
| Schleifer, RA | 1 |
| Zullino, DF | 1 |
| Benguettat, D | 1 |
| Khan, R | 1 |
| Goodyear-Smith, F | 1 |
| Butler, R | 1 |
| Wheeler, A | 1 |
| Gohns, A | 1 |
| Bird, SB | 1 |
| Rosenbaum, C | 1 |
| Cantwell, K | 1 |
| McGee, MR | 1 |
| Teixeira, PA | 1 |
| Kakko, J | 1 |
| Heilig, M | 2 |
| Sarman, I | 2 |
| Saris, AJ | 1 |
| Kantelip, JP | 1 |
| Gerritsen-van Schieveen, P | 1 |
| Davani, S | 1 |
| Ryan, A | 1 |
| Rea, F | 1 |
| Mitchell Heggs, L | 1 |
| Genée, O | 1 |
| Fichet, J | 1 |
| Graham, NA | 1 |
| Merlo, LJ | 2 |
| Goldberger, BA | 1 |
| Cowell, AJ | 1 |
| Hanson, T | 1 |
| Alessi, SM | 1 |
| Tennant, FS | 6 |
| Washton, AM | 12 |
| Resnick, RB | 12 |
| Clouet, DH | 1 |
| Yonehara, N | 1 |
| Kantor, TG | 1 |
| Cantor, R | 1 |
| Tom, E | 1 |
| Pottash, AL | 7 |
| Extein, I | 6 |
| El-Guebaly, N | 2 |
| Davidson, WJ | 1 |
| Sures, HA | 1 |
| Griffin, W | 1 |
| Kraus, JJ | 1 |
| Avnon, MH | 1 |
| Stolerman, I | 1 |
| Mintz, J | 5 |
| Tennant, F | 2 |
| McLellan, AT | 42 |
| Marcovici, M | 4 |
| Wang, RI | 4 |
| Kochar, C | 3 |
| Hasegawa, AT | 2 |
| Roh, BL | 3 |
| Liebson, IA | 31 |
| Hawthorne, JW | 1 |
| Pullan, PT | 1 |
| Watson, FE | 1 |
| Seow, SS | 2 |
| Rappeport, W | 1 |
| Miranda, L | 1 |
| Obert, J | 1 |
| McCaul, ME | 12 |
| Boren, JJ | 1 |
| Henningfield, JE | 2 |
| Lange, WR | 1 |
| Baskerville, JC | 1 |
| Hirst, M | 1 |
| Gowdey, CW | 1 |
| Wilson, GS | 2 |
| Desmond, MM | 2 |
| Wait, RB | 1 |
| Mello, NK | 3 |
| Bree, MP | 2 |
| Mendelson, JH | 5 |
| Schecter, A | 1 |
| Martin, DA | 1 |
| Finn, LB | 1 |
| Sweeney, DR | 4 |
| Pottash, AC | 2 |
| Martin, D | 1 |
| Korts, D | 6 |
| Jackson, G | 7 |
| Gilbert, HS | 1 |
| Glazer, W | 1 |
| Wilber, CH | 2 |
| Weissman, MM | 6 |
| Prusoff, BA | 1 |
| Riordan, CE | 3 |
| Weiss, DG | 1 |
| Charuvastra, VC | 3 |
| Geyer, G | 1 |
| Loeb, PC | 1 |
| Kushner, M | 1 |
| Ternes, J | 1 |
| Hans, SL | 2 |
| Marcus, J | 2 |
| Hough, G | 1 |
| Leifer, ED | 1 |
| Goldman, J | 1 |
| Dole, VP | 4 |
| Nyswander, ME | 2 |
| Senay, EC | 4 |
| Hunt, DE | 2 |
| Lipton, DS | 3 |
| Goldsmith, DS | 2 |
| Strug, DL | 2 |
| Liu, SJ | 1 |
| Chasnoff, IJ | 2 |
| Burns, WJ | 2 |
| Ginzburg, HM | 1 |
| Allison, M | 2 |
| Hubbard, RL | 6 |
| Richardson, BS | 1 |
| O'Grady, JP | 1 |
| Olsen, GD | 1 |
| Singleton, EG | 1 |
| Sherman, MF | 1 |
| Graham-Bafus, S | 1 |
| Allen, RH | 1 |
| Gordon, JR | 1 |
| Manganiello, AJ | 1 |
| Luborsky, L | 10 |
| Fox, S | 1 |
| Herman, I | 2 |
| Beck, AT | 2 |
| Hartman, N | 3 |
| Brizer, D | 1 |
| Eth, S | 1 |
| Lemons, PK | 1 |
| Schloemer, NF | 1 |
| Skidmore, JW | 1 |
| Bradley, B | 6 |
| Connell, P | 1 |
| Soudaly, C | 1 |
| Singh, BK | 3 |
| Lehman, W | 3 |
| Sells, SB | 3 |
| Langrod, J | 1 |
| Alksne, L | 1 |
| Lowinson, J | 2 |
| Ausubel, DP | 1 |
| Hebert, SW | 1 |
| Lauterbach, EC | 1 |
| Cohen, M | 5 |
| Hanbury, R | 6 |
| Sturiano, V | 5 |
| Cohen, AJ | 1 |
| Klett, CJ | 2 |
| Barnes, E | 1 |
| Aloizou, M | 1 |
| Liebson, I | 6 |
| Jacobs, PE | 1 |
| Lurie, A | 1 |
| Cuzzi, L | 1 |
| Houston, CC | 1 |
| Milby, JB | 6 |
| Lange, DG | 1 |
| Roerig, SC | 1 |
| Fujimoto, JM | 1 |
| Busse, LW | 1 |
| Vescovi, PP | 3 |
| Rastelli, G | 2 |
| Ceda, GP | 1 |
| Valenti, G | 1 |
| Ellingboe, J | 1 |
| Judson, BA | 1 |
| Goldstein, A | 1 |
| Dackis, CA | 1 |
| Annitto, W | 1 |
| Shoham, SG | 1 |
| Baruch, I | 1 |
| Rahav, G | 1 |
| Markowski, R | 1 |
| Chard, F | 1 |
| Ben-Haim, M | 1 |
| Ildefonso y Romo, LE | 1 |
| Karp-Gelernter, E | 1 |
| Savage, C | 1 |
| McCabe, OL | 1 |
| Bourgeois, M | 1 |
| Daubech, JF | 1 |
| Allison, W | 1 |
| Allison, F | 1 |
| de Saint-Affrique, H | 1 |
| Meggle, D | 1 |
| Keup, W | 1 |
| Caccavari, R | 1 |
| Butturini, U | 1 |
| McLeod, DR | 1 |
| Perzel, JF | 1 |
| Garwood, J | 2 |
| Annitto, WJ | 2 |
| Kanzler, M | 1 |
| Friedman, L | 2 |
| Havassy, BE | 3 |
| Butler, P | 1 |
| Atkinson, CA | 1 |
| Crowley, TJ | 4 |
| Perzel, J | 1 |
| Johnson, MM | 1 |
| Evans, M | 1 |
| Robson, PJ | 1 |
| Chadd, MA | 1 |
| Evans, CM | 1 |
| Fry, DM | 1 |
| Lifschitz, MH | 1 |
| Smith, EO | 1 |
| Wilber, C | 3 |
| Hole, A | 1 |
| Cushman, P | 3 |
| Gunne, LM | 4 |
| Olofsson, M | 3 |
| Buckley, W | 3 |
| Andersen, GE | 3 |
| Friis-Hansen, B | 3 |
| Hatcher, R | 2 |
| Fultz, JM | 1 |
| Pray, BJ | 1 |
| Thornton, WE | 1 |
| Uhde, TW | 1 |
| Redmond, DE | 3 |
| McCafferty, L | 1 |
| Connell, PH | 2 |
| Evans, BD | 1 |
| Terenius, L | 2 |
| Wahlström, A | 1 |
| Krivoy, W | 1 |
| Bracy, SA | 1 |
| Gordis, EN | 1 |
| Sereny, G | 1 |
| Shaw, BF | 1 |
| Blaine, JD | 1 |
| Renault, PR | 1 |
| Thomas, DB | 1 |
| Whysner, JA | 1 |
| Cole, SG | 1 |
| Lehman, WE | 1 |
| Cole, EA | 1 |
| Ben-Yehuda, N | 4 |
| DesJarlais, D | 1 |
| Burstein, Y | 1 |
| Rausen, AR | 1 |
| Peterson, CM | 1 |
| Crits-Christoph, K | 1 |
| Kleber, H | 4 |
| Haglund, RM | 1 |
| Howerton, LL | 1 |
| Khatami, M | 1 |
| O'Brien, C | 2 |
| Nilsson, MI | 1 |
| Anggård, E | 1 |
| Holmstrand, J | 1 |
| Maddux, JF | 5 |
| Desmond, DP | 5 |
| Charney, DS | 5 |
| Murburg, M | 1 |
| Braverman, P | 1 |
| Sternberg, DE | 1 |
| Heninger, GR | 1 |
| Garland, J | 1 |
| Householder, J | 1 |
| Burns, W | 1 |
| Chasnoff, I | 1 |
| Titievsky, J | 1 |
| Seco, G | 1 |
| Barranco, M | 1 |
| Kyle, EM | 1 |
| Chaney, EF | 2 |
| Roszell, DK | 3 |
| Cummings, C | 1 |
| Mari, F | 1 |
| Bertol, E | 1 |
| Masten, LW | 3 |
| Way, EL | 1 |
| Young, GA | 1 |
| Steinfels, GF | 1 |
| Khazan, N | 2 |
| Lichtblau, L | 2 |
| Sparber, SB | 5 |
| Kuwahara, MD | 1 |
| Moreton, JE | 1 |
| Milkman, H | 1 |
| Metcalf, D | 1 |
| Reed, P | 1 |
| Achim, D | 1 |
| Lehmann, F | 1 |
| Ball, JC | 6 |
| Rosen, L | 1 |
| Dittmar, W | 1 |
| Kury, H | 1 |
| Digregorio, GJ | 2 |
| Bukovinsky, MA | 1 |
| McGlothlin, WH | 1 |
| Havassy, B | 1 |
| Neidert, GL | 1 |
| Kay, DC | 1 |
| Eisenberg, M | 1 |
| Isaacs, CD | 1 |
| Bourque, A | 1 |
| Moise, R | 1 |
| Reed, BG | 1 |
| Conell, C | 1 |
| Swensen, G | 1 |
| Willis, D | 1 |
| Hartfield, M | 1 |
| Chapman, C | 1 |
| Haertzen, CA | 2 |
| Ross, FE | 1 |
| Burt, MR | 1 |
| DuPont, RL | 2 |
| Lawrence, C | 1 |
| Krasnegor, N | 1 |
| D'Lugoff, B | 1 |
| Hawthorne, J | 1 |
| Rosenzweig, J | 1 |
| Treece, C | 1 |
| Nicholson, B | 1 |
| Kacian, J | 1 |
| Streltzer, J | 1 |
| Chatham, LR | 2 |
| Knight, K | 1 |
| Camí, J | 6 |
| Lamas, X | 1 |
| Dansereau, DF | 5 |
| Powell, J | 1 |
| Teusch, L | 1 |
| Böhme, H | 1 |
| Bender, S | 1 |
| Eschmann-Mehl, G | 1 |
| Simpson, D | 1 |
| Reilly, PM | 1 |
| Banys, P | 3 |
| Tusel, DJ | 3 |
| Krumenaker, CL | 1 |
| Shopshire, MS | 1 |
| Biederman, J | 1 |
| Kiely, K | 1 |
| Bredin, E | 1 |
| Spencer, TJ | 1 |
| Lafolie, P | 1 |
| Martel, J | 1 |
| Ottosson, EC | 1 |
| Boreus, LO | 1 |
| Hjemdahl, P | 1 |
| Kell, MJ | 2 |
| Rhoades, H | 2 |
| Elk, R | 4 |
| Schmitz, J | 3 |
| Creson, D | 5 |
| Kirby, K | 1 |
| Eriksen, J | 1 |
| Rutherford, MJ | 10 |
| Alterman, AI | 15 |
| Cacciola, JS | 12 |
| Snider, EC | 2 |
| June, HL | 2 |
| Schuh, KJ | 1 |
| Lundstedt, C | 1 |
| Olesen, OV | 1 |
| Rosenberg, R | 1 |
| Husband, SD | 2 |
| Iguchi, MY | 11 |
| Weller, SB | 1 |
| Walker, SR | 1 |
| Quitkin, F | 2 |
| Post-Koenig, T | 1 |
| Petrakis, I | 3 |
| Carroll, K | 1 |
| Gordon, L | 2 |
| Cushing, G | 1 |
| Rounsaville, B | 3 |
| Wrede, AF | 2 |
| Stanton, V | 1 |
| Barthwell, A | 2 |
| Marks, R | 3 |
| Bokos, PJ | 1 |
| DePetrillo, PB | 1 |
| Rice, JM | 2 |
| Katz, SM | 1 |
| Lifshutz, H | 1 |
| Maslansky, R | 2 |
| Krystal, JH | 4 |
| Woods, SW | 2 |
| Rosen, MI | 4 |
| Seibyl, JP | 1 |
| van Dyck, CC | 1 |
| Price, LH | 2 |
| Zubal, IG | 1 |
| Hoffer, PB | 1 |
| Mattick, R | 2 |
| Ward, J | 4 |
| Stimson, G | 1 |
| Knight, DK | 1 |
| McLean, PC | 3 |
| Weber, I | 3 |
| Johns, A | 2 |
| Schütz, CG | 2 |
| Rapiti, E | 1 |
| Vlahov, D | 2 |
| Anthony, JC | 1 |
| Persico, AM | 1 |
| Serretti, A | 1 |
| Tempesta, E | 1 |
| Kaltenbach, KA | 1 |
| Levinson, I | 1 |
| Scott, RT | 1 |
| Gruer, LD | 1 |
| Wood, SH | 1 |
| DeMaria, PA | 3 |
| Dugarin, J | 1 |
| Menerath, C | 1 |
| Nominé, P | 1 |
| Sonntag, I | 1 |
| Rees, V | 1 |
| Brewer, C | 3 |
| Stimson, GV | 1 |
| Schmidt, CW | 2 |
| Felch, LJ | 3 |
| Gazaway, PM | 1 |
| Clark, LL | 1 |
| Hay, AW | 5 |
| Ghodse, H | 2 |
| Myles, J | 2 |
| Smith, SE | 2 |
| Hohmann, AA | 2 |
| Gentile, M | 2 |
| Huggins, N | 1 |
| Sims, MK | 2 |
| Haas, N | 2 |
| Rousar, E | 1 |
| Regier, MW | 2 |
| Melin, L | 1 |
| Hiltunen, A | 1 |
| Blansfield, HN | 3 |
| Farley, TA | 1 |
| Cartter, ML | 1 |
| Wassell, JT | 1 |
| Hadler, JL | 1 |
| Addiss, SS | 1 |
| Horosko, S | 1 |
| Kolar, AF | 4 |
| Michaelson, BS | 2 |
| Raistrick, D | 8 |
| Bradshaw, J | 1 |
| Tober, G | 1 |
| Weiner, J | 1 |
| Allison, J | 1 |
| Healey, C | 1 |
| Rittmannsberger, H | 2 |
| Ruschak, M | 2 |
| Silberbauer, C | 2 |
| Randall, M | 1 |
| Rezza, G | 1 |
| Morganti, S | 1 |
| Binkin, N | 1 |
| O'Neill, WM | 1 |
| Onen, TS | 1 |
| Handelsman, L | 8 |
| Silberstein, CH | 1 |
| O'Dowd, MA | 1 |
| Chartock, P | 1 |
| Hartel, D | 2 |
| McKegney, FP | 1 |
| Arndt, IO | 4 |
| Dorozynsky, L | 3 |
| Petitjean, S | 4 |
| Hörler, C | 1 |
| Bardeleben, U | 1 |
| Ladewig, D | 9 |
| von Bardeleben, U | 3 |
| Natsch, C | 1 |
| Dole, V | 1 |
| Bertschy, G | 4 |
| Baettig, D | 1 |
| Swift, W | 1 |
| Ross, M | 1 |
| Nurco, DN | 6 |
| Hanlon, TE | 6 |
| Brettle, RP | 1 |
| Willocks, L | 1 |
| Hamilton, BA | 1 |
| Leen, CL | 1 |
| Richardson, A | 1 |
| Gore, SM | 1 |
| Richards, D | 1 |
| Goehl, L | 2 |
| Hilton, I | 1 |
| Sellers, EM | 1 |
| Ciraulo, DA | 1 |
| Romach, MK | 1 |
| Neshin, SF | 1 |
| Butler, S | 1 |
| Unnithan, S | 2 |
| Ottomanelli, G | 2 |
| Zaballero, AR | 1 |
| Anglin, D | 1 |
| Powers, K | 1 |
| Simonsen, KW | 2 |
| Worm, K | 2 |
| Steentoft, A | 2 |
| Kringsholm, B | 2 |
| Schilling, RF | 3 |
| Turnbull, JE | 1 |
| Su, KH | 1 |
| Gaughwin, M | 2 |
| Kliewer, E | 1 |
| Faulkner, C | 1 |
| Anderson, G | 1 |
| Sharma, J | 1 |
| Rachal, JV | 2 |
| Nightingale, SL | 2 |
| Peyser, NP | 2 |
| Amass, L | 1 |
| Cutler, R | 1 |
| Kanof, PD | 2 |
| Aronson, MJ | 2 |
| Ness, R | 3 |
| Calvert, R | 3 |
| Glass, RM | 1 |
| Hemmeter, U | 1 |
| Kocher, R | 1 |
| Herd, D | 1 |
| Bekir, P | 1 |
| McLellan, T | 1 |
| Gariti, P | 2 |
| Falcioni, J | 1 |
| Cheskin, LJ | 1 |
| Chami, TN | 1 |
| McKay, JR | 8 |
| Charuvastra, C | 1 |
| Zombek, S | 1 |
| Harris, RM | 1 |
| Kavanagh, KH | 1 |
| Cnaan, RA | 1 |
| Barber, N | 1 |
| Wasserman, W | 1 |
| Panero, MS | 1 |
| Selwyn, PA | 3 |
| Gabbay, MB | 1 |
| Judson, M | 1 |
| Callaway, E | 1 |
| Camacho, LM | 2 |
| Cloud, MA | 1 |
| Seligman, M | 1 |
| Foote, J | 3 |
| Lovejoy, M | 1 |
| Spadone, C | 2 |
| Foltin, RW | 2 |
| Fischman, MW | 2 |
| Herbst, MD | 1 |
| Manfredi, LB | 1 |
| Jones, T | 1 |
| Sutton, N | 1 |
| de Vos, JW | 1 |
| Ufkes, JG | 1 |
| Hay, A | 2 |
| Wimbush, J | 1 |
| Amicarelli, A | 1 |
| Greenfield, L | 1 |
| Brady, JV | 1 |
| Besteman, KJ | 1 |
| De Smet, A | 1 |
| Chutuape, MA | 4 |
| Ferrando, SJ | 1 |
| Wall, TL | 2 |
| Kemp, K | 1 |
| Orr, M | 1 |
| Ball, J | 1 |
| Cejtin, HE | 1 |
| Mills, A | 1 |
| Swift, EL | 1 |
| Baylé, FJ | 1 |
| Jalfre, V | 1 |
| Leifert, K | 2 |
| Gross, A | 1 |
| Dinwiddie, SH | 1 |
| Cottler, L | 1 |
| Compton, W | 1 |
| Abdallah, AB | 1 |
| Sawyer, RC | 1 |
| Cobb, MN | 1 |
| Colborn, DC | 1 |
| Narang, PK | 1 |
| Pierce, TL | 2 |
| Hope, W | 1 |
| Raper, C | 1 |
| Calman, L | 1 |
| Powis, B | 1 |
| Simon, DL | 1 |
| Meyer, TJ | 1 |
| Lin, MM | 1 |
| Orn, P | 1 |
| Sheedy, JJ | 1 |
| Schneider, C | 1 |
| Diamant, K | 1 |
| Hauk, R | 1 |
| Pezawas, L | 3 |
| Lenzinger, E | 1 |
| Manji, H | 1 |
| Chen, G | 1 |
| Potter, W | 1 |
| Poser, W | 1 |
| Ehrenreich, H | 1 |
| Herman, M | 1 |
| Mader, U | 1 |
| Sadava, D | 1 |
| Alonso, D | 1 |
| Hong, H | 1 |
| Pettit-Barrett, DP | 1 |
| Bates, M | 1 |
| Pemberton, DA | 1 |
| Knoll, B | 1 |
| Haefeli, WE | 1 |
| Connerney, I | 1 |
| Meaney, PJ | 1 |
| Ventayol, P | 1 |
| Busquets, X | 1 |
| Walzer, C | 1 |
| Guimón, J | 1 |
| Gruer, L | 3 |
| Dore, GM | 2 |
| Hargreaves, G | 1 |
| Niven, BE | 1 |
| Scott, R | 2 |
| Harden, K | 1 |
| Forrester, E | 1 |
| Hinshelwood, S | 1 |
| McNulty, H | 1 |
| Silk, P | 1 |
| Kalke, J | 1 |
| Ryrie, IW | 1 |
| Dickson, J | 1 |
| Robbins, C | 1 |
| Maclean, K | 1 |
| Climpson, C | 1 |
| Krook, A | 1 |
| Pitre, U | 1 |
| San, L | 2 |
| Martinez, A | 2 |
| Castillo, C | 1 |
| Alonso, J | 1 |
| Chamberlain, N | 1 |
| Morral, AR | 3 |
| Belding, MA | 3 |
| Lamb, RJ | 1 |
| Prihoda, TJ | 1 |
| Vogtsberger, KN | 1 |
| Kraft, MK | 1 |
| Hadley, TR | 1 |
| Asch, DA | 1 |
| McCarthy, JH | 1 |
| Sedgwick, P | 1 |
| Lee, JH | 1 |
| Willems, JC | 1 |
| Bux, DA | 1 |
| Vaupel, DB | 1 |
| Pham-Huy, C | 2 |
| Chikhi-Chorfi, N | 2 |
| Galons, H | 2 |
| Sadeg, N | 1 |
| Aymard, N | 1 |
| Massicot, F | 1 |
| Warnet, JM | 2 |
| Claude, JR | 2 |
| Glanz, M | 1 |
| Klawansky, S | 1 |
| McAullife, W | 1 |
| Chalmers, T | 1 |
| Gilhooly, TC | 1 |
| Wojnar-Horton, RE | 1 |
| Kristensen, JH | 1 |
| Yapp, P | 1 |
| Ilett, KF | 1 |
| Dusci, LJ | 1 |
| Hackett, LP | 1 |
| Quitkin, FM | 1 |
| Donovan, SJ | 1 |
| Deliyannides, D | 1 |
| Ocepek-Welikson, K | 1 |
| Koenig, T | 1 |
| McGrath, PJ | 1 |
| Milne, E | 2 |
| English, DR | 2 |
| Holman, CD | 2 |
| Finnegan, L | 2 |
| Boardman, CR | 1 |
| Rhoades, HM | 3 |
| Brown, AS | 1 |
| Fleming, PM | 2 |
| Peters, AD | 1 |
| Reid, MM | 1 |
| Hollander, JR | 1 |
| Hussein, I | 1 |
| Kosten, TA | 4 |
| Hameedi, FA | 1 |
| Ruz Franzi, I | 1 |
| Ruiz Avila, F | 1 |
| MacQueen, AR | 1 |
| Mino, A | 3 |
| Page, D | 1 |
| Dumont, P | 2 |
| Carnwath, T | 1 |
| Hardman, J | 1 |
| Caplehorn, RM | 1 |
| Lumley, TS | 1 |
| Irwig, L | 1 |
| Saunders, JB | 2 |
| McDermott, PA | 1 |
| Mulvaney, F | 1 |
| Finlay-Jones, R | 1 |
| Gössling, HW | 1 |
| Gunkel, S | 1 |
| Wegener, U | 1 |
| Woiton, V | 1 |
| Britton, KA | 1 |
| Mahaffey, D | 1 |
| Brizendine, E | 1 |
| Hiett, AK | 1 |
| Turnquest, MA | 1 |
| Montoya, I | 1 |
| Cone, EJ | 3 |
| Taylor, JR | 1 |
| Watson, ID | 1 |
| Tames, FJ | 1 |
| Lowe, D | 1 |
| Frei, A | 1 |
| Steffen, T | 1 |
| Gasser, M | 1 |
| Kümmerle, U | 1 |
| Stierli, M | 1 |
| Dobler-Mikola, A | 1 |
| Gutzwiller, F | 1 |
| Stühlinger, G | 3 |
| Bouchez, J | 1 |
| Beauverie, P | 2 |
| Touzeau, D | 1 |
| McCarthy, M | 1 |
| Charnaud, B | 1 |
| Griffiths, V | 1 |
| Kang, SY | 2 |
| Zane, EH | 1 |
| Wong, CJ | 3 |
| Umbricht-Schneiter, A | 1 |
| Yuan, CS | 1 |
| Foss, JF | 1 |
| O'Connor, M | 1 |
| Moss, J | 1 |
| Roizen, MF | 1 |
| Jaffe, C | 1 |
| Comtois, KA | 1 |
| Hamilton, SP | 2 |
| Klimchak, C | 1 |
| Brewer, DD | 1 |
| Voegeli, JP | 1 |
| Raschke, P | 1 |
| Carrero, EJ | 1 |
| Agustí, M | 1 |
| Fábregas, N | 1 |
| Valldeoriola, F | 1 |
| Fernández, C | 1 |
| Mascovich, A | 1 |
| DePhilippis, D | 1 |
| Chesney, M | 1 |
| Manuel, N | 1 |
| Lowenstein, W | 2 |
| Archie, C | 1 |
| Terán, MT | 1 |
| Roset, PN | 1 |
| Mas, M | 1 |
| Solomon, P | 1 |
| Mulvaney, FD | 2 |
| Cooney, NL | 1 |
| Rosenheck, RA | 1 |
| Li, SH | 1 |
| Klein, S | 1 |
| Kaube, H | 1 |
| Cheung, YW | 1 |
| Ch'ien, JM | 1 |
| Goodman, G | 1 |
| Cox, SM | 1 |
| Hirtl, C | 1 |
| Blatchley, RJ | 1 |
| Fallon, B | 1 |
| Bernstein, D | 1 |
| Stein, Z | 1 |
| Saez, H | 1 |
| el-Sadr, W | 1 |
| Healton, C | 1 |
| Mannheimer, S | 1 |
| Messeri, P | 1 |
| Scimeca, MM | 1 |
| Van Devanter, N | 1 |
| Zimmerman, R | 1 |
| Betne, P | 1 |
| Phillips, CD | 1 |
| Dunteman, G | 1 |
| Fountain, DL | 1 |
| Czechowicz, D | 1 |
| Cooper, JR | 1 |
| Wartenberg, AA | 2 |
| Blaney, T | 1 |
| Kastner, B | 1 |
| Taeusch, HW | 1 |
| Hauser, C | 1 |
| Cooney, EL | 1 |
| Otero, MJ | 1 |
| Fuertes, A | 1 |
| Sánchez, R | 1 |
| Luna, G | 1 |
| Amin, H | 1 |
| Nilssen, O | 1 |
| Hartz, DT | 1 |
| Meek, P | 1 |
| Piotrowski, NA | 1 |
| Henke, CJ | 1 |
| Delucchi, K | 1 |
| Sees, K | 1 |
| Wang, NS | 1 |
| Stewart, RB | 1 |
| Nwakeze, PC | 1 |
| Demsky, S | 1 |
| Rutherford, M | 1 |
| Cook, TG | 2 |
| Mirsky, AF | 1 |
| Cooper, GA | 1 |
| Seymour, A | 1 |
| Cassidy, MT | 1 |
| Oliver, JS | 1 |
| Villafuerte, RA | 1 |
| Kukes, TJ | 1 |
| Rose, SL | 1 |
| Cohen, BM | 1 |
| Wasserman, DA | 3 |
| Korcha, R | 1 |
| Sarfraz, A | 1 |
| Alcorn, RJ | 1 |
| Aschauer, HN | 2 |
| Frank, RG | 1 |
| Denmead, GC | 1 |
| Tenore, P | 1 |
| Freeman, K | 1 |
| Zweben, JE | 2 |
| Aly, T | 1 |
| Wengrofsky, S | 1 |
| Bacci, J | 1 |
| Meddaugh, R | 1 |
| Folz-Murphy, N | 1 |
| Lin, X | 1 |
| Rashiq, S | 1 |
| Lord, FR | 1 |
| Askey, AW | 1 |
| Levinson, D | 1 |
| Lehmann, P | 1 |
| Savoy, J | 1 |
| Laget, J | 1 |
| Charpentier, P | 1 |
| Sanchez-Mazas, P | 1 |
| Halfon, O | 1 |
| Serota, RD | 1 |
| Wu-Pong, S | 1 |
| Kniseley, JS | 1 |
| Borg, L | 1 |
| Broe, DM | 1 |
| Griffith, JD | 1 |
| Roark, RR | 1 |
| Giner, F | 1 |
| Liu, JG | 2 |
| Gong, ZH | 2 |
| Qin, BY | 2 |
| Walker, JD | 1 |
| Paice, JR | 1 |
| Clarkson, S | 1 |
| Stephens, BG | 1 |
| Anderson, IB | 1 |
| Kearney, TE | 1 |
| Farber, S | 1 |
| Ulmer, A | 1 |
| Zerdick, J | 1 |
| Chermack, ST | 1 |
| Reilly, M | 1 |
| Davis, L | 1 |
| Kilaru, U | 1 |
| Henry, S | 1 |
| Durante, AJ | 1 |
| Clark, HW | 2 |
| Robillard, H | 1 |
| Weinrich, M | 1 |
| Stuart, M | 1 |
| Hensel, M | 1 |
| Kox, WJ | 1 |
| Baño Rodrigo, MD | 1 |
| Agujetas Rodríguez, M | 1 |
| López García, ML | 1 |
| Guillén Llera, JL | 1 |
| Gordon, LT | 1 |
| Lehner, R | 1 |
| Shen, Q | 1 |
| Merrill, JC | 1 |
| Durell, J | 1 |
| Pakes, J | 1 |
| Widman, M | 1 |
| Platt, AK | 1 |
| Platt, JJ | 1 |
| Frosch, DL | 1 |
| Nahom, D | 1 |
| Jarvik, ME | 1 |
| Kábrt, J | 1 |
| Svobodová, J | 1 |
| Haluzík, M | 1 |
| Kotrlíková, E | 1 |
| Urdaneta, ME | 1 |
| Maksad, J | 2 |
| Sobota, M | 2 |
| Hanna, L | 1 |
| Markson, LE | 1 |
| Ducharme, LJ | 1 |
| Luckey, JW | 1 |
| Thürauf, N | 1 |
| Michel, MC | 2 |
| Pozzi, G | 1 |
| Conte, G | 1 |
| Harnett, PH | 1 |
| Staiger, P | 1 |
| Dadds, MR | 1 |
| Tagliamonte, A | 1 |
| Gessa, GL | 1 |
| Kristensen, O | 1 |
| Sivolap, IuP | 1 |
| Savchenkov, VA | 1 |
| Chen, MH | 1 |
| Barrau, K | 2 |
| Haramburu, F | 1 |
| Sanmarco, JL | 2 |
| Hien, DA | 1 |
| Fraser, D | 1 |
| Rolfe, A | 2 |
| Bleich, A | 2 |
| Lloyd, LV | 1 |
| Buntwal, N | 1 |
| Janal, M | 1 |
| Weber, L | 1 |
| Kelly, C | 1 |
| Sterling, R | 1 |
| Hutchinson, SJ | 1 |
| Taylor, A | 1 |
| Barr, C | 1 |
| Mills, C | 1 |
| Goldberg, DJ | 1 |
| Warburton, LA | 1 |
| Heinemann, A | 1 |
| Iwersen-Bergmann, S | 1 |
| Stein, S | 1 |
| Schmoldt, A | 1 |
| Püschel, K | 1 |
| Leo, RJ | 1 |
| Narendran, R | 1 |
| DeGuiseppe, B | 1 |
| Banbery, J | 1 |
| Kintaudi, K | 1 |
| Ziegler, M | 1 |
| Poustka, F | 1 |
| von Loewenich, V | 1 |
| Englert, E | 1 |
| Dragsholt, C | 1 |
| Hansen, AC | 1 |
| Müller, IB | 1 |
| Toft, J | 1 |
| Kaa, E | 2 |
| Anderson, RA | 1 |
| Lawford, BR | 1 |
| Young, RM | 1 |
| Noble, EP | 1 |
| Sargent, J | 1 |
| Rowell, J | 1 |
| Shadforth, S | 1 |
| Ritchie, T | 1 |
| Bourquin, M | 1 |
| Livoti, S | 2 |
| Powell, K | 1 |
| Déglon, J | 1 |
| Campbell, VC | 1 |
| Dewey, WL | 1 |
| Welch, SP | 1 |
| Weinstein, AM | 1 |
| Feldtkeller, BT | 1 |
| Goldstein, MF | 1 |
| Deren, S | 1 |
| Beardsley, M | 1 |
| Richman, BL | 2 |
| Winick, C | 1 |
| Kott, A | 1 |
| Habel, E | 1 |
| Nottingham, W | 1 |
| Gelkopf, M | 1 |
| Hayward, R | 1 |
| Nap, TJ | 1 |
| Djezzar, S | 1 |
| Lambert, H | 1 |
| Lagier, G | 1 |
| Heuter, T | 1 |
| Waldvogel, D | 1 |
| Richards, AH | 1 |
| Berbatis, CG | 1 |
| Sunderland, VB | 1 |
| Bulsara, M | 1 |
| Kroch, S | 1 |
| Dłuzniewska, K | 1 |
| Lang-Młynarska, D | 1 |
| Menelaou, A | 1 |
| Charlier, C | 1 |
| Dessalles, MC | 1 |
| Plomteux, G | 1 |
| Koch, M | 1 |
| Yui, K | 1 |
| Cummins, M | 1 |
| Welch, S | 1 |
| Reese, TV | 1 |
| Cancrini, L | 1 |
| Conover, C | 1 |
| Ridzon, R | 1 |
| Valway, S | 1 |
| Schoenstadt, L | 1 |
| McAuley, J | 1 |
| Onorato, I | 1 |
| Paul, W | 1 |
| Broly, F | 1 |
| Meili, D | 1 |
| Chevalley, AF | 1 |
| Zullino, D | 1 |
| Kosel, M | 2 |
| Lo, R | 1 |
| Rothbard, A | 1 |
| Wagner-Servais, D | 1 |
| Flynn, N | 1 |
| McCaffrey, BR | 1 |
| Dürsteler-Mac Farland, KM | 1 |
| Eichenberger, A | 1 |
| Rössler, W | 1 |
| Kleckham, J | 1 |
| Wanigaratne, S | 1 |
| Meyer, K | 2 |
| Zwehl, W | 1 |
| Nagengast, O | 1 |
| Eichenlaub, D | 2 |
| Moolchan, ET | 1 |
| Epstein, D | 1 |
| McLachlan-Troup, N | 1 |
| Cordero, R | 1 |
| Dohnal, M | 1 |
| Carman, S | 1 |
| Rodgers, JH | 1 |
| Bloch, DA | 1 |
| Grillon, CG | 1 |
| Morgan, CA | 1 |
| Shreeram, SS | 1 |
| McDonald, T | 1 |
| Dennison, S | 1 |
| Mistral, W | 1 |
| Hollingworth, M | 1 |
| Stancliff, S | 1 |
| Krambeer, LL | 1 |
| von McKnelly, W | 1 |
| Gabrielli, WF | 1 |
| Penick, EC | 1 |
| Schwejda, C | 1 |
| Bystron, C | 1 |
| Federmann, M | 1 |
| Schmidt, J | 1 |
| Bussello-Spieth, S | 1 |
| Mutasa, HC | 1 |
| Pach, J | 3 |
| Maj, JC | 1 |
| Foryś, Z | 1 |
| Janowska, E | 1 |
| Winnik, L | 1 |
| Radomska, M | 1 |
| West, SL | 1 |
| O'Neal, KK | 1 |
| Graham, CW | 1 |
| Prendergast, ML | 1 |
| Podus, D | 1 |
| Coviello, D | 1 |
| Appling, SE | 1 |
| Huang, DB | 1 |
| Gunne, L | 1 |
| Dallery, J | 1 |
| Fontdevila, J | 1 |
| Voisin, D | 1 |
| Pitchell, P | 1 |
| Carter, H | 1 |
| Hanlon, C | 1 |
| Hailwood, C | 1 |
| Massarotto, A | 1 |
| Callaly, T | 1 |
| Trauer, T | 1 |
| Munro, L | 1 |
| Whelan, G | 1 |
| Bovasso, GB | 1 |
| Simoni, JM | 1 |
| Cooper, DK | 1 |
| Welle-Strand, G | 1 |
| Hole, R | 1 |
| Lazaridis, KB | 1 |
| Sandvold, M | 1 |
| Moen, S | 1 |
| Høiseth, T | 1 |
| Higa, KD | 1 |
| Ho, T | 1 |
| Boone, KB | 1 |
| Roubicek, MC | 1 |
| Pakes, JP | 1 |
| Burgess, FW | 1 |
| Stewart, AL | 1 |
| Hillebrand, J | 1 |
| Höjd, C | 1 |
| Horak, M | 1 |
| Dittert, S | 1 |
| Dickerson, ED | 1 |
| Rihtar, TK | 1 |
| Hayes, M | 1 |
| Currens, M | 1 |
| Carter, JA | 1 |
| Eriksson, N | 1 |
| Schindler, S | 2 |
| Topitz, A | 1 |
| Gundersen, R | 1 |
| Mas, A | 1 |
| Moreno, V | 1 |
| Pallenbach, E | 1 |
| Robles-Sotelo, E | 1 |
| Correia, CJ | 1 |
| Mitchell, SM | 1 |
| Lane, B | 1 |
| Podreka, I | 1 |
| Brücke, T | 1 |
| Thurnher, M | 1 |
| Sevarino, KA | 1 |
| Begré, S | 1 |
| Jaquet-Rochat, S | 1 |
| Cosendai-Savary, L | 1 |
| Ballard, JL | 1 |
| Clarke, S | 2 |
| Mulcahy, F | 1 |
| Bergin, C | 1 |
| Reynolds, H | 1 |
| Boyle, N | 1 |
| Barry, M | 1 |
| Back, DJ | 1 |
| McGarry, KA | 1 |
| Wilbourne, P | 1 |
| Wallerstedt, C | 1 |
| Dorato, V | 1 |
| Curet, LB | 1 |
| Southwick, SM | 1 |
| Furlan, V | 1 |
| Edel, YA | 1 |
| Fontaa, V | 1 |
| Bronner, C | 1 |
| Iguchi, M | 1 |
| Dargan, P | 1 |
| Finnie, A | 1 |
| Nicolson, P | 1 |
| Eissenberg, T | 1 |
| San Narciso, GI | 1 |
| Sánchez del Río, J | 1 |
| Siney, C | 1 |
| Shaw, NJ | 1 |
| McCarthy, JE | 1 |
| Davis, PE | 1 |
| Liddiard, H | 1 |
| McMillan, TM | 1 |
| Chin, AT | 1 |
| Kuo, I | 1 |
| Leukefeld, C | 1 |
| Montagne, M | 1 |
| Howells, C | 1 |
| Allen, S | 1 |
| Gupta, J | 1 |
| Cornish, JW | 1 |
| Herman, BH | 1 |
| Robbins, SJ | 1 |
| Bead, V | 1 |
| Esmonde, CA | 1 |
| Martz, K | 1 |
| Caruso, FS | 1 |
| Mc Lellan, AT | 1 |
| Ternes, JW | 1 |
| Wellerstein, H | 1 |
| Jordan-Hayes, J | 1 |
| Barnes, TB | 1 |
| Pryor, GT | 1 |
| Howd, RA | 1 |
| Beverley, CL | 1 |
| Wells, AO | 1 |
| Curtis, JL | 1 |
| Sonderegger, T | 1 |
| Zimmermann, E | 1 |
| Abrahms, JL | 1 |
| Lloyd, MR | 1 |
| Green, M | 1 |
| Silverman, I | 1 |
| Suffet, F | 1 |
| Taleporos, E | 1 |
| Turkel, WV | 1 |
| Rajegowda, BK | 1 |
| Kandall, SR | 2 |
| Falciglia, H | 1 |
| Gostomzyk, JG | 1 |
| Fernández, T | 2 |
| Ollé, JM | 2 |
| Peri, JM | 2 |
| Weddington, WW | 3 |
| Haertzen, CC | 1 |
| Rubner, O | 1 |
| Shaffer, HJ | 1 |
| LaSalvia, TA | 1 |
| McDougle, CJ | 1 |
| Aghajanian, GK | 1 |
| Dennison, SJ | 1 |
| Brooke, D | 1 |
| Fudala, PJ | 6 |
| Steels, MD | 1 |
| Hamilton, M | 1 |
| Schwartz, BD | 1 |
| Evans, WJ | 1 |
| Sautter, F | 1 |
| Pena, JM | 1 |
| Winstead, DK | 1 |
| Barnas, C | 1 |
| Rossmann, M | 1 |
| Roessler, H | 1 |
| Fleischhacker, WW | 1 |
| Tiong, GK | 1 |
| Olley, JE | 1 |
| Loimer, N | 8 |
| Schmid, R | 3 |
| Morgan, C | 4 |
| Jain, RB | 1 |
| Weng, TS | 1 |
| Lee, ML | 1 |
| Tiwari, RC | 1 |
| Gross, AJ | 1 |
| Follmann, D | 1 |
| Geller, N | 1 |
| Morgan, CM | 1 |
| Falcione, J | 1 |
| Incmikoski, R | 1 |
| Patterson, L | 1 |
| Dhopesh, V | 4 |
| Mezochow, J | 1 |
| Marks, J | 2 |
| Wenston, J | 1 |
| Friedman, SR | 1 |
| Sotheran, JL | 1 |
| Marmor, M | 1 |
| Horvath, T | 1 |
| Aronson, M | 1 |
| Jacobson, J | 1 |
| Wiener, J | 1 |
| Peterson, A | 1 |
| Herman, S | 1 |
| Schuler, S | 1 |
| Freye, E | 1 |
| Derks, J | 1 |
| Engeseth, M | 1 |
| Julsrud, OJ | 1 |
| Grapendaal, M | 1 |
| Skogstad, M | 1 |
| Pettersen, RB | 1 |
| Furuholmen, D | 1 |
| Wright, C | 3 |
| Mavis, BE | 1 |
| DeVoss, GH | 1 |
| Stöffelmayr, BE | 1 |
| Hays, JR | 1 |
| Gay, W | 1 |
| Swift, G | 1 |
| Travers, R | 1 |
| Siddiqi, Q | 1 |
| Shapiro, J | 1 |
| Grossman, JI | 1 |
| Weisenfeld, L | 1 |
| Amann, KR | 1 |
| Koger, J | 1 |
| Vedovelli, H | 1 |
| Presslich, O | 5 |
| Werner, E | 1 |
| Hollerer, E | 2 |
| Pfersmann, V | 2 |
| Schmid-Siegel, B | 1 |
| Sundby, P | 2 |
| Condelli, WS | 1 |
| Fairbank, JA | 1 |
| Dennis, ML | 1 |
| Weissman, DE | 1 |
| Feely, M | 1 |
| Blaes, PA | 1 |
| Haver, VM | 1 |
| Greenberg, DM | 1 |
| Kennedy, JA | 2 |
| Sbriglio, R | 1 |
| Khuri, E | 1 |
| Albeck, H | 1 |
| Sam, L | 1 |
| Druley, P | 1 |
| DePhillips, D | 1 |
| Navaline, H | 1 |
| Morgan, CH | 1 |
| Diakogiannis, IA | 1 |
| Steinberg, M | 1 |
| Senay, E | 2 |
| White, R | 2 |
| Burns, B | 1 |
| Wittmann, BK | 1 |
| Segal, S | 1 |
| Chernaik, SJ | 1 |
| Griffiths, P | 3 |
| Linzmayer, L | 4 |
| Grünberger, J | 4 |
| Ochshorn, M | 2 |
| Sass, H | 1 |
| Täschner, KL | 1 |
| Feinberg, DT | 1 |
| Schinke, SP | 1 |
| Nichols, S | 1 |
| Botvin, GJ | 1 |
| Orlandi, MA | 1 |
| Stark, MJ | 1 |
| Campbell, BK | 1 |
| Sanderson, M | 1 |
| Neppe, VM | 1 |
| Sindorf, J | 1 |
| Brockmeyer, NH | 1 |
| Mertins, L | 1 |
| Goos, M | 1 |
| Gordis, E | 1 |
| Tokåker, PO | 1 |
| Spångberg, L | 1 |
| Pehrson, P | 1 |
| Morino, U | 1 |
| Nobili, M | 1 |
| Vivalda, L | 1 |
| Klee, H | 1 |
| Faugier, J | 1 |
| Hayes, C | 1 |
| Stastny, D | 1 |
| Potter, M | 1 |
| Hoegerman, G | 1 |
| Schnoll, S | 1 |
| Lenz, K | 1 |
| Thornton, L | 1 |
| Clune, M | 1 |
| Maguire, R | 1 |
| Griffin, E | 1 |
| Maas, U | 2 |
| Kattner, E | 2 |
| Koch, S | 1 |
| Schfer, A | 1 |
| Obladen, M | 2 |
| Barrett, ME | 1 |
| May, B | 1 |
| Boschek, HJ | 1 |
| Kühlkamp, V | 1 |
| Rösinger, C | 1 |
| Schumacher, B | 1 |
| Schwegler, U | 1 |
| Hofmeister-Wagner, WD | 1 |
| Peters, M | 1 |
| Streidl, C | 1 |
| Radlbeck, J | 1 |
| Fuchs, WJ | 1 |
| Oliveros, SC | 1 |
| Caballero, L | 1 |
| Iruela, LM | 1 |
| Segest, E | 1 |
| Mygind, O | 1 |
| Bay, H | 1 |
| Elias, H | 1 |
| Fodor, G | 1 |
| Praitner, M | 1 |
| Fraser, AD | 1 |
| Wehinger, G | 1 |
| Battista, HJ | 1 |
| Holmes, VF | 1 |
| Duszynski, KR | 3 |
| Nolimal, D | 2 |
| Macfadden, W | 1 |
| Maany, I | 3 |
| Ravi, NV | 1 |
| Burke, WM | 1 |
| Creighton, FJ | 2 |
| Bhat, AV | 1 |
| Meystre-Agustoni, G | 1 |
| Wietlisbach, V | 1 |
| Haller-Maslov, E | 1 |
| Summerhill, D | 1 |
| Weingart-Jesse, B | 1 |
| Schäfer, A | 1 |
| Pfersmann, D | 1 |
| Pakesch, G | 1 |
| Gawin, FH | 2 |
| Nelson, JC | 1 |
| Bickel, W | 1 |
| Bronson, ME | 1 |
| Nelson, FL | 1 |
| Kabacy, M | 1 |
| Burke, W | 1 |
| Maurice, L | 1 |
| Willenbring, ML | 1 |
| Morley, JE | 1 |
| Krahn, DD | 1 |
| Carlson, GA | 1 |
| Levine, AS | 1 |
| Shafer, RB | 1 |
| Tiuseco, D | 1 |
| Cho, JK | 1 |
| Jacobsen, LK | 2 |
| Phillips, G | 2 |
| Rosati, P | 1 |
| Noia, G | 1 |
| De Santis, M | 1 |
| Exacoustos, S | 1 |
| Puggioni, GF | 1 |
| Di Lieto, MP | 1 |
| Mancuso, S | 1 |
| Kuhn, KL | 1 |
| Halikas, JA | 1 |
| Kemp, KD | 1 |
| Collins, CC | 1 |
| DiPhilipis, D | 1 |
| Bianchi, MS | 1 |
| Turkington, D | 1 |
| Drummond, DC | 1 |
| Arndt, I | 1 |
| Elmoghazy, E | 1 |
| Johnson, BD | 1 |
| Alling, FA | 1 |
| De Ford, HA | 1 |
| Olson, R | 1 |
| Shalton, G | 1 |
| Fram, DH | 1 |
| Marmo, J | 1 |
| Holden, R | 1 |
| Good, P | 1 |
| Wilkinson, K | 1 |
| Archie, CL | 1 |
| Lee, MI | 1 |
| Sokol, RJ | 1 |
| Norman, G | 1 |
| Ruben, SM | 1 |
| Melville, J | 1 |
| Speckart, GR | 1 |
| Booth, MW | 1 |
| Ryan, TM | 1 |
| Patterson, MA | 2 |
| Appiotti, A | 1 |
| Gaspari, J | 2 |
| Swift, R | 1 |
| Riordan, C | 1 |
| Santangelo, S | 1 |
| Neil, A | 1 |
| Foley, KM | 1 |
| Ehrman, R | 2 |
| Pashko, S | 1 |
| Peachey, JE | 4 |
| Corty, E | 2 |
| Petroski, SP | 1 |
| Bond, H | 1 |
| Tommasello, A | 1 |
| Graff, H | 1 |
| Walton, RG | 1 |
| Balabanova, S | 1 |
| Wolf, HU | 1 |
| Seligman, PJ | 1 |
| Campbell, RJ | 1 |
| Keeler, GP | 1 |
| Halpin, TJ | 1 |
| Facchinetti, F | 1 |
| Comitini, G | 1 |
| Petraglia, F | 1 |
| Volpe, A | 1 |
| Genazzani, AR | 1 |
| Morris, D | 1 |
| Dewey, W | 1 |
| Shine, D | 1 |
| Moll, B | 1 |
| Emeson, E | 1 |
| Spigland, I | 1 |
| Harris, C | 1 |
| Small, CB | 1 |
| Weiss, SH | 1 |
| Bodner, AJ | 1 |
| Gorman, E | 1 |
| Warfield, CA | 1 |
| Ehrlich, S | 1 |
| Friend, HJ | 1 |
| Seran, GF | 1 |
| Techman, TM | 1 |
| Shaffer, JW | 3 |
| Stephenson, P | 2 |
| Marsh, DT | 1 |
| Stile, SA | 1 |
| Stoughton, NL | 1 |
| Trout-Landen, BL | 1 |
| Mackie-Ramos, RL | 1 |
| Lowinson, JH | 2 |
| Ceriello, A | 1 |
| Giugliano, D | 1 |
| Passariello, N | 1 |
| Quatraro, A | 1 |
| Dello Russo, P | 1 |
| Torella, R | 1 |
| D'Onofrio, F | 1 |
| Johnston, BB | 1 |
| Franklin, T | 2 |
| Wells, B | 1 |
| Lei, H | 1 |
| Minovitz, O | 1 |
| Haastrup, S | 1 |
| Jepsen, PW | 2 |
| Chordia, PL | 1 |
| Escovar, IL | 1 |
| Gold, ML | 1 |
| McCanlies, N | 1 |
| Trier, M | 1 |
| Dlugosch, G | 1 |
| Ragni, G | 1 |
| De Lauretis, L | 1 |
| Bestetti, O | 1 |
| Sghedoni, D | 1 |
| Gambaro, V | 1 |
| Angelo, HR | 1 |
| Kristensen, F | 1 |
| Cerri, C | 1 |
| Cocco, E | 1 |
| Rovati, L | 1 |
| Hartog, J | 1 |
| Dougherty, PM | 1 |
| Pearl, J | 1 |
| Krajewski, KJ | 1 |
| Pellis, NR | 1 |
| Dafny, N | 1 |
| Wermuth, L | 2 |
| Brummett, S | 1 |
| Sanchez-Ramos, JR | 1 |
| Suljaga, K | 1 |
| Kaswan, M | 1 |
| Skovron, ML | 1 |
| Gaspar, L | 1 |
| Chan, JS | 1 |
| Seidah, NG | 1 |
| Chrétien, M | 1 |
| Carney, AC | 1 |
| Shanley, C | 1 |
| Gurwitch, RH | 2 |
| Wiebe, DJ | 2 |
| Doberczak, TM | 1 |
| Thornton, JC | 1 |
| Gibson, D | 1 |
| Menicucci, L | 1 |
| Bernal, G | 1 |
| Schumann, B | 1 |
| Wright, D | 1 |
| Carney, MK | 1 |
| Cochrane, KJ | 1 |
| Rubinstein, KJ | 1 |
| Costello, R | 1 |
| Chenitz, WC | 1 |
| Krumenaker, C | 1 |
| Tsang, D | 1 |
| Ho, KP | 1 |
| Wen, HL | 1 |
| Winsløw, JH | 1 |
| Jepsen, J | 1 |
| Ege, P | 1 |
| Offidani, C | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Falasconi, AM | 1 |
| Bernstein, VJ | 1 |
| Jeremy, RJ | 1 |
| Millman, RB | 1 |
| Phillips, GT | 1 |
| Robertson, K | 1 |
| Truitt, L | 1 |
| Alexander, BK | 1 |
| Beyerstein, BL | 1 |
| MacInnes, TM | 1 |
| Shilo, L | 1 |
| Liebermann, N | 1 |
| Solomon, G | 1 |
| Shenkman, L | 1 |
| Pumphrey, E | 1 |
| Seecof, R | 1 |
| Okpaku, SO | 1 |
| Marsh, KL | 1 |
| Osborn, E | 2 |
| Grey, C | 2 |
| Reznikoff, M | 2 |
| Freitas, PM | 1 |
| Bewley, TH | 1 |
| Kearney, MK | 1 |
| Ceresini, G | 1 |
| Moccia, G | 1 |
| Charney, D | 1 |
| Hogan, I | 1 |
| O'Connor, C | 1 |
| Auerbach, A | 1 |
| Levadi, DI | 1 |
| Dolan, MP | 1 |
| Black, JL | 1 |
| Penk, WE | 1 |
| Robinowitz, R | 1 |
| DeFord, HA | 1 |
| Johns, AR | 1 |
| Borders, OT | 1 |
| Ruffing-Rahal, MA | 1 |
| McMahon, RC | 1 |
| Davidson, RS | 1 |
| Keen, MR | 1 |
| Owen, A | 1 |
| Hill, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO)[NCT01936857] | Phase 4 | 281 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Neurocognitive Effects of Opiate Agonist Treatment[NCT01733693] | Phase 4 | 135 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics[NCT04706624] | 640 participants (Anticipated) | Interventional | 2020-11-02 | Active, not recruiting | |||
| Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse (OPTIMA Trial)[NCT03033732] | Phase 4 | 272 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| Substance Use Treatment and Recovery Team[NCT05086796] | 325 participants (Actual) | Interventional | 2021-11-11 | Active, not recruiting | |||
| Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area[NCT05973838] | 180 participants (Anticipated) | Interventional | 2023-06-15 | Recruiting | |||
| Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department[NCT00913770] | 329 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Bup/Nx - Facilitated Rehab for Opioid Dependent Adolescents[NCT00078130] | Phase 3 | 223 participants | Interventional | 2003-07-31 | Completed | ||
| Starting Treatment With Agonist Replacement Therapies (START)[NCT00315341] | Phase 4 | 1,269 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients[NCT00879996] | Phase 4 | 54 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment[NCT02032433] | Phase 4 | 570 participants (Actual) | Interventional | 2014-01-29 | Completed | ||
| A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients[NCT01559454] | Phase 4 | 19 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Examining Access to Primary Care for People With Opioid Use Disorder: a Randomized Controlled Audit Study[NCT05484609] | 383 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence. An Adaptive, Single-blind, Placebo-controlled Ascending Dose Study of Acute Baclofen on Safety Parameters in Opioid Dependence During Methadone-maintenance[NCT05161351] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-01-11 | Recruiting | ||
| Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia[NCT02396979] | Phase 4 | 300 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Behavioral Intervention to Improve Insomnia Symptoms in Patients With Opioid Use Disorder[NCT05588726] | 0 participants (Actual) | Interventional | 2022-01-01 | Withdrawn (stopped due to Staff no longer available to continue enrollment and other research activities) | |||
| Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for Opioid Use and Chronic Pain Management Pilot[NCT03894501] | 30 participants (Actual) | Interventional | 2019-01-31 | Completed | |||
| A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of O[NCT05594121] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | ||
| Pilot Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy[NCT03022890] | 40 participants (Actual) | Interventional | 2017-04-01 | Completed | |||
| Pomegranate Juice Consumption by Patients Under Medication for Addiction Treatment as a Regulator of Craving and Blood Redox Status: The Study Protocol of a Randomized Control Trial (the NUTRIDOPE Study)[NCT05861544] | 58 participants (Anticipated) | Interventional | 2023-03-23 | Enrolling by invitation | |||
| START Follow-up Study (NIDA CTN Protocol 0050)[NCT01592461] | 877 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| Evaluating the Impact of Trauma, Trauma-Focused Therapy Services, and COVID-19 Among Patients in the University of Kentucky SMART Clinic[NCT04760418] | 21 participants (Actual) | Interventional | 2021-05-26 | Completed | |||
| Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry[NCT01999946] | Phase 4 | 217 participants (Actual) | Interventional | 2014-06-27 | Completed | ||
| Developing and Testing the Opioid Rapid Response System[NCT04589676] | 400 participants (Actual) | Interventional | 2020-12-01 | Completed | |||
| Adjuvant Laser Meridian Massage in Heroin Addicts With Methadone Treatment: an Observational Case-controlled Study[NCT04003077] | 30 participants (Anticipated) | Interventional | 2019-02-26 | Recruiting | |||
| The Long-Term Treatment of Drug Addiction and Unemployment[NCT02487745] | 91 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons Who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care[NCT04804072] | 450 participants (Anticipated) | Interventional | 2021-06-02 | Enrolling by invitation | |||
| A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail[NCT02334215] | 225 participants (Actual) | Interventional | 2014-12-15 | Completed | |||
| Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center: Identifying Patients at Risk and Simplifying ECG Monitoring[NCT02898337] | 170 participants (Anticipated) | Observational | 2016-11-30 | Completed | |||
| The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Opioid Use Disorders: Analysis of Clinical Outcomes, Functional Magnetic Resonance Imaging, Biomarkers, and Neuropsychological Tests[NCT03229642] | 60 participants (Anticipated) | Interventional | 2017-08-01 | Recruiting | |||
| A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil.[NCT01847729] | 263 participants (Actual) | Observational | 2013-07-11 | Completed | |||
| The Norwegian Addiction, Pain and Trauma Study[NCT04908410] | 1,500 participants (Anticipated) | Observational | 2021-03-23 | Recruiting | |||
| Effectiveness of Disulfiram for Treating Cocaine Dependence in Individuals With Different Dopamine Beta Hydroxylase (DBH) Genes[NCT00149630] | Phase 2 | 93 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303] | Phase 4 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551] | Phase 4 | 31 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-02-21 | Recruiting | ||
| Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722] | Phase 4 | 40 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476] | Phase 3 | 117 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707] | Phase 2 | 29 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Pilot Study to Permit Opioid Treatment Program Physicians to Prescribe Methadone Through Community Pharmacies for Their Stable Methadone Patients[NCT04308694] | Early Phase 1 | 20 participants (Actual) | Interventional | 2020-08-06 | Completed | ||
| Enhancing Office-based Buprenorphine Treatment: An Adaptive Psychosocial Approach[NCT04650386] | 250 participants (Anticipated) | Interventional | 2020-09-21 | Recruiting | |||
| Acceptability/Feasibility Testing of an Intervention Targeting Intolerance of Uncertainty[NCT05172427] | 45 participants (Anticipated) | Interventional | 2021-09-15 | Recruiting | |||
| Prospective Randomized Blinded Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)[NCT04455802] | Phase 3 | 0 participants (Actual) | Interventional | 2020-10-01 | Withdrawn (stopped due to termination of funding) | ||
| Automated Recovery Line for Medication Assisted Treatment[NCT02124980] | 60 participants (Anticipated) | Interventional | 2015-11-30 | Completed | |||
| Comparison of Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology[NCT03740243] | Phase 4 | 0 participants (Actual) | Interventional | 2018-11-30 | Withdrawn (stopped due to No enrollment) | ||
| Reengineering Methadone Treatment: A Randomized Clinical Trial[NCT01442493] | 300 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| The Effect of Kangaroo Mother Care Applied to the Healthy Newborns in the Early Postpartum Period on Breastfeeding: Randomized Controlled Study[NCT04619459] | 112 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression[NCT02200406] | Phase 4 | 18 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Descriptive, Prospective Study of the Characteristics of Chronic Pain in Patients With Addiction to at Least One Substance[NCT05976178] | 300 participants (Anticipated) | Observational | 2022-12-10 | Recruiting | |||
| Targeted Focus Groups Discussions (FGDs) and Cross-sectional Questionnaire to Address Questions Regarding Telemedicine Concept and Knowledge, and Social Media Usage Among People Who Inject Drugs (PWID) in Greece[NCT05794984] | 220 participants (Anticipated) | Observational | 2023-05-01 | Active, not recruiting | |||
| Addressing Opioid Use Disorder in the Elderly Through Primary Care Innovation: Pain and Opioid Management in Older Adults[NCT05037682] | 1,035 participants (Anticipated) | Interventional | 2020-09-30 | Recruiting | |||
| Comparing Opium Tincture (OT) and Methadone for Medication-assisted Treatment of Opioid Use Disorder: A Randomized Double-blind Controlled Clinical Trial[NCT02502175] | Phase 3 | 204 participants (Actual) | Interventional | 2017-06-22 | Completed | ||
| Intensive Models of HCV Care for Injection Drug Users[NCT01857245] | 150 participants (Actual) | Interventional | 2013-10-01 | Completed | |||
| A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 (Doravirine) on Methadone Pharmacokinetics[NCT02715700] | Phase 1 | 14 participants (Actual) | Interventional | 2015-09-28 | Completed | ||
| Using Difference-in-Differences to Evaluate the Effect of a Statewide Quality Improvement Program on New Persistent Opioid Use After Surgery[NCT04805229] | 30,000 participants (Actual) | Observational | 2013-01-01 | Completed | |||
| Open-labeled Dose-extending Placebos as an Adjunct to Methadone Treatment: A Pilot Study[NCT02941809] | 133 participants (Actual) | Interventional | 2017-12-05 | Completed | |||
| MOms in REcovery (MORE): Defining Optimal Care for Pregnant Women and Infants[NCT04251208] | 444 participants (Actual) | Observational | 2019-07-30 | Active, not recruiting | |||
| Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment Who Are Undergoing Ambulatory Surgery- a Case Series[NCT04716413] | Phase 4 | 3 participants (Actual) | Interventional | 2021-09-27 | Terminated (stopped due to Terminated early due to funding, lack of participants) | ||
| A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.[NCT03098407] | 55 participants (Actual) | Interventional | 2017-04-20 | Completed | |||
| Maternal Opioid Treatment: Human Experimental Research[NCT00271219] | Phase 3 | 175 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| ECG Device for Long QT Syndrome Screening in Newborns[NCT02412709] | Phase 2 | 4,000 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs[NCT03282890] | 237 participants (Actual) | Interventional | 2017-11-20 | Completed | |||
| Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors[NCT01131273] | Phase 3 | 68 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomized Pilot Study of Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films[NCT03744663] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to Funding for uninsured subjects could not be realized and staffing after COVID hit was also a problem.) | ||
| Pilot Study to Look at Feasibility of Testing and Treatment of Combination Fentanyl and Opioid Dependent Individuals With Different Buprenorphine Induction Methods[NCT04794790] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2022-05-09 | Recruiting | ||
| Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics[NCT05910580] | 600 participants (Anticipated) | Interventional | 2024-04-01 | Not yet recruiting | |||
| A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial in Subjects on Stable Methadone Maintenance Therapy, to Investigate the Potential Interaction Between TMC278 25 mg q.d. and Methadone, at Steady-state.[NCT00744770] | Phase 1 | 13 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Entry Into Comprehensive Methadone Treatment Via Interim Maintenance[NCT00712036] | 230 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville[NCT00657397] | Phase 3 | 197 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Randomised, Controlled Clinical Study Regarding the Feasibility of Converting Opiate Dependents From Methadone Substitutes to Slow Release Morphine Sulphate (Sevre-Long™)[NCT01079117] | Phase 3 | 276 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers[NCT02926482] | 76 participants (Actual) | Interventional | 2016-10-26 | Completed | |||
| Time to Detox: A Patient-Centered Comparison of Length of Detoxification Treatment and Time to Naltrexone Maintenance Therapy in Opioid-Dependent Individuals[NCT03678792] | Phase 3 | 0 participants (Actual) | Interventional | 2019-11-15 | Withdrawn (stopped due to Infeasible to conduct at this time.) | ||
| A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment[NCT01416584] | 98 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| Factors Associated With the Variance of Oral Methadone Dosage at Steady State of Maintenance Treatment: Description of Bio-markers of Phenotype and Genotype.[NCT00894452] | 210 participants (Actual) | Observational | 2008-12-31 | Completed | |||
| Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients[NCT01378858] | 100 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Services Research: Psychiatric Comorbidity in Drug Abuse[NCT00787735] | 380 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users[NCT00175357] | Phase 3 | 192 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Effectiveness of an Information-Motivation-Behavioral Skills Model-based Intervention on Adherence to Domiciliary Non-invasive Ventilation of Patients With Chronic Hypercapnic Respiratory Failure: A Randomized Controlled Study[NCT05008211] | 104 participants (Anticipated) | Interventional | 2021-09-16 | Recruiting | |||
| PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)[NCT05128071] | Early Phase 1 | 40 participants (Anticipated) | Interventional | 2022-02-04 | Recruiting | ||
| The Behavioral Activation for Chinese Substance Users (C-BA) Research Protocol[NCT03705143] | 90 participants (Actual) | Interventional | 2018-06-04 | Completed | |||
| An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine[NCT01911845] | Phase 2 | 38 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Randomized Trail of Continues Methadone Maintenance Versus Detoxification in Jail[NCT01874964] | 450 participants (Anticipated) | Interventional | 2010-06-30 | Active, not recruiting | |||
| Barriers and Effect of Optimizing Intervention Protocols for Heroin Dependence in Community-based Methadone Maintenance Treatment (MMT): a Cohort Study[NCT01144390] | 240 participants (Anticipated) | Interventional | 2010-04-30 | Active, not recruiting | |||
| Effects of Cognitive Training in Methadone Maintenance Patients[NCT01271413] | Phase 2 | 134 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| Train Your Brain: A Pilot Project to Improve Memory and Decision Making to Improve Outcomes Among Youth[NCT05879198] | 23 participants (Anticipated) | Interventional | 2023-06-15 | Enrolling by invitation | |||
| Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C[NCT01707030] | 138 participants (Actual) | Interventional | 2015-03-01 | Completed | |||
| Peer-Delivered Behavioral Activation Intervention to Improve Adherence to MAT Among Low-Income, Minority Individuals With OUD - Pilot Phase[NCT04248933] | 37 participants (Actual) | Interventional | 2020-10-09 | Completed | |||
| A Prospective, Randomized Trial of the Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post Operative Opioid Use Disorder Symptoms[NCT03266445] | Phase 4 | 76 participants (Anticipated) | Interventional | 2018-10-05 | Not yet recruiting | ||
| Towards Ending HCV Infection Among Active Drug Users: a Community-based Intervention in Montpellier.[NCT04008927] | 554 participants (Actual) | Interventional | 2020-09-18 | Completed | |||
| Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV)[NCT03155906] | 240 participants (Anticipated) | Interventional | 2017-05-18 | Active, not recruiting | |||
| A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are on Opiate Substitution Therapy[NCT02105688] | Phase 3 | 301 participants (Actual) | Interventional | 2014-09-02 | Completed | ||
| Chronic Pain and Opioid Dependence Assessment and Treatment[NCT00727675] | 15 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Clinical Trial of Integrated Treatment for Pain and Opioid Dependence[NCT00634803] | Phase 1/Phase 2 | 90 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth[NCT02712034] | 417 participants (Actual) | Interventional | 2016-04-21 | Completed | |||
| Comparing Health & Social Outcomes Between Opioid-Dependent Individuals in Compulsory Drug Rehabilitation Centers and Voluntary Drug Treatment Clinics in Klang Valley, Malaysia[NCT02698098] | 281 participants (Actual) | Observational | 2012-08-31 | Terminated (stopped due to 1) Policy change affecting C&Cs; 2) interm analysis revealing overt differences) | |||
| Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients[NCT01471145] | Phase 4 | 40 participants (Anticipated) | Interventional | 2013-01-31 | Completed | ||
| Treating Cocaine Abuse: A Behavioral Approach[NCT01822327] | Phase 2 | 124 participants (Anticipated) | Interventional | 2007-12-31 | Active, not recruiting | ||
| A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Clinical Efficacy, Safety, and Immunogenicity of a Human Cocaine Vaccine (TA-CD) in the Treatment of Cocaine Dependence[NCT00969878] | Phase 2 | 300 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Insomnia and Drug Relapse Risk[NCT00253890] | Phase 3 | 137 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| Vagal Tone and Neonatal Abstinence Syndrome[NCT00496951] | 65 participants (Actual) | Observational | 2006-09-30 | Completed | |||
| Identifying an Effective and Cost Beneficial Approach to Preventing OUD in Justice-Involved Youth[NCT04901312] | 215 participants (Anticipated) | Interventional | 2021-01-20 | Recruiting | |||
| SALOME: Multi-Centre, Double Blind Randomized Controlled Trial Comparing The Effectiveness Of Diacetylmorphine Vs. Hydromorphone For The Treatment Of Long-Term Injection Opioid Users Who Do Not Benefit From Available Therapies[NCT01447212] | Phase 3 | 202 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| SBIR Phase 1: Scalable Digital Delivery of Evidence-based Training for Family to Maximize Treatment Admission Rates of Opioid Use Disorder in Loved Ones-- We The Village Family Support Study[NCT04250077] | 45 participants (Actual) | Interventional | 2020-01-09 | Completed | |||
| Exploring the Utility and Safety of Benzodiazepine Prescribing Among People Receiving Opiate Replacement Therapy in Scotland (the BENZORT Study).[NCT04622995] | 46,899 participants (Actual) | Observational | 2021-08-01 | Completed | |||
| Efficacy of Drug and Risk Behavior Counseling Intervention Among Injecting Drug Users at Opioid Substitution Treatment[NCT03721380] | 118 participants (Actual) | Interventional | 2012-05-14 | Completed | |||
| Improving Self-Management of Chronic Conditions Among Homeless Persons: a Community-Based Participatory Approach Using Text Messaging[NCT03034993] | 64 participants (Actual) | Interventional | 2017-07-21 | Completed | |||
| A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans[NCT03331978] | 306 participants (Actual) | Interventional | 2018-01-23 | Completed | |||
| Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study)[NCT00263458] | Phase 4 | 37 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Treating the Partners of Drug Using Pregnant Women: Stage II[NCT00496990] | Phase 2/Phase 3 | 158 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Place of Low-Dose Naltrexone in Opiate Detoxification[NCT00135759] | Phase 2 | 174 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder[NCT05047627] | 63 participants (Actual) | Interventional | 2021-09-15 | Completed | |||
| A Double Blind, Randomized Clinical Trial Comparing Postoperative Narcotic Usage in Patients Receiving Periarticular Liposomal Bupivicaine vs. Those Patients Receiving Standard Periarticular Joint Injections[NCT02682498] | Phase 4 | 38 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Fetal Neurobehavior in Non-methadone Maintained Women in Substance Abuse Treatment[NCT00522626] | 19 participants (Actual) | Observational | 2006-08-31 | Completed | |||
| Methadone, Buprenorphine and Fetal Neurobehavior[NCT00653692] | 29 participants (Actual) | Observational | 2007-05-31 | Completed | |||
| Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence[NCT02496403] | 239 participants (Actual) | Interventional | 2015-12-31 | Completed | |||
| Effectiveness of Screening and Treatment for PTSD in SUD Patients[NCT00265564] | 117 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Safety, Efficacy, Pharmacokinetics, and Pharmacogenomics of Extended-Release Naltrexone in Pregnant Women[NCT03718104] | 100 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| Methadone Maintenance and HIV Prevention: A Window of Opportunity in China Version[NCT01532609] | 220 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| A Brief Alcohol Intervention for Incarcerated Women[NCT00237003] | Phase 3 | 326 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| The Effects of Opioid Taper on Opioid-Induced Hyperalgesia[NCT03063905] | 15 participants (Actual) | Observational | 2017-01-31 | Terminated (stopped due to funding expired) | |||
| Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone in Human Subjects[NCT00504413] | Phase 1 | 20 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| Evaluation of an Eye Tracking Sensor to Detect Cannabis Impairment[NCT03994926] | Early Phase 1 | 3 participants (Actual) | Interventional | 2020-02-03 | Terminated (stopped due to COVID-19 Pandmic halted study) | ||
| Telemedicine for Smoking Cessation in Rural Primary Care[NCT00843505] | Phase 3 | 566 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Encouraging Opioid Abstinence Behavior: Incentivizing Inputs and Outcomes - Pilot[NCT04235582] | 36 participants (Actual) | Interventional | 2020-08-25 | Completed | |||
| Encouraging Abstinence Behavior in a Drug Epidemic: Does Age Matter?[NCT05521854] | 600 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | |||
| Encouraging Abstinence Behavior in a Drug Epidemic[NCT04927143] | Phase 2 | 600 participants (Anticipated) | Interventional | 2021-09-15 | Recruiting | ||
| Donor Human Milk for Infants With Neonatal Abstinence Syndrome[NCT02182973] | 12 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit[NCT02025855] | Phase 4 | 46 participants (Anticipated) | Interventional | 2014-01-31 | Enrolling by invitation | ||
| Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management[NCT02335398] | Phase 4 | 34 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Treatment of Adult ADHD in Methadone Patients[NCT00061087] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1998-02-28 | Completed | ||
| Methadone, Buprenorphine and Fetal Development[NCT00067184] | 157 participants (Actual) | Observational | 2002-09-30 | Completed | |||
| [NCT00292123] | Phase 1 | 200 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| Personalizing Perioperative Morphine Analgesia for Adolescents Undergoing Major Spine Surgeries[NCT01839461] | 137 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| Genetic, Epigenetic, Psychosocial, and Biological Determinants of Post-surgical Pain After Pectus or Spine Surgery[NCT04031716] | 600 participants (Anticipated) | Interventional | 2018-07-06 | Enrolling by invitation | |||
| Predicting Perioperative Opioid Adverse Effects and Personalizing Analgesia in Children: A Multicenter Pharmacogenetic Study[NCT01495611] | 1,000 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| Non-Interventional Pharmacogenetic Study of Patient / Proxy Controlled Analgesia in Children Undergoing Surgery[NCT01731873] | 182 participants (Actual) | Observational | 2012-01-17 | Completed | |||
| The Effect of Acute Intravenous Morphine Administration on Sleep Disordered Breathing (SDB) in Patients With Moderate Obstructive Sleep Apnoea (OSA): A Paired Design Trial[NCT03127800] | Phase 3 | 6 participants (Actual) | Interventional | 2016-05-20 | Terminated (stopped due to Difficulties with recruitment) | ||
| Get Your Mind Right: Feasibility of a Mental Health Intervention for African American Fathers in North Omaha[NCT03552783] | 10 participants (Actual) | Interventional | 2019-03-08 | Completed | |||
| Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial[NCT00510016] | Phase 2 | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.[NCT00398034] | Phase 2 | 0 participants (Actual) | Interventional | 2006-10-30 | Withdrawn (stopped due to The original PI (David Siegel) Left the VA) | ||
| fMRI Imaging of Opioid Withdrawal in Healthy Human Volunteers[NCT01006707] | 15 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion: A Randomized Controlled Study[NCT04095624] | 84 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine: an Open Label, Hypothesis Generator Study[NCT04361721] | 40 participants (Anticipated) | Observational | 2020-01-15 | Recruiting | |||
| Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care[NCT01621711] | 504 participants (Actual) | Interventional | 2011-03-31 | Active, not recruiting | |||
| Four Models of Telephone Support for Stimulant Recovery[NCT00744068] | 302 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Buprenorphine Maintenance Protocol[NCT00000205] | Phase 3 | 0 participants | Interventional | 1990-10-31 | Completed | ||
| Cocaine Effects in Humans: Physiology and Behavior[NCT00000200] | Phase 2 | 19 participants (Actual) | Interventional | 1997-01-31 | Completed | ||
| Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts[NCT00000216] | Phase 3 | 0 participants | Interventional | Completed | |||
| Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
| The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.[NCT03018236] | Phase 4 | 100 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| A Randomized Community Intervention Trial on Reducing HIV Infection Among Drug Users Attending Methadone Maintenance Treatment(MMT) and Preventing Secondary Transmission From HIV Positive Clients to Their Sexual Partners in China[NCT01108614] | Phase 3 | 12,000 participants (Anticipated) | Interventional | 2009-06-30 | Recruiting | ||
| Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans[NCT01222091] | Phase 2 | 10 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [NCT00344812] | Phase 2 | 220 participants | Interventional | 1996-01-31 | Completed | ||
| Participatory System Dynamics vs Audit and Feedback: A Cluster Randomized Trial of Mechanisms of Implementation Change to Expand Reach of Evidence-based Addiction and Mental Health Care[NCT04356274] | 720 participants (Anticipated) | Interventional | 2019-02-01 | Enrolling by invitation | |||
| Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management[NCT00292110] | Phase 1 | 140 participants (Actual) | Interventional | 2004-02-01 | Completed | ||
| Naloxegol for Opioid-Related Gastroparesis: A Double-Blind Study With an Open Label Extension[NCT03036891] | Phase 2 | 0 participants (Actual) | Interventional | 2016-12-29 | Withdrawn | ||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Examination of Palonosetron and Hydroxyzine Pre-treatment as a Possible Method to Reduce the Objective Signs of Experimentally-induced Acute Opioid Withdrawal in Humans: a Double-blind, Randomized, Placebo-controlled Crossover Study[NCT00661674] | 10 participants (Actual) | Interventional | 2008-04-30 | Completed | |||
| Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD: A Pilot Double-blind, Randomized Clinical Trial[NCT04759703] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2022-01-24 | Recruiting | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Initiation of and retention on treatment with antiretroviral medications. (NCT01936857)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Buprenorphine/Naloxone | 108 |
| Methadone Maintenance Therapy | 116 |
HIV clinic visit in past 3 months (NCT01936857)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Buprenorphine/Naloxone | 111 |
| Methadone Maintenance Therapy | 118 |
(NCT01936857)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Buprenorphine/Naloxone | 64 |
| Methadone Maintenance Therapy | 67 |
(NCT01936857)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Buprenorphine/Naloxone | 66 |
| Methadone Maintenance Therapy | 72 |
HIV-1 RNA < 200 copies/mL (NCT01936857)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Viral suppression at baseline | Viral suppression at 12 months | |
| Buprenorphine/Naloxone | 97 | 74 |
| Methadone Maintenance Therapy | 92 | 99 |
(NCT00913770)
Timeframe: 30 days post randomization
| Intervention | Mean Number of Days (Mean) |
|---|---|
| Standard Care | 2.3 |
| SBIRT | 2.4 |
| SBI+Bup | 0.9 |
Defined as enrollment and receiving formal addiction treatment on the 30th day following randomization. This is assessed by direct contact with facility, clinician, or both. (NCT00913770)
Timeframe: 30 days post randomization
| Intervention | Mean Number of Outpatient Visits (Mean) |
|---|---|
| Standard Care | 4.99 |
| SBIRT | 5.67 |
| SBI+Bup | 3.71 |
"Participants were categorized according liver transaminase (ALT, AST) levels in blood comparing the baseline sample to any and all subsequent samples in the following manner:~A: both ALT and AST started at less than or equal to two times the ULN and remained at two times or less ULN throughout the study~B: either ALT or AST started at less than or equal to 2 x ULN and at any point in study exceeded 2 x ULN~C: Either ALT or AST started > 2 x ULN, decreased (both ALT and AST) to < 2 x ULN, and remained < 2 x ULN~D: Either ALT or AST started > 2 x ULN and remained above 2 x ULN throughout the study" (NCT00315341)
Timeframe: 24 Weeks
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| ALT - A (low, stays low) | ALT - B (low, goes high) | ALT - C (high, goes low, stays low) | ALT - D (high, stays high) | AST - A (low, stay low) | AST - B (low, goes high) | AST - C (high, goes low, stays low) | AST - D (high, stays high) | |
| Buprenorphine/Nx | 278 | 41 | 4 | 17 | 291 | 37 | 3 | 9 |
| Methadone | 318 | 62 | 1 | 10 | 328 | 54 | 1 | 8 |
This outcome assesses the number of participants who completed the treatment after 6 months. (NCT00879996)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Methadone | 13 |
| Buprenorphine/Naloxone | 13 |
We assessed functioning measured on a 0-10 point numerical rating scale (NRS)with 0 being the least amount of functioning and 10 the best amount of functioning. (NCT00879996)
Timeframe: 6 months
| Intervention | units on a 0-10 point NRS scale (Mean) |
|---|---|
| Methadone | 5.0 |
| Buprenorphine/Naloxone | 5.3 |
Pain was measured using a 0-10 point numerical rating scale (NRS) with 0 representing no pain and 10 representing worst pain possible. (NCT00879996)
Timeframe: 6 months
| Intervention | units on a 0-10 NRS scale (Mean) |
|---|---|
| Methadone | 5.4 |
| Buprenorphine/Naloxone | 5.6 |
(NCT00879996)
Timeframe: 6 months
| Intervention | number of participants (Number) |
|---|---|
| Methadone | 0 |
| Buprenorphine/Naloxone | 5 |
Adverse events reported by participants and assessed by clinical staff for relatedness to study medication. These determinations were reviewed by the study medical monitor. (NCT02032433)
Timeframe: Weeks 0-36
| Intervention | events (Number) |
|---|---|
| Extended-Release Naltrexone | 115 |
| Buprenorphine-Naloxone | 113 |
Alcohol use over time, drinks per day (NCT02032433)
Timeframe: Week 24
| Intervention | drinks per day (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .4 |
Alcohol use over time, drinks per day, past 30 days, at week 0 (NCT02032433)
Timeframe: Week 0
| Intervention | drinks per day (Mean) |
|---|---|
| Extended-Release Naltrexone | .8 |
| Buprenorphine-Naloxone | 1.2 |
Participants average cigarettes/day, in past 4 weeks, at week 24, equals 10 or less. (NCT02032433)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 70 |
| Buprenorphine-Naloxone | 78 |
Participants average cigarettes/day, in past 4 weeks, at week 0, equals none (NCT02032433)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 17 |
| Buprenorphine-Naloxone | 18 |
Participants average cigarettes/day, in past 4 weeks, at week 0, equals 11-20. (NCT02032433)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 106 |
| Buprenorphine-Naloxone | 112 |
Participants average cigarettes/day, in past 4 weeks, at week 0, equals 21-30 (NCT02032433)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 18 |
| Buprenorphine-Naloxone | 21 |
Participants average cigarettes/day, in past 4 weeks, at week 0, equals 31 or more (NCT02032433)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 3 |
| Buprenorphine-Naloxone | 8 |
Participants average cigarettes/day, in past 4 weeks, at week 0, equals 10 or less. (NCT02032433)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 112 |
| Buprenorphine-Naloxone | 109 |
Participants average cigarettes/day, in past 4 weeks, at week 24, equals none (NCT02032433)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 32 |
| Buprenorphine-Naloxone | 29 |
Participants average cigarettes/day, in past 4 weeks, at week 24, equals 11-20. (NCT02032433)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 57 |
| Buprenorphine-Naloxone | 71 |
Participants average cigarettes/day, in past 4 weeks, at week 24, equals 21-30 (NCT02032433)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 2 |
| Buprenorphine-Naloxone | 11 |
Participants average cigarettes/day, in past 4 weeks, at week 24, equals 31 or more (NCT02032433)
Timeframe: Week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 1 |
| Buprenorphine-Naloxone | 5 |
Binary Y/N assessment of whether the participant was or was not able to initiate their assigned study medication. (NCT02032433)
Timeframe: Weeks 0-24
| Intervention | participants (Number) |
|---|---|
| Extended-Release Naltrexone | 204 |
| Buprenorphine-Naloxone | 270 |
A urine sample was obtained and tested for opioids at each in person visit; screening, prior to induction onto study medication, weekly through week 24 and at each of the follow up visits. (NCT02032433)
Timeframe: Weeks 0-24
| Intervention | Weeks (Median) |
|---|---|
| Extended-Release Naltrexone | 13 |
| Buprenorphine-Naloxone | 11 |
Self report of opioid use by participants using the TLFB. At each visit, the TLFB was completed for dates going back to the last participant encounter. (NCT02032433)
Timeframe: Weeks 0-24
| Intervention | days (Median) |
|---|---|
| Extended-Release Naltrexone | 123 |
| Buprenorphine-Naloxone | 87 |
Opioid craving over time via VAS at week 0 (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 68.7 |
| Buprenorphine-Naloxone | 68.8 |
Other drug use over time measuring cannabis at week 0 (NCT02032433)
Timeframe: week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 123 |
| Buprenorphine-Naloxone | 135 |
Other drug use over time measuring cannabis at week 24 (NCT02032433)
Timeframe: week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 20 |
| Buprenorphine-Naloxone | 20 |
Other drug use over time measuring cocaine at week 0 (NCT02032433)
Timeframe: week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 61 |
| Buprenorphine-Naloxone | 80 |
Other drug use over time measuring cocaine at week 0 (NCT02032433)
Timeframe: week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 5 |
| Buprenorphine-Naloxone | 2 |
Other drug use over time measuring stimulant (cocaine, crack and amphetamine) at week 0 (NCT02032433)
Timeframe: week 0
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 132 |
| Buprenorphine-Naloxone | 166 |
Other drug use over time measuring stimulant (cocaine, crack and amphetamine) at week 24 (NCT02032433)
Timeframe: week 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended-Release Naltrexone | 5 |
| Buprenorphine-Naloxone | 3 |
The Alcohol Subscale within ASI is one question that asks how bothered one has been by alcohol problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .1 |
The Alcohol Subscale within ASI is one question that asks how bothered one has been by alcohol problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | 0.0 |
The Sexual Behavior Subscale consists of 3 questions. Each question is scored from 0-5, for a total score range of 0-15. Higher scores indicate a greater degree of risk-taking behavior. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 3.6 |
| Buprenorphine-Naloxone | 4.3 |
The Sexual Behavior Subscale consists of 3 questions. Each question is scored from 0-5, for a total score range of 0-15. Higher scores indicate a greater degree of risk-taking behavior. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 4.8 |
| Buprenorphine-Naloxone | 4.3 |
The Drug Use Subscale within ASI is one question that asks how bothered one has been by drug use problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 0.3 |
| Buprenorphine-Naloxone | .3 |
The Drug Use Subscale within ASI is one question that asks how bothered one has been by drug use problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .1 |
The Family / Social Relationship Subscale within ASI contains 2 questions that ask how bothered one has been by family or social problems. The total range of the subscale is 0-8. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .1 |
The Legal Status Subscale within ASI is one question that asks how bothered one has been by legal problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .2 |
| Buprenorphine-Naloxone | .2 |
The Legal Status Subscale within ASI is one question that asks how bothered one has been by legal problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .1 |
The Medical Status Subscale within ASI is one question that asks how bothered one has been by medical problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .2 |
| Buprenorphine-Naloxone | .2 |
The Medical Status Subscale within ASI is one question that asks how bothered one has been by medical problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .1 |
| Buprenorphine-Naloxone | .2 |
The Psychiatric Status Subscale within ASI is one question that asks how bothered one has been by psychiatric or emotional problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .3 |
| Buprenorphine-Naloxone | .3 |
The Psychiatric Status Subscale within ASI is one question that asks how bothered one has been by psychiatric or emotional problems. The total range of the subscale is 0-4. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .2 |
| Buprenorphine-Naloxone | .2 |
The Sexual Behavior Subscale consists of 5 questions. Each question is scored from 0-5, for a total score range of 0-25. Higher scores indicate a greater degree of risk-taking behavior. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 5.5 |
| Buprenorphine-Naloxone | 5.9 |
The Sexual Behavior Subscale consists of 5 questions. Each question is scored from 0-5, for a total score range of 0-25. Higher scores indicate a greater degree of risk-taking behavior. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 7.3 |
| Buprenorphine-Naloxone | 6.0 |
The Social Relationship Subscale within ASI contains 2 questions that ask how bothered one has been by family or social problems. The total range of the subscale is 0-8. The higher the score, the bigger the problem. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | .3 |
| Buprenorphine-Naloxone | .3 |
The Subacute Withdrawal Symptoms Subscale consists of 6 symptoms. Classification of symptoms can be scored as: 0 - absent, 1 - doubtful or trivial, 2 - present. The total range of scores is 0 - 12, and the higher the total score the more severe the depression. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 8.6 |
| Buprenorphine-Naloxone | 9.3 |
The Subacute Withdrawal Symptoms Subscale consists of 6 symptoms. Classification of symptoms can be scored as: 0 - absent, 1 - doubtful or trivial, 2 - present. The total range of scores is 0 - 12, and the higher the total score the more severe the depression. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 5.2 |
| Buprenorphine-Naloxone | 4.8 |
"The color card contains 100 patches of between 3-5 different colors. The patient's task is to utter the names of the colored patches as rapidly as possible, scanning the rows from left to right. The score is the total time (in seconds) it takes to utter the 100 colors." (NCT02032433)
Timeframe: Week 0
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 69.3 |
| Buprenorphine-Naloxone | 70.5 |
"The color card contains 100 patches of between 3-5 different colors. The patient's task is to utter the names of the colored patches as rapidly as possible, scanning the rows from left to right. The score is the total time (in seconds) it takes to utter the 100 colors." (NCT02032433)
Timeframe: Week 24
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 75.3 |
| Buprenorphine-Naloxone | 76.1 |
"The color-word card contains the printed names of colors, but printed in an ink of a conflicting color (e.g. the word RED might be printed in green, yellow, or blue). The patient is required to name the colors of the inks while ignoring the conflicting printed color names. The basic score is the total time (in seconds) to utter the 100 colors." (NCT02032433)
Timeframe: Week 0
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 41.1 |
| Buprenorphine-Naloxone | 42.2 |
"The color-word card contains the printed names of colors, but printed in an ink of a conflicting color (e.g. the word RED might be printed in green, yellow, or blue). The patient is required to name the colors of the inks while ignoring the conflicting printed color names. The basic score is the total time (in seconds) to utter the 100 colors." (NCT02032433)
Timeframe: Week 24
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 47.6 |
| Buprenorphine-Naloxone | 48.8 |
Problems related to drug abuse is assessed through this questionnaire, which consists of 5 conditions. Each condition is scored from 0-2 for a total score range of 0-10. The higher the score, the more problems. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 6.8 |
| Buprenorphine-Naloxone | 6.8 |
Problems related to drug abuse is assessed through this questionnaire, which consists of 5 conditions. Each condition is scored from 0-2 for a total score range of 0-10. The higher the score, the more problems. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 5.8 |
| Buprenorphine-Naloxone | 6.1 |
OCS is a brief 3-item measure used to measure opioid craving. The scale consists of 3 items rated on a visual analogue scale (VAS) from 1-10. The total range of score is 0-30, and a higher score indicates a stronger craver / desire to use opiates. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 9.9 |
| Buprenorphine-Naloxone | 9.4 |
The SOWS is a self-administered scale for grading opioid withdrawal symptoms. It contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely). The total range of scores is 0-64; the higher the score, the more intense the withdrawal. (NCT02032433)
Timeframe: Week 0
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 15.6 |
| Buprenorphine-Naloxone | 15.6 |
The SOWS is a self-administered scale for grading opioid withdrawal symptoms. It contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely). The total range of scores is 0-64; the higher the score, the more intense the withdrawal. (NCT02032433)
Timeframe: Week 24
| Intervention | score on a scale (Mean) |
|---|---|
| Extended-Release Naltrexone | 4.5 |
| Buprenorphine-Naloxone | 5.3 |
Trail Making Test Part A consists of 25 circles distributed over a sheet of paper. The circles are number 1-25, and the patient is asked to draw lines to connect the numbers in ascending order. The patient is instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Higher scores reveal greater impairment. (NCT02032433)
Timeframe: Week 0
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 26.8 |
| Buprenorphine-Naloxone | 25.8 |
Trail Making Test Part A consists of 25 circles distributed over a sheet of paper. The circles are number 1-25, and the patient is asked to draw lines to connect the numbers in ascending order. The patient is instructed to connect the circles as quickly as possible, without lifting the pen or pencil from the paper. Higher scores reveal greater impairment. (NCT02032433)
Timeframe: Week 24
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 21.6 |
| Buprenorphine-Naloxone | 20.3 |
Part B consists of 25 circles distributed over a sheet of paper. In Part B, the circles include both numbers (1-13) and letters (A-L); the patient draws lines to connect the circles in an ascending pattern, by alternating between the numbers and letters. Results are reported as the number of seconds required to complete the task. (NCT02032433)
Timeframe: Week 0
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 79.1 |
| Buprenorphine-Naloxone | 78.3 |
Part B consists of 25 circles distributed over a sheet of paper. In Part B, the circles include both numbers (1-13) and letters (A-L); the patient draws lines to connect the circles in an ascending pattern, by alternating between the numbers and letters. Results are reported as the number of seconds required to complete the task. (NCT02032433)
Timeframe: Week 24
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 61.2 |
| Buprenorphine-Naloxone | 58.1 |
"The word card of the Stoop Test has the names of colors printed in black and white (100 items to be named). The patient's basic score is the total time he/she takes to utter the 100 words on the card." (NCT02032433)
Timeframe: Week 0
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 95.8 |
| Buprenorphine-Naloxone | 96.4 |
"The word card of the Stoop Test has the names of colors printed in black and white (100 items to be named). The patient's basic score is the total time he/she takes to utter the 100 words on the card." (NCT02032433)
Timeframe: Week 24
| Intervention | seconds (Mean) |
|---|---|
| Extended-Release Naltrexone | 103.2 |
| Buprenorphine-Naloxone | 102.9 |
Relapse occurs if the participant is using any non-protocol prescribed opioids regularly starting at day 21 post-randomization or thereafter. Operationally, relapse is defined as either: (a) four consecutive opioid use weeks, or (b) seven consecutive days of use by self-report. A use week is defined as any week during which a participant self-reports at least one day of use during that week, provides a urine sample positive for non-protocol opioids, or fails to provide a urine sample. Self-report of opioid (heroin or prescription opioids) and other substance use is ascertained at each weekly study visit using the Timeline Follow-Back for each day leading back to the previous visit. Urine is collected at each study visit and tested for opioids. A missed UDS counts as a use week. (NCT02032433)
Timeframe: Weeks 3-24
| Intervention | weeks (Median) |
|---|---|
| Extended-Release Naltrexone | 8.4 |
| Buprenorphine-Naloxone | 14.4 |
Relapse occurs if the participant is using any non-protocol prescribed opioids regularly starting at day 21 post-randomization or thereafter. Operationally, relapse is defined as either: (a) four consecutive opioid use weeks, or (b) seven consecutive days of use by self-report. A use week is defined as any week during which a participant self-reports at least one day of use during that week, provides a urine sample positive for non-protocol opioids, or fails to provide a urine sample. Self-report of opioid (heroin or prescription opioids) and other substance use is ascertained at each weekly study visit using the Timeline Follow-Back for each day leading back to the previous visit. Urine is collected at each study visit and tested for opioids. A missed UDS counts as a use week. (NCT02032433)
Timeframe: Weeks 3-24
| Intervention | weeks (Median) |
|---|---|
| Extended-Release Naltrexone | 20.4 |
| Buprenorphine-Naloxone | 15.2 |
Pain severity will be measured using the Visual Analogue Scale (VAS) which has a range of 0-100 with 0 being no pain and 100 being worse possible pain. (NCT01559454)
Timeframe: 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 36.3 |
| Buprenorphine/Naloxone | 71.8 |
Cravings will be assessed using the Visual Analogue Scale (VAS) with 0 being no cravings and 100 being worse possible cravings (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 11.7 |
| Buprenorphine/Naloxone | 27.2 |
"Depression will be assessed using the Beck Depression Inventory, a 63 point scale with 0 being none and 63 being severe." (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a BDI scale (Mean) |
|---|---|
| Methadone | 17.0 |
| Buprenorphine/Naloxone | 15.3 |
"Functioning will be assessed using the Visual Analogue Scale (VAS) with 0 being no limits and 100 being bedridden." (NCT01559454)
Timeframe: at 6 months
| Intervention | units on a VAS scale (Mean) |
|---|---|
| Methadone | 31.7 |
| Buprenorphine/Naloxone | 71.3 |
Illicit opioid use will be measured by self-report and confirmed with urine toxicology. (NCT01559454)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| illicit drug use at 6 months | no illicit drug use at 6 months | |
| Buprenorphine/Naloxone | 0 | 4 |
| Methadone | 0 | 6 |
Number of participants that completed the study protocol (NCT01559454)
Timeframe: 6 months
| Intervention | participants (Number) | |
|---|---|---|
| completed | did not complete | |
| Buprenorphine/Naloxone | 4 | 6 |
| Methadone | 6 | 3 |
The number of participants who completed 16-week assessments. (NCT03894501)
Timeframe: At 16-weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| 16-Weeks Completed | 29 |
The number of participants who complete 8-week assessments. (NCT03894501)
Timeframe: At 8-weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| 8-weeks Completed | 30 |
Anxiety was measured with the Beck Anxiety Inventory (BAI). The BAI is also a widely used, reliable, and valid scale that consists of 21 items with potential scores ranging from 0 to 63. A score of 16 or higher indicates clinically sig-nificant symptoms of anxiety. A higher score on the BAI indicates greater anxiety. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 41.05 |
| Methadone Program Behavioral Treatment as Usual | 50.83 |
The number of participants who complete baseline assessments. (NCT03894501)
Timeframe: At baseline,
| Intervention | Participants (Count of Participants) |
|---|---|
| Baselines Completed | 30 |
"Research staff asked participants if they used various drugs (i.e., heroin, cocaine, opioids, marijuana, amphetamines, inhalants, hallucinogens, benzodiazepines, zolpidem, methylphenidate, or other drugs) in the past 30 days and the number of days of use for each drug in the past 30 days. Days of illicit drug use was determined by counting the number of days each participant used drugs based on past-30 day self-reports at the16-week assessments." (NCT03894501)
Timeframe: 16-weeks
| Intervention | days (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 6.37 |
| Methadone Program Behavioral Treatment as Usual | 15.56 |
"Research staff asked participants if they used illicit opioids in the past 30 days and the number of days of use for each drug in the past 30 days. Days of illicit opioid use was determined by counting the number of days each participant used illicit opioids based on past-30 day self-reports at the 16-week assessment." (NCT03894501)
Timeframe: 16-weeks
| Intervention | days (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 2.47 |
| Methadone Program Behavioral Treatment as Usual | 5.49 |
Depression was measured with Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D scale is a widely used valid and reliable measure that consists of 20 items with potential scores ranging from 0 to 60. A score above 16 on the CES-D indicates clinically significant symptoms of depression. Higher scores on the CES-D indicates greater depression. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 34.11 |
| Methadone Program Behavioral Treatment as Usual | 42.93 |
The number of individuals consented. (NCT03894501)
Timeframe: Baseline (study enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Eligible Participants Consented | 31 |
The number of individuals screened and eligible/ineligible. (NCT03894501)
Timeframe: Baseline (study enrollment)
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Screened and Ineligible. | 0 |
The mean number of sessions completed by study participants in the MORE intervention. (NCT03894501)
Timeframe: At 8-weeks (post treatment period completion).
| Intervention | number of sessions (Mean) |
|---|---|
| The Mean Number of Sessions Completed by Study Participants in the MORE Intervention. | 6.4 |
Number of participants who drop out of the study. (NCT03894501)
Timeframe: At 16 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Number of Participants Who Dropped Out of the Study. | 0 |
Research staff assessed opioid craving with a version of the Penn Alcohol Craving Scale (PACS; Flannery et al., 1999) that was adapted to assess craving to opioids at 16-weeks. Scores range from 0 to 36. Higher scores indicate greater craving. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 15.52 |
| Methadone Program Behavioral Treatment as Usual | 21.35 |
Pain was assess with the pain subscale (i.e., bodily pain severity and interference) of the RAND 36-Item Short Form Health Survey. Scores range from 0 to 100, with higher scores indicating better functioning, health, and well-being and less pain, limitations, and symptom severity or interference as compared to lower scores. (NCT03894501)
Timeframe: 16-weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Mindfulness Oriented Recovery Enhancement | 50.76 |
| Methadone Program Behavioral Treatment as Usual | 26.65 |
Percentage of participants who completed 8-week assessments. (NCT03894501)
Timeframe: At 8-weeks.
| Intervention | percentage of 8-week assessments. (Number) |
|---|---|
| Percentage 8-weeks Completed | 100 |
Percentage of people who completed baseline assessments. (NCT03894501)
Timeframe: At baseline,
| Intervention | percentage of baseline assessments (Number) |
|---|---|
| Percentage Baselines Completed | 100 |
Percentage of participants who completed 16-week assessments. (NCT03894501)
Timeframe: At 16-weeks.
| Intervention | percentage of 16-week assessments. (Number) |
|---|---|
| Percentage of 16-weeks Completed | 96.7 |
The mean percentage of sessions completed by study participants randomized to MORE. (NCT03894501)
Timeframe: At 8-weeks (post treatment period completion).
| Intervention | percentage of sessions (Mean) |
|---|---|
| The Mean Percentage of Sessions Completed by Study Participants Randomized to MORE. | 76 |
Percentage of participants who drop out of the study. (NCT03894501)
Timeframe: At 16 weeks.
| Intervention | percentage of particpants (Number) |
|---|---|
| Percentage of Participants Who Dropped Out of the Study. | 0 |
The number of individuals who refuse participation after/during consent process. (NCT03894501)
Timeframe: Enrollment
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Who Refuse Participation After/During Consent Process. | 1 |
The number of individuals who express interest in the study. (NCT03894501)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants Who Expressed Interest in the Study | 32 |
The number of individuals who who refuse participation when offered. (NCT03894501)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| The Number of Individuals Who Who Refuse Study Participation When Offered. | 2 |
Our primary aim is to compare time-to-relapse among participants treated with XR-NTX vs. randomized ETAU following release from jail measured up to 24 weeks by Urine Toxicology results and self-report on the TLFB. (NCT01999946)
Timeframe: up to 24 weeks
| Intervention | Weeks (Mean) |
|---|---|
| Extended-Release Naltrexone (XR-NTX) | 8.6 |
| Enhanced Treatment As Usual (ETAU) | 5.9 |
(# opiate- and cocaine-negative urine samples/divided by possible #) x 100 (NCT02487745)
Timeframe: 1 year
| Intervention | percentage of urine samples (Mean) |
|---|---|
| IPS Only | 44.9 |
| IPS Plus Wage Supplement | 64.6 |
(# participants employed /divided by total # of participants) x 100 (NCT02487745)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| IPS Only | 27.7 |
| IPS Plus Wage Supplement | 59.1 |
Cost in US Dollars of substance abuse services on the modified Substance Abuse Services Cost Analysis Program (NCT02334215)
Timeframe: 12 months post-release from incarceration
| Intervention | US Dollars (Mean) |
|---|---|
| Methadone Plus Patient Navigation | 3052 |
| Methadone | 2377 |
| Enhanced Treatment as Usual | 1884 |
Mean number of days hospitalized during the 12 months post-release from incarceration (NCT02334215)
Timeframe: 12 months post-release from incarceration
| Intervention | Days (Mean) |
|---|---|
| Methadone Plus Patient Navigation | 2.0 |
| Methadone | 3.4 |
| Enhanced Treatment as Usual | 1.2 |
Official data on participant arrests subsequent to release from index incarceration. (NCT02334215)
Timeframe: one year post-release from incarceration
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone Plus Patient Navigation | 32 |
| Methadone | 39 |
| Enhanced Treatment as Usual | 36 |
Predicted probability derived from the general linear mixed model of self-reported entry into treatment for opioid use disorder following release from incarceration and being in treatment 30 days post-release (0= no entry in treatment; 1= entry in treatment). (NCT02334215)
Timeframe: 30 days post-release from incarceration
| Intervention | Probability (Least Squares Mean) |
|---|---|
| Methadone Plus Patient Navigation | 0.65 |
| Methadone | 0.62 |
| Enhanced Treatment as Usual | 0.225 |
Drug Risk Scale Score on the Risk Assessment Battery. The scale's range goes from 0 to 22. Higher score represents greater frequency of drug risk behaviors (NCT02334215)
Timeframe: Baseline and 6, and 12 months post-release from incarceration
| Intervention | score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | 6 month post-release from incarceration | 12 month post-release | |
| Enhanced Treatment as Usual | 3.11 | 2.16 | 1.03 |
| Methadone | 2.43 | 1.81 | 1.35 |
| Methadone Plus Patient Navigation | 2.30 | 1.52 | .50 |
Environmental domain score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. A higher score represents a better quality of life. (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 months post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 54.9 | 65.1 | 63.7 | 57.2 | 59.3 |
| Methadone | 54.6 | 63.6 | 55.1 | 60.6 | 59.4 |
| Methadone Plus Patient Navigation | 48.0 | 56.1 | 51.9 | 59.0 | 54.8 |
Mean number of days reported by participants of their criminal activity during the 30 days preceding the Addiction Severity Index interviews (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | Days (Least Squares Mean) | |||
|---|---|---|---|---|
| 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 8.22 | 10.59 | 11.49 | 10.18 |
| Methadone | 8.18 | 9.35 | 9.74 | 9.97 |
| Methadone Plus Patient Navigation | 5.22 | 9.79 | 9.24 | 6.88 |
Mean number of participant self-reported days of heroin use in the 30 days preceding the interview on the Addiction Severity Index (ASI) (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | Days (Least Squares Mean) | |||
|---|---|---|---|---|
| 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 14.88 | 16.18 | 15.42 | 15.35 |
| Methadone | 12.07 | 15.15 | 14.02 | 14.70 |
| Methadone Plus Patient Navigation | 8.66 | 13.46 | 13.56 | 12.35 |
Self report quality of life as reported by participants following release from their index incarceration on a scale from 1 to 5. A higher score is a better outcome. (NCT02334215)
Timeframe: 1, 3, 6, and 12 month post-release from incarceration
| Intervention | units on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 3.1 | 3.40 | 3.57 | 3.53 | 3.45 |
| Methadone | 2.8 | 3.56 | 3.46 | 3.58 | 3.43 |
| Methadone Plus Patient Navigation | 2.7 | 3.49 | 3.15 | 3.51 | 3.29 |
Participant self-reported mean number of days of cocaine use in the 30 days preceding the interview on the Addiction Severity Index (ASI) (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | Days (Least Squares Mean) | |||
|---|---|---|---|---|
| 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 11.01 | 11.94 | 11.94 | 12.63 |
| Methadone | 9.05 | 11.32 | 13.57 | 14.46 |
| Methadone Plus Patient Navigation | 5.95 | 8.83 | 10.74 | 9.60 |
The score on the Physical Domain Scale of the World Health Organization Quality of Life Scale-BREF (WHOQOL-BREF). The scales range is from 0 to 100. The higher score represents better quality of life. (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-incarceration
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 months post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 57.1 | 68.7 | 67.3 | 61.2 | 60.3 |
| Methadone | 58.3 | 62.2 | 60.1 | 66.3 | 63.8 |
| Methadone Plus Patient Navigation | 54.6 | 62.8 | 60.3 | 68.6 | 63.1 |
Predicted probability derived from the Generalized Linear Mixed Model of meeting the Data and Statistical Manual - 5 criteria for Opioid Use Disorder in response to modified CIDI interview (0= does not meet criteria; 1= meets criteria). (NCT02334215)
Timeframe: one month period prior to the 3, 6, and 12 month post-release from incarceration
| Intervention | Probability (Least Squares Mean) | ||
|---|---|---|---|
| 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 0.76 | 0.77 | 0.59 |
| Methadone | 0.70 | 0.59 | 0.77 |
| Methadone Plus Patient Navigation | 0.66 | 0.51 | 0.54 |
Predicted Probability derived from the Generalized Linear Mixed of self-reported enrolled in treatment for Opioid Use Disorder at the time of the follow-up interview (0=not enrolled; 1=enrolled). (NCT02334215)
Timeframe: 12 months post-release from incarceration
| Intervention | Probability (Least Squares Mean) | |||
|---|---|---|---|---|
| 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | .26 | .19 | .24 | .29 |
| Methadone | .56 | .47 | .52 | .27 |
| Methadone Plus Patient Navigation | .63 | .57 | .52 | .40 |
Predicted Probability Derived from the Generalized Linear Mixed Model meeting Data and Statistical Manual - 5 criteria for Cocaine Use Disorder on the modified Composite International Diagnostic Interview (CIDI) (0=Does not meet criteria; 1=meets criteria). (NCT02334215)
Timeframe: 3, 6, and 12 months post-release from incarceration
| Intervention | Probability (Least Squares Mean) | ||
|---|---|---|---|
| 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | .32 | .36 | .30 |
| Methadone | .32 | .35 | .40 |
| Methadone Plus Patient Navigation | .20 | .22 | .32 |
Predicted probability derived from the generalized linear mixed model opioid positive urine tests (0= negative; 1- positive) for heroin, oxycodone, methadone, or buprenorphine -- excluding the latter two positives when they results from prescribed medications to treat opioid use disorder) (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | Probability (Least Squares Mean) | |||
|---|---|---|---|---|
| 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 0.66 | 0.73 | 0.71 | 0.59 |
| Methadone | 0.72 | 0.72 | 0.63 | 0.71 |
| Methadone Plus Patient Navigation | 0.70 | 0.59 | 0.49 | 0.46 |
Scale score on the Psychological Domain on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. (NCT02334215)
Timeframe: 1, 3, 6, and 12 months post-release from incarceration
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 55.9 | 66.7 | 66.6 | 64.8 | 64.4 |
| Methadone | 56.9 | 64.0 | 61.2 | 63.9 | 61.8 |
| Methadone Plus Patient Navigation | 56.8 | 65.5 | 62.6 | 64.9 | 62.0 |
Sex Risk Score on the Risk Assessment Battery (RAB). Higher scores represents greater risk. The score ranges from 0 to 18. (NCT02334215)
Timeframe: Baseline and 6, and 12 months post-release from incarceration
| Intervention | score on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Baseline | 6 months post-release | 12 month post-release | |
| Enhanced Treatment as Usual | 4.68 | 4.27 | 4.17 |
| Methadone | 4.78 | 3.94 | 4.61 |
| Methadone Plus Patient Navigation | 4.52 | 3.93 | 3.78 |
Social domain scale score on the World Health Organization Quality of Life Scale (WHOQOL-BREF) goes from 1 to 100. The higher score represents a better quality of life. (NCT02334215)
Timeframe: 1, 3, 6, and 12 month post-release from incarceration
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month post-release from incarceration | 3 months post-release from incarceration | 6 months post-release from incarceration | 12 months post-release from incarceration | |
| Enhanced Treatment as Usual | 51.3 | 64.9 | 66.4 | 58.8 | 59.1 |
| Methadone | 57.7 | 57.5 | 62.4 | 63.3 | 55.4 |
| Methadone Plus Patient Navigation | 56.9 | 63.6 | 60.9 | 63.3 | 56.6 |
Treatment retention for full 12 weeks of study. (NCT00149630)
Timeframe: 12 weeks
| Intervention | % of subjects who complete 12 wks study (Number) |
|---|---|
| Disulfiram | 77 |
| Placebo | 87 |
(NCT00149630)
Timeframe: Thrice weekly, baseline through week 14.
| Intervention | % cocaine + urines over 2 week blocks (Mean) |
|---|---|
| Placebo CC | 84 |
| Placebo CT/TT | 68 |
| Disulfiram CC | 56 |
| Disulfiram CT/TT | 67 |
Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 5 |
| Methadone | 5 |
Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 17.9 |
| Methadone | 16.1 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 14.7 |
| Methadone | 12.8 |
clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 1 |
| Methadone | 0 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 11 |
| Methadone | 6 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 0 |
| Methadone | 3 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | morphine equivalents mg (Mean) |
|---|---|
| Morphine | 9.86 |
| Methadone | 33.0 |
Total number days of treatment (NCT01734551)
Timeframe: 120 days
| Intervention | days (Median) |
|---|---|
| Morphine | 39 |
| Clonidine | 27 |
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Bayley III motor | Cognitive | Language total | Language Receptive | Language Expressive | |
| Clonidine | 95.8 | 93.3 | 95.8 | 95.0 | 99.2 |
| Morphine | 97.6 | 92.9 | 98.0 | 101.1 | 100.0 |
Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Finnegan scores day 2 of treatment | Finnegan scores day 7 of treatment | Finnegan scores day 14 of treatment | |
| Clonidine | 8.5 | 5.7 | 6.7 |
| Morphine | 7.5 | 6.6 | 7.1 |
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts
| Intervention | scores on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attention | Handling | Quality of movement | Regulation | Non-optimal reflexes | Asymmetric reflexes | Stress/abstinence | Arousal | Hypertonicity | Hypotonicity | Excitability | Lethargy | |
| Clonidine | 4.51 | 0.42 | 4.92 | 5.26 | 4.13 | 0.00 | 0.08 | 3.95 | 0.25 | 0.19 | 2.38 | 5.13 |
| Morphine | 5.06 | 0.36 | 4.77 | 5.2 | 3.73 | 0.20 | 0.07 | 3.91 | 0.40 | 0.13 | 2.6 | 3.6 |
Up to 12 months (NCT01723722)
Timeframe: Up to 12 months
| Intervention | days (Mean) |
|---|---|
| Deodorized Tincture Opium After Phenobarbital for Withdrawal | 19.1 |
| Methadone After Phenobarbital for Withdrawal | 17.7 |
Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 47.8 |
| Neonatal Morphine Solution | 48.2 |
Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 82.1 |
| Neonatal Morphine Solution | 81.7 |
Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit
| Intervention | lbs (Mean) |
|---|---|
| Methadone | 19.1 |
| Neonatal Morphine Solution | 18.7 |
Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 21.8 |
| Neonatal Morphine Solution | 23.2 |
Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 18.9 |
| Neonatal Morphine Solution | 21.1 |
Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.
| Intervention | days (Mean) |
|---|---|
| Methadone | 14.7 |
| Neonatal Morphine Solution | 16.6 |
"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 22 |
| Neonatal Morphine Solution | 28 |
Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 10 |
| Neonatal Morphine Solution | 17 |
The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit
| Intervention | scores on a scale (Composite) (Mean) | ||
|---|---|---|---|
| Cognitive Composite | Language Composite | Motor Composite | |
| Methadone | 100.1 | 96.0 | 103.6 |
| Neonatal Morphine Solution | 98.1 | 94.2 | 99.1 |
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
The percentage of positive urine drug screens over the study duration will be examined. (NCT04308694)
Timeframe: Up to 3 months per participant
| Intervention | Percentage of positive tests (Number) |
|---|---|
| Pharmacy-based Methadone Treatment | 3.8 |
Percentage of participants with call backs with evidence of methadone tampering. (NCT04308694)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacy-based Methadone Treatment | 0 |
Adherence to pharmacy-based methadone treatment will be defined as the percentage of methadone take-home doses dispensed at the pharmacy out of the total number of take home doses prescribed. (NCT04308694)
Timeframe: Up to 3 months per participant
| Intervention | percentage of dose adherence (Number) |
|---|---|
| Pharmacy-based Methadone Treatment | 100 |
Treatment retention will be determined by the percentage of participants who remain in treatment at the pharmacy during the 3-month follow-up phase. (NCT04308694)
Timeframe: Up to 3 months per participant
| Intervention | percentage of participants retained (Number) |
|---|---|
| Pharmacy-based Methadone Treatment | 80 |
Participant satisfaction with treatment delivery will be measured on a monthly basis and a percentage of overall monthly ratings (combined) of satisfied or very satisfied will be calculated. (NCT04308694)
Timeframe: Over 3 months of treatment
| Intervention | percentage of satisfied ratings (Number) |
|---|---|
| Pharmacy-based Methadone Treatment | 87.5 |
We will measure the prevalence of any fatal or non-fatal substance-related overdose and any substance-related emergency department visit or hospitalization. (NCT04308694)
Timeframe: Up to 3 months per participant
| Intervention | percentage (Number) | |
|---|---|---|
| % of fatal and non-fatal overdoses | % of substance-related emergency department visits or hospitalizations | |
| Pharmacy-based Methadone Treatment | 0 | 0 |
The recruitment rate will be assessed on a monthly basis (e.g, Month 1, 2 and 3) until the enrollment target is reached. The recruitment rate is operationalized as the total number of participants consented in one month. (NCT04308694)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Month 1 | Month 2 | Month 3 | |
| Pharmacy-based Methadone Treatment | 3 | 12 | 5 |
Days of criminal behavior (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | Number of Days in the Past 30 days (Mean) |
|---|---|
| Patient-Centered Methadone Treatment | 2.99 |
| Methadone Treatment as Usual | 3.72 |
HIV Drug Use Risk Assessment Battery Score ranges from 0 to 22. A higher score is considered to be associated with higher risk. (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Patient-Centered Methadone Treatment | 0.72 |
| Methadone Treatment as Usual | 1.36 |
Scale from 1 through 5. A higher score reflects a better quality of life. (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Patient-Centered Methadone Treatment | 3.70 |
| Methadone Treatment as Usual | 3.47 |
Number of participants meeting DSM-IV cocaine dependence criteria (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient-Centered Methadone Treatment | 41 |
| Methadone Treatment as Usual | 52 |
Diagnostic and Statistical Manual (DSM)-IV criteria for opiate dependence (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient-Centered Methadone Treatment | 88 |
| Methadone Treatment as Usual | 103 |
Cocaine positive urine drug test (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient-Centered Methadone Treatment | 67 |
| Methadone Treatment as Usual | 85 |
Number of participants with opiate positive urine tests (NCT01442493)
Timeframe: 12-months post-baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Patient-Centered Methadone Treatment | 89 |
| Methadone Treatment as Usual | 90 |
The AUC0-24 of the R- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by liquid chromatographic-tandem mass spectrometric (LC-MS/MS) detection. The lower limit of quantification (LLoQ) was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng*hr/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 55.8 |
| Maintenance Methadone + Doravirine | 53.2 |
The AUC0-24 of the S- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng*hr/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 52.0 |
| Maintenance Methadone + Doravirine | 50.8 |
The AUC0-24 of total methadone was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng*hr/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 109 |
| Maintenance Methadone + Doravirine | 105 |
The C24 of the S- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 1.51 |
| Maintenance Methadone + Doravirine | 1.47 |
The C24 of total methadone was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 3.48 |
| Maintenance Methadone + Doravirine | 3.34 |
The Cmax of the S- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 3.77 |
| Maintenance Methadone + Doravirine | 3.67 |
The Cmax of total methadone was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 7.19 |
| Maintenance Methadone + Doravirine | 7.01 |
The Cmax of the R- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 3.41 |
| Maintenance Methadone + Doravirine | 3.33 |
The C24 of the R- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: 24 hours postdose on Day 1 and Day 6
| Intervention | ng/mL/mg (Geometric Mean) |
|---|---|
| Maintenance Methadone | 1.91 |
| Maintenance Methadone + Doravirine | 1.82 |
The Tmax of the R- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | Hours (Median) |
|---|---|
| Maintenance Methadone | 2.00 |
| Maintenance Methadone + Doravirine | 2.01 |
The Tmax of the S- methadone enantiomer was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | Hours (Median) |
|---|---|
| Maintenance Methadone | 1.99 |
| Maintenance Methadone + Doravirine | 2.00 |
The Tmax of total methadone was determined on Day 1 (methadone alone) and on Day 6 (methadone + doravirine). Plasma samples collected for methadone assay were analyzed for R- and S-methadone concentrations by Pharma Medica Research Inc. (Ontario, Canada). The analytical method used liquid-liquid extraction for analyte isolation followed by LC-MS/MS detection. The LLoQ was 0.0250 ng/mL for each enantiomer. The analytical range was 0.0250 - 15.0 ng/mL. (NCT02715700)
Timeframe: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 12, 16, and 24 hours postdose on Day 1 and Day 6
| Intervention | Hours (Median) |
|---|---|
| Maintenance Methadone | 2.00 |
| Maintenance Methadone + Doravirine | 2.01 |
(NCT00271219)
Timeframe: birth
| Intervention | cm (Mean) |
|---|---|
| A Methadone | 33.0 |
| B Buprenorphine | 33.8 |
(NCT00271219)
Timeframe: delivery until hospital discharge (min=2 days, max=79 days)
| Intervention | days (Mean) |
|---|---|
| A Methadone | 17.5 |
| B Buprenorphine | 10.0 |
NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal. (NCT00271219)
Timeframe: minimum twice daily from birth until NAS no longer measured (min=10 days)
| Intervention | Score on the scale (Mean) |
|---|---|
| A Methadone | 12.8 |
| B Buprenorphine | 11.0 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of HIV risk behaviors (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study. (NCT00271219)
Timeframe: from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | dose increase per trimester (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study. (NCT00271219)
Timeframe: at delivery
| Intervention | Score on the scale (Mean) |
|---|---|
| Methadone | .014 |
| Buprenorphine | .088 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of drug use (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death. (NCT00271219)
Timeframe: From birth until hospital discharge (min=4 days, max=10, depending on site)
| Intervention | participants (Number) |
|---|---|
| A Methadone | 41 |
| B Buprenorphine | 27 |
Total amount in mg (NCT00271219)
Timeframe: Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)
| Intervention | mg (Mean) |
|---|---|
| A Methadone | 10.4 |
| B Buprenorphine | 1.1 |
Was each participant's urine sample negative for cocaine at each of the Monday, Wednesday, Friday urine samples scheduled throughout the intervention evaluation period? (NCT01416584)
Timeframe: 6 months
| Intervention | percentage of urine samples (Mean) |
|---|---|
| Usual Care Control | 25 |
| Methadone Contingency Group | 44 |
| Methadone & Abstinence Contingency | 48 |
Was each participant's urine sample negative for opiates at each of the Monday, Wednesday, Friday urine samples scheduled throughout the intervention evaluation period? (NCT01416584)
Timeframe: 6 months
| Intervention | percentage of M,W,F urine samples (Mean) |
|---|---|
| Usual Care Control | 43 |
| Methadone Contingency Group | 50 |
| Methadone & Abstinence Contingency | 65 |
Percentage of urine sample negative for opiates at each of the six 30-day assessments scheduled throughout the intervention evaluation (NCT01416584)
Timeframe: 6 months
| Intervention | percentage of opiate negative (Mean) |
|---|---|
| Usual Care Control | 54 |
| Methadone Contingency Group | 61 |
| Methadone & Abstinence Contingency | 75 |
Was the participant's urine sample negative for cocaine at each of the six 30-day assessments scheduled throughout the intervention evaluation period? (NCT01416584)
Timeframe: 6 months
| Intervention | percentage of cocaine negative (Mean) |
|---|---|
| Usual Care Control | 32 |
| Methadone Contingency Group | 55 |
| Methadone & Abstinence Contingency | 57 |
The percentage of months in which participants were enrolled in methadone treatment during the 6-month intervention evaluation period? (NCT01416584)
Timeframe: 6 months
| Intervention | percent of months in methadone treatment (Mean) |
|---|---|
| Usual Care Control | 81 |
| Methadone Contingency Group | 82 |
| Methadone & Abstinence Contingency | 88 |
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m., missing = smoking (NCT01378858)
Timeframe: Week 12 of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline Treatment as Usual (TAU) | 9 |
| Varenicline Directly Observed Therapy | 5 |
Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) < 8 p.p.m. (NCT01378858)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Varenicline Treatment as Usual (TAU) | 6 |
| Varenicline Directly Observed Therapy | 2 |
Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure (NCT01378858)
Timeframe: Weeks 0-1, 1-2, 2-3, 4-6, 7-9, 10-12
| Intervention | percentage pills taken/pills dispensed (Mean) |
|---|---|
| Varenicline Treatment as Usual (TAU) | 61.8 |
| Varenicline Directly Observed Therapy | 78.5 |
The percentage of participants with sustained virologic response (plasma hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantification [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01911845)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 97.4 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment) or fail to suppress (HCV RNA ≥ LLOQ) persistently during treatment with at least 6 weeks [≥ 36 days] of treatment. (NCT01911845)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, and 12
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. Completion of treatment was defined as a study drug duration ≥ 77 days. (NCT01911845)
Timeframe: From the end of treatment through 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV | 0 |
Blood samples were collected pre-dose (time 0) and at 2, 4, 6, and 24 hours post-dose at one visit between treatment week 2 and treatment week 12, and were analyzed using validated analytical methods. A total of 22/38 participants consented for intensive pharmacokinetic blood sampling. Area under the plasma concentration-time curve from time 0 to 24 hours (AUC24 in ng*hr/mL)] was estimated using noncompartmental analyses. For ABT-450, ritonavir, and ABT-267, the AUC from time 0 to the last measureable concentration (AUCt in ng*hr/mL) was calculated instead of AUC24 due to time deviations at 24 hours. The AUCt values are approximately equivalent to AUC24. For ABT-333, ABT-333 M1, and RBV, the AUC from time 0 to 12 hours (AUC12 in ng*hr/mL) after the morning dose was calculated using the 24-hour concentration as the 12-hour concentration as dosing was twice a day and a 12-hour sample was not collected in this study. (NCT01911845)
Timeframe: Pre-dose (time 0) and 2, 4, 6, and 24 hours post-dose
| Intervention | ng*hr/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| ABT-450 | Ritonavir | ABT-267 | ABT-333 | ABT-333 M1 metabolite | Ribavirin | |
| Buprenorphine ± Naloxone | 27438.94 | 14303.27 | 1523.48 | 5666.15 | 3086.73 | 33362.24 |
| Methadone | 37174.89 | 11375.38 | 1486.72 | 5021.41 | 2950.36 | 33499.39 |
Blood samples were collected pre-dose (time 0) and at 2, 4, 6, and 24 hours post-dose at one visit between treatment week 2 and treatment week 12, and were analyzed using validated analytical methods. A total of 22/38 participants consented for intensive pharmacokinetic blood sampling. Maximum plasma concentration (Cmax; measured in ng/mL) was directly determined from the concentration-time data. (NCT01911845)
Timeframe: Pre-dose (time 0) and 2, 4, 6, and 24 hours post-dose
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| ABT-450 | Ritonavir | ABT-267 | ABT-333 | ABT-333 M1 metabolite | Ribavirin | |
| Buprenorphine ± Naloxone | 3269.50 | 1261.92 | 102.00 | 805.08 | 469.92 | 3389.17 |
| Methadone | 2973.30 | 888.70 | 95.98 | 671.90 | 439.64 | 3232.00 |
Blood samples were collected pre-dose (time 0) and at 2, 4, 6, and 24 hours post-dose at one visit between treatment week 2 and treatment week 12, and analyzed using validated analytical methods. A total of 22/38 participants consented for intensive pharmacokinetic blood sampling. Minimum plasma concentration (C trough; measured in ng/mL) was directly determined from the concentration-time data. (NCT01911845)
Timeframe: Pre-dose (time 0) and 2, 4, 6, and 24 hours post-dose
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| ABT-450 | Ritonavir | ABT-267 | ABT-333 | ABT-333 M1 metabolite | Ribavirin | |
| Buprenorphine ± Naloxone | 170.01 | 167.35 | 33.75 | 223.76 | 86.98 | 2555.83 |
| Methadone | 458.53 | 136.87 | 32.78 | 147.95 | 71.10 | 2632.00 |
Blood samples were collected pre-dose (time 0) and at 2, 4, 6, and 24 hours post-dose at one visit between treatment week 2 and treatment week 12, and analyzed using validated analytical methods. A total of 22/38 participants consented for intensive pharmacokinetic blood sampling. The time to maximum plasma concentration (Tmax; measured in hours) was directly determined from the concentration-time data. (NCT01911845)
Timeframe: Pre-dose (time 0) and 2, 4, 6, and 24 hours post-dose
| Intervention | hours (Mean) | |||||
|---|---|---|---|---|---|---|
| ABT-450 | Ritonavir | ABT-267 | ABT-333 | ABT-333 M1 metabolite | Ribavirin | |
| Buprenorphine ± Naloxone | 4.38 | 4.18 | 4.69 | 4.25 | 4.40 | 3.72 |
| Methadone | 6.81 | 7.01 | 5.26 | 4.05 | 4.65 | 5.83 |
Change in maximum number of digits correctly recalled in Digit Span Backwards task, from baseline to 7 weeks (NCT01271413)
Timeframe: baseline, 7 weeks
| Intervention | digits recalled (Mean) |
|---|---|
| Adaptive Cognitively Stimulating Activities | 0.86 |
| Non-adaptive Cognitively Stimulating Activities | 0.04 |
Total costs in dollars of all VA and non-VA inpatient, outpatient and pharmacy costs. (NCT01707030)
Timeframe: Baseline and 12 months
| Intervention | US Dollars (Mean) |
|---|---|
| Web-Based BAI Arm | 42412 |
| Usual Care Arm | 51667 |
The number of days on which alcohol was consumed beyond recommended levels in the last 30 days. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | Unhealthy drinking days in last 30 (Mean) | ||
|---|---|---|---|
| Baseline Days of Unhealthy Alcohol Consumption | 3-mo Days of Unhealthy Alcohol Consumption | 6-mo Days of Unhealthy Alcohol Consumption | |
| BAI Arm | 5.46 | 2.72 | 2.29 |
| Usual Care | 7.16 | 5.56 | 4.78 |
The number of days on which alcohol was consumed at any level in the last 30 days. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | Number of drinking days in last 30 (Mean) | ||
|---|---|---|---|
| Baseline drinking days | 3-mo drinking days | 6-mo drinking days | |
| Control: Usual Care | 12.41 | 7.77 | 8.26 |
| Intervention: Web Based BAI | 9.39 | 5.20 | 4.61 |
The number of standard drinks (0.5 ounce ethanol equivalent) consumed on those days that an individual drank in the last 30 days. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | Drinks per Drinking Day (Mean) | ||
|---|---|---|---|
| Baseline Drinks per Drinking Day | 3-mo Drinks per Drinking Day | 6-mo Drinks per Drinking Day | |
| Control: Usual Care | 3.72 | 2.17 | 1.87 |
| Intervention: Web Based BAI | 3.57 | 2.29 | 1.98 |
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population. The SF-12 has demonstrated good internal consistency reliability and construct validity. This reflects the mental health component of the SF-12. Scores range from 0-100 and higher scores are better. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline SF-12 Mental Health | 3mo SF-12 Mental Health | 6 mo SF-12 Mental Health | |
| Control: Usual Care | 48.91 | 49.25 | 48.51 |
| Intervention: Web Based BAI | 49.10 | 50.83 | 50.63 |
The Short Form-12 (SF-12) is a 12-item health survey based on the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) designed to assess two component health status summary scales (physical and mental component summaries) in the general U.S. population . The SF-12 has demonstrated good internal consistency reliability and construct validity. This reflects the physical health component of the SF-12. Scores range from 0-100 and higher scores are better. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline SF-12 Health | 3mo SF-12 Health | 6mo SF-12 Health | |
| Control: Usual Care | 40.49 | 41.59 | 40.75 |
| Intervention: Web Based BAI | 40.43 | 39.92 | 42.21 |
Symptoms of psychological distress will be measured using the Patient Health Questionnaire (PHQ-9). The PHQ-9 provides an assessment of depression severity. The minimum value is 0 and the maximum value is 27. Lower scores are better. The reliability, validity, and clinical utility of the PHQ-9 instrument are well-established. (NCT01707030)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| Baseline PHQ-9 | 3-mo PHQ-9 | 6-mo PHQ-9 | |
| Control: Usual Care | 6.68 | 6.91 | 7.44 |
| Intervention: Web Based BAI | 6.00 | 6.03 | 5.57 |
Acceptability, defined as satisfaction with or tolerability of the proposed approach, was measured quantitatively by session attendance. Specifically, we measured the % of patients who attended ≥75% of core intervention sessions. (NCT04248933)
Timeframe: Assessed between the baseline assessment and the acute outcome (approximately 12-weeks post-baseline assessment/ post-treatment assessment)
| Intervention | Participants (Count of Participants) |
|---|---|
| "Peer-Delivered Behavioral Activation (Peer Activate)" | 26 |
Feasibility, defined as the suitability and practicability of the approach, was measured quantitatively as the % of patients who agreed to participate in the intervention. (NCT04248933)
Timeframe: Assessed between the baseline assessment and the acute outcome (approximately 12-weeks post-baseline assessment/ post-treatment assessment)
| Intervention | Participants (Count of Participants) |
|---|---|
| "Peer-Delivered Behavioral Activation (Peer Activate)" | 32 |
Fidelity, defined as the delivery of the intervention as intended, was measured based on PRS adherence to the intervention delivery. A random selection of 20% of sessions was rated for fidelity, and we assessed the % of intervention components delivered as intended. (NCT04248933)
Timeframe: Assessed between the baseline assessment and the acute outcome (approximately 12-weeks post-baseline assessment/ post-treatment assessment)
| Intervention | Percentage fidelity to treatment (Mean) |
|---|---|
| "Peer-Delivered Behavioral Activation (Peer Activate)" | 87.9 |
Percent of patients retained in MOUD treatment at three months (i.e. still engaged in care) after intervention enrollment. (NCT04248933)
Timeframe: Measured daily from intake to post-treatment (approximately 12-weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| "Peer-Delivered Behavioral Activation (Peer Activate)" | 31 |
Blood was drawn from each participant to assess Hepatitis C Virus ribonucleic acid (HCV RNA) plasma levels using the Roche COBAS® AmpliPrep/COBAS® Taqman HCV Test, v2.0, which had a lower limit of quantification of 15 IU/mL. SVR12 was defined as HCV RNA below the lower limit of detection (
Timeframe: 12 weeks after end of all therapy (Study Week 24 for Immediate Treatment Arm and Study Week 40 for Deferred Treatment Arm)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment Arm: Grazoprevir/Elbasvir | 95.5 |
| Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir | 96.6 |
Blood was drawn from each participant to assess HCV RNA plasma levels using the Roche COBAS® AmpliPrep/COBAS® Taqman HCV Test, v2.0, which has an LLOQ of 15 IU/mL. SVR24 was defined as HCV RNA
Timeframe: 24 weeks after end of all therapy (Study Week 36 for Immediate Treatment Arm and Study Week 52 for Deferred Treatment Arm)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment Arm: Grazoprevir/Elbasvir | 94.1 |
| Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir | 96.5 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product, was also an AE. For this outcome measure, the primary safety analysis compared the percentage of participants discontinuing study therapy due to an AE in the Immediate Treatment Arm during the double-blinded active treatment period to that of the Deferred Treatment Arm during the double-blinded placebo treatment period. (NCT02105688)
Timeframe: DB Treatment period (up to Study Week 12)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment Arm: Grazoprevir/Elbasvir | 0.5 |
| Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir | 1.0 |
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product, was also an AE. For this outcome measure, the primary safety analysis compared the percentage of participants experiencing an AE in the Immediate Treatment Arm during the double-blinded active treatment period to that of the Deferred Treatment Arm during the double-blinded placebo treatment period. (NCT02105688)
Timeframe: DB Treatment period plus first 14 follow-up days (up to Study Week 14)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Immediate Treatment Arm: Grazoprevir/Elbasvir | 83.1 |
| Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir | 83.0 |
"Reduced illicit opioid use is defined as the number of documented opioid negative urine tests in each of the time periods.This measures the reduction in illicit opioid use - more opioid-negative tests means greater reductions in illicit opioid use. The highest possible score is 4- which would indicate 4 negative urine tests during the assessment period. Originally titled Reduced illicit opioid use and the timeframe was listed as 16 weeks." (NCT00634803)
Timeframe: 3 Months
| Intervention | opioid negative urine tests (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 0.67 | 2.67 | 2.96 | 2.80 |
| Educational Counseling for POD | 0.67 | 2.80 | 3.30 | 3.25 |
| Physician Management | 0.55 | 2.48 | 2.56 | 2.04 |
Pain intensity comprises the average of 4 items related to current pain and past-week average pain, pain at its worst, and pain at its least. Pain intensity is scored on 0-10 scale (average score ranges from 0-10), where higher scores indicate higher pain intensity.Originally labeled as Pain Reduction at 16 weeks- 3 months was the correct timeframe. (NCT00634803)
Timeframe: 3 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 5.43 | 4.75 | 4.79 | 4.41 |
| Educational Counseling for POD | 5.92 | 5.02 | 4.98 | 4.62 |
| Physician Management | 5.28 | 4.53 | 4.72 | 4.84 |
Pain interference comprises the average of 7 items related to past-week pain-related interference in general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. Each item is scored on a 0-10 scale (averaged 0-10), where higher scores indicate higher pain interference. (NCT00634803)
Timeframe: 3 Months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Intake/Induction | Month 1 | Month 2 | Month 3 | |
| CBT for POD | 5.75 | 4.15 | 4.08 | 3.22 |
| Educational Counseling for POD | 5.48 | 3.74 | 3.61 | 3.23 |
| Physician Management | 5.01 | 3.32 | 3.45 | 3.87 |
Peak antibody levels after five vaccinations with TA-CD, which occurred at week 16. (NCT00969878)
Timeframe: During the 18 weeks study period.
| Intervention | micrograms/ml (Mean) |
|---|---|
| Placebo Injection | 0 |
| TA-CD Vaccination | 59 |
Number of patients having at least 2 weeks of cocaine-free urines between weeks 9-16 after vaccination with five doses of TA-CD 400 µg compared to placebo (NCT00969878)
Timeframe: Over 8 weeks ( Study Weeks 9 to 16 inclusive)
| Intervention | participants (Number) |
|---|---|
| Placebo Injection | 21 |
| TA-CD Vaccination | 30 |
Number of minutes spent sleeping during sleep period, as measured by daily sleep diary. (NCT00253890)
Timeframe: Baseline to 1-month
| Intervention | minutes (Mean) |
|---|---|
| Trazodone | 339 |
| Placebo | 329 |
Knowledge score calculated by adding the number of correct multiple-choice answers to 10 scenarios. Minimum score was 0 and maximum was 10. Higher scores reflect greater knowledge. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | 1.692307692 |
| CRAFT-C | 1.454545455 |
| PEER | 0.4 |
Total mood disturbance (TMD) score calculated by adding scores (1-5) from the tension (6 items), depression (8 items), anger (7 items), fatigue (5 items), and confusion (5 items) subscales, then subtracting the score form the vigor (6 items) subscale. Minimum TMD possible score was 1 and maximum was 149. Higher scores reflect greater mood disturbance. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | -43.1 |
| CRAFT-C | -28.8 |
| PEER | -3.916666667 |
Social Adjustment Scale, Self-Report. Standardized scale to assess individual's level of satisfaction in their role performance over the past two weeks key life areas. We used subscales representing the work, housework, and school areas of functioning. Each subscale consisted of 6 items scored on a 1-5 scale. A subscale adjustment score was obtained by summing the scores of all the items and dividing by the number of items actually answered. Thus, each subscale summary score had a minimum score of 1 and a maximum score of 5. Lower scores indicate higher satisfaction in their role performance. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | 0.5714285714 |
| CRAFT-C | -0.875 |
| PEER | 0.2222222222 |
The 5-item scale was transformed so that is had a mean of 50 and a s.d. of 10 in the general US population. Scores above and below 50 are above and below the average with each point representing a difference of 1/10th of a standard deviation. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | 0.23875 |
| CRAFT-C | 0.782613 |
| PEER | -1.238238333 |
The 7-item scale was transformed so that is had a mean of 50 and a s.d. of 10 in the general US population. Scores above and below 50 are above and below the average with each point representing a difference of 1/10th of a standard deviation. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | 5.309448182 |
| CRAFT-C | 0.192893 |
| PEER | -3.127840833 |
Participants reported whether their loved one had attended any treatment for their opioid problem since the last assessment by answering 8 questions regarding participation in treatment. Reports of new MAT and MAT at the follow-up assessment which was not reported at baseline were categorized as new MAT. In addition, reports of MAT entry to WTV staff were included. Outcome was the proportion of participants reporting that their loved one entered MAT. This differs from Outcome Measure 1 in that Outcome Measure 1 included drug-free and medication-assisted treatments of any type, while this measure included only MAT. (NCT04250077)
Timeframe: 3-month post study
| Intervention | Participants (Count of Participants) |
|---|---|
| CRAFT-A | 5 |
| CRAFT-C | 3 |
| PEER | 4 |
Global score from the 10-item scale was calculated by adding scores (1-10) from 10 items. Minimum possible score was 10 and maximum was 100. Higher scores reflect greater Relationship Happiness. (NCT04250077)
Timeframe: 3-month post study
| Intervention | units on a scale (Mean) |
|---|---|
| CRAFT-A | 21.54545455 |
| CRAFT-C | 23.3 |
| PEER | 1.5 |
Participants reported whether their loved one had attended any treatment for their opioid problem since the last assessment by answering 8 questions regarding participation in treatment (e.g., detox, any treatment, new treatment, MAT, new MAT, counseling, support group, and other group). Reports of new treatment, new MAT, and treatment at the follow-up assessment which were not reported at baseline were categorized as treatment entry. In addition, entry into WTV recovery coaching, WTV family coaching, or reports of treatment entry to WTV staff were categorized as treatment entry. Outcome was the proportion of participants reporting that their loved one entered new treatment. (NCT04250077)
Timeframe: 3-month post study
| Intervention | count of participants (Number) |
|---|---|
| CRAFT-A | 10 |
| CRAFT-C | 8 |
| PEER | 6 |
Percentage of doses taken of those prescribed from electronic monitoring. Here we present all data collected at all time points used in analysis. Evaluation of intervention efficacy was performed with repeated measures regression using continuous adherence measurements at all 6 months post-intervention (7th through 12th month post-baseline) and was restricted to those with adherence data at baseline. (NCT03331978)
Timeframe: baseline (pre-treatment) and post-treatment observations at 7, 8, 9, 10, 11, and 12 months post-baseline
| Intervention | percentage of doses taken (Mean) | |||||
|---|---|---|---|---|---|---|
| 7 months post-baseline | 8 months post-baseline | 9 months post-baseline | 10 months post-baseline | 11 months post-baseline | 12 months post-baseline | |
| Control - No Treatment Education | 70.95 | 70.02 | 64.62 | 71.08 | 63.76 | 70.46 |
| Rise - Treatment Education | 68.80 | 72.76 | 72.09 | 71.27 | 69.87 | 70.32 |
Number of Participants who Reported Taking Greater Than or Equal to 75% of Prescribed Dosage, based on electronic monitoring. Here we present all data collected at all time points used in analysis. Evaluation of intervention efficacy was performed with repeated measures regression using adherence measurements at all 6 months post-intervention (7th through 12th month post-baseline) and was restricted to those with adherence data at baseline. (NCT03331978)
Timeframe: baseline (pre-treatment) and post-treatment observations at 7, 8, 9, 10, 11, and 12 months post-baseline
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 7 months post-baseline | 8 months post-baseline | 9 months post-baseline | 10 months post-baseline | 11 months post-baseline | 12 months post-baseline | |
| Control - No Treatment Education | 43 | 40 | 38 | 32 | 29 | 28 |
| Rise - Treatment Education | 45 | 44 | 43 | 42 | 40 | 37 |
"Measure is count of participants who slightly agree or strongly agree with either Most people with AIDS are responsible for having their illness or A person with AIDS must have done something wrong and deserves to be punished." (NCT03331978)
Timeframe: baseline (pre-treatment) and post-treatment observations at 7 and 12 months post-baseline
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 7 months post-baseline | 12 months post-baseline | |
| Control - No Treatment Education | 29 | 26 |
| Rise - Treatment Education | 25 | 15 |
Outcome is mean agreement with 9 HIV-related conspiracy beliefs, each measured on a 5-point scale from 1=Strongly Disagree to 5=Strongly Agree. (NCT03331978)
Timeframe: baseline (pre-treatment) and post-treatment observations at 7 and 12 months post-baseline
| Intervention | score on a scale (Mean) | |
|---|---|---|
| 7 months post-baseline | 12 months post-baseline | |
| Control - No Treatment Education | 2.65 | 2.56 |
| Rise - Treatment Education | 2.62 | 2.41 |
Viral load undetectable per venipuncture or medical records (NCT03331978)
Timeframe: baseline (pre-treatment) and post-treatment observations at 7 and 12 months post-baseline. For 7M, medical records were used if within 90 days of survey completion; for 13 months, medical records were used if within 90 days before or 180 days after survey
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 7 month post-baseline | 12 month post-baseline | |
| Control - No Treatment Education | 60 | 56 |
| Rise - Treatment Education | 45 | 50 |
A comparison of group means between the control group and study group with regards to 48 hour opioid use. (NCT02682498)
Timeframe: 48 hours
| Intervention | morphine equivalents (Mean) |
|---|---|
| EXPAREL® Bupivacaine Liposome Suspension | 5.32 |
| Standard Periarticular Joint Injection | 5.07 |
Opioid use will be monitored daily from the time of admission in comparison of standard knee injection post-operatively. (NCT02682498)
Timeframe: Up to 48 hours
| Intervention | Total Morphine Equivalents (Mean) |
|---|---|
| EXPAREL® Bupivacaine Liposome Suspension | 100 |
| Standard Periarticular Joint Injection | 103 |
Examining the average daily patient pain score in comparison of standard knee injection post-operatively. The measure is the Visual-Analog-Scale (VAS) for subjective pain reporting. The minimum 0 (no pain) and the maximum is 10 (worst pain imagineable). There is only one measure in the scale (i.e. there are no subscales). Lower scores on the VAS scale equate to less pain and are therefore desirable. (NCT02682498)
Timeframe: Up to 48 hours
| Intervention | Visual Analog Scale Rating (Mean) |
|---|---|
| EXPAREL® Bupivacaine Liposome Suspension | 4.75 |
| Standard Periarticular Joint Injection | 5.75 |
Examining the post-operative complication in comparison of standard knee injection post-operatively. (NCT02682498)
Timeframe: Up to 1 month
| Intervention | complications (Number) |
|---|---|
| EXPAREL® Bupivacaine Liposome Suspension | 0 |
| Standard Periarticular Joint Injection | 0 |
Post anesthesia care unit (recovery room) opioid use in total mg morphine IV equivalent in comparison of standard knee injection post-operatively. (NCT02682498)
Timeframe: Up to 48 hours
| Intervention | Total morphine equivalents (Median) |
|---|---|
| EXPAREL® Bupivacaine Liposome Suspension | 5 |
| Standard Periarticular Joint Injection | 5 |
Fetal heart rate in beats per minute (NCT00522626)
Timeframe: 60 minutes
| Intervention | beats per minute (Mean) |
|---|---|
| Trough Fetal Heart Rate | 142.34 |
Addiction Severity Index (ASI) drug composite scores measure past 30 days substance use (McLellan et al., 1992). The ASI assesses lifetime and current use of all major classes of drugs of abuse, history of substance-related problems, and history of SUD treatment. Scored as values between 0 and 1 with higher values indicating more severe substance use (i.e. lower values indicate a better outcome). (NCT00265564)
Timeframe: 1 year
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Seeking Safety | .089 | .057 | .051 | .046 |
| Usual Care | .106 | .095 | .088 | .066 |
"Composite measures of PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). Total score ranging from 0 (not at all) to 88 (extremely)" (NCT00265564)
Timeframe: Administered at 3 months, 6 months and 12 months post enrollment
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Seeking Safety | 46.76 | 40.80 | 38.90 | 35.26 |
| Usual Care | 47.66 | 42.40 | 36.47 | 34.07 |
Alcohol and drug use composite scores were separately analyzed. The ASI alcohol composite score measures the severity of substance use and amount of use in the past 30 days and consequences of use. Scored as values between 0 and 1 with higher values indicating more severe substance use (i.e. lower values indicate a better outcome). (NCT00265564)
Timeframe: Administered at baseline and 3 months, 6 months and 12 months post baseline.
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 3 months | 6 months | 12 months | |
| Seeking Safety | .259 | .169 | .138 | .149 |
| Usual Care | .225 | .152 | .141 | .134 |
The primary endpoint is the longest period of continuous abstinence from illicit opioids, where abstinence is measured using lab-verified in-person urine-tests, saliva tests, or subject reporting (in the absence of urine testing). (NCT04235582)
Timeframe: Time = 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Outcomes Group | 6 |
| Inputs Group | 5 |
| Combination Group | 5 |
The primary endpoint is the longest period of continuous abstinence from illicit opioids, where abstinence is measured using lab-verified in-person urine-tests, saliva tests, or subject reporting (in the absence of urine testing). (NCT04235582)
Timeframe: Time = 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Outcomes Group | 6 |
| Inputs Group | 5 |
| Combination Group | 3 |
The primary endpoint is the % of opioid-negative saliva or urine tests in each group at Week 12 (NCT04235582)
Timeframe: Time = 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Outcomes Group | 6 |
| Inputs Group | 5 |
| Combination Group | 3 |
Change in head circumference from day 1 to day 14 (cm/wk) (NCT02182973)
Timeframe: 2 weeks
| Intervention | cm/wk (Mean) |
|---|---|
| Donor Human Milk | 0.4 |
| Historical Control | 0.6 |
Minimum score:0; Maximum score 13. Higher scores mean more GI distress (NCT02182973)
Timeframe: 2 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Donor Human Milk | 39 |
| Historical Controls | 61 |
Change in weight from study day 1 to study day 14 (grams/day) Weight day 14 - weight day 1 divided by 14 (NCT02182973)
Timeframe: 2 weeks
| Intervention | grams/day (Mean) |
|---|---|
| Donor Human Milk | 19.1 |
| Historical Control | 20.5 |
The OOWS consists of 13 observable physical symptoms that are assessed over a five-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from a low of 0 to a high of 13. A score of 0 would suggest that no objective signs of withdrawal were observed while a score of 13 would suggest that every observable sign of withdrawal was observed. (NCT01006707)
Timeframe: 15 Minutes Following Ondansetron or Placebo Administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 2.7 |
| Placebo | 2.2 |
The OOWS consists of 13 observable physical symptoms that are assessed over a five-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from a low of 0 to a high of 13. A score of 0 would suggest that no objective signs of withdrawal were observed while a score of 13 would suggest that every observable sign of withdrawal was observed. (NCT01006707)
Timeframe: 5 Minutes Following Ondansetron or Placebo Administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 1 |
| Placebo | 2 |
The SOWS consists of 16 physical and emotional symptoms that are rated by the participant on a scale from 0 (not at all) to 4 (extremely), to indicate the extent to which the symptom describes how they are feeling at the time. The total SOWS score is determined by summing the scores of the 16 items. Scores range from a low of 0 to a high of 64. A score of 0 would suggest that the individual is experiencing no symptoms of withdrawal while a score of 64 would suggest that the individual is experiencing all 16 symptoms of withdrawal to the fullest extent possible. (NCT01006707)
Timeframe: 20 minutes following Ondansetron or Placebo administration
| Intervention | units on a scale (Mean) |
|---|---|
| Ondansetron | 5.7 |
| Placebo | 8.1 |
Changes are reporting using Spearman's correlation coefficient, using within-subject factors of time (pre-naloxone, post-naloxone) and pre-treatment (placebo, ondansetron). Changes in Objective Opioid Withdrawal Scale (OOWS) and Subjective Opioid Withdrawal Scale (SOWS) with correlation coefficient >0.45 are reported. The OOWS consists of 13 observable physical symptoms assessed over a 5-minute observation period and scored as present (score of 1) or absent (score of 0). The total OOWS scores is determined by summing the scores of the 13 items. OOWS scores can range from 0 to 13; lower scores correspond to fewer symptoms. SOWS consists of 16 physical and emotional symptoms rated by the participant on a scale from 0 (not at all) to 4 (extremely), to indicate the extent to which the symptom describes how they are feeling at the time. The total SOWS score is determined by summing the scores of the 16 items. Scores range from 0 to 64; lower scores correspond to fewer symptoms. (NCT01006707)
Timeframe: 36 minutes
| Intervention | correlation coefficient (Number) | |||||
|---|---|---|---|---|---|---|
| Left inferior frontal gyrus, orbital (OOWS) | Right inferior frontal gyrus, orbital (OOWS) | Right superior frontal gyrus, medial (SOWS) | Right inferior frontal gyrus, orbital (SOWS) | Left superior temporal gyrus (OOWS) | Left caudate head (SOWS) | |
| All Ondansetron | 0.519 | 0.562 | 0.478 | 0.486 | -0.612 | 0.475 |
OOWS: Is a 13-item instrument of documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score = 13, minimum score = 0. Lower scores correspond to fewer symptoms. (NCT01222091)
Timeframe: Pretreatment [90 min prior to 60-min REM infusion]; 30 min prior to 60-min REM infusion; 15 and 40 min after start of 60-min REM infusion; 5, 15, and 75 minutes after finish of 60-min REM infusion)
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Pretreatment | 30 min prior to REM infusion | 15 min after start of REM infusion | 40 min after start of REM infusion | 5 minutes after finish of REM infusion | 15 minutes after finish of REM infusion | 75 minutes after finish of REM infusion | |
| Placebo | 1.1 | 1.1 | 0.8 | 0.5 | 1.8 | 2.1 | 1.6 |
| Propranolol | 1.2 | 1.1 | 0.1 | 0.8 | 3 | 2.8 | 1.7 |
A slightly modified version of a previously described model of secondary hyperalgesia was used. Two copper wires contained in a microdialysis catheter were inserted in parallel over a length of 5 mm into the dermis of the right volar forearm. The wires were connected to a constant current stimulator controlled by a pulse generator to deliver rectangular and monophasic pulses with a duration of 0.5 mg at 2 Hz. Over a period of 15 min, the current was increased by targeting a pain rating of 5 on an 11-point numeric rating scale (0 = no pain and 10 = maximum tolerable pain) until the hyperalgesic area surrounding the stimulation site was fully established. Once the area was established, the current was held constant. Percent change from baseline in size (area) of secondary hyperalgesia after cessation of remifentanil infusion was calculated per group. (NCT01222091)
Timeframe: Baseline; 15 min post remifentanil (REM) infusion; 60 min post REM infusion
| Intervention | percentage of change (Number) | |
|---|---|---|
| 15 min post remifentanil infusion | 60 min post remifentanil infusion | |
| Placebo | -34 | 141.5 |
| Propranolol | -28 | -19 |
"The OOWS is a 13-item instrument documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score possible = 13, minimum score possible = 0. T=15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~OOWS scores at T=180 is the primary outcome measure of the study compared with baseline OOWS scores at T=-30 (30 minutes prior to study medication administration). Reported time frames are in relation to time past since administration of study medications.~Mean post-Naloxone OOWS scores (+/- SEM) were determined for pretreatment groups" (NCT00661674)
Timeframe: Change from baseline in OOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (OOWS Scale) (Mean) |
|---|---|
| Placebo | 3.5 |
| Palonosetron | 1.0 |
| Palonosetron + Hydroxyzine | 0 |
"The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. 15 minutes post naloxone administration coordinates with T = 180 (min) for the entire study session.~The highest score possible (64) would indicate that the individual was experiencing every symptom of opioid withdrawal to the fullest extent possible while the lowest score (0) would indicate that the individual was not experiencing any symptoms of opioid withdrawal.~Mean post-naloxone SOWS scores (+/- SEM) were computed for pretreatment groups: Placebo, palonosetron, and palonosetron with hydroxyzine" (NCT00661674)
Timeframe: Change from baseline in SOWS score at 180 minutes (15 minutes post naloxone administration)
| Intervention | units on a scale (SOWS Scale) (Mean) |
|---|---|
| Placebo | 6.0 |
| Palonosetron | 4.0 |
| Palonosetron + Hydroxyzine | 3.5 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
461 reviews available for methadone and Addiction, Opioid
| Article | Year |
|---|---|
Problematic Opioid Use Among Older Adults: Epidemiology, Adverse Outcomes and Treatment Considerations.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Pain | 2021 |
Opioid treatment programs, telemedicine and COVID-19: A scoping review.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Female; Humans; Methadone; Opiate Substi | 2022 |
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2021 |
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Female; Humans; Male; Methadone; Naltrexone; Narcotic | 2022 |
Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2022 |
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.
Topics: Acute Pain; Analgesia; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Opiate Su | 2021 |
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
Topics: Buprenorphine; Humans; Methadone; Methamphetamine; Opiate Substitution Treatment; Opioid-Related Dis | 2021 |
Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs' perspectives of and experiences with the extramedical use and diversion of buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opi | 2022 |
Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care.
Topics: Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Buprenorphine; Critical Care; Humans; Meth | 2022 |
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Disease Management; Drug Overdose; Female; Fe | 2022 |
Public health risks associated with methadone in Iran: A systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Child; Female; Humans; Iran; Male; Methadone; Opiate Substitution Treatme | 2022 |
A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.
Topics: Buprenorphine; Calcium-Calmodulin-Dependent Protein Kinases; Eye Proteins; Genome-Wide Association S | 2021 |
Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; | 2022 |
Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Health Servic | 2022 |
Interim opioid agonist treatment for opioid addiction: a systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Observational Studies as Topic; Opiate Substit | 2022 |
An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2022 |
Medication for opioid use disorder in the Arab World: A systematic review.
Topics: Analgesics, Opioid; Arab World; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opi | 2022 |
Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Infant; Methadone; Opiate Substitution Tre | 2022 |
Review of medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; COVID-19; COVID-19 Drug Treatment; Humans; Methadone; Naltrexone; Opiate Substitution | 2022 |
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Naltrexone; Network Meta-Analysis; O | 2022 |
Progress in pretreatment of methadone: an update since 2015.
Topics: Humans; Methadone; Opioid-Related Disorders; Solid Phase Extraction | 2023 |
Systematic review on the clinical management of chronic pain and comorbid opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; O | 2023 |
Side Effects of Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements.
Topics: Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Methadone; Opioid-Related D | 2023 |
Buprenorphine Compared with Methadone in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Infant, Newborn; Methadone; Opiate Substit | 2022 |
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Buprenorphine; Hospitals; Humans; Methadone; Naltr | 2022 |
Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Opiate Substitution Treatment; O | 2022 |
Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Hospitalization; Humans; Methadone; Opiate Overdose; Opioi | 2022 |
Opioid agonist treatment take-home doses ('carries'): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?
Topics: Analgesics, Opioid; Canada; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opioid-Related Disorders; | 2022 |
Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.
Topics: Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders; S | 2022 |
Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opiate Substitution Treat | 2023 |
Opioid Use Disorder in Pregnant Patients.
Topics: Analgesics, Opioid; Anesthetics; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treat | 2022 |
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiat | 2022 |
Opioid Use Disorder Treatments: An Evidence Map.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2022 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action | 2023 |
The Growing Epidemic of Opioid Use Disorder in the Elderly and Its Treatment: A Review of the Literature.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Drug-Related Side Effects and Adverse Reactions; Humans; Me | 2023 |
Prenatal Opioid Exposure and Neurodevelopmental Outcomes.
Topics: Analgesics, Opioid; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal A | 2023 |
Opioids and Opioid Use Disorder in Pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2023 |
Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy.
Topics: COVID-19; Humans; Methadone; Opioid-Related Disorders; Pandemics; Policy | 2023 |
Risk of motor vehicle collisions after methadone use: A systematic review and meta-analysis.
Topics: Accidents, Traffic; Humans; Methadone; Motor Vehicles; Opiate Substitution Treatment; Opioid-Related | 2023 |
Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Tr | 2023 |
Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.
Topics: Adolescent; Adult; Analgesics, Opioid; Australia; Buprenorphine; Cocaine; Female; Humans; Male; Meth | 2023 |
Harmful effects of opioid use in pregnancy: A scientific review commissioned by the European Board and College of obstetrics and gynaecology (EBCOG).
Topics: Analgesics, Opioid; Buprenorphine; Female; Gynecology; Humans; Infant; Methadone; Obstetrics; Opiate | 2023 |
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2023 |
Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.
Topics: Australia; Canada; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disord | 2023 |
Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Topics: Buprenorphine; Case Management; Central Nervous System Stimulants; Humans; Methadone; Motivational I | 2023 |
Errors in Data Reported in Meta-Analysis on Opioid Agonist Treatment and Mortality.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials.
Topics: Bayes Theorem; Buprenorphine; Clonidine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Ran | 2023 |
Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Cohort Studies; Databases, Factual; | 2019 |
Medication Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Subst | 2020 |
Monitoring Prenatal Exposure to Buprenorphine and Methadone.
Topics: Analgesics, Opioid; Buprenorphine; Drug Monitoring; Female; Hair; Humans; Meconium; Methadone; Opiat | 2020 |
The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.
Topics: Analgesics, Opioid; Buprenorphine; Cardiovascular Diseases; HIV Infections; Humans; Inflammation; Me | 2019 |
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Topics: Adolescent; Adolescent Behavior; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; O | 2019 |
Medication-Assisted Treatment for Opioid-Use Disorder.
Topics: Algorithms; Buprenorphine; Decision Trees; Humans; Methadone; Naltrexone; Opiate Substitution Treatm | 2019 |
Opioid Use Disorder: Medical Treatment Options.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Evidence-Based Medicine; Female; Humans; Male; M | 2019 |
Neonatal Abstinence Syndrome: Review of Epidemiology, Care Models, and Current Understanding of Outcomes.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Hypnotics and Sedatives; Infant, | 2019 |
Opioid Use in Pregnancy.
Topics: Buprenorphine; Child Development; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Sy | 2019 |
Adjunctive memantine for opioid use disorder treatment: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Hum | 2019 |
Opioid substitution therapy for people living in German prisons-inequality compared with civic sector.
Topics: Delivery of Health Care; Female; Germany; Healthcare Disparities; Hepatitis C, Chronic; HIV Infectio | 2019 |
The effect of methadone on the hypothalamic pituitary gonadal axis and sexual function: A systematic review.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Female; Gonadal Disorders; Humans; Hypothalamo-Hypophysea | 2020 |
Medications Development for Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Drug Development; Evidence-Based Medicine; Human | 2021 |
Adhesion Molecules as Potential Novel Biomarkers for Opioid Dependence.
Topics: Biomarkers; Cadherins; Humans; Methadone; Neural Cell Adhesion Molecules; Opioid-Related Disorders | 2020 |
Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.
Topics: Analgesics, Opioid; Excitatory Amino Acid Antagonists; Humans; Ketamine; Memantine; Methadone; Opiat | 2020 |
Opioids and sleep - a review of literature.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Slee | 2020 |
Buprenorphine initiation to treat opioid use disorder in emergency rooms.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Opioi | 2020 |
Levorphanol versus methadone use: safety considerations.
Topics: Analgesics, Opioid; Central Nervous System; Chronic Pain; Dose-Response Relationship, Drug; Humans; | 2020 |
Cognitive Outcomes of Young Children After Prenatal Exposure to Medications for Opioid Use Disorder: A Systematic Review and Meta-analysis.
Topics: Analgesics, Opioid; Buprenorphine; Child Development; Child, Preschool; Cognition; Cognitive Dysfunc | 2020 |
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Humans; Methadone; Naltrexone; Narc | 2020 |
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Topics: Adolescent; Buprenorphine; Child; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substi | 2020 |
Global opioid agonist treatment: a review of clinical practices by country.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narc | 2020 |
Case Report: Buprenorphine Induction Using Transdermal Buprenorphine in a Veteran With Opioid Use Disorder and Psychosis, Managing Precipitated Withdrawal.
Topics: Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Psychotic Disorders; Substance Withdrawa | 2020 |
Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Development; Methadone; Opioid-Related Disorders; R | 2020 |
Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review.
Topics: Analgesics, Opioid; Buprenorphine; Canada; Humans; Male; Methadone; Methicillin-Resistant Staphyloco | 2020 |
Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
Topics: Analgesics, Opioid; Buprenorphine; Harm Reduction; Hospitalization; Humans; Methadone; Naltrexone; N | 2020 |
Pharmacogenomics of methadone: a narrative review of the literature.
Topics: Analgesics, Opioid; Animals; Genetic Variation; Humans; Methadone; Opiate Substitution Treatment; Op | 2020 |
Opioid Management in Pregnancy and Postpartum.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cesarean Section; Female; Humans; Infant, Newborn; Labor, | 2020 |
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Brain; Buprenorphine; Disease Models, Animal; Endo | 2020 |
Changing Outdated Methadone Regulations That Harm Pregnant Patients.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Health Policy; Humans; Methadone; Opia | 2021 |
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Ai | 2020 |
Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Topics: Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 Enzyme System; H | 2021 |
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.
Topics: Analgesics, Opioid; Antidepressive Agents; Central Nervous System Stimulants; Cocaine; Cocaine-Relat | 2020 |
The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: A systematic review.
Topics: Buprenorphine; Cannabis; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorder | 2020 |
Maintenance agonist treatments for opiate-dependent pregnant women.
Topics: Birth Weight; Buprenorphine; Delayed-Action Preparations; Female; Humans; Infant; Infant, Newborn; M | 2020 |
The effect of methadone on depression among addicts: a systematic review and meta-analysis.
Topics: Depression; Humans; Iran; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Quetiapine and other antipsychotics combined with opioids in legal autopsy cases: A random finding or cause of fatal outcome?
Topics: Adolescent; Adult; Analgesics, Opioid; Animals; Antipsychotic Agents; Arrhythmias, Cardiac; Autopsy; | 2021 |
Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
Topics: Buprenorphine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Me | 2021 |
Factors Associated with Low Bone Density in Opioid Substitution Therapy Patients: A Systematic Review.
Topics: Alcoholism; Body Mass Index; Bone Diseases, Metabolic; Buprenorphine; Female; Heroin; Humans; Male; | 2021 |
Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers.
Topics: Acute Pain; Analgesics, Opioid; Anesthesia, Conduction; Buprenorphine, Naloxone Drug Combination; Ch | 2021 |
Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review.
Topics: Analgesics, Opioid; Cardiotoxicity; Cardiovascular Diseases; Humans; Methadone; Opioid-Related Disor | 2021 |
[STIGMA AND MISINFORMATION ABOUT METHADONE MAINTENANCE THERAPY].
Topics: Analgesics, Opioid; Communication; Humans; Maintenance; Methadone; Opiate Substitution Treatment; Op | 2021 |
Economic Evaluation in Opioid Modeling: Systematic Review.
Topics: Analgesics, Opioid; Costs and Cost Analysis; Humans; Methadone; Models, Economic; Naloxone; Narcotic | 2021 |
Recent Advances in the Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Implants; Humans; Injections, I | 2021 |
Methadone bioavailability and dose conversion implications with intravenous and enteral administration: A scoping review.
Topics: Administration, Intravenous; Analgesics, Opioid; Biological Availability; Humans; Methadone; Neoplas | 2021 |
Pharmacotherapy for Management of 'Kratom Use Disorder': A Systematic Literature Review With Survey of Experts.
Topics: Buprenorphine; Humans; Methadone; Mitragyna; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Opioid use disorder treatment for people experiencing homelessness: A scoping review.
Topics: Buprenorphine; Health Services Accessibility; Health Services Misuse; Humans; Ill-Housed Persons; Me | 2021 |
Interim methadone - Effective but underutilized: A scoping review.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Prospective Studies; Retrospective | 2021 |
Mobile methadone medication units: A brief history, scoping review and research opportunity.
Topics: Humans; Methadone; Opioid-Related Disorders; Pharmaceutical Preparations; Prospective Studies; Syste | 2021 |
Correlates of methamphetamine use severity among patients receiving methadone maintenance treatment for opioid use disorder in Vietnam.
Topics: Humans; Methadone; Methamphetamine; Opiate Substitution Treatment; Opioid-Related Disorders; Vietnam | 2022 |
Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related | 2022 |
Opium tincture-assisted treatment for opioid use disorder: A systematic review.
Topics: Buprenorphine; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Opi | 2021 |
Insights into the mechanisms underlying opioid use disorder and potential treatment strategies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United S | 2021 |
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Child; Cross-Sectional Studies; Female; Humans | 2021 |
Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review.
Topics: Drug Prescriptions; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pharmacies | 2021 |
Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Observational Studies as Topic; Opioid-Related | 2021 |
The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
Topics: Buprenorphine; COVID-19; Cross-Sectional Studies; Drug Overdose; Emergency Medical Services; Health | 2021 |
Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Methado | 2017 |
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Topics: Buprenorphine; Drug Overdose; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Re | 2017 |
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Directly Observed Therapy; Humans; Met | 2017 |
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Nar | 2017 |
Use and misuse of opioid agonists in opioid addiction.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2017 |
A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Drug Implants; Female; Humans; Meth | 2017 |
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; | 2017 |
Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review.
Topics: Abnormalities, Drug-Induced; Analgesics, Opioid; Female; Humans; Methadone; Morphine Derivatives; Op | 2017 |
Buprenorphine implants in medical treatment of opioid addiction.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Implants; Humans; Methadone; Na | 2017 |
Opioid Addiction: Social Problems Associated and Implications of Both Current and Possible Future Treatments, including Polymeric Therapeutics for Giving Up the Habit of Opioid Consumption.
Topics: Analgesics, Opioid; Behavior, Addictive; Habits; Humans; Methadone; Opioid-Related Disorders; Substa | 2017 |
[Treatment of acute pain in opioid addicts].
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Opiate Substitution Trea | 2017 |
Pharmacoepigenomics of opiates and methadone maintenance treatment: current data and perspectives.
Topics: Animals; Cell Line; DNA Methylation; Epigenesis, Genetic; Humans; Methadone; Opiate Substitution Tre | 2017 |
Primary care models for treating opioid use disorders: What actually works? A systematic review.
Topics: Adult; Buprenorphine; Delivery of Health Care; Humans; Methadone; Opioid-Related Disorders; Primary | 2017 |
Pharmacogenetics of Methadone Response.
Topics: Gene Regulatory Networks; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.
Topics: Buprenorphine; Consensus; Europe; Humans; Mental Disorders; Methadone; Opiate Substitution Treatment | 2017 |
Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Humans; Methadone; Naltrexone; Op | 2018 |
[Pain management for cancer patients in drug-assisted rehabilitation].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2018 |
Treatment outcomes in patients with opioid use disorder initiated by prescription: a systematic review protocol.
Topics: Analgesics, Opioid; Humans; Illicit Drugs; Methadone; North America; Opiate Substitution Treatment; | 2018 |
Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern.
Topics: Adult; Amphetamine-Related Disorders; Central Nervous System Stimulants; Female; Humans; Iran; Male; | 2018 |
Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Topics: Analgesics, Opioid; Animals; Cytochrome P-450 Enzyme System; Humans; Methadone; Opioid-Related Disor | 2018 |
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorder | 2018 |
The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review.
Topics: Analgesics, Opioid; Animals; Case-Control Studies; Cross-Sectional Studies; Humans; Methadone; Opioi | 2018 |
Opioid Use Disorders: Perioperative Management of a Special Population.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Drug Tolerance; Humans; Interdisciplinary Communic | 2018 |
Developing an opioid use disorder treatment cascade: A review of quality measures.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonist | 2018 |
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Metha | 2019 |
Treatment of Perinatal Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Decision Making; Female; Humans; Infant, Newborn; Methadone; Neonatal Abs | 2018 |
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain Management; Perioperati | 2018 |
Supervised Injectable Opioid Treatment for the Management of Opioid Dependence.
Topics: Analgesics, Opioid; Drug Overdose; Follow-Up Studies; Heroin; Humans; Methadone; Opiate Substitution | 2018 |
CE: Acute Pain Management for People with Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Anta | 2018 |
Opioid Detoxification in Pregnancy: Systematic Review and Meta-Analysis of Perinatal Outcomes.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2019 |
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Op | 2018 |
Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment.
Topics: Body Weight Maintenance; Diagnosis, Dual (Psychiatry); Humans; Methadone; Narcotics; Opiate Substitu | 2018 |
Neonatal abstinence syndrome.
Topics: Adult; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Subs | 2018 |
Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis.
Topics: Child; Child Development; Child, Preschool; Female; Humans; Infant; Methadone; Narcotics; Opioid-Rel | 2019 |
Pharmacotherapy for opioid addiction in community corrections.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Re | 2018 |
Morphine and Methadone for Neonatal Abstinence Syndrome: A Systematic Review.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Length of Stay; Male; Methadone; Morphi | 2018 |
[An overview on the opioid substitution therapy service model].
Topics: Analgesics, Opioid; China; Delivery of Health Care; Humans; Methadone; Opiate Substitution Treatment | 2018 |
Youth and the Opioid Epidemic.
Topics: Adolescent; Analgesics, Opioid; Behavior, Addictive; Epidemics; Humans; Methadone; Opioid-Related Di | 2019 |
Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction.
Topics: Analgesics, Opioid; Buprenorphine; Cognitive Behavioral Therapy; Humans; Methadone; Naloxone; Narcot | 2019 |
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Treatment Ou | 2019 |
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction.
Topics: Analgesics, Opioid; Global Health; Humans; Internationality; Methadone; Narcotic Antagonists; Opiate | 2019 |
Opioid use disorder during pregnancy: An overview.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cognitive Behavioral Therapy; Female; Fetal Di | 2019 |
Pharmacological treatment of opioid use disorder in pregnancy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Guidelines as Topic; Humans; Methadone; Narcotic A | 2019 |
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorder | 2019 |
A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; Female; Humans; Male; Methadone; North | 2019 |
Meeting the challenges of opioid dependence in China: experience of opioid agonist treatment.
Topics: Adult; China; Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Rela | 2019 |
Slow release oral morphine versus methadone for the treatment of opioid use disorder.
Topics: Administration, Oral; Delayed-Action Preparations; Humans; Methadone; Morphine; Narcotics; Opiate Su | 2019 |
Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery.
Topics: Analgesia, Patient-Controlled; Buprenorphine; Cesarean Section; Female; Humans; Methadone; Naltrexon | 2019 |
Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Central Nervous System Stimulants; Cocaine-Related Disorders; Dex | 2019 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine | 2019 |
Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; | 2019 |
A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Topics: Analgesics, Opioid; Buprenorphine; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Metha | 2019 |
Prevention of Opioid Overdose.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Drug Overdose; Humans; Methadone; Naloxone; Narcoti | 2019 |
Management and monitoring of opioid use in pregnancy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Maternal-Fetal Exchange; Methadone; Narcot | 2020 |
Comprehensive Perioperative Management Considerations in Patients Taking Methadone.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Pain M | 2019 |
Consideration of opioid agonist treatment in a pregnant adolescent: A case report and literature review.
Topics: Adolescent; Ambulatory Care; Analgesics, Opioid; Buprenorphine; Child, Foster; Female; Humans; Lost | 2020 |
Medications for management of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Evidence-Based Medicine; Humans; Methadone; N | 2019 |
Methadone at tapered doses for the management of opioid withdrawal.
Topics: Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Co | 2013 |
Cigarette smoking in methadone maintained patients: an up-to-date review.
Topics: Behavior, Addictive; Drug Interactions; Humans; Methadone; Narcotics; Nicotine; Nicotinic Agonists; | 2013 |
Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Interactions; Humans; Methadone; Opiate Substitutio | 2013 |
Problem based review: The patient taking methadone.
Topics: Adult; Humans; Male; Methadone; Naloxone; Narcotic Antagonists; Narcotics; Opiate Substitution Treat | 2013 |
Mitigating the risk of HIV infection with opioid substitution treatment.
Topics: Antiretroviral Therapy, Highly Active; Buprenorphine; Comorbidity; Evidence-Based Medicine; Harm Red | 2013 |
The role of the Chinese police in methadone maintenance therapy: a literature review.
Topics: Analgesics, Opioid; China; Cooperative Behavior; Crime; Drug and Narcotic Control; Drug Users; Fear; | 2013 |
The experience of long-term opiate maintenance treatment and reported barriers to recovery: a qualitative systematic review.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Regi | 2013 |
Medication-assisted treatment of opiate dependence is gaining favor.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Seco | 2013 |
Methadone maintenance treatment and cognitive function: a systematic review.
Topics: Cognition; Cognition Disorders; Dose-Response Relationship, Drug; Humans; Methadone; Opiate Substitu | 2013 |
QTc interval screening for cardiac risk in methadone treatment of opioid dependence.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Torsades de Pointes | 2013 |
Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Developing Countries; Humans; Medication Adherence; Methadone; Op | 2014 |
Chronic opioid use during pregnancy: maternal and fetal implications.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2013 |
[Levamethadone as substitution treatment of opioid-dependent patients].
Topics: Analgesics, Opioid; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Germany; Methadone | 2013 |
Retention in methadone maintenance treatment in mainland China, 2004-2012: a literature review.
Topics: Age Factors; China; Humans; Medication Adherence; Methadone; Narcotics; Opiate Substitution Treatmen | 2014 |
Managing opioid dependence in pregnancy -- a general practice perspective.
Topics: Adult; Buprenorphine; Female; General Practice; Humans; Methadone; Narcotics; Neonatal Abstinence Sy | 2013 |
Medication-assisted treatment with methadone: assessing the evidence.
Topics: Analgesics, Opioid; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorde | 2014 |
The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: a meta-analysis study.
Topics: Buprenorphine; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pre | 2014 |
Epidemiology of syphilis infection among drug users at methadone maintenance treatment clinics in China: systematic review and meta-analysis.
Topics: Adult; China; Drug Users; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Rel | 2014 |
Maintenance agonist treatments for opiate-dependent pregnant women.
Topics: Birth Weight; Buprenorphine; Delayed-Action Preparations; Female; Humans; Infant; Infant, Newborn; M | 2013 |
Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.
Topics: Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; AT | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2014 |
Alpha2-adrenergic agonists for the management of opioid withdrawal.
Topics: Acute Disease; Adrenergic alpha-2 Receptor Agonists; Controlled Clinical Trials as Topic; Humans; Me | 2014 |
Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline.
Topics: Arrhythmias, Cardiac; Chronic Pain; Drug Overdose; Humans; Methadone; Opioid-Related Disorders; Prac | 2014 |
Buprenorphine and methadone for opioid addiction during pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Female; Humans; Methadone; Neonatal | 2014 |
Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review.
Topics: Analgesics, Opioid; Canada; Humans; Methadone; Noscapine; Opioid-Related Disorders; Oxycodone; Pract | 2014 |
Maintenance treatments for opiate -dependent adolescents.
Topics: Adolescent; Buprenorphine; Humans; Maintenance Chemotherapy; Methadone; Methadyl Acetate; Naloxone; | 2014 |
Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Models, Statistical; Neonatal Abstinence | 2014 |
Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Brain; Buprenorphine; Chemical and Drug Induced Liver I | 2015 |
Older adults prescribed methadone: a review of the literature across the life span from opiate initiation to methadone maintenance treatment.
Topics: Age Factors; Aged; Humans; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related Dis | 2014 |
Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis.
Topics: Adolescent; Adult; China; Crime; Drug Users; Employment; Female; Humans; Interpersonal Relations; Ma | 2015 |
Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.
Topics: Analgesics, Opioid; Behavior Therapy; Buprenorphine; Female; Humans; Methadone; Opiate Substitution | 2015 |
Testosterone suppression in opioid users: a systematic review and meta-analysis.
Topics: Adult; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Sex Characteristics; Te | 2015 |
Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
Topics: Buprenorphine; Female; Humans; Kaplan-Meier Estimate; Methadone; Narcotic Antagonists; Narcotics; Op | 2015 |
[Analgesic management of acute pain in patients receiving methadone or buprenorphine].
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Drug Tolerance; Drug Users; Humans; Methadone; Morphi | 2015 |
Question: is breastfeeding useful in the management of neonatal abstinence syndrome?
Topics: Breast Feeding; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; | 2015 |
Resting EEG and ERPs findings in methadone-substituted opiate users: a review.
Topics: Electroencephalography; Evoked Potentials; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2015 |
Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.
Topics: Analgesics, Opioid; Bupropion; Forecasting; Humans; Methadone; Opioid-Related Disorders; Randomized | 2015 |
Pharmacological Management of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Opiate Subst | 2015 |
The US Congressional "Decade on Pain Control and Research" 2001-2011: A Review.
Topics: Analgesics, Opioid; Biomedical Research; Drug and Narcotic Control; Humans; Methadone; Opioid-Relate | 2015 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcot | 2016 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcot | 2016 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcot | 2016 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcot | 2016 |
Short term health-related quality of life improvement during opioid agonist treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; Female; | 2015 |
Pharmacotherapy of Opioid Addiction: "Putting a Real Face on a False Demon".
Topics: Analgesics, Opioid; Attitude of Health Personnel; Behavior, Addictive; History, 20th Century; Histor | 2016 |
An Ageing Methadone Population: A Challenge to Aged Persons' Mental Health Services?
Topics: Age Factors; Aged; Humans; Mental Health Services; Methadone; Opiate Substitution Treatment; Opioid- | 2015 |
Opioid substitution therapy: Lowering the treatment thresholds.
Topics: Buprenorphine; Health Services Accessibility; Humans; Methadone; Narcotics; Opiate Substitution Trea | 2016 |
New Pain Management Options for the Surgical Patient on Methadone and Buprenorphine.
Topics: Buprenorphine; Drug Administration Schedule; Female; Humans; Methadone; Neonatal Abstinence Syndrome | 2016 |
Economic Evaluations of Opioid Use Disorder Interventions.
Topics: Cost-Benefit Analysis; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; R | 2016 |
A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2016 |
Pain and Opioid Addiction: A Systematic Review and Evaluation of Pain Measurement in Patients with Opioid Dependence on Methadone Maintenance Treatment.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2016 |
Breastfeeding among Mothers on Opioid Maintenance Treatment: A Literature Review.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Health Promotion; Humans; Infant, Newborn | 2016 |
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.
Topics: Animals; Antiviral Agents; Buprenorphine; Drug Interactions; Hepatitis C; Humans; Methadone; Opioid- | 2016 |
Alpha₂-adrenergic agonists for the management of opioid withdrawal.
Topics: Acute Disease; Adrenergic alpha-2 Receptor Agonists; Clonidine; Controlled Clinical Trials as Topic; | 2016 |
Opioid agonist treatment for pharmaceutical opioid dependent people.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opio | 2016 |
Buprenorphine Versus Methadone for Opioid Dependence in Pregnancy.
Topics: Buprenorphine; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Neonatal Abstinen | 2016 |
Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.
Topics: Abnormalities, Drug-Induced; Analgesics, Opioid; Birth Weight; Buprenorphine; Female; Fetal Death; F | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug T | 2016 |
Treatment of Opioid-Use Disorders.
Topics: Adrenergic alpha-Agonists; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-R | 2016 |
A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2016 |
Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain | 2017 |
Long-Term Outcomes of Infants with Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Child Abuse; Epigenesis, Genetic; Female; Humans; Infant, Newborn; Methadone; Ne | 2016 |
Caring for patients with opioid use disorder in the hospital.
Topics: Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Dru | 2016 |
Opioid dependence and pregnancy: minimizing stress on the fetal brain.
Topics: Brain Diseases; Buprenorphine; Female; Fetal Diseases; Humans; Methadone; Opioid-Related Disorders; | 2017 |
Update on pharmacotherapy for treatment of opioid use disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Combined Modality Therapy; Humans; M | 2016 |
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.
Topics: Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Modality Therapy; Heroin Depend | 2017 |
Neonatal Abstinence Syndrome.
Topics: Female; Humans; Incidence; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Opiat | 2016 |
Alpha-adrenergic Agonists for the Management of Opioid Withdrawal.
Topics: Adrenergic alpha-2 Receptor Agonists; Controlled Clinical Trials as Topic; Female; Humans; Male; Met | 2017 |
Buprenorphine for managing opioid withdrawal.
Topics: Acute Disease; Buprenorphine; Clonidine; Female; Humans; Male; Methadone; Narcotic Antagonists; Opia | 2017 |
Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Topics: Age Factors; Buprenorphine, Naloxone Drug Combination; Evidence-Based Medicine; Female; Health Statu | 2017 |
Pregnancy and injecting drug use.
Topics: Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Care Planning; Pregnancy; Pr | 2008 |
Practical considerations for the clinical use of buprenorphine.
Topics: Buprenorphine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Educat | 2004 |
Using behavioral reinforcement to improve methadone treatment participation.
Topics: Analgesics, Opioid; Behavior Therapy; Combined Modality Therapy; Humans; Methadone; Models, Psycholo | 2002 |
Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.
Topics: Combined Modality Therapy; Humans; Methadone; Narcotics; Opioid-Related Disorders; Psychotherapy; Ra | 2008 |
Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates.
Topics: Buprenorphine; Diagnosis, Dual (Psychiatry); Female; GABA Modulators; Humans; Infant, Newborn; Menta | 2008 |
Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.
Topics: Combined Modality Therapy; Humans; Methadone; Narcotics; Opioid-Related Disorders; Psychotherapy; Ra | 2008 |
Psychotherapeutic benefits of opioid agonist therapy.
Topics: Anxiety Disorders; Brain; Buprenorphine; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiat | 2008 |
Drug addiction in China.
Topics: Adolescent; Adult; Alcoholism; China; Female; Health Policy; HIV Infections; Humans; Illicit Drugs; | 2008 |
Methadone: dental risks and preventive action.
Topics: Health Policy; Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Care Team; Pharmaceut | 2008 |
Methadone exposure during lactation.
Topics: Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Lactation; Maternal Exposure; | 2008 |
Foucault on methadone: beyond biopower.
Topics: Drug and Narcotic Control; Humans; Methadone; Opioid-Related Disorders; Philosophy, Medical; Policy | 2009 |
A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms.
Topics: Acupuncture Therapy; Adult; Analgesics, Opioid; Combined Modality Therapy; Humans; Male; Medicine, C | 2009 |
Methadone: a new old drug with promises and pitfalls.
Topics: Animals; Anti-Bacterial Agents; Drug Interactions; Humans; Methadone; Opioid-Related Disorders | 2009 |
Opiate and cocaine addiction: from bench to clinic and back to the bench.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Cocaine; Genome-Wide Association Study; Heroin; Hu | 2009 |
Harm reduction for injecting opiate users: an update and implications in China.
Topics: Acquired Immunodeficiency Syndrome; China; Europe; Harm Reduction; Humans; Methadone; Needle-Exchang | 2009 |
Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
Topics: Buprenorphine; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Humans; Methadone; Na | 2009 |
Maintenance treatments for opiate dependent adolescent.
Topics: Adolescent; Buprenorphine; Humans; Methadone; Methadyl Acetate; Naloxone; Narcotics; Opioid-Related | 2009 |
[Accompanying patients in substitution treatment for opiates: consulting and coaching in the office]].
Topics: Buprenorphine; Counseling; Drug Delivery Systems; Drug Tolerance; Humans; Methadone; Narcotics; Opio | 2009 |
Medical profiteering: the economics of methadone dispensation.
Topics: Canada; Drug Prescriptions; Economics, Pharmaceutical; Humans; Methadone; Opioid-Related Disorders; | 2009 |
Opioid dependence treatment: options in pharmacotherapy.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; Humans; Meth | 2009 |
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
Topics: Humans; Inactivation, Metabolic; Methadone; Narcotics; Opioid-Related Disorders; Randomized Controll | 2009 |
Methadone and the heart: what the clinician needs to know.
Topics: Animals; Dose-Response Relationship, Drug; Female; Heart Conduction System; Humans; Infusions, Intra | 2008 |
[Opiate replacement therapy in France: assessment of the public policies].
Topics: Buprenorphine; France; Health Policy; Humans; Legislation, Medical; Mental Disorders; Methadone; Nar | 2009 |
[Mechanisms of opioid-induced overdose: experimental approach to clinical concerns].
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Interactions; Drug Overdose; France; Humans; Methad | 2009 |
Smoking cessation interventions among individuals in methadone maintenance: a brief review.
Topics: Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Smoking; Smoking Cessation; So | 2010 |
A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Buprenorphine; Clonidine; Data Inte | 2010 |
Methadone deaths: risk factors in pain and addicted populations.
Topics: Analgesics, Opioid; Chronic Disease; Death, Sudden, Cardiac; Drug Overdose; Humans; Methadone; Opiat | 2010 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans | 2010 |
Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials.
Topics: Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Humans; Methadone; Narcotics; Opioid-Rel | 2009 |
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2010 |
A review of the community reinforcement approach in the treatment of opioid dependence.
Topics: Adult; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Psychotherapy; Reinfor | 2009 |
[Treatment of acute pain during drug-assisted rehabilitation].
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents | 2010 |
Methadone maintenance dosing guideline for opioid dependence, a literature review.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Methadone; Narcotics; Observ | 2010 |
Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran.
Topics: Alcoholism; Analgesics, Opioid; Health Services Accessibility; HIV Infections; Humans; Iran; Methado | 2010 |
Methadone, buprenorphine, and street drug interactions with antiretroviral medications.
Topics: Analgesics, Opioid; Anti-HIV Agents; Buprenorphine; Drug Interactions; HIV Infections; Humans; Illic | 2010 |
[Opioid rotation: a therapeutic choice in the management of refractory cancer pain].
Topics: Adult; Age Factors; Aged; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Hum | 2010 |
Pharmacotherapies for adolescent substance use disorders.
Topics: Adolescent; Alcohol Deterrents; Alcoholism; Cocaine-Related Disorders; Disulfiram; Humans; Marijuana | 2010 |
Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis.
Topics: Cohort Studies; Databases, Bibliographic; Dose-Response Relationship, Drug; Female; Humans; Infant, | 2010 |
Buprenorphine: a more accessible treatment for opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Humans; Methadone; Opioid-Related Disorders; United S | 2010 |
Heroin anticraving medications: a systematic review.
Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narco | 2010 |
Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women.
Topics: Anti-HIV Agents; Buprenorphine; Cocaine; Drug Interactions; Female; HIV Infections; Humans; Methadon | 2011 |
The anesthetic implications of illicit opioid abuse.
Topics: Analgesics, Opioid; Anesthesia; Drug Overdose; Humans; Methadone; Opioid-Related Disorders | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cognitive Behavioral Therapy; Humans; Methadone | 2011 |
Drug-related decrease in neuropsychological functions of abstinent drug users.
Topics: Alcoholism; Amphetamine-Related Disorders; Cannabis; Central Nervous System Stimulants; Cocaine; Coc | 2011 |
Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development.
Topics: Analgesics, Opioid; Buprenorphine; Child; Child Development; Cognition; Female; Humans; Male; Methad | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Heroin Dependence; Humans; Incidence; Me | 2009 |
Oral substitution treatment of injecting opioid users for prevention of HIV infection.
Topics: Administration, Oral; Buprenorphine; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related Di | 2011 |
Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Dysthymic Disorder; | 2011 |
Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.
Topics: Adult; Buprenorphine; Combined Modality Therapy; Female; Humans; Male; Methadone; Narcotics; Opioid- | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Heroin Dependence; Humans; Incidence; Me | 2011 |
The effectiveness of opioid maintenance treatment in prison settings: a systematic review.
Topics: Buprenorphine; Cocaine-Related Disorders; Continuity of Patient Care; Crime; Epidemiologic Methods; | 2012 |
[Breast feeding during methadon- and buprenorphin therapy].
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Contraindications; Dose-Response Relationship, Dr | 2011 |
Acute pain management in opioid-tolerant patients: a growing challenge.
Topics: Acute Disease; Analgesics; Analgesics, Opioid; Animals; Australia; Buprenorphine; Buprenorphine, Nal | 2011 |
[Pregnant opioid addicted patients and additional drug intake. Part I. Toxic effects and therapeutic consequences].
Topics: Adult; Alcoholism; Central Nervous System Stimulants; Drug Monitoring; Female; Heroin Dependence; Hu | 2011 |
Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Buprenorphine; Humans; Methadone; Mid | 2011 |
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Topics: Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Humans; Methadone; Naltrexone; Na | 2012 |
[Review of cases of prolonged QTC and wave burst arrhythmia in patients treated with methadone].
Topics: Adult; Analgesics, Opioid; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Interactio | 2012 |
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administrat | 2012 |
Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcoti | 2013 |
Methadone and buprenorphine for the management of opioid dependence in pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2012 |
Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis.
Topics: Adult; Age Factors; China; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Narcotics; | 2012 |
Maintenance medication for opiate addiction: the foundation of recovery.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonis | 2012 |
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.
Topics: Animals; Basal Ganglia; Cocaine-Related Disorders; Dopamine; Dopaminergic Neurons; Gene Expression R | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.
Topics: Buprenorphine; Child Development; Female; Fetus; Humans; Infant, Newborn; Length of Stay; Methadone; | 2012 |
Medications development for opioid abuse.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Endocannabinoids; Evidence-Based Medicine; Human | 2013 |
Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?
Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Opiate Substitution Treatment; Opioid-R | 2014 |
Pharmacological maintenance treatments of opiate addiction.
Topics: Buprenorphine; Drug Overdose; Heroin; Heroin Dependence; Humans; Methadone; Opiate Substitution Trea | 2014 |
Opioid addiction in pregnancy.
Topics: Analgesics, Opioid; Breast Feeding; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neona | 2012 |
Pharmacologic management of neonatal abstinence syndrome in a community hospital.
Topics: Analgesics, Opioid; Female; Florida; Humans; Infant, Newborn; Intensive Care, Neonatal; Length of St | 2013 |
Neonatal abstinence syndrome: treatment and pediatric outcomes.
Topics: Developmental Disabilities; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinen | 2013 |
Chronic and acute pain and pain management for patients in methadone maintenance treatment.
Topics: Acute Pain; Analgesics; Catastrophization; Chronic Pain; Drug Tolerance; Female; Humans; Methadone; | 2013 |
Prescribing to drug misusers in practice--often effective, but rarely straightforward.
Topics: Drug Prescriptions; Euphoria; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Dis | 2002 |
Impact of opioid use on dentistry.
Topics: Adolescent; Adult; Dental Anxiety; Dental Care for Disabled; Dental Caries; Female; Humans; Male; Me | 2002 |
Characterization of methadone overdose: clinical considerations and the scientific evidence.
Topics: Depression; Diagnosis, Differential; Drug Overdose; Drug Tolerance; Forensic Medicine; Humans; Metha | 2002 |
History and current status of opioid maintenance treatments: blending conference session.
Topics: Buprenorphine; Clinical Trials as Topic; History, 20th Century; Humans; Methadone; Methadyl Acetate; | 2002 |
Clinical practice. Office-based treatment of opioid-dependent patients.
Topics: Adult; Drug and Narcotic Control; Heroin Dependence; Humans; Male; Methadone; Narcotics; Opioid-Rela | 2002 |
Heroin-assisted treatment as a response to the public health problem of opiate dependence.
Topics: Australia; Canada; Clinical Trials as Topic; Crime; Europe; Heroin; Humans; Methadone; Opioid-Relate | 2002 |
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Topics: Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Injection | 2002 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomi | 2002 |
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
Topics: Humans; Inactivation, Metabolic; Methadone; Narcotics; Opioid-Related Disorders; Randomized Controll | 2002 |
From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States.
Topics: Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Humans; Methadone; Morphine; Opioid-Related | 2003 |
Clinical efficacy of buprenorphine: comparisons to methadone and placebo.
Topics: Buprenorphine; Controlled Clinical Trials as Topic; Humans; Methadone; Narcotic Antagonists; Opioid- | 2003 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomi | 2003 |
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.
Topics: Humans; Inactivation, Metabolic; Methadone; Narcotics; Opioid-Related Disorders; Randomized Controll | 2003 |
Methadone maintenance at different dosages for opioid dependence.
Topics: Controlled Clinical Trials as Topic; Humans; Methadone; Narcotics; Opioid-Related Disorders; Randomi | 2003 |
[Ultrashort withdrawal from opiate dependence].
Topics: Anesthesia; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2003 |
Substitution management in opioid dependence.
Topics: Animals; Buprenorphine; Drug Therapy, Combination; Humans; Methadone; Opioid-Related Disorders | 2003 |
Clinical use of methadone.
Topics: Analgesics, Opioid; Biological Availability; Dosage Forms; Drug Administration Schedule; Drug Intera | 2002 |
Treating opioid dependence. Growing implications for primary care.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Europe; Humans; Methadone; Methadyl Acetate | 2004 |
Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents, Tricyclic; Buprenorphine; Humans; Methadone; Narco | 2004 |
[Economic efficiency of methadone maintenance and factors affecting it].
Topics: Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Humans; Methadone; Opioid-Related Disord | 2004 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomi | 2004 |
The effects of methadone and its role in fatalities.
Topics: Cause of Death; Drug Interactions; Drug Overdose; Humans; Metabolic Clearance Rate; Methadone; Narco | 2004 |
Methadone at tapered doses for the management of opioid withdrawal.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Subst | 2004 |
Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Psychotherapy | 2004 |
Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.
Topics: Analgesics, Opioid; Chronic Disease; Humans; Methadone; Opioid-Related Disorders; Pain | 2004 |
[Evaluation of methadone dispensing in Belgium--study synopsis].
Topics: Adult; Analgesics, Opioid; Belgium; Cocaine-Related Disorders; Female; Heroin Dependence; Humans; Ma | 2004 |
Treatment of depression in patients with opiate dependence.
Topics: Affect; Antidepressive Agents; Behavior Therapy; Depressive Disorder; Humans; Methadone; Narcotics; | 2004 |
Pharmacotherapy for pregnant women with addictions.
Topics: Adolescent; Adult; Behavior, Addictive; Cocaine-Related Disorders; Female; Follow-Up Studies; Gestat | 2004 |
A new work placement model for unemployed methadone maintenance patients.
Topics: Employment; Humans; Methadone; Models, Theoretical; Narcotics; Opioid-Related Disorders; Self Effica | 2004 |
Eyes wide shut?--A conceptual and empirical critique of methadone maintenance treatment.
Topics: Comorbidity; Humans; Illicit Drugs; Long-Term Care; Mental Disorders; Methadone; Opioid-Related Diso | 2005 |
[Therapeutic strategies for opioid addiction: the role of substitution therapy].
Topics: Buprenorphine; Female; Humans; Mental Disorders; Methadone; Narcotic Antagonists; Narcotics; Opioid- | 2004 |
The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.
Topics: Adolescent; Adult; Aged; Buprenorphine; Community Health Services; Humans; Methadone; Middle Aged; N | 2005 |
Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.
Topics: Codeine; Genetics, Population; Haplotypes; Heroin Dependence; Humans; Male; Methadone; Molecular Bio | 2005 |
Inpatient versus other settings for detoxification for opioid dependence.
Topics: Hospitalization; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2005 |
Review article: perioperative pain management of patients on methadone therapy.
Topics: Drug Interactions; Drug Overdose; Humans; Methadone; Opioid-Related Disorders; Pain, Postoperative | 2005 |
An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research.
Topics: Buprenorphine; Humans; Information Dissemination; Methadone; Narcotic Antagonists; Opioid-Related Di | 2005 |
Methadone at tapered doses for the management of opioid withdrawal.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Subst | 2005 |
From opioid maintenance to abstinence: a literature review.
Topics: Buprenorphine; Humans; Inactivation, Metabolic; Methadone; Narcotic Antagonists; Opioid-Related Diso | 2005 |
Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology.
Topics: Buprenorphine; Community Mental Health Services; Cost-Benefit Analysis; Evaluation Studies as Topic; | 2006 |
Provider satisfaction with office-based treatment of opioid dependence: a systematic review.
Topics: Ambulatory Care; Attitude of Health Personnel; Buprenorphine; Cooperative Behavior; Humans; Methadon | 2005 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexon | 2006 |
Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm.
Topics: Alcoholism; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cocaine-Related Disorders; Comorbid | 2006 |
Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence.
Topics: Animals; Anti-HIV Agents; Buprenorphine; Drug Interactions; Humans; Methadone; Methadyl Acetate; Nar | 2006 |
Innovations in agonist maintenance treatment of opioid-dependent patients.
Topics: Buprenorphine; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Heroin; Humans; Met | 2006 |
The medical management of opioid dependence in HIV primary care settings.
Topics: Anti-HIV Agents; Buprenorphine; HIV Infections; Humans; Methadone; Narcotic Antagonists; Narcotics; | 2006 |
Opioid dependence: rationale for and efficacy of existing and new treatments.
Topics: Buprenorphine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fe | 2006 |
Initial strategies for integrating buprenorphine into HIV care settings in the United States.
Topics: Antiretroviral Therapy, Highly Active; Buprenorphine; Centers for Disease Control and Prevention, U. | 2006 |
Methadone tolerance testing in drug misusers.
Topics: Drug Interactions; Drug Tolerance; Humans; Methadone; Narcotics; Opioid-Related Disorders; Risk Fact | 2006 |
[Maintenance treatment of opiate addicts].
Topics: Germany; Humans; Incidence; Methadone; Opioid-Related Disorders; Practice Patterns, Physicians' | 2007 |
Methadone death, dosage and torsade de pointes: risk-benefit policy implications.
Topics: Electrocardiography; Humans; Methadone; Opioid-Related Disorders; Risk; Torsades de Pointes | 2006 |
Buprenorphine for opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders | 2007 |
Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology.
Topics: Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Electr | 2007 |
Drug addiction from a psychodynamic perspective: methadone maintenance treatment (MMT) as transitional phenomena.
Topics: Adult; Analgesics, Opioid; Female; Humans; Life Style; Methadone; Object Attachment; Opioid-Related | 2007 |
Opioid addiction and incarceration: an overview.
Topics: Analgesics, Opioid; Chronic Disease; Criminal Law; Forensic Psychiatry; Humans; Methadone; Opioid-Re | 2007 |
The effect of methadone maintenance treatment on alcohol consumption: a systematic review.
Topics: Alcohol Drinking; Alcoholism; Analgesics, Opioid; Clinical Trials as Topic; Humans; Methadone; Opioi | 2008 |
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Topics: Antiretroviral Therapy, Highly Active; Buprenorphine; HIV Infections; Humans; Methadone; Narcotics; | 2007 |
Efficacy of maintenance treatment with methadone for opioid dependence: a meta-analytical study.
Topics: Adult; Analgesics, Opioid; Humans; Methadone; Middle Aged; Opioid-Related Disorders; Patient Selecti | 2007 |
Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.
Topics: Adaptation, Psychological; Buprenorphine; Cognitive Behavioral Therapy; Combined Modality Therapy; C | 2007 |
Offer detoxification as a treatment option for opioid misuse.
Topics: Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topi | 2007 |
The impact of substitution treatment in prisons--a literature review.
Topics: Analgesics, Opioid; Crime; Health Services Accessibility; Humans; Methadone; Opioid-Related Disorder | 2007 |
Methadone maintenance therapy in residential therapeutic community settings: challenges and promise.
Topics: Counseling; Health Personnel; Humans; Interprofessional Relations; Methadone; Narcotics; Opioid-Rela | 2007 |
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Office Visits; Opioid-Related Disorders; Prima | 2008 |
Treatment of opioid-dependent pregnant women: clinical and research issues.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; Decision Making; Female; Humans; Infant | 2008 |
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Op | 2007 |
Opioid dependence and pregnancy.
Topics: Buprenorphine; Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy | 2008 |
Interindividual variability of methadone response: impact of genetic polymorphism.
Topics: ATP-Binding Cassette Transporters; Cytochrome P-450 Enzyme System; Drug Interactions; Genetic Hetero | 2008 |
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomi | 2008 |
Maintenance agonist treatments for opiate dependent pregnant women.
Topics: Birth Weight; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Narcotics; Opioid-R | 2008 |
Narrative review: buprenorphine for opioid-dependent patients in office practice.
Topics: Adult; Buprenorphine; Drug Combinations; Female; Humans; Methadone; Naloxone; Narcotic Antagonists; | 2008 |
Biochemical reactions between opiate receptor binding and inhibition of neurotransmission.
Topics: Adenylyl Cyclases; Animals; Brain Chemistry; Calcium; Calmodulin; Etorphine; Humans; Methadone; Mole | 1984 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; | 1980 |
Opioid interactions with alcohol.
Topics: Alcohol Oxidoreductases; Alcoholism; Animals; Disease Models, Animal; Drug Interactions; Estradiol; | 1984 |
Major medical problems and detoxification treatment of parenteral drug-abusing alcoholics.
Topics: Acquired Immunodeficiency Syndrome; Alcoholism; Homosexuality; Humans; Hypnotics and Sedatives; Infe | 1984 |
Psychotherapeutic treatment of opiate addiction.
Topics: Behavior Therapy; Goals; Humans; Male; Methadone; Opioid-Related Disorders; Psychotherapy; Social Be | 1981 |
Clinical status of methadyl acetate (LAAM).
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Evaluation; Humans; Kinetics; Male; Methadone; Met | 1981 |
Detoxification after methadone maintenance treatment.
Topics: Drug Administration Schedule; Evaluation Studies as Topic; Humans; Methadone; Opioid-Related Disorde | 1981 |
Inpatient vs outpatient treatment of alcohol and drug abusers.
Topics: Alcoholism; Ambulatory Care; Follow-Up Studies; Hospitalization; Humans; Inpatients; Methadone; Moti | 1981 |
Private practice, competition, and methadone maintenance.
Topics: Community Mental Health Services; Economic Competition; Humans; Methadone; Opioid-Related Disorders; | 1982 |
Antidepressant treatment in methadone maintenance patients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combinati | 1994 |
Opiate withdrawal.
Topics: Animals; Brain; Conditioning, Classical; Humans; Methadone; Motivation; Naloxone; Narcotic Antagonis | 1994 |
Opiate treatments.
Topics: Combined Modality Therapy; Follow-Up Studies; HIV Infections; Humans; Methadone; Opioid-Related Diso | 1994 |
Effects of in-utero opiate exposure: new paradigms for old questions.
Topics: Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Syndrome; Opioid-Related | 1994 |
Methadone maintenance treatment. When and how to refer patients.
Topics: Acquired Immunodeficiency Syndrome; Drug Interactions; Hospitalization; Humans; Mental Disorders; Me | 1995 |
Biological correlates of methadone maintenance pharmacotherapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Chromatography, Gas; Cocaine; Heroin Dependence; Humans; | 1994 |
Methadone maintenance treatment in opiate dependence: a review.
Topics: Counseling; Crime; Humans; Methadone; Opioid-Related Disorders; Randomized Controlled Trials as Topi | 1994 |
[Treatment of drug dependent patients in a general hospital].
Topics: Hospitalization; Hospitals, General; Humans; Illicit Drugs; Methadone; Opioid-Related Disorders; Pat | 1994 |
The nature and status of drug abuse treatment.
Topics: Crime; Humans; Maryland; Methadone; Opioid-Related Disorders; Substance-Related Disorders; Treatment | 1994 |
Alprazolam and benzodiazepine dependence.
Topics: Adult; Alcoholism; Alprazolam; Benzodiazepines; Comorbidity; Diazepam; Female; Humans; Incidence; Ma | 1993 |
Methadone maintenance treatment: dispelling myths and recovering truths.
Topics: Humans; Methadone; Opioid-Related Disorders; Time Factors | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; | 1993 |
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Di | 1993 |
Opiate-dependent patients receiving methadone. How physicians should manage therapy.
Topics: Adult; Cost of Illness; Humans; Male; Methadone; Narcotics; Needle Sharing; Opioid-Related Disorders | 1996 |
Managing drug misusers--a guide.
Topics: Family Practice; Female; Humans; Male; Methadone; Opioid-Related Disorders; Referral and Consultatio | 1996 |
Treatment of depressive syndromes in detoxified drug addicts: use of methadone.
Topics: Affective Disorders, Psychotic; Depression; Female; Humans; Male; Methadone; Opioid-Related Disorder | 1996 |
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Topics: Alcoholism; Delayed-Action Preparations; Follow-Up Studies; Heroin Dependence; Humans; Methadone; Na | 1996 |
Opiate and cocaine addictions: challenge for pharmacotherapies.
Topics: Animals; Cocaine; Drug Therapy; Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1997 |
Helping patients who misuse drugs.
Topics: Central Nervous System Depressants; Family Practice; Female; Humans; Methadone; Narcotics; Opioid-Re | 1997 |
Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials.
Topics: Adult; Female; Humans; Male; Methadone; Methadyl Acetate; Middle Aged; Narcotics; Opioid-Related Dis | 1997 |
The relationship between maternal use of heroin and methadone and infant birth weight.
Topics: Birth Weight; Female; Heroin; Humans; Infant, Low Birth Weight; Infant, Newborn; Methadone; Opioid-R | 1997 |
Opioid dependence during pregnancy. Effects and management.
Topics: Delivery, Obstetric; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinence Synd | 1998 |
[The effects of methadone maintenance in clinical opiate dependence].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1998 |
The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis.
Topics: Crime; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related Disorders; Risk-Taking | 1998 |
Assessing the relationship between maternal opiate use and neonatal mortality.
Topics: Female; Heroin; Humans; Infant Mortality; Infant, Newborn; Methadone; Narcotics; Opioid-Related Diso | 1998 |
Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction.
Topics: Cost of Illness; Counseling; Disease Progression; Drug and Narcotic Control; Humans; Methadone; Narc | 1998 |
Methadone in the management of narcotic addiction in pregnancy.
Topics: Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 1998 |
Role of maintenance treatment in opioid dependence.
Topics: Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders | 1999 |
Methadone patients and alcohol abuse.
Topics: Alcohol Drinking; Alcoholism; Comorbidity; Confounding Factors, Epidemiologic; Female; Humans; Male; | 1999 |
Treatment considerations in the opioid dependent patient.
Topics: Analgesics, Opioid; Buprenorphine; Drug and Narcotic Control; Humans; Methadone; Methadyl Acetate; O | 1999 |
Pharmacologic treatments for drug and alcohol dependence.
Topics: Alcohol Deterrents; Alcoholism; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Cocaine- | 1999 |
[Drug-related emergencies with opiates].
Topics: Drug Overdose; Emergencies; Heroin Dependence; Humans; Internal Medicine; Methadone; Narcotics; Opio | 1999 |
Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
Topics: Clonidine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled | 1999 |
Contingency management in outpatient methadone treatment: a meta-analysis.
Topics: Behavior Therapy; Humans; Methadone; Narcotics; Opioid-Related Disorders; Reward; Treatment Outcome | 2000 |
Drug abuse treatment as an HIV prevention strategy: a review.
Topics: Clinical Trials as Topic; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Methadone; | 2000 |
Cognitive-motor performance of methadone-maintained patients.
Topics: Adult; Attention; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Neuropsychological Tests; | 2000 |
Parent training skills and methadone maintenance: clinical opportunities and challenges.
Topics: Child; Child Behavior; Child, Preschool; Humans; Methadone; Narcotics; Opioid-Related Disorders; Par | 2000 |
[Clinical application of opioid agonists for the treatment of opiate dependence].
Topics: Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders | 2000 |
[Opiate addiction as a chronic brain disease: new concept of an old problem, and re-evaluation of methadone treatment].
Topics: Brain Diseases; Chronic Disease; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2000 |
A case for addressing cigarette use in methadone and other opioid treatment programs.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Prevalence; Psychotherapy, Brief; Regional M | 2000 |
Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Outcome Assessment, Health Care; Patient Dis | 2001 |
[Therapeutic prescription of heroin to drug addicts].
Topics: England; Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders; Switzerland | 2001 |
The physical and psychosocial consequences of opioid addiction: an overview of changes in opioid treatment.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance | 2000 |
[Critical aspects of current methadone treatment in Germany].
Topics: Contraindications; Drug and Narcotic Control; Drug Approval; Germany; Humans; Methadone; National He | 2001 |
Therapeutic drug monitoring in methadone maintenance: choosing a matrix.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Female; | 2001 |
A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence.
Topics: Analysis of Variance; Buprenorphine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient | 2001 |
Methadone therapy for opioid dependence.
Topics: Adult; Female; Goals; Health Status; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; P | 2001 |
A meta-analysis comparing the effectiveness of buprenorphine and methadone.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndr | 2000 |
Meta-analysis of HIV risk-reduction interventions within drug abuse treatment programs.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Health Education; HIV Infections; Huma | 2001 |
Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.
Topics: Buprenorphine; Humans; Methadone; Methadyl Acetate; Narcotics; Opioid-Related Disorders; Patient Dro | 2002 |
[Blessing or problem child? Substitution therapy for opiate-addicted patients].
Topics: Buprenorphine; Heroin Dependence; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2002 |
Alpha2-adrenergic agonists in opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Confidence Intervals; Controlled Clinical Trials as Topic; Hum | 2002 |
Treatment of neonatal abstinence syndrome with breast milk containing methadone.
Topics: Breast Feeding; Drug Administration Schedule; Female; Humans; Infant, Newborn; Labor, Obstetric; Met | 2002 |
Clinical management of methadone dependence during pregnancy.
Topics: Female; Fetus; Humans; Infant, Newborn; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Co | 2001 |
Rationale for maintenance pharmacotherapy of opiate dependence.
Topics: Brain; Combined Modality Therapy; Heroin Dependence; Humans; Methadone; Neurotransmitter Agents; Opi | 1992 |
[Drug interactions in methadone therapy].
Topics: Drug Interactions; Germany; Humans; Methadone; Opioid-Related Disorders; Risk Factors; Survival Rate | 1992 |
Methadone maintenance and recovery from opioid dependence.
Topics: Follow-Up Studies; Heroin Dependence; Humans; Long-Term Care; Methadone; Opioid-Related Disorders; R | 1992 |
Cocaine use by clients in methadone programs: significance, scope, and behavioral interventions.
Topics: Adolescent; Adult; Behavior Therapy; Cocaine; Cross-Sectional Studies; Humans; Incidence; Methadone; | 1991 |
In vivo and in vitro studies of opiates and cellular immunity in narcotic addicts.
Topics: Adult; Antibody Formation; Cells, Cultured; Cytotoxicity, Immunologic; Disease Susceptibility; Endor | 1991 |
[Do we need a methadone maintenance program?].
Topics: HIV Infections; Humans; Methadone; Opioid-Related Disorders; Risk Factors; Substance Abuse, Intraven | 1991 |
[Methadone maintenance as a therapeutic approach in the treatment of opiate dependent patients].
Topics: Follow-Up Studies; Germany; Humans; Methadone; Opioid-Related Disorders; Recurrence | 1991 |
Narcotic use in pregnancy.
Topics: Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Prevalence; | 1991 |
Buprenorphine: beyond methadone?
Topics: Acquired Immunodeficiency Syndrome; Buprenorphine; Cocaine; Humans; Methadone; Opioid-Related Disord | 1991 |
[Clonidine-naltrexone: a new technic for the detoxification of opiate addicts].
Topics: Clonidine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disor | 1990 |
Drugs of abuse--opiates.
Topics: Central Nervous System; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotics; | 1990 |
Methadone maintenance in the treatment of opioid dependence. A current perspective.
Topics: Acquired Immunodeficiency Syndrome; Attitude of Health Personnel; Cocaine; Drug Interactions; Ethano | 1990 |
Clinical toxicology of drugs used in the treatment of opiate dependency.
Topics: Buprenorphine; Clonidine; Humans; Methadone; Methadyl Acetate; Naltrexone; Opioid-Related Disorders | 1990 |
Pediatric uses of opioids.
Topics: Child; Child, Preschool; Codeine; Drug Interactions; Fentanyl; Humans; Infant; Infant, Newborn; Mepe | 1989 |
Implications of methadone maintenance for theories of narcotic addiction.
Topics: Drug Administration Schedule; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Dis | 1988 |
Receptor mechanisms for nociception.
Topics: Analgesics, Opioid; Animals; Codeine; Drug Tolerance; Methadone; Morphine; Naloxone; Neurons, Affere | 1986 |
Methadone maintenance to abstinence. How many make it?
Topics: Humans; Methadone; Opioid-Related Disorders; Prognosis; Psychotherapy; Research Design | 1988 |
The opioid-dependent patient with acute pain.
Topics: Acute Disease; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pain; Pain, Postoperative; Su | 1987 |
Opiate-ethanol interactions: implications for the biological basis and treatment of combined addictive diseases.
Topics: Alcoholism; Animals; Drug Interactions; Heroin Dependence; Humans; Methadone; Opioid-Related Disorde | 1988 |
The treatment of alcoholic methadone patients: a review.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Disulfiram; Humans; Methadone; Opioid-Relat | 1987 |
Treatment perspectives in drug misuse: the opiate paradigm.
Topics: Endorphins; Female; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Mal | 1987 |
The criminality of narcotic addicts.
Topics: Crime; Criminal Law; Criminal Psychology; Heroin Dependence; Humans; Longitudinal Studies; Methadone | 1985 |
Behavioral pharmacology of buprenorphine.
Topics: Adult; Animals; Buprenorphine; Conditioning, Operant; Eating; Heroin Dependence; Humans; Macaca; Mal | 1985 |
Narcotic withdrawal in the emergency department.
Topics: Clonidine; Emergency Service, Hospital; Endorphins; Humans; Methadone; Narcotics; Nervous System Dis | 1985 |
Treatment of narcotic addicts.
Topics: Behavior Therapy; Combined Modality Therapy; Humans; Methadone; Narcotic Antagonists; Opioid-Related | 1985 |
541 trials available for methadone and Addiction, Opioid
| Article | Year |
|---|---|
Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Comorbidity; Depressive | 2021 |
Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.
Topics: Analgesics, Opioid; Buprenorphine; HIV Infections; Humans; Male; Methadone; Opiate Substitution Trea | 2022 |
Substance of choice, impact of heroin or opium on treatment retention in a multicentre randomised controlled trial in Iran.
Topics: Analgesics, Opioid; Heroin; Humans; Iran; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2022 |
Hyperbaric Oxygen Therapy for Pain, Opioid Withdrawal, and Related Symptoms: A Pilot Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Humans; Hyperbaric Oxygenation; Methadone; Opioid-Related Disorders; Oxyg | 2022 |
An adaptive design to screen, treat, and retain people with opioid use disorders who use methamphetamine in methadone clinics (STAR-OM): study protocol of a clinical trial.
Topics: Adolescent; Amphetamine-Related Disorders; COVID-19; HIV Infections; Humans; Methadone; Methamphetam | 2022 |
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Drug Ove | 2022 |
Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Female; Fentany | 2022 |
The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use
Topics: Aftercare; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial.
Topics: Analgesics, Opioid; Double-Blind Method; Female; Humans; Methadone; Opiate Substitution Treatment; O | 2023 |
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadon
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cost-Benefit Analysis; Delayed-Action Preparations; Humans | 2022 |
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; | 2022 |
Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Humans; Methadone; Naloxone; Narco | 2022 |
Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Pain; Humans; M | 2022 |
Examining Access to Primary Care for People With Opioid Use Disorder in Ontario, Canada: A Randomized Clinical Trial.
Topics: Female; Humans; Methadone; Ontario; Opioid-Related Disorders; Physicians, Family; Primary Health Car | 2022 |
The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study.
Topics: Animals; Heroin; Humans; Male; Methadone; Narcotics; Neoplasm Recurrence, Local; Opioid-Related Diso | 2022 |
FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study.
Topics: Analgesics, Opioid; Baclofen; Bayes Theorem; Carbon Dioxide; Cholecalciferol; GABA-B Receptor Agonis | 2022 |
Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Control | 2022 |
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia.
Topics: Analgesics, Opioid; HIV Infections; Humans; Malaysia; Male; Methadone; Opiate Substitution Treatment | 2022 |
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Depression; Hum | 2023 |
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Depression; Hum | 2023 |
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Depression; Hum | 2023 |
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Depression; Hum | 2023 |
Effect of light needle in the treatment of opioid use disorder: A protocol for a randomized controlled trial.
Topics: Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders; Quality of Life; Randomized Controll | 2022 |
Investigating the effect of zinc supplementation on probability of relapse and mental health in patients with opioid use disorder undergoing methadone maintenance treatment.
Topics: Dietary Supplements; Humans; Iran; Mental Health; Methadone; Opiate Substitution Treatment; Opioid-R | 2023 |
Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
Topics: Bupropion; Cocaine; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Male; Methadone; | 2023 |
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone | 2023 |
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Topics: Analgesics, Opioid; Bayes Theorem; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cannabis | 2023 |
Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Cognition; Cues; Feasibility Studies; Humans; Metha | 2023 |
Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Topics: Adult; Analgesics, Opioid; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Quality o | 2023 |
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; | 2023 |
Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Methado | 2023 |
Clinics Optimizing MEthadone Take-homes for opioid use disorder (COMET): Protocol for a stepped-wedge randomized trial to facilitate clinic level changes.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opioid-Related Disorders; Randomized Controlled Tri | 2023 |
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Heroin; Humans; | 2023 |
Intraoperative Methadone in Next-day Discharge Outpatient Surgery: A Randomized, Double-blinded, Dose-finding Pilot Study.
Topics: Aftercare; Ambulatory Surgical Procedures; Analgesics, Opioid; Humans; Methadone; Opioid-Related Dis | 2023 |
Quality of life of patients treated with opium tincture or methadone: A randomized controlled trial.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Opium; Qua | 2023 |
Pragmatic, randomized, blinded trial to shorten pharmacologic treatment of newborns with neonatal opioid withdrawal syndrome (NOWS).
Topics: Analgesics, Opioid; Family; Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinenc | 2023 |
Effects of Roy's Adaptation Model on Quality of Life in People with Opioid Abuse under Methadone Maintenance Treatment: A Randomized Trial.
Topics: Humans; Methadone; Opioid-Related Disorders; Quality of Life | 2023 |
Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study.
Topics: Analgesics, Opioid; Dronabinol; Female; Humans; Male; Methadone; Opioid-Related Disorders; Pain | 2023 |
Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2023 |
Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
Topics: Adolescent; Adult; Affect; Analgesics, Opioid; Chronic Pain; Combined Modality Therapy; Craving; Eco | 2019 |
Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
Topics: Adolescent; Adult; Affect; Analgesics, Opioid; Chronic Pain; Combined Modality Therapy; Craving; Eco | 2019 |
Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
Topics: Adolescent; Adult; Affect; Analgesics, Opioid; Chronic Pain; Combined Modality Therapy; Craving; Eco | 2019 |
Mindfulness-Oriented Recovery Enhancement reduces opioid craving among individuals with opioid use disorder and chronic pain in medication assisted treatment: Ecological momentary assessments from a stage 1 randomized controlled trial.
Topics: Adolescent; Adult; Affect; Analgesics, Opioid; Chronic Pain; Combined Modality Therapy; Craving; Eco | 2019 |
A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Feasibility Studies; Female; Health Educatio | 2019 |
Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Cross-Over Studies; Double-Blind Method; Gabapentin; H | 2020 |
Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.
Topics: Adolescent; Adult; Aged; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Health | 2019 |
Sleep reductions associated with illicit opioid use and clinic-hour changes during opioid agonist treatment for opioid dependence: Measurement by electronic diary and actigraphy.
Topics: Actigraphy; Adult; Ambulatory Care Facilities; Appointments and Schedules; Buprenorphine; Cross-Over | 2019 |
Adjuvant laser meridian massage in men with opioid use disorder on methadone maintenance treatment: Protocol for a case-controlled study.
Topics: Acupuncture Points; Adult; Analgesics, Opioid; Case-Control Studies; Humans; Lasers; Male; Massage; | 2019 |
Effectiveness of a Psycho-Social Intervention Aimed at Reducing Attrition at Methadone Maintenance Treatment Clinics: A Propensity Score Matching Analysis.
Topics: China; Female; Humans; Male; Medication Adherence; Methadone; Middle Aged; Opiate Substitution Treat | 2019 |
Pain, psychological flexibility, and continued substance use in a predominantly hispanic adult sample receiving methadone treatment for opioid use disorder.
Topics: Adaptation, Psychological; Adolescent; Adult; Analgesics, Opioid; Chronic Pain; Cross-Sectional Stud | 2020 |
Methadone treatment of arrestees: A randomized clinical trial.
Topics: Adult; Analgesics, Opioid; Baltimore; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; O | 2020 |
Abstinence-contingent wage supplements to promote drug abstinence and employment: a randomised controlled trial.
Topics: Adult; Analgesics, Opioid; Baltimore; Cocaine-Related Disorders; Employment; Female; Humans; Male; M | 2020 |
Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial.
Topics: Adult; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Overdose; Equivalence Trials as Topi | 2020 |
Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment outcomes.
Topics: Adult; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Depression; Female; Galantamine; Hum | 2020 |
Impact of methadone treatment initiated in jail on subsequent arrest.
Topics: Adult; Analgesics, Opioid; Baltimore; Humans; Jails; Methadone; Opiate Substitution Treatment; Opioi | 2020 |
Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Methadone; Naltr | 2020 |
Neonatal Abstinence Syndrome Severity Index Predicts 18-Month Neurodevelopmental Outcome in Neonates Randomized to Morphine or Methadone.
Topics: Analgesics, Opioid; Cluster Analysis; Female; Humans; Infant; Infant, Newborn; Length of Stay; Male; | 2020 |
Cost and cost-effectiveness of interim methadone treatment and patient navigation initiated in jail.
Topics: Adult; Analgesics, Opioid; Cost-Benefit Analysis; Female; Humans; Jails; Male; Methadone; Middle Age | 2020 |
Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Combined Modality Therapy; Humans; Male; Methadone; Opioid | 2021 |
Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes.
Topics: Adult; Analgesics, Opioid; Baltimore; Cocaine-Related Disorders; Costs and Cost Analysis; Crime; Dru | 2021 |
HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment.
Topics: Adult; Baltimore; HIV Infections; Humans; Methadone; Opioid-Related Disorders; Risk-Taking | 2021 |
Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
Topics: Adult; Analgesics, Opioid; COVID-19; Female; Humans; Male; Medication Adherence; Methadone; Opiate S | 2021 |
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Topics: Adult; Animals; Benzazepines; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections | 2021 |
Add-on repetitive transcranial magnetic stimulation in patients with opioid use disorder undergoing methadone maintenance therapy.
Topics: Adult; China; Craving; Depressive Disorder, Major; Female; Heroin Dependence; Humans; Male; Methadon | 2021 |
HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Buprenorphine; CD4 Lymphocyte Count; | 2021 |
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.
Topics: Adult; Alleles; Cocaine; Cocaine-Related Disorders; Disulfiram; Female; Genotype; Humans; Male; Meth | 2021 |
Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatme | 2021 |
Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Follow-Up Studie | 2022 |
Precision dosing of methadone during pregnancy: A pharmacokinetics virtual clinical trials study.
Topics: Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy | 2021 |
A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Illicit Drugs; Methadone; Mindfulness; Opiate Substitution | 2021 |
Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.
Topics: Analgesics, Opioid; Drug Tolerance; Humans; Hydromorphone; Methadone; Opioid-Related Disorders | 2021 |
Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Topics: Analgesics, Opioid; Feasibility Studies; Humans; Methadone; Opiate Substitution Treatment; Opioid-Re | 2022 |
Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.
Topics: Adult; Buprenorphine; Continuity of Patient Care; Female; Hospitalization; Humans; Male; Methadone; | 2017 |
Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients.
Topics: Adult; Drug Tolerance; Female; Humans; Male; Methadone; Methadyl Acetate; Middle Aged; Opiate Substi | 2017 |
Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Clonidine; Craving; Double-Blind Metho | 2017 |
Clinical trial of the effects of vitamin D supplementation on psychological symptoms and metabolic profiles in maintenance methadone treatment patients.
Topics: Adult; Biomarkers; Dietary Supplements; Double-Blind Method; Humans; Methadone; Narcotics; Opioid-Re | 2017 |
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Buprenorphine; Buprenorphine, Naloxo | 2017 |
Rosa Damascena oil improved methadone-related sexual dysfunction in females with opioid use disorder under methadone maintenance therapy - results from a double-blind, randomized, and placebo-controlled trial.
Topics: Adult; Analgesics, Opioid; Double-Blind Method; Female; Gonadal Steroid Hormones; Happiness; Humans; | 2017 |
Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Female; Humans; Male; Methadone; Middle Aged; Nicotine; | 2018 |
Cognitive rehabilitation for individuals with opioid use disorder: A randomized controlled trial
Topics: Adult; Cognition; Cognitive Behavioral Therapy; Combined Modality Therapy; Follow-Up Studies; Humans | 2019 |
Comparison of Two Naloxone Regimens in Opioid-dependent Methadoneoverdosed Patients: A Clinical Trial Study.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Overdose; Female | 2017 |
Customized recommendations and reminder text messages for automated, computer-based treatment during methadone.
Topics: Adult; Analgesics, Opioid; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opiate S | 2017 |
Randomized Clinical Trial of Standard- Versus High-Calorie Formula for Methadone-Exposed Infants: A Feasibility Study.
Topics: Double-Blind Method; Energy Intake; Feasibility Studies; Female; Humans; Infant Formula; Infant, New | 2018 |
Methadone Dose Adjustments, Plasma R-Methadone Levels and Therapeutic Outcome of Heroin Users: A Randomized Clinical Trial.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Re | 2018 |
A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release.
Topics: Adult; Analgesics, Opioid; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Op | 2018 |
Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes.
Topics: Adult; Buprenorphine; Child Development; Child, Preschool; Cognition; Female; Humans; Infant, Newbor | 2018 |
Knowledge about nutrition, eating habits and weight reduction intervention among methadone maintenance treatment patients.
Topics: Adult; Feeding Behavior; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; Nut | 2018 |
Service providers' adherence to methadone maintenance treatment protocol in China.
Topics: Adult; China; Clinical Protocols; Female; Guideline Adherence; Humans; Male; Methadone; Middle Aged; | 2018 |
The effect of Housing First on adherence to methadone maintenance treatment.
Topics: Adult; Community Mental Health Services; Drug Overdose; Female; Housing; Humans; Ill-Housed Persons; | 2018 |
The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Topics: Adult; Analgesics, Opioid; Behavior Observation Techniques; Buprenorphine, Naloxone Drug Combination | 2018 |
Treatment initiation strategies for syringe exchange referrals to methadone maintenance: A randomized clinical trial.
Topics: Adult; Analgesics, Opioid; Counseling; Female; Humans; Male; Methadone; Motivation; Needle-Exchange | 2018 |
A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.
Topics: Adult; Antidepressive Agents; Anxiety; Craving; Depressive Disorder, Major; Desvenlafaxine Succinate | 2018 |
The Effectiveness of Group Spiritual Intervention on Self-esteem and Happiness Among Men Undergoing Methadone Maintenance Treatment.
Topics: Adult; Happiness; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opiate Substitution Tr | 2019 |
Positive reinforcement targeting abstinence in substance misuse (PRAISe): Study protocol for a Cluster RCT & process evaluation of contingency management.
Topics: Adult; Behavior Therapy; Buprenorphine; Cluster Analysis; Drug Misuse; Female; Heroin Dependence; Hu | 2018 |
The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.
Topics: Adult; Analgesics, Opioid; Antioxidants; Anxiety; Blood Glucose; C-Reactive Protein; Cholesterol, HD | 2019 |
The effectiveness of acupuncture on HPA functional in depressed patients under methadone maintenance treatment, a randomized double-blind sham-controlled trial.
Topics: Acupuncture Therapy; Adult; Depressive Disorder; Double-Blind Method; Female; Humans; Hydrocortisone | 2018 |
Relapse prevention: Using sound to reduce the probability of recidivism and suffering following detoxification.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Brain; Female; Florida; Humans; Male; Methadone; Mid | 2018 |
Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Polymorphism, Single | 2018 |
Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up S | 2018 |
Re-engineering methadone-Cost-effectiveness analysis of a patient-centered approach to methadone treatment.
Topics: Adult; Analgesics, Opioid; Choice Behavior; Cost-Benefit Analysis; Follow-Up Studies; Health Care Co | 2018 |
Barriers to progressing through a methadone maintenance treatment programme: perspectives of the clients in the Mid-West of Ireland's drug and alcohol services.
Topics: Adult; Adult Survivors of Child Abuse; Analgesics, Opioid; Attitude to Health; Benzodiazepines; Comp | 2018 |
An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Cognitive Behavioral Therapy; Combined Modality Therapy; Fe | 2019 |
Initiating methadone in jail and in the community: Patient differences and implications of methadone treatment for reducing arrests.
Topics: Adult; Baltimore; Community Health Services; Criminal Law; Female; Humans; Male; Methadone; Middle A | 2019 |
Transcranial Direct Current Stimulation on Opium Craving, Depression, and Anxiety: A Preliminary Study.
Topics: Adolescent; Adult; Anxiety; Combined Modality Therapy; Craving; Depression; Humans; Male; Methadone; | 2019 |
Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.
Topics: Adult; Clinical Protocols; Double-Blind Method; Female; Humans; Male; Methadone; Opiate Substitution | 2019 |
Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; California; Criminal Law; Femal | 2019 |
Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
Topics: Analgesics, Opioid; Antiviral Agents; Directly Observed Therapy; Drug Users; Female; Hepatitis C, Ch | 2019 |
Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants.
Topics: Adult; Anti-HIV Agents; Buprenorphine, Naloxone Drug Combination; Cross-Over Studies; Drug Interacti | 2019 |
Ginseng treatment improves the sexual side effects of methadone maintenance treatment.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatm | 2019 |
Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Asian People; Dose-Response Relationship, Drug; Drug Inter | 2019 |
Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.
Topics: Adult; Analgesics, Opioid; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combinatio | 2020 |
Methadone serum concentrations and influencing factors: A naturalistic observational study.
Topics: Adult; Aged; Analgesics, Opioid; Drug Interactions; Female; Humans; Male; Methadone; Middle Aged; No | 2019 |
Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Cholinesterase Inhibitors; Cocaine-Related Disorders; D | 2019 |
Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
Topics: Adult; Drug Prescriptions; Female; Humans; Male; Maryland; Methadone; Narcotic Antagonists; Opiate S | 2019 |
Stigma towards people who use drugs: A case vignette study in methadone maintenance treatment clinics in China.
Topics: Adult; Attitude of Health Personnel; China; Cross-Sectional Studies; Female; Health Personnel; Human | 2019 |
Retention in clinical trials after prison release: results from a clinical trial with incarcerated men with HIV and opioid dependence in Malaysia.
Topics: Adult; Behavior Therapy; Clinical Trials as Topic; HIV Infections; Humans; Malaysia; Male; Methadone | 2019 |
Clinical and metabolic responses to crocin in patients under methadone maintenance treatment: A randomized clinical trial.
Topics: Adult; Blood Glucose; Carotenoids; Dietary Supplements; Double-Blind Method; Female; Humans; Insulin | 2019 |
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Topics: Administration, Sublingual; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chronic Pain; D | 2013 |
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Topics: Administration, Sublingual; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chronic Pain; D | 2013 |
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Topics: Administration, Sublingual; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chronic Pain; D | 2013 |
A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Topics: Administration, Sublingual; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Chronic Pain; D | 2013 |
Retention in methadone and buprenorphine treatment among African Americans.
Topics: Adult; Black or African American; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; Opiat | 2013 |
Neurofeedback training for opiate addiction: improvement of mental health and craving.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Male; Mental Health; Methadone; Middle Aged; Motiv | 2013 |
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans.
Topics: Adult; Analgesics, Opioid; Black or African American; Buprenorphine; Buprenorphine, Naloxone Drug Co | 2013 |
Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation.
Topics: Adult; Ambulatory Care; Baltimore; Comorbidity; Delivery of Health Care, Integrated; Female; Humans; | 2013 |
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Heroin Dependence; Humans; M | 2013 |
Methadone maintenance treatment versus methadone maintenance treatment plus auricular acupuncture: impacts on patient satisfaction and coping mechanism.
Topics: Acupuncture, Ear; Adaptation, Psychological; Adult; Combined Modality Therapy; Humans; Longitudinal | 2013 |
Nonserious adverse events in randomized trials with opioid-dependent pregnant women: direct versus indirect measurement.
Topics: Analgesics, Opioid; Buprenorphine; Data Collection; Double-Blind Method; Female; Humans; Infant, New | 2012 |
Effectiveness of prize-based contingency management in a methadone maintenance program in China.
Topics: Adult; Behavior Therapy; China; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opio | 2013 |
A randomized controlled trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment.
Topics: Adult; Female; Health Behavior; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; | 2013 |
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.
Topics: Adult; Alcohol Deterrents; Alleles; Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase | 2013 |
Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Topics: Adult; Buprenorphine; Female; Georgia (Republic); Hepatitis C; HIV Infections; Humans; Male; Methado | 2013 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Fema | 2014 |
Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Medication Adherence; Methadone; Opiate Substitutio | 2014 |
Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.
Topics: Adolescent; Adult; Aged; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Integrase In | 2013 |
The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.
Topics: Adult; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, C | 2013 |
Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment.
Topics: Adult; Behavior Therapy; Community Health Services; Female; Follow-Up Studies; Humans; Internet; Mal | 2014 |
Attentional bias for nondrug reward is magnified in addiction.
Topics: Adult; Attention; Behavior, Addictive; Female; Humans; Impulsive Behavior; Male; Memory, Short-Term; | 2013 |
Abnormal brain activity during a reward and loss task in opiate-dependent patients receiving methadone maintenance therapy.
Topics: Adult; Analysis of Variance; Brain; Brain Mapping; Female; Humans; Image Processing, Computer-Assist | 2014 |
The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
Topics: Adolescent; Adult; Analgesics, Opioid; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination | 2014 |
Interim versus standard methadone treatment: a benefit-cost analysis.
Topics: Adult; Cost-Benefit Analysis; Counseling; Female; Health Care Costs; Humans; Male; Methadone; Middle | 2014 |
Regaining control: the patient experience of supervised compared with unsupervised consumption in opiate substitution treatment.
Topics: Attitude of Health Personnel; Buprenorphine; Directly Observed Therapy; Female; Focus Groups; Humans | 2014 |
Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial).
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; Predictive Valu | 2014 |
Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial.
Topics: Adult; Buprenorphine; Crime; Female; Humans; Maintenance Chemotherapy; Male; Medication Adherence; M | 2014 |
Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone.
Topics: Administration, Oral; Adult; Codeine; Cross-Over Studies; Delayed-Action Preparations; Female; Human | 2014 |
The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial.
Topics: Analgesics, Opioid; Baltimore; Cocaine-Related Disorders; Employment; Health Behavior; Hospitals, Te | 2014 |
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.
Topics: Adult; Buprenorphine; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Naloxone; Narcot | 2014 |
Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Drug Administra | 2014 |
Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics.
Topics: Adult; Benzazepines; Cross-Sectional Studies; Directly Observed Therapy; Female; Follow-Up Studies; | 2014 |
Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment.
Topics: Adult; Community Health Services; Female; Humans; Male; Mental Disorders; Methadone; Opiate Substitu | 2014 |
A pilot trial of a videogame-based exercise program for methadone maintained patients.
Topics: Adult; Exercise Therapy; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Rela | 2014 |
Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence.
Topics: Administration, Oral; Adult; Cross-Over Studies; Delayed-Action Preparations; Europe; Female; Humans | 2014 |
Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.
Topics: Adult; Birth Weight; Buprenorphine; Female; Humans; Infant, Newborn; Length of Stay; Methadone; Neon | 2014 |
A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Heroin; Humans; Hydromorphone; | 2014 |
Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users.
Topics: Adult; Behavior Therapy; Cocaine-Related Disorders; Combined Modality Therapy; Drug Users; Employmen | 2014 |
Changes in resting EEG following methadone treatment in opiate addicts.
Topics: Adult; Brain Waves; Controlled Before-After Studies; Electroencephalography; Female; Humans; Male; M | 2015 |
Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.
Topics: Adult; Cocaine-Related Disorders; Cognition Disorders; Diagnosis, Dual (Psychiatry); Double-Blind Me | 2015 |
Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville).
Topics: Adult; Female; France; Humans; Induction Chemotherapy; Male; Methadone; Opioid-Related Disorders; Pr | 2014 |
Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study.
Topics: Administration, Oral; Adult; Alcohol Drinking; Behavioral Symptoms; Cross-Over Studies; Delayed-Acti | 2015 |
Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Counseling; Drug Users; Female; Geor | 2015 |
Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder.
Topics: Adult; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Methadone; Middle Aged; | 2015 |
A placebo-controlled trial of dextromethorphan as an adjunct in opioid-dependent patients undergoing methadone maintenance treatment.
Topics: Adult; Analgesics, Opioid; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Dextromethorphan; | 2015 |
The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.
Topics: Adult; Alcohol Drinking; Female; Humans; Incidence; Infant, Newborn; Length of Stay; Methadone; Neon | 2016 |
Attentional bias and treatment adherence in substitute-prescribed opiate users.
Topics: Analysis of Variance; Attention; Buprenorphine; Craving; Female; Humans; Impulsive Behavior; Male; M | 2015 |
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Analgesics, Opioid; Anilides; Antiviral Agents; Buprenorph | 2015 |
Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial.
Topics: Analgesics, Opioid; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Dopamine Agents; Double-B | 2015 |
Quantitative EEG and Low-Resolution Electromagnetic Tomography (LORETA) Imaging of Patients Undergoing Methadone Treatment for Opiate Addiction.
Topics: Adult; Analgesics, Opioid; Brain Mapping; Diagnosis, Computer-Assisted; Electroencephalography; Fema | 2016 |
Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.
Topics: Adult; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle Aged; Opiate Substituti | 2015 |
Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial.
Topics: Adult; China; Cognitive Behavioral Therapy; Female; Heroin Dependence; Humans; Male; Methadone; Midd | 2015 |
A randomized controlled trial of the effects of working memory training in methadone maintenance patients.
Topics: Adult; Attention; Delay Discounting; Female; Humans; Learning; Male; Memory, Episodic; Memory, Short | 2015 |
A randomized controlled trial of the effects of working memory training in methadone maintenance patients.
Topics: Adult; Attention; Delay Discounting; Female; Humans; Learning; Male; Memory, Episodic; Memory, Short | 2015 |
A randomized controlled trial of the effects of working memory training in methadone maintenance patients.
Topics: Adult; Attention; Delay Discounting; Female; Humans; Learning; Male; Memory, Episodic; Memory, Short | 2015 |
A randomized controlled trial of the effects of working memory training in methadone maintenance patients.
Topics: Adult; Attention; Delay Discounting; Female; Humans; Learning; Male; Memory, Episodic; Memory, Short | 2015 |
Predictors of outcome from computer-based treatment for substance use disorders: Results from a randomized clinical trial.
Topics: Adult; Analgesics, Opioid; Attitude to Health; Employment; Female; Humans; Male; Methadone; Middle A | 2015 |
Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up S | 2016 |
A Spiking Neural Network Methodology and System for Learning and Comparative Analysis of EEG Data From Healthy Versus Addiction Treated Versus Addiction Not Treated Subjects.
Topics: Adult; Brain; Cognition; Diagnosis, Computer-Assisted; Electroencephalography; Female; Humans; Machi | 2016 |
Can persons with a history of multiple addiction treatment episodes benefit from technology delivered behavior therapy? A moderating role of treatment history at baseline.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Biomedical Technology; Cocaine-Related Disorders; Couns | 2016 |
Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics.
Topics: Adult; Analgesics, Opioid; Double-Blind Method; Drug Substitution; Female; Headache; Humans; Ibogain | 2016 |
Design considerations for a pilot trial using a novel approach for evaluating smoking-cessation medication in methadone-maintained smokers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Clinical Protocols; Cross-Over Studi | 2016 |
Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Cocaine-Related Disorders; C | 2016 |
Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Cocaine-Related Disorders; C | 2016 |
Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Cocaine-Related Disorders; C | 2016 |
Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study).
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Cocaine-Related Disorders; C | 2016 |
Extended-release naltrexone opioid treatment at jail reentry (XOR).
Topics: Analgesics, Opioid; Cause of Death; Delayed-Action Preparations; Drug Overdose; Humans; Injections, | 2016 |
The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Topics: Analgesics, Opioid; Cooperative Behavior; Criminal Law; Delayed-Action Preparations; Humans; Injecti | 2016 |
Effects of attention control training on drug abusers' attentional bias and treatment outcome.
Topics: Adult; Arousal; Attention; Attentional Bias; Behavior Therapy; Female; Humans; Iran; Male; Methadone | 2016 |
Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial.
Topics: Analgesics, Opioid; Community Health Services; Cost-Benefit Analysis; Costs and Cost Analysis; Femal | 2016 |
Psychometric assessment of the Neonatal Abstinence Scoring System and the MOTHER NAS Scale.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Absti | 2016 |
Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study.
Topics: Aged; Ambulatory Care Facilities; Cancer Pain; Dose-Response Relationship, Drug; Female; Humans; Mal | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzofurans; Buprenorphine; Buprenorphine, Naloxone Drug | 2016 |
Feasibility of alcohol screening among patients receiving opioid treatment in primary care.
Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Controlled Before-After Studies; Fea | 2016 |
Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; | 2016 |
Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combinati | 2017 |
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Combined Modality | 2016 |
Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: A national contingency management approach trial.
Topics: Adult; Age of Onset; Alcohol Drinking; Birth Weight; Buprenorphine; Cigarette Smoking; Female; Human | 2017 |
Individual Placement and Support (IPS) for Methadone Maintenance Therapy Patients: A Pilot Randomized Controlled Trial.
Topics: Adult; Employment, Supported; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Trea | 2017 |
Factors related to client satisfaction with methadone maintenance treatment in China.
Topics: Adult; Age Factors; China; Counseling; Cross-Sectional Studies; Depression; Female; Humans; Male; Me | 2017 |
Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes.
Topics: Adult; Buprenorphine; Cocaine; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Maternal | 2008 |
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.
Topics: Adult; Analgesics, Opioid; Community Mental Health Services; Disruptive, Impulse Control, and Conduc | 2009 |
Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cognition Disorders; Dose-Response Relationship, Drug; Fem | 2008 |
Personality factors associated with methadone maintenance dose.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle | 2008 |
Developing therapies for depression in drug dependence: results of a stage 1 therapy study.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry | 2008 |
Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Buprenorphine; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; HIV | 2009 |
Auricular acupuncture as an adjunct to opiate detoxification treatment: effects on withdrawal symptoms.
Topics: Acupuncture, Ear; Adult; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Patie | 2009 |
Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial.
Topics: Analgesics, Opioid; Attention; Buprenorphine; Cognition; Humans; Memory; Methadone; Neuropsychologic | 2008 |
Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV.
Topics: Adult; Anti-Retroviral Agents; Delivery of Health Care; Drug Costs; Female; Follow-Up Studies; HIV I | 2009 |
Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers.
Topics: Adolescent; Adult; Baltimore; Cocaine-Related Disorders; Female; Humans; Illicit Drugs; Leisure Acti | 2008 |
Maternal methadone dosing schedule and fetal neurobehaviour.
Topics: Adult; Behavior; Cognition; Drug Administration Schedule; Female; Fetal Monitoring; Fetal Movement; | 2009 |
A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.
Topics: Adult; Analgesics, Opioid; Europe; Female; Humans; Male; Methadone; Methadyl Acetate; Middle Aged; O | 2009 |
A randomized effectiveness trial of methadone, TENS and methadone plus TENS in management of opiate withdrawal symptoms.
Topics: Analgesics, Opioid; Analysis of Variance; Combined Modality Therapy; Humans; Male; Methadone; Opioid | 2008 |
Voucher-based contingent reinforcement of smoking abstinence among methadone-maintained patients: a pilot study.
Topics: Adult; Cocaine-Related Disorders; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male | 2008 |
Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Behavior Therapy; Black or African American; Cocain | 2009 |
Intensity of opiate withdrawal in relation to the 825C>T polymorphism of the G-protein beta 3 subunit gene.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Clonidine; | 2009 |
Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Drug Interactions; Drug Therapy, Combinat | 2009 |
Electrocardiographic effects of lofexidine and methadone coadministration: secondary findings from a safety study.
Topics: Adult; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Fema | 2009 |
Methadone-nicotine interactions in methadone maintenance treatment patients.
Topics: Adult; Double-Blind Method; Drug Interactions; Female; Humans; Male; Methadone; Middle Aged; Narcoti | 2009 |
Home polysomnography in methadone maintenance patients with subjective sleep complaints.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; P | 2009 |
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification.
Topics: Buprenorphine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Prisoners; Prisons; Research | 2009 |
A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Methadone; Morphine; | 2009 |
An integrated drug counseling and employment intervention for methadone clients.
Topics: Adult; Counseling; Employment; Female; Humans; Male; Methadone; Opioid-Related Disorders; Risk-Takin | 2009 |
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
Topics: Adolescent; Adult; Cocaine-Related Disorders; Double-Blind Method; Enzyme-Linked Immunosorbent Assay | 2009 |
Gabapentin improves cold-pressor pain responses in methadone-maintained patients.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cold Temperature; Cyclohexanecarboxylic Acids; Double-Blind | 2010 |
Effect of raltegravir on the pharmacokinetics of methadone.
Topics: Adolescent; Adult; Cross-Over Studies; Drug Interactions; Female; HIV Integrase Inhibitors; Humans; | 2010 |
Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples.
Topics: Adult; Cocaine-Related Disorders; Female; Health Behavior; Humans; Methadone; Narcotics; Opioid-Rela | 2009 |
Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
Topics: Adult; Double-Blind Method; Follow-Up Studies; Heroin; Heroin Dependence; Humans; Hydromorphone; Inj | 2010 |
Is heroin-assisted treatment effective for patients with no previous maintenance treatment? Results from a German randomised controlled trial.
Topics: Adult; Female; Germany; Heroin; Humans; Male; Medication Adherence; Methadone; Narcotics; Opioid-Rel | 2010 |
Naltrexone implants compared to methadone: outcomes six months after prison release.
Topics: Adult; Crime; Drug Implants; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; | 2010 |
Nocturnal sleep architecture disturbances in early methadone treatment patients.
Topics: Adult; Body Mass Index; Case-Control Studies; Humans; Linear Models; Male; Methadone; Narcotics; Opi | 2010 |
Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women.
Topics: Administration, Oral; Adult; Female; Health Status; Heroin; Humans; Injections; Male; Methadone; Mid | 2010 |
Contingency management for cocaine use in methadone maintenance patients: when does abstinence happen?
Topics: Adult; Analysis of Variance; Behavior Therapy; Chi-Square Distribution; Cocaine-Related Disorders; F | 2010 |
Discrepancies in perceptions of maternal aggression: implications for children of methadone-maintained mothers.
Topics: Adolescent; Aggression; Child; Child Behavior Disorders; Child, Preschool; Depression; Female; Human | 2010 |
Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial.
Topics: Anti-Anxiety Agents; Benzodiazepines; Drug Prescriptions; Female; Germany; Heroin; Heroin Dependence | 2010 |
Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence.
Topics: Adult; Aged; Aged, 80 and over; Case Management; Counseling; Education; Female; Heroin; Heroin Depen | 2010 |
The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment.
Topics: Adult; Buprenorphine; Choice Behavior; England; Female; Humans; Male; Methadone; Opiate Substitution | 2010 |
QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Topics: Adult; Death, Sudden; Death, Sudden, Cardiac; Female; France; Heart Diseases; Humans; Long QT Syndro | 2011 |
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.
Topics: Adult; Alcohol Drinking; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Disulfira | 2011 |
Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial.
Topics: Antiretroviral Therapy, Highly Active; Directly Observed Therapy; Female; HIV Infections; Humans; Ma | 2011 |
Outpatient versus inpatient opioid detoxification: a randomized controlled trial.
Topics: Analgesics, Opioid; Clonidine; Female; Heroin; Heroin Dependence; Humans; Inpatients; Male; Methadon | 2011 |
Quality of life profiles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence.
Topics: Adult; Depressive Disorder, Major; Female; Health Status; Heroin; Humans; Male; Methadone; Opiate Su | 2011 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Neonatal abstinence syndrome after methadone or buprenorphine exposure.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Head; History, Ancient; Humans; Infant, Newborn; | 2010 |
Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance.
Topics: Analgesics, Opioid; Comorbidity; Crime; Drug Administration Schedule; Female; Heroin; Heroin Depende | 2011 |
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.
Topics: Adult; China; Counseling; Female; Heroin Dependence; HIV Infections; HIV Seropositivity; Humans; Mal | 2011 |
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.
Topics: Adult; China; Counseling; Female; Heroin Dependence; HIV Infections; HIV Seropositivity; Humans; Mal | 2011 |
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.
Topics: Adult; China; Counseling; Female; Heroin Dependence; HIV Infections; HIV Seropositivity; Humans; Mal | 2011 |
Behavioral drug and HIV risk reduction counseling (BDRC) in MMT programs in Wuhan, China: a pilot randomized clinical trial.
Topics: Adult; China; Counseling; Female; Heroin Dependence; HIV Infections; HIV Seropositivity; Humans; Mal | 2011 |
(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Female; Fetal Blood; Humans; Infant | 2010 |
Comparison of antiretroviral adherence questions.
Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Male; Medication Adherence; Methadone; Middle A | 2012 |
Comparison of antiretroviral adherence questions.
Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Male; Medication Adherence; Methadone; Middle A | 2012 |
Comparison of antiretroviral adherence questions.
Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Male; Medication Adherence; Methadone; Middle A | 2012 |
Comparison of antiretroviral adherence questions.
Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Male; Medication Adherence; Methadone; Middle A | 2012 |
Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships.
Topics: Family Relations; Female; Follow-Up Studies; Health Status; Humans; Male; Mental Disorders; Methadon | 2011 |
Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.
Topics: Analgesics, Opioid; Apgar Score; Birth Weight; Body Size; Cephalometry; Cocaine; Female; Gestational | 2011 |
A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.
Topics: Adult; Cocaine-Related Disorders; Double-Blind Method; Female; Fluoxetine; Humans; Male; Methadone; | 2011 |
The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
Topics: Ambulatory Care; Buprenorphine; Buprenorphine, Naloxone Drug Combination; HIV Infections; Humans; Me | 2011 |
Treating the partners of opioid-dependent pregnant patients: feasibility and efficacy.
Topics: Adult; Counseling; Feasibility Studies; Female; Humans; Interpersonal Relations; Interview, Psycholo | 2011 |
Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.
Topics: Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Double-Blind Method; Female; Humans; Infant, | 2011 |
Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Body Mass Index; Echocardiography; Electrocardiogra | 2011 |
Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methadone; Na | 2011 |
Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.
Topics: Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Female; Heroin; Heroin Dependence; Humans; I | 2011 |
Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Female; Humans; | 2011 |
Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
Topics: Adult; Analgesics, Opioid; Canada; Dose-Response Relationship, Drug; Female; Heroin; Humans; Injecti | 2011 |
Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China.
Topics: Adult; Analysis of Variance; China; Female; HIV Infections; Humans; Male; Methadone; Narcotic Antago | 2011 |
Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women.
Topics: Adult; Austria; Birth Weight; Buprenorphine; Double-Blind Method; Female; Gestational Age; Humans; I | 2011 |
Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine; Drug Therapy, Combination; Educational Status; Fe | 2011 |
Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cognition; Female; Follow-Up Studies; Humans; Male; Methad | 2011 |
Importance of gabapentin dose in treatment of opioid withdrawal.
Topics: Adult; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2011 |
Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?
Topics: Birth Weight; Buprenorphine; Double-Blind Method; Female; Humans; Infant, Newborn; Male; Methadone; | 2011 |
Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Buprenorphine; Humans; Methadone; Mid | 2011 |
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Disease Management; Dose-Respons | 2012 |
Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepacivirus; Hepatitis C; Humans; Interf | 2012 |
A randomized trial of methadone initiation prior to release from incarceration.
Topics: Adult; Analgesics, Opioid; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Op | 2012 |
Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics.
Topics: Adolescent; Adult; Buprenorphine; Double-Blind Method; Europe; Female; Humans; Infant, Newborn; Meth | 2012 |
A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.
Topics: Adult; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Long QT Syndrome; Male | 2012 |
Peripartum pain management in opioid dependent women.
Topics: Adult; Analgesics; Buprenorphine; Cesarean Section; Delivery, Obstetric; Dose-Response Relationship, | 2012 |
A stage I pilot study of acceptance and commitment therapy for methadone detoxification.
Topics: Adult; Counseling; Diagnostic and Statistical Manual of Mental Disorders; Fear; Female; Humans; Inac | 2012 |
Psychiatric comorbidity of patients on methadone maintenance treatment with a history of sexual abuse.
Topics: Adult; Comorbidity; Female; Humans; Maintenance Chemotherapy; Male; Mental Disorders; Methadone; Mid | 2012 |
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Follow-Up Studies; Health Po | 2013 |
Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial.
Topics: Follow-Up Studies; France; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorder | 2012 |
An intervention targeting service providers and clients for methadone maintenance treatment in China: a cluster-randomized trial.
Topics: Adult; Ambulatory Care Facilities; China; Cluster Analysis; Female; Follow-Up Studies; Health Knowle | 2013 |
Prescription medication exchange patterns among methadone maintenance patients.
Topics: Adult; Cohort Studies; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; | 2013 |
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.
Topics: Adult; Cocaine-Related Disorders; Disulfiram; Dopamine beta-Hydroxylase; Drug Therapy, Combination; | 2013 |
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.
Topics: Adolescent; Adult; Buprenorphine; Chemical and Drug Induced Liver Injury; Drug Combinations; Female; | 2013 |
Epidemiology of pain among outpatients in methadone maintenance treatment programs.
Topics: Adult; Comorbidity; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opi | 2013 |
Directly administered antiretroviral therapy: pilot study of a structural intervention in methadone maintenance.
Topics: Adult; Anti-HIV Agents; Delivery of Health Care, Integrated; Directly Observed Therapy; Feasibility | 2012 |
Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses.
Topics: Adolescent; Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Sy | 2012 |
Fetal assessment before and after dosing with buprenorphine or methadone.
Topics: Adolescent; Adult; Analgesics, Opioid; Biophysical Phenomena; Buprenorphine; Double-Blind Method; Fe | 2012 |
Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
Topics: Adolescent; Adult; Analgesics, Opioid; Birth Weight; Buprenorphine; Dose-Response Relationship, Drug | 2012 |
Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Double-Blind Method; Female; Humans; | 2012 |
Neonatal neurobehavior effects following buprenorphine versus methadone exposure.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant Behavior; Infant, Newbo | 2012 |
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.
Topics: Adolescent; Adult; Analgesics, Opioid; Anxiety; Buprenorphine; Comorbidity; Depression; Double-Blind | 2012 |
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.
Topics: Adolescent; Adult; Analgesics, Opioid; Anxiety; Buprenorphine; Comorbidity; Depression; Double-Blind | 2012 |
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.
Topics: Adolescent; Adult; Analgesics, Opioid; Anxiety; Buprenorphine; Comorbidity; Depression; Double-Blind | 2012 |
Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes.
Topics: Adolescent; Adult; Analgesics, Opioid; Anxiety; Buprenorphine; Comorbidity; Depression; Double-Blind | 2012 |
Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine.
Topics: Adolescent; Adult; Analgesics, Opioid; Analysis of Variance; Buprenorphine; Communicable Diseases; F | 2012 |
Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Female; gamma-Glutamyltransferase; Hepatitis C | 2012 |
Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women.
Topics: Adolescent; Adult; Buprenorphine; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Infa | 2013 |
A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine.
Topics: Adolescent; Adult; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-R | 2013 |
[Replacement therapy as a method to promote social and professional re-adaptation].
Topics: Adult; Analgesics, Opioid; Crime; Employment; Female; Humans; Male; Methadone; Opiate Substitution T | 2013 |
Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cross-Over Studies; Dietary Sucrose; Doubl | 2013 |
The Recovery Line: A pilot trial of automated, telephone-based treatment for continued drug use in methadone maintenance.
Topics: Adaptation, Psychological; Adult; Automation; Cocaine-Related Disorders; Feasibility Studies; Female | 2013 |
A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence.
Topics: Adult; Behavior Therapy; Cocaine; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Female; H | 2002 |
Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
Topics: Adult; Anticonvulsants; Buprenorphine; Carbamazepine; Double-Blind Method; Drug Administration Sched | 2002 |
Ultrarapid high-dose methadone detoxification.
Topics: Adult; Dose-Response Relationship, Drug; Humans; Inactivation, Metabolic; Intubation, Intratracheal; | 2003 |
A novel cognitive-behavioral approach for treatment-resistant drug dependence.
Topics: Adult; Cognitive Behavioral Therapy; Female; Humans; Illicit Drugs; Male; Methadone; Opioid-Related | 2002 |
Sensitivity to acute methadone dose changes in maintenance patients.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Narcotics; Opioid-Related | 2002 |
Neuropsychological correlates of opioid dependence and withdrawal.
Topics: Adolescent; Adult; Cognition Disorders; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Neu | 2003 |
Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.
Topics: Adult; Buprenorphine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Metha | 2003 |
Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Baltimore; Behavior Therapy; Cocaine-Related Disord | 2003 |
A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients.
Topics: Adult; Aspartic Acid; Cocaine-Related Disorders; Drug Administration Schedule; Female; Humans; Illic | 2003 |
Use of very low-dose naltrexone during opiate detoxification.
Topics: Adult; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltr | 2003 |
Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Heroin; Humans; Iran; M | 2003 |
Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Buprenorphine; Cocaine-Related Disorder | 1999 |
Do noncontingent vouchers increase drug use?
Topics: Adult; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; | 2003 |
Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Delayed-Action Preparations; Fema | 2003 |
The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving.
Topics: Adult; Automobile Driving; Buprenorphine; Drug Combinations; Ethanol; Female; Humans; Male; Methadon | 2003 |
Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
Topics: Adult; Ambulatory Care; Biological Availability; Combined Modality Therapy; Comorbidity; Delayed-Act | 2003 |
Improving on-time counseling attendance in a methadone treatment program: a contingency management approach.
Topics: Adult; Aged; Analgesics, Opioid; Analysis of Variance; Counseling; Female; Follow-Up Studies; Humans | 2003 |
Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Cocaine-Related Disorders; Connecticut; Cost-Benefit Analysis; Disulfiram | 2004 |
The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: an open-label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone [ISRCT
Topics: Adolescent; Adult; Buprenorphine; Codeine; England; Follow-Up Studies; Health Services Research; Her | 2004 |
Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification.
Topics: Adult; Cost-Benefit Analysis; Female; Humans; Inactivation, Metabolic; Male; Methadone; Narcotics; O | 2004 |
Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure.
Topics: Adult; Analysis of Variance; Blood Pressure; Dextromethorphan; Discrimination Learning; Dose-Respons | 2004 |
Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Stereoisom | 2004 |
Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.
Topics: Adult; Analysis of Variance; Buprenorphine; Female; Heroin Dependence; Humans; Male; Methadone; Opio | 2004 |
Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence.
Topics: Adult; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Male; Methadone; Middle Aged | 2004 |
Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Female; Humans; Male; Methadone; Methadyl Acetate; | 2004 |
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Confidence Intervals; Drug Administration Sche | 2004 |
Motivational enhancement therapy for nicotine dependence in methadone-maintained pregnant women.
Topics: Adolescent; Adult; Analysis of Variance; Female; Humans; Linear Models; Methadone; Motivation; Opioi | 2004 |
Behavioral contingencies improve counseling attendance in an adaptive treatment model.
Topics: Adult; Alcoholism; Ambulatory Care; Baltimore; Behavior Therapy; Cocaine-Related Disorders; Comorbid | 2004 |
Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre.
Topics: Administration, Oral; Adult; Humans; Methadone; Middle Aged; Morphine; Narcotics; Opioid-Related Dis | 2004 |
[Buprenorphine or methadone for detoxification of young opioid addicts?].
Topics: Adolescent; Adult; Buprenorphine; Female; Germany; Humans; Male; Methadone; Narcotics; Opioid-Relate | 2004 |
Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence.
Topics: Adult; Buprenorphine; Depression; Female; Humans; Male; Methadone; Narcotic Antagonists; Narcotics; | 2004 |
Efficacy of the customized employment supports (CES) model of vocational rehabilitation for unemployed methadone patients: preliminary results.
Topics: Adult; Counseling; Employment; Female; Humans; Male; Methadone; Middle Aged; Models, Theoretical; Na | 2004 |
Learning from disappointing outcomes: an evaluation of prevocational interventions for methadone maintenance patients.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Problem So | 2004 |
[Buprenorphine and methadone to opiate addicts--a randomized trial].
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Surveys | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Cocaine-Related Disorders; Combined Moda | 2005 |
Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Humans; Methadone; Morphine; Opioid-Related Disor | 2005 |
The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Methadone; Narcotics; Opioid-R | 2005 |
Driving capacity of patients treated with methadone and slow-release oral morphine.
Topics: Adult; Analgesics, Opioid; Austria; Automobile Driving; Humans; Methadone; Morphine; Opioid-Related | 2005 |
Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy.
Topics: Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; M | 2005 |
Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
Topics: Adult; Algorithms; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Attention Deficit D | 2006 |
Group psychotherapy for opiate addicts in methadone maintenance treatment--a controlled trial.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans; Male; Methadone; Nar | 2005 |
Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial.
Topics: Adult; Aging; Attention; Automobile Driving; Buprenorphine; Cognition; Female; Humans; Male; Memory, | 2005 |
Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Heroin Dependence; | 2005 |
Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
Topics: Adult; Anticonvulsants; Buprenorphine; Carbamazepine; Diagnostic and Statistical Manual of Mental Di | 2005 |
Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
Topics: Administration, Oral; Administration, Sublingual; Adolescent; Adult; Buprenorphine; Dose-Response Re | 2005 |
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Topics: Adult; Alleles; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochro | 2005 |
Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial.
Topics: Adult; Baltimore; Behavior Therapy; Case Management; Community Mental Health Services; Female; Healt | 2006 |
Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Meth | 2005 |
Prize-based contingency management does not increase gambling.
Topics: Adult; Alcoholism; Ambulatory Care; Amphetamine-Related Disorders; Central Nervous System Stimulants | 2006 |
Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
Topics: Adult; Austria; Buprenorphine; Delayed-Action Preparations; Female; Humans; Male; Methadone; Morphin | 2006 |
Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations.
Topics: Adult; Analgesics; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blind Method; Drug R | 2006 |
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.
Topics: Administration, Inhalation; Adult; Analgesics, Opioid; Blood Pressure; Double-Blind Method; Heart Ra | 2006 |
Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study.
Topics: Buprenorphine; Double-Blind Method; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence | 2006 |
Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
Topics: Adult; Alcohol-Related Disorders; Analgesics, Opioid; Behavior Therapy; Central Nervous System Stimu | 2006 |
A smoking cessation intervention for the methadone-maintained.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; Methadone; Middle Aged; Nicotine; Opioid-Rel | 2006 |
Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Behavior Therapy; Black or African American; Cocain | 2007 |
HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone.
Topics: Adult; Buprenorphine; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Hum | 2006 |
Controlled trial of prescribed heroin in the treatment of opioid addiction.
Topics: Adult; Counseling; Drug Administration Schedule; Drug Prescriptions; Female; Health Status; Hepatiti | 2006 |
Management of neonatal abstinence syndrome in neonates born to opioid maintained women.
Topics: Adult; Apgar Score; Female; Gestational Age; Humans; Infant, Newborn; Male; Methadone; Morphine; Neo | 2007 |
In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analgesics, Opioid; Clonidine; Cohort Studies; Double- | 2007 |
Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Topics: Adult; Antifungal Agents; Area Under Curve; Back Pain; Dose-Response Relationship, Drug; Double-Blin | 2007 |
A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model.
Topics: Adult; Alcoholism; Baltimore; Counseling; Female; Follow-Up Studies; Heroin Dependence; Humans; Illi | 2006 |
Addressing the efficacy of dihydrocodeine versus methadone as an alternative maintenance treatment for opiate dependence: A randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Codeine; Female; Follow-Up Studies; Hum | 2006 |
Linking opioid-dependent hospital patients to drug treatment: Health care use and costs 6 months after randomization.
Topics: Adolescent; Adult; Aged; Case Management; Emergency Medical Services; Female; Health Care Costs; Hos | 2006 |
Comparing adaptive stepped care and monetary-based voucher interventions for opioid dependence.
Topics: Adaptation, Psychological; Adult; Behavior Therapy; Counseling; Demography; Drug Administration Sche | 2007 |
Composition of EEG oscillations and their temporal characteristics: methadone treatment.
Topics: Adult; Brain; Cortical Synchronization; Electroencephalography; Female; Humans; Male; Methadone; Nar | 2007 |
A new gender-based model for women's recovery from substance abuse: results of a pilot outcome study.
Topics: Adult; Convalescence; Demography; Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pa | 2007 |
Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Buprenorphine; Diazepam; Female; Humans; Male; Methadon | 2007 |
Relationship of depression to smoking outcomes in a methadone-maintained population.
Topics: Administration, Cutaneous; Adolescent; Adult; Depressive Disorder, Major; Diagnostic and Statistical | 2007 |
A stepped care approach for reducing cannabis use in opioid-dependent outpatients.
Topics: Adult; Analgesics, Opioid; Behavior Control; Cognitive Behavioral Therapy; Counseling; Female; Human | 2007 |
Reducing potential for child abuse among methadone-maintained parents: results from a randomized controlled trial.
Topics: Adult; Child; Child Abuse; Child, Preschool; Family Therapy; Female; Humans; Linear Models; Male; Me | 2007 |
Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2007 |
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
Topics: Administration, Sublingual; Adult; Buprenorphine; Cognition Disorders; Double-Blind Method; Drug Com | 2007 |
The effect of opioids on sleep architecture.
Topics: Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Admini | 2007 |
The effect of opioids on sleep architecture.
Topics: Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Admini | 2007 |
The effect of opioids on sleep architecture.
Topics: Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Admini | 2007 |
The effect of opioids on sleep architecture.
Topics: Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Admini | 2007 |
Influence of peak and trough levels of opioid maintenance therapy on driving aptitude.
Topics: Adult; Attention; Austria; Automobile Driving; Buprenorphine; Decision Making; Female; Humans; Male; | 2007 |
A behavioral treatment for opioid-dependent patients with antisocial personality.
Topics: Adult; Antisocial Personality Disorder; Cognitive Behavioral Therapy; Demography; Female; Humans; Ma | 2008 |
Heroin-assisted treatment for opioid dependence: randomised controlled trial.
Topics: Adult; Algorithms; Female; Heroin; Humans; Injections, Intravenous; Logistic Models; Male; Methadone | 2007 |
Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.
Topics: Adult; Buprenorphine; Cross-Over Studies; Diazepam; Double-Blind Method; Drug Interactions; Drug The | 2007 |
Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates.
Topics: Adult; Apgar Score; Arrhythmia, Sinus; Electrocardiography; Female; Heart; Humans; Infant, Newborn; | 2007 |
Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study.
Topics: Administration, Oral; Adult; Antiviral Agents; Buprenorphine; Comorbidity; Drug Therapy, Combination | 2007 |
Exposure to opioid maintenance treatment reduces long-term mortality.
Topics: Adolescent; Adult; Australia; Buprenorphine; Cause of Death; Double-Blind Method; Female; Follow-Up | 2008 |
Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.
Topics: Adult; Analysis of Variance; Buprenorphine; Chi-Square Distribution; Double-Blind Method; Female; Hu | 2008 |
Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Cold Temperature; Drug Interactions; Drug Tolerance; Humans; Infusions, I | 2008 |
Quality of life in patients receiving opioid maintenance therapy. A comparative study of slow-release morphine versus methadone treatment.
Topics: Adult; Analgesics, Opioid; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Fem | 2008 |
Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: follow-up of a randomised trial.
Topics: Adult; Australia; Buprenorphine; Directly Observed Therapy; Drug Administration Schedule; Drug Combi | 2008 |
Clonidine versus methadone for opiate detoxification.
Topics: Clinical Trials as Topic; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Opioid- | 1980 |
Propoxyphene form maintenance treatment of narcotic addiction.
Topics: Adult; Dextropropoxyphene; Humans; Methadone; Middle Aged; Opioid-Related Disorders; Substance Withd | 1981 |
Propoxyphene napsylate compared to methadone for opiate dependence.
Topics: Adult; Dextropropoxyphene; Electrocardiography; Electroencephalography; Humans; Male; Methadone; Opi | 1981 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; | 1980 |
Clinical utility of clonidine in opiate withdrawal: a study of 100 patients.
Topics: Blood Pressure; Clinical Trials as Topic; Clonidine; Humans; Methadone; Naloxone; Norepinephrine; Op | 1981 |
Failure of mean red cell volume to serve as a biologic marker for alcoholism in narcotic dependence. A randomized control trial.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Erythrocyte Volume; Erythrocytes, Abnormal; | 1983 |
Short-term interpersonal psychotherapy in methadone-maintained opiate addicts.
Topics: Adult; Antisocial Personality Disorder; Anxiety Disorders; Clinical Trials as Topic; Depressive Diso | 1983 |
Imipramine as treatment for depression in addicts.
Topics: Adult; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramin | 1983 |
Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Disulfiram; Double-Blind Method; Drug | 1983 |
Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects.
Topics: Adult; Ambulatory Care; Antihypertensive Agents; Clinical Trials as Topic; Clonidine; Humans; Male; | 1983 |
Methadone dose decreases and anxiety reduction.
Topics: Adult; Anxiety; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Methadone; Opioi | 1984 |
Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: the Veterans Administration-Penn study.
Topics: Adolescent; Adult; Ambulatory Care; Counseling; Humans; Male; Mental Disorders; Methadone; Middle Ag | 1984 |
Chronic opiate use during methadone detoxification: effects of a dose increase treatment.
Topics: Adult; Dose-Response Relationship, Drug; Humans; Male; Methadone; Narcotics; Opioid-Related Disorder | 1984 |
Is there a need for "professional psychotherapy" in methadone programs?
Topics: Adult; Combined Modality Therapy; Counseling; Female; Humans; Male; Methadone; Opioid-Related Disord | 1984 |
Insomnia among addicts during supervised withdrawal from opiates: a comparison of oral methadone and electrostimulation.
Topics: Adult; Arousal; Electric Stimulation Therapy; Female; Humans; Male; Methadone; Opioid-Related Disord | 1984 |
Treatment outcome in methadone detoxification: relationship to initial levels of illicit opiate use.
Topics: Adult; Ambulatory Care; Educational Status; Employment; Ethnicity; Humans; Illicit Drugs; Male; Meth | 1983 |
Drug-seeking behavior and its mediation: effects of aversion therapy with narcotic addicts on methadone.
Topics: Adult; Aversive Therapy; Behavior; Electroshock; Humans; Male; Methadone; Opioid-Related Disorders; | 1983 |
Contingency management interventions: effects on treatment outcome during methadone detoxification.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Humans; Methadone; Opioid-Related Disorders; Pro | 1984 |
The effect of alcoholism in methadone-maintained persons on productive activity: a randomized control trial.
Topics: Alcohol Drinking; Alcoholism; Behavior Therapy; Crime; Humans; Methadone; Opioid-Related Disorders; | 1982 |
The ability of a Self-Administered Alcohol Screening Test (mSAAST) to detect future excessive alcohol consumption in persons on methadone maintenance.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Female; Humans; Male; Methadone; Middle Aged; | 1982 |
Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study.
Topics: Adult; Clinical Trials as Topic; Humans; Male; Methadone; Methadyl Acetate; Opioid-Related Disorders | 1982 |
[Withdrawal of drug addicts from opiates using Limoge-type electrotherapy. Evaluation of 400 treatments].
Topics: Adolescent; Adult; Clinical Trials as Topic; Clonidine; Double-Blind Method; Electric Stimulation Th | 1982 |
Administration of meptazinol to opiate-dependent patients.
Topics: Adolescent; Adult; Azepines; Double-Blind Method; Female; Humans; Male; Meptazinol; Methadone; Opioi | 1983 |
Psychotherapy for opiate addicts. Does it help?
Topics: Adult; Behavior Therapy; Counseling; Humans; Male; Methadone; Opioid-Related Disorders; Outcome and | 1983 |
Is treatment for alcoholism effective in persons on methadone maintenance?
Topics: Alcohol Drinking; Alcoholism; Behavior Therapy; Female; Follow-Up Studies; Humans; Male; Methadone; | 1983 |
[Effectiveness of methadone maintenance treatment. A controlled study in the care of narcotic addicts].
Topics: Adult; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related | 1980 |
Clinical status of methadyl acetate (LAAM).
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Evaluation; Humans; Kinetics; Male; Methadone; Met | 1981 |
Short-term effects of oral methadone in methadone maintenance subjects.
Topics: Adult; Blood Pressure; Dose-Response Relationship, Drug; Euphoria; Heart Rate; Humans; Male; Methado | 1982 |
Initial methadone dose in treating opiate addiction.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Methadone; Naloxone; Narcotics; Opioi | 1982 |
Biofeedback treatment of narcotic addiction: a double-blind study.
Topics: Adult; Biofeedback, Psychology; Double-Blind Method; Electromyography; Follow-Up Studies; Humans; Ma | 1982 |
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
Topics: Adult; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; Female; Heart R | 1982 |
Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study.
Topics: Adult; Depressive Disorder; Double-Blind Method; Doxepin; Drug Therapy, Combination; Female; Humans; | 1982 |
Efficacy of urine monitoring in methadone maintenance.
Topics: Adult; Consumer Behavior; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Outc | 1981 |
Morphinelike arousal by methadone during sleep.
Topics: Adult; Arousal; Double-Blind Method; Humans; Male; Methadone; Middle Aged; Morphine; Muscle Contract | 1981 |
Acute effects of tramadol in methadone-maintained volunteers.
Topics: Adult; Double-Blind Method; Humans; Male; Methadone; Opioid-Related Disorders; Tramadol | 1994 |
Attentional difficulties and the effectiveness of a visual representation strategy for counseling drug-addicted clients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Attention; Audiovisual Aids; Counseling; Female; Goals; H | 1995 |
Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts.
Topics: Adult; Female; Humans; Interview, Psychological; Male; Mental Disorders; Methadone; Narcotics; Neuro | 1995 |
Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials.
Topics: Adult; Cocaine; Demography; Double-Blind Method; Female; Fluoxetine; Humans; Male; Methadone; Opioid | 1995 |
Psychotherapy in community methadone programs: a validation study.
Topics: Adult; Community Mental Health Services; Counseling; Female; Follow-Up Studies; Humans; Male; Methad | 1995 |
Effects of buprenorphine and methadone in methadone-maintained subjects.
Topics: Administration, Oral; Adult; Buprenorphine; Dose-Response Relationship, Drug; Humans; Male; Methadon | 1995 |
Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.
Topics: Adolescent; Adult; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Double-Blind Method; Fe | 1994 |
Psychiatric disorders of opioid addicts entering treatment: preliminary data.
Topics: Adult; Antisocial Personality Disorder; Comorbidity; Cross-Sectional Studies; Depressive Disorder; F | 1994 |
Contingency management of urinalysis results and intensity of counseling services have an interactive impact on methadone maintenance treatment outcome.
Topics: Adolescent; Adult; Behavior Therapy; Combined Modality Therapy; Counseling; Feedback; Female; Follow | 1994 |
Medical maintenance: an interim report.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Counseling; Female; Follow-Up Studies; Humans; M | 1994 |
Methadone dosing and pregnancy: impact on program compliance.
Topics: Ambulatory Care; Cocaine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hu | 1995 |
Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT).
Topics: Adult; Analysis of Variance; Basal Ganglia; Blood Pressure; Brain; Cerebral Cortex; Double-Blind Met | 1995 |
Node-link mapping for counseling cocaine users in methadone treatment.
Topics: Adult; Cocaine; Cognitive Behavioral Therapy; Combined Modality Therapy; Communication; Follow-Up St | 1994 |
Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance.
Topics: Adult; Buprenorphine; Cocaine; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; D | 1994 |
The role of node-link mapping in individual and group counseling.
Topics: Adult; Alcoholism; Cocaine; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cr | 1994 |
Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Clonidine; Dose-Response Relationship, Drug; Double-Blind | 1994 |
Outcome after methadone treatment: influence of prior treatment factors and current treatment status.
Topics: Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admini | 1994 |
Clonidine is not a useful adjunct to methadone gradual detoxification in opioid addiction.
Topics: Adolescent; Adult; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 1994 |
Comparison of buprenorphine and methadone in the treatment of opioid dependence.
Topics: Administration, Oral; Administration, Sublingual; Adult; Buprenorphine; Cocaine; Comorbidity; Double | 1994 |
Desipramine treatment for cocaine dependence. Role of antisocial personality disorder.
Topics: Adult; Antisocial Personality Disorder; Cocaine; Comorbidity; Desipramine; Humans; Male; Methadone; | 1994 |
Methadone dose and treatment outcome.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; | 1993 |
The effects of psychosocial services in substance abuse treatment.
Topics: Combined Modality Therapy; Counseling; Family Therapy; Hospitals, Veterans; Humans; Male; Methadone; | 1993 |
Dose-response effects of methadone in the treatment of opioid dependence.
Topics: Adult; Cocaine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Methado | 1993 |
Buprenorphine versus methadone maintenance for opioid dependence.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Sch | 1993 |
Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
Topics: Adult; Arousal; Autonomic Nervous System; Constipation; Dose-Response Relationship, Drug; Gastrointe | 1995 |
Evaluating the reinforcement value of clinic-based privileges through a multiple choice procedure.
Topics: Adult; Behavior Therapy; Choice Behavior; Combined Modality Therapy; Counseling; Dose-Response Relat | 1995 |
A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.
Topics: Adult; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administr | 1996 |
Efficacy of enhanced outreach counseling to reenroll high-risk drug users 1 year after discharge from treatment.
Topics: Adult; Aged; Counseling; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opioid-Related Dis | 1996 |
Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
Topics: Adult; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intraven | 1996 |
Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome.
Topics: Adolescent; Adult; Ancillary Services, Hospital; Behavior Therapy; Cocaine; Combined Modality Therap | 1996 |
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Topics: Adolescent; Adult; Alcoholism; Buprenorphine; Cocaine; Double-Blind Method; Female; Heroin Dependenc | 1996 |
The efficacy of L-methadone and racemic methadone in substitution treatment for opiate addicts--a double-blind comparison.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methadone; Narcotics | 1996 |
A protocol to switch high-dose, methadone-maintained subjects to buprenorphine.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Buprenorphine; Clonidine; Cocaine; Drug Administration Schedule | 1997 |
Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment.
Topics: Adult; Female; Follow-Up Studies; Health Status Indicators; Humans; Male; Methadone; Narcotics; Opio | 1997 |
Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administr | 1997 |
Are supplementary services provided during methadone maintenance really cost-effective?
Topics: Adult; Combined Modality Therapy; Cost-Benefit Analysis; Counseling; Female; Follow-Up Studies; Heal | 1997 |
Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women.
Topics: Adolescent; Adult; Ambulatory Care; Black or African American; Cocaine; Female; Humans; Infant, Newb | 1997 |
Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Female; Humans; Infant, Newbor | 1997 |
Prognostic factors in Buprenorphine- versus methadone-maintained patients.
Topics: Adult; Alcoholism; Antisocial Personality Disorder; Benzodiazepines; Buprenorphine; Cocaine-Related | 1998 |
Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial.
Topics: Adult; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychiatry); Double-Blind Method; Drug The | 1998 |
Preliminary evidence of good treatment response in antisocial drug abusers.
Topics: Adult; Analysis of Variance; Behavior Therapy; Chi-Square Distribution; Combined Modality Therapy; F | 1998 |
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.
Topics: Adult; Behavior Therapy; Female; HIV Infections; Humans; Illicit Drugs; Male; Methadone; Middle Aged | 1998 |
Medication take-home doses and contingency management.
Topics: Adult; Cocaine-Related Disorders; Female; Fluoxetine; Humans; Male; Methadone; Middle Aged; Opioid-R | 1998 |
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.
Topics: Adult; Antidepressive Agents, Second-Generation; Behavior, Addictive; Cocaine; Cocaine-Related Disor | 1998 |
Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Dose-Response Relationship, Drug; D | 1998 |
Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal.
Topics: Adrenergic alpha-Agonists; Adult; Ambulatory Care; Blood Pressure; Chi-Square Distribution; Clonidin | 1998 |
Detection of drug use in a methadone maintenance clinic: sweat patches versus urine testing.
Topics: Adult; Cross-Over Studies; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Pat | 1998 |
[Economic evaluation in a trial of medically controlled prescription of narcotics to dependent users (PROVE)].
Topics: Depression; Digestive System Diseases; Drug Prescriptions; Epilepsy; Health Care Costs; Heroin; Huma | 1998 |
Comparison of buprenorphine and methadone maintenance in opiate addicts.
Topics: Adolescent; Adult; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; | 1998 |
Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Morphine; N | 1998 |
Broad beneficial effects of cocaine abstinence reinforcement among methadone patients.
Topics: Adult; Analysis of Variance; Behavior Therapy; Cocaine-Related Disorders; Female; Humans; Longitudin | 1998 |
When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments.
Topics: Adolescent; Adult; Analysis of Variance; Anxiety Disorders; Female; Humans; Male; Methadone; Opioid- | 1998 |
Abuse liability of flunitrazepam among methadone-maintained patients.
Topics: Adult; Anti-Anxiety Agents; Blood Pressure; Body Temperature; Cross-Over Studies; Double-Blind Metho | 1998 |
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost.
Topics: Adult; Cocaine-Related Disorders; Cost-Benefit Analysis; Day Care, Medical; Female; Follow-Up Studie | 1999 |
Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Anesthesia; Clonidine; Female; Humans; Male; Methadone | 1998 |
Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure.
Topics: Acute Kidney Injury; Adult; Anesthesia; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; | 1999 |
The autonomy of mood disorders among cocaine-using methadone patients.
Topics: Adult; Alcoholism; Bipolar Disorder; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Comorb | 1999 |
Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methadone; Narcotics | 1999 |
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.
Topics: Adolescent; Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Models, Biological; Opioid-R | 1999 |
A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment.
Topics: Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Inactivation, Metabolic; Mental Hea | 1999 |
Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators.
Topics: Adult; Aged; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Pati | 1999 |
Detection of illicit opioid and cocaine use in methadone maintenance treatment.
Topics: Adult; Analgesics, Opioid; Appointments and Schedules; Cocaine-Related Disorders; Female; Humans; Ma | 1999 |
[Buprenorphine vs. methadone as maintenance treatment for opioid dependence].
Topics: Administration, Sublingual; Adult; Buprenorphine; Female; Humans; Male; Methadone; Narcotic Antagoni | 1999 |
Three oral formulations of methadone. A clinical and pharmacodynamic comparison.
Topics: Adult; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 1999 |
Buprenorphine versus methadone maintenance for the treatment of opioid dependence.
Topics: Adolescent; Adult; Ambulatory Care; Ambulatory Care Facilities; Buprenorphine; Female; Humans; Male; | 1999 |
Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: results from the National Treatment Outcome Research Study.
Topics: Adolescent; Adult; Child; Family Practice; Female; Humans; Male; Methadone; Middle Aged; Narcotics; | 1999 |
Comparing buprenorphine and methadone maintenance.
Topics: Buprenorphine; Drug Administration Schedule; Humans; Methadone; Opioid-Related Disorders; Research D | 1994 |
Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.
Topics: Adult; Female; Humans; Inactivation, Metabolic; Male; Methadone; Models, Statistical; Narcotics; Opi | 2000 |
Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts.
Topics: Cocaine-Related Disorders; Disulfiram; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Male; | 2000 |
Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorde | 2000 |
Acute detoxification of opioid-addicted patients with naloxone during propofol or methohexital anesthesia: a comparison of withdrawal symptoms, neuroendocrine, metabolic, and cardiovascular patterns.
Topics: Adult; Anesthesia, General; Anesthetics, Intravenous; Catecholamines; Female; Humans; Male; Methadon | 2000 |
Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combina | 2000 |
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence.
Topics: Adolescent; Adult; Behavior, Addictive; Buprenorphine; Double-Blind Method; Female; Humans; Male; Me | 2000 |
The effects of offering free treatment to street-recruited opioid injectors.
Topics: Adolescent; Adult; Aged; Female; Humans; Illicit Drugs; Male; Methadone; Middle Aged; Narcotics; Opi | 2000 |
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dr | 2000 |
The effect of sertraline on methadone plasma levels in methadone-maintenance patients.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Interactions; Female; Humans; Male; Methadone; | 2000 |
Pain responses in methadone-maintained opioid abusers.
Topics: Adult; Cold Temperature; Drug Interactions; Female; Humans; Hydromorphone; Ketorolac; Male; Methadon | 2000 |
Pain responses in methadone-maintained opioid abusers.
Topics: Adult; Cold Temperature; Drug Interactions; Female; Humans; Hydromorphone; Ketorolac; Male; Methadon | 2000 |
Pain responses in methadone-maintained opioid abusers.
Topics: Adult; Cold Temperature; Drug Interactions; Female; Humans; Hydromorphone; Ketorolac; Male; Methadon | 2000 |
Pain responses in methadone-maintained opioid abusers.
Topics: Adult; Cold Temperature; Drug Interactions; Female; Humans; Hydromorphone; Ketorolac; Male; Methadon | 2000 |
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine-Related Disorders; Double-Blind Method; Drug Admin | 2000 |
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine-Related Disorders; Double-Blind Method; Drug Admin | 2000 |
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine-Related Disorders; Double-Blind Method; Drug Admin | 2000 |
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cocaine-Related Disorders; Double-Blind Method; Drug Admin | 2000 |
Effects of urine testing frequency on outcome in a methadone take-home contingency program.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Cocaine-Related Disorders; Female; Humans; Mal | 2001 |
Double-blind randomized trial of buprenorphine and methadone in opiate dependence.
Topics: Adult; Analysis of Variance; Behavior, Addictive; Buprenorphine; Chi-Square Distribution; Double-Bli | 2001 |
The relationship between mood state and plasma methadone concentration in maintenance patients.
Topics: Adult; Affect; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Diso | 2001 |
Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient?
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Hydrocortisone; Male; | 2001 |
Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome.
Topics: Administration, Oral; Adult; Drug Costs; Feasibility Studies; Female; Follow-Up Studies; Humans; Inj | 2000 |
Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Topics: Adolescent; Adult; Analysis of Variance; Confidence Intervals; Cytochrome P-450 CYP2D6; Female; Geno | 2001 |
Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study.
Topics: Adult; Affect; Analysis of Variance; Behavior, Addictive; Cognition; Cross-Over Studies; Dose-Respon | 2001 |
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
Topics: Adult; Buprenorphine; Cold Temperature; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related | 2001 |
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
Topics: Adult; Buprenorphine; Cold Temperature; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related | 2001 |
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
Topics: Adult; Buprenorphine; Cold Temperature; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related | 2001 |
Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent.
Topics: Adult; Buprenorphine; Cold Temperature; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related | 2001 |
An evaluation of breathing nervous regulation of opiate dependent patients during in 6 months' methadone maintenance treatment programme.
Topics: Adult; Anxiety; Female; Humans; Lung; Male; Methadone; Middle Aged; Opioid-Related Disorders; Respir | 2001 |
The changes in spirometric measurements during 6 months' methadone maintenance treatment in opiate dependent patients.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Respiration; Respirat | 2001 |
[Use of buprenorphine as a substitute treatment for opiate dependence in the Toxicology Clinics--introductory clinical report].
Topics: Adolescent; Adult; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists | 2001 |
A community-based trial of vocational problem-solving to increase employment among methadone patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Educational Measurement; Employment; Female; F | 2001 |
Human methadone self-administration: effects of diazepam pretreatment.
Topics: Adult; Anti-Anxiety Agents; Diazepam; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Dis | 2001 |
Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude.
Topics: Adult; Cocaine-Related Disorders; Drug Resistance; Female; Humans; Male; Methadone; Narcotics; Opioi | 2001 |
Shaping cocaine abstinence by successive approximation.
Topics: Adult; Behavior Therapy; Cocaine-Related Disorders; Female; Humans; Male; Methadone; Middle Aged; Mo | 2001 |
Methadone maintenance in primary care: a randomized controlled trial.
Topics: Adult; Family Practice; Feasibility Studies; Female; Humans; Male; Methadone; Middle Aged; Opioid-Re | 2001 |
Social support and abstinence from opiates and cocaine during opioid maintenance treatment.
Topics: Adult; Aged; Analgesics, Opioid; Behavior Therapy; Chi-Square Distribution; Cocaine-Related Disorder | 2001 |
A multicenter randomized evaluation of methadone medical maintenance.
Topics: Adult; Baltimore; Counseling; Female; Follow-Up Studies; Humans; Male; Mental Health Services; Metha | 2002 |
Voucher-based reinforcement of opiate abstinence during methadone detoxification.
Topics: Adult; Brain; Cocaine; Female; Humans; Inactivation, Metabolic; Male; Methadone; Narcotics; Opioid-R | 2002 |
The brief abstinence test: effects of continued incentive availability on cocaine abstinence.
Topics: Adult; Analgesics, Opioid; Cocaine-Related Disorders; Female; Humans; Male; Methadone; Motivation; O | 2002 |
Ketoconazole increases cocaine and opioid use in methadone maintained patients.
Topics: Analysis of Variance; Antifungal Agents; Chi-Square Distribution; Cocaine-Related Disorders; Double- | 2002 |
Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
Topics: Adult; Analgesics, Opioid; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Human | 2002 |
Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients.
Topics: Adult; Behavior Therapy; Cocaine-Related Disorders; Community Mental Health Services; Cost-Benefit A | 2002 |
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients.
Topics: Adrenergic alpha-Antagonists; Adult; Analgesics, Opioid; Anxiety; Blood Pressure; Double-Blind Metho | 2002 |
24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
Topics: Administration, Oral; Adult; Aftercare; Anti-Anxiety Agents; Benzodiazepines; Clonidine; Drug Implan | 2002 |
Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Buprenorphine; Clinical Trials as Topic | 2002 |
Abstinence reinforcement maintenance contingency and one-year follow-up.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Female; Follow-Up Studies; Humans; Male; Metha | 2002 |
Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clonidine; Double-Blind Method; Humans; Male; | 2002 |
A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients.
Topics: Adult; Analysis of Variance; Dextromethorphan; Double-Blind Method; Humans; Inpatients; Male; Methad | 2002 |
Usefulness of propoxyphene napsylate for maintenance treatment of narcotic addiction.
Topics: Adult; Clinical Trials as Topic; Dextropropoxyphene; Double-Blind Method; Humans; Methadone; Middle | 1979 |
Reducing benzodiazepine self-administration with contingent reinforcement.
Topics: Adult; Diazepam; Humans; Methadone; Opioid-Related Disorders; Self Administration; Substance-Related | 1979 |
Assessment and management of opioid withdrawal symptoms in buprenorphine-dependent subjects.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Heroin Dependence; Humans; Male; Methadone; Neuro | 1992 |
Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine.
Topics: Adolescent; Adult; Amantadine; Baltimore; Cocaine; Desipramine; Female; Follow-Up Studies; Humans; M | 1992 |
Weighing up the pros and cons: help-seeking by drug misusers in Baltimore, USA.
Topics: Adult; Bromocriptine; Buprenorphine; Cocaine; Desipramine; Fear; Female; Fluoxetine; Humans; Male; M | 1992 |
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
Topics: Adult; Blood Pressure; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Methoxyh | 1992 |
Background and design of a controlled clinical trial (ARC 090) for the treatment of opioid dependence.
Topics: Adult; Buprenorphine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Metha | 1992 |
Desipramine treatment of cocaine dependence in methadone-maintained patients.
Topics: Adult; Cocaine; Comorbidity; Desipramine; Double-Blind Method; Drug Therapy, Combination; Follow-Up | 1992 |
Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine.
Topics: Adult; Amantadine; Cocaine; Desipramine; Double-Blind Method; Female; Humans; Male; Methadone; Opioi | 1992 |
A randomized double-blind study of neuroelectric therapy in opiate and cocaine detoxification.
Topics: Adult; Cocaine; Double-Blind Method; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; | 1992 |
Contingent take-home incentive: effects on drug use of methadone maintenance patients.
Topics: Adult; Female; Humans; Male; Methadone; Motivation; Opioid-Related Disorders; Patient Compliance; Se | 1992 |
A controlled trial of buprenorphine treatment for opioid dependence.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Heroin; Heroin Dependence; Humans; Male; Methadon | 1992 |
Acute physical dependence in humans: repeated naloxone-precipitated withdrawal after a single dose of methadone.
Topics: Adult; Arousal; Humans; Male; Methadone; Middle Aged; Naloxone; Neurologic Examination; Opioid-Relat | 1991 |
Time course of naloxone-precipitated withdrawal after acute methadone exposure in humans.
Topics: Adult; Arousal; Humans; Injections, Intramuscular; Male; Metabolic Clearance Rate; Methadone; Naloxo | 1991 |
Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to "estimate" methadone plasma levels.
Topics: Adult; Chromatography, High Pressure Liquid; Humans; Illicit Drugs; Methadone; Middle Aged; Opioid-R | 1991 |
Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients.
Topics: Adult; Amantadine; Cocaine; Desipramine; Double-Blind Method; Female; Humans; Male; Methadone; Opioi | 1990 |
Should opiate addicts be involved in controlling their own detoxification? A comparison of fixed versus negotiable schedules.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Methado | 1991 |
Comparison of oral preparations of heroin and methadone to stabilise opiate misusers as inpatients.
Topics: Administration, Oral; Adult; Double-Blind Method; Heroin; Humans; Methadone; Opioid-Related Disorder | 1990 |
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
Topics: Adult; Butorphanol; Cognition; Double-Blind Method; Humans; Hydromorphone; Injections, Intramuscular | 1988 |
Antagonist effects of nalbuphine in opioid-dependent human volunteers.
Topics: Adult; Dose-Response Relationship, Drug; Humans; Hydromorphone; Male; Methadone; Morphinans; Nalbuph | 1989 |
The Bethlem Study on NET: putting the record straight.
Topics: Clinical Trials as Topic; Double-Blind Method; Electric Stimulation Therapy; Humans; Methadone; Opio | 1989 |
How should opiate withdrawal be measured?
Topics: Arousal; Chlordiazepoxide; Clinical Trials as Topic; Double-Blind Method; Humans; Methadone; Nursing | 1989 |
Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes.
Topics: Adult; Female; Heroin Dependence; Humans; Male; Methadone; Opioid-Related Disorders; Psychiatric Dep | 1989 |
Desipramine treatment of cocaine abuse in methadone maintenance patients.
Topics: Clinical Trials as Topic; Cocaine; Combined Modality Therapy; Desipramine; Double-Blind Method; Huma | 1989 |
A pilot study of a Neuro-Stimulator Device vs. methadone in alleviating opiate withdrawal symptoms.
Topics: Double-Blind Method; Electric Stimulation Therapy; Humans; Methadone; Opioid-Related Disorders; Pilo | 1989 |
Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
Topics: Double-Blind Method; Drug Administration Schedule; Humans; Methadone; Naloxone; Opioid-Related Disor | 1989 |
Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aversive Therapy; Benzodiazepines; Cocaine; Dose-R | 1988 |
Legal status and long-term outcomes for addicts in the DARP followup project.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Crime; Criminal Law; Female; Follow-Up Studies; Human | 1988 |
Is the counselor an "active ingredient" in substance abuse rehabilitation? An examination of treatment success among four counselors.
Topics: Combined Modality Therapy; Counseling; Crime; Employment; Humans; Male; Methadone; Opioid-Related Di | 1988 |
Twelve-month follow-up of psychotherapy for opiate dependence.
Topics: Adolescent; Adult; Allied Health Personnel; Behavior Therapy; Combined Modality Therapy; Counseling; | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Two new rating scales for opiate withdrawal.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Psychologi | 1987 |
Contingent methadone delivery: effects on illicit-opiate use.
Topics: Adult; Contraceptives, Oral, Combined; Dose-Response Relationship, Drug; Drug Administration Schedul | 1986 |
Success and failure at outpatient opioid detoxification. Evaluating the process of clonidine- and methadone-assisted withdrawal.
Topics: Adult; Ambulatory Care; Clinical Trials as Topic; Clonidine; Female; Follow-Up Studies; Humans; Male | 1985 |
Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts.
Topics: Adult; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Male; Methadone; Op | 1985 |
Clonidine in outpatient detoxification from methadone maintenance.
Topics: Adult; Ambulatory Care; Clonidine; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Diso | 1985 |
Therapist success and its determinants.
Topics: Adolescent; Adult; Attitude of Health Personnel; Attitude to Health; Behavior Therapy; Clinical Comp | 1985 |
Sociopathy and psychotherapy outcome.
Topics: Adolescent; Adult; Ambulatory Care; Antisocial Personality Disorder; Counseling; Depressive Disorder | 1985 |
Limit setting on drug abuse in methadone maintenance patients.
Topics: Female; Humans; Illicit Drugs; Male; Methadone; Opioid-Related Disorders; Patient Compliance; Patien | 1985 |
Comparison of the effects of intramuscular meptazinol, methadone and placebo in opiate addicts (editors' abstract).
Topics: Adult; Azepines; Blood Pressure; Body Temperature; Female; Heart Rate; Humans; Male; Meptazinol; Met | 1985 |
2733 other studies available for methadone and Addiction, Opioid
| Article | Year |
|---|---|
Opioid Use Disorder and Perinatal Outcomes.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Female; Humans; Incidence; Infant, Newbo | 2021 |
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.
Topics: Analgesics, Opioid; Cohort Studies; HIV Infections; Humans; Methadone; Opiate Substitution Treatment | 2022 |
Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences.
Topics: Analgesics, Opioid; Buprenorphine; Disclosure; Humans; Methadone; Opiate Substitution Treatment; Opi | 2022 |
A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2021 |
Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2021 |
Health professionals' attitudes toward medications for opioid use disorder.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Humans; Methadone; Opiate Substitut | 2022 |
A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2022 |
Perioperative Management of Buprenorphine/Naloxone in a Large, National Health Care System: a Retrospective Cohort Study.
Topics: Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Humans; Male; Methadone; Naloxone; Opiat | 2022 |
Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study.
Topics: HIV Infections; Humans; Male; Methadone; Methamphetamine; Opioid-Related Disorders; Vietnam | 2021 |
Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder?
Topics: Ambulatory Care; Buprenorphine; Hospitals; Humans; Methadone; Opioid-Related Disorders; Outpatients; | 2022 |
A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Topics: Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Veterans; | 2022 |
Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2021 |
A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narc | 2021 |
Use of Methadone Maintenance Therapy for Opioid Use Disorder in Pregnancy.
Topics: Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2021 |
Treatment provider perceptions of take-home methadone regulation before and during COVID-19.
Topics: COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics; Per | 2021 |
Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; National Institute on Drug Abuse (U.S.); Opiat | 2021 |
Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Health Expenditures; Humans; Methadone; | 2022 |
Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Male; M | 2022 |
COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Topics: Analgesics, Opioid; COVID-19; Humans; Leadership; Methadone; Opiate Substitution Treatment; Opioid-R | 2022 |
Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Humans; Longitudinal St | 2021 |
Compulsivity and impulsivity in opioid dependence.
Topics: Buprenorphine; Cross-Sectional Studies; Heroin Dependence; Humans; Impulsive Behavior; Methadone; Op | 2021 |
Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional | 2022 |
Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
Topics: Analgesics, Opioid; British Columbia; Correctional Facilities; Humans; Methadone; Opiate Substitutio | 2022 |
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospital Mortality; Humans; Length of Stay; Logist | 2022 |
Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.
Topics: Analgesics, Opioid; Avena; British Columbia; Buprenorphine; Humans; Methadone; Opiate Substitution T | 2022 |
Improving methadone access for rural communities in the USA: lessons learned from COVID-19 adaptations and international models of care.
Topics: COVID-19; Delivery of Health Care; Health Services Accessibility; Humans; Methadone; Opiate Substitu | 2021 |
"No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
Topics: Adolescent; Adult; Aged; Boston; COVID-19; Female; Humans; Male; Methadone; Middle Aged; Opiate Over | 2022 |
Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Humans; Methadone; On | 2021 |
Comparisons of injection and non-injection opioid use among Black people in methadone treatment: A pilot in Detroit.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Opioid-Related Disorders; Pilot Projects | 2022 |
Implementing a Methadone Delivery System in New York City in Response to COVID-19.
Topics: Adult; Communicable Disease Control; Comorbidity; COVID-19; Female; Humans; Male; Methadone; Middle | 2021 |
Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.
Topics: Adult; Alleles; Analgesics, Opioid; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genotype; Human | 2021 |
Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program.
Topics: Female; HIV Infections; Humans; Kyrgyzstan; Male; Methadone; Opioid-Related Disorders; Prisoners; Pr | 2022 |
Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study.
Topics: Adolescent; Adult; Buprenorphine; England; Female; Follow-Up Studies; Hospitalization; Humans; Male; | 2022 |
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Female; Humans; Medicaid; Methadone; Naltrexone; Ohio | 2022 |
Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Opiate Substitution Treat | 2021 |
Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cancer Pain; Delphi Technique; Female; Humans; Male | 2021 |
Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily.
Topics: Analgesics, Opioid; HIV Infections; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Opioid Use Disorder Treatment Initiation and Continuation: a Qualitative Study of Patients Who Received Addiction Consultation and Hospital-Based Providers.
Topics: Analgesics, Opioid; Buprenorphine; Hospitals; Humans; Methadone; Opiate Substitution Treatment; Opio | 2022 |
A genetic-based population PK/PD modeling of methadone in Chinese opiate dependence patients.
Topics: China; Dose-Response Relationship, Drug; Electrocardiography; Humans; Long QT Syndrome; Methadone; O | 2022 |
Neonatal Abstinence Syndrome: Prevention, Recognition, Treatment, and Follow-up.
Topics: Analgesics, Opioid; Child, Preschool; Female; Follow-Up Studies; Humans; Infant, Newborn; Methadone; | 2021 |
Methadone on Wheels-A New Option to Expand Access to Care Through Mobile Units.
Topics: Health Services Accessibility; Humans; Methadone; Mobile Health Units; Opiate Substitution Treatment | 2022 |
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cost Sharing; Female; He | 2022 |
Harm Reduction for Patients With Substance Use Disorders.
Topics: Adult; Buprenorphine; Contraception; Drug Overdose; Female; Harm Reduction; Heroin; Humans; Male; Me | 2022 |
Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Humans; Male; Methadone; Opiate Substitut | 2022 |
Perioperative Management of Patients on Maintenance Medication for Addiction Treatment: The Development of an Institutional Guideline.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2022 |
The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14.
Topics: Analgesics, Opioid; British Columbia; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
"
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Risk factors for preterm birth among gravid individuals receiving buprenorphine for opioid use disorder.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Opioid-Related Disorders; Placenta; Pregn | 2022 |
Does self-reported consumption of heroin correlate with dose of methadone among pregnant people with opioid use disorder?
Topics: Analgesics, Opioid; Female; Heroin; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Retrospe | 2022 |
Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients' and prescribers' experiences with changes in unsupervised dosing.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19; Humans; Methadone; Ontario; Opiate Substitution Treatme | 2022 |
Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Cross-Sectional Studies; Humans; Methadone; Opiate Sub | 2022 |
Comparison Between Preoperative Methadone and Buprenorphine Use on Postoperative Opioid Requirement: A Retrospective Cohort Study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Pain, Postoperative; | 2022 |
Understanding and co-managing medication treatment options for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2022 |
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Subst | 2022 |
The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.
Topics: Adult; Cannabis; Female; Humans; Kenya; Male; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Methadone and buprenorphine: The search for a non-addictive opioid.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders | 2022 |
Pharmacological Management of Heroin Withdrawal Syndrome: A Century of Expert Opinions in Cecil Textbook of Medicine.
Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Expert Testimony; Heroin; Humans; Methadone; Narcotics | 2022 |
High cardiovascular risk in older patients with opioid use disorder: Differences with the general population.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Female; Heart Disease Risk Factors; Humans; Male; Methad | 2022 |
Opioid use disorder in anaesthesia and intensive care: Prevention, diagnosis and management.
Topics: Analgesics, Opioid; Anesthesia; Australia; Buprenorphine; Critical Care; Drug Tolerance; Humans; Met | 2022 |
Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk.
Topics: Affect; Craving; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Trends in the severity of opioid use disorder during pregnancy over time.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2022 |
Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada.
Topics: Analgesics, Opioid; British Columbia; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Developing a cascade of care for opioid use disorder among individuals in jail.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Jails; Methadone; Opiate Substitution Trea | 2022 |
Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
Topics: Analgesics, Opioid; Avena; Correctional Facilities; Follow-Up Studies; Humans; Methadone; Ontario; O | 2022 |
Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
Topics: Analgesics, Opioid; Buprenorphine; Housing; Humans; Methadone; Missouri; Naltrexone; Opiate Substitu | 2022 |
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone | 2022 |
Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Drug Ov | 2022 |
Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID-19; Humans; Metha | 2022 |
Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Outpat | 2022 |
Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Opiate Su | 2022 |
Chronic Kidney Disease from Polyvinylpyrrolidone Deposition in Persons with Intravenous Drug Use.
Topics: Adult; Atrophy; Biopsy; Endothelial Cells; Humans; Kidney; Methadone; Opioid-Related Disorders; Povi | 2022 |
Undetected Respiratory Depression in People with Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Carbon Dioxide; Drug Overdose; Humans; Methadone; Opiate Substitu | 2022 |
"You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
Topics: Analgesics, Opioid; Buprenorphine; Child; Fear; Female; Humans; Infant, Newborn; Methadone; Opiate S | 2022 |
The Methadone Manifesto: Treatment Experiences and Policy Recommendations From Methadone Patient Activists.
Topics: Humans; Methadone; Opioid-Related Disorders; Policy | 2022 |
Federal and State Regulatory Changes to Methadone Take-Home Doses: Impact of Sociostructural Factors.
Topics: Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 2022 |
Structural Adaptations to Methadone Maintenance Treatment and Take-Home Dosing for Opioid Use Disorder in the Era of COVID-19.
Topics: COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
State policy uptake does not require formal action: A comment on Nesoff et al.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Poli | 2022 |
Disparities in expected driving time to opioid treatment and treatment completion: findings from an exploratory study.
Topics: Analgesics, Opioid; Automobile Driving; Humans; Male; Methadone; Opiate Substitution Treatment; Opio | 2022 |
Attitudes and beliefs among Georgia addiction treatment staff about medication for opioid use disorder in adolescents, young adults, and adults: a multi-mixed methods study.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Female; Georgia; Humans; Male; Methadone | 2022 |
A pilot implementation study to scale-up methadone in incarcerated persons with opioid use disorder and retain them on treatment after release in Moldova.
Topics: Humans; Methadone; Moldova; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2022 |
"Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Opiate Substituti | 2022 |
Familial support in integrated treatment with antiretroviral therapy and medications for opioid use disorder in Vietnam: A qualitative study.
Topics: Analgesics, Opioid; Buprenorphine; HIV Infections; Humans; Methadone; Opiate Substitution Treatment; | 2022 |
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Cross-Sectional Studies; Health Services | 2022 |
Association of Duration of Methadone or Buprenorphine Use During Pregnancy With Risk of Nonfatal Drug Overdose Among Pregnant Persons With Opioid Use Disorder in the US.
Topics: Buprenorphine; Drug Overdose; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Identifying the Physical and Mental Healthcare Needs of Opioid Treatment Program Clients.
Topics: Analgesics, Opioid; Humans; Mental Health Services; Methadone; Opiate Substitution Treatment; Opioid | 2022 |
Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Humans; Methadone; Opiate Substitution T | 2022 |
Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Topics: Analgesics, Opioid; COVID-19; Drug Users; Humans; Methadone; Ontario; Opiate Substitution Treatment; | 2022 |
Long-acting depot buprenorphine in people who are homeless: Views and experiences.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Ill-Housed Persons; Male; Methadone; Opiate Subst | 2022 |
Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID-19; Humans; Metha | 2022 |
"The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Topics: Analgesics, Opioid; COVID-19; Drug Overdose; Female; Freedom; Humans; Male; Methadone; Middle Aged; | 2022 |
Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Implementation of a comprehensive hospitalist-led initiative to improve care for patients with opioid use disorder.
Topics: Aftercare; Analgesics, Opioid; Hospitalists; Humans; Methadone; Opiate Substitution Treatment; Opioi | 2022 |
Kamini, a little recognised source of illicit opioid: A case series of 12 patients.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19; Humans; Methadone; Narcotic Antagonists; Opiate Substit | 2022 |
Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Overdose; Opiate Substitution T | 2022 |
Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2022 |
Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment.
Topics: Craving; Heroin; Humans; Lasers; Male; Massage; Meridians; Methadone; Opioid-Related Disorders; Qual | 2022 |
County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; | 2022 |
Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2022 |
Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2022 |
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opi | 2022 |
Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: A predictive modeling study.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Humans; Methadone; Opiate Substitution T | 2022 |
Intra-individual variability and stability of affect and craving among individuals receiving medication treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Craving; Humans; Methadone; Opioid-Related Disorders | 2022 |
Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Female; | 2022 |
Attitudes on Methadone Utilization in the Emergency Department: A Physician Cross-sectional Study.
Topics: Analgesics, Opioid; Attitude; Buprenorphine; Cross-Sectional Studies; Emergency Service, Hospital; H | 2022 |
Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Development of an intravenous low-dose buprenorphine initiation protocol.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Methadone; Opiate Substitution Trea | 2022 |
Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.
Topics: Analgesics, Opioid; Buprenorphine; Bupropion; Central Nervous System Stimulants; Cross-Over Studies; | 2022 |
Opioid Use Disorder and Older Adults: Navigating Treatment Options.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Re | 2022 |
Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Cancer Pain; Consensus; Female; Humans; Male; Me | 2022 |
Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Opiate Substitu | 2022 |
Verbal and nonverbal memory in school-aged children born to opioid-dependent mothers.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Longitudinal Studies; Methadone; Opiate Su | 2022 |
Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Canada; Humans; Methadone; | 2022 |
Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021.
Topics: Aged; Humans; Medicaid; Medicare; Methadone; Opioid Epidemic; Opioid-Related Disorders; United State | 2022 |
Methadone-Involved Overdose Deaths in the US Before and After Federal Policy Changes Expanding Take-Home Methadone Doses From Opioid Treatment Programs.
Topics: Analgesics, Opioid; Drug Overdose; Humans; Methadone; Opiate Overdose; Opiate Substitution Treatment | 2022 |
A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder.
Topics: Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Trea | 2023 |
Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis.
Topics: Analgesics, Opioid; Drug Overdose; Georgia; Humans; Methadone; Opiate Overdose; Opiate Substitution | 2022 |
Cumulative barriers to retention in methadone treatment among adults from rural and small urban communities.
Topics: Adult; Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorder | 2022 |
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Infant, Newborn; Methadone; | 2022 |
Adapting methadone inductions to the fentanyl era.
Topics: Analgesics, Opioid; Fentanyl; Heroin; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relat | 2022 |
Improving geographic access to methadone clinics.
Topics: Ambulatory Care Facilities; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorde | 2022 |
Identifying Clinically Relevant Drug-Drug Interactions With Methadone and Buprenorphine: A Translational Approach to Signal Detection.
Topics: Baclofen; Bayes Theorem; Benzodiazepines; Buprenorphine; Clonidine; Drug Interactions; Fluconazole; | 2022 |
Insulinoma mimic: methadone-induced hypoglycaemia.
Topics: Blood Glucose; Female; Humans; Hyperinsulinism; Hypoglycemia; Insulin; Insulinoma; Methadone; Opioid | 2022 |
Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
Topics: Actigraphy; Analgesics, Opioid; Animals; Buprenorphine; Humans; Macaca mulatta; Male; Methadone; Nal | 2022 |
Perspectives Regarding Medications for Opioid Use Disorder Among Individuals with Mental Illness.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-R | 2023 |
Effect of TRV130 and methadone on fentanyl-vs.-food choice and somatic withdrawal signs in opioid-dependent and post-opioid-dependent rats.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Fentanyl; Male; Methadone; Narcotics; Opioid-Related Dis | 2022 |
Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cana | 2022 |
[Opioid Substitution Treatment in Prisons: Comparison of Cost of Buprenorphine Depot with other Medications - a Health-Economic Calculation].
Topics: Analgesics, Opioid; Buprenorphine; Germany; Humans; Methadone; Opiate Substitution Treatment; Opioid | 2023 |
Peer recovery specialist-delivered, behavioral activation intervention to improve retention in methadone treatment: Results from an open-label, Type 1 hybrid effectiveness-implementation pilot trial.
Topics: Behavior Therapy; Humans; Methadone; Opioid-Related Disorders; Pilot Projects; Poverty | 2022 |
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Nurse Practitioners; Opiate Substitution Treatment; Op | 2022 |
Hypermethylation in the promoter region of the ADRA1A gene is associated with opioid use disorder in Han Chinese.
Topics: China; CpG Islands; DNA Methylation; Heroin; Humans; Methadone; Opioid-Related Disorders; Promoter R | 2022 |
Comprehensive analysis of discharge reasons from methadone outpatient treatment programs.
Topics: Analgesics, Opioid; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Interaction between methadone and clarithromycin as the suspected cause of an opioid toxidrome.
Topics: Analgesics, Opioid; Clarithromycin; Humans; Methadone; Opioid-Related Disorders | 2023 |
Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Methadone; Naltrexone; Opiate Substitution | 2022 |
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Topics: Aged; Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Female; Humans; Longitudinal Studi | 2022 |
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narc | 2022 |
Inter-trial variability in postural control and brain activation: Effects of previous opiate abuse.
Topics: Brain; Humans; Methadone; Opioid-Related Disorders; Postural Balance; Reaction Time | 2022 |
What's in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment.
Topics: Adult; Ambulatory Care; Behavior, Addictive; Child; Cross-Sectional Studies; Humans; Male; Methadone | 2023 |
Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study.
Topics: Adult; Analgesics, Opioid; Hepatitis C; Heroin; Humans; Illicit Drugs; Methadone; Methamphetamine; M | 2022 |
Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Trea | 2022 |
Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Nalo | 2022 |
Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Humans; Insurance; Male; Methadone; Opioid-Relate | 2022 |
Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Feasibility Studies; Humans; Methadone; Opiate Substitution Treatment; | 2022 |
OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
Topics: Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Massachusetts; Met | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross- | 2022 |
Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
Topics: Analgesics, Opioid; Buprenorphine; Communicable Disease Control; COVID-19; Humans; Methadone; Opiate | 2022 |
Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Topics: Analgesics, Opioid; Arizona; Buprenorphine; COVID-19; COVID-19 Drug Treatment; Humans; Methadone; Op | 2022 |
Interest without uptake: A mixed-methods analysis of methadone utilization in Kyrgyz prisons.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treat | 2022 |
Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-17.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Jails; Male; Methadone; New | 2023 |
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Humans; Methadone; New South Wales; Opioid-Related Dis | 2022 |
The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Health Service | 2022 |
Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada.
Topics: Adolescent; Analgesics, Opioid; Canada; Female; Humans; Methadone; Methamphetamine; Opiate Substitut | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Opioid replacement therapy with methadone or buprenorphine effects on male mice reproduction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Chromatin; Male; Methadone; Mice; Morphine; Morphine Dep | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2023 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2022 |
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
Topics: Buprenorphine; Cesarean Section; Cohort Studies; Female; Humans; Infant; Infant, Low Birth Weight; I | 2022 |
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
Topics: Buprenorphine; Cesarean Section; Cohort Studies; Female; Humans; Infant; Infant, Low Birth Weight; I | 2022 |
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
Topics: Buprenorphine; Cesarean Section; Cohort Studies; Female; Humans; Infant; Infant, Low Birth Weight; I | 2022 |
Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy.
Topics: Buprenorphine; Cesarean Section; Cohort Studies; Female; Humans; Infant; Infant, Low Birth Weight; I | 2022 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
GC-MS Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples.
Topics: Buprenorphine; Gas Chromatography-Mass Spectrometry; Humans; Methadone; Opioid-Related Disorders; Py | 2022 |
GC-MS Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples.
Topics: Buprenorphine; Gas Chromatography-Mass Spectrometry; Humans; Methadone; Opioid-Related Disorders; Py | 2022 |
GC-MS Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples.
Topics: Buprenorphine; Gas Chromatography-Mass Spectrometry; Humans; Methadone; Opioid-Related Disorders; Py | 2022 |
GC-MS Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples.
Topics: Buprenorphine; Gas Chromatography-Mass Spectrometry; Humans; Methadone; Opioid-Related Disorders; Py | 2022 |
Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study.
Topics: Adult; Female; Humans; Kenya; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Re | 2022 |
Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study.
Topics: Adult; Female; Humans; Kenya; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Re | 2022 |
Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study.
Topics: Adult; Female; Humans; Kenya; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Re | 2022 |
Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study.
Topics: Adult; Female; Humans; Kenya; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Re | 2022 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Methadone-involved overdose deaths in the United States before and during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Disease Progression; Drug Overdose; Humans; Methadone; Opiate Overdose | 2023 |
Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opi | 2022 |
Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opi | 2022 |
Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opi | 2022 |
Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Motivation; Opiate Substitution Treatment; Opi | 2022 |
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Topics: Analgesics, Opioid; Canada; COVID-19; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opia | 2022 |
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Topics: Analgesics, Opioid; Canada; COVID-19; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opia | 2022 |
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Topics: Analgesics, Opioid; Canada; COVID-19; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opia | 2022 |
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.
Topics: Analgesics, Opioid; Canada; COVID-19; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opia | 2022 |
The Case for Medication for Opioid Use Disorder during Incarceration as Standard of Care.
Topics: Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Prisoners; Prisons; Standard of Care | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Nalt | 2023 |
Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Illicit | 2023 |
Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder.
Topics: Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitutio | 2022 |
Splice-Site Variants in the Gene Encoding GABA-A Receptor Delta Subunit Are Associated with Amphetamine Use in Patients under Methadone Maintenance Treatment.
Topics: Amphetamine; Genotype; Humans; Methadone; Opioid-Related Disorders; Receptors, GABA-A; RNA Splice Si | 2022 |
Exploring potential moderators of depressive symptoms and treatment outcomes among patients with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Depression; Humans; Methadone; Opiate Substitution Treatment; Opi | 2023 |
How does a clinician approach the pharmacological management of opioid use disorders in pregnant women and pregnant people?
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2023 |
Comparative Safety Analysis of Opioid Agonist Treatment in Pregnant Women with Opioid Use Disorder: A Population-Based Study.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2023 |
The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.
Topics: Buprenorphine, Naloxone Drug Combination; Canada; Costs and Cost Analysis; Drugs, Generic; Humans; I | 2023 |
Should I Stay or Should I Go? A Qualitative Exploration of Stigma and Other Factors Influencing Opioid Agonist Treatment Journeys.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Soci | 2023 |
Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Opiate Substitu | 2023 |
Changes and trends in medication-assisted treatment in Israel.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Israel; Methadone; Naloxone; Opioid-Related Disorders; Ph | 2023 |
Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.
Topics: Humans; Methadone; Opioid-Related Disorders; Prior Authorization; United States | 2023 |
Intrapartum Pain Management for People on Medication-Assisted Therapy for Opioid Use Disorder: AWHONN Practice Brief Number 17.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pain Management | 2023 |
Intrapartum Pain Management for People on Medication-Assisted Therapy for Opioid Use Disorder Practice Brief: AWHONN Practice Brief Number 17.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pain Management | 2023 |
[Buprenorphine depot in opiate use disorder].
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Alkaloids; Opioid-Related Disorders | 2023 |
Examination of methadone involved overdoses during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Drug Overdose; Humans; Methadone; Opiate Overdose; Opioid-Related Diso | 2023 |
Retention of service users on opioid substitution therapy in the City of Tshwane, South Africa.
Topics: Adult; Analgesics, Opioid; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Di | 2023 |
Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20.
Topics: Analgesics, Opioid; British Columbia; Buprenorphine; COVID-19; Eating; Health Expenditures; Humans; | 2023 |
Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Meth | 2023 |
Harm reduction behaviors are associated with carrying naloxone among patients on methadone treatment.
Topics: Analgesics, Opioid; Drug Overdose; Harm Reduction; Humans; Male; Methadone; Middle Aged; Naloxone; N | 2023 |
Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers.
Topics: Communication; Humans; Jails; Mental Processes; Methadone; Opioid-Related Disorders | 2023 |
Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Hydromo | 2023 |
Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Topics: Aged; Analgesics, Opioid; Australia; Buprenorphine; Cohort Studies; Drug Overdose; Humans; Methadone | 2023 |
"Sometimes you have to take the person and show them how": adapting behavioral activation for peer recovery specialist-delivery to improve methadone treatment retention.
Topics: Behavior Therapy; Focus Groups; Humans; Methadone; Opioid-Related Disorders | 2023 |
Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities.
Topics: Budgets; Humans; Jails; Methadone; Opioid-Related Disorders; Prisons | 2023 |
Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
Topics: Analgesics, Opioid; Baltimore; COVID-19; Humans; Male; Methadone; Middle Aged; Opioid-Related Disord | 2023 |
Buprenorphine versus Methadone in Pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy | 2023 |
Buprenorphine versus Methadone in Pregnancy. Reply.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy | 2023 |
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.
Topics: Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substituti | 2023 |
Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2023 |
Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; | 2023 |
Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2023 |
Stimulant use among patients in opioid treatment settings: Provider perspectives.
Topics: Analgesics, Opioid; Drug Overdose; Fentanyl; Humans; Methadone; Opiate Substitution Treatment; Opioi | 2023 |
The interaction of race and age in methadone treatment retention outcomes: A single-center analysis.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Retr | 2023 |
Patients' perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; COVID-19; Humans; Methadone; Opiate Substituti | 2023 |
"Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
Topics: Analgesics, Opioid; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2023 |
Phenobarbital for alcohol withdrawal in the context of the opioid epidemic: a neglected caveat.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opi | 2023 |
Economic, social, and clinic influences on opioid treatment program retention in Dar es Salaam, Tanzania: a qualitative study.
Topics: Analgesics, Opioid; Female; HIV Infections; Humans; Methadone; Opiate Substitution Treatment; Opioid | 2023 |
Lived experiences of Oxford House residents prescribed medication-assisted treatment.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Qualitativ | 2023 |
Treatment access for opioid use disorder among women with medicaid in Florida.
Topics: Analgesics, Opioid; Buprenorphine; Female; Florida; Humans; Medicaid; Methadone; Opiate Substitution | 2023 |
Single-Center Retrospective Comparison of Opioid-Based and Multimodal Analgesic Regimens in Adult Cardiac Surgery.
Topics: Adult; Analgesics; Analgesics, Opioid; Cardiac Surgical Procedures; Dexmedetomidine; Humans; Methado | 2023 |
METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Opiate Substituti | 2023 |
A Comparative Effectiveness Study on Opioid Use Disorder Prediction Using Artificial Intelligence and Existing Risk Models.
Topics: Analgesics, Opioid; Artificial Intelligence; Buprenorphine; Female; Humans; Male; Methadone; Middle | 2023 |
Is Providing Medications for Opioid Use Disorder to Incarcerated Individuals a Cost-effective Strategy?
Topics: Cost-Benefit Analysis; Humans; Methadone; Opioid-Related Disorders; Prisoners | 2023 |
Psychosocial challenges affecting patient-defined medication for opioid use disorder treatment outcomes in a low-income, underserved population: Application of the social-ecological framework.
Topics: Focus Groups; Humans; Methadone; Opioid-Related Disorders; Poverty; Vulnerable Populations | 2023 |
More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment.
Topics: Analgesics, Opioid; Heroin; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorde | 2023 |
United States county jail treatment and care of pregnant incarcerated persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Humans; Jails; Methadone; Opiate | 2023 |
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Humans; Methadone; Opiate Substitution Treatment; Opioid | 2023 |
Treating Opioid Use Disorder in Patients Who Are Incarcerated: Quandaries of a Hospitalist.
Topics: Analgesics, Opioid; Buprenorphine; Hospitalists; Humans; Methadone; Opiate Substitution Treatment; O | 2023 |
Opioid Use Disorder During Breastfeeding.
Topics: Analgesics, Opioid; Breast Feeding; Female; Humans; Methadone; Opioid-Related Disorders | 2023 |
Augmenting project ECHO for opioid use disorder with data-informed quality improvement.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid | 2023 |
Methadone alters transcriptional programs associated with synapse formation in human cortical organoids.
Topics: Analgesics, Opioid; Brain; Female; Humans; Infant; Methadone; Opiate Substitution Treatment; Opioid- | 2023 |
Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Self Report; Social Medi | 2023 |
Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.
Topics: Analgesics, Opioid; Chromatography, Liquid; Cocaine; Fentanyl; Heroin; Humans; Methadone; Methamphet | 2023 |
Predictors of Linkage to an Opioid Treatment Program and Methadone Treatment Retention following Hospital Discharge in a Safety-Net Setting.
Topics: Adult; Aftercare; Analgesics, Opioid; Hospitals; Humans; Methadone; Opiate Substitution Treatment; O | 2023 |
Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Topics: Aged; Buprenorphine; COVID-19; Cross-Sectional Studies; Female; Humans; Male; Medicare Part C; Metha | 2023 |
A comparison of postpartum opioid consumption and opioid discharge prescriptions among opioid-naïve patients and those with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Female; Humans; Methadone; Morphine Derivativ | 2023 |
Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Crack Cocaine; Drug Overdose; Fentanyl; Heroin; | 2023 |
Things We Do for No Reason™: Avoiding methadone for opioid withdrawal.
Topics: Analgesics, Opioid; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syn | 2023 |
Informing youth-centred opioid agonist treatment: Findings from a retrospective chart review of youths' characteristics and patterns of opioid agonist treatment engagement in a novel integrated youth services program.
Topics: Adolescent; Adult; Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Rela | 2023 |
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Topics: Analgesics, Opioid; British Columbia; Buprenorphine; Buprenorphine, Naloxone Drug Combination; COVID | 2023 |
Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2023 |
Rescue Analgesia for Opioid-Dependent Individuals on Opioid Agonist Treatment during Hospitalization: Adherence to Guideline Treatment.
Topics: Adult; Analgesics; Analgesics, Opioid; Female; Hospitalization; Humans; Male; Methadone; Middle Aged | 2023 |
Opioid and Methadone Use for Infants With Surgically Treated Necrotizing Enterocolitis.
Topics: Analgesics, Opioid; Child; Cohort Studies; Enterocolitis, Necrotizing; Female; Humans; Infant; Infan | 2023 |
Trends in smoking during pregnancy stratified by the use of opioid agonist therapy and the contribution of smoking to poor outcome in neonates prenatally exposed to opioid agonist treatment.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Opiate Substitution T | 2023 |
Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Medicare; Methadone; | 2023 |
Trends in Rates of Opioid Agonist Treatment and Opioid-Related Deaths for Youths in Ontario, Canada, 2013-2021.
Topics: Adolescent; Adult; Analgesics, Opioid; Cross-Sectional Studies; Female; Humans; Male; Methadone; Ont | 2023 |
Technical violations and infractions are drivers of disengagement from methadone treatment among people with opioid use disorder discharged from Connecticut jails 2014-2018.
Topics: Analgesics, Opioid; Connecticut; Humans; Jails; Male; Methadone; Opiate Substitution Treatment; Opio | 2023 |
Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada: A population-based time series analysis.
Topics: Administration, Oral; Analgesics, Opioid; Delayed-Action Preparations; Female; Humans; Male; Methado | 2023 |
Trajectories of drug treatment and illicit opioid use in the AIDS Linked to the IntraVenous Experience cohort, 2014-2019.
Topics: Acquired Immunodeficiency Syndrome; Aged; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opia | 2023 |
Attitudes toward methadone treatment among Black/African Americans: Implications for engagement and retention.
Topics: Attitude; Black or African American; Humans; Methadone; Minority Groups; Opiate Substitution Treatme | 2023 |
Comparison of oral versus intravenous methadone on postoperative pain and opioid use after adult spinal deformity surgery: A retrospective, non-inferiority analysis.
Topics: Adult; Analgesics, Opioid; Cohort Studies; Humans; Long QT Syndrome; Methadone; Morphine; Opioid-Rel | 2023 |
A truly patient-centred evaluation of opioid agonist treatment.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2023 |
Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant.
Topics: Analgesics, Opioid; Benzodiazepines; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2023 |
Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Phar | 2023 |
Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.
Topics: Analgesics, Opioid; Humans; Latent Class Analysis; Methadone; Opiate Substitution Treatment; Opioid- | 2023 |
Buprenorphine and methadone differentially alter early brain development in human cortical organoids.
Topics: Analgesics, Opioid; Brain; Buprenorphine; Humans; Infant, Newborn; Methadone; N-Methylaspartate; Nar | 2023 |
Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Methamphetamine; Opiate Substitution Treatment | 2023 |
Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
Topics: Analgesics, Opioid; Buprenorphine; COVID-19; Female; Humans; Male; Methadone; Middle Aged; Opiate Su | 2023 |
"I thought it was for guys that did needles": Medication perceptions and lay expertise among medical research participants.
Topics: British Columbia; Buprenorphine, Naloxone Drug Combination; Humans; Male; Methadone; Opiate Substitu | 2023 |
Impact of combination of intermittent theta burst stimulation and methadone maintenance treatment in individuals with opioid use disorder: A comparative study.
Topics: Anxiety; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Transcranial Ma | 2023 |
Re-Purposing FDA-Approved Drugs for Opioid Use Disorder.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Comorbidity; Humans; Methadone; Middle A | 2023 |
Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Topics: Buprenorphine; Humans; Long QT Syndrome; Methadone; Naltrexone; Opiate Substitution Treatment; Opioi | 2023 |
Risk and Protective Factors Affecting Drug Craving among Patients with Substance Use Disorders Undergoing Opioid Agonists Maintenance Therapy.
Topics: Analgesics, Opioid; Buprenorphine; Craving; Family Health; Humans; Methadone; Opiate Substitution Tr | 2023 |
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Humans; Methadone; Naltrexone; Opiate Substitution Treat | 2023 |
Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage.
Topics: Aftercare; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opio | 2023 |
Using ADAPT-ITT framework to tailor evidence-based interventions for addressing methamphetamine use among methadone patients in Vietnam.
Topics: Evidence-Based Medicine; Humans; Methadone; Methamphetamine; Opiate Substitution Treatment; Opioid-R | 2023 |
State-Specific Barriers to Methadone for Opioid Use Disorder Treatment.
Topics: Humans; Methadone; Opiate Overdose; Opioid-Related Disorders | 2023 |
Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pharmaceutical Services; Pharmacies | 2023 |
Rapid Methadone Induction in a General Hospital Setting: A Retrospective, Observational Analysis.
Topics: Analgesics, Opioid; Hospitals, General; Humans; Methadone; Opioid-Related Disorders; Retrospective S | 2023 |
"Get in and get out, get on with life": Patient and provider perspectives on methadone van implementation for opioid use disorder treatment.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Opiate Substitu | 2023 |
Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
Topics: Analgesics, Opioid; Cocaine; Drug Overdose; Emergency Service, Hospital; Fentanyl; Humans; Illicit D | 2023 |
Large variations in all-cause and overdose mortality among >13,000 patients in and out of opioid maintenance treatment in different settings: a comparative registry linkage study.
Topics: Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid | 2023 |
Medications for Opioid Use Disorder and Mortality and Hospitalization Among People With Opioid Use-related Infections.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospitalization; Humans; Male; Methadone; Opiate S | 2024 |
Shift in hospital opioid use during the COVID-19 pandemic in Brazil: a time-series analysis of one million prescriptions.
Topics: Adult; Analgesics, Opioid; Brazil; COVID-19; Fentanyl; Humans; Methadone; Morphine; Opioid-Related D | 2023 |
Regaining control over opioid use? The potential application of auricular transcutaneous vagus nerve stimulation to improve opioid treatment in China.
Topics: Analgesics, Opioid; China; Humans; Methadone; Opioid-Related Disorders; Vagus Nerve Stimulation | 2023 |
Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy.
Topics: Analgesics, Opioid; Buprenorphine; Educational Status; Humans; Methadone; Opiate Substitution Treatm | 2023 |
Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2023 |
Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Topics: Analgesics, Opioid; COVID-19; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; Opioi | 2023 |
Juggling Two Full-Time Jobs - Methadone Clinic Engagement and Cancer Care.
Topics: Humans; Methadone; Neoplasms; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Health and Neurodevelopment of Children Born to Opioid-Dependent Mothers at School Entry.
Topics: Child of Impaired Parents; Child, Preschool; Female; Health Status; Humans; Infant; Infant, Newborn; | 2020 |
Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Topics: Adult; Age Factors; Analgesics, Opioid; Black People; Buprenorphine; Confidence Intervals; Correlati | 2020 |
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
Topics: Buprenorphine; Drug Overdose; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Narcotic A | 2020 |
Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway.
Topics: Adult; Buprenorphine; Child Development; Czech Republic; Female; Humans; Infant, Newborn; Logistic M | 2019 |
Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Metha | 2019 |
Innovations in efforts to expand treatment for opioid use disorder.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; | 2019 |
Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related D | 2020 |
The need to broaden and strengthen the evidence base for supervised consumption sites.
Topics: Humans; Methadone; Opioid-Related Disorders | 2019 |
The imperative of clinical and molecular research on neonatal opioid withdrawal syndrome.
Topics: Analgesics, Opioid; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opioid | 2019 |
Correlation between interleukin-6 levels and methadone maintenance therapy outcomes.
Topics: Adolescent; Adult; Aged; Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Female; | 2019 |
Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Fentanyl; Heroin; Humans; Male; Met | 2019 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Dr | 2019 |
Multi-level predictors of psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam.
Topics: Adult; Anxiety; Comorbidity; Cross-Sectional Studies; Depression; Humans; Male; Methadone; Middle Ag | 2019 |
Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
Topics: Adolescent; Adult; Attitude; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methado | 2020 |
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Continuity of Patient Care; Delayed-Action Preparations; F | 2019 |
Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States.
Topics: Analgesics, Opioid; Health Services Accessibility; Humans; Methadone; Opioid-Related Disorders; Rena | 2019 |
Relationship of County Opioid Epidemic Severity to Changes in Access to Substance Use Disorder Treatment, 2009-2017.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Logistic Models; Medicaid; | 2020 |
Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Cohort Studies; Emergency Service, Hospital; Fe | 2019 |
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Topics: Adolescent; Adult; Age Distribution; Analgesics, Opioid; Buprenorphine; Databases, Factual; Drug Ove | 2020 |
Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.
Topics: Buprenorphine; Cost-Benefit Analysis; Decision Support Techniques; Female; Humans; Methadone; Narcot | 2019 |
Opioid agonist therapy during residential treatment of opioid use disorder: Cohort study on access and outcomes.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Ontario; Opiate Substitution Treatment; | 2019 |
Characteristics Associated with Nonmedical Methadone Use among People Who Inject Drugs in California.
Topics: Adult; California; Cross-Sectional Studies; Female; Humans; Illicit Drugs; Male; Methadone; Middle A | 2020 |
Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Cocaine; Cocaine-Related Disorders; Decision Making; Female; Follow-Up St | 2019 |
Characteristics and current clinical practices of opioid treatment programs in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opia | 2019 |
Health-Seeking Behavior for Erectile Dysfunction in Methadone Maintenance Treatment Patients.
Topics: Adult; Drug Users; Erectile Dysfunction; Health Behavior; Humans; Malaysia; Male; Methadone; Middle | 2019 |
Factors Associated with Sleep Disorders among Methadone-Maintained Drug Users in Vietnam.
Topics: Adult; Cross-Sectional Studies; Drug Users; Female; Humans; Male; Methadone; Opiate Substitution Tre | 2019 |
Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.
Topics: Adolescent; Adult; Analgesics, Opioid; Australia; Chronic Pain; Drug Overdose; Drug Prescriptions; F | 2019 |
Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine, Naloxone Drug Combination; Cohort Studie | 2019 |
Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: Possible role as a biomarker in severe opioid use disorder.
Topics: Adult; Animals; Biomarkers; Case-Control Studies; Dynorphins; Humans; Lymphocytes; Male; Methadone; | 2019 |
Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities.
Topics: Analgesics, Opioid; Global Health; Hospitals; Humans; Incidence; Methadone; Opioid-Related Disorders | 2020 |
Medications for opioid use disorders: clinical and pharmacological considerations.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Topics: Analgesics, Opioid; Beneficence; Buprenorphine; Correctional Facilities; Evidence-Based Practice; He | 2020 |
Buprenorphine compared with methadone in opioid-dependent pregnant women: How does it affect neonatal abstinence syndrome?
Topics: Adult; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Narcotic A | 2019 |
Is Methadone an Opioid Sparing Strategy?
Topics: Analgesics, Opioid; Cohort Studies; Humans; Methadone; Opioid-Related Disorders | 2020 |
Multimodal assessment of sleep in men and women during treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Ecological Momentary Assessment; Electroen | 2020 |
Private Coverage of Methadone in Outpatient Treatment Programs.
Topics: Health Expenditures; Health Services Accessibility; Humans; Insurance Coverage; Methadone; Opioid-Re | 2020 |
Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Methadone; Naltrexone; Opioid-Related Dis | 2020 |
Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment.
Topics: Adult; Buprenorphine; Cost of Illness; Female; Germany; Health Care Costs; Humans; Male; Methadone; | 2019 |
Haplotype-Based Association and In Silico Studies of OPRM1 Gene Variants with Susceptibility to Opioid Dependence Among Addicted Iranians Undergoing Methadone Treatment.
Topics: Adult; Haplotypes; Humans; Iran; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-R | 2020 |
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Female; Hepatitis C; Humans; Ill-Housed | 2020 |
Preferences for methadone clinics among drug users in Vietnam: a comparison between public and private models.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Drug Users; Female; Humans; Male; Methadone; Mid | 2020 |
Investigating opioid-related fatalities in southern Sweden: contact with care-providing authorities and comparison of substances.
Topics: Adult; Aged; Analgesics, Opioid; Buprenorphine; Female; Fentanyl; Heroin; Humans; Male; Methadone; M | 2020 |
Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
Topics: Adult; Age Factors; British Columbia; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male | 2020 |
Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Endocarditis; Female; Humans; Injections; Male; Methadone; | 2020 |
COPD and asthma in patients with opioid dependency: a cross-sectional study in primary care.
Topics: Adult; Analgesics, Opioid; Asthma; Case-Control Studies; Cigarette Smoking; Cross-Sectional Studies; | 2020 |
Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Drug Utilization; Fem | 2020 |
Acute Pain Management for Patients Receiving Medication-Assisted Therapy.
Topics: Acute Pain; Adult; Aged; Aged, 80 and over; Analgesics; Buprenorphine; Female; Humans; Male; Methado | 2019 |
Substance use disorder treatment services for pregnant and postpartum women in residential and outpatient settings.
Topics: Buprenorphine; Female; Health Services Accessibility; Humans; Methadone; Opioid-Related Disorders; O | 2020 |
Initial Management of Incarcerated Pregnant Women With Opioid Use Disorder.
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2020 |
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Topics: Adolescent; Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Comparative Effectiveness Re | 2020 |
Delirium Prolonged for Three Days after Addition of One Dose of 5 mg Methadone to Ongoing Opioid.
Topics: Analgesics, Opioid; Delirium; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Methad | 2020 |
Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Health Services Accessibility; Humans; M | 2020 |
Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? A retrospective cohort study.
Topics: Adult; Cause of Death; Cohort Studies; Drug Overdose; Female; Humans; Ireland; Male; Methadone; Midd | 2020 |
Opioid Crisis Along Mexico's Northern Border: Treatment Needs Mexican Opioid Crisis.
Topics: Adolescent; Adult; Female; Heroin; Humans; Male; Methadone; Mexico; Opioid Epidemic; Opioid-Related | 2019 |
Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa.
Topics: Adult; Comorbidity; Dose-Response Relationship, Drug; Female; Health Status; Heroin Dependence; Huma | 2020 |
The impact of chronic liver disease in patients receiving active pharmacological therapy for opioid use disorder: One-year findings from a prospective cohort study.
Topics: Adult; Analgesics, Opioid; Cohort Studies; End Stage Liver Disease; Female; Humans; Male; Methadone; | 2020 |
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Cohort Studies; Drug Overdose; | 2020 |
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Massachusetts | 2020 |
Urine toxicology screen negative for Methadone metabolite but positive for Methadone in a patient on Methadone maintenance therapy (MMT).
Topics: Humans; Male; Methadone; Middle Aged; Narcotics; Opiate Substitution Treatment; Opioid-Related Disor | 2020 |
Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Topics: Analgesics, Opioid; Buprenorphine; Cost of Illness; Geography; Healthcare Disparities; Humans; Medic | 2020 |
Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Humans; Incidence; Methadone; Na | 2020 |
Emerging therapies for the treatment of neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Ab | 2022 |
The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Medicaid; Methadone; Opiat | 2020 |
Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Diagnosis, Dual (Psychiatry); Ethnicity; Femal | 2020 |
Understanding concurrent stimulant use among people on methadone: A qualitative study.
Topics: Adult; Analgesics, Opioid; Central Nervous System Stimulants; Female; Humans; Methadone; Middle Aged | 2020 |
Methadone, Buprenorphine, or Detoxification for Management of Perinatal Opioid Use Disorder: A Cost-Effectiveness Analysis.
Topics: Buprenorphine; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Methadone; Opiate Substitutio | 2020 |
In Reply.
Topics: Buprenorphine; Cost-Benefit Analysis; Humans; Methadone; Opioid-Related Disorders | 2020 |
HIV care continuum characteristics among people with opioid use disorder and HIV in Vietnam: baseline results from the BRAVO study.
Topics: Adult; Analgesics, Opioid; Anti-Retroviral Agents; Buprenorphine; Continuity of Patient Care; Female | 2020 |
Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.
Topics: Adolescent; Adult; British Columbia; Buprenorphine; Cause of Death; Cohort Studies; Emergencies; Fem | 2020 |
The psychiatrist at the centre of the opioid crisis.
Topics: Alcoholism; Cocaine-Related Disorders; Dopamine; Drug Overdose; Heroin Dependence; History, 20th Cen | 2020 |
Necrotizing enterocolitis and its association with the neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Enterocolitis, Necrotizing; Female; Fetal Blood; | 2020 |
High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion.
Topics: Adult; Analgesics, Opioid; Female; Harm Reduction; Humans; Male; Methadone; Opiate Substitution Trea | 2020 |
Toward precision prescribing for methadone: Determinants of methadone deposition.
Topics: Alleles; Analgesics, Opioid; Cross-Sectional Studies; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3 | 2020 |
Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study.
Topics: Analgesics, Opioid; Bupropion; Cotinine; Female; Humans; Methadone; Nicotine; Opiate Substitution Tr | 2020 |
Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations.
Topics: Ambulatory Care; Analgesics, Opioid; Anxiety; China; Coronavirus Infections; COVID-19; Delivery of H | 2020 |
Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment.
Topics: Betacoronavirus; Buprenorphine; Continuity of Patient Care; Coronavirus Infections; COVID-19; Humans | 2020 |
Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Health Services Accessibility; Humans; Male; Methadon | 2020 |
Diagnosis and Treatment of Opioid Use Disorder in 2020.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disor | 2020 |
Non-Opioid Substances Acute Poisonings with Suicidal Intent in Patients with Opioid Use Disorder.
Topics: Adolescent; Adult; Analgesics, Opioid; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2020 |
Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy.
Topics: Buprenorphine; Child; Female; Follow-Up Studies; Humans; Methadone; Opiate Substitution Treatment; O | 2020 |
Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substituti | 2020 |
Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Criminals; Cross-Sectional Studies; Drug Industry; Florida; Human | 2020 |
Association of
Topics: Adult; Analgesics, Opioid; Asian People; Biomarkers, Pharmacological; Case-Control Studies; Catechol | 2020 |
Experiences of Clients in Three Types of Methadone Maintenance Therapy in an Atlantic Canadian City: A Qualitative Study.
Topics: Analgesics, Opioid; Canada; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorde | 2021 |
The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Humans; Longitudinal Studies; Male | 2021 |
Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Topics: Adult; Ambulatory Care; Buprenorphine; Cohort Studies; Female; Humans; Male; Methadone; Middle Aged; | 2021 |
TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Topics: Analgesics, Opioid; Betacoronavirus; Buprenorphine; Coronavirus Infections; COVID-19; Humans; Methad | 2020 |
Opioid Use Disorder Treatment Facilities With Programs for Special Populations.
Topics: Adolescent; Adult; Depression, Postpartum; Female; Humans; Infant, Newborn; Male; Methadone; Middle | 2020 |
Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Topics: Adult; Black or African American; Buprenorphine; Female; Healthcare Disparities; Hispanic or Latino; | 2020 |
Commentary on Gibson et al. (2020): Medications for opioid use disorder- access, retention, and safety.
Topics: Buprenorphine; England; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; | 2020 |
Pain outcomes among patients after cesarean consuming buprenorphine or methadone and opioid-naïve patients.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opioid-Related Disorders; Pain; Pregna | 2020 |
Associations Among Sleep Disturbance, Pain Catastrophizing, and Pain Intensity for Methadone-maintained Patients With Opioid Use Disorder and Chronic Pain.
Topics: Adult; Catastrophization; Chronic Pain; Cross-Sectional Studies; Female; Humans; Male; Methadone; Mi | 2020 |
[Opioid Agonist Therapy (OAT) for opioid dependency].
Topics: Analgesics, Opioid; Buprenorphine; Europe; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2020 |
Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Outp | 2020 |
Scotland's 2009-2015 methadone-prescription cohort: Quintiles for daily dose of prescribed methadone and risk of methadone-specific death.
Topics: Buprenorphine; Female; Humans; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related | 2021 |
Methadone-related deaths among youth and young adults in Sweden 2006-15.
Topics: Adolescent; Adult; Drug Overdose; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorde | 2021 |
Stress indices in methadone maintenance treatment - Cross sectional and follow up study.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Follow-Up Studies; Heart Rate; Humans; Hydrocort | 2020 |
Genetic variants in NECTIN4 encoding an adhesion molecule are associated with continued opioid use.
Topics: Adult; Analgesics, Opioid; Cell Adhesion Molecules; Female; Genetic Predisposition to Disease; Genom | 2020 |
Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment.
Topics: Adult; Analgesics, Opioid; Disorders of Excessive Somnolence; Female; Humans; Male; Methadone; Middl | 2020 |
Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies | 2021 |
Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care.
Topics: Administration, Oral; Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, | 2020 |
One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission.
Topics: Analgesics, Opioid; Fentanyl; Follow-Up Studies; Humans; Methadone; Opiate Substitution Treatment; O | 2020 |
Effects of polysubstance exposure on neonatal outcomes for infants with intrauterine opioid exposure.
Topics: Analgesics, Opioid; Female; Humans; Infant; Infant, Newborn; Length of Stay; Methadone; Morphine; Ne | 2020 |
Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes.
Topics: Adaptive Immunity; Analgesics, Opioid; Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections | 2020 |
Methadone for Opioid Use Disorder-Decades of Effectiveness but Still Miles Away in the US.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?
Topics: Analgesics, Opioid; Buprenorphine; Coronavirus Infections; COVID-19; Humans; Methadone; Opiate Subst | 2020 |
Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies.
Topics: Birth Weight; Buprenorphine; Delivery, Obstetric; Female; Humans; Infant, Newborn; Length of Stay; M | 2020 |
Validation and psychometric properties of the community assessment inventory in Iranian persons who use drug.
Topics: Female; Humans; Iran; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Psyc | 2020 |
Medications for opioid use disorder in pregnancy in a state women's prison facility.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; North Carolina; Opioid-Related | 2020 |
Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Topics: Ambulatory Care Facilities; Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Health Servi | 2020 |
Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Topics: Analgesics, Opioid; Australia; Betacoronavirus; Buprenorphine; Canada; Community Pharmacy Services; | 2020 |
Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; North Carolina; Opiate Substitution Treatment; | 2020 |
Adverse neonatal outcomes associated with maternal severe mental health diagnoses and opioid use.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Mental Health; Methadone; Neonat | 2020 |
Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution | 2020 |
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Behavior Therapy; Buprenorphine; Cohort Studies; Female; H | 2020 |
Integration of a contraception clinic into an opioid treatment setting to improve contraception knowledge, accessibility and uptake: a pilot study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Contraception; Delivery of Health Care, Integr | 2020 |
A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Buprenorphine; Continui | 2020 |
Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
Topics: Adolescent; Adult; Aged; Continuity of Patient Care; Endemic Diseases; Female; Health Services Needs | 2020 |
Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
Topics: Adolescent; Adult; Aged; Female; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Methadone; Middl | 2020 |
Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Buprenorphine, Naloxone Drug Combination | 2020 |
Orchestrated Testing of Formula Type to Reduce Length of Stay in Neonatal Abstinence Syndrome.
Topics: Energy Intake; Female; Humans; Infant Formula; Infant, Newborn; Lactose; Length of Stay; Methadone; | 2020 |
Correlates of Homelessness Among Patients in Methadone Maintenance Treatment.
Topics: Adult; Age Factors; Female; Humans; Ill-Housed Persons; Logistic Models; Male; Mental Disorders; Met | 2020 |
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Delayed-Action Preparations; Drug a | 2020 |
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Case Managers; Counselors; Criminal Law; Criminals; Cross-Section | 2020 |
Long term pre-treatment opioid use trajectories in relation to opioid agonist therapy outcomes among people who use drugs in a Canadian setting.
Topics: Adolescent; Analgesics, Opioid; Canada; Humans; Male; Methadone; Opioid-Related Disorders; Pharmaceu | 2021 |
Contraception Practices Among Women on Opioid Agonist Therapy.
Topics: Adult; British Columbia; Buprenorphine, Naloxone Drug Combination; Contraception; Contraception Beha | 2021 |
Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials.
Topics: Adult; Behavior Therapy; Clinical Trials as Topic; Cluster Analysis; Cocaine-Related Disorders; Fema | 2020 |
Retention and outcomes for clients attending a methadone clinic in a resource-constrained setting: a mixed methods prospective cohort study in Imphal, Northeast India.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Female; Humans; India; Male; Methadone; Middle Age | 2020 |
Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Buprenorphine; Drug Overdose; Female; Health Services Ac | 2020 |
Pay for Performance and Treatment Outcome in Agonist Treatment for Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opioid-R | 2021 |
Overdue for an Overhaul: How Opioid Treatment Programs Can Learn From COVID-19.
Topics: Analgesics, Opioid; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Infection Control; Me | 2020 |
Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
Topics: Ambulatory Care Facilities; Coronavirus Infections; COVID-19; Health Services Accessibility; Humans; | 2020 |
Neurobehavior of newborn infants exposed prenatally to methadone and identification of a neurobehavioral profile linked to poorer neurodevelopmental outcomes at age 24 months.
Topics: Adult; Analgesics, Opioid; Attention; Case-Control Studies; Child Development; Female; Humans; Infan | 2020 |
Improvement in Cognitive Performance after One Year of Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Cognition; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; | 2020 |
Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
Topics: Analgesics, Opioid; Buprenorphine; Coronavirus Infections; COVID-19; Drug Overdose; Humans; Methadon | 2020 |
Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.
Topics: Adult; Buprenorphine; Female; Humans; Interprofessional Relations; Male; Methadone; Middle Aged; Nal | 2021 |
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Humans; Methadone; Opiate Substitution T | 2021 |
From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia.
Topics: British Columbia; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Topics: Black or African American; Buprenorphine; COVID-19; Health Services Accessibility; Healthcare Dispar | 2021 |
Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder.
Topics: Analgesics, Opioid; Cocaine-Related Disorders; Humans; Methadone; Opiate Substitution Treatment; Opi | 2021 |
Dyadic associations between relationship quality and risk of opioid use among couples receiving methadone for opioid use disorder.
Topics: Adolescent; Adult; Analgesics, Opioid; Family Characteristics; Female; Humans; Interpersonal Relatio | 2021 |
System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2021 |
COVID-19 and treating incarcerated populations for opioid use disorder.
Topics: Buprenorphine; COVID-19; Humans; Massachusetts; Methadone; Naltrexone; Opiate Substitution Treatment | 2021 |
The provision of counseling to patients receiving medications for opioid use disorder: Telehealth innovations and challenges in the age of COVID-19.
Topics: Buprenorphine; Continuity of Patient Care; Counseling; COVID-19; Delivery of Health Care; Humans; Me | 2021 |
Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
Topics: Big Data; Buprenorphine; COVID-19; Drug Overdose; Health Policy; Humans; Methadone; Narcotic Antagon | 2021 |
Prevalence and Geographic Distribution of Obstetrician-Gynecologists Who Treat Medicaid Enrollees and Are Trained to Prescribe Buprenorphine.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Female; Humans; Infant, Newborn; Male; Medicaid; Meth | 2020 |
Is Maternal Methadone Dose Associated with the Severity of Neonatal Abstinence Syndrome?
Topics: Female; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Syndrome; Opioid-Related D | 2022 |
Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives.
Topics: Clinical Decision-Making; COVID-19; Health Personnel; Health Services Accessibility; Humans; Methado | 2021 |
Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program.
Topics: Adult; Female; Humans; Long QT Syndrome; Male; Methadone; Middle Aged; Opioid-Related Disorders; Pro | 2021 |
Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
Topics: Analgesics, Opioid; Buprenorphine; Hepacivirus; Humans; Medicaid; Methadone; New York; Opiate Substi | 2021 |
A qualitative investigation of addiction counselors' perceptions and experiences implementing an open-access model for treating opioid use disorder.
Topics: Adult; Counselors; Delivery of Health Care; Female; Health Services Accessibility; Humans; Male; Met | 2021 |
The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opi | 2021 |
Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.
Topics: Adult; Analgesics, Opioid; Australia; Female; Humans; Male; Methadone; New South Wales; Opiate Subst | 2021 |
Impulsivity and craving in subjects with opioid use disorder on methadone maintenance treatment.
Topics: Adult; Cognition; Craving; Executive Function; Female; Humans; Impulsive Behavior; Male; Methadone; | 2021 |
Factors predicting 6-month retention among people with opioid use disorders accessing outpatient methadone maintenance therapy in Tshwane, South Africa.
Topics: Adult; Cohort Studies; Female; Heroin Dependence; Humans; Male; Methadone; Opiate Substitution Treat | 2020 |
Shortages of Medication-Assisted Treatment for Opioid Use Disorder in Underserved Michigan Counties: Examining the Influence of Urbanicity and Income Level.
Topics: Buprenorphine; Humans; Methadone; Michigan; Opioid-Related Disorders; Rural Population | 2020 |
Neonatal abstinence syndrome in neonates born of mothers in drug-assisted rehabilitation.
Topics: Female; Humans; Infant; Infant, Newborn; Methadone; Mothers; Neonatal Abstinence Syndrome; Norway; O | 2021 |
Methadone dose at delivery is not an accurate proxy for fetal exposure.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Opioid-Related Disorders; Substance Withdrawal Sy | 2021 |
Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cerebral Palsy; Cost-Benefit Analysis; Female; Fetal Growth Retar | 2022 |
Prenatal methadone exposure and child developmental outcomes in 2-year-old children.
Topics: Adult; Child Development; Child, Preschool; Confounding Factors, Epidemiologic; Female; Humans; Infa | 2021 |
Managing opioid withdrawal precipitated by buprenorphine with buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Female; France; H | 2021 |
An anesthesiologist-led inpatient buprenorphine initiative.
Topics: Analgesics, Opioid; Anesthesiologists; Buprenorphine; Humans; Inpatients; Methadone; Naltrexone; Opi | 2021 |
Medication for Adolescents and Young Adults With Opioid Use Disorder.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorde | 2021 |
Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.
Topics: Analgesics, Opioid; Cross-Sectional Studies; Health Services Accessibility; Humans; Male; Methadone; | 2021 |
Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample.
Topics: Adolescent; Adult; Alaskan Natives; American Indian or Alaska Native; Buprenorphine; Databases, Fact | 2021 |
Associations between opioid dependence and sweet taste preference.
Topics: Adolescent; Adult; Dysgeusia; Female; Food Preferences; Humans; Male; Methadone; Middle Aged; Opiate | 2021 |
Imperfect progress: treatment options for opioid dependence.
Topics: Buprenorphine; HIV Infections; Humans; Maintenance; Methadone; Naloxone; Nitriles; Opioid-Related Di | 2021 |
What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; France; Humans; Male; Methadone; | 2021 |
Beyond abstinence and relapse II: momentary relationships between stress, craving, and lapse within clusters of patients with similar patterns of drug use.
Topics: Affect; Buprenorphine; Cocaine-Related Disorders; Craving; Ecological Momentary Assessment; Female; | 2021 |
Augmentation in Healthcare Utilization of Patients with Opioid Use Disorder After Methadone Maintenance Treatment: A Retrospective Nationwide Study.
Topics: Delivery of Health Care; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; | 2021 |
Changes in opioid-related deaths following increased access to opioid substitution treatment.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2021 |
Why comparative epidemiological indicators suggest that New Zealand is unlikely to experience a severe opioid epidemic.
Topics: Analgesics, Opioid; Humans; Methadone; New Zealand; Opioid Epidemic; Opioid-Related Disorders; Unite | 2021 |
A chance to do it better: Methadone maintenance treatment in the age of Covid-19.
Topics: COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improv | 2021 |
Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder.
Topics: Buprenorphine; COVID-19; Health Services Needs and Demand; Humans; Methadone; Narcotic Antagonists; | 2021 |
Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
Topics: Adolescent; Adult; COVID-19; Drug Dosage Calculations; Female; Humans; Male; Methadone; North Caroli | 2021 |
Impact of Intravenous Methadone Administered Intraoperatively on Postoperative Opioid Utilization.
Topics: Adolescent; Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pain, Postoperative; Pr | 2021 |
Topics: Humans; Methadone; Nova Scotia; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related D | 2022 |
Comparison of psychological symptoms and cognitive functions in patients under maintenance treatment with methadone or buprenorphine, current opioid users and healthy subjects.
Topics: Analgesics, Opioid; Buprenorphine; Cognition; Healthy Volunteers; Humans; Methadone; Opioid-Related | 2021 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; C | 2021 |
Retention in the Austrian opioid agonist treatment system: a national prospective cohort study.
Topics: Analgesics, Opioid; Austria; Cohort Studies; Humans; Male; Methadone; Opiate Substitution Treatment; | 2021 |
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Huma | 2021 |
Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Family; Female; Goals; Humans; Male; Methadone; Middle Age | 2021 |
Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; Male; Methadone; Opiate Subs | 2021 |
COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Topics: Adult; Alcoholism; Analgesics, Opioid; Buprenorphine; COVID-19; Delivery of Health Care; Feasibility | 2021 |
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Topics: Ambulatory Care; Buprenorphine; COVID-19; Health Services Accessibility; Humans; Insurance, Health, | 2021 |
Prenatal methadone exposure disrupts behavioral development and alters motor neuron intrinsic properties and local circuitry.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Brain; Female; Humans; Male; Maternal Exposure; Metha | 2021 |
Chronic Pain Among Patients With an Opioid Use Disorder.
Topics: Adolescent; Adult; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Female; Humans; Male; Metha | 2021 |
Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Drug Monitoring; Fe | 2021 |
The "Methadone Crisis" in Iran: An Issue With the Need for New Policy.
Topics: Humans; Iran; Methadone; Opioid-Related Disorders; Policy | 2021 |
Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
Topics: Buprenorphine; COVID-19; Emergency Service, Hospital; Health Services Accessibility; Humans; Methado | 2021 |
Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study.
Topics: Adult; COVID-19; Female; Health Personnel; Health Services Accessibility; Humans; Interviews as Topi | 2021 |
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; M | 2021 |
Accuracy of a single-lead mobile smartphone electrocardiogram for QT interval measurement in patients undergoing maintenance methadone therapy.
Topics: Adult; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Methadone; Middle Aged; Opioid-R | 2021 |
Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio.
Topics: Adult; Buprenorphine; Female; Health Personnel; Humans; Infant, Newborn; Methadone; Neonatal Abstine | 2021 |
Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients.
Topics: Buprenorphine; Cross-Sectional Studies; Heroin; Humans; Methadone; Opiate Substitution Treatment; Op | 2021 |
Cost-effectiveness of Treatments for Opioid Use Disorder.
Topics: Adult; Buprenorphine; Combined Modality Therapy; Cost-Benefit Analysis; Delayed-Action Preparations; | 2021 |
Leveraging Telehealth in the United States to Increase Access to Opioid Use Disorder Treatment in Pregnancy and Postpartum During the COVID-19 Pandemic.
Topics: Adult; Buprenorphine; Comorbidity; Comprehensive Health Care; COVID-19; Delivery of Health Care; Evi | 2021 |
Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.
Topics: Age Factors; Alcoholism; Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Hepatitis C, Chr | 2021 |
Methadone and suboxone
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Narcotic Antagonist | 2021 |
Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Black or African American; Buprenorphine; Correctional Facilities; Ethnic | 2021 |
Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders.
Topics: Buprenorphine; Functional Status; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related D | 2021 |
The effect of buprenorphine vs methadone on sleep breathing disorders.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Middle Aged | 2021 |
European Court of Human Rights.
Topics: Adult; Buprenorphine; Europe; Female; Hospitals, State; Human Rights; Humans; Male; Methadone; Middl | 2020 |
Estimate cost of providing methadone maintenance treatment at a methadone clinic in Nairobi Kenya: direct costs.
Topics: Ambulatory Care Facilities; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Humans; Kenya; Met | 2021 |
[Methadone and buprenorphine maintenance therapy of opioid dependence - 10 years of experience].
Topics: Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Patient Discharge; Treatment Outcome | 2021 |
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.
Topics: Animals; Cohort Studies; Female; Humans; Methadone; Middle Aged; Opiate Substitution Treatment; Opio | 2021 |
Methadone overdose in patients following methadone mainte- nance treatment:A three years overview in the district of Bari (South-Italy).
Topics: Humans; Italy; Methadone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
A Virtual Reality Meditative Intervention Modulates Pain and the Pain Neuromatrix in Patients with Opioid Use Disorder.
Topics: Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain; Prospectiv | 2021 |
Incarceration and compulsory rehabilitation impede use of medication for opioid use disorder and HIV care engagement in Vietnam.
Topics: Analgesics, Opioid; Buprenorphine; HIV Infections; Humans; Methadone; Opiate Substitution Treatment; | 2022 |
Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes.
Topics: Adult; Analgesics, Opioid; Anxiety; Benzodiazepines; Buprenorphine; Cross-Sectional Studies; Diazepa | 2021 |
Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Jails; Methadone; Opiate Substitution Treatment; Opioid-R | 2021 |
Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Topics: Analgesics, Opioid; Buprenorphine; Duration of Therapy; Humans; Methadone; Opiate Substitution Treat | 2021 |
Challenges in methadone dispensing during Covid-19: An innovative approach using videocall based services.
Topics: COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; SARS-CoV-2 | 2021 |
Qualitative Analysis of Community Support to Methadone Access in Kenya.
Topics: Counseling; Humans; Kenya; Methadone; Opioid-Related Disorders; Qualitative Research | 2021 |
Outcomes associated with the use of medications for opioid use disorder during pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant, Newborn; Methadone; Neonatal Abst | 2021 |
Interaction between methadone and clarithromycin as the suspected cause of an opioid toxidrome.
Topics: Adult; Analgesics, Opioid; Clarithromycin; Humans; Male; Methadone; Opioid-Related Disorders; Retros | 2021 |
Nail disease in neonatal abstinence syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Methadone; Nail Diseases; Neonatal Abstinence Syndrom | 2021 |
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Opiat | 2021 |
Increased utilization of buprenorphine and methadone in 2018 compared to 2015 among Seattle-area persons who inject drugs.
Topics: Buprenorphine; Drug Users; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorder | 2021 |
Transporting to treatment: Evaluating the effectiveness of a mobile engagement unit.
Topics: Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospec | 2021 |
Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Topics: Analgesics, Opioid; British Columbia; Buprenorphine; Humans; Methadone; Opiate Substitution Treatmen | 2021 |
Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid Epidemic | 2021 |
"It could potentially be dangerous... but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Humans; Methadone; Opioid-Related Disorders | 2021 |
Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2021 |
Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Topics: Analgesics, Opioid; Connecticut; COVID-19; Drug Overdose; Humans; Methadone; Opiate Substitution Tre | 2021 |
Mobile methadone dispensing in Delhi, India: implementation research.
Topics: Adult; Analgesics, Opioid; Female; Health Plan Implementation; Humans; India; Male; Methadone; Middl | 2021 |
Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV.
Topics: Buprenorphine; Cohort Studies; HIV Infections; Humans; Methadone; Opioid-Related Disorders | 2022 |
Views of barriers and facilitators to continuing methadone treatment upon release from jail among people receiving patient navigation services.
Topics: Analgesics, Opioid; Female; Humans; Jails; Male; Methadone; Opiate Substitution Treatment; Opioid-Re | 2021 |
Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Germany; Health Status; Humans; Male; Methad | 2021 |
Gender disparities in access and retention in outpatient methadone treatment for opioid use disorder in low-income urban communities.
Topics: Analgesics, Opioid; Female; Hispanic or Latino; Humans; Los Angeles; Male; Methadone; Opiate Substit | 2021 |
Gender disparities in opioid treatment progress in methadone versus counseling.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Female; Humans; Male; Methadone; Opiate Substitution | 2021 |
The prevalence of constipation and its relation to sweet taste preference among patients receiving methadone maintenance treatment.
Topics: Constipation; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence | 2021 |
The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs.
Topics: Cohort Studies; Humans; Illicit Drugs; Methadone; Methamphetamine; Opiate Substitution Treatment; Op | 2021 |
Pronounced Regional Disparities in United States Methadone Distribution.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Narcotic Antagonists; Opiate Sub | 2022 |
Plausibility of patient-centred care in high-intensity methadone treatment: reflections of providers and patients.
Topics: Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient-C | 2021 |
Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2022 |
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Opi | 2021 |
Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Child; Criminals; Humans; Methadone; Opiate Substitution Treatmen | 2022 |
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Tr | 2021 |
Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol™ (morphine sulfate).
Topics: Adult; Aged; Aged, 80 and over; Buprenorphine; Codeine; Female; Humans; Hydromorphone; Male; Methado | 2021 |
Acute Pain Management for Patients with Substance Use Disorder Receiving Buprenorphine or Methadone Compared to Patients without Opioid-Dependence Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Pain Management; Pai | 2021 |
Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada.
Topics: Ambulatory Care Facilities; Analgesics, Opioid; Canada; COVID-19; Cross-Sectional Studies; Financing | 2021 |
Changes in methadone take-home dosing before and after COVID-19.
Topics: Adult; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemi | 2022 |
Factors influencing engagement and utilisation of opium tincture-assisted treatment for opioid use disorder: A qualitative study in Tehran, Iran.
Topics: Analgesics, Opioid; Humans; Iran; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series.
Topics: Analgesics, Opioid; Buprenorphine; Heroin; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2022 |
Can buprenorphine be used for opioid use disorder during pregnancy?
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2021 |
Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Opiate Substitution Treatment; Opioi | 2022 |
Factors affecting addiction severity index (ASI) among clients enrolled in methadone maintenance treatment (MMT) program in Myanmar.
Topics: Aged; Cross-Sectional Studies; Humans; Methadone; Myanmar; Opiate Substitution Treatment; Opioid-Rel | 2021 |
Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014-2018.
Topics: Analgesics, Opioid; Case-Control Studies; Connecticut; Drug Overdose; Humans; Jails; Male; Methadone | 2021 |
Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year.
Topics: Analgesics, Opioid; COVID-19; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2022 |
"It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Policy | 2021 |
Associations between relationship quality and treatment-related stress among couples receiving methadone for opioid use disorder.
Topics: Adolescent; Cross-Sectional Studies; Female; Humans; Interpersonal Relations; Male; Marriage; Methad | 2022 |
Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Metha | 2021 |
Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; G | 2021 |
History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018-June 30, 2020.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Overdose; Opiate Substitution Treatment | 2021 |
Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.
Topics: Adult; Aged; Analgesics, Opioid; Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens | 2021 |
Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; Narcotic Antagonist | 2021 |
Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.
Topics: Adolescent; Adult; Benzodiazepines; Buprenorphine; Drug Overdose; Drug Prescriptions; Female; Humans | 2017 |
Variations in Infant CYP2B6 Genotype Associated with the Need for Pharmacological Treatment for Neonatal Abstinence Syndrome in Infants of Methadone-Maintained Opioid-Dependent Mothers.
Topics: Adult; Analgesics, Opioid; Cohort Studies; Cytochrome P-450 CYP2B6; Female; Genetic Variation; Human | 2017 |
Gender-related psychopathology in opioid use disorder: Results from a representative sample of Italian addiction services.
Topics: Adult; Buprenorphine; Comorbidity; Cross-Sectional Studies; Female; Humans; Italy; Male; Mental Diso | 2017 |
Infants Born to Opioid-Dependent Women in Ontario, 2002-2014.
Topics: Adult; Buprenorphine; Congenital Abnormalities; Databases, Factual; Female; Health Care Costs; Human | 2017 |
The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy.
Topics: Adult; Age of Onset; Analgesics, Opioid; Comorbidity; Female; Health Status; Humans; Male; Methadone | 2017 |
Tobacco and alcohol use among drug users receiving methadone maintenance treatment: a cross-sectional study in a rural prefecture of Yunnan Province, Southwest China.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Analgesics, Opioid; China; Cross-Sectional Studies; Hepat | 2017 |
Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences.
Topics: Adolescent; Adult; Aged; Cannabis; Female; Humans; Male; Marijuana Smoking; Methadone; Middle Aged; | 2017 |
Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Heroin Dependence; Humans; Longitudinal Studies; M | 2017 |
HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study.
Topics: Adult; Analgesics, Opioid; Anti-Retroviral Agents; Coinfection; Comorbidity; Dose-Response Relations | 2017 |
Re-entry and related predictors among HIV-infected clients receiving methadone maintenance treatment in Guangdong province, China.
Topics: Adult; China; Employment; Female; HIV Infections; Humans; Male; Marital Status; Methadone; Multivari | 2017 |
An Outpatient Methadone Weaning Program by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome.
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Intensive Care Units, Neonatal; Male; Methadone | 2017 |
Opioid substitution treatment is linked to reduced risk of death in opioid use disorder.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk | 2017 |
Positive percentages of urine morphine tests among methadone maintenance treatment clients with HIV/AIDS: a 12-month follow-up study in Guangdong Province, China.
Topics: Acquired Immunodeficiency Syndrome; Adult; China; Female; Follow-Up Studies; Humans; Male; Methadone | 2017 |
Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: An interrupted time series analysis.
Topics: Adult; British Columbia; Drug and Narcotic Control; Female; Health Care Reform; HIV Infections; Huma | 2017 |
A comparison of bone quality and its determinants in young opioid-dependent women with healthy control group.
Topics: Adult; Analgesics, Opioid; Body Composition; Body Height; Body Mass Index; Body Weight; Bone and Bon | 2017 |
Is a History of Sexual Abuse Related to Poor Sleep Among Former Opioid-Addicted Women With and Without Methadone Maintenance Treatment?
Topics: Adult; Adult Survivors of Child Abuse; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle A | 2017 |
Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Behavior, Addictive; Buprenorphine; Comorbidit | 2017 |
Reliability and validity of the Treatment Outcome Profile among patients attending methadone maintenance treatment programs in Kunming, China.
Topics: Adult; China; Female; Humans; Interviews as Topic; Male; Methadone; Middle Aged; Observer Variation; | 2017 |
QT interval prolongation in opioid agonist treatment: analysis of continuous 12-lead electrocardiogram recordings.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Electrocardiography; Fem | 2017 |
Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Topics: Buprenorphine; Cost-Benefit Analysis; Crime; Health Services; Hepatitis C; HIV Infections; Humans; M | 2017 |
A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Topics: Adult; Australia; Buprenorphine; Drug Administration Routes; Female; Humans; Incidence; Infant, Newb | 2017 |
Characteristics and Outcome of Male and Female Methadone Maintenance Patients: MMT in Tel Aviv and Las Vegas.
Topics: Adult; Age Factors; Analgesics, Opioid; Benzodiazepines; Cocaine; Female; Humans; Israel; Male; Meth | 2018 |
Context and craving during stressful events in the daily lives of drug-dependent patients.
Topics: Adult; Affect; Buprenorphine; Craving; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opia | 2017 |
Prevalence of Heavy Alcohol Use Among People Receiving Methadone Following Change to Methadose.
Topics: Adult; Alcohol Drinking; British Columbia; Drug Compounding; Female; Humans; Male; Methadone; Middle | 2018 |
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Topics: Adult; Buprenorphine; Cohort Studies; Drug Implants; Drug Overdose; Female; Humans; Male; Methadone; | 2017 |
Cognitive function is largely intact in methadone maintenance treatment patients.
Topics: Adult; Cognition; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Neuropsychological Tests; | 2019 |
Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Female; Finland; Humans; Male; Methadone; | 2017 |
A qualitative assessment of an abstinence-oriented therapeutic community for prisoners with substance use disorders in Kyrgyzstan.
Topics: Adult; Attitude; Female; Humans; Kyrgyzstan; Male; Methadone; Middle Aged; Opiate Substitution Treat | 2017 |
Hepatitis C Cascade of Care Among Pregnant Women on Opioid Agonist Pharmacotherapy Attending a Comprehensive Prenatal Program.
Topics: Adult; Analgesics, Opioid; Female; Hepacivirus; Hepatitis C; Humans; Mass Screening; Methadone; Mexi | 2017 |
Sensorimotor outcomes in children with prenatal exposure to methadone.
Topics: Age of Onset; Exotropia; Female; Humans; Infant; Methadone; Narcotics; Neonatal Abstinence Syndrome; | 2017 |
Factors associated with nicotine dependence during methadone maintenance treatment: findings from a multisite survey in Vietnam.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Cross-Sectional Studies; Developing Countries; Female; | 2017 |
Combined Effect of CYP2B6 Genotype and Other Candidate Genes on a Steady-State Serum Concentration of Methadone in Opioid Maintenance Treatment.
Topics: Adult; Alleles; Analgesics, Opioid; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P- | 2017 |
Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Drug Prescriptions; Female; Human | 2017 |
Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
Topics: Adult; Buprenorphine; Comorbidity; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution | 2018 |
Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
Topics: Adult; Buprenorphine; Comorbidity; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution | 2018 |
Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
Topics: Adult; Buprenorphine; Comorbidity; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution | 2018 |
Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
Topics: Adult; Buprenorphine; Comorbidity; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution | 2018 |
Experiences and Perceived Social Support among Iranian Men on Methadone Maintenance Therapy: A Qualitative Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Humans; Iran; Male; Methadone; Middle Aged; Opiate Substituti | 2017 |
Association of methadone dose with substance use and treatment retention in pregnant and postpartum women with opioid use disorder.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Methadone; Opiate Subst | 2017 |
Intolerance of uncertainty in opioid dependency - Relationship with trait anxiety and impulsivity.
Topics: Adult; Analgesics, Opioid; Anxiety; Case-Control Studies; Decision Making; Female; Heroin; Humans; I | 2017 |
Utilization of buprenorphine and methadone among opioid users who inject drugs.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Humans; Male; Methadone; Nar | 2018 |
Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.
Topics: Adult; Buprenorphine; Cohort Studies; Delivery of Health Care, Integrated; Dose-Response Relationshi | 2017 |
Rationale for cannabis-based interventions in the opioid overdose crisis.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Drug Overdose; Evidence-Based Medicine | 2017 |
Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic.
Topics: Adult; Age Factors; Ambulatory Care Facilities; Continuity of Patient Care; Electronic Health Record | 2017 |
Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Substitution; Female; Humans; Infant, Newborn; Methad | 2018 |
Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder.
Topics: Adult; Attitude of Health Personnel; Canada; Female; Humans; Male; Methadone; Middle Aged; Opiate Su | 2018 |
Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Health Services Accessi | 2018 |
Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers.
Topics: Adult; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Case-Control Studies; Coho | 2017 |
Maternal buprenorphine treatment and infant outcome.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Subs | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Buprenorphine for the Neonatal Abstinence Syndrome.
Topics: Buprenorphine; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution | 2017 |
Barriers to retention in methadone maintenance therapy among people who inject drugs in Bangkok, Thailand: a mixed-methods study.
Topics: Adult; Analgesics, Opioid; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Ag | 2017 |
Death From Opioid Overdose After Deep Brain Stimulation: A Case Report.
Topics: Adult; Analgesics, Opioid; Antisocial Personality Disorder; Clinical Trials as Topic; Combined Modal | 2018 |
Cardiovascular effects of methadone and concomitant use of diazepam during methadone maintenance treatment induction: low concentration risk.
Topics: Adult; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Electrocardiography; Female; H | 2017 |
A naturalistic longitudinal analysis of post-detoxification outcomes in opioid-dependent patients.
Topics: Adult; Aftercare; Female; Humans; Longitudinal Studies; Male; Methadone; Narcotic Antagonists; Opioi | 2018 |
Why People Who Inject Drugs Voluntarily Transition Off Methadone in Ukraine.
Topics: Adult; Drug Users; Female; Focus Groups; Humans; Male; Methadone; Opiate Substitution Treatment; Opi | 2017 |
Methadone maintenance-lessons from two systems in China.
Topics: Analgesics, Opioid; China; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorder | 2017 |
Poor sleep quality is significantly associated with low sexual satisfaction in Chinese methadone-maintained patients.
Topics: Adult; China; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opiate Substitution Treatment | 2017 |
Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine.
Topics: Budgets; Buprenorphine; Drug Users; Health Policy; HIV Infections; Humans; Methadone; Narcotics; Opi | 2017 |
Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Canada; Cohort Studies; Crime; Female; Humans; Male; Me | 2018 |
Opioid tapering in patients with prescription opioid use disorder: A retrospective study.
Topics: Analgesics, Opioid; Chronic Pain; Drug Prescriptions; Female; Humans; Male; Methadone; Middle Aged; | 2017 |
Antenatal methadone vs buprenorphine exposure and length of hospital stay in infants admitted to the intensive care unit with neonatal abstinence syndrome.
Topics: Adult; Buprenorphine; Female; Gestational Age; Humans; Infant, Newborn; Intensive Care Units, Neonat | 2018 |
Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Case-Control Studies; Constipation; Depression; | 2017 |
Expanding Treatment Opportunities for Hospitalized Patients with Opioid Use Disorders.
Topics: Analgesics, Opioid; Buprenorphine; Hospitalization; Humans; Inpatients; Methadone; Opiate Substituti | 2018 |
Forensic Toxicology Perspectives of Methadone-associated Deaths in Tehran, Iran, a 7-year Overview.
Topics: Adult; Cause of Death; Controlled Substances; Cross-Sectional Studies; Drug Overdose; Female; Forens | 2018 |
Methadone Maintenance Treatment for Older Adults: Cost and Logistical Considerations.
Topics: Aged; Aging; Analgesics, Opioid; Humans; Medicare; Methadone; Middle Aged; Opiate Substitution Treat | 2018 |
Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Absti | 2018 |
Evaluation of Methadone Treatment in Malaysia: Findings from the Malaysian Methadone Treatment Outcome Study (MyTOS).
Topics: Adult; Aged; Analgesics, Opioid; Cross-Sectional Studies; Female; Humans; Malaysia; Male; Methadone; | 2018 |
Traditional Chinese medicine-facilitated treatments may relieve anxiety symptoms during drug switching from methadone to buprenorphine/naloxone for treating opioid dependence.
Topics: Anxiety; Buprenorphine, Naloxone Drug Combination; Drug Substitution; Drugs, Chinese Herbal; Humans; | 2017 |
Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.
Topics: Adult; Cross-Sectional Studies; Eligibility Determination; Female; Health Services Accessibility; Hu | 2017 |
Invited Commentary: A Novel Strategy for Addressing Unmeasured Confounding When Comparing Opioid Agonist Therapies in Pregnancy.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Medicaid; Methadone; Opiate Substitution Treatment; | 2018 |
Neonatal Outcomes in a Medicaid Population With Opioid Dependence.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Narcotics; Opioid-Related Disorders; Preg | 2018 |
Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California.
Topics: Adult; California; Cost-Benefit Analysis; Female; Humans; Male; Methadone; Narcotics; Opiate Substit | 2018 |
Impact of SNP-SNP interaction among ABCB1, ARRB2, DRD1 and OPRD1 on methadone dosage requirement in Han Chinese patients.
Topics: Adult; Analgesics, Opioid; Asian People; ATP Binding Cassette Transporter, Subfamily B; beta-Arresti | 2017 |
Excess overdose mortality immediately following transfer of patients and their care as well as after cessation of opioid substitution therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Drug Overdose; Female; Humans; Male; Metha | 2018 |
Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Humans; Methadone; | 2018 |
Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study.
Topics: Adolescent; Adult; Aged; Buprenorphine; Cross-Sectional Studies; Erectile Dysfunction; Humans; Male; | 2017 |
Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine.
Topics: Adult; Buprenorphine; Criminal Law; Female; Humans; Male; Methadone; Narcotic Antagonists; Opiate Su | 2017 |
Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; History, 20th Century; Humans; Met | 2018 |
Epigenetic Regulation of the Promotor Region of Vascular Endothelial Growth Factor-A and Nerve Growth Factor in Opioid-Maintained Patients.
Topics: Adult; Analgesics, Opioid; DNA Methylation; Epigenesis, Genetic; Female; Heroin; Humans; Male; Metha | 2017 |
Changing the Treatment Direction for Opiate Addiction: Dr. Dole's Research.
Topics: History, 20th Century; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
From Narcotic to Normalizer: The Misperception of Methadone Treatment and the Persistence of Prejudice and Bias.
Topics: Analgesics, Opioid; Bias; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Cross-Sectional Studies; Female; Humans; Inje | 2018 |
Plasma Testosterone and Sexual Function in Southeast Asian Men Receiving Methadone and Buprenorphine Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Depression; Female; Humans; Hypogonadism; Male; Methadone; | 2018 |
Prescribing Opioid Replacement Therapy in U.S. Correctional Settings.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Relate | 2017 |
Increasing diversion of methadone in Vancouver, Canada, 2005-2015.
Topics: Adult; Canada; Female; Humans; Illicit Drugs; Male; Methadone; Opioid-Related Disorders; Prescriptio | 2018 |
Oxford House Residents' Attitudes Toward Medication Assisted Treatment Use in Fellow Residents.
Topics: Analgesics, Opioid; Analysis of Variance; Attitude to Health; Buprenorphine; Cross-Sectional Studies | 2018 |
Healthcare utilization and costs associated with treatment for opioid dependence.
Topics: Adult; Age Factors; Buprenorphine; Comorbidity; Counseling; Delayed-Action Preparations; Health Expe | 2018 |
"I'm Doing the Best That I Can for Her": Infant-Feeding Decisions of Mothers Receiving Medication-Assisted Treatment for an Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Breast Feeding; Decision Making; Feeding Behavior; Female; Focus Groups; | 2018 |
APBB2 is associated with amphetamine use and plasma beta-amyloids in patients receiving methadone maintenance treatment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Amphetamine-Related Disorders; Amyloid beta-Peptides; B | 2018 |
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Female; Genotype; Humans; Male; Methadone; Narcotic | 2018 |
Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opio | 2018 |
Harm reduction program use, psychopathology and medical severity in patients with methadone maintenance treatment.
Topics: Adult; Female; Harm Reduction; Humans; Male; Methadone; Middle Aged; Narcotics; Opiate Substitution | 2018 |
Improving recruitment to pharmacological trials for illicit opioid use: findings from a qualitative focus group study.
Topics: Adult; Aged; Attitude to Health; Buprenorphine; Clinical Trials as Topic; Female; Focus Groups; Hero | 2018 |
Tobacco withdrawal among opioid-dependent smokers.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cigarette Smoking; Comorbidity; Craving; Female; Humans; M | 2018 |
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction.
Topics: Animals; Brain; Caudate Nucleus; Cerebral Cortex; Hippocampus; Male; Methadone; Naltrexone; Narcotic | 2019 |
Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Apgar Score; Buprenorphine; Czech Republic; Female | 2018 |
Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
Topics: Adult; Buprenorphine; Humans; Male; Methadone; Naloxone; Ontario; Opiate Substitution Treatment; Opi | 2018 |
Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?
Topics: Adult; Demography; Female; General Practitioners; Health Policy; Humans; Male; Methadone; Middle Age | 2018 |
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.
Topics: Adolescent; Adult; Buprenorphine; Cause of Death; Drug Overdose; Female; Fentanyl; Health Plan Imple | 2018 |
An investigation of an open-access model for scaling up methadone maintenance treatment.
Topics: Adult; Connecticut; Delivery of Health Care; Female; Health Services Accessibility; Humans; Male; Me | 2018 |
Disulfiram attenuates morphine or methadone withdrawal syndrome in mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Disulfiram; Male; Methadone; Mice; Mice, Inbred C57BL | 2018 |
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Humans; Male; Methadone; | 2018 |
Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure.
Topics: Adult; Appalachian Region; Birth Weight; Buprenorphine, Naloxone Drug Combination; Female; Humans; I | 2018 |
Sexual Desire in Opiate-Dependent Men Receiving Methadone-Assisted Treatment.
Topics: Adult; Age Factors; Cross-Sectional Studies; Follow-Up Studies; Humans; Libido; Logistic Models; Mal | 2018 |
[Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program].
Topics: Alleles; Case-Control Studies; Drug Dosage Calculations; Genotype; Humans; Methadone; Opiate Substit | 2018 |
Pregnancy and the Opioid Epidemic.
Topics: Analgesics, Opioid; Epidemics; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndr | 2018 |
Counseling Staff's Views of Patient-Centered Methadone Treatment: Changing Program Rules and Staff Roles.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Baltimore; Black or African American; Counselors; | 2018 |
Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis.
Topics: Adult; Analgesics, Opioid; Canada; Cohort Studies; Coinfection; Female; Food Supply; Hepatitis C; HI | 2018 |
Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome.
Topics: Adult; Analgesics, Opioid; Female; Humans; Injections, Intramuscular; Male; Methadone; Middle Aged; | 2018 |
Concurrent drug use among methadone maintenance patients in mountainous areas in northern Vietnam.
Topics: Adolescent; Adult; Analgesics, Opioid; Cross-Sectional Studies; Humans; Logistic Models; Male; Medic | 2018 |
Factors affecting the dose of methadone among patients receiving methadone maintenance therapy in Taiwan.
Topics: Adult; Age Factors; Analgesics, Opioid; Cohort Studies; Comorbidity; Dose-Response Relationship, Dru | 2018 |
Ageing opioid users' increased risk of methadone-specific death in the UK.
Topics: Adolescent; Adult; Aging; Analgesics, Opioid; Databases, Factual; Female; Heroin; Humans; Male; Meth | 2018 |
Time-Dependent Postmortem Redistribution of Opioids in Blood and Alternative Matrices.
Topics: Analgesics, Opioid; Autopsy; Biotransformation; Chromatography, High Pressure Liquid; Fentanyl; Fore | 2018 |
Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
Topics: Adult; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Drug Cont | 2018 |
Opioid Utilization by Pregnant Women with Sickle Cell Disease and the Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Anemia, Sickle Cell; Case-Control Studies; Female; Humans; Incidence; Met | 2018 |
Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
Topics: Adult; Analgesics, Opioid; Biobehavioral Sciences; Condoms; Feasibility Studies; Female; HIV Infecti | 2018 |
Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
Topics: British Columbia; Cost-Benefit Analysis; Crime; Double-Blind Method; Equivalence Trials as Topic; He | 2018 |
Barriers and Facilitators of Breastfeeding Reported by Postpartum Women in Methadone Maintenance Therapy.
Topics: Adolescent; Adult; Breast Feeding; Cross-Sectional Studies; Female; Humans; Infant; Infant Nutrition | 2018 |
Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; | 2018 |
Examination of Hospital, Maternal, and Infant Characteristics Associated with Breastfeeding Initiation and Continuation Among Opioid-Exposed Mother-Infant Dyads.
Topics: Adult; Breast Feeding; Evidence-Based Practice; Female; Humans; Infant; Infant Nutritional Physiolog | 2018 |
Methadone Maintenance Treatment: A 15-year Retrospective Study in Split-Dalmatia County, Croatia.
Topics: Adolescent; Adult; Age Factors; Analgesics, Opioid; Croatia; Databases, Factual; Drug Overdose; Fema | 2018 |
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.
Topics: Adult; Buprenorphine; Cause of Death; Cohort Studies; Drug Overdose; Female; Humans; Male; Methadone | 2018 |
Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective.
Topics: Adolescent; Adult; Buprenorphine; Drug Users; Health Knowledge, Attitudes, Practice; Health Services | 2018 |
Opioid Deaths in Milwaukee County, Wisconsin 2013-2017: The Primacy of Heroin and Fentanyl.
Topics: Analgesics, Opioid; Buprenorphine; Coroners and Medical Examiners; Fentanyl; Heroin; Humans; Hydroco | 2019 |
Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury.
Topics: Analgesics, Opioid; Brain Injuries, Traumatic; Buprenorphine; Humans; Methadone; Naltrexone; Opioid- | 2018 |
The effect of standardizing treatment when managing neonatal abstinence syndrome
Topics: Adolescent; Adult; Analgesics, Opioid; Clinical Protocols; Comorbidity; Female; Humans; Infant; Infa | 2019 |
Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.
Topics: Analgesics, Opioid; Costs and Cost Analysis; Delivery of Health Care; Directly Observed Therapy; Fee | 2018 |
The oral health status and behaviour of methadone users in Lithuania.
Topics: Adult; Analgesics, Opioid; DMF Index; Female; Humans; Lithuania; Male; Methadone; Middle Aged; Opioi | 2018 |
Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART).
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Comorbidity; Connecticut; Female; HIV Infections; Humans | 2018 |
Commentary on Bansback et al. (2018): Estimating the cost of stigma against injection.
Topics: Cost-Benefit Analysis; Heroin; Humans; Hydromorphone; Methadone; Opioid-Related Disorders | 2018 |
Medical, psychosocial, and treatment predictors of opioid overdose among high risk opioid users.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Friends; Hepatitis C, Chronic; Huma | 2018 |
Perceived barriers to methadone maintenance treatment among Iranian opioid users.
Topics: Adult; DNA Helicases; Female; Humans; Iran; Male; Methadone; Middle Aged; Opiate Substitution Treatm | 2018 |
Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Topics: Adult; Analgesics, Opioid; British Columbia; Cohort Studies; Community Health Centers; Drug Overdose | 2018 |
Medicines for Patients After an Opioid Overdose.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; | 2018 |
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Massachus | 2018 |
A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees.
Topics: Adolescent; Adult; Buprenorphine; Drug Utilization; Ethnicity; Female; Healthcare Disparities; Human | 2018 |
Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Topics: Analgesics, Opioid; Appalachian Region; Buprenorphine; Female; Health Expenditures; Health Personnel | 2019 |
Intent to Refer: Exploring Bias Toward Specific Medication-Assisted Treatments by Community Corrections Employees.
Topics: Adult; Buprenorphine; Female; Humans; Intention; Male; Methadone; Opiate Substitution Treatment; Opi | 2018 |
Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
Topics: Analgesics, Opioid; Focus Groups; General Practitioners; Humans; Ireland; Methadone; Opiate Substitu | 2018 |
Influence of social network on drug use among clients of methadone maintenance treatment centers in Kunming, China.
Topics: Adult; China; Cross-Sectional Studies; Female; Heroin; Humans; Male; Methadone; Middle Aged; Narcoti | 2018 |
Methadone in Primary Care - One Small Step for Congress, One Giant Leap for Addiction Treatment.
Topics: Drug Approval; Drug Prescriptions; Government Regulation; Humans; Methadone; Narcotics; Opioid-Relat | 2018 |
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.
Topics: Buprenorphine; Drug Approval; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Op | 2018 |
Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada.
Topics: Adult; Aged; Analgesics, Opioid; British Columbia; Female; Focus Groups; Harm Reduction; Health Serv | 2018 |
Before and after: craving, mood, and background stress in the hours surrounding drug use and stressful events in patients with opioid-use disorder.
Topics: Adult; Affect; Analgesics, Opioid; Cocaine; Craving; Female; Humans; Male; Methadone; Middle Aged; O | 2018 |
Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts.
Topics: Adult; Buprenorphine; Drug Overdose; Female; Humans; Massachusetts; Methadone; Opiate Substitution T | 2018 |
Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
Topics: Adult; Aged; Buprenorphine; Drug Substitution; Female; Humans; Interviews as Topic; Male; Methadone; | 2019 |
Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report.
Topics: Analgesics, Opioid; Colonic Pseudo-Obstruction; Constipation; Decompression, Surgical; Humans; Hydro | 2019 |
The economic costs of jail-based methadone maintenance treatment.
Topics: Analgesics, Opioid; Cost-Benefit Analysis; Health Care Costs; Humans; Methadone; Opiate Substitution | 2018 |
Characteristics of Medicaid recipients in Methadone Maintenance Treatment: A comparison across the lifespan.
Topics: Adolescent; Adult; Age Factors; Aged; Cross-Sectional Studies; Female; Health Status; Humans; Logist | 2018 |
Overview of Drugs Used to Treat Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Nurse's Role; Opiate Substitution | 2018 |
Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; British Columbia; Cause of Death; Criminals; Female; Hu | 2018 |
Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
Topics: Adult; Cohort Studies; Community Pharmacy Services; Female; Humans; Male; Medication Adherence; Meth | 2018 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug | 2018 |
Correlation of cytokines, BDNF levels, and memory function in patients with opioid use disorder undergoing methadone maintenance treatment.
Topics: Adult; Biomarkers; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Female; Humans; Interleuki | 2018 |
Health-related work productivity loss is low for patients in a methadone maintenance program in Vietnam.
Topics: Absenteeism; Adult; Cross-Sectional Studies; Efficiency; Employment; Female; Health Status; Humans; | 2018 |
Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Emergency Service, Hospital; Hospitalization; Huma | 2018 |
Telemedicine's Role in Addressing the Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Epidemics; Health Policy; Humans; Methadone; Naltrexone; Opiate S | 2018 |
Mobilizing community support in people receiving opioid-agonist treatment: A group approach.
Topics: Adult; Family; Family Therapy; Female; Friends; Humans; Male; Methadone; Middle Aged; Motivational I | 2018 |
Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington.
Topics: Adult; Female; Humans; Linear Models; Male; Medication Adherence; Methadone; Middle Aged; Opiate Sub | 2018 |
Management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagoni | 2018 |
Expanded table: Some drugs for management of opioid withdrawal symptoms.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Humans; Methadone; Narcotic Antagoni | 2018 |
In vitro evaluation of effects of metformin on morphine and methadone tolerance through mammalian target of rapamycin signaling pathway.
Topics: AMP-Activated Protein Kinase Kinases; Analgesics, Opioid; Animals; Cell Line, Tumor; Cyclic AMP; Dru | 2019 |
Improving Rural Access to Opioid Treatment Programs.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Health Services Accessibility; Health Services Nee | 2018 |
Prenatal Treatment and Outcomes of Women With Opioid Use Disorder.
Topics: Adult; Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disor | 2018 |
Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Female; Gabapentin; Humans; Infant; Infan | 2018 |
The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System.
Topics: Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Trea | 2018 |
Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Topics: Adolescent; Behavior Therapy; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotics; | 2018 |
One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
Topics: Adult; Age Factors; Analgesics, Opioid; Buprenorphine; Employment; Family Relations; Female; Friends | 2019 |
Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; Glomerular Filtration | 2019 |
High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine, Naloxone Drug Combination; Female; Human | 2018 |
Long-acting Opioid Use and the Risk of Serious Infections: A Retrospective Cohort Study.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Hospitalization; Humans; Immunosupp | 2019 |
Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.
Topics: Adult; British Columbia; Cohort Studies; Female; Heroin Dependence; Humans; Male; Methadone; Middle | 2018 |
Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence.
Topics: Adult; Buprenorphine; Factor Analysis, Statistical; Female; Humans; Infant, Newborn; Medication Adhe | 2018 |
Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments.
Topics: Adult; Female; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Kyrgyzstan; Male; | 2018 |
Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario.
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Administration Schedule; Female; Humans; Methadone; Midd | 2019 |
Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Management; Female; Hepatitis C; Humans; | 2019 |
Utilization of opioid agonist therapy among incarcerated persons with opioid use disorder in Vancouver, Canada.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Canada; Case-Control Studies; D | 2018 |
Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
Topics: Adult; Analgesics, Opioid; Cannabis; Commerce; Dose-Response Relationship, Drug; Ethanol; Female; Ge | 2018 |
Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.
Topics: Buprenorphine; Hospitals, Veterans; Humans; Implementation Science; Methadone; Naltrexone; Opiate Su | 2018 |
The Role of Patient Payment Method in Premature Discharge from Methadone Maintenance Treatment.
Topics: Adolescent; Adult; Female; Health Expenditures; Humans; Male; Methadone; Middle Aged; Opiate Substit | 2019 |
Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Chronic Pain; Female; Humans; Male; Methadone; Opiate Su | 2018 |
Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Craving; Cues; Depression; Female; Humans; Male; Methadone; O | 2019 |
Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Act | 2018 |
Injection opioid use as a predictor of treatment outcomes among methadone-maintained opioid-dependent patients.
Topics: Analgesics, Opioid; Female; Humans; Injections; Length of Stay; Male; Methadone; Middle Aged; Narcot | 2019 |
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo | 2019 |
Could prenatal food insecurity influence neonatal abstinence syndrome severity?
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Food Supply; Humans; Methadone; Neonatal Abstinenc | 2019 |
Interrelationship of Opioid Dependence, Impaired Impulse Control, and Depressive Symptoms: An Open-Label Cross-Sectional Study of Patients in Maintenance Therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Cross-Sectional Studies; Depression; Educatio | 2019 |
Methadone maintenance treatment as social control: Analyzing patient experiences.
Topics: Adult; Female; Humans; Interviews as Topic; Male; Methadone; Opiate Substitution Treatment; Opioid-R | 2019 |
Evidence-based treatment for opioid use disorders: A national study of methadone dose levels, 2011-2017.
Topics: Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Methadone; Opiate Substitution Tr | 2019 |
Association Between Socio-Demographic and Health Functioning Variables Among Patients with Opioid Use Disorder Introduced by Prescription: A Prospective Cohort Study.
Topics: Adult; Aged; Analgesics, Opioid; Canada; Chronic Pain; Female; Humans; Male; Methadone; Middle Aged; | 2018 |
The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Czech Republic; Female; Health Services Access | 2018 |
Methadone maintenance treatment patients with a history of childhood trauma succeed more in a cognitive paradigm that is associated with a negative reward.
Topics: Adult Survivors of Child Adverse Events; Cues; Female; Humans; Male; Methadone; Middle Aged; Narcoti | 2019 |
Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Hospitals, Veterans; Humans; Male; Methad | 2018 |
Medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Nurse Practitioners; Opiate Subs | 2019 |
Coordinating Outpatient Care for Pregnant and Postpartum Women with Opioid Use Disorder: Implications from the COACHH Program.
Topics: Adult; Ambulatory Care; Analgesics, Opioid; Female; Humans; Interviews as Topic; Massachusetts; Meth | 2019 |
Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study.
Topics: Adult; Analgesics, Opioid; Aspartate Aminotransferases; Cross-Sectional Studies; Hepatitis C, Chroni | 2018 |
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
Topics: Analgesics, Opioid; Buprenorphine; Diagnostic and Statistical Manual of Mental Disorders; Evidence-B | 2019 |
Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder.
Topics: Buprenorphine; Female; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related D | 2019 |
Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Topics: Administration, Intravenous; Adolescent; Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; | 2019 |
Prevention of post-operative hyperalgesia in a heroin-addicted patient on methadone maintenance.
Topics: Analgesics, Opioid; Heroin; Humans; Hyperalgesia; Ketamine; Male; Methadone; Middle Aged; Opioid-Rel | 2019 |
Medical specialty of buprenorphine prescribers for pregnant women with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Female; Humans; Medicaid; Methadone; Opiate S | 2019 |
Should Physicians Recommend Replacing Opioids With Cannabis?
Topics: Analgesics, Opioid; Buprenorphine; Chronic Pain; Evidence-Based Medicine; Government Regulation; Hum | 2019 |
Hospitalization of children after prenatal exposure to opioid maintenance therapy during pregnancy: a national registry study from the Czech Republic.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Child, Preschool; Czech Republic; Di | 2019 |
Psychological distress mediated the effects of self-stigma on quality of life in opioid-dependent individuals: A cross-sectional study.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Female; Humans; Male; Methadone; Middle Aged; Op | 2019 |
Sociodemographic characteristics of patients with children in a methadone maintenance program: a cross-sectional study.
Topics: Adolescent; Adult; Canada; Child; Cross-Sectional Studies; Family; Female; Humans; Male; Methadone; | 2019 |
Comparing Canadian and United States opioid agonist therapy policies.
Topics: Buprenorphine; Canada; Drug Overdose; Health Policy; Humans; Insurance Coverage; Methadone; Naloxone | 2019 |
Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment.
Topics: Adult; Buprenorphine; Electronic Nicotine Delivery Systems; Female; Humans; Male; Methadone; Middle | 2019 |
Inadequate prenatal care utilization among women with and without methadone-treated opioid use disorders in Taiwan.
Topics: Adult; Case-Control Studies; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Relate | 2019 |
Opioid addiction: long-acting formulations for a long-term disorder.
Topics: Buprenorphine; Double-Blind Method; Drug Compounding; Humans; Methadone; Opioid-Related Disorders | 2019 |
Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder.
Topics: Adult; Age Factors; Aged; Barbiturates; Buprenorphine; Delayed-Action Preparations; Dose-Response Re | 2019 |
Opioid Use Disorder and Incarceration - Hope for Ensuring the Continuity of Treatment.
Topics: Adult; Buprenorphine; Humans; Legislation, Medical; Male; Methadone; Narcotic Antagonists; Opiate Su | 2019 |
Prescription Drug and Alcohol Use Disorders: Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatm | 2019 |
A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Dis | 2019 |
Association of Methadone Treatment With Substance-Related Hospital Admissions Among a Population in Canada With a History of Criminal Convictions.
Topics: Adolescent; Adult; Aged; British Columbia; Criminals; Female; Hospitalization; Humans; Male; Methado | 2019 |
Non drug-related and opioid-specific causes of 3262 deaths in Scotland's methadone-prescription clients, 2009-2015.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Cohort Studies; Female; Heroin; Humans; Ma | 2019 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug S | 2019 |
Gender-specific predictors of methadone treatment outcomes among African Americans at an urban clinic.
Topics: Academic Medical Centers; Adult; Age of Onset; Ambulatory Care Facilities; Analgesics, Opioid; Black | 2019 |
Implications of perinatal buprenorphine exposure on infant head circumference at birth.
Topics: Buprenorphine; Female; Humans; Infant; Infant, Newborn; Male; Methadone; Neonatal Abstinence Syndrom | 2021 |
Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.
Topics: Adult; Cross-Sectional Studies; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2D6; Dose-Response Rela | 2019 |
News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Female; Health Education; Health Information Management; Humans; | 2019 |
Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Databases, Factual; Female; Hu | 2019 |
VMAT2 gene (
Topics: Adult; Analgesics, Opioid; Case-Control Studies; Female; Genetic Predisposition to Disease; Heroin D | 2019 |
Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.
Topics: Adult; Buprenorphine; Cohort Studies; Disease Transmission, Infectious; Drug Users; Female; Hepatiti | 2019 |
Buprenorphine unobserved "home" induction: a survey of Ontario's addiction physicians.
Topics: Addiction Medicine; Attitude of Health Personnel; Buprenorphine; Cross-Sectional Studies; Female; He | 2019 |
Medication-Based Treatment to Address Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Subst | 2019 |
Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cities; Drug Tra | 2019 |
Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Cocaine; Cross-Sectional Studies; Del | 2019 |
Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment.
Topics: Adult; Baltimore; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
The case for a medication first approach to the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Certification; Health Plan Implementation; Health Services Access | 2019 |
Quality of primary care among individuals receiving treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Middle A | 2019 |
Methadone and buprenorphine treatments in patients with schizophrenia.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Female; Humans; Male; Methadone; Opiate Subst | 2019 |
The optimization of methadone dosing whilst treating with rifampicin: A pharmacokinetic modeling study.
Topics: Adult; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combin | 2019 |
Intervention stigma: How medication-assisted treatment marginalizes patients and providers.
Topics: Analgesics, Opioid; Buprenorphine; Grounded Theory; Health Services Accessibility; Humans; Methadone | 2019 |
Changing Trends in Opioid Overdose Deaths and Prescription Opioid Receipt Among Veterans.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Heroin; Humans; Male; Methadone; Middle Aged; Opio | 2019 |
Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Topics: Adult; Buprenorphine; Female; Health Services Needs and Demand; Humans; Male; Methadone; Middle Aged | 2019 |
Insomnia and excessive daytime sleepiness in women and men receiving methadone and buprenorphine maintenance treatment.
Topics: Adult; Analgesics, Opioid; Anxiety; Buprenorphine; Comorbidity; Cross-Sectional Studies; Depression; | 2019 |
Letter to the Editor: A Novel Therapeutic for Opioid Use Disorder Targeting the Cholinergic System.
Topics: Analgesics, Opioid; Cholinergic Agents; Cocaine; Double-Blind Method; Galantamine; Humans; Methadone | 2019 |
[Improve the benefit/risk balance of methadone by respecting its pharmacological specificities].
Topics: Analgesics, Opioid; Drug Overdose; France; Humans; Methadone; Opiate Substitution Treatment; Opioid- | 2019 |
Detection of legal highs in the urine of methadone-treated patient by LC-MS.
Topics: Chromatography, High Pressure Liquid; Female; Humans; Limit of Detection; Methadone; Methamphetamine | 2019 |
Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection.
Topics: Adult; Cross-Sectional Studies; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Opiate Su | 2019 |
Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: A 17-year Canadian Cohort Study.
Topics: Adult; Antipsychotic Agents; British Columbia; Cohort Studies; Comorbidity; Criminal Law; Diagnosis, | 2019 |
Morphine vs methadone in the treatment of neonatal abstinence syndrome.
Topics: Humans; Infant, Newborn; Methadone; Morphine; Narcotics; Neonatal Abstinence Syndrome; Opioid-Relate | 2019 |
Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.
Topics: Adult; Case-Control Studies; Cleft Palate; Comorbidity; Europe; Female; Gestational Age; Humans; Inf | 2020 |
Loneliness and Illicit Opioid Use Among Methadone Maintenance Treatment Patients.
Topics: Adult; Aged; Analgesics, Opioid; Cross-Sectional Studies; Female; Heroin; Humans; Loneliness; Male; | 2019 |
Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment.
Topics: Adult; Alcoholic Beverages; Cannabis; Commerce; Duration of Therapy; Female; Health Services Accessi | 2020 |
Methadone in primary care in France: Using evidence for action against hepatitis C.
Topics: France; Hepatitis C; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pri | 2019 |
Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Topics: Adolescent; Adult; Age Factors; Buprenorphine; Drug Utilization; Female; Humans; Male; Medicaid; Met | 2019 |
Psycho-physiological response to pain among individuals with comorbid pain and opioid use disorder: Implications for patients with prolonged abstinence.
Topics: Adaptation, Psychological; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; M | 2019 |
An ageing methadone population: A challenge for treating doctors.
Topics: Aging; General Practice; Humans; Medication Reconciliation; Methadone; Opiate Substitution Treatment | 2019 |
Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
Topics: Adult; Autopsy; Buprenorphine; Cause of Death; Female; Humans; Male; Methadone; Middle Aged; Opiate | 2019 |
A New Way Forward in the Emergency Department.
Topics: Adult; Aged; Aged, 80 and over; Buprenorphine; Emergency Service, Hospital; Female; Forecasting; Hum | 2019 |
The becoming-methadone-body: on the onto-politics of health intervention translations.
Topics: Analgesics, Opioid; Diphenhydramine; Humans; Hypnotics and Sedatives; Implementation Science; Interv | 2019 |
Evaluation of the treatment failure ratio in individuals receiving methadone maintenance therapy via the network scale up method.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Iran; Male; Methadone; Middle Aged; Opia | 2019 |
Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States.
Topics: Buprenorphine; Drug Overdose; Health Policy; Health Services Accessibility; Humans; Methadone; Opiat | 2019 |
Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Opiate Substitution | 2019 |
Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Drug Substitution; Female; Humans; Male; Met | 2019 |
A national survey of approaches to manage the ICU patient with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Critical Care; Critical Illness; Hospitalization; Hospitals; Huma | 2019 |
Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients.
Topics: Adult; Anxiety; Arousal; Comorbidity; Correlation of Data; Female; Hope; Humans; Male; Methadone; Mi | 2019 |
Treating perinatal opioid use disorder in rural settings: Challenges and opportunities.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; New Hampshire; Opiate Substitut | 2019 |
Stress, craving and mood as predictors of early dropout from opioid agonist therapy.
Topics: Adult; Affect; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Craving; Ecological Mom | 2019 |
Prevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015.
Topics: Adult; Analgesics, Opioid; Drug Prescriptions; Female; Humans; Incidence; Infant, Newborn; Insurance | 2019 |
Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
Topics: Adult; Aged; Aged, 80 and over; Buprenorphine; Female; Health Services Accessibility; Humans; Male; | 2019 |
A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Topics: Adult; Buprenorphine; Emergency Service, Hospital; Female; Health Care Costs; Humans; Male; Medicaid | 2019 |
Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes.
Topics: Adult; Buprenorphine; Databases, Factual; Female; Hospitals, Community; Humans; Infant Health; Massa | 2019 |
Use of naltrexone in treating opioid use disorder in pregnancy.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Human | 2020 |
Comparison of psychiatric comorbidity in treatment-seeking, opioid-dependent patients with versus without chronic pain.
Topics: Adult; Analgesics, Opioid; Anti-Anxiety Agents; Antimanic Agents; Chronic Pain; Cohort Studies; Como | 2020 |
Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.
Topics: Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Humans; Male; Methadone; Morphine; Off-L | 2020 |
Prevention. Opiate substitute therapy reduces HIV transmission.
Topics: HIV Infections; Humans; Methadone; Opioid-Related Disorders; Substance Abuse, Intravenous | 2012 |
Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia.
Topics: Adolescent; Adult; Ethnicity; HIV Infections; Humans; Kaplan-Meier Estimate; Malaysia; Male; Methado | 2013 |
A review of methadone deaths between 2001 and 2005 in Victoria, Australia.
Topics: Adolescent; Adult; Australia; Cause of Death; Chronic Pain; Dose-Response Relationship, Drug; Female | 2013 |
Mothers in methadone treatment and their involvement with the child protection system: a replication and extension study.
Topics: Adolescent; Adult; Australia; Child; Child Welfare; Child, Preschool; Cross-Sectional Studies; Famil | 2013 |
Risk factors for fatal outcome in patients with opioid dependence treated with methadone in a family medicine setting in Croatia.
Topics: Adult; Aged; Analgesics, Opioid; Croatia; Family Practice; Female; Humans; Male; Methadone; Middle A | 2013 |
Risk factors of erectile dysfunction in patients receiving methadone maintenance therapy.
Topics: Adult; Aged; Erectile Dysfunction; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; R | 2013 |
Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies.
Topics: Adult; Aging; Blood Vessels; Buprenorphine; Cross-Sectional Studies; Endothelium, Vascular; Female; | 2013 |
Italy's electronic health record system for opioid agonist treatment.
Topics: Adult; Age Factors; Buprenorphine; Electronic Health Records; Female; Humans; Italy; Length of Stay; | 2013 |
Opioid substitution: improving cost-efficiency.
Topics: Cost-Benefit Analysis; HIV Infections; Humans; International Cooperation; Methadone; Opiate Substitu | 2013 |
Scaling up opioid dependence treatment in low- and middle-income settings.
Topics: Cost-Benefit Analysis; Counseling; Developing Countries; Global Health; Harm Reduction; Hepatitis C; | 2013 |
Opioid treatment in Ukraine risks losing momentum.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Diso | 2013 |
Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services.
Topics: Capacity Building; China; Health Personnel; HIV Infections; Humans; Methadone; Opiate Substitution T | 2013 |
Voluntary treatment, not detention, in the management of opioid dependence.
Topics: Cross-Cultural Comparison; Evidence-Based Practice; Human Rights Abuses; Humans; Interinstitutional | 2013 |
Treating opioid use disorders during pregnancy: historical, current, and future directions.
Topics: Buprenorphine; Disease Management; Female; History, 19th Century; History, 20th Century; History, 21 | 2013 |
A metaphor analysis of recovering substance abusers' sensemaking of medication-assisted treatment.
Topics: Adult; Aged; Aged, 80 and over; Communication; Drug Users; Female; Focus Groups; Humans; Male; Metap | 2013 |
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.
Topics: Female; Gene Expression; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Diso | 2013 |
Abstinence versus agonist maintenance treatment: an outdated debate?
Topics: Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Substance | 2013 |
Trends in the average prescribed dose of methadone: more than a proxy for the evolution of severity of opioid dependence.
Topics: Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 2013 |
Re: Letter from J. Trujols, N. Siñol & J. Pérez De Los Cobos.
Topics: Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 2013 |
Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.
Topics: Adult; Analgesics, Opioid; Drug Users; Family Relations; Female; Humans; Interviews as Topic; Longit | 2013 |
Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Income; Male; Methadone; New York City; Opiate Su | 2013 |
Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Income; Male; Methadone; New York City; Opiate Su | 2013 |
Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Income; Male; Methadone; New York City; Opiate Su | 2013 |
Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Income; Male; Methadone; New York City; Opiate Su | 2013 |
The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy.
Topics: Adult; Cohort Studies; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; Opi | 2013 |
Engagement, retention, and abstinence for three types of opioid users in Florida.
Topics: Adult; Buprenorphine; Female; Heroin Dependence; Humans; Male; Medication Adherence; Methadone; Narc | 2013 |
Changes in the characteristics and levels of comorbidity among new patients into methadone maintenance treatment program in British Columbia during its expansion period from 1998-2006.
Topics: Adult; Age Factors; British Columbia; Canada; Chronic Disease; Comorbidity; Female; Humans; Male; Me | 2013 |
Categorising methadone: Addiction and analgesia.
Topics: Analgesics, Opioid; Behavior, Addictive; Chronic Pain; Drug Users; Humans; Methadone; Opiate Substit | 2013 |
Driving under the influence (DUI) among patients in opioid maintenance treatment (OMT): a registry-based national cohort study.
Topics: Adult; Automobile Driving; Buprenorphine; Crime; Female; Humans; Male; Methadone; Narcotics; Norway; | 2013 |
Correlates of depressive symptoms among alcohol-using methadone maintained adults.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Analgesics, Opioid; Cross-Sectional Studies; Dep | 2012 |
Psychopathology and pain correlates of dispositional optimism in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Attitude; Chronic Pain; Depressive Disorder; Female; Health Status; Human | 2012 |
QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study.
Topics: Aged; Electrocardiography; Female; Follow-Up Studies; Humans; Long QT Syndrome; Male; Methadone; Mid | 2013 |
QTc interval screening in an opioid treatment program.
Topics: Adult; Analgesics, Opioid; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Male; Mass Scr | 2013 |
Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET.
Topics: Adult; Aged; Analgesics, Opioid; Anticipation, Psychological; Buprenorphine; Corpus Striatum; Dopami | 2014 |
Take home maintenance medication in opiate dependence.
Topics: Adolescent; Adult; Aged; Female; Germany; Humans; Maintenance Chemotherapy; Male; Methadone; Middle | 2013 |
Factors associated with high-frequency illicit methadone use among rural Appalachian drug users.
Topics: Adult; Appalachian Region; Drug Users; Female; Humans; Longitudinal Studies; Male; Methadone; Middle | 2013 |
Effectiveness and feasibility study of routine HIV rapid testing in an urban methadone maintenance treatment program.
Topics: Adolescent; Adult; Aged; Ambulatory Care Facilities; Counseling; Feasibility Studies; Female; HIV In | 2013 |
Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China.
Topics: Adult; China; Comorbidity; Depression; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Op | 2013 |
Coexisting addiction and pain in people receiving methadone for addiction.
Topics: Adult; Chronic Pain; Female; Humans; Male; Methadone; Middle Aged; Narration; Opioid-Related Disorde | 2014 |
Quality of life in patients on methadone maintenance treatment: a three-month assessment.
Topics: Adult; Analysis of Variance; Female; Humans; Iran; Male; Methadone; Narcotics; Opiate Substitution T | 2012 |
Higher methadone doses are associated with lower mortality in patients of opioid dependence in Taiwan.
Topics: Adult; Female; Follow-Up Studies; HIV Infections; Humans; Male; Methadone; Middle Aged; Mortality; O | 2013 |
Advice on methadone and oral health: dental public health in action.
Topics: Cariostatic Agents; Dental Care; Dental Caries; Diet; Fluorides; Health Education, Dental; Health Pr | 2013 |
Evaluation of metabolite/drug ratios in blood and urine as a tool for confirmation of a reduced tolerance in methadone-related deaths in Denmark.
Topics: Adult; Aged; Cause of Death; Denmark; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; N | 2013 |
Time to first treatment interruption in the Chinese methadone maintenance treatment programme.
Topics: Algorithms; China; Female; Humans; Kaplan-Meier Estimate; Male; Methadone; Narcotics; Needle Sharing | 2013 |
Risk of QTc prolongation in a cohort of opioid-dependent HIV-infected patients on methadone maintenance therapy.
Topics: Adult; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Linear Models; | 2013 |
Editorial commentary: the methadone menace.
Topics: Female; HIV Infections; Humans; Long QT Syndrome; Male; Methadone; Opioid-Related Disorders | 2013 |
Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants.
Topics: Adult; Breast Feeding; Buprenorphine; Cohort Studies; Female; Humans; Infant, Newborn; Methadone; Na | 2013 |
Pain management discussion forum.
Topics: Analgesics, Opioid; Hemophilia B; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Rel | 2013 |
A call for evidence-based medical treatment of opioid dependence in the United States and Canada.
Topics: Analgesics, Opioid; Canada; Cost-Benefit Analysis; Evidence-Based Medicine; Health Services Accessib | 2013 |
Response to Chandler et al., Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.
Topics: Analgesics, Opioid; Drug Users; Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opio | 2013 |
Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders' perspective.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Poland; Qualitative Rese | 2013 |
Commentary on Jacek Moskalewicz and Marta Welbel, Walking through mud; history of the Polish methadone maintenance treatment from its stakeholders' perspective.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2013 |
Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Topics: Buprenorphine; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Health Care Costs; Health | 2013 |
Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction.
Topics: Bosnia and Herzegovina; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; H | 2013 |
Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Drug Users; Health Knowledge, Attitudes, Practice; He | 2013 |
The lethal burden of drug overdose.
Topics: Cause of Death; Cost Control; Cross-Cultural Comparison; Drug Overdose; Heroin Dependence; Humans; I | 2013 |
Syncope: a tale of two triggers.
Topics: Bradycardia; Dose-Response Relationship, Drug; Electrocardiography; Humans; Male; Methadone; Middle | 2013 |
Social determinants of methadone in pregnancy: violence, social capital, and mental health.
Topics: Domestic Violence; Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Risk F | 2013 |
Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up.
Topics: Adult; Aged; Buprenorphine; Comorbidity; Dose-Response Relationship, Drug; Electrocardiography; Epid | 2013 |
Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Cobicistat; Drug Interactions; Female; Humans; | 2013 |
Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway.
Topics: Adolescent; Adult; Analgesics, Opioid; Attention Deficit Disorder with Hyperactivity; Buprenorphine; | 2014 |
A Preliminary Study Examining Nutritional Risk Factors, Body Mass Index, and Treatment Retention in Opioid-Dependent Patients.
Topics: Adult; Body Mass Index; Female; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Nutritio | 2015 |
Treatment outcome predictors in flexible dose-duration methadone detoxification program.
Topics: Adolescent; Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Prospective Studies; T | 2013 |
Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective study.
Topics: Adult; China; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Medication Adherence; Meth | 2013 |
Commentary on Brooner et al. (2013): one-stop shopping--what sells and what doesn't.
Topics: Delivery of Health Care, Integrated; Female; Humans; Male; Mental Disorders; Methadone; Narcotics; O | 2013 |
Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.
Topics: Analgesics, Opioid; Buprenorphine; Confidentiality; Dose-Response Relationship, Drug; Emergency Serv | 2014 |
Integrated care for pregnant women on methadone maintenance treatment: Canadian primary care cohort study.
Topics: Adolescent; Adult; Analgesics, Opioid; Canada; Cohort Studies; Delivery of Health Care, Integrated; | 2013 |
'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'.
Topics: Adult; Buprenorphine; Crime; Female; Heroin Dependence; Humans; Illicit Drugs; Male; Methadone; Midd | 2013 |
Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden.
Topics: Adolescent; Adult; Attitude of Health Personnel; Buprenorphine; Data Interpretation, Statistical; Da | 2013 |
Reply: To PMID 23727040.
Topics: Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 2014 |
The obstetric and neonatal impact of maternal opioid detoxification in pregnancy.
Topics: Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 2014 |
Opioid substitution treatment in pretrial prison detention: a case study from Geneva, Switzerland.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Continuity of Patient Care; Female; Health Services Access | 2013 |
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.
Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti | 2014 |
Dispensing maintenance medication to take home not allowed.
Topics: Female; Humans; Maintenance Chemotherapy; Male; Methadone; Opiate Substitution Treatment; Opioid-Rel | 2013 |
Not registered.
Topics: Female; Humans; Maintenance Chemotherapy; Male; Methadone; Opiate Substitution Treatment; Opioid-Rel | 2013 |
In reply.
Topics: Female; Humans; Maintenance Chemotherapy; Male; Methadone; Opiate Substitution Treatment; Opioid-Rel | 2013 |
Lessons from Tanzania on the integration of HIV and tuberculosis treatments into methadone assisted treatment.
Topics: Delivery of Health Care, Integrated; HIV Infections; Humans; Mental Health Services; Methadone; Opia | 2014 |
From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Opioid-Related Disorders | 2014 |
ALDH5A1 variability in opioid dependent patients could influence response to methadone treatment.
Topics: Adolescent; Adult; Aged; Alleles; Female; Genotyping Techniques; Humans; Male; Methadone; Middle Age | 2014 |
[Methadone and levomethadone - dosage and side effects].
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Ger | 2014 |
From oxycodone to heroin: two cases of transitioning opioid use in young Australians.
Topics: Administration, Intravenous; Adult; Australia; Drug Users; Female; Heroin; Humans; Male; Methadone; | 2014 |
External validation of the medication taper complexity score for methadone tapers in children with opioid abstinence syndrome.
Topics: Analgesics, Opioid; Child; Drug Administration Schedule; Humans; Methadone; Neonatal Abstinence Synd | 2014 |
Methadone treatment providers' views of drug court policy and practice: a case study of New York State.
Topics: Attitude of Health Personnel; Communication; Health Policy; Humans; Interprofessional Relations; Law | 2013 |
Reduced fetal growth in methadone-maintained pregnancies is not fully explained by smoking or socio-economic deprivation.
Topics: Adult; Analgesics, Opioid; Birth Weight; Cohort Studies; Female; Fetal Growth Retardation; Head; Hum | 2014 |
An ECG-based cardiac safety initiative is well received by opioid treatment program staff: results from a qualitative assessment.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Attitude of Health Personnel; Electrocardiography; Humans; | 2013 |
Why do patients stay in opioid maintenance treatment?
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Female; Germany; Humans; Male; Medication Adherence; Me | 2014 |
Public opinion of drug treatment policy: exploring the public's attitudes, knowledge, experience and willingness to pay for drug treatment strategies.
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Female; Financing, Personal; Harm Reduction; Healt | 2014 |
Datapoints: regional variation in benzodiazepine prescribing for patients on opioid agonist therapy.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Drug Prescriptions; Humans; Methadone; Narcotic | 2014 |
Outcome evaluation of the opioid agonist maintenance treatment in Iran.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Status; Humans; Iran; Male; Mental Health; | 2014 |
Commentary on Freelemyer et al. (2014): medication-assisted treatment in Africa-need is growing but response remains tepid.
Topics: Analgesics, Opioid; Buprenorphine; Developing Countries; Humans; Medication Adherence; Methadone; Op | 2014 |
Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; M | 2014 |
Evaluation of a pharmacist-managed methadone taper*.
Topics: Adolescent; Analgesics, Opioid; Case-Control Studies; Child; Child, Preschool; Female; Hospitals, Pe | 2014 |
Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals.
Topics: Adolescent; Adult; Black or African American; Buprenorphine; Databases, Factual; Female; Financing, | 2014 |
Access to treatment for opioid dependence in rural America: challenges and future directions.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Delayed-Action Preparations; Drug | 2014 |
Methadone-related deaths - epidemiological, pathohistological, and toxicological traits in 10-year retrospective study in Vojvodina, Serbia.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Diazepam; Forensic Toxicology; Hepatitis, Viral, | 2014 |
Impact of methadone maintenance treatment on women offenders' post-release recidivism.
Topics: Adult; Canada; Cohort Studies; Crime; Criminals; Female; Humans; Maintenance Chemotherapy; Methadone | 2014 |
[No opiates against cannabis hyperemesis syndrome].
Topics: Adult; Antiemetics; Dronabinol; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combina | 2014 |
Commentary on Mactier et al. (2014): Methadone-assisted treatment and the complexity of influences on fetal development.
Topics: Analgesics, Opioid; Birth Weight; Female; Fetal Growth Retardation; Humans; Male; Methadone; Opioid- | 2014 |
Stigma and its determinants among male drug dependents receiving methadone maintenance treatment.
Topics: Adult; Aged; Analgesics, Opioid; Confidentiality; Heroin Dependence; Humans; Iran; Male; Men; Methad | 2014 |
Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response.
Topics: Adult; Female; Follow-Up Studies; HIV Infections; Humans; Longitudinal Studies; Male; Methadone; Opi | 2014 |
Confronting the stigma of opioid use disorder--and its treatment.
Topics: Buprenorphine; Chronic Disease; Criminal Law; Humans; Illicit Drugs; Methadone; Narcotic Antagonists | 2014 |
When higher doses in opioid replacement treatment are still inadequate - association to multidimensional illness severity: a cohort study.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Opiate Sub | 2014 |
Execution of control among 'non-compliant', imprisoned individuals in opioid maintenance treatment.
Topics: Adult; Buprenorphine; Data Collection; Female; Humans; Internal-External Control; Male; Medication A | 2014 |
Commentary on Holland et al. (2014): Opioid maintenance treatment--how much supervision is helpful?
Topics: Buprenorphine; Female; Humans; Male; Medication Adherence; Methadone; Narcotics; Opiate Substitution | 2014 |
Methadone: who tapers, when, where, and how?*.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Opioid-Related Disorders; Pharmacists; Substanc | 2014 |
Continued drug use during methadone treatment in China: a retrospective analysis of 19,026 service users.
Topics: China; Female; HIV Infections; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Op | 2014 |
Achievement of take-home dose privileges is associated with better-perceived sleep and with cognitive status among methadone maintenance treatment patients.
Topics: Chronic Pain; Cognition; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Neuropsychological | 2014 |
'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings.
Topics: Adult; Ambulatory Care Facilities; Analgesics, Opioid; Attitude of Health Personnel; Australia; Deli | 2014 |
Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders | 2014 |
Selections of reality: applying Burke's dramatism to a harm reduction program.
Topics: Denmark; Harm Reduction; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; | 2014 |
Severity and interference of chronic pain in methadone-maintained outpatients.
Topics: Adult; Age Factors; Baltimore; Benzodiazepines; Chronic Pain; Cocaine; Cocaine-Related Disorders; Co | 2014 |
Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study.
Topics: Adult; Aged; Attitude of Health Personnel; Buprenorphine; Cross-Sectional Studies; Female; Humans; L | 2014 |
The safe implementation of a prison-based methadone maintenance programme: 7 year time-series analysis of primary care prescribing data.
Topics: Analgesics, Opioid; Drug Prescriptions; Electronic Prescribing; Episode of Care; General Practice; H | 2014 |
Treatment outcome unaffected by initiation of full weekend closure of methadone maintenance treatment clinic.
Topics: Ambulatory Care Facilities; Appointments and Schedules; Female; Health Facility Closure; Holidays; H | 2014 |
Cognitive control in opioid dependence and methadone maintenance treatment.
Topics: Adult; Amphetamine; Cognition; Comorbidity; Demography; Humans; Maintenance Chemotherapy; Male; Meth | 2014 |
Opioid-related mortality and filled prescriptions for buprenorphine and methadone.
Topics: Adolescent; Adult; Aged; Buprenorphine; Databases, Factual; Female; Heroin Dependence; Humans; Male; | 2014 |
Renal lipidosis in patients enrolled in a methadone substitution program.
Topics: Adult; Biopsy; Disease Progression; Female; Humans; Kidney; Kidney Diseases; Lipid Metabolism; Lipid | 2014 |
Role of ALDH5A1 in methadone treatment.
Topics: gamma-Aminobutyric Acid; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related | 2014 |
OPRM1 polymorphism and lifetime suicide attempts among stabilized, methadone-maintained outpatients.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related D | 2014 |
A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
Topics: Adult; Buprenorphine; Female; Humans; Internal Medicine; Male; Methadone; Narcotic Antagonists; Narc | 2014 |
Are methadone counselors properly equipped to meet the palliative care needs of older adults in methadone maintenance treatment? Implications for training.
Topics: Age Factors; Aged; Chronic Disease; Counseling; Female; Humans; Male; Methadone; Middle Aged; Needs | 2014 |
"In their perception we are addicts": social vulnerabilities and sources of support for men released from drug treatment centers in Vietnam.
Topics: Adult; Drug Users; Harm Reduction; HIV Infections; Humans; Interviews as Topic; Male; Mandatory Prog | 2014 |
Advertising representation, treatment menu and economic circulation of substance misuse treatment centers in Iran: a rapid survey based on newspaper advertisements.
Topics: Advertising; Buprenorphine; Data Collection; Humans; Iran; Methadone; Newspapers as Topic; Opioid-Re | 2014 |
Patterns of non-compliant buprenorphine, levomethadone, and methadone use among opioid dependent persons in treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Medication Adherence; Methadone; Nar | 2014 |
Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol.
Topics: Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; | 2014 |
Psychiatric comorbidity differences between women with history of childhood sexual abuse who are methadone-maintained former opiate addicts and non-addicts.
Topics: Adult; Comorbidity; Dissociative Disorders; Female; Humans; Methadone; Middle Aged; Obsessive-Compul | 2014 |
Neuropsychological performance of methadone-maintained opiate users.
Topics: Adolescent; Adult; Attention; Case-Control Studies; Cognition Disorders; Drug Users; Executive Funct | 2014 |
Postpartum changes in methadone maintenance dose.
Topics: Adult; Benzodiazepines; Cohort Studies; Female; Humans; Methadone; Narcotics; Opiate Substitution Tr | 2014 |
Opioid substitution treatment in New Zealand: a 40 year perspective.
Topics: Analgesics, Opioid; History, 20th Century; History, 21st Century; Humans; Methadone; New Zealand; Op | 2014 |
Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels.
Topics: Dose-Response Relationship, Drug; Evidence-Based Medicine; Health Services Accessibility; Heroin Dep | 2014 |
A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: do stable patients receive more unsupervised doses?
Topics: Age Factors; Buprenorphine; Cross-Sectional Studies; Female; Humans; Male; Medication Adherence; Met | 2014 |
Characteristics and quality of life of opioid-dependent pregnant women in Austria.
Topics: Administration, Oral; Adult; Austria; Buprenorphine; Delayed-Action Preparations; Female; Humans; Me | 2014 |
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
Topics: Adult; Alcoholism; British Columbia; Cohort Studies; Female; Hepatitis C; Humans; Illicit Drugs; Mal | 2014 |
A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study.
Topics: Administration, Sublingual; Adolescent; Adult; Age Distribution; Analgesics, Opioid; Analysis of Var | 2014 |
Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012.
Topics: Adolescent; Adult; California; Community Mental Health Services; Female; Humans; Male; Methadone; Mi | 2014 |
Methadone maintenance treatment may improve completion rates and delay opioid relapse for opioid dependent individuals under community corrections supervision.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Criminal Law; Criminals; Female; Humans; Interviews | 2014 |
Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.
Topics: Analgesics, Opioid; Buprenorphine; Fear; Female; Humans; Male; Methadone; Middle Aged; Motivation; O | 2015 |
Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis.
Topics: Adult; Emigrants and Immigrants; Ethnicity; Female; HIV Infections; Humans; Male; Methadone; Narcoti | 2014 |
Impact of lifetime psychiatric diagnosis on long-term retention and survival of former opiate addicts in methadone maintenance treatment.
Topics: Adult; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Medication Adherence; Mental Disorders; | 2014 |
Methadone induces testosterone suppression in patients with opioid addiction.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Male; Menstrual Cycle; Methadone; Middle Aged; Opiat | 2014 |
Risk reduction with buprenorphine-naloxone and methadone: patient's choice.
Topics: Buprenorphine; Female; HIV Infections; Humans; Male; Methadone; Naloxone; Narcotic Antagonists; Opio | 2014 |
Methadone maintenance patients show a selective deficit to reverse positive outcomes in drug-related conditions compared to medication free prolonged opiate abstinence.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Female; Humans; Male; Methadone; Middle Aged; Opiate | 2014 |
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltre | 2014 |
Police interference with methadone treatment in Bangkok, Thailand.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related D | 2015 |
Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance.
Topics: Adult; Analgesics, Opioid; Humans; Hydrocortisone; Male; Medication Adherence; Methadone; Opiate Sub | 2015 |
Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice".
Topics: Buprenorphine; Female; HIV Infections; Humans; Male; Methadone; Naloxone; Narcotic Antagonists; Opio | 2014 |
Psychological predictors of retention in a low-threshold methadone maintenance treatment for opioid addicts: a 1-year follow-up study.
Topics: Adolescent; Adult; Crime; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Methadone; | 2015 |
Dynamics in the costs of criminality among opioid dependent individuals.
Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Cost of Illness; Crime; Criminals; Female; Follow-U | 2014 |
Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Topics: Administration, Oral; Australia; Cohort Studies; Humans; Methadone; Naltrexone; Narcotic Antagonists | 2015 |
Methadone induced Torsades de Pointes mimicking seizures in clinical presentation.
Topics: Adult; Female; Humans; Methadone; Opioid-Related Disorders; Seizures; Torsades de Pointes | 2014 |
Conversation with Walter Ling.
Topics: Behavior, Addictive; Biomedical Research; Career Choice; Humans; Methadone; Narcotics; Opioid-Relate | 2015 |
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Disease Transmission, Infectious; Drug Users; Fema | 2014 |
Executive function in preschool children prenatally exposed to methadone or buprenorphine.
Topics: Analgesics, Opioid; Buprenorphine; Case-Control Studies; Child; Child Development; Child, Preschool; | 2015 |
Using the PRECEDE model in understanding determinants of quality of life among Iranian male addicts.
Topics: Adult; Analgesics, Opioid; Demography; Humans; Interviews as Topic; Iran; Male; Methadone; Middle Ag | 2014 |
Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?
Topics: Buprenorphine; Hepacivirus; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorde | 2014 |
Increases in body mass index following initiation of methadone treatment.
Topics: Adult; Body Mass Index; Body Weight; Female; Humans; Male; Methadone; Middle Aged; Opiate Substituti | 2015 |
Retention and its predictors among methadone maintenance treatment clients in China: a six-year cohort study.
Topics: Adult; China; Cohort Studies; Female; Humans; Male; Medication Adherence; Methadone; Opiate Substitu | 2014 |
Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain.
Topics: Acute Pain; Adult; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Comorbidity; Female; Huma | 2014 |
Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.
Topics: Adolescent; Adult; Aged; Asian People; Cross-Sectional Studies; Ethnicity; Female; Humans; Male; Met | 2014 |
Infants of opioid-dependent mothers: neurodevelopment at six months.
Topics: Adult; Analgesics, Opioid; Case-Control Studies; Child Development; Female; Humans; Infant; Infant, | 2015 |
Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors.
Topics: Adult; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Opiate Substitution Treatmen | 2015 |
Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study.
Topics: Adult; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Female; Heroin Dependence; Human | 2014 |
The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.
Topics: Adult; Anti-HIV Agents; Buprenorphine; Cocaine; Cocaine-Related Disorders; Drug Interactions; Female | 2015 |
Diversion of methadone and buprenorphine from opioid substitution treatment: patients who regularly sell or share their medication.
Topics: Analgesics, Opioid; Buprenorphine; Commerce; Female; Humans; Interviews as Topic; Male; Methadone; M | 2015 |
Predictors of treatment retention in a major methadone maintenance treatment program in iran: a survival analysis.
Topics: Adult; Analgesics, Opioid; Female; Humans; Iran; Male; Methadone; Opiate Substitution Treatment; Opi | 2014 |
A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Crime; Female; Humans; Longitudinal Studies; Male; Medicat | 2015 |
Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use-buprenorphine/naloxone treatment and recovery in a surgical patient.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Codeine; Disease Management; Female; Heroin; Heroin Depend | 2014 |
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.
Topics: Adult; China; Cross-Sectional Studies; Female; Hepatitis C; Humans; Male; Methadone; Opiate Substitu | 2015 |
Who uses methadone services in China? Monitoring the world's largest methadone programme.
Topics: Adult; Analgesics, Opioid; China; Cohort Studies; Database Management Systems; Drug Users; Female; H | 2015 |
Predictors of accessing antiretroviral therapy among HIV-positive drug users in China's National Methadone Maintenance Treatment Programme.
Topics: Adult; Anti-HIV Agents; China; Cohort Studies; Drug Users; Female; Follow-Up Studies; Health Service | 2015 |
Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China.
Topics: Adult; Analgesics, Opioid; Anxiety; China; Comorbidity; Cross-Sectional Studies; Depression; Drug Us | 2015 |
Illicit use of opioid substitution drugs: prevalence, user characteristics, and the association with non-fatal overdoses.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Drug Overdose; Drug Users; Female; Heroin; Humans; Il | 2015 |
Comparing treatment-seeking codeine users and strong opioid users: Findings from a novel case series.
Topics: Adult; Codeine; Female; Humans; Male; Methadone; Middle Aged; Morphine; Opiate Substitution Treatmen | 2015 |
Methadone and prescription drug overdose.
Topics: Analgesics, Opioid; Chronic Pain; Drug Overdose; Drug Prescriptions; Formularies as Topic; Humans; M | 2014 |
Determining Smoking Cessation Related Information, Motivation, and Behavioral Skills among Opiate Dependent Smokers in Methadone Treatment.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Models, Psychological; Motivation; Narcotics; O | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Buprenorphine and naloxone compared with methadone treatment in pregnancy.
Topics: Adult; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naloxone; Narcotic Antagonists; Na | 2015 |
Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers.
Topics: Adult; Attention; Cognition; Double-Blind Method; Ethanol; Female; Humans; Male; Methadone; Middle A | 2015 |
A satisfaction survey of opioid-dependent patients with methadone maintenance treatment.
Topics: Adult; Delivery of Health Care; Female; Humans; Male; Methadone; Middle Aged; New South Wales; Opiat | 2015 |
Factors associated with work and taking prescribed methadone or buprenorphine among Swedish opiate addicts.
Topics: Adult; Buprenorphine; Educational Status; Employment; Female; Humans; Male; Methadone; Opiate Substi | 2015 |
Past-year gambling behaviour among patients receiving opioid substitution treatment.
Topics: Adult; Age Factors; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies | 2015 |
[Quality of life among people addicted to psychoactive substances participating in the opiate substitution treatment].
Topics: Adult; Age Factors; Aged; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatmen | 2014 |
Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10.
Topics: Adolescent; Adult; Age of Onset; California; Cohort Studies; Female; Humans; Male; Methadone; Narcot | 2015 |
Adolescents at risk: pain pills to heroin: part II.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Drug Substitution; Heroin; Heroin Dependence; Humans; | 2015 |
Maternal Substance Use and Neonatal Abstinence Syndrome: A Descriptive Study.
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Length of Stay; Methadone; Mothers; Neonatal Abs | 2015 |
Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice.
Topics: Adult; Attitude; Heroin; HIV Infections; Humans; Indonesia; Male; Methadone; Narcotics; Needle Shari | 2015 |
Diversion of methadone and buprenorphine from opioid substitution treatment: the importance of patients' attitudes and norms.
Topics: Adult; Attitude; Buprenorphine; Female; Humans; Individuality; Male; Methadone; Morals; Motivation; | 2015 |
Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users.
Topics: Adult; Cocaine-Related Disorders; Female; Housing; Humans; Male; Methadone; Narcotics; Opiate Substi | 2015 |
Promethazine use among chronic pain patients.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Chronic Pain; Female; Histamine H1 Antagonists; Humans; | 2015 |
First Dutch national guidelines--pharmacological care for detained opioid addicts.
Topics: Buprenorphine; Communicable Diseases; Comorbidity; Continuity of Patient Care; Female; Health Policy | 2009 |
HIV-gp120 and physical dependence to buprenorphine.
Topics: Animals; Buprenorphine; HIV Envelope Protein gp120; HIV Infections; Male; Methadone; Opioid-Related | 2015 |
Commentary on Burns et al. (2015): retention in buprenorphine treatment.
Topics: Buprenorphine; Burns; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2015 |
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Topics: Adolescent; Adult; Aged; Buprenorphine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action P | 2015 |
Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.
Topics: Alcohol-Related Disorders; Breast Feeding; Counseling; Female; Humans; Incidence; Infant, Newborn; M | 2015 |
Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment.
Topics: Adult; Aged; Cannabinoids; Cocaine; Cocaine-Related Disorders; Female; Forecasting; Humans; Male; Ma | 2015 |
A qualitative assessment of methadone maintenance therapy program in Nepal: evidence to scaling up at national level.
Topics: Focus Groups; Humans; Methadone; Narcotics; Nepal; Opiate Substitution Treatment; Opioid-Related Dis | 2014 |
Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders | 2015 |
The Impact of Social Support and Attachment Style on Quality of Life and Readiness to Change in a Sample of Individuals Receiving Medication-Assisted Treatment for Opioid Dependence.
Topics: Adaptation, Psychological; Adult; Aged; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle | 2015 |
Associations between chronic non-cancer pain and medication assisted treatment outcomes for opiate addiction.
Topics: Adult; Anxiety; Chronic Pain; Comorbidity; Depression; Female; Humans; Kentucky; Male; Methadone; Op | 2015 |
Perceived barriers to utilise methadone maintenance therapy among male injection drug users in rural areas of southern Thailand.
Topics: Adult; Cross-Sectional Studies; Health Services Accessibility; Humans; Interviews as Topic; Male; Me | 2015 |
Vermont responds to its opioid crisis.
Topics: Buprenorphine; Cost-Benefit Analysis; Health Care Costs; Health Policy; Health Services Accessibilit | 2015 |
The relevance of the psychological evaluation in drug dependence.
Topics: Adult; Counseling; Humans; Methadone; Opioid-Related Disorders; Psychotherapy; Substance Withdrawal | 2014 |
Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Topics: Adult; Buprenorphine; Drug Users; Female; Health Services Accessibility; Humans; Interviews as Topic | 2015 |
Relationship between plasma concentrations of the l-enantiomer of methadone and response to methadone maintenance treatment.
Topics: Adult; Cross-Sectional Studies; Heroin Dependence; Humans; Methadone; Middle Aged; Opiate Substituti | 2015 |
Maternal methadone treatment and neonatal abstinence syndrome.
Topics: Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Length of Stay; Logistic Models | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination | 2015 |
Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Female; Finland; Humans; M | 2015 |
Interim treatment: Bridging delays to opioid treatment access.
Topics: Adult; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Methadone; Narcotic Antag | 2015 |
Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; British Columbia; Dose-Response Relationship, Drug; Fema | 2015 |
Does therapeutic use of tapentadol cause false-positive urine screens for methadone or opiates?
Topics: Adult; Aged, 80 and over; Analgesics, Opioid; Chromatography, Gas; Chromatography, Liquid; False Pos | 2015 |
Coherent long-term treatment approaches-superior in the treatment of opioid dependence.
Topics: Analgesics, Opioid; Humans; Long-Term Care; Methadone; Narcotics; Opioid-Related Disorders | 2015 |
Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study.
Topics: Adolescent; Adult; Analgesics, Opioid; Cohort Studies; Dose-Response Relationship, Drug; Female; Hum | 2015 |
Psychosocial Interventions for Problem Alcohol Use in Primary Care Settings (PINTA): Baseline Feasibility Data.
Topics: Adult; Alcoholism; Feasibility Studies; Female; Humans; Male; Methadone; Middle Aged; Opiate Substit | 2015 |
Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Buprenorphine; Combined Modality Therapy; Comorbidity; | 2015 |
Analysis of connectivity in NeuCube spiking neural network models trained on EEG data for the understanding of functional changes in the brain: A case study on opiate dependence treatment.
Topics: Adult; Artificial Intelligence; Brain; Brain Mapping; Electroencephalography; Humans; Methadone; Mod | 2015 |
Obstetrical and neonatal outcomes of methadone-maintained pregnant women: a canadian multisite cohort study.
Topics: Adult; Birth Weight; Breast Feeding; Canada; Female; Gestational Age; Humans; Infant, Newborn; Lengt | 2015 |
Maternal use of methadone and risk of sudden neonatal death.
Topics: Adult; Female; Humans; Infant, Newborn; Male; Methadone; Narcotics; Opioid-Related Disorders; Perina | 2015 |
Predictors of Opioid-Related Death During Methadone Therapy.
Topics: Adult; Analgesics, Opioid; Case-Control Studies; Female; Humans; Male; Methadone; Middle Aged; Ontar | 2015 |
The paradox of control: An ethnographic analysis of opiate maintenance treatment in a Norwegian prison.
Topics: Anthropology, Cultural; Buprenorphine; Humans; Methadone; Norway; Opiate Substitution Treatment; Opi | 2015 |
Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Female; Humans; Male; Methadone; Opiate Substitu | 2016 |
Withdrawal from methadone in US prisons: cruel and unusual?
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2015 |
Auditory event-related potentials in methadone substituted opiate users.
Topics: Adult; Analgesics, Opioid; Case-Control Studies; Evoked Potentials; Female; Humans; Male; Methadone; | 2015 |
A Retrospective Evaluation of Inpatient Transfer from High-Dose Methadone to Buprenorphine Substitution Therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Inpatients; Male; Methadone; Naloxone; Opi | 2015 |
Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.
Topics: Adult; Buprenorphine; Case-Control Studies; Coinfection; Female; Hepatitis C; HIV Infections; Humans | 2015 |
Severe opioid withdrawal syndrome after a single dose of nalmefene.
Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; | 2015 |
Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.
Topics: Analgesics, Opioid; Buprenorphine; Controlled Substances; Drug and Narcotic Control; Drug Prescripti | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Capacity Building; Health Services Needs and Demand; Health Surve | 2015 |
Stigma from the Viewpoint of the Patient.
Topics: Buprenorphine; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders | 2015 |
Opioid Overdose Deaths in the City and County of San Francisco: Prevalence, Distribution, and Disparities.
Topics: Adolescent; Adult; Aged; Black or African American; Cocaine; Drug Overdose; Female; Health Status Di | 2015 |
Predictors of patient retention in methadone maintenance treatment.
Topics: Adolescent; Adult; Analgesics, Opioid; Cocaine-Related Disorders; Female; Humans; Male; Methadone; M | 2015 |
Pain Among High-Risk Patients on Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Canada; Chronic Pain; Cohort Studies; Dose-Response Relationship, Drug; F | 2015 |
Methadone Medical Maintenance: An Early 21st-Century Perspective.
Topics: Attitude of Health Personnel; Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Re | 2015 |
Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Topics: Behavior, Addictive; Buprenorphine; Global Health; Health Services Accessibility; Humans; Methadone; | 2015 |
[Opening the window].
Topics: Female; Heroin Dependence; Humans; Male; Methadone; Nurse-Patient Relations; Nursing, Team; Opioid-R | 2015 |
Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2015 |
Counselor training and attitudes toward pharmacotherapies for opioid use disorder.
Topics: Buprenorphine; Counselors; Female; Health Knowledge, Attitudes, Practice; Humans; Information Dissem | 2016 |
Use of a multi-state model in a claims database: illustration with methadone.
Topics: Adult; Chemistry, Pharmaceutical; Databases, Factual; Female; Follow-Up Studies; France; Humans; Ins | 2015 |
Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
Topics: Buprenorphine; Female; Humans; Insurance Coverage; Medicaid; Methadone; Opiate Substitution Treatmen | 2015 |
A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.
Topics: Adult; Age of Onset; Buprenorphine; Cost-Benefit Analysis; Deinstitutionalization; Female; Humans; M | 2015 |
Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas.
Topics: Adult; Buprenorphine; Community Health Centers; Female; Health Services Accessibility; Humans; Infan | 2015 |
Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study.
Topics: Adolescent; Adult; Aged; Cohort Studies; Female; Humans; Ireland; Male; Methadone; Middle Aged; Opia | 2016 |
Child poisonings with methadone in France: A 6-year prospective national survey since the availability of capsules in 2008.
Topics: Administration, Oral; Adolescent; Age Distribution; Age Factors; Capsules; Child; Child, Preschool; | 2015 |
Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study.
Topics: Adaptation, Psychological; Adult; Female; Humans; Male; Marijuana Smoking; Methadone; Narcotics; Opi | 2015 |
An Examination of Women Ex-Offenders With Methadone Histories.
Topics: Adult; Chicago; Criminal Behavior; Female; Follow-Up Studies; Heroin Dependence; Humans; Income; Met | 2017 |
Is Internet Addiction Prevalent Among Methadone Maintenance Treatment Patients? Data from Las Vegas and Tel Aviv.
Topics: Adult; Behavior, Addictive; Benzodiazepines; Cross-Sectional Studies; Depression; Female; Humans; In | 2015 |
Ten Years of Abstinence in Former Opiate Addicts: Medication-Free Non-Patients Compared to Methadone Maintenance Patients.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Chronic Pain; Cognition; Comorbidity; Female; Humans | 2015 |
A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients.
Topics: Adult; Alleles; Depressive Disorder, Major; Female; Humans; Male; Methadone; Middle Aged; Opiate Sub | 2015 |
Methadone-related deaths. A ten year overview.
Topics: Adolescent; Adult; Child; Child, Preschool; Chromatography, Liquid; Drug Overdose; Female; Forensic | 2015 |
Implementation of a Neonatal Abstinence Syndrome Weaning Protocol: A Multicenter Cohort Study.
Topics: Adult; Analgesics, Opioid; Clinical Protocols; Cohort Studies; Female; Humans; Infant, Newborn; Leng | 2015 |
Opioid dependency rehabilitation with the opioid maintenance treatment programme - a qualitative study from the clients' perspective.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; Norway; Opiate Substitution Trea | 2015 |
Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.
Topics: Adult; Buprenorphine; Cause of Death; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Male; M | 2015 |
Comparative safety of methadone and buprenorphine.
Topics: Buprenorphine; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders; Safety | 2015 |
Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest.
Topics: Administration, Oral; Delayed-Action Preparations; Electrocardiography; Heart Arrest; Humans; Male; | 2015 |
Improving methadone maintenance therapy for prisoner populations.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2015 |
Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
Topics: Analgesics, Opioid; Buprenorphine; Drug Interactions; Health Care Costs; Humans; Infections; Mental | 2015 |
Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study.
Topics: Adult; Brain-Derived Neurotrophic Factor; Canada; Female; Gene Frequency; Genotype; Humans; Male; Me | 2015 |
Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Combined Modality Therapy; Dru | 2016 |
The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting.
Topics: Adult; British Columbia; Canada; Cause of Death; Cohort Studies; Databases, Factual; Female; Humans; | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Ag | 2015 |
Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
Topics: Buprenorphine; Health Services Accessibility; HIV Infections; Humans; Methadone; Narcotic Antagonist | 2015 |
Improvement of saccadic functions after dosing with methadone in opioid addicted individuals.
Topics: Adult; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Prospective Studies; Re | 2016 |
Revision of Breastfeeding Guidelines in the Setting of Maternal Opioid Use Disorder: One Institution's Experience.
Topics: Analgesics, Opioid; Boston; Breast Feeding; Buprenorphine; Female; Health Promotion; Humans; Infant, | 2016 |
Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.
Topics: Adaptation, Psychological; Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Female; Humans; M | 2015 |
Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Topics: Buprenorphine; Health Policy; Health Services Accessibility; Humans; Medicaid; Methadone; Narcotic A | 2016 |
Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain.
Topics: Adult; Aged; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Chronic Pain; Drug Overdose; Fe | 2016 |
Emergence of methadone as a street drug in St. Petersburg, Russia.
Topics: Adult; Data Collection; Female; Heroin Dependence; Humans; Illicit Drugs; Male; Methadone; Opiate Su | 2016 |
The Persian methamphetamine use in methadone treatment in Iran: implication for prevention and treatment in an upper-middle income country.
Topics: Analgesics, Opioid; Health Education; Humans; Income; Iran; Methadone; Methamphetamine; Opiate Subst | 2015 |
Retrospective chart review comparing morphine and methadone in neonates treated for neonatal abstinence syndrome.
Topics: Administration, Oral; Analgesics, Opioid; Female; Humans; Infant, Newborn; Male; Methadone; Morphine | 2015 |
Correlates of Skin and Soft Tissue Infections in Injection Drug Users in a Syringe-Exchange Program in Malmö, Sweden.
Topics: Adult; Amphetamine-Related Disorders; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug | 2015 |
Demographic Trends of Adults in New York City Opioid Treatment Programs--An Aging Population.
Topics: Adult; Age Distribution; Aged; Analgesics, Opioid; Ethnicity; Female; Humans; Male; Methadone; Middl | 2015 |
Rooming-in for Infants at Risk of Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Bottle Feeding; Breast Feeding; Canada; Female; Humans; Infant, Newborn; | 2016 |
Response to Bird et al.: The importance of post-release engagement in treatment in estimating impacts on post-release deaths.
Topics: Animals; Birds; Drug Overdose; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Diso | 2016 |
Evaluation of an implementation of methadone maintenance treatment in China.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; China; Female; Humans; Male; Methadone; Middle Aged; Op | 2015 |
Preventing and Treating Narcotic Addiction--Century of Federal Drug Control.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Government Regulation; History, 19th Century; History | 2015 |
Communicating risk in the context of methadone formulation changes: A qualitative study of overdose warning posters in Vancouver, Canada.
Topics: Adult; British Columbia; Chemistry, Pharmaceutical; Drug Overdose; Female; Health Communication; Hum | 2016 |
Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related | 2016 |
Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life.
Topics: Adult; Analgesics, Opioid; Antisocial Personality Disorder; Comorbidity; Humans; Malaysia; Male; Men | 2016 |
A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Cohort Studies; Female; Humans; Infant | 2016 |
Community pharmacy services for people with drug problems over two decades in Scotland: Implications for future development.
Topics: Adult; Attitude of Health Personnel; Buprenorphine; Community Pharmacy Services; Cross-Sectional Stu | 2016 |
"I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments.
Topics: Adult; Female; Grounded Theory; Humans; Male; Methadone; Middle Aged; New York City; Opiate Substitu | 2016 |
Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Pain; Cohort Studies; Comorbidity; Cross-Sectional Studies; | 2016 |
A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study).
Topics: Adult; Analgesics, Opioid; Female; Humans; Longitudinal Studies; Male; Methadone; Narcotic Antagonis | 2016 |
New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Chromatography, Liquid; Female; Humans; Illicit Dru | 2016 |
Commentary on Pierce et al. (2016): Raising the bar of addiction treatment--first do no harm.
Topics: Buprenorphine; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2016 |
Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Knowledge, Attitudes, Practice; Humans; Mal | 2016 |
Elevated methylation and decreased serum concentrations of BDNF in patients in levomethadone compared to diamorphine maintenance treatment.
Topics: Adult; Analgesics, Opioid; Brain-Derived Neurotrophic Factor; Case-Control Studies; Depression; Epig | 2017 |
Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
Topics: Adult; Buprenorphine; Comorbidity; Demography; Female; Health Status; Humans; Male; Methadone; Middl | 2016 |
Accessing methadone within Moldovan prisons: Prejudice and myths amplified by peers.
Topics: Adult; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Male; M | 2016 |
Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
Topics: Buprenorphine; Cross-Sectional Studies; Drug Users; Germany; Health Status; Methadone; Motivation; O | 2016 |
Report: Demographic profiles and sleep quality among patients on methadone maintenance therapy (MMT) in Malaysia.
Topics: Adult; Cross-Sectional Studies; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Slee | 2016 |
Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Middle A | 2016 |
Behavioral and quality-of-life outcomes in different service models for methadone maintenance treatment in Vietnam.
Topics: Adult; Cross-Sectional Studies; Delivery of Health Care; Female; HIV Seropositivity; Humans; Male; M | 2016 |
Methadone for prisoners.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2016 |
Methadone for prisoners.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2016 |
Methadone for prisoners--Authors' reply.
Topics: Female; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners | 2016 |
Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
Topics: Abscess; Adolescent; Adult; Alcoholism; Amphetamine-Related Disorders; Analgesics, Opioid; Australia | 2016 |
Therapeutic and recreational methadone cardiotoxicity.
Topics: Adult; Cardiotoxicity; Death, Sudden, Cardiac; Forensic Toxicology; Humans; Male; Methadone; Myocard | 2016 |
Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices.
Topics: Community Health Services; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; M | 2016 |
Opioid tolerance in methadone maintenance treatment: comparison of methadone and levomethadone in long-term treatment.
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Drug Tolerance; Female; Humans; Long-Term Care; Ma | 2016 |
An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy.
Topics: Adult; Cognitive Dysfunction; Factor Analysis, Statistical; Female; Humans; Male; Methadone; Neurops | 2016 |
Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.
Topics: Adult; Female; Harm Reduction; Health Services Accessibility; Heroin Dependence; HIV Infections; Hum | 2016 |
Impact of blended treatment literacy and psychoeducation on methadone maintenance treatment outcomes in Yunnan, China.
Topics: Adult; China; Combined Modality Therapy; Female; Heroin Dependence; Humans; Male; Medication Adheren | 2016 |
Economic vulnerability of methadone maintenance patients: Implications for policies on co-payment services.
Topics: Adolescent; Adult; Analgesics, Opioid; Cross-Sectional Studies; Drug Costs; Drug Users; Female; Heal | 2016 |
Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.
Topics: Analgesics, Opioid; Female; Humans; Linear Models; Male; Medicaid; Methadone; Opiate Substitution Tr | 2016 |
Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'?
Topics: Adult; Analgesics, Opioid; Disease Management; Evidence-Based Medicine; Female; Humans; Male; Methad | 2016 |
Relationships between perceived social support and retention among patients in methadone maintenance treatment in mainland China.
Topics: Adult; China; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Male; Medication Adherence | 2017 |
Medication-assisted treatment for hospitalized patients with intravenous-drug-use related infective endocarditis.
Topics: Adult; Buprenorphine; Endocarditis; Female; Hospitalization; Humans; Inpatients; Male; Methadone; Mi | 2016 |
Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.
Topics: Adult; Ambulatory Care Facilities; Buprenorphine; Cost-Benefit Analysis; Humans; Markov Chains; Meth | 2016 |
Time course of attentional bias to drug cues in opioid dependence.
Topics: Adult; Attention; Attentional Bias; Cues; Female; Humans; Male; Methadone; Narcotic Antagonists; Opi | 2016 |
ADHD risk alleles associated with opiate addiction: study of addicted parents and their children.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Female; | 2016 |
Comparison of Pain Tolerance between Opioid Dependent Patients on Methadone Maintenance Therapy (MMT) and Opioid Naive Individuals.
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Tolerance; Female; Humans; Male; Methadone; Middle Aged; | 2016 |
Criminal Charges Prior to and After Enrollment in Opioid Agonist Treatment: A Comparison of Methadone Maintenance and Office-based Buprenorphine.
Topics: Buprenorphine; Criminals; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Finding what works: identification of implementation strategies for the integration of methadone maintenance therapy and HIV services in Vietnam.
Topics: Health Plan Implementation; Health Services Accessibility; HIV Infections; Humans; Interviews as Top | 2016 |
'Crisis' and 'everyday' initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation.
Topics: Adult; British Columbia; Coercion; Cohort Studies; Female; Humans; Interviews as Topic; Male; Methad | 2017 |
[Does substitution with heroin make sense?].
Topics: Germany; Heroin; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient | 2016 |
Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.
Topics: Analgesics, Opioid; Black or African American; Buprenorphine; Ethnicity; Female; Hispanic or Latino; | 2016 |
[Investigation of the medical and social situation of patients managed by opiate replacement regimens for over 10 years by their GP].
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Follow-Up Studies; France; General Practitioners; | 2016 |
Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia.
Topics: Adult; Humans; Malaysia; Male; Methadone; Middle Aged; Opiate Substitution Treatment; Opioid-Related | 2016 |
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Interviews as Topic; Male; Methad | 2016 |
How clients' during-treatment motivations relate to their perceptions and impressions of methadone maintenance treatment: A multilevel analysis of a cross-sectional survey in Guangdong Province, China.
Topics: Adult; China; Cross-Sectional Studies; Family Relations; Female; Humans; Male; Methadone; Middle Age | 2016 |
[Characteristics of subjects under opiate maintenance treatment in primary care using the OPEMA data 2013].
Topics: Adolescent; Adult; Alcohol Drinking; Anxiety; Benzodiazepines; Buprenorphine; Depressive Disorder; D | 2016 |
The prevalence of QT prolongation in a population of patients with substance use disorders.
Topics: Adult; Age Factors; Aged; Electrocardiography; Female; Hospitals, General; Humans; Long QT Syndrome; | 2017 |
Methadone-Related Overdose Deaths in a Liberal Opioid Maintenance Treatment Programme.
Topics: Adult; Benzodiazepines; Denmark; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; Opiate | 2016 |
Impact of a Casino Opening on Gambling Behaviors of People Engaged in Methadone Maintenance.
Topics: Analgesics, Opioid; Behavior, Addictive; Female; Gambling; Humans; Male; Methadone; Middle Aged; Opi | 2017 |
Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Me | 2017 |
Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Dose-Response Relationship, Drug; Humans; L | 2016 |
Relationship between CYP2B6*6 and cold pressor pain sensitivity in opioid dependent patients on methadone maintenance therapy (MMT).
Topics: Adult; Alleles; Analgesics, Opioid; Cytochrome P-450 CYP2B6; Genotype; Heterozygote; Humans; Male; M | 2016 |
Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder.
Topics: Adult; Cohort Studies; Disabled Persons; Female; Follow-Up Studies; Humans; Longitudinal Studies; Ma | 2016 |
Patients with OUD.
Topics: Acute Pain; Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; United States | 2016 |
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Drug Overdose; Female; Humans; Ma | 2016 |
Methadone for the treatment of Prescription Opioids Dependence. A retrospective chart review.
Topics: Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opiate Substitution Treatment; Opioid-Relat | 2016 |
Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.
Topics: Adult; Analgesics, Opioid; Canada; Female; Harm Reduction; HIV Infections; Hospitalization; Humans; | 2016 |
Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study.
Topics: Adult; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders; Methadone; | 2016 |
Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Craving; Cross-Sectional Studies; Depression | 2016 |
Multifaceted impairments in impulsivity and brain structural abnormalities in opioid dependence and abstinence.
Topics: Adult; Analgesics, Opioid; Decision Making; Gray Matter; Humans; Impulsive Behavior; Male; Methadone | 2016 |
Evaluation of the vaginal flora in pregnant women receiving opioid maintenance therapy: a matched case-control study.
Topics: Adult; Analgesics, Opioid; Asymptomatic Infections; Austria; Birth Weight; Buprenorphine; Candidiasi | 2016 |
CYP2B6 and OPRM1 Receptor Polymorphisms at Methadone Clinics And Novel OPRM1 Haplotypes: A Cross-Sectional Study.
Topics: Adult; Cross-Sectional Studies; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Genotype; | 2016 |
Association between cannabis use and treatment outcomes in patients receiving methadone maintenance treatment: a systematic review protocol.
Topics: Analgesics, Opioid; Cannabis; Humans; Marijuana Abuse; Marijuana Smoking; Methadone; Opiate Substitu | 2016 |
Methadone maintenance dose/weight ratio, long QTc, and EKG screening.
Topics: Adult; Body Weight; Brugada Syndrome; Cardiac Conduction System Disease; Dose-Response Relationship, | 2016 |
HIV seroconversion and risk factors among drug users receiving methadone maintenance treatment in China: A qualitative study.
Topics: Adult; China; Counseling; Drug Users; Female; HIV Infections; Humans; Male; Methadone; Needle Sharin | 2016 |
Effectiveness of Methadone Maintenance Therapy and Improvement in Quality of Life Following a Decade of Implementation.
Topics: Adult; Follow-Up Studies; Hepatitis B; Heroin Dependence; HIV Infections; Humans; Interpersonal Rela | 2016 |
Opioid detoxification during pregnancy: the door continues to open.
Topics: Analgesics, Opioid; Female; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Pregn | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
Psychiatric Disorders Among Patients Seeking Treatment for Co-Occurring Chronic Pain and Opioid Use Disorder.
Topics: Adult; Buprenorphine; Chronic Pain; Comorbidity; Cross-Sectional Studies; Disability Evaluation; Fem | 2016 |
High prevalence of constipation and reduced quality of life in opioid-dependent patients treated with opioid substitution treatments.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Constipation; Female; Heroin Dependence; Humans; Italy; Ma | 2016 |
Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China.
Topics: Adult; China; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Status Schedule; Methad | 2016 |
Characteristics of Maternal-Infant Interaction During Treatment for Opioid Withdrawal.
Topics: Adolescent; Adult; Bottle Feeding; Case-Control Studies; Female; Humans; Infant, Newborn; Male; Meth | 2016 |
Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Ontario; Opioid-Related Disorders | 2016 |
Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.
Topics: Adult; Analgesics, Opioid; Female; Heroin; Heroin Dependence; Humans; Male; Methadone; Middle Aged; | 2016 |
Community-Based Methadone Maintenance in a Large Detention Center is Associated with Decreases in Inmate Recidivism.
Topics: Adult; Analgesics, Opioid; Continuity of Patient Care; Criminals; Female; Follow-Up Studies; Humans; | 2016 |
Factors associated with illicit opioid use in methadone maintenance treatment clients in 5 Provinces, China.
Topics: Adult; China; Female; Humans; Logistic Models; Male; Methadone; Middle Aged; Opiate Substitution Tre | 2016 |
Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use.
Topics: Adult; Analgesics, Opioid; Canada; Cocaine; Cocaine-Related Disorders; Crack Cocaine; Female; HIV In | 2016 |
Neonatal Abstinence Syndrome: Twelve Years of Experience at a Regional Referral Center.
Topics: Buprenorphine; Diseases in Twins; Female; Hospitalization; Humans; Infant, Newborn; Male; Methadone; | 2017 |
Multi-Family Therapy with a Reflecting Team: A Preliminary Study on Efficacy among Opiate Addicts in Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Family Therapy; Female; Humans; Male; Methadone; Opiate Substitution Trea | 2017 |
Biliary and pancreatic ductal dilation in patients on methadone maintenance therapy.
Topics: Adult; Aged; Bile Ducts; Case-Control Studies; Contrast Media; Female; Humans; Magnetic Resonance Im | 2017 |
NPS and the methadone queue: Spillages of space and time.
Topics: Adult; Central Nervous System Stimulants; Female; HIV Infections; Humans; Interviews as Topic; Male; | 2017 |
Tailoring a brief intervention for illicit drug use and alcohol use in Irish methadone maintained opiate dependent patients: a qualitative process.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Combined Modality Therapy; Culturally Competent Care; F | 2016 |
[Trend in buprenorphine and methadone shopping behavior in France from 2004 to 2014].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; | 2016 |
Resilience associated with mental health problems among methadone maintenance treatment patients in Guangzhou, China.
Topics: Adult; Anxiety; China; Depression; Female; Humans; Male; Mental Health; Methadone; Middle Aged; Opia | 2017 |
Methadone complications amongst opioid-dependent patients in Malaysia: A case series.
Topics: Adult; Child, Preschool; Drug Overdose; Edema; Female; Humans; Malaysia; Male; Methadone; Narcotics; | 2018 |
Neonatal abstinence syndrome and the gastrointestinal tract.
Topics: Analgesics, Opioid; Buprenorphine; Child; Child, Preschool; Dysbiosis; Female; Gastrointestinal Trac | 2016 |
The relationship between gestational age and the severity of neonatal abstinence syndrome.
Topics: Adult; Analgesics, Opioid; Female; Gestational Age; Humans; Infant, Newborn; Intensive Care Units, N | 2017 |
Club drugs and alcohol abuse predicted dropout and poor adherence among methadone maintenance treatment patients in Guangzhou, China.
Topics: Adult; Alcohol Drinking; Alcoholism; China; Cohort Studies; Designer Drugs; Female; Humans; Male; Me | 2017 |
Retention in Georgia opioid substitution therapy program and associated factors.
Topics: Adolescent; Adult; Aged; Cohort Studies; Female; Georgia (Republic); Hepatitis C, Chronic; Humans; K | 2016 |
A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence.
Topics: 3' Untranslated Regions; Adult; Alleles; Analgesics, Opioid; Australia; Buprenorphine; Buprenorphine | 2018 |
Relapse to opioid use in opioid-dependent individuals released from compulsory drug detention centres compared with those from voluntary methadone treatment centres in Malaysia: a two-arm, prospective observational study.
Topics: Adolescent; Adult; Analgesics, Opioid; Counseling; Humans; Malaysia; Mandatory Programs; Methadone; | 2017 |
Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study.
Topics: Adult; Anti-Retroviral Agents; China; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; | 2017 |
Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions.
Topics: Analgesics, Opioid; Communication; Decision Making; Dose-Response Relationship, Drug; Drug Administr | 2017 |
Delayed villous maturation in term placentas exposed to opioid maintenance therapy: a retrospective cohort study.
Topics: Adult; Buprenorphine; Case-Control Studies; Chorionic Villi; Cohort Studies; Female; Humans; Methado | 2017 |
Response to Smith and Brogly et al. commentaries on Zedler et al.
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2016 |
The comparative safety of buprenorphine versus methadone in pregnancy-what about confounding?
Topics: Buprenorphine; Female; Humans; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatmen | 2016 |
Sleep quality in opioid-naive and opioid-dependent patientson methadone maintenance therapy in Malaysia.
Topics: Analgesics, Opioid; Humans; Malaysia; Male; Methadone; Opioid-Related Disorders; Sleep; Sleep Wake D | 2016 |
Methadone Inpatient and Discharge Prescribing Patterns for Pain at an Academic Health System.
Topics: Adult; Chronic Pain; Female; Humans; Inpatients; Male; Medical Audit; Methadone; Middle Aged; Opioid | 2017 |
Implementation of methadone therapy for opioid use disorder in Russia - a modeled cost-effectiveness analysis.
Topics: Cost-Benefit Analysis; Health Care Costs; Humans; Methadone; Models, Economic; Opiate Substitution T | 2017 |
Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1.
Topics: Adult; Alleles; Analgesics, Opioid; Black or African American; Dose-Response Relationship, Drug; Fem | 2017 |
The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.
Topics: Adult; Benzodiazepines; Cohort Studies; Female; Humans; Length of Stay; Male; Methadone; Ontario; Op | 2017 |
Widening the perspective on opioid substitution treatment.
Topics: Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2017 |
Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013.
Topics: Adult; Aftercare; Aged; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opiate Sub | 2017 |
Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians.
Topics: Analgesics, Opioid; Buprenorphine; Drug-Related Side Effects and Adverse Reactions; Female; Germany; | 2017 |
Hepatitis C in a Mobile Low-Threshold Methadone Program.
Topics: Adult; Aged; Alcohol-Related Disorders; Coinfection; Comorbidity; Cross-Sectional Studies; Drug User | 2017 |
Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment.
Topics: Adult; Buprenorphine; Continuity of Patient Care; Female; Hepatitis C; Humans; Male; Methadone; Midd | 2017 |
Commentary on Nikoo et al. (2017): The role of research.
Topics: Buprenorphine; Heroin Dependence; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders | 2017 |
Prioritizing the patient in patient-centered addictions treatment.
Topics: Behavior, Addictive; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pat | 2017 |
Drug Counselor Responses to Patients' Pain Reports: A Qualitative Investigation of Barriers and Facilitators to Treating Patients with Chronic Pain in Methadone Maintenance Treatment.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Female; Health Knowledge, Attitudes, Practice; Humans; Male | 2017 |
Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Topics: Analgesics, Opioid; Cytochrome P-450 CYP2B6; Drug Overdose; Humans; Methadone; Opioid-Related Disord | 2017 |
Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment.
Topics: Adult; Cross-Sectional Studies; Female; HIV Infections; Homosexuality, Male; Humans; Male; Methadone | 2017 |
J-shaped relationship between supervised methadone consumption and retention in methadone maintenance treatment (MMT) in primary care: National cohort study.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Ireland; Length of Stay; Ma | 2017 |
Characterizing fentanyl use in methadone-maintained clients.
Topics: Female; Fentanyl; Heroin Dependence; Humans; Male; Methadone; Michigan; Middle Aged; Opiate Substitu | 2017 |
Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Delivery of Health Care, Integrated; Female; Health S | 2017 |
Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Medication Adherence; Methadone | 2017 |
Changes in substance use in patients receiving opioid substitution therapy and resulting clinical challenges: a 17-year treatment case register analysis.
Topics: Adult; Alcoholism; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; | 2017 |
Commentary on Gibson et al. (2017): Gestational age and the severity of neonatal abstinence syndrome.
Topics: Buprenorphine; Gestational Age; Humans; Infant, Newborn; Methadone; Morphine; Neonatal Abstinence Sy | 2017 |
Opioid Agonist Treatment for Patients With Dependence on Prescription Opioids.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Relate | 2017 |
Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Trea | 2017 |
Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Trea | 2017 |
Challenges to Opioid Treatment Programs After Hurricane Sandy: Patient and Provider Perspectives on Preparation, Impact, and Recovery.
Topics: Adult; Attitude of Health Personnel; Civil Defense; Cyclonic Storms; Female; Focus Groups; Health Se | 2018 |
The prevalence of mental and physical health disorders among older methadone patients.
Topics: Aged; Alcoholism; Anxiety Disorders; Chronic Disease; Comorbidity; Depressive Disorder, Major; Femal | 2008 |
Community treatment programs take up buprenorphine.
Topics: Buprenorphine; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Narcotic | 2004 |
Response: Still room to improve an effective treatment.
Topics: Analgesics, Opioid; Humans; Mental Health Services; Methadone; Opioid-Related Disorders; United Stat | 2005 |
Methadone treatment at forty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Humans; Mental Health Services; Meth | 2005 |
An experimental study of aggressive and neutral interpretative bias in opiate-dependent and opiate-abstinent men.
Topics: Adult; Aggression; Bias; Case-Control Studies; Cognition; Drug Users; Humans; Male; Methadone; Middl | 2009 |
Response: the neurobiological model in community treatment programs.
Topics: Analgesics, Opioid; Attitude to Health; Brain; Humans; Methadone; Models, Neurological; Opioid-Relat | 2002 |
Response: the new environment of accountability for OTPs.
Topics: Analgesics, Opioid; Humans; Interprofessional Relations; Methadone; Opioid-Related Disorders; Qualit | 2002 |
Treatment practice and research issues in improving opioid treatment outcomes.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Evidence-Based Medicine; Health Plan Implementation; | 2002 |
Response: implementing motivational stepped care.
Topics: Analgesics, Opioid; Behavior Therapy; Combined Modality Therapy; Humans; Methadone; Opioid-Related D | 2002 |
Neonatal abstinence syndrome.
Topics: Female; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal Exchange; Methadone; Morphine; Mothers | 2008 |
Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
Topics: Adult; Buprenorphine; Community Pharmacy Services; Cross-Sectional Studies; Dose-Response Relationsh | 2008 |
Comparison of characteristics of opioid-using pregnant women in rural and urban settings.
Topics: Adult; Buprenorphine; Demography; Female; Humans; Mass Screening; Methadone; Narcotic Antagonists; O | 2008 |
Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.
Topics: Adult; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Methadyl Acetate; Naloxone | 2008 |
A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.
Topics: Buprenorphine; Drug Therapy, Combination; Female; Heroin Dependence; History, 19th Century; History, | 2008 |
Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
Topics: Adolescent; Adult; Aged; Buprenorphine; Developing Countries; Female; HIV Infections; Humans; Male; | 2008 |
A shift in focus.
Topics: Analgesics, Opioid; Canada; Drug and Narcotic Control; Humans; Methadone; Nurse Practitioners; Opioi | 2008 |
Methadone: a closer look at the controversy.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pain; Palliative Care | 2008 |
[Quality of life for drug abusers accepting methadone maintenance treatment].
Topics: Female; Humans; Male; Methadone; Opioid-Related Disorders; Quality of Life; Substance Withdrawal Syn | 2008 |
Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Cerebrovascular Circulation; Depression; Female; Gyrus | 2009 |
Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance.
Topics: Apoptosis; Blotting, Western; Doxorubicin; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, | 2008 |
Illicit methadone use and abuse in young people accessing treatment for opiate dependence.
Topics: Adolescent; Adult; Age Factors; Female; Humans; Male; Methadone; Opioid-Related Disorders; Substance | 2008 |
Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes.
Topics: Buprenorphine; Humans; Male; Methadone; Middle Aged; Narcotic Antagonists; Opioid-Related Disorders; | 2008 |
A primary care/multidisciplinary harm reduction clinic including opiate bridging.
Topics: Adult; Alberta; Ambulatory Care Facilities; Female; Humans; Interdisciplinary Communication; Male; M | 2008 |
Prevalence of long QTc interval in methadone maintenance patients.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Rate; Humans; Logistic M | 2009 |
[Weight gain among the patients in methadone maintenance program as come-back to population norm].
Topics: Adult; Body Mass Index; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Weight | 2008 |
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Buprenorphine; Epidemiologic Studies; Female; HIV Infe | 2008 |
Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Cost of Illness; Costs and Cost Analysis; Data Int | 2009 |
[High-dose methadone detoxification in a hospital unit. Clinical experience].
Topics: Hospital Units; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Abuse Treatment Ce | 2008 |
Divided doses for methadone maintenance.
Topics: Cause of Death; Drug Administration Schedule; Drug Overdose; Humans; Methadone; Narcotics; Opioid-Re | 2008 |
[Use of SF-6D utility index in methadone maintenance programs].
Topics: Health Status Indicators; Humans; Methadone; Narcotics; Opioid-Related Disorders; Quality of Life; S | 2008 |
Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates.
Topics: Analgesics, Opioid; Benzodiazepines; Female; Gestational Age; Humans; Infant, Newborn; Male; Methado | 2008 |
Electrocardiogram characteristics of methadone and buprenorphine maintained subjects.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Long QT | 2008 |
The impact of benzodiazepine use on methadone maintenance treatment outcomes.
Topics: Adult; Alcoholism; Benzodiazepines; Cocaine-Related Disorders; Comorbidity; Depressive Disorder; Dia | 2008 |
Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
Topics: Adolescent; Adult; Analgesics, Opioid; Attitude to Health; Buprenorphine; Data Collection; Female; H | 2009 |
Methadone patients in the therapeutic community: a test of equivalency.
Topics: Adult; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Methadone; Middle Aged; Opioid | 2009 |
Character pathology and neuropsychological test performance in remitted opiate dependence.
Topics: Adult; Character; Female; Humans; Male; Methadone; Middle Aged; Neuropsychological Tests; Opioid-Rel | 2008 |
Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Male; Methadone; Middle Aged; Morphine; Narcotic | 2008 |
Treating opioid dependency and coexistent chronic nonmalignant pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Humans; Methadone; Opioid-Related Disorders; Pai | 2008 |
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination | 2009 |
A case study using a patient satisfaction survey to improve the delivery and effectiveness of drug addiction treatment services: marketing implications and organizational impact.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Marketing of Health Services; Methadone; Middle Age | 2007 |
European pain management discussion forum.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Europe; Herpes Zoster; Humans; Methadone; Morphine; Neural | 2008 |
Correlates of alcohol use among methadone-maintained adults.
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Black People; Depression; Ethnicity; Female; Healt | 2009 |
Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients.
Topics: Adult; Analgesics, Opioid; Chronic Disease; Drug Tolerance; Female; Humans; Hyperalgesia; Male; Meth | 2009 |
Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms.
Topics: Adult; Australia; Case-Control Studies; Depression; Female; Humans; Male; Methadone; Middle Aged; Na | 2008 |
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-45 | 2009 |
Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.
Topics: Adult; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Methadone; Na | 2009 |
The effect of methadone maintenance on positive outcomes for opiate injection drug users.
Topics: Adult; Colorado; Female; Follow-Up Studies; HIV Infections; Humans; Logistic Models; Male; Methadone | 2009 |
Tribute to Peter Lee, pioneer of methadone treatment in Hong Kong.
Topics: Analgesics, Opioid; History, 20th Century; HIV Infections; Hong Kong; Humans; Male; Methadone; Opioi | 2009 |
[General practitioner views on drug-assisted rehabilitation and the Norwegian substance abuse reform].
Topics: Adult; Attitude of Health Personnel; Buprenorphine; Family Practice; Female; Health Policy; Humans; | 2009 |
[Treatment of opioid withdrawal].
Topics: Buprenorphine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Social Support; Substance Wit | 2009 |
Gender Differences Among In- and Out-of-Treatment Opioid-Addicted Individuals.
Topics: Adolescent; Adult; Age of Onset; Analgesics, Opioid; Baltimore; Cocaine-Related Disorders; Crime; Fe | 2009 |
Providers' experiences treating chronic pain among opioid-dependent drug users.
Topics: Chronic Disease; Decision Making; Delivery of Health Care, Integrated; Humans; Methadone; Opioid-Rel | 2009 |
Swiss recommendations for substitution treatment: a report that "got it right".
Topics: Buprenorphine; Europe; Health Planning Guidelines; Health Policy; Humans; Methadone; Narcotics; Opio | 2009 |
An 18-year follow-up of patients admitted to methadone treatment for the first time.
Topics: Adolescent; Adult; Cause of Death; Criminology; Diagnosis, Dual (Psychiatry); Female; Follow-Up Stud | 2009 |
Opioid dependence as a chronic disease: the interrelationships between length of stay, methadone dose, and age on treatment outcome at an urban opioid treatment program.
Topics: Adult; Age Factors; Chronic Disease; Ethnicity; Female; Humans; Length of Stay; Male; Methadone; Mid | 2009 |
Methadone and impairment in apprehended drivers.
Topics: Adult; Automobile Driving; Female; Forensic Toxicology; Humans; Law Enforcement; Male; Methadone; Na | 2009 |
[Substitution treatment of drug addicts during pregnancy: consequences for the children?].
Topics: Buprenorphine; Developmental Disabilities; Female; Humans; Infant, Newborn; Methadone; Narcotics; Ne | 2009 |
Self-efficacy and depression as mediators of the relationship between pain and antiretroviral adherence.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Depressive Disorder; Female; HIV Infections; Humans; Male; | 2009 |
Women and opioid dependence treatment: office-based versus opioid treatment program-based care?
Topics: Adult; Female; Humans; Mental Health Services; Methadone; Narcotics; Opioid-Related Disorders; Progr | 2007 |
[Comparison of quality of life for drug addicts in methadone maintenance treatment clinics, community and compulsory detoxification institutions in Sichuan Province].
Topics: Adult; China; Drug Users; Female; Humans; Linear Models; Male; Methadone; Opioid-Related Disorders; | 2009 |
Expression of mu opioid receptor splice variants mRNA in human blood lymphocytes: a peripheral marker for opioid addiction studies.
Topics: Adult; Alternative Splicing; Biomarkers; Biomedical Research; Humans; Lymphocytes; Male; Methadone; | 2009 |
Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Humans; Infant, Newborn; Male; Methadone; Neonatal Abs | 2009 |
Medicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states.
Topics: Adult; Crime; Criminal Psychology; Female; Health Services Accessibility; Humans; Linear Models; Lon | 2009 |
Preventing death among the recently incarcerated: an argument for naloxone prescription before release.
Topics: Analgesics, Opioid; Cocaine; Drug Overdose; Emergency Medical Services; Female; Humans; Male; Methad | 2009 |
Epidemiological trends in abuse and misuse of prescription opioids.
Topics: Censuses; Drug Utilization; Humans; Methadone; Narcotics; Opioid-Related Disorders; Poison Control C | 2009 |
Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.
Topics: Adult; Aged; Analgesics, Opioid; Drug Users; Female; Heroin Dependence; Humans; Male; Medication Adh | 2009 |
Drug testing by chemical analysis of fingerprint deposits from methadone-maintained opioid dependent patients using UPLC-MS/MS.
Topics: Chromatography, Liquid; Dermatoglyphics; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pyr | 2008 |
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution.
Topics: Adult; Female; Genetic Variation; Humans; Male; Methadone; Middle Aged; Models, Genetic; Narcotics; | 2009 |
Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Drug Users; Female; Health Facili | 2008 |
Methadone capsules: new formulation. A long-awaited formulation.
Topics: Capsules; Chemistry, Pharmaceutical; Drug Approval; France; Humans; Methadone; Opioid-Related Disord | 2009 |
Buprenorphine and pregnancy.
Topics: Buprenorphine; Congenital Abnormalities; Female; France; Humans; Infant, Newborn; Methadone; Neonata | 2009 |
Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Female; Humans; Long QT Syndrome; Male; M | 2009 |
A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran.
Topics: Adult; Attitude of Health Personnel; Cross-Sectional Studies; Health Knowledge, Attitudes, Practice; | 2010 |
Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose.
Topics: Adult; Benzodiazepines; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Met | 2009 |
What more do we need to know about medication-assisted treatment for prescription opioid abusers?
Topics: Buprenorphine; Humans; Medication Adherence; Methadone; Narcotic Antagonists; Opioid-Related Disorde | 2009 |
A selection model for longitudinal binary responses subject to non-ignorable attrition.
Topics: Biometry; Databases, Factual; Humans; Likelihood Functions; Linear Models; Longitudinal Studies; Met | 2009 |
Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-06).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Female; France; Humans; Male; Methadone; | 2009 |
Comparing overdose mortality associated with methadone and buprenorphine treatment.
Topics: Adult; Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Male; Methadone; Middle Age | 2009 |
Supervised methadone consumption: client issues and stigma.
Topics: Adult; Analgesics, Opioid; Canada; Female; Humans; Interviews as Topic; Male; Methadone; Middle Aged | 2009 |
The making of the chronic addict.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Chronic Disease; Denmark; Drug Users; Female; Harm R | 2009 |
Dopamine receptors in human peripheral blood lymphocytes: changes in mRNA expression in opioid addiction.
Topics: Adult; Humans; Male; Methadone; Narcotics; Neutrophils; Opioid-Related Disorders; Polymerase Chain R | 2009 |
Reliability of the Lifetime Inventory of Drug Use Consequences (INDUC) in methadone maintenance patients.
Topics: Adult; Analgesics, Opioid; Behavior, Addictive; Drug Users; Female; Humans; Impulsive Behavior; Inte | 2009 |
Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Buprenorphine; Controlled Clinic | 2009 |
Comparison of costs and utilization among buprenorphine and methadone patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Drug Utilization; Health Care Costs; Huma | 2009 |
Electrocardiographic abnormalities in opiate addicts.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cross-Sectional Studies; Electrocardiography; Female; Human | 2008 |
[Commentary] Opioids and cardiogram abnormalities: providing treatment based on understanding the risks and benefits.
Topics: Arrhythmias, Cardiac; Electrocardiography; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2008 |
The influence of maternal opiate use in pregnancy on second trimester biochemical markers for Down syndrome.
Topics: Adult; Biomarkers; Case-Control Studies; Down Syndrome; Female; Heroin; Humans; Methadone; Opioid-Re | 2009 |
Gender difference in the treatment outcome of patients served in the mixed-gender program.
Topics: Adolescent; Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Recurrence; Sex Factor | 2009 |
Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Comb | 2009 |
Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Female; Humans; Male; Medication Adherenc | 2009 |
[Study on the change of quality of life and its influential factors for drug abusers accepting methadone maintenance treatment].
Topics: Adult; Drug Users; Female; Humans; Male; Methadone; Opioid-Related Disorders; Patient Acceptance of | 2009 |
[A study of mix-infections with different genotypes of hepatitis C virus in patients from a methadone maintenance clinic in Wuhan].
Topics: Adult; China; Genes, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Methadone; Middle Aged; Opio | 2009 |
Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue.
Topics: Adult; Documentation; Drug Interactions; Female; Humans; Male; Medical Records; Medical Records Syst | 2009 |
Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients.
Topics: Adult; Chronic Disease; Comorbidity; Connecticut; Female; Humans; Male; Mental Disorders; Methadone; | 2009 |
Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
Topics: Adult; Buprenorphine; Cause of Death; Data Interpretation, Statistical; Databases, Factual; Drug Ove | 2009 |
Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results.
Topics: Adult; Attention; Brain; Case-Control Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Methado | 2009 |
Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study.
Topics: Adult; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Methadone; Narcotics; Opioid-Re | 2009 |
Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program.
Topics: Adult; Analgesics, Opioid; Comorbidity; Female; Humans; Methadone; Odds Ratio; Opioid-Related Disord | 2009 |
Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
Topics: Analgesics, Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections; Male; Methadone; N | 2009 |
Comparison of urine results concerning co-consumption of illicit heroin and other drugs in heroin and methadone maintenance programs.
Topics: Amphetamines; Benzodiazepines; Cannabinoids; Chromatography, Liquid; Cocaine; Forensic Toxicology; H | 2010 |
Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.
Topics: Adult; Female; Heroin Dependence; Humans; Male; Methadone; Opioid-Related Disorders; Prisoners; Subs | 2009 |
Exploring the relationship between perceived inter-dose opioid withdrawal and patient characteristics in methadone maintenance treatment.
Topics: Adult; Affect; Anxiety; Behavior, Addictive; Female; Humans; Male; Methadone; Opioid-Related Disorde | 2009 |
Using enhanced and integrated services to improve response to standard methadone treatment: changing the clinical infrastructure of treatment networks.
Topics: Baltimore; Behavior Therapy; Community Mental Health Services; Counseling; Drug Administration Sched | 2010 |
The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases.
Topics: Adult; Analgesics, Opioid; Autopsy; Benzodiazepines; Central Nervous System Depressants; Drug Overdo | 2010 |
Can we use an innocuous stimulus to replace methadone maintenance therapy for opioid dependence?
Topics: Animals; Conditioning, Classical; Disease Models, Animal; Electroacupuncture; Humans; Immune System; | 2010 |
Opioid use affects antioxidant activity and purine metabolism: preliminary results.
Topics: Adolescent; Adult; Analgesics, Opioid; Antioxidants; Female; Humans; Male; Metabolomics; Methadone; | 2009 |
Challenges in providing services in methadone maintenance therapy clinics in China: service providers' perceptions.
Topics: Adult; Attitude of Health Personnel; China; Female; Health Services Needs and Demand; Humans; Male; | 2010 |
Alcohol usage and associated treatment outcomes for opiate users entering treatment in Ireland.
Topics: Adult; Age Factors; Alcohol Drinking; Female; Humans; Ireland; Male; Methadone; Opioid-Related Disor | 2010 |
Compliance towards methadone maintenance therapy and its associated factors in Selangor primary care centers and Kuala Lumpur hospital.
Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Male; Medication Adherence; Methadone; Middle | 2009 |
[A political order].
Topics: Buprenorphine; Health Policy; Humans; Methadone; Narcotics; Norway; Opioid-Related Disorders; Patien | 2009 |
Screening for hepatitis C virus infection in methadone-maintained mothers and their infants.
Topics: Adult; Analgesics, Opioid; Female; Hepatitis C; Humans; Infant; Infant, Newborn; Methadone; Neonatal | 2009 |
Alteration of lymphocyte opioid receptors in methadone maintenance subjects.
Topics: Heroin; Humans; Lymphocytes; Methadone; Opioid-Related Disorders; Receptors, Opioid; Reverse Transcr | 2010 |
15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Anxiety Agents; Benzodiazepines; Female; Follow-Up Studie | 2010 |
Methadone restores local and remote EEG functional connectivity in opioid-dependent patients.
Topics: Adult; Alpha Rhythm; Beta Rhythm; Data Interpretation, Statistical; Electroencephalography; Female; | 2009 |
Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
Topics: Adult; Behavior, Addictive; Buprenorphine; Employment; Feasibility Studies; Female; HIV Infections; | 2010 |
Why do patients report transferring between methadone and buprenorphine?
Topics: Buprenorphine; Humans; Methadone; Opioid-Related Disorders; Patient Compliance | 2009 |
Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine.
Topics: Adult; Buprenorphine; Chronobiology Disorders; Female; Humans; Infant; Infant Behavior; Infant, Newb | 2009 |
[Interactions with methadone and buprenorphine].
Topics: Buprenorphine; Drug Interactions; Humans; Methadone; Narcotics; Opioid-Related Disorders; Risk Facto | 2009 |
Diacetylmorphine versus methadone for opioid addiction.
Topics: Clinical Trials as Topic; Heroin; Humans; Injections, Intravenous; Methadone; Opioid-Related Disorde | 2009 |
Diacetylmorphine versus methadone for opioid addiction.
Topics: Cost Savings; Drug Costs; Heroin; Humans; Methadone; Opioid-Related Disorders; Patient Dropouts; Ris | 2009 |
Sense of coherence as a stable predictor for methadone maintenance treatment (MMT) outcome.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Female; Humans; Israel; Longitudinal Studies; Male; Me | 2009 |
Premature discharge from methadone treatment: patient perspectives.
Topics: Adult; Appointments and Schedules; Counseling; Crime; Ethnicity; Female; Heroin Dependence; Humans; | 2009 |
Methadone maintenance treatment for youth: experiences of clients, staff, and parents.
Topics: Adult; Attitude of Health Personnel; Behavior Therapy; Female; Focus Groups; Humans; Male; Methadone | 2009 |
Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study.
Topics: Adolescent; Adult; Demography; Female; Humans; Methadone; Opioid-Related Disorders; Patient Selectio | 2009 |
Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screening.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Opioid-Related Disorders; Policy Making; Prev | 2009 |
Structural-level factors affecting implementation of the methadone maintenance therapy program in China.
Topics: Adult; Aged; China; Female; Health Care Surveys; Humans; Interviews as Topic; Male; Methadone; Middl | 2010 |
Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel.
Topics: Adult; Drug Users; Female; Health Knowledge, Attitudes, Practice; Hepatitis C; Humans; Israel; Male; | 2010 |
A focus-group study on spirituality and substance-user treatment.
Topics: Adult; Drug Users; Female; Focus Groups; Humans; Male; Methadone; Middle Aged; Opioid-Related Disord | 2010 |
Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
Topics: Adult; Australia; Buprenorphine; Drug Users; Female; Humans; Illicit Drugs; Injections; Male; Methad | 2010 |
Effects of receiving additional off-site services on abstinence from illicit drug use among men on methadone: a longitudinal study.
Topics: Adult; Health Services; Humans; Illicit Drugs; Interviews as Topic; Longitudinal Studies; Male; Meth | 2010 |
[Burden of disease and level of patient's medical care in substitution treatment for opiates].
Topics: Adult; Asthma; Comorbidity; Cooperative Behavior; Cost of Illness; Cross-Sectional Studies; Female; | 2009 |
Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study.
Topics: Adult; Analgesics, Opioid; Antisocial Personality Disorder; Borderline Personality Disorder; Confide | 2009 |
A longitudinal study of incarceration and HIV risk among methadone maintained men and their primary female partners.
Topics: Adult; Aged; Female; HIV Infections; Humans; Interviews as Topic; Longitudinal Studies; Male; Methad | 2011 |
Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment.
Topics: Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Drug Administration Schedule; Humans; Meth | 2010 |
Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
Topics: Analgesics, Opioid; Buprenorphine; Community Pharmacy Services; Cross-Sectional Studies; Female; Hum | 2010 |
Drug injecting in patients in New Zealand Methadone Maintenance Treatment programs: an anonymous survey.
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; New Zealand; Opioid-R | 2010 |
Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints.
Topics: Adult; Body Mass Index; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Diso | 2010 |
Expression of NR3B but not NR2D subunit of NMDA receptor in human blood lymphocytes can serve as a suitable peripheral marker for opioid addiction studies.
Topics: Adult; Biomarkers; Humans; Male; Methadone; Opioid-Related Disorders; Receptors, N-Methyl-D-Aspartat | 2010 |
Insomnia among methadone-maintained individuals: the feasibility of collecting home polysomnographic recordings.
Topics: Adult; Clinical Trials as Topic; Feasibility Studies; Female; Humans; Illicit Drugs; Male; Methadone | 2009 |
What is diversion of supervised buprenorphine and how common is it?
Topics: Attitude of Health Personnel; Australia; Buprenorphine; Community Pharmacy Services; Cross-Sectional | 2009 |
High dose versus moderate dose methadone maintenance: is there a better outcome?
Topics: Adult; Aged; Analgesics, Opioid; Cocaine-Related Disorders; Female; Georgia; Humans; Male; Medical R | 2009 |
Maximising the treatment outcomes of opioid substitution treatment.
Topics: Buprenorphine; Counseling; Evidence-Based Medicine; Humans; Methadone; Narcotics; Opioid-Related Dis | 2010 |
Attentional bias, inhibitory control and acute stress in current and former opiate addicts.
Topics: Acute Disease; Adult; Attention; Employment; Female; Humans; Inhibition, Psychological; Male; Mental | 2010 |
Ventricular arrhythmias in patients treated with methadone for opioid dependence.
Topics: Adult; Cardiac Pacing, Artificial; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 2010 |
The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Diagnosis, Dual (Psychiatry); Female; Genital | 2009 |
The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Diagnosis, Dual (Psychiatry); Female; Genital | 2009 |
The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Diagnosis, Dual (Psychiatry); Female; Genital | 2009 |
The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Diagnosis, Dual (Psychiatry); Female; Genital | 2009 |
Infant autonomic functioning and neonatal abstinence syndrome.
Topics: Adult; Apgar Score; Autonomic Nervous System; Cocaine-Related Disorders; Data Interpretation, Statis | 2010 |
Symptom complaints of patients prescribed either oral methadone or injectable heroin.
Topics: Administration, Oral; Adult; Female; Heroin; Humans; Injections; Male; Methadone; Narcotics; Opioid- | 2010 |
What factors affect medication-storage practice among patients on methadone maintenance treatment?
Topics: Adult; Aged; Drug Storage; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders | 2009 |
What factors affect medication-storage practice among patients on methadone maintenance treatment?
Topics: Adult; Aged; Drug Storage; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders | 2009 |
Uzbekistan: government discontinues pilot opiate substitution therapy program.
Topics: Buprenorphine; Government; Humans; Methadone; Opioid-Related Disorders; Pilot Projects; Uzbekistan | 2009 |
Developing of LC/MS method with microwave assisted extraction for determination of methadone and it major metabolite (EDDP) in the blood of patients of methadone maintenance treatment.
Topics: Calibration; Chromatography, Liquid; Humans; Mass Spectrometry; Methadone; Microwaves; Opioid-Relate | 2009 |
[Status quo of opioid agonist maintenance therapy in Germany].
Topics: Analgesics, Opioid; Germany; Humans; Methadone; Opioid-Related Disorders; Practice Patterns, Physici | 2010 |
Growth restriction in pregnancies of opioid-dependent mothers.
Topics: Adult; Body Mass Index; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Fetal Growt | 2010 |
Onsite QTc interval screening for patients in methadone maintenance treatment.
Topics: Aged; Dose-Response Relationship, Drug; Electrocardiography; Feasibility Studies; Female; Heart Cond | 2010 |
The relationship of social support to treatment entry and engagement: the Community Assessment Inventory.
Topics: Adult; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; Opioid-Related Disord | 2010 |
Treatment of acute pain in opioid tolerant patients.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Tolerance; Humans; | 2010 |
Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006.
Topics: Adult; British Columbia; Databases, Factual; Dose-Response Relationship, Drug; Female; Guideline Adh | 2010 |
[Preliminary investigation on the long-term follow-up by the general practitioner of patients receiving methadone maintenance].
Topics: Cross-Sectional Studies; Family Practice; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; N | 2010 |
The acceptability of combined methadone-naloxone treatment: Consumer and provider views on the potential utility of methadone-naloxone.
Topics: Adult; Attitude of Health Personnel; Communication; Drug Combinations; Female; Humans; Male; Methado | 2010 |
Multidisciplinary antenatal care for opiate-using women: Child-care issues.
Topics: Appointments and Schedules; Female; Foster Home Care; Heroin; Heroin Dependence; Humans; Infant, New | 2010 |
Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
Topics: Administration, Sublingual; Adolescent; Adult; Age Factors; Analgesics, Opioid; Behavior, Addictive; | 2010 |
The role of patient satisfaction in methadone treatment.
Topics: Adult; Female; Follow-Up Studies; Health Care Surveys; Humans; Male; Methadone; Narcotics; Opioid-Re | 2010 |
Predictors of attrition from a national sample of methadone maintenance patients.
Topics: Adult; Age Factors; Black or African American; Databases, Factual; Diagnosis, Dual (Psychiatry); Fem | 2010 |
Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome.
Topics: Cohort Studies; Female; Humans; Incidence; Infant, Newborn; Methadone; Narcotics; Neonatal Abstinenc | 2010 |
Maternal and neonatal factors impacting response to methadone therapy in infants treated for neonatal abstinence syndrome.
Topics: Breast Feeding; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Infant, Premature | 2011 |
β-Arrestin2 influences the response to methadone in opioid-dependent patients.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Arrestins; beta-Arrestin 2; beta-Arrestins; Chi-Square | 2011 |
Does electrocardiography improve methadone safety?
Topics: Cause of Death; Electrocardiography; Humans; Long QT Syndrome; Methadone; Narcotics; Norway; Opioid- | 2010 |
Does low urine creatinine level indicate the presence of urine alcohol in methadone maintenance treatment patients?
Topics: Analgesics, Opioid; Biomarkers, Pharmacological; Creatinine; Ethanol; Humans; Medical Records; Metha | 2010 |
Post-marketing surveillance of methadone and buprenorphine in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Data Collection; Humans; Marketing; Methadone; Opioid-Related Dis | 2010 |
Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes.
Topics: Adult; Aged; Alleles; Analgesics, Opioid; Female; Genotype; Humans; Male; Methadone; Middle Aged; Nu | 2010 |
Predictors of early dropout in methadone maintenance treatment program in Yunnan province, China.
Topics: Adolescent; Adult; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Me | 2010 |
Cost-utility analysis of methadone maintenance treatment in Lithuania.
Topics: Adult; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Informed Consent; Lithuania; Male; | 2010 |
Gender and NAS: does sex matter?
Topics: Analgesics, Opioid; Female; Humans; Infant, Newborn; Male; Methadone; Morphine; Neonatal Abstinence | 2010 |
Excretion of methadone in sweat of pregnant women throughout gestation after controlled methadone administration.
Topics: Adult; Analgesics, Opioid; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Monitoring; | 2010 |
Evidence based policy for illicit [corrected] drugs.
Topics: Evidence-Based Medicine; Health Policy; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related | 2010 |
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment.
Topics: Adult; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Methadone; Narcotics; Opioid-Rel | 2010 |
The cost of concordance with opiate substitution treatment guidelines.
Topics: Cost-Benefit Analysis; Delivery of Health Care; Female; Guideline Adherence; Health Care Costs; Huma | 2010 |
No opiate substitutes for the masses of IDUs.
Topics: Female; Harm Reduction; HIV Infections; Humans; Male; Methadone; Methadyl Acetate; Narcotics; Needle | 2010 |
Law enforcement and drug treatment: a culture clash.
Topics: Buprenorphine; Female; Harm Reduction; HIV Infections; Humans; Law Enforcement; Male; Methadone; Nar | 2010 |
Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy.
Topics: Adult; Female; Humans; Infant, Newborn; Logistic Models; Methadone; Narcotics; Neonatal Abstinence S | 2010 |
Monthly take-home methadone maintenance regime for elderly opium-dependent users in Singapore.
Topics: Aged; Caregivers; Cross-Sectional Studies; Female; Home Care Services; Humans; Interviews as Topic; | 2010 |
Russian injected drug use soars in face of political inertia.
Topics: Drug Implants; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Politi | 2010 |
The global diversion of pharmaceutical drugs: opiate treatment and the diversion of pharmaceutical opiates: a clinician's perspective.
Topics: Analgesics, Opioid; Australia; Clinical Audit; Drug and Narcotic Control; France; Humans; Methadone; | 2010 |
Were the changes to Sweden's maintenance treatment policy 2000-06 related to changes in opiate-related mortality and morbidity?
Topics: Adult; Buprenorphine; Clinical Protocols; Drug Overdose; Female; Hospitalization; Humans; Male; Meth | 2010 |
Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan.
Topics: Adult; Delivery of Health Care; Electronic Health Records; Female; Health Care Costs; Humans; Male; | 2010 |
Medical treatment of opioid dependence within the South African context.
Topics: Buprenorphine; Drug Combinations; Drug Overdose; Humans; Methadone; Motivation; Naloxone; Narcotic A | 2010 |
Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control study.
Topics: Adult; Case-Control Studies; Comorbidity; Cross-Sectional Studies; Eligibility Determination; Female | 2010 |
Pathological gambling in methadone maintenance clinics where gambling is legal versus illegal.
Topics: Adult; Analysis of Variance; Female; Gambling; Humans; Israel; Male; Methadone; Middle Aged; Multiva | 2010 |
Exploring relations among traumatic, posttraumatic, and physical pain experiences in methadone-maintained patients.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Female; Humans; Life Change Events; Male; Methad | 2011 |
Mortality and employment after in-patient opiate detoxification.
Topics: Adolescent; Adult; Age Factors; Employment; Female; Follow-Up Studies; Hospitalization; Humans; Male | 2012 |
Postnatal weight loss in substitute methadone-exposed infants: implications for the management of breast feeding.
Topics: Adolescent; Adult; Birth Weight; Bottle Feeding; Breast Feeding; Female; Gestational Age; Humans; In | 2012 |
Specialists question agency's proposal to time limit methadone prescribing.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Prescription Drugs | 2010 |
Breastfeeding rates among mothers of infants with neonatal abstinence syndrome.
Topics: Adult; Breast Feeding; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Mothers; Neonatal | 2010 |
The first 38 methadone maintenance treatment patients in Stockholm: 15-year follow-up with a main focus on detoxification from methadone.
Topics: Adult; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; Methadone; Middle Aged; Narcotics; Op | 2011 |
Methadone disposition in oral fluid during pharmacotherapy for opioid-dependence.
Topics: Chromatography, Liquid; Female; Humans; Hydrogen-Ion Concentration; Mass Spectrometry; Methadone; Me | 2011 |
Lapse and relapse following inpatient treatment of opiate dependence.
Topics: Adolescent; Adult; Aftercare; Age Factors; Analgesics, Opioid; Female; Follow-Up Studies; Humans; In | 2010 |
The impact of vascular leg disorders on physical activity in methadone-maintained adults.
Topics: Adult; Aged; Analgesics, Opioid; Attitude to Health; Chi-Square Distribution; Exercise; Factor Analy | 2010 |
Factors associated with complicated buprenorphine inductions.
Topics: Adult; Benzodiazepines; Buprenorphine; Community Health Centers; Dose-Response Relationship, Drug; F | 2010 |
A special type of 'hard-to-reach' patient: experiences of pregnant women on methadone.
Topics: Female; Humans; Interviews as Topic; Maternal Health Services; Methadone; New Zealand; Opioid-Relate | 2010 |
Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment.
Topics: Adaptation, Psychological; Adult; Analgesics, Opioid; Cross-Sectional Studies; Female; Health Status | 2011 |
Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
Topics: Anti-Retroviral Agents; Attitude to Health; Buprenorphine; Cohort Studies; Depression; Female; Franc | 2010 |
Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008): analyses using OD4 index in England and Scotland.
Topics: Adult; Directly Observed Therapy; Drug Overdose; England; Humans; Methadone; Mortality; Narcotics; O | 2010 |
Assessing sleep in opioid dependence: a comparison of subjective ratings, sleep diaries, and home polysomnography in methadone maintenance patients.
Topics: Adult; Female; Humans; Male; Medical Records; Methadone; Middle Aged; Opiate Substitution Treatment; | 2011 |
Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome.
Topics: Adult; Analgesics, Opioid; Cocaine; Cocaine-Related Disorders; Female; Gestational Age; Humans; Infa | 2010 |
Opioid dependence - management in general practice.
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Chronic Disease; Disease Management; Female; Ge | 2010 |
Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Comorbidity; Conduct Disorder; Female; Humans; | 2011 |
Infant mortality among women on a methadone program during pregnancy.
Topics: Adult; Female; Humans; Infant Mortality; Infant, Newborn; Live Birth; Medical Record Linkage; Methad | 2010 |
Addiction treatment in Russia.
Topics: Behavior, Addictive; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narc | 2010 |
Low rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program.
Topics: Female; Hepatitis A Vaccines; Hepatitis A virus; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis | 2010 |
Advances in the treatment of opioid dependence: continued progress and ongoing challenges.
Topics: Buprenorphine; Drug Implants; Health Services Accessibility; Humans; Methadone; Narcotic Antagonists | 2010 |
Nicotine dependence and depression among women smokers on methadone maintenance.
Topics: Adult; Cross-Sectional Studies; Depression; Female; Humans; Linear Models; Methadone; Middle Aged; N | 2010 |
Decreased bone density in men on methadone maintenance therapy.
Topics: Absorptiometry, Photon; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Control Gr | 2011 |
Cessation of groin injecting behaviour among patients on oral opioid substitution treatment.
Topics: Adult; Chronic Disease; Cross-Sectional Studies; England; Female; Femoral Vein; Groin; Humans; Logis | 2011 |
"Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
Topics: Analgesics, Opioid; Buprenorphine; Consumer Health Information; Cross-Sectional Studies; Female; Hum | 2011 |
Main reasons for hospital admissions by women with a history of methadone maintenance.
Topics: Adolescent; Adult; Comorbidity; Female; Hospitalization; Humans; Mental Disorders; Methadone; Middle | 2010 |
Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.
Topics: Adolescent; Adult; Buprenorphine; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Re | 2010 |
Alcohol use problem among patients in methadone maintenance treatment in Taiwan.
Topics: Adult; Age Factors; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Breath Tests; Female; F | 2011 |
Adapting problem-solving therapy for depressed older adults in methadone maintenance treatment.
Topics: Aged; Behavior Therapy; Depressive Disorder; Diagnosis, Dual (Psychiatry); Humans; Methadone; Narcot | 2011 |
Accidental and non-accidental ingestion of methadone and buprenorphine in childhood: a single center experience, 1999-2009.
Topics: Adolescent; Age Factors; Buprenorphine; Child, Preschool; Female; Humans; Infant; Male; Methadone; O | 2011 |
Opiate substitution and death. GPs need guidance, please.
Topics: Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topi | 2010 |
The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Topics: Administration, Inhalation; Administration, Intranasal; Adult; Age Factors; Analgesics, Opioid; Aust | 2011 |
New community-based methadone maintenance treatment programs in Guangdong, China, and their impact on patient quality of life.
Topics: Adolescent; Adult; China; Community Health Services; Female; Humans; Male; Methadone; Middle Aged; O | 2011 |
Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.
Topics: Adult; Cohort Studies; Female; Humans; Male; Methadone; Middle Aged; Opiate Substitution Treatment; | 2011 |
Epidemiologic trends and geographic patterns of fatal opioid intoxications in Connecticut, USA: 1997-2007.
Topics: Adolescent; Adult; Analgesics, Opioid; Cause of Death; Connecticut; Drug Overdose; Female; Heroin; H | 2011 |
Cardiovascular-associated disease in an addicted population: an observation study.
Topics: Adult; Buprenorphine; Cardiovascular Diseases; Electrocardiography; Female; Humans; Hypertension; Lo | 2011 |
Association between intrapartum fetal heart rate patterns and neonatal abstinence syndrome in methadone exposed neonates.
Topics: Adult; Analgesics, Opioid; Female; Heart Rate, Fetal; Humans; Infant, Newborn; Labor, Obstetric; Mat | 2011 |
Methadone and perinatal outcomes: a retrospective cohort study.
Topics: Age Factors; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; Narcotics | 2011 |
Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review.
Topics: Antiretroviral Therapy, Highly Active; Directly Observed Therapy; HIV Infections; Humans; Medication | 2011 |
Effect of psychiatric severity on the outcome of methadone maintenance treatment.
Topics: Adult; Cocaine; Cohort Studies; Female; Heroin; Humans; Male; Mental Disorders; Methadone; Opiate Su | 2011 |
Diverse behavioral, monoaminergic and Fos protein responses to opioids in Warsaw high-alcohol preferring and Warsaw low-alcohol preferring rats.
Topics: Alcohol Drinking; Analgesics, Opioid; Animals; Behavior, Animal; Biogenic Monoamines; Brain; Disease | 2011 |
Higher maternal doses of methadone does not increase neonatal abstinence syndrome.
Topics: Adult; Birth Weight; Dose-Response Relationship, Drug; Female; Humans; Infant, Newborn; Methadone; N | 2011 |
[Inhaled methadone-induced non cardiogenic pulmonary edema with Acute Respiratory Distress Syndrome].
Topics: Administration, Inhalation; Coma; Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pu | 2011 |
[Assisted reproductive technique for an opiates dependant couple].
Topics: Adult; Female; Fertilization in Vitro; Hepatitis C, Chronic; Humans; Male; Methadone; Opiate Substit | 2011 |
Predictors of methadone treatment retention from a multi-site study: a survival analysis.
Topics: Adult; Baltimore; Crime; Dose-Response Relationship, Drug; Drug Overdose; Female; Humans; Male; Meth | 2011 |
A qualitative study exploring the reason for low dosage of methadone prescribed in the MMT clinics in China.
Topics: Adult; Ambulatory Care Facilities; China; Drug Overdose; Female; Health Communication; Heroin Depend | 2011 |
Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Buprenorphine; Buprenorphine, Naloxon | 2011 |
Painkillers fuel growth in drug addiction. Opioid overdoses now kill more people than cocaine or heroin.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Drug Overdose; Drug Prescriptions; Health Knowledge, Att | 2011 |
Differing age related trajectories of dysfunction in several organ systems in opiate dependence.
Topics: Adult; Aged; Aging; Aging, Premature; Analgesics, Opioid; Disease Progression; Female; Hair Color; H | 2012 |
Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.
Topics: Adolescent; Adult; Analgesics, Opioid; Breast Feeding; Dose-Response Relationship, Drug; Female; Hum | 2011 |
Methadone and buprenorphine prescribing patterns of Victorian general practitioners: their first 5 years after authorisation.
Topics: Buprenorphine; Databases, Factual; Drug Prescriptions; Drug Utilization; General Practitioners; Huma | 2011 |
The Cedar Project: methadone maintenance treatment among young Aboriginal people who use opioids in two Canadian cities.
Topics: Adolescent; Adult; Canada; Female; Health Services Accessibility; Humans; Indians, North American; M | 2011 |
Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
Topics: Attitude of Health Personnel; Australia; Buprenorphine; Data Collection; Humans; Medication Adherenc | 2011 |
[Develop rapid and inexpensive method for the determination of methadone and its major metabolites for monitoring therapy].
Topics: Drug Monitoring; Humans; Methadone; Opioid-Related Disorders; Pyrrolidines; Reproducibility of Resul | 2010 |
Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Cocaine; Data Interpretation, Statistic | 2011 |
(R)-methadone versus racemic methadone: what is best for patient care?
Topics: Arrhythmias, Cardiac; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2011 |
Methadone maintenance therapy as evidence based drug abuse planning in developed countries: can developing countries afford and learn from this experience?
Topics: Developed Countries; Developing Countries; Evidence-Based Medicine; Female; Health Planning; HIV Inf | 2010 |
Family support, quality of life and concurrent substance use among methadone maintenance therapy clients in China.
Topics: Adolescent; Adult; China; Cross-Sectional Studies; Family Health; Family Relations; Female; Humans; | 2011 |
Opiate users' perceived barriers against attending methadone maintenance therapy: a qualitative study in China.
Topics: Adult; Analgesics, Opioid; China; Female; Humans; Interviews as Topic; Male; Methadone; Middle Aged; | 2011 |
Determination of methadone in exhaled breath condensate by liquid chromatography-tandem mass spectrometry.
Topics: Adult; Analgesics, Opioid; Breath Tests; Chromatography, Liquid; Female; Humans; Illicit Drugs; Male | 2011 |
Factors associated with Medicaid patients' access to buprenorphine treatment.
Topics: Adult; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Medicaid; Methadone; Midd | 2011 |
A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals.
Topics: Adult; Employment; Humans; Methadone; Middle Aged; Opioid-Related Disorders; Qualitative Research; Q | 2011 |
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Buprenorphine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2D | 2011 |
Prediction of the outcome of inpatient opiate detoxification treatment: results from a multicenter study.
Topics: Adult; Follow-Up Studies; Hospitalization; Humans; Logistic Models; Male; Methadone; Opioid-Related | 2011 |
Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment.
Topics: Antiretroviral Therapy, Highly Active; Depression; Female; HIV Infections; Humans; Male; Medication | 2011 |
Motivational profiles of clients seeking methadone maintenance therapy in China.
Topics: Adult; China; Female; Humans; Male; Methadone; Middle Aged; Motivation; Narcotics; Opiate Substituti | 2011 |
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Sub | 2011 |
Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study.
Topics: Adolescent; Adult; Cohort Studies; Databases, Factual; Female; Humans; Lung Diseases; Male; Medical | 2011 |
A high proportion of users of low-threshold facilities with needle exchange programmes in Switzerland are currently on methadone treatment: implications for new approaches in harm reduction and care.
Topics: Adult; Age Factors; Cocaine; Cross-Sectional Studies; Female; Harm Reduction; HIV Seropositivity; Hu | 2012 |
Prolonged use of benzodiazepines is associated with childhood trauma in opioid-maintained patients.
Topics: Age Factors; Analgesics, Opioid; Benzodiazepines; Child; Child Abuse; Comorbidity; Cross-Sectional S | 2011 |
Delay discounting, impulsiveness, and addiction severity in opioid-dependent patients.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Behavior, Addictive; Computers; Disease Progression; Fe | 2011 |
The effect of pain on stroop performance in patients with opiate dependence in sustained remission.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Pain; Pain | 2011 |
No change of sleep after 6 and 12 months of methadone maintenance treatment.
Topics: Adult; Aged; Analgesics, Opioid; Follow-Up Studies; Humans; Israel; Male; Methadone; Middle Aged; Op | 2011 |
Methadone and perinatal outcomes: another perspective.
Topics: Female; Humans; Methadone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Relat | 2011 |
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Cy | 2013 |
Duration of methadone maintenance treatment during pregnancy and pregnancy outcome parameters in women with opiate addiction.
Topics: Adult; Birth Weight; Dose-Response Relationship, Drug; Female; Gestational Age; Humans; Infant, Newb | 2012 |
Patterns in admission delays to outpatient methadone treatment in the United States.
Topics: Adult; Ambulatory Care; Analgesics, Opioid; Databases, Factual; Ethnicity; Female; Health Services A | 2011 |
A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.
Topics: Analgesics, Opioid; Attitude; Attitude of Health Personnel; Buprenorphine; Counseling; Culture; Fema | 2011 |
Longitudinal patterns of benzodiazepine consumption in a German cohort of methadone maintenance treatment patients.
Topics: Adolescent; Adult; Benzodiazepines; Cluster Analysis; Female; Follow-Up Studies; Germany; Humans; Lo | 2011 |
Risks and realities: dyadic interaction between 6-month-old infants and their mothers in opioid maintenance treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant; Infant Behavior; Longitudinal Stud | 2011 |
Group-based strategies for stress reduction in methadone maintenance treatment: what do patients want?
Topics: Adult; Age Distribution; Complementary Therapies; Female; Humans; Male; Methadone; Middle Aged; Narc | 2011 |
Is it time to reformulate racemic methadone?
Topics: Adult; Arrhythmias, Cardiac; Chemistry, Pharmaceutical; Chronic Disease; Death, Sudden, Cardiac; Fem | 2011 |
The source of methadone in overdose deaths in Western Virginia in 2004.
Topics: Adult; Cause of Death; Coroners and Medical Examiners; Drug Overdose; Drug Prescriptions; Female; Hu | 2011 |
Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Topics: Adult; Age Distribution; Benzodiazepines; Cohort Studies; Comorbidity; Female; Follow-Up Studies; He | 2011 |
The use of psychotherapeutic interventions by primary care GPs in Ireland in the treatment of their methadone patients: a grounded theory study.
Topics: Attitude of Health Personnel; Directive Counseling; General Practice; Humans; Ireland; Methadone; Na | 2012 |
A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study.
Topics: Adult; Buprenorphine; Case-Control Studies; Cognition; Female; Heroin; Humans; Male; Methadone; Midd | 2011 |
Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.
Topics: Adolescent; Adult; Humans; Longitudinal Studies; Male; Methadone; Narcotics; New South Wales; Opiate | 2012 |
Neonatal abstinence syndrome: transitioning methadone-treated infants from an inpatient to an outpatient setting.
Topics: Ambulatory Care; Female; Hospitalization; Humans; Infant, Newborn; Infant, Premature, Diseases; Leng | 2012 |
Injectable extended-release naltrexone for opioid dependence.
Topics: Administration, Oral; Delayed-Action Preparations; Drug Implants; Humans; Injections; Methadone; Nal | 2011 |
Promise of extended-release naltrexone is a red herring.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections; Methadone; Naltrexone; Narcotic Anta | 2011 |
Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Follow-Up Studies; Humans; Logistic Models; Longitudin | 2011 |
Availability of dopamine and serotonin transporters in opioid-dependent users--a two-isotope SPECT study.
Topics: Adult; Amphetamine-Related Disorders; Case-Control Studies; Corpus Striatum; Cross-Sectional Studies | 2012 |
The effect of methadone on emotional reactivity.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Depressive Disorder; Emotions; Female; Humans; Male; | 2012 |
Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study.
Topics: Adult; Buprenorphine; Crime; Female; Humans; Longitudinal Studies; Male; Methadone; Narcotic Antagon | 2012 |
The worldwide opioid epidemic: implications for treatment and research in pregnancy and the newborn.
Topics: Analgesics, Opioid; Biomedical Research; Buprenorphine; Female; Humans; Infant, Newborn; Internation | 2011 |
An fMRI investigation of cerebellar function during verbal working memory in methadone maintenance patients.
Topics: Adult; Cerebellar Diseases; Cerebellum; Female; Humans; Magnetic Resonance Imaging; Male; Memory Dis | 2012 |
Methadone and lung transplants.
Topics: Alcohol Drinking; Analgesics, Opioid; Confusion; Female; Heroin Dependence; Humans; Lung Transplanta | 2011 |
Characteristics of Iranian women seeking drug treatment.
Topics: Adolescent; Adult; Analysis of Variance; Female; Health Status; Hepatitis C; HIV Infections; Humans; | 2011 |
Brief interventions are effective in reducing alcohol consumption in opiate-dependent methadone-maintained patients: results from an implementation study.
Topics: Adult; Alcohol Drinking; Alcoholism; Feasibility Studies; Female; Harm Reduction; Humans; Male; Meth | 2012 |
Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment.
Topics: Adult; Cross-Sectional Studies; Ejaculation; Heroin; Humans; Interviews as Topic; Male; Methadone; M | 2012 |
[Pharmacokinetics interaction between methadone and metamizole: study of 53 cases].
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Dipyrone; Dose-Response Relationship, D | 2012 |
A procedure that differentiates unintentional from intentional overdose in opioid abusers.
Topics: Adult; Analgesics, Opioid; Drug Overdose; Female; Follow-Up Studies; Hospitals, University; Humans; | 2012 |
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interfer | 2012 |
QT or not QT, that is the question: routine electrocardiograms for individuals in methadone maintenance treatment.
Topics: Humans; Long QT Syndrome; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patien | 2011 |
First, do no harm: QT interval screening in methadone maintenance treatment.
Topics: Humans; Long QT Syndrome; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patien | 2011 |
QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.
Topics: Humans; Long QT Syndrome; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patien | 2011 |
CSAT's QT interval screening in methadone report: outrageous fortune or sea of troubles?
Topics: Humans; Long QT Syndrome; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Patien | 2011 |
Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2011 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes.
Topics: Adult; Female; Fetal Monitoring; Humans; Illicit Drugs; Infant, Newborn; Methadone; Neonatal Abstine | 2012 |
Use of other opioids during methadone therapy: a population-based study.
Topics: Adolescent; Adult; Analgesics, Opioid; Drug Prescriptions; Female; Humans; Male; Methadone; Middle A | 2012 |
Abstinence orientation and treatment practice: an analysis of German settings providing opioid maintenance therapy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Germany; Humans; Male; Methadone; Opiate Substitution Tre | 2012 |
Patient satisfaction with methadone maintenance treatment: the relevance of participation in treatment and social functioning.
Topics: Adult; Educational Status; Female; Heroin Dependence; Humans; Linear Models; Logistic Models; Male; | 2012 |
Takotsubo cardiomyopathy due to iatrogenic methadone withdrawal.
Topics: Analgesics, Opioid; Coronary Angiography; Drug Overdose; Echocardiography; Electrocardiography; Huma | 2011 |
The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Topics: Adolescent; Adult; Age Factors; Buprenorphine; Drug Utilization; Ethnicity; Female; Humans; Male; Me | 2012 |
Prescription opioid misuse: characteristics of earliest and most recent memory of hydromorphone use.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Utilizati | 2012 |
Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
Topics: Adult; Age Factors; Buprenorphine; Female; Hospitals, Veterans; Humans; Male; Methadone; Middle Aged | 2012 |
The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants.
Topics: Adolescent; Adult; Analysis of Variance; Breast Feeding; Female; Humans; Infant Formula; Infant, New | 2011 |
New approaches to dealing with opioid drug dependence.
Topics: Buprenorphine; General Practice; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Di | 2011 |
An increased risk of motor vehicle accidents after prescription of methadone.
Topics: Accidents, Traffic; Adolescent; Adult; Aged; Cohort Studies; Female; Humans; Male; Methadone; Middle | 2012 |
Factors associated with methadone treatment among injection drug users in Bangkok, Thailand.
Topics: Adult; Age Factors; Alcohol Drinking; Cross-Sectional Studies; Female; Humans; Male; Methadone; Meth | 2012 |
Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
Topics: Adult; Cross-Sectional Studies; Dose-Response Relationship, Drug; Electrocardiography; Female; Human | 2012 |
Selective attention and drug related attention bias in methadone maintenance patients.
Topics: Adult; Attention; Bias; Humans; Male; Methadone; Opioid-Related Disorders | 2011 |
Use and misuse of opioid replacement therapies: a Queensland study.
Topics: Analgesics, Opioid; Buprenorphine; Drug Combinations; Harm Reduction; Humans; Methadone; Naloxone; N | 2012 |
A pilot study of the nutritional status of opiate-using pregnant women on methadone maintenance therapy.
Topics: Adult; Body Composition; Body Mass Index; Energy Intake; Fatty Acids, Essential; Female; Humans; Mal | 2012 |
Personality differences between drug injectors and non-injectors among substance-dependent patients in substitution treatment.
Topics: Adult; Buprenorphine; Drug Users; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opiate Su | 2012 |
Methadone as social control: institutionalized stigma and the prospect of recovery.
Topics: Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prejudice; So | 2012 |
A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.
Topics: Adult; Attitude to Health; Buprenorphine; Clinical Trials as Topic; Female; Humans; Male; Methadone; | 2012 |
Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China.
Topics: Adult; Alcohol Drinking; Antiviral Agents; China; Cross-Sectional Studies; Female; Health Knowledge, | 2012 |
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime.
Topics: Adult; Analgesics, Opioid; Baltimore; Crime; Female; Heroin Dependence; Humans; Longitudinal Studies | 2012 |
Rate of community methadone treatment reporting at jail reentry following a methadone increased dose quality improvement effort.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Heroin Dependence; Humans; Male; Methadone; New Yo | 2012 |
Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
Topics: Analgesics, Opioid; Buprenorphine; Harm Reduction; Health Services Accessibility; Humans; Methadone; | 2012 |
Prevalence and trends of non-medical opioid and other drug use histories among federal correctional inmates in methadone maintenance treatment in Canada.
Topics: Adult; Canada; Drug Users; Humans; Illicit Drugs; Male; Methadone; Narcotics; Opiate Substitution Tr | 2012 |
Premorbid and current neuropsychological function in opiate abusers receiving treatment.
Topics: Aged; Buprenorphine; Cognition; Female; Frontal Lobe; Heroin; Humans; Male; Methadone; Middle Aged; | 2012 |
Superior methadone treatment outcome in Hmong compared with non-Hmong patients.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; | 2012 |
Strength in numbers: a step closer to standardising perinatal care for drug-misusing women and their infants.
Topics: Female; Humans; Methadone; Narcotics; Neonatal Abstinence Syndrome; Opioid-Related Disorders; Pregna | 2012 |
Addiction treatment-related employment barriers: the impact of methadone maintenance.
Topics: Adult; British Columbia; Cohort Studies; Employment; Female; Follow-Up Studies; Humans; Male; Methad | 2012 |
[Analysis of quality of life and its influencing factors of heroin dependent patients with methadone maintenance therapy in Dehong prefecture, Yunnan province].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; China; Factor Analysis, Statistical; Female; | 2011 |
Methadone and perinatal outcomes: a prospective cohort study.
Topics: Adult; Benzodiazepines; Dose-Response Relationship, Drug; Female; Heroin Dependence; Humans; Infant, | 2012 |
Differentiation between opiate addicts in relation to judicial problems.
Topics: Adult; Crime; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk | 2011 |
Misconceptions predict dropout and poor adherence prospectively among newly admitted first-time methadone maintenance treatment clients in Guangzhou, China.
Topics: Adult; Aged; Attitude to Health; China; Female; Humans; Male; Medication Adherence; Methadone; Middl | 2012 |
Commentary on Kurdyak et al. (2012): Methadone and other opioids - need for coordinated prescribing.
Topics: Analgesics, Opioid; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Prescripti | 2012 |
Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome.
Topics: Adult; Buprenorphine; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule | 2012 |
Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study.
Topics: Adult; Aged; British Columbia; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 2012 |
Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers.
Topics: Baltimore; Commerce; Crime; Female; Hospitals, General; Humans; Male; Methadone; Narcotics; Opiate S | 2012 |
Long waiting period to enter methadone maintenance treatment: relation to patient characteristics and outcome.
Topics: Adult; Age Factors; Cohort Studies; Female; Humans; Methadone; Middle Aged; Opioid-Related Disorders | 2012 |
Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.
Topics: Adult; Analgesics, Opioid; British Columbia; Chronic Disease; Cohort Studies; Cost-Benefit Analysis; | 2012 |
In control?: Ukrainian opiate substitution treatment patients strive for a voice in their treatment.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Users; Female; Health Services Accessibility; HIV Inf | 2012 |
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Drug Interactions; Female; | 2012 |
Rhabdomyolysis with acute renal failure secondary to taking methadone.
Topics: Acute Kidney Injury; Adult; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Rhabdomyol | 2012 |
Mortality and causes of death among users of methadone maintenance treatment in Israel, 1999-2008.
Topics: Adolescent; Adult; Age Factors; Cause of Death; Cohort Studies; Confidence Intervals; Databases, Fac | 2012 |
Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.
Topics: Adolescent; Adult; Female; Hair; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; O | 2012 |
Development of a substance abuse program for opioid-dependent nonurban pregnant women improves outcome.
Topics: Buprenorphine; Cohort Studies; Combined Modality Therapy; Female; Health Services Accessibility; Hum | 2012 |
Buprenorphine versus methadone use in opiate detoxification, are there other factors that should be considered?
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Relate | 2012 |
ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Neonatal Abstinence S | 2012 |
Predictors of methadone program non-retention for opioid analgesic dependent patients.
Topics: Adult; Analgesics, Opioid; Canada; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Methadon | 2013 |
A 12-month evaluation of health-related quality of life outcomes of methadone maintenance program in a rural Malaysian sample.
Topics: Adult; Cost of Illness; Female; Health Status; Health Surveys; Humans; Longitudinal Studies; Malaysi | 2012 |
Response inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation.
Topics: Adult; Affect; Analysis of Variance; Brain Chemistry; Cognition; Dose-Response Relationship, Drug; E | 2012 |
Are infants exposed to methadone in utero at an increased risk for mortality?
Topics: Adult; Analgesics, Opioid; Cause of Death; Female; Humans; Infant; Infant Mortality; Infant, Newborn | 2012 |
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
Topics: Adult; Depression; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Su | 2012 |
Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system.
Topics: Australia; Costs and Cost Analysis; Financing, Government; Humans; Methadone; Models, Economic; Opia | 2012 |
Treatment of opioid dependence in the setting of pregnancy.
Topics: Adolescent; Alcohol-Related Disorders; Analgesics, Opioid; Buprenorphine; Child; Comorbidity; Delive | 2012 |
Methadone replacement therapy: tried, tested, effective?
Topics: Behavior, Addictive; Health Care Costs; Humans; Methadone; Narcotics; Opiate Substitution Treatment; | 2012 |
Methadone dose, take home status, and hospital admission among methadone maintenance patients.
Topics: Adult; Comorbidity; Dose-Response Relationship, Drug; Electronic Health Records; Female; Humans; Mal | 2012 |
The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
Topics: Analgesics, Opioid; Buprenorphine; Drug and Narcotic Control; Drug Approval; Health Services Accessi | 2012 |
Rifampicin reduces methadone concentrations.
Topics: Antibiotics, Antitubercular; Drug Interactions; Humans; Methadone; Narcotics; Opioid-Related Disorde | 2012 |
Depression, Testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV Infection.
Topics: Adult; Cross-Sectional Studies; Depression; Female; HIV Infections; Humans; Hypogonadism; Iran; Logi | 2012 |
Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users.
Topics: Adult; Buprenorphine; Case-Control Studies; Cognition; Female; Humans; Male; Mental Recall; Methadon | 2012 |
The role of perceived belongingness to a drug subculture among opioid-dependent patients.
Topics: Drug Users; Female; Humans; Male; Methadone; Narcotic Antagonists; Opiate Substitution Treatment; Op | 2012 |
Pain depression and sleep disorders among methadone maintenance treatment patients.
Topics: Adult; Analysis of Variance; Depressive Disorder; Female; Health Status; Humans; Male; Mental Health | 2012 |
A national study of the retention of Irish opiate users in methadone substitution treatment.
Topics: Adolescent; Adult; Age Factors; Cohort Studies; Dose-Response Relationship, Drug; Female; Health Ser | 2012 |
Neurodevelopmental investigation of the mirror neurone system in children of women receiving opioid maintenance therapy during pregnancy.
Topics: Adult; Analysis of Variance; Buprenorphine; Case-Control Studies; Child, Preschool; Developmental Di | 2013 |
The cost of providing methadone maintenance treatment in Ontario, Canada.
Topics: Adult; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Female; Health Care Costs; Humans; Mal | 2012 |
Financial factors and the implementation of medications for treating opioid use disorders.
Topics: Buprenorphine; Community Mental Health Centers; Criminal Law; Financing, Government; Health Plan Imp | 2012 |
Use of a 'microecologic technique' to study crime incidents around methadone maintenance treatment centers - a response: The journal publishes both invited and unsolicited letters.
Topics: Crime; Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Dis | 2012 |
[Lactic acidosis due to thiamine deficiency].
Topics: Acidosis, Lactic; Anorexia; Asthenia; Buprenorphine; Cachexia; Humans; Male; Methadone; Middle Aged; | 2012 |
Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Follow-Up Studies; Humans; Infant, | 2013 |
Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Crime; Drug Users; Female; Ger | 2012 |
Commentary on Nosyk et al. (2012): detoxification from methadone maintenance therapy: how important is the exact technique that is used?
Topics: Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders | 2012 |
Commentary on Boyd et al. (2012): debunking myths about methadone and crime.
Topics: Crime; Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Dis | 2012 |
[Long term effectiveness of methadone maintenance treatments in persons with addiction to opiates].
Topics: Humans; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Time Factors | 2012 |
Medication-assisted recovery from opioid addiction: historical and contemporary perspectives.
Topics: Analgesics, Opioid; Attitude to Health; Behavior, Addictive; Humans; Long-Term Care; Methadone; Opia | 2012 |
Reducing stigma through education to enhance Medication-Assisted Recovery.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Humans; Methadone; Opiate Substitut | 2012 |
Housing First for severely mentally ill homeless methadone patients.
Topics: Adult; Analgesics, Opioid; Community Mental Health Services; Diagnosis, Dual (Psychiatry); Female; H | 2012 |
The development of Methadone Maintenance Treatment in the Maldives.
Topics: Humans; Indian Ocean Islands; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pr | 2013 |
Comparison of fatal poisonings by prescription opioids.
Topics: Accidents; Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; | 2012 |
Methadone is no panacea.
Topics: Analgesics, Opioid; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Unit | 2012 |
Clinical history and characteristics of persons with oxycodone-related deaths in Hillsborough County, Florida in 2009.
Topics: Adult; Age Distribution; Aged; Alprazolam; Analgesics, Opioid; Central Nervous System Depressants; D | 2012 |
Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.
Topics: Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; | 2013 |
Opioid overdose prevention with intranasal naloxone among people who take methadone.
Topics: Administration, Intranasal; Adult; Drug Overdose; Female; HIV Infections; Humans; Male; Massachusett | 2013 |
Treating opioid addiction.
Topics: Analgesics, Opioid; Female; Heroin; Humans; Male; Methadone; Opiate Substitution Treatment; Opioid-R | 2012 |
Semantic priming and verbal learning in current opiate users, ex-users and non-user controls.
Topics: Adult; Case-Control Studies; Drug Users; Female; Humans; Learning; Male; Memory; Memory, Episodic; M | 2012 |
Substance use predictors of poor medication adherence: the role of substance use coping among HIV-infected patients in opioid dependence treatment.
Topics: Adaptation, Psychological; Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte | 2013 |
Methadone treatment centers and crime: the journal publishes both invited and unsolicited letters.
Topics: Crime; Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Dis | 2012 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Nalox | 2012 |
Methadone use in pregnancy: evidence of progression in the severity of addiction.
Topics: Adult; England; Female; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Pregnancy | 2012 |
Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.
Topics: Adult; Arrhythmias, Cardiac; Buprenorphine; Electrocardiography; Female; Humans; International Class | 2013 |
Treatment of addicts in Bosnia and Herzegovina--constraints and opportunities.
Topics: Adult; Analgesics, Opioid; Bosnia and Herzegovina; Buprenorphine; Buprenorphine, Naloxone Drug Combi | 2012 |
Do drug treatment variables predict cognitive performance in multidrug-treated opioid-dependent patients? A regression analysis study.
Topics: Adult; Analgesics, Opioid; Attention; Buprenorphine; Cognition Disorders; Drug Therapy, Combination; | 2012 |
Profiles of quality of life in opiate-dependent individuals after starting methadone treatment: a latent class analysis.
Topics: Adult; Analysis of Variance; Belgium; Chi-Square Distribution; Cross-Sectional Studies; Female; Heal | 2013 |
Take-home "privileges" for methadone maintenance patients: policies versus practices.
Topics: Female; Humans; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; | 2012 |
Patterns of symptom reporting during pregnancy comparing opioid maintained and control women.
Topics: Adult; Buprenorphine; Case-Control Studies; Female; Humans; Methadone; Opiate Substitution Treatment | 2012 |
Deficits in social perception in opioid maintenance patients, abstinent opioid users and non-opioid users.
Topics: Adult; Analysis of Variance; Buprenorphine; Case-Control Studies; Cognition Disorders; Emotions; Fem | 2013 |
Just call it "treatment".
Topics: Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Counseling; Humans; Me | 2012 |
Methadone in the chronic pain patient with a substance use disorder.
Topics: Analgesics, Opioid; Chronic Pain; Humans; Methadone; Opioid-Related Disorders; Substance-Related Dis | 2012 |
Methadone dosing and prescribed medication use in a prospective cohort of opioid-dependent pregnant women.
Topics: Anti-Bacterial Agents; Antidepressive Agents; Benzodiazepines; Female; Humans; Hypnotics and Sedativ | 2013 |
Prescription patterns of pain medicine physicians.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Drug Prescriptions; Humans; Methadone; Opioid-Related | 2013 |
Comments on: Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
Topics: Buprenorphine; Female; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; P | 2012 |
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Topics: Alleles; Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Chromatography, Liquid; Cohort Studies; | 2013 |
Impulsivity as a moderator of the intention-behavior relationship for illicit drug use in patients undergoing treatment.
Topics: Adult; Counseling; Exploratory Behavior; Female; Humans; Impulsive Behavior; Intention; Male; Methad | 2013 |
Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Health Status; Humans; Male; Methadone; Norway; Opiate | 2013 |
Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcoti | 2013 |
Blocking endogenous opioids during development--do we understand the consequences?
Topics: Animals; Brain; Buprenorphine; Female; Fetal Development; Humans; Methadone; Naltrexone; Narcotic An | 2013 |
Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
Topics: Benzazepines; Cardiovascular Diseases; Comorbidity; Data Interpretation, Statistical; Female; Humans | 2013 |
Management of the pregnant substance abusing woman.
Topics: Analgesics, Opioid; Female; Humans; Maternal Health Services; Methadone; Opioid-Related Disorders; P | 2013 |
Three weeks from diagnosis to death: the chaotic journey of a long-term methadone maintenance patient with terminal cancer.
Topics: Australia; Fatal Outcome; Humans; Male; Methadone; Middle Aged; Neoplasms; Opioid-Related Disorders; | 2013 |
Antisocial personality disorder is associated with receipt of physical disability benefits in substance abuse treatment patients.
Topics: Adult; Antisocial Personality Disorder; Cocaine-Related Disorders; Confidence Intervals; Disability | 2013 |
The psychometric properties of the iowa personality disorder screen in methadone-maintained patients: an initial investigation.
Topics: Adult; Factor Analysis, Statistical; Female; Humans; Interview, Psychological; Iowa; Male; Mass Scre | 2015 |
Methadone maintenance treatment and drugs.
Topics: Adolescent; Adult; Automobile Driving; Croatia; Female; Humans; Male; Methadone; Opioid-Related Diso | 2002 |
Dangers involved in rapid opioid detoxification while using opioid antagonists: dehydration and renal failure.
Topics: Acute Kidney Injury; Adult; Dehydration; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; | 2002 |
Taste function in methadone-maintained opioid-dependent men.
Topics: Adult; Citric Acid; Feeding Behavior; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; | 2002 |
Successful use of oral methadone after failure of intravenous morphine and ketamine.
Topics: Acute Disease; Administration, Oral; Adult; Analgesia, Patient-Controlled; Analgesics; Analgesics, O | 2002 |
[Subjective Quality of Life in opiate-dependent patients before admission after six months and one-year participation in methadone program].
Topics: Adult; Ambulatory Care; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Patien | 2002 |
Estimating the number of opiate users in amsterdam by capture-recapture: the importance of case definition.
Topics: Bayes Theorem; Epidemiologic Methods; Humans; Linear Models; Methadone; Netherlands; Opioid-Related | 2001 |
The Personality Assessment Inventory Drug Problems Scale: a validity analysis.
Topics: Adult; Female; Humans; Male; Methadone; New York City; Opioid-Related Disorders; Personality Invento | 2002 |
A latent autoregressive model for longitudinal binary data subject to informative missingness.
Topics: Algorithms; Biometry; Buprenorphine; Clinical Trials as Topic; Humans; Longitudinal Studies; Methado | 2002 |
Methadone maintenance treatment, criminality and overdose-related deaths. An ecological study, 1983-1999.
Topics: Crime; Drug Overdose; Heroin; Humans; Methadone; Opioid-Related Disorders; Prevalence; Switzerland | 2002 |
Development and psychometric properties of the Verona Service Satisfaction Scale for methadone-treated opioid-dependent patients (VSSS-MT).
Topics: Adult; Cross-Sectional Studies; Factor Analysis, Statistical; Female; Humans; Male; Mental Health Se | 2002 |
[Long-term follow-up of the health status of opiate abusers treated with methadone--pilot study].
Topics: Adult; Blood Cell Count; Blood Chemical Analysis; Female; Follow-Up Studies; Health Status Indicator | 2002 |
Comment on: Doverty et al, Hyperalgesic responses in methadone maintenance patients (Pain 2001;90;91-6).
Topics: Animals; Humans; Hyperalgesia; Methadone; Opioid-Related Disorders; Pain Threshold; Patients | 2002 |
[Is methadone therapy inexpensive?].
Topics: Denmark; Drug Costs; Humans; Methadone; Narcotics; Opioid-Related Disorders; Self Administration | 2002 |
Prison optics.
Topics: Canada; Federal Government; Humans; Methadone; Narcotics; Opioid-Related Disorders; Prisons; State G | 2002 |
Methadone maintenance expands inside federal prisons.
Topics: Analgesics, Opioid; Canada; Hepatitis C; HIV Infections; Human Rights; Humans; Methadone; Opioid-Rel | 2002 |
[Pros and cons of methadone?].
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Treatment Outcome | 2002 |
A staging system to predict prognosis among methadone maintenance patients, based on admission characteristics.
Topics: Adult; Cohort Studies; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disor | 2002 |
Methadone trough levels in pregnancy.
Topics: Female; Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; Pregnancy Complic | 2002 |
Relationship between maternal methadone dosage and neonatal withdrawal.
Topics: Adult; Analysis of Variance; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration S | 2002 |
The activity of beta-hexosaminidase (uHex) and gamma-glutamyltransferase (uGGT) in urine as non-invasive markers of chronic alcohol abuse: II. Opiate-dependent subjects receiving methadone substitution.
Topics: Adult; Alcoholism; beta-N-Acetylhexosaminidases; Chronic Disease; Follow-Up Studies; gamma-Glutamylt | 2002 |
Behavioral naltrexone therapy: an integrated treatment for opiate dependence.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Methadone; Naltrexone; Nar | 2002 |
Office-based treatment of opioid-dependent patients.
Topics: Buprenorphine; Drug and Narcotic Control; Drug Combinations; Drug Overdose; Family Practice; Humans; | 2003 |
Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey.
Topics: Drug Utilization; Humans; Methadone; Narcotics; Ontario; Opioid-Related Disorders; Practice Patterns | 2002 |
Opioid "holiday" following antagonist supported detoxification during general anesthesia improves opioid agonist response in a cancer patient with opioid addiction.
Topics: Analgesia, Epidural; Analgesics, Opioid; Anesthesia, General; Anesthetics, Local; Bone Neoplasms; Bu | 2003 |
A tale of two policies: the French connection, methadone, and heroin epidemics.
Topics: Drug and Narcotic Control; Heroin; Heroin Dependence; History, 20th Century; Humans; Methadone; Narc | 2002 |
Biperiden for excessive sweating from methadone.
Topics: Adult; Biperiden; Drug Administration Schedule; Humans; Hyperhidrosis; Male; Methadone; Muscarinic A | 2003 |
Buprenorphine: an alternative to methadone.
Topics: Administration, Sublingual; Buprenorphine; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2003 |
Contraceptive practice of women with opiate addiction in a rural centre.
Topics: Adult; Age Factors; Attitude to Health; Contraception; Contraception Behavior; Family Planning Servi | 2003 |
Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Fem | 2003 |
[Urine testing in the treatment of opiate addiction].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Abuse Detection; Urinalysis | 2003 |
Clinical treatment of opioid addiction and dependence.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Humans; Inactivation, Metabolic; Me | 2003 |
Strabismus in infants of opiate-dependent mothers.
Topics: Australia; Codeine; Cross-Sectional Studies; Female; Heroin; Humans; Infant; Infant, Newborn; Male; | 2003 |
[Methadone].
Topics: Administration, Oral; Contraindications; Drug Administration Schedule; Drug and Narcotic Control; Dr | 2003 |
Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Confidence Intervals; Female; HIV Infections; Huma | 2003 |
The impact of methadone treatment on registered convictions and arrests in HIV-positive and HIV-negative men and women with one or more treatment periods.
Topics: Adolescent; Adult; Confidence Intervals; Female; HIV Infections; Humans; Male; Methadone; Opioid-Rel | 2003 |
User views on supervised methadone consumption.
Topics: Adult; Attitude; Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Satisfaction | 2003 |
Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test.
Topics: Adult; Drug Tolerance; Female; Humans; Hydromorphone; Male; Methadone; Middle Aged; Narcotics; Opioi | 2003 |
Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment.
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Quality | 2003 |
[Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment].
Topics: Adult; Analgesics, Opioid; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Male; Methad | 2003 |
Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Hypokalemia; Lon | 2003 |
Evaluation of a minimal services treatment track for noncompliant patients in opioid substitution treatment.
Topics: Drug and Narcotic Control; Health Services Accessibility; Humans; Methadone; Opioid-Related Disorder | 2003 |
Prescribing to drug misusers in practice--often effective, but rarely straightforward.
Topics: Drug Prescriptions; Humans; International Classification of Diseases; Methadone; Narcotic Antagonist | 2003 |
[Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Male; Methadone; | 2003 |
Gaps in the drug-free and methadone treatment program response to Hepatitis C.
Topics: Health Care Surveys; Health Services Accessibility; Hepatitis C; Humans; Methadone; Opioid-Related D | 2003 |
Methadone treatment for opiate dependent patients in general practice and specialist clinic settings: Outcomes at 2-year follow-up.
Topics: Family Practice; Female; Follow-Up Studies; Humans; Male; Methadone; Narcotics; Needle Sharing; Opio | 2003 |
Is opiate detoxification unsafe in pregnancy?
Topics: Abortion, Spontaneous; Adult; Female; Heroin; Humans; Methadone; Obstetric Labor, Premature; Opioid- | 2003 |
Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report.
Topics: Adult; Analgesics, Opioid; Autopsy; Chronic Disease; Decision Making; Expert Testimony; Florida; Hum | 2003 |
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.
Topics: Adult; Cytochrome P-450 CYP2D6; Female; Genotype; Homozygote; Humans; Male; Methadone; Middle Aged; | 2003 |
Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction.
Topics: Humans; Hyperalgesia; Methadone; Opioid-Related Disorders; Polymorphism, Genetic; Receptors, Opioid, | 2003 |
Managing opioid dependence. Comparing buprenorphine with methadone.
Topics: Buprenorphine; Clinical Trials as Topic; Comorbidity; Humans; Mental Disorders; Meta-Analysis as Top | 2003 |
The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Methadone; Narcotics; Opioid-Related Dis | 2003 |
Effect of national guidelines on prescription of methadone: analysis of NHS prescription data, England 1990-2001.
Topics: Drug Prescriptions; England; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pharmacies; Pra | 2003 |
Methadone therapy in Croatia.
Topics: Computer Graphics; Croatia; Humans; Methadone; Narcotics; Opioid-Related Disorders; Treatment Outcom | 2003 |
[Maintenance treatment for opiate dependence. Which should we deliver and how should we prescribe it?].
Topics: Analgesics, Opioid; Buprenorphine; France; Humans; Methadone; Opioid-Related Disorders; Treatment Ou | 2003 |
Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls.
Topics: Adult; Alcoholism; Case-Control Studies; Emotions; Facial Expression; Female; Humans; Male; Methadon | 2003 |
Loss of tolerance and overdose mortality with detoxification: abstinence is a valid choice.
Topics: Drug Overdose; Drug Tolerance; Methadone; Narcotics; Opioid-Related Disorders | 2003 |
Alberta court orders methadone maintenance therapy for prisoner on interim basis.
Topics: Alberta; Humans; Jurisprudence; Male; Methadone; Opioid-Related Disorders | 2003 |
[Relevance of toxicological identification of narcotics in hair for maintenance therapy of opiate addicts].
Topics: Adult; Female; Gas Chromatography-Mass Spectrometry; Hair; Humans; Male; Methadone; Middle Aged; Nar | 2003 |
Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?
Topics: Adult; Cohort Studies; Crime; England; Family Practice; Female; Humans; Longitudinal Studies; Male; | 2003 |
The treatment of narcotics addiction.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Pentobarbital; Psychotherapy; Rehabilitation | 1963 |
EXPERIMENTAL NARCOTIC ADDICTION.
Topics: Animals; Codeine; Conditioning, Psychological; Equipment and Supplies; Haplorhini; Injections, Intra | 1964 |
CONGENITAL NEONATAL NARCOTICS ADDICTION: A NATURAL HISTORY.
Topics: Chlorpromazine; Female; Humans; Maternal-Fetal Exchange; Meperidine; Methadone; Morphine Dependence; | 1964 |
NARCOTIC DRUG ADDICTION: ONE YEAR'S EXPERIECES AT PILGRIM STATE HOSPITAL.
Topics: Drug Therapy; Hepatitis; Homosexuality; Hospitals, Psychiatric; Hospitals, State; Humans; Legislatio | 1965 |
Liver transplantation for methadone-maintained opiate dependents: making the case for cautious optimism.
Topics: Contraindications; Female; Hepatitis C; Humans; Liver Transplantation; Male; Methadone; Narcotics; O | 2003 |
[Substitutions therapy of opiate addiction in Denmark].
Topics: Benzodiazepines; Buprenorphine; Denmark; Humans; Methadone; Methadyl Acetate; Narcotic Antagonists; | 2003 |
Methadone treatment in an intermediate care setting?
Topics: Delivery of Health Care; Humans; Intermediate Care Facilities; Methadone; Narcotics; Opioid-Related | 2003 |
Comments on Mattick et al.: the need for independent data re-analyses.
Topics: Buprenorphine; Clinical Trials as Topic; Humans; Methadone; Narcotics; Opioid-Related Disorders; Reg | 2003 |
Methadone and affairs of the heart and of the brain.
Topics: Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Electrocardiography; Humans; Long QT Syndr | 2003 |
Impact of methadone program philosophy changes on early treatment outcomes.
Topics: Adult; Clinical Protocols; Cohort Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug | 2003 |
[Opioid-related disorders].
Topics: Behavior Therapy; Buprenorphine; Diagnostic and Statistical Manual of Mental Disorders; Humans; Inte | 2003 |
Recovery from opioid addiction in DATOS.
Topics: Adult; Alcoholism; Ambulatory Care; Cocaine-Related Disorders; Comorbidity; Crime; Female; Follow-Up | 2003 |
Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Chronic Disease; Comorbidity; Cross-Sectional Studi | 2004 |
[Comprehensive care of drug addiction during a 5-year period at the methadone center in Prague].
Topics: Adult; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Substance Abuse Treatme | 2003 |
Specialized drug liaison midwife services for pregnant opioid dependent women in Dublin, Ireland.
Topics: Adult; Crime; Female; Humans; Infant, Newborn; Ireland; Mental Disorders; Methadone; Midwifery; Narc | 2004 |
The effects of time and money prices on treatment attendance for methadone maintenance clients.
Topics: Adult; Drug Costs; Ethnicity; Female; Humans; Income; Male; Methadone; Michigan; Models, Psychologic | 2004 |
The emperor' s new clothes.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; Clonidine; Heroin Dependence; Humans; M | 2003 |
Guideline development for office-based pharmacotherapies for opioid dependence.
Topics: Consensus Development Conferences as Topic; Family Practice; Humans; Methadone; Narcotics; Opioid-Re | 2003 |
Prescription opioid abuse in patients presenting for methadone maintenance treatment.
Topics: Adult; Comorbidity; Drug Prescriptions; Female; Humans; Male; Mental Disorders; Methadone; Narcotics | 2004 |
Psychiatric and social barriers to HIV medication adherence in a triply diagnosed methadone population.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Mental Disorders; Methadone; New York | 2003 |
A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients.
Topics: Adult; Analgesics, Opioid; Comorbidity; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Transpla | 2004 |
Methadone and excessive sweating.
Topics: Histamine H1 Antagonists; Humans; Hyperhidrosis; Methadone; Narcotics; Opioid-Related Disorders | 2004 |
[Monopoly of the methadone treatment].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Rights | 2004 |
[Opiate users in methadone-assisted rehabilitation one year and two years after admission].
Topics: Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Guidelines as Topic; Humans; Male; Methadon | 2004 |
Decreased immunodensities of micro-opioid receptors, receptor kinases GRK 2/6 and beta-arrestin-2 in postmortem brains of opiate addicts.
Topics: Adult; Arrestins; beta-Adrenergic Receptor Kinases; beta-Arrestin 2; beta-Arrestins; Case-Control St | 2004 |
Application of linear discriminant analysis to the biochemical and haematological differentiation of opiate addicts from healthy subjects: a case-control study.
Topics: Adult; alpha-Tocopherol; Ascorbic Acid; Case-Control Studies; Discriminant Analysis; Female; Health | 2004 |
Heroin prescription in Europe: heroin treatment is a pragmatic way of reducing the risks associated with addiction.
Topics: Drug Prescriptions; Europe; Health Care Rationing; Health Policy; Heroin; Heroin Dependence; Humans; | 2003 |
Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program.
Topics: Administration, Oral; Adult; Carrier State; Female; Heroin; Humans; Injections, Intravenous; Male; M | 2004 |
Maintenance therapy with synthetic opioids and driving aptitude.
Topics: Adolescent; Adult; Aptitude; Automobile Driving; Buprenorphine; Chi-Square Distribution; Female; Hum | 2004 |
Methadone implants for methadone maintenance treatment. In vitro and in vivo animal studies.
Topics: Animals; Biocompatible Materials; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug I | 2004 |
A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain.
Topics: Adolescent; Adult; Analysis of Variance; Female; Humans; Male; Mental Health Services; Methadone; Mi | 2004 |
Patients prescribed injectable heroin or methadone -their opinions and experiences of treatment.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; England; Female; Heroin; Humans; Male; Methadone; Mi | 2004 |
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; | 2004 |
["Is opiate detoxification unsafe in pregnancy?"].
Topics: Adult; Female; Humans; Infant, Newborn; Methadone; Narcotics; Opioid-Related Disorders; Pregnancy; P | 2004 |
Sleep disturbances among methadone maintained patients.
Topics: Adult; Alcohol Drinking; Female; Humans; Least-Squares Analysis; Male; Methadone; Opioid-Related Dis | 2004 |
Sociodemographic disparities in supplemental service utilization among male methadone patients.
Topics: Community Health Services; Ethnicity; Health Services Accessibility; Humans; Logistic Models; Male; | 2004 |
Unexpected delirium during Rapid Opioid Detoxification (ROD).
Topics: Adult; Alcohol Withdrawal Delirium; Clonidine; Diagnostic and Statistical Manual of Mental Disorders | 2004 |
Depression and hostility as predictors of long-term outcomes among opiate users.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Hostility; Humans; Male; Methadone; Narcotics | 2004 |
Is it time for treatment trials in addiction?
Topics: Alcohol Drinking; Amphetamine-Related Disorders; Crime; Data Collection; Humans; Methadone; New Zeal | 2004 |
Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand.
Topics: Costs and Cost Analysis; Crime; Humans; Income; Male; Methadone; Narcotics; Native Hawaiian or Other | 2004 |
Physicians practicing in methadone treatment programs: who are they and what do they do?
Topics: Accreditation; Adult; Analgesics, Opioid; Female; Health Care Surveys; Humans; Institutional Practic | 2004 |
Treatment options for opiate addiction.
Topics: Buprenorphine; Evidence-Based Medicine; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-R | 2004 |
Compliance with methadone-based substitutive treatment: a proposed model based on immunoassay urinary sample screening.
Topics: Adult; Cross-Sectional Studies; Enzyme Multiplied Immunoassay Technique; Female; Humans; Hydrogen-Io | 2004 |
French field experience with buprenorphine.
Topics: Adult; Buprenorphine; Cause of Death; Cross-Cultural Comparison; Drug Approval; Drug Overdose; Drug | 2004 |
Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care.
Topics: Adolescent; Adult; Female; Focus Groups; Humans; Male; Medical Audit; Methadone; Middle Aged; Multic | 2004 |
Comparative drug use and psychosocial profiles of opioid dependents applying for medication versus medication-free treatment.
Topics: Adult; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Inactivation, Metaboli | 2004 |
Improving the management of opioid-dependent pregnancies.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Female; Gestational Age; Humans; Infant, Newborn; | 2004 |
Pupillometry in the detection of concomitant drug use in opioid-maintained patients.
Topics: Adult; Biometry; Buprenorphine; Diagnostic Techniques, Ophthalmological; Drug Interactions; Female; | 2004 |
Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies.
Topics: Adult; Animals; Behavior, Addictive; Carbon Radioisotopes; Diprenorphine; Humans; Male; Methadone; M | 2005 |
French version of the addiction severity index (5th Edition): validity and reliability among Swiss opiate-dependent patients. French validation of the Addiction Severity Index.
Topics: Adult; Alcoholism; Cocaine-Related Disorders; Comorbidity; Cross-Cultural Comparison; Female; Heroin | 2004 |
Leaving methadone maintenance treatment: the role of personality traits and psychiatric status.
Topics: Adult; Female; Humans; Male; Mental Disorders; Methadone; Opioid-Related Disorders; Patient Dropouts | 2004 |
[Life-threatening, recurrent arrhythmia in patients on high-dose methadone treatment: torsade de pointes].
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Risk Facto | 2004 |
[Initiation of methadone replacement therapy in the hospital, prescribing guidelines].
Topics: France; Humans; Methadone; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topic; Practi | 2004 |
Development and validation of a Client Problem Profile and Index for drug treatment.
Topics: Adult; Alcoholism; Cohort Studies; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; Methadone | 2004 |
Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.
Topics: Adult; Buprenorphine; Estradiol; Humans; Male; Methadone; Opioid-Related Disorders; Sex Hormone-Bind | 2005 |
Validation of the Cozart microplate EIA for cocaine and metabolites in oral fluid.
Topics: Algorithms; Antibody Specificity; Cocaine; Cocaine-Related Disorders; Cross Reactions; Enzyme-Linked | 2004 |
[Micronuclei as markers of DNA damage in patients addicted to opioid drugs].
Topics: Adult; Cell Culture Techniques; DNA Damage; Female; Genetic Markers; Humans; Lymphocytes; Male; Meth | 2004 |
[Nutritional status of opiate-dependent persons before and during methadone maintenance therapy].
Topics: Adult; Body Composition; Body Mass Index; Body Size; Female; Humans; Male; Methadone; Middle Aged; N | 2004 |
[Intake of nutrients in daily nutritional ratios by opiate dependent persons during methadone maintenance therapy].
Topics: Adult; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Energy Intake; Feeding | 2004 |
Methadone and nicotine self-administration in humans: a behavioral economic analysis.
Topics: Adult; Choice Behavior; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interac | 2005 |
Smoking cessation services in U.S. methadone maintenance facilities.
Topics: Adult; Combined Modality Therapy; Comorbidity; Counseling; Cross-Sectional Studies; Female; Health S | 2004 |
A psychometric study of the prevalence of DSM-IV personality disorders among office-based methadone maintenance patients.
Topics: Adult; Ambulatory Care; Canada; Comorbidity; Depressive Disorder; Diagnostic and Statistical Manual | 2004 |
[Routine ECG in methadone-assisted rehabilitation is wrong prioritization].
Topics: Dose-Response Relationship, Drug; Electrocardiography; Humans; Long QT Syndrome; Methadone; Narcotic | 2004 |
Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.
Topics: Adult; Area Under Curve; Blood Pressure; Female; Heart Rate; Humans; Isomerism; Male; Methadone; Mid | 2004 |
[Long QT and torsade de pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450].
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Antifungal Agents; Antiretroviral Therapy, H | 2004 |
[Outcome of a substitution therapy program in an outpatient treatment setting of a psychiatric hospital].
Topics: Adult; Buprenorphine; Crime; Female; Follow-Up Studies; Germany; Hospitals, Psychiatric; Humans; Mal | 2004 |
A preventive ethics approach to methadone maintenance programmes.
Topics: Disclosure; Humans; Informed Consent; Methadone; New Zealand; Opioid-Related Disorders; Paternalism; | 2001 |
Ethical aspects of substance abuse and intervention: reflecting on methadone maintenance in New Zealand.
Topics: Ethical Analysis; Health Personnel; Health Policy; Humans; Methadone; Morals; New Zealand; Opioid-Re | 2001 |
Appropriateness versus practicality of MMT. Response.
Topics: Health Care Rationing; Humans; Informed Consent; Methadone; New Zealand; Opioid-Related Disorders; P | 2001 |
Methadone maintenance treatment: the consumer perspective. Response.
Topics: Consumer Advocacy; Health Services Accessibility; Humans; Methadone; New Zealand; Opioid-Related Dis | 2001 |
Competing ideologies in substance abuse treatment. Response.
Topics: Alcoholics Anonymous; Family Practice; Humans; Methadone; New Zealand; Opioid-Related Disorders | 2001 |
Challenging perspectives on MMT. Response.
Topics: Counseling; Humans; Informed Consent; Methadone; New Zealand; Opioid-Related Disorders; Paternalism | 2001 |
A community pharmacist's perspective on the methadone maintenance programme. Response.
Topics: Attitude of Health Personnel; Humans; Methadone; New Zealand; Opioid-Related Disorders; Pharmacists; | 2001 |
The impact of welfare reform on methadone treatment: policy lessons from service providers in New York city.
Topics: Attitude of Health Personnel; Counseling; Data Collection; Disabled Persons; Eligibility Determinati | 2004 |
The most critical unresolved issue associated with contemporary vocational rehabilitation for substance users.
Topics: Employment; Humans; Methadone; Motivation; Narcotics; Opioid-Related Disorders; Problem Solving; Voc | 2004 |
Increased caseloads in methadone treatment programs: implications for the delivery of services and retention in treatment.
Topics: Case Management; Delivery of Health Care; England; Female; Humans; Male; Methadone; Narcotics; Opioi | 2004 |
[A new route].
Topics: Buprenorphine; Family Practice; France; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-R | 2004 |
Correlates of motivation to quit smoking in methadone-maintained smokers enrolled in a smoking cessation trial.
Topics: Adult; Attitude to Health; Cross-Sectional Studies; Female; Humans; Male; Methadone; Motivation; Opi | 2005 |
Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
Topics: Adult; Ambulatory Care; Attitude of Health Personnel; Combined Modality Therapy; Comorbidity; Cultur | 2004 |
Predicting methadone maintenance treatment outcomes using the Addiction Severity Index and the MMPI-2 Content Scales (Negative Treatment Indicators and Cynism scales).
Topics: Adult; Black People; Combined Modality Therapy; Hispanic or Latino; Humans; Male; Methadone; Middle | 2004 |
Physicians with opioid dependence.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Physician Impairment | 2005 |
Diversion and abuse of methadone prescribed for pain management.
Topics: Analgesics, Opioid; Drug and Narcotic Control; Drug Prescriptions; Humans; Methadone; Opioid-Related | 2005 |
Extensive cutaneous fibrosis and ulceration caused by methadone injection.
Topics: Drug Eruptions; Female; Fibrosis; Humans; Injections, Intradermal; Methadone; Middle Aged; Narcotics | 2005 |
Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies.
Topics: Adult; Birth Weight; Cocaine-Related Disorders; Cohort Studies; Dose-Response Relationship, Drug; Dr | 2005 |
Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal | 2005 |
Tighten Ontario's methadone program states inquest.
Topics: Adolescent; Adult; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Ontario; | 2005 |
Treating opiate addiction, Part I. Detoxification and maintenance.
Topics: Buprenorphine; Drug Combinations; Humans; Methadone; Naloxone; Narcotics; Opioid-Related Disorders; | 2004 |
Something of value: the introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service.
Topics: Attitude of Health Personnel; Behavior Therapy; Health Plan Implementation; Humans; Inservice Traini | 2005 |
Looking for poppa: parenting status of men versus women seeking drug abuse treatment.
Topics: Adult; Ambulatory Care; Cohort Studies; Father-Child Relations; Female; Humans; Male; Mass Screening | 2005 |
Deaths of clients in methadone treatment in Texas: 1994-2002.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Texas | 2005 |
Policy changes and the methadone maintenance treatment system for opioid dependence in Ontario, 1996 to 2001.
Topics: Adult; Female; Health Policy; Humans; Longitudinal Studies; Male; Mental Health Services; Methadone; | 2005 |
Management of opiate detoxification in jails.
Topics: Acute Disease; Adrenergic alpha-Agonists; Clonidine; Health Care Surveys; Humans; Methadone; Narcoti | 2005 |
Perceptions of health risk susceptibility in methadone maintained smokers.
Topics: Adult; Attitude to Health; Female; Health Status; Humans; Lung Neoplasms; Male; Methadone; Middle Ag | 2005 |
Opioid poisoning deaths in New Zealand.
Topics: Humans; Methadone; Morphine; Narcotics; New Zealand; Opioid-Related Disorders | 2005 |
Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Health S | 2005 |
Impact of methadone treatment on cardiac repolarization and conduction in opioid users.
Topics: Administration, Oral; Adult; Arrhythmias, Cardiac; Electrocardiography; Female; Humans; Male; Methad | 2005 |
Methadone maintenance and male sexual dysfunction.
Topics: Adult; Demography; Erectile Dysfunction; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Rel | 2005 |
[Methadone and sleep apnea syndrome].
Topics: Adult; Brain; Clonidine; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Drug Administr | 2005 |
Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Feeding Behavior; Flunitrazepam; GABA M | 2005 |
Methadone medical maintenance in primary care. An implementation evaluation.
Topics: Adult; Analgesics, Opioid; Comorbidity; Female; Health Status Indicators; Humans; Linear Models; Mal | 2005 |
Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction with treatment.
Topics: Adolescent; Adult; Attitude to Health; Drug Administration Schedule; Female; Health Services Researc | 2005 |
Torsades de pointes with methadone.
Topics: Analgesics, Opioid; Aryl Hydrocarbon Hydroxylases; Drug Interactions; Heroin; Humans; Hypokalemia; L | 2005 |
Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence.
Topics: Adult; Age Factors; Female; Health Personnel; Humans; Logistic Models; Male; Methadone; Narcotics; O | 2005 |
Attitudes and practices regarding the use of methadone in US state and federal prisons.
Topics: Drug Utilization; Federal Government; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Dis | 2005 |
QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Databases, Factual; Female; Humans | 2005 |
Sublingual buprenorphine and methadone maintenance treatment: a three-year follow-up of quality of life assessment.
Topics: Administration, Sublingual; Adult; Buprenorphine; Female; Follow-Up Studies; Humans; Male; Methadone | 2005 |
Intimate partner violence and monogamy among women in methadone treatment.
Topics: Adult; Assertiveness; Domestic Violence; Fear; Female; HIV Infections; Humans; Methadone; Middle Age | 2005 |
Methadone-induced bradycardia.
Topics: Administration, Oral; Adult; Bradycardia; Diagnosis, Differential; Electrocardiography; Headache; Hu | 2005 |
The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales.
Topics: Analgesics, Opioid; Buprenorphine; Codeine; Cohort Studies; England; Family Practice; Female; Humans | 2005 |
Methadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-up.
Topics: Adult; Aged; Analgesics, Opioid; Chronic Disease; Drug Administration Schedule; Female; Follow-Up St | 2006 |
Involving significant others in the care of opioid-dependent patients receiving methadone.
Topics: Adaptation, Psychological; Adult; Family; Female; Humans; Male; Methadone; Narcotics; Opioid-Related | 2005 |
Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Behavior; Female; Heroin Dependence; Humans; Male; | 2005 |
Determinants of methadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy.
Topics: Adult; Age Factors; Female; HIV Infections; Humans; Italy; Male; Methadone; Narcotics; Opioid-Relate | 2005 |
Methadone vs buprenorphine.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders | 2005 |
[The real border for the treatment of drug addicts].
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders | 2005 |
Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis.
Topics: Adult; Area Under Curve; Differential Threshold; Female; Humans; Male; Methadone; Narcotics; Odds Ra | 2006 |
Prevalence of methadone injection in three Swiss cities.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Humans; Injections, Intravenous; Male; Methadone | 2005 |
Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.
Topics: Buprenorphine; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dose-Response Relationship, Dru | 2005 |
Examining the influence of drop-outs in a follow-up of maintained opiate users.
Topics: Adult; Bias; Buprenorphine; Data Interpretation, Statistical; Female; Follow-Up Studies; France; Hum | 2005 |
Prescribing to substance misusers.
Topics: Analgesics, Opioid; Clinical Competence; Delivery of Health Care; England; Family Practice; Humans; | 2005 |
Methadone treatment marks 40 years.
Topics: Heroin Dependence; History, 20th Century; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2005 |
High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes.
Topics: Adult; Analgesics, Opioid; Female; Gestational Age; Humans; Infant, Newborn; Length of Stay; Methado | 2005 |
Fetal response to maternal methadone administration.
Topics: Adult; Analgesics, Opioid; Female; Fetal Movement; Fetus; Heart Rate, Fetal; Humans; Male; Methadone | 2005 |
Fetal response to maternal methadone administration.
Topics: Adult; Analgesics, Opioid; Female; Fetal Movement; Fetus; Heart Rate, Fetal; Humans; Male; Methadone | 2005 |
Fetal response to maternal methadone administration.
Topics: Adult; Analgesics, Opioid; Female; Fetal Movement; Fetus; Heart Rate, Fetal; Humans; Male; Methadone | 2005 |
Fetal response to maternal methadone administration.
Topics: Adult; Analgesics, Opioid; Female; Fetal Movement; Fetus; Heart Rate, Fetal; Humans; Male; Methadone | 2005 |
Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients.
Topics: Adult; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Israel; Male; Methadon | 2006 |
Sexual abuse history and treatment outcomes among women undergoing methadone treatment.
Topics: Adult; Female; Humans; Methadone; Opioid-Related Disorders; Sex Offenses; Texas; Treatment Outcome | 2005 |
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.
Topics: Adult; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; | 2005 |
Maintenance for opioid addiction with buprenorphine and methadone: "The only thing new in the world is the history you don't know".
Topics: Buprenorphine; Heroin Dependence; Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related | 2005 |
Methadone dosage and retention: an examination of the 60 mg/day threshold.
Topics: Adult; Ambulatory Care; Critical Pathways; Dose-Response Relationship, Drug; Female; Humans; Long-Te | 2005 |
Linkage with methadone treatment upon release from incarceration: a promising opportunity.
Topics: Crime; Health Services Needs and Demand; Hepatitis B; Hepatitis C; HIV Infections; Humans; Long-Term | 2005 |
Public policy statement on Office-Based Opioid Agonist Treatment (OBOT).
Topics: Ambulatory Care; Buprenorphine; Combined Modality Therapy; Comprehensive Health Care; Continuity of | 2005 |
Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.
Topics: Adult; Area Under Curve; Female; Heart Rate; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid | 2005 |
Induction of patients with moderately severe methadone dependence onto buprenorphine.
Topics: Adult; Buprenorphine; Clonidine; Drug Administration Schedule; Female; Humans; Male; Methadone; Narc | 2005 |
Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
Topics: Adult; Buprenorphine; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; M | 2005 |
In-patient treatment of opiate dependence: medium-term follow-up outcomes.
Topics: Adult; Family; Female; Follow-Up Studies; Heroin Dependence; Hospitalization; Humans; Length of Stay | 2005 |
Pregnancy outcome in women who use opiates.
Topics: Adult; England; Female; Heroin; Humans; Infant, Newborn; Male; Medical Records; Methadone; Neonatal | 2006 |
Response to methadone maintenance treatment of opiate dependent patients with and without significant pain.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; P | 2006 |
Age estimation of unidentified corpses by measurement of root translucency.
Topics: Adult; Age Determination by Teeth; Aged; Asian People; Dentin; Diabetes Mellitus; Female; Humans; In | 2004 |
Opiate maintenance alternatives: new studies.
Topics: Buprenorphine; Humans; Methadone; Morphine; Narcotic Antagonists; Narcotics; Opioid-Related Disorder | 2005 |
Assessment of daily nutrition ratios of opiate-dependent persons before and after 4 years of methadone maintenance treatment.
Topics: Adult; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Energy Intake; Feeding | 2005 |
Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment.
Topics: Adult; Body Composition; Body Weight; Energy Intake; Feeding Behavior; Female; Follow-Up Studies; Fo | 2005 |
The changes in taste preferences during 4 years period of methadone maintenance treatment.
Topics: Adult; Cluster Analysis; Dietary Carbohydrates; Dietary Fats; Dietary Fiber; Dietary Proteins; Feedi | 2005 |
[Social competence evaluated by patients on methadone maintenance treatment program].
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Poland; Re | 2005 |
Evaluation of the effect of methadone maintenance treatment program on the frequency of DNA lesions revealed as micronuclei and sister chromatid exchanges.
Topics: Adult; DNA Damage; Female; Genetic Markers; Humans; Life Style; Lymphocytes; Male; Methadone; Micron | 2005 |
Cytogenetic aspects of buprenorphine maintenance treatment program--preliminary report.
Topics: Adult; Buprenorphine; Female; Genetic Markers; Humans; Lymphocytes; Male; Methadone; Micronuclei, Ch | 2005 |
Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution.
Topics: Adult; Buprenorphine; Female; HIV Seropositivity; Humans; Infant Care; Infant, Newborn; Methadone; N | 2006 |
Dental management of patients taking methadone.
Topics: Dental Care; Dental Caries; Hepatitis C; HIV Infections; Humans; Methadone; Narcotics; Opioid-Relate | 2005 |
Buprenorphine retention in primary care.
Topics: Adult; Ambulatory Care; Buprenorphine; Cohort Studies; Drug Administration Schedule; Female; Humans; | 2005 |
Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients.
Topics: Adult; Appointments and Schedules; Baltimore; Behavior Therapy; Cost-Benefit Analysis; Counseling; F | 2005 |
Psychiatric diagnoses in a sample of HIV-infected people of color in methadone treatment.
Topics: Adult; Black or African American; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders | 2005 |
Is methadone too dangerous for opiate addiction?
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Opioid-Related Disorders | 2005 |
Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies.
Topics: Adult; Buprenorphine; Cognition Disorders; Decision Making; Female; Gambling; Humans; Male; Methadon | 2006 |
Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey.
Topics: Humans; Hypnotics and Sedatives; Infant, Newborn; Injections, Intravenous; Intensive Care Units, Neo | 2006 |
Cost-utility analysis of methadone maintenance treatment: a methodological approach.
Topics: Costs and Cost Analysis; Humans; Lithuania; Methadone; Opioid-Related Disorders; Quality of Life; Re | 2006 |
Is methadone too dangerous for opiate addiction? Methadone is still needed in addiction treatments.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 2006 |
Is methadone too dangerous for opiate addiction? Issue is one of toxicity v acceptability.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 2006 |
Mothers in substance abuse treatment: differences in characteristics based on involvement with child welfare services.
Topics: Adolescent; Adult; Alcoholism; Ambulatory Care; Amphetamine-Related Disorders; California; Child; Ch | 2006 |
Comparison of Cozart microplate ELISA and GC-MS detection of methadone and metabolites in human hair.
Topics: Enzyme-Linked Immunosorbent Assay; False Negative Reactions; False Positive Reactions; Forensic Medi | 2005 |
Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns.
Topics: Adult; Cohort Studies; Ethnicity; Female; Gestational Age; Heart Rate, Fetal; Humans; Methadone; Opi | 2006 |
An overview of illegal opioid use and health services utilization in Canada.
Topics: Adolescent; Adult; Canada; Drug Overdose; Female; Health Services; Health Services Research; Humans; | 2006 |
Effectiveness of drug and alcohol counselling during methadone treatment: content, frequency, and duration of counselling and association with substance use outcomes.
Topics: Adult; Alcohol-Related Disorders; Cocaine-Related Disorders; Cohort Studies; Counseling; Female; Fol | 2006 |
Health correlates of pathological gambling in a methadone maintenance clinic.
Topics: Behavior, Addictive; Female; Gambling; Health Status; Humans; Male; Mental Health; Methadone; Opioid | 2006 |
Abstinence-oriented treatment for opiate addiction.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Selection; Treatment Outcome | 2006 |
[Quality assurance in patient addiction treated with drug substitution].
Topics: Antiviral Agents; Buprenorphine; Comorbidity; Drug Information Services; Drug Interactions; Drug The | 2005 |
Determinants of health-related quality of life of opiate users at entry to low-threshold methadone programs.
Topics: Adolescent; Adult; Child Abuse; Child Abuse, Sexual; Cocaine-Related Disorders; Comorbidity; Female; | 2006 |
Opioid substitution treatment reduces substance use equivalently in patients with and without posttraumatic stress disorder.
Topics: Adult; Aged; Alcoholism; Cocaine-Related Disorders; Combat Disorders; Comorbidity; Female; Follow-Up | 2006 |
Effect of opioid substitution therapy on alcohol metabolism.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Dose-Response Relation | 2006 |
Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
Topics: Adolescent; Buprenorphine; Female; Humans; Male; Methadone; Narcotic Antagonists; Narcotics; New Sou | 2006 |
Elimination of methadone benefits in the Oregon Health Plan and its effects on patients.
Topics: Eligibility Determination; Female; Financing, Personal; Follow-Up Studies; Health Policy; Humans; In | 2006 |
Galactorrhoea may be associated with methadone use.
Topics: Adult; Female; Galactorrhea; Humans; Hyperprolactinemia; Methadone; Narcotics; Opioid-Related Disord | 2006 |
[Heroin substitution treatments. Analysis of current solutions, trends, and perspectives].
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Combinations; Humans; Methadone; Nalox | 2006 |
Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Middle Aged; N | 2006 |
Pills for speedballing or cocaine dependence.
Topics: Bupropion; Cocaine-Related Disorders; Dopamine Uptake Inhibitors; Humans; Methadone; Narcotics; Opio | 2006 |
What to look for in methadone clinic software. IT solutions can save time, produce better data, and help with the bottom line.
Topics: Decision Making; Forms and Records Control; Humans; Management Information Systems; Methadone; Opioi | 2006 |
Cause and motivation in cases of non-fatal drug overdoses in opiate addicts.
Topics: Adult; Drug Overdose; Female; Humans; Male; Methadone; Motivation; Narcotics; Opioid-Related Disorde | 2006 |
Methadone maintenance improves cognitive performance after two months of treatment.
Topics: Adult; Cognition; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Time Facto | 2006 |
Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic.
Topics: Adult; Age Factors; Cocaine-Related Disorders; Cohort Studies; Comorbidity; Emigration and Immigrati | 2006 |
Comment on "An overview of illegal opioid use and health services utilization in Canada" by S. Popova, J. Rehm, B. Fischer.
Topics: Canada; Europe; Health Services Accessibility; Humans; Methadone; Opioid-Related Disorders; Prisons | 2006 |
Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Behavior, Addictive; Cocaine-Related Disorders; Comorbidity; Drug Administration S | 2006 |
Medicalising the treatment of opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disord | 2006 |
Differences in orbitofrontal activation during decision-making between methadone-maintained opiate users, heroin users and healthy volunteers.
Topics: Adult; Age Factors; Analgesics, Opioid; Analysis of Variance; Behavior, Addictive; Decision Making; | 2006 |
A chart review comparing paregoric to methadone in the treatment of neonatal opioid withdrawal.
Topics: Analgesics, Opioid; Documentation; Drug Administration Schedule; Female; Humans; Infant, Newborn; Ma | 2006 |
Mortality in a cohort of opiate and amphetamine users in Perth, Western australia: Comment on Bartu et al. (2006).
Topics: Amphetamine-Related Disorders; Follow-Up Studies; Humans; Methadone; Narcotics; Opioid-Related Disor | 2006 |
Opiate substitution treatment in the former Soviet Union.
Topics: Health Services Needs and Demand; Humans; Methadone; Opioid-Related Disorders; Russia | 2006 |
Buprenorphine: reflections of an addictions psychiatrist.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Legislation, Drug; Methadone; Narcotics; Opioid-Related D | 2006 |
[Insufficient involvement of psychiatrists in substitution treatment].
Topics: Comorbidity; Germany; Humans; Mental Disorders; Methadone; Opioid-Related Disorders; Physician-Patie | 2006 |
Depression in methadone maintenance treatment patients: rate and risk factors.
Topics: Adult; Benzodiazepines; Brief Psychiatric Rating Scale; Cocaine; Cocaine-Related Disorders; Comorbid | 2007 |
Buprenorphine for heroin addicts: the issue of illicit opioid abuse during maintenance.
Topics: Buprenorphine; Combined Modality Therapy; Double-Blind Method; Heroin Dependence; Humans; Methadone; | 2006 |
Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004.
Topics: Administration, Oral; Adult; Age Distribution; Drug and Narcotic Control; England; Family Practice; | 2006 |
A 5-year evaluation of a methadone medical maintenance program.
Topics: Adult; Community Pharmacy Services; Counseling; Cross-Sectional Studies; Female; Follow-Up Studies; | 2006 |
One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients.
Topics: Adolescent; Adult; Aged; Buprenorphine; Cohort Studies; Female; Follow-Up Studies; Germany; Humans; | 2006 |
Methadone and the QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone.
Topics: Adult; Drug Monitoring; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Methadone; Narc | 2006 |
Women on methadone.
Topics: Amenorrhea; Contraceptives, Oral, Hormonal; Female; Humans; Hypogonadism; Methadone; Narcotics; Opio | 2006 |
Methadone tolerance testing in drug misusers: beyond the edge of safety.
Topics: Drug Tolerance; Humans; Methadone; Narcotics; Opioid-Related Disorders; Risk Factors | 2006 |
The Beck Depression Inventory in patients undergoing opiate agonist maintenance treatment.
Topics: Adolescent; Adult; Alcoholism; Buprenorphine; Comorbidity; Denmark; Depressive Disorder; Female; Fol | 2006 |
Stereoselective determination of methadone and its main metabolite in serum and urine from methadone maintenance patients.
Topics: Adult; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; | 2006 |
Mood disorders affect drug treatment success of drug-dependent pregnant women.
Topics: Adult; Diagnosis, Dual (Psychiatry); Diagnostic and Statistical Manual of Mental Disorders; Female; | 2007 |
Access to treatment-related and support services in methadone treatment programs.
Topics: Adolescent; Adult; Demography; Female; Health Services Accessibility; Humans; Inactivation, Metaboli | 2007 |
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, | 2006 |
Immune response in addicts with chronic hepatitis C treated with interferon and ribavirin.
Topics: Adult; Antiviral Agents; Case-Control Studies; Chi-Square Distribution; Disease Progression; Drug Th | 2007 |
[Heart arrhythmia and sudden death during methadone therapy].
Topics: Death, Sudden; Death, Sudden, Cardiac; Humans; Long QT Syndrome; Methadone; Narcotics; Opioid-Relate | 2007 |
Excessive alcohol consumption is associated with reduced quality of life among methadone patients.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Cross-Sectional Studies; England; Health Status; Humans; | 2007 |
Methadone in pregnancy: treatment retention and neonatal outcomes.
Topics: Adult; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Methad | 2007 |
Commentary: decline in methadone-related deaths probably relates to increased supervision of methadone in UK.
Topics: Delivery of Health Care; Heroin; Heroin Dependence; Humans; Methadone; Narcotics; Opioid-Related Dis | 2006 |
Liver transplant and hepatitis C in methadone maintenance therapy: a case report.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interfe | 2007 |
Different components of opioid-substitution treatment predict outcomes of patients with and without a parent with substance-use problems.
Topics: Adult; Alcoholism; Child; Child of Impaired Parents; Cocaine-Related Disorders; Combined Modality Th | 2007 |
Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment.
Topics: Adolescent; Adult; Australia; Benzodiazepines; Buprenorphine; Drug Interactions; Drug Therapy, Combi | 2007 |
On-site medical care in methadone maintenance: associations with health care use and expenditures.
Topics: Ambulatory Care; Cluster Analysis; Comorbidity; Cost Savings; Delivery of Health Care, Integrated; H | 2007 |
Client and counselor attitudes toward the use of medications for treatment of opioid dependence.
Topics: Adult; Ambulatory Care; Attitude of Health Personnel; Buprenorphine; Clonidine; Counseling; Culture; | 2007 |
Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments.
Topics: Amisulpride; Animals; Behavior, Animal; Buprenorphine; Disulfides; Male; Methadone; Mice; Morphine; | 2007 |
Psychometric evaluation of the Dutch version of the Subjective Opiate Withdrawal Scale (SOWS).
Topics: Adult; Anxiety; Body Temperature; Body Temperature Regulation; Facial Expression; Heroin Dependence; | 2007 |
[Drugs, pregnancy and newborn infants from the viewpoint of pediatric nursing].
Topics: Breast Feeding; Education; Female; Humans; Infant, Newborn; Male; Methadone; Mother-Child Relations; | 2002 |
Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.
Topics: Adult; Alcohol Deterrents; Alcoholism; Comorbidity; Cyanamide; Disulfiram; Female; Follow-Up Studies | 2007 |
Zopiclone misuse: an update from Dublin.
Topics: Adult; Azabicyclo Compounds; Benzodiazepines; Comorbidity; Cross-Sectional Studies; Female; Hepatiti | 2007 |
Treatment entry and predictors among opiate-using injection drug users.
Topics: Case Management; Catchment Area, Health; Colorado; Community-Institutional Relations; Female; Follow | 2007 |
Recovery and spiritual transformation among peer leaders of a modified methadone anonymous group.
Topics: Anonyms and Pseudonyms; Humans; Leadership; Methadone; Opioid-Related Disorders; Spirituality | 2006 |
The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program.
Topics: Amphetamine-Related Disorders; Antiretroviral Therapy, Highly Active; Benzodiazepines; Cocaine-Relat | 2007 |
Prescription opioid abuse among enrollees into methadone maintenance treatment.
Topics: Adult; Analgesics, Opioid; Comorbidity; Cross-Sectional Studies; Drug Prescriptions; Female; Health | 2007 |
Drugs--facing facts.
Topics: Family Practice; Harm Reduction; Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Edu | 2007 |
QTc prolongation and torsades de pointes associated with methadone therapy.
Topics: Electrocardiography; Female; Humans; Long QT Syndrome; Methadone; Middle Aged; Narcotics; Opioid-Rel | 2007 |
Drug-abusing fathers: patterns of pair bonding, reproduction, and paternal involvement.
Topics: Adult; Data Collection; Family Health; Father-Child Relations; Fathers; Humans; Interpersonal Relati | 2007 |
Outpatient methadone maintenance treatment program. Quality of life and health of opioid-dependent persons in Lithuania.
Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Data Interpretation, Statistical; Education; Femal | 2007 |
[Evaluation of first 8 pilot methadone maintenance treatment clinics in China].
Topics: Adult; Analgesics, Opioid; China; Follow-Up Studies; Humans; Methadone; Opioid-Related Disorders; Ou | 2007 |
[Methadone and arrhythmia--final comment].
Topics: Humans; Long QT Syndrome; Methadone; Narcotics; Opioid-Related Disorders; Risk Factors | 2007 |
Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients.
Topics: Adult; Analgesics, Opioid; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administr | 2007 |
Primary care affiliations of adults in a methadone program with onsite care.
Topics: Adult; Ambulatory Care; Cardiovascular Diseases; Continuity of Patient Care; Diabetes Mellitus; Drug | 2007 |
Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Topics: Adolescent; Adult; Alcoholism; Antiviral Agents; Anxiety Disorders; Australia; Buprenorphine; Comorb | 2007 |
An epidemiological investigation into an outbreak of rash illness among methadone maintenance clients in Australia.
Topics: Acute Disease; Administration, Oral; Adult; Australia; Case-Control Studies; Causality; Cross-Sectio | 2007 |
Methadone-associated QT prolongation and torsades de pointes.
Topics: Analgesics, Opioid; Humans; Long QT Syndrome; Methadone; Opioid-Related Disorders; Torsades de Point | 2007 |
Methadone-associated QT prolongation and torsades de pointes. Dubrey and Groscott-Mason's patient was underttreated for her atrial fibrillation.
Topics: Analgesics, Opioid; Atrial Fibrillation; Humans; Long QT Syndrome; Methadone; Opioid-Related Disorde | 2007 |
Medical treatment of opiate dependence: expanding treatment options.
Topics: Administration, Sublingual; Ambulatory Care; Buprenorphine; Drug Combinations; Humans; Methadone; Na | 2007 |
Benzodiazepine prescription for patients in opioid maintenance treatment in Norway.
Topics: Adult; Benzodiazepines; Buprenorphine; Drug Prescriptions; Drug Utilization Review; Female; Humans; | 2007 |
Factors affecting the outcome of methadone maintenance treatment in opiate dependence.
Topics: Adolescent; Adult; Female; Humans; Illicit Drugs; Ireland; Male; Methadone; Middle Aged; Opioid-Rela | 2007 |
Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005.
Topics: Buprenorphine; Drug Prescriptions; England; Family Practice; Humans; Medical Staff, Hospital; Methad | 2007 |
Does naltrexone affect craving in abstinent opioid-dependent patients?
Topics: Adult; Female; Heroin; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Middle Aged | 2007 |
Medical examiners, coroners, and public health.
Topics: Coroners and Medical Examiners; Forensic Pathology; Heroin; History, 20th Century; Humans; Informati | 2007 |
Cerebral metabolism and mood in remitted opiate dependence.
Topics: Adult; Affect; Brain; Dysthymic Disorder; Female; Fluorodeoxyglucose F18; Humans; Male; Methadone; N | 2007 |
Variability in the evaluation and management of opiate-exposed newborns in Maryland.
Topics: Adolescent; Adult; Data Collection; Female; Humans; Infant, Newborn; Maryland; Methadone; Neonatal A | 2007 |
Re: Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users.
Topics: Buprenorphine; Canada; Cohort Studies; Delayed-Action Preparations; Drug Therapy, Combination; Human | 2007 |
Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
Topics: Australia; Buprenorphine; Drug Prescriptions; Drug Therapy; Episode of Care; Humans; Methadone; Nalt | 2007 |
Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Topics: Analgesics, Opioid; Harm Reduction; Health Promotion; Hepacivirus; Hepatitis C; Humans; Methadone; N | 2007 |
Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls.
Topics: Adult; Buprenorphine; Cognition; Cognition Disorders; Drug Therapy, Combination; Female; Humans; Mal | 2007 |
Test-retest reliability of self-reported drug treatment variables.
Topics: Ambulatory Care; Crime; Health Knowledge, Attitudes, Practice; Health Services Accessibility; HIV Se | 2007 |
Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services.
Topics: Adult; Ambulatory Care; Buprenorphine; Counseling; Delivery of Health Care, Integrated; Female; Heal | 2007 |
Optimizing opioid detoxification: rearranging deck chairs on the Titanic.
Topics: Aftercare; Buprenorphine; Cost Control; Follow-Up Studies; Humans; Length of Stay; Methadone; Narcot | 2007 |
Buprenorphine and methadone: a comparison of patient completion rates during inpatient detoxification.
Topics: Adolescent; Adult; Buprenorphine; Female; Follow-Up Studies; Hospitals, Teaching; Humans; Length of | 2007 |
Two-step tuberculin skin testing in drug users.
Topics: Adult; AIDS-Related Opportunistic Infections; Alcoholism; CD4 Lymphocyte Count; Comorbidity; Female; | 2007 |
Acute myocardial infarction after consumption of aspirin in a chronic methadone user patient.
Topics: Adult; Aspirin; Chronic Disease; Cyclooxygenase Inhibitors; Electrocardiography; Humans; Male; Metha | 2007 |
Body composition, gender, and illicit drug use in an urban cohort.
Topics: Baltimore; Black People; Body Composition; Body Mass Index; Cocaine-Related Disorders; Comorbidity; | 2007 |
Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Hydrocodone; Methadone; Opio | 2007 |
Diphenoxylate hydrochloride dependency.
Topics: Adult; Antidiarrheals; Clonidine; Diphenoxylate; Dose-Response Relationship, Drug; Drug Therapy, Com | 2007 |
Dentition of addiction in Queensland: poor dental status and major contributing drugs.
Topics: Adult; Age Factors; Alcohol-Related Disorders; Amphetamine-Related Disorders; Cross-Sectional Studie | 2007 |
Using population data to examine the prevalence and correlates of neonatal abstinence syndrome.
Topics: Adult; Cross-Sectional Studies; Databases, Factual; Female; Gravidity; Humans; Infant, Newborn; Inte | 2007 |
Attitudes and beliefs towards methadone maintenance treatment among Australian prison health staff.
Topics: Adult; Attitude of Health Personnel; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, P | 2007 |
Clinical update: codeine maintenance in opioid dependence.
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Codeine; Europe; Health Policy; Heroin; Humans; | 2007 |
Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
Topics: Adult; Alleles; Analgesics, Opioid; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Male; Methado | 2007 |
Drug misusers and incentives: Methadone works if used properly.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 2007 |
Pharmacotherapeutic environments for substance use disorders.
Topics: Ambulatory Care; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Family Pr | 2007 |
Methadone maintenance treatment (MMT) in general practice or in specialized centers: profile of patients in the Swiss Canton of Vaud.
Topics: Adult; AIDS Serodiagnosis; Antipsychotic Agents; Cocaine-Related Disorders; Cross-Sectional Studies; | 2007 |
Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance.
Topics: Adult; Body Mass Index; Choice Behavior; Dietary Carbohydrates; Energy Intake; Feeding Behavior; Fem | 2007 |
Rooming-in compared with standard care for newborns of mothers using methadone or heroin.
Topics: Adult; Breast Feeding; British Columbia; Child Custody; Cohort Studies; Comorbidity; Female; Heroin; | 2007 |
Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
Topics: Adult; Female; Humans; Length of Stay; Male; Methadone; Opioid-Related Disorders; Severity of Illnes | 2008 |
[Treatment of opiate addicts in general practice].
Topics: Buprenorphine; Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Ab | 2007 |
Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment.
Topics: Adult; Chi-Square Distribution; Cross-Sectional Studies; Depression; Female; Health Surveys; HIV Inf | 2007 |
Heroin-assisted treatment: no difference in treatment retention.
Topics: Drug Combinations; Heroin; Humans; Methadone; Opioid-Related Disorders; Patient Compliance; Treatmen | 2007 |
Necrolytic migratory erythema in an opiate-dependent patient.
Topics: Adolescent; Analgesics, Opioid; Diagnosis, Differential; Erythema; Female; Heroin; Humans; Methadone | 2008 |
Auditory target processing in methadone substituted opiate addicts: the effect of nicotine in controls.
Topics: Case-Control Studies; Event-Related Potentials, P300; Evoked Potentials, Auditory; Female; Ganglioni | 2007 |
NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats.
Topics: Animals; Behavior, Animal; Buprenorphine; Dizocilpine Maleate; Drug Tolerance; Excitatory Amino Acid | 2008 |
Diagnostic value of self-report of alcohol use in patients enrolled in a methadone maintenance treatment program (MMTP).
Topics: Alcoholism; Cohort Studies; Humans; Methadone; Narcotics; Opioid-Related Disorders; Retrospective St | 2007 |
Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.
Topics: Adult; Aged; Attitude of Health Personnel; Buprenorphine; Community Pharmacy Services; Delivery of H | 2008 |
[Chronic fatigue. IV--Assessment of a 40-year-old patient].
Topics: Adult; Anemia, Iron-Deficiency; Antiviral Agents; Diagnosis, Differential; Drug Therapy, Combination | 2007 |
QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Double-Blind Method; Ele | 2007 |
Outcomes of neonates conceived on methadone maintenance therapy.
Topics: Adult; Analgesics, Opioid; Birth Weight; Female; Follow-Up Studies; Gestational Age; Humans; Infant, | 2008 |
Patient versus therapist alliance: whose perception matters?
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; P | 2008 |
[End of opioid addicts' dancing around?].
Topics: Buprenorphine; Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2007 |
Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Topics: Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Finland; F | 2007 |
Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment.
Topics: Adult; Age Factors; Buprenorphine; Depression; Dose-Response Relationship, Drug; Erectile Dysfunctio | 2008 |
Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.
Topics: Adult; Buprenorphine; Cross-Sectional Studies; Drug Overdose; Female; Follow-Up Studies; Humans; Mal | 2008 |
Opioid dependent patients' experiences of and attitudes towards having their injecting sites examined.
Topics: Adult; Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Cross-Sectional Studies; Dru | 2009 |
The safety of methadone hydrochloride.
Topics: Animals; Humans; Methadone; Opioid-Related Disorders; Pain; Respiratory Insufficiency | 2008 |
BDNF variability in opioid addicts and response to methadone treatment: preliminary findings.
Topics: Adult; Aged; Analgesics, Opioid; Brain-Derived Neurotrophic Factor; Cohort Studies; Comorbidity; Dru | 2008 |
Drug abuse and responsible fathering: a comparative study of men enrolled in methadone maintenance treatment.
Topics: Adult; Child; Data Collection; Family Health; Father-Child Relations; Fathers; Humans; Male; Methado | 2008 |
High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction.
Topics: Adult; Analgesics, Opioid; Carcinoma, Squamous Cell; Female; Humans; Methadone; Opioid-Related Disor | 2008 |
Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention.
Topics: Buprenorphine; Health Services Accessibility; Human Rights; Humans; Methadone; Narcotics; Opioid-Rel | 2008 |
Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit.
Topics: Adolescent; Adult; Benzodiazepines; Cocaine-Related Disorders; Female; Heroin Dependence; Humans; In | 2008 |
Barriers to, and incentives for, the transfer of opioid-dependent people on methadone maintenance treatment from secondary care to primary health care.
Topics: Adult; Family Practice; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; | 2008 |
Onset of symptoms after methadone overdose.
Topics: Drug Overdose; Humans; Methadone; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorder | 2008 |
New hot topics sections: 1. China's new march forward in addiction treatment: methadone for the masses. 2. Issues in formulating DSM V.
Topics: Analgesics, Opioid; China; Diagnostic and Statistical Manual of Mental Disorders; HIV Infections; Hu | 2008 |
Methadone- and buprenorphine-related ambulance attendances: a population-based indicator of adverse events.
Topics: Adult; Ambulances; Buprenorphine; Databases, Factual; Drug Overdose; Emergency Medical Services; Fem | 2008 |
Evaluation of ongoing oxycodone abuse among methadone-maintained patients.
Topics: Adolescent; Adult; Cocaine-Related Disorders; Enzyme Multiplied Immunoassay Technique; Female; Human | 2008 |
Can urban methadone patients complete health utility assessments?
Topics: Adult; Attitude to Health; Female; Game Theory; Health Status; Hepatitis C, Chronic; Humans; Male; M | 2008 |
Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series.
Topics: Birth Weight; Buprenorphine; Female; Fetal Growth Retardation; Heroin Dependence; Humans; Infant Mor | 2008 |
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Community Pharm | 2008 |
An uncertain dominion: Irish psychiatry, methadone, and the treatment of opiate abuse.
Topics: Adolescent; Adult; Crime; Culture; Heroin Dependence; Humans; Illicit Drugs; Ireland; Male; Mental H | 2008 |
Bi-ventricular failure following methadone overdose.
Topics: Adult; Drug Overdose; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Ventricular Dysf | 2008 |
Methadone- and heroin-related deaths in Florida.
Topics: Analgesics, Opioid; Cause of Death; Coroners and Medical Examiners; Databases, Factual; Drug Overdos | 2008 |
Examining variation in treatment costs: a cost function for outpatient methadone treatment programs.
Topics: Ambulatory Care; Analgesics, Opioid; Costs and Cost Analysis; Health Care Costs; Health Care Surveys | 2008 |
Increased assessment and monitoring needed for patients receiving methadone.
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Pain | 2008 |
Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients.
Topics: Adult; Analgesics, Opioid; Behavior Therapy; Female; HIV Infections; Humans; Male; Methadone; Needle | 2008 |
Guanabenz acetate: a new, long-acting alpha-two adrenergic agonist for opioid withdrawal.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Female; Guanabenz; Guanidines; Heroin Dependence | 1984 |
Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare.
Topics: Adult; Aftercare; Attitude to Health; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; | 1984 |
A study of hospitalized surgical patients on methadone maintenance.
Topics: Adult; Analgesics, Opioid; Drug Interactions; Drug Tolerance; Female; Hospitalization; Humans; Male; | 1980 |
Anti-endorphin effects of methadone.
Topics: Endorphins; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
Clonidine and opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
The monitoring of saliva drug levels: psychiatric applications.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Male; Mental Disorders; Me | 1981 |
Acute phase of drug withdrawal management by clothiapine (Entumin): a pilot project.
Topics: Adolescent; Adult; Alcoholism; Dibenzothiazepines; Female; Humans; Lysergic Acid Diethylamide; Male; | 1980 |
Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention.
Topics: Adult; Anti-Anxiety Agents; Behavior Therapy; Benzodiazepines; Humans; Male; Methadone; Opioid-Relat | 1982 |
Methadone-induced hypoadrenalism.
Topics: Adrenal Insufficiency; Humans; Methadone; Opioid-Related Disorders | 1983 |
Outpatient treatment of prescription opioid dependence: comparison of two methods.
Topics: Adult; Aged; Ambulatory Care; Dextropropoxyphene; Drug Prescriptions; Female; Humans; Male; Methadon | 1983 |
(-)-alpha-Acetylmethadol for treatment of chronic pain patients who abuse opioids.
Topics: Adult; Analgesics, Opioid; Chronic Disease; Female; Humans; Male; Methadone; Methadyl Acetate; Middl | 1983 |
Contingency management of supplemental drug use during methadone maintenance treatment.
Topics: Alcohol Drinking; Anti-Anxiety Agents; Behavior Therapy; Benzodiazepines; Humans; Methadone; Narcoti | 1984 |
Progress report from the NIDA Addiction Research Center, Baltimore, Maryland.
Topics: Anti-Anxiety Agents; Buprenorphine; Double-Blind Method; Dronabinol; Drug Synergism; Heroin Dependen | 1984 |
Zinc tannate salts of heroin, LAAM and hydromorphone attenuate opiate withdrawal syndrome.
Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Codeine; Delayed-Action Preparations; Hero | 1980 |
Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications.
Topics: Adult; Developmental Disabilities; Female; Follow-Up Studies; Health Status; Humans; Infant; Infant, | 1981 |
Comparison of the effects of buprenorphine and methadone on opiate self-administration in primates.
Topics: Animals; Buprenorphine; Dose-Response Relationship, Drug; Eating; Heroin Dependence; Humans; Hydromo | 1982 |
Comparison of buprenorphine and methadone effects on opiate self-administration in primates.
Topics: Animals; Buprenorphine; Depression, Chemical; Disease Models, Animal; Feeding Behavior; Heroin; Huma | 1983 |
Intravenous hydromorphone: effects in opiate-free and methadone maintenance subjects.
Topics: Adult; Blood Pressure; Heart Rate; Humans; Hydromorphone; Injections, Intravenous; Male; Methadone; | 1983 |
Evidence for an endorphin dysfunction in methadone addicts: lack of ACTH response to naloxone.
Topics: Adrenocorticotropic Hormone; Endorphins; Humans; Male; Methadone; Naloxone; Opioid-Related Disorders | 1981 |
Methadone-induced endorphin dysfunction in addicts.
Topics: Adrenocorticotropic Hormone; Brain; Endorphins; Humans; Hydrocortisone; Male; Methadone; Naloxone; N | 1982 |
Use of naltrexone to extinguish opioid-conditioned responses.
Topics: Adult; Combined Modality Therapy; Conditioning, Classical; Extinction, Psychological; Heroin Depende | 1984 |
Initial opiate use and treatment outcome in methadone detoxification patients.
Topics: Humans; Hypnotics and Sedatives; Male; Methadone; Morphine; Narcotics; Opioid-Related Disorders; Soc | 1983 |
Motoric and attentional behavior in infants of methadone-maintained women.
Topics: Aging; Attention; Behavior; Female; Humans; Infant; Male; Methadone; Motor Activity; Opioid-Related | 1983 |
Addressing the diversion of take-home methadone: LAAM as the sole treatment choice for patients seeking maintenance therapy.
Topics: Ambulatory Care; Female; Humans; Male; Methadone; Methadyl Acetate; Opioid-Related Disorders; Sex Fa | 1983 |
Prevalence and implications of multi-drug abuse in a population of methadone-maintained women.
Topics: Amphetamine; Diazepam; Female; Heroin; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pregn | 1983 |
Recent advances in opiate detoxification: clonidine and lofexidine.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Pharmacological treatment of narcotic addiction (the eighth Nathan B. Eddy memorial award lecture).
Topics: Euphoria; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 1983 |
Methadone maintenance: an update.
Topics: Humans; Methadone; Methadyl Acetate; Opioid-Related Disorders | 1983 |
Behavioral intervention techniques in drug abuse treatment: summary of discussion.
Topics: Behavior Therapy; Combined Modality Therapy; Delivery of Health Care; Humans; Methadone; Opioid-Rela | 1984 |
Treatment of behavioral and psychiatric problems associated with opiate dependence.
Topics: Antisocial Personality Disorder; Behavior Therapy; Combined Modality Therapy; Humans; Mental Disorde | 1984 |
The role of behavioral contingency management in drug abuse treatment.
Topics: Behavior Therapy; Combined Modality Therapy; Conditioning, Operant; Humans; Methadone; Opioid-Relate | 1984 |
Problems in methadone treatment: the influence of reference groups.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Patient Compliance; Patient Dropou | 1984 |
Relationship of plasma level and pharmacological activity of methadone.
Topics: Animals; Biotransformation; Brain; Dose-Response Relationship, Drug; Humans; Metabolic Clearance Rat | 1984 |
Self-administration of clonidine and oxazepam by methadone detoxification patients.
Topics: Adult; Clonidine; Humans; Male; Methadone; Opioid-Related Disorders; Oxazepam; Psychomotor Performan | 1984 |
Perinatal addiction: the effects of maternal narcotic and nonnarcotic substance abuse on the fetus and neonate.
Topics: Adult; Arousal; Birth Weight; Female; Heroin Dependence; Humans; Infant, Newborn; Infant, Newborn, D | 1984 |
Comparison of a behavioral and a pharmacological treatment for reduction of illicit opiate use.
Topics: Adult; Behavior Therapy; Dose-Response Relationship, Drug; Humans; Male; Methadone; Narcotics; Opioi | 1984 |
Methadone detoxification: effects of methadone dose versus time in treatment.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; | 1984 |
Depressive symptoms in drug abuse treatment clients: correlates, treatment, and changes.
Topics: Adult; Age Factors; Alcoholism; Ambulatory Care; Depressive Disorder; Female; Heroin Dependence; Hum | 1984 |
Fetal breathing movements and the response to carbon dioxide in patients on methadone maintenance.
Topics: Carbon Dioxide; Female; Fetus; Humans; Methadone; Movement; Opioid-Related Disorders; Pregnancy; Pre | 1984 |
Psychotherapeutic approaches in the treatment of drug abuse.
Topics: Combined Modality Therapy; Follow-Up Studies; Humans; Individuality; Methadone; Opioid-Related Disor | 1984 |
Contingent methadone dose increases as a method for reducing illicit opiate use in detoxification patients.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; M | 1984 |
Outpatient methadone detoxification: effects of diazepam and doxepin as adjunct medications.
Topics: Adult; Diazepam; Doxepin; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1984 |
Effects of a dose increase on chronic opiate use during methadone detoxification.
Topics: Adult; Dose-Response Relationship, Drug; Humans; Male; Methadone; Narcotics; Opioid-Related Disorder | 1984 |
The index of choice: indications of methadone patients' selection of naltrexone treatment.
Topics: Adult; Attitude; Humans; Internal-External Control; Male; Methadone; Motivation; Naloxone; Naltrexon | 1984 |
Strategies to improve compliance with narcotic antagonists.
Topics: Combined Modality Therapy; Humans; Life Style; Methadone; Naloxone; Naltrexone; Opioid-Related Disor | 1984 |
Evaluation of a methadone rehabilitation program.
Topics: Adult; Crime; Employment; Female; Health Status; Humans; Male; Methadone; Middle Aged; Opioid-Relate | 1984 |
A comparative study of hypnotherapy and psychotherapy in the treatment of methadone addicts.
Topics: Adult; Female; Humans; Hypnosis; Male; Methadone; Opioid-Related Disorders; Psychotherapy | 1984 |
Ethical considerations in research on methadone in the treatment of schizophrenia.
Topics: Double-Blind Method; Ethics, Medical; Euphoria; Fluphenazine; Human Experimentation; Humans; Informe | 1984 |
The sequelea to addiction.
Topics: Female; Fetal Alcohol Spectrum Disorders; Fetal Diseases; Heroin; Humans; Methadone; Opioid-Related | 1983 |
Opiate withdrawal with clonidine.
Topics: Clonidine; Humans; Methadone; Nursing Assessment; Opioid-Related Disorders; Substance Withdrawal Syn | 1983 |
The clinical effectiveness of electrostimulation vs oral methadone in managing opiate withdrawal.
Topics: Adult; Electric Stimulation Therapy; Female; Humans; Male; Methadone; Opioid-Related Disorders; Subs | 1984 |
Lessons from a methadone treatment program in Laos, 1972-75.
Topics: Adult; Aged; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule | 1984 |
Agency differences in posttreatment outcomes: a follow-up of drug abuse treatment clients.
Topics: Alcoholism; Crime; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; Out | 1983 |
Locus of control and initiation of detoxification among male methadone maintenance patients.
Topics: Adolescent; Adult; Humans; Internal-External Control; Male; Methadone; Middle Aged; New York City; O | 1983 |
Methadone maintenance treatment: the other side of the coin.
Topics: Drug Tolerance; Euphoria; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders; Personalit | 1983 |
Methadone maintenance in the small community drug abuse clinic.
Topics: Adult; Community Mental Health Centers; Counseling; Female; Humans; Male; Methadone; North Carolina; | 1983 |
Alcoholism among narcotic addicts and patients on methadone maintenance.
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Methadone; Middle Aged; Opioi | 1983 |
Patient perspectives of opiate withdrawal.
Topics: Attitude of Health Personnel; Attitude to Health; Humans; Male; Methadone; Opioid-Related Disorders; | 1983 |
Loitering by patients on methadone maintenance: a perception or a problem.
Topics: Adult; Alcoholic Intoxication; Crime; Female; Humans; Male; Methadone; New York City; Opioid-Related | 1983 |
Coordination of services to methadone mothers and their addicted newborns.
Topics: Child Abuse; Child Welfare; Child, Preschool; Female; Hospital Departments; Humans; Infant; Infant, | 1983 |
Withdrawal tolerance and unidirectional non-cross-tolerance in narcotic pellet-implanted mice.
Topics: Animals; Dose-Response Relationship, Drug; Drug Implants; Drug Tolerance; Etorphine; Heroin; Humans; | 1983 |
Effect of methadone on TSH and thyroid hormone secretion.
Topics: Adult; Humans; Male; Methadone; Opioid-Related Disorders; Thyroid Hormones; Thyrotropin | 1984 |
Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal.
Topics: Adult; Humans; Luteinizing Hormone; Male; Methadone; Methadyl Acetate; Opioid-Related Disorders; Pit | 1984 |
The dexamethasone suppression test for major depression among opiate addicts.
Topics: Adult; Clonidine; Depressive Disorder; Dexamethasone; Heroin Dependence; Humans; Hydrocortisone; Met | 1984 |
Electroencephalographic and behavioral correlates of buprenorphine administration.
Topics: Adult; Behavior; Buprenorphine; Double-Blind Method; Drug Evaluation; Electroencephalography; Humans | 1984 |
Personality core dynamics and drug preference.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Oral Stage; Personali | 1984 |
[Ministerial order for the regulation of treatment with methadone].
Topics: Humans; Legislation, Drug; Methadone; Opioid-Related Disorders; Spain | 1984 |
[Clonidine in opiate withdrawal. I. Principles of application (author's transl)].
Topics: Clonidine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
[Behavior of prolactin in secondary amenorrhea in opioid toxico-dependence].
Topics: Adolescent; Adult; Amenorrhea; Female; Humans; Methadone; Opioid-Related Disorders; Prolactin; Thyro | 1982 |
Self-regulated opioid detoxification by humans: effects of methadone pretreatment.
Topics: Adult; Humans; Male; Methadone; Opioid-Related Disorders; Premedication; Self Administration; Substa | 1982 |
Comparison of three outpatient methadone detoxification procedures.
Topics: Adult; Humans; Male; Methadone; Methods; Opioid-Related Disorders; Time Factors | 1982 |
Opiate detoxification using lofexidine.
Topics: Antihypertensive Agents; Clonidine; Humans; Male; Methadone; Opioid-Related Disorders | 1982 |
Lofexidine blocks acute opiate withdrawal.
Topics: Antihypertensive Agents; Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawa | 1982 |
Methodology for assessing agents that suppress methadone withdrawal: a study of baclofen.
Topics: Adult; Baclofen; Double-Blind Method; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders | 1982 |
Urine monitoring of methadone maintenance clients: does it prevent illicit drug use?
Topics: Adult; Female; Humans; Illicit Drugs; Male; Methadone; Opioid-Related Disorders | 1982 |
Contingent reinforcement of benzodiazepine-free urines from methadone maintenance patients.
Topics: Adult; Benzodiazepines; Humans; Male; Methadone; Opioid-Related Disorders | 1982 |
Patient self-adjustment of methadone maintenance dose.
Topics: Humans; Methadone; Opioid-Related Disorders; Self Administration | 1982 |
A comparison of urine collection schedules with different predictability in a methadone clinic.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Specimen Handling; Urine | 1982 |
LAAM instead of take-home methadone.
Topics: Humans; Methadone; Methadyl Acetate; Opioid-Related Disorders | 1982 |
Clonidine in opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Fetal and postnatal growth of children born to narcotic-dependent women.
Topics: Body Height; Female; Fetus; Growth; Heroin Dependence; Humans; Infant, Newborn; Longitudinal Studies | 1983 |
Identifying alcoholism in treated opiate addicts.
Topics: Alcoholism; Humans; Methadone; Opioid-Related Disorders; Personality Inventory; Psychiatric Status R | 1983 |
1983 perspectives on the pharmacotherapy of opiate addiction.
Topics: England; Humans; Methadone; Naloxone; Opioid-Related Disorders; Outcome and Process Assessment, Heal | 1983 |
The case of the Swedish methadone maintenance treatment programme.
Topics: Adult; Humans; Methadone; Opioid-Related Disorders; Rehabilitation Centers; Sweden | 1983 |
[Condition of 89 newborn infants of drug-addicted mothers].
Topics: Abnormalities, Drug-Induced; Adult; Apgar Score; Female; Heroin Dependence; Humans; Infant, Low Birt | 1983 |
Pentazocine and tripelennamine ('T's and blue's'): effects on the fetus and neonate.
Topics: Adult; Female; Fetus; Humans; Infant, Newborn; Infant, Newborn, Diseases; Methadone; Opioid-Related | 1983 |
Investigation of 89 children born by drug-dependent mothers. I. Neonatal course.
Topics: Adult; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infant, Small | 1983 |
Investigation of 89 children born by drug-dependent mothers. II. Follow-up 1-10 years after birth.
Topics: Adult; Child; Child Behavior Disorders; Child, Institutionalized; Child, Preschool; Female; Follow-U | 1983 |
When a narcotic addict is hospitalized.
Topics: Heroin Dependence; Hospitalization; Humans; Inactivation, Metabolic; Methadone; Opioid-Related Disor | 1980 |
Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study.
Topics: Adult; Clonidine; Double-Blind Method; Female; Humans; Male; Methadone; Opioid-Related Disorders; Su | 1980 |
Changes in the dose levels of opiates used by addicts admitted for withdrawal between 1969-1979.
Topics: Dose-Response Relationship, Drug; Humans; Methadone; Opioid-Related Disorders; United Kingdom | 1981 |
Opiate withdrawal syndrome: acute and protracted aspects.
Topics: Humans; Methadone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal S | 1981 |
Long-term outcomes after termination from methadone maintenance treatment.
Topics: Adult; Alcoholism; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Male; Methadone; | 1981 |
Opiate addiction and alcoholism: the feasibility of combined treatment approaches.
Topics: Alcoholism; Feasibility Studies; Humans; Methadone; Opioid-Related Disorders; Random Allocation | 1981 |
Psychotherapy for opiate addiction: some preliminary results.
Topics: Adolescent; Adult; Behavior Therapy; Counseling; Evaluation Studies as Topic; Humans; Methadone; Mid | 1981 |
Assessment of an urgent admission procedure to an in-patient drug dependence unit.
Topics: Emergencies; Humans; Methadone; Opioid-Related Disorders; Patient Admission; Substance-Related Disor | 1982 |
Statement and resolution regarding methadone maintenance treatment. Subcommittee on Drug Abuse, Committee on Public Health of the New York Academy of Medicine.
Topics: Heroin Dependence; Humans; Methadone; New York; Opioid-Related Disorders; United States | 1982 |
The use of antidepressants with methadone in depressed maintenance patients.
Topics: Depressive Disorder; Doxepin; Female; Humans; Imipramine; Male; Methadone; Middle Aged; Opioid-Relat | 1982 |
The interaction of a treatment program using opiates for mental illness and an addiction treatment program.
Topics: Humans; Methadone; Opioid-Related Disorders; Patient Compliance; Schizophrenia | 1982 |
Endorphin levels in opioid-dependent human subjects: a longitudinal study.
Topics: Adult; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Subst | 1982 |
Six-year follow-up of opioid addicts after admission to treatment.
Topics: Adult; Alcoholism; Ambulatory Care; Community Mental Health Services; Female; Follow-Up Studies; Her | 1982 |
Effect of prior narcotic addiction on response to treatment of alcoholism.
Topics: Adolescent; Adult; Aged; Aging; Alcoholism; Female; Heroin Dependence; Humans; Male; Marriage; Metha | 1980 |
Sounding Board. Performance-based rating of methadone maintenance programs.
Topics: Community Health Services; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders; Outcome a | 1982 |
Duration of thrombocytosis in infants of polydrug (including methadone) users.
Topics: Female; Humans; Infant; Infant, Newborn; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy C | 1982 |
Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-R | 1982 |
Heterogeneity of psychiatric diagnosis in treated opiate addicts.
Topics: Adult; Alcoholism; Anxiety Disorders; Depressive Disorder; Female; Humans; Male; Mental Disorders; M | 1982 |
Ritalin: consequences of abuse in a clinical population.
Topics: Adult; Female; Humans; Injections, Intravenous; Male; Methadone; Methylphenidate; Opioid-Related Dis | 1982 |
Outpatient opiate detoxification with clonidine.
Topics: Ambulatory Care; Clonidine; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Human | 1982 |
Addict death rates during a four-year posttreatment follow-up.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; United States; | 1982 |
The significance of alcoholism in treated opiate addicts.
Topics: Adult; Age Factors; Alcoholism; Female; Heroin Dependence; Humans; Life Change Events; Longitudinal | 1982 |
Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.
Topics: Adaptation, Physiological; Adult; Biological Availability; Drug Tolerance; Humans; Kinetics; Methado | 1982 |
Retention rates among New York City methadone patients: a response to Bayer and Koenigsberg.
Topics: Humans; Methadone; New York City; Opioid-Related Disorders; Patient Dropouts | 1982 |
Residence relocation inhibits opioid dependence.
Topics: Adult; Conditioning, Psychological; Heroin Dependence; Humans; Imitative Behavior; Longitudinal Stud | 1982 |
A descriptive overview of treatment modalities in federally funded drug abuse treatment programs.
Topics: Adult; Age Factors; Crime; Educational Status; Employment; Female; Financing, Government; Humans; In | 1982 |
Infants born to narcotic-addicted mothers.
Topics: Child Development; Female; Heroin; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Metha | 1982 |
The response of out-patient opiate addicts to the provision of a temporary increase in their prescribed drugs.
Topics: Adult; Alcohol Drinking; Employment; Female; Heroin; Heroin Dependence; Humans; Illicit Drugs; Male; | 1982 |
Relapse in opiate addicts: a behavioral analysis.
Topics: Adult; Cues; Humans; Interpersonal Relations; Male; Methadone; Motivation; Opioid-Related Disorders; | 1982 |
[Experience and results of the Forensic Toxicology Chemical Laboratory of the Institute of Legal Medicine in Florence].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1982 |
Suppression of withdrawal jumping: comparison of narcotic tolerance and dependence.
Topics: Animals; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Male; Methadone; Mice; Mice, Inbr | 1980 |
Narcotic abstinence in dependent rats: EEG and behavioral correlates.
Topics: Animals; Behavior, Animal; Electroencephalography; Female; Humans; Methadone; Methadyl Acetate; Morp | 1980 |
Opiate withdrawal in utero increases neonatal morbidity in the rat.
Topics: Animals; Drug Tolerance; Embryo Implantation; Female; Fetal Death; Humans; Litter Size; Methadone; M | 1981 |
Prenatal withdrawal from opiates interferes with hatching of otherwise viable chick fetuses.
Topics: Animals; Chick Embryo; Humans; Methadone; Methadyl Acetate; Naloxone; Opioid-Related Disorders; Subs | 1981 |
Outcome of pregnancy in rats chronically exposed to 1-alpha-acetylmethadol (LAAM).
Topics: Animals; Animals, Newborn; Birth Weight; Body Weight; Female; Humans; Methadone; Methadyl Acetate; O | 1981 |
Differential electroencephalographic and behavioral cross tolerance to morphine and methadone in the l-alpha-acetylmethadol (LAAM)-maintained rat.
Topics: Animals; Behavior, Animal; Drug Tolerance; Electroencephalography; Female; Humans; Methadone; Methad | 1982 |
An innovative approach to methadone detoxification.
Topics: Fantasy; Heroin Dependence; Humans; Massage; Methadone; Milieu Therapy; Opioid-Related Disorders; Ps | 1980 |
Are addicts' self-reports to be trusted?
Topics: Humans; Methadone; Opioid-Related Disorders; Self Disclosure; Truth Disclosure | 1980 |
Success and failure in rehabilitation: the case of methadone maintenance.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Outcome and Process Assessment, He | 1981 |
[Methadone maintenance treatment for narcotic addicts. Experience of the C.L.S.C. Center-South].
Topics: Adolescent; Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders | 1981 |
Pretreatment source of income and response to methadone maintenance: a follow-up study.
Topics: Adult; Crime; Employment; Family; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorde | 1981 |
[Various therapeutic methods in the treatment of drug-dependent patients].
Topics: Germany, West; Humans; Methadone; Opioid-Related Disorders; Self-Help Groups; Substance-Related Diso | 1981 |
Clonidine for narcotic withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1981 |
Long-term follow-up of clients of high- and low-dose methadone programs.
Topics: Age Factors; Alcoholism; Costs and Cost Analysis; Crime; Follow-Up Studies; Humans; Methadone; Opioi | 1981 |
The effects of community structure on during-treatment outcomes of methadone maintenance programs.
Topics: Adolescent; Adult; Anomie; Crime; Ethnicity; Female; Humans; Male; Methadone; Opioid-Related Disorde | 1981 |
Reduction of the frequency of drug use of veterans Enrolled in an outpatient methadone maintenance treatment program.
Topics: Adult; Ambulatory Care; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Outcome and Pr | 1981 |
Women in drug abuse treatment programs: factors that influence retention at very early and later stages in two treatment modalities. A summary.
Topics: Adult; Female; Humans; Length of Stay; Methadone; Opioid-Related Disorders; Parents; Patient Accepta | 1981 |
The clinical use of clonidine in outpatient detoxification from opiates.
Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; Naltrexone; Opioi | 1981 |
Effect of methadone dosage on clonidine detoxification efficacy.
Topics: Clonidine; Double-Blind Method; Humans; Male; Methadone; Opioid-Related Disorders; Substance Withdra | 1980 |
Extraneous drug use in methadone-supported patients.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Substance-Related Disorders | 1980 |
Strength of drug habits: for heroin, morphine, methadone, alcohol, barbiturates, pentobarbital, benzedrine, cocaine, and marijuana.
Topics: Adult; Alcoholism; Amphetamines; Barbiturates; Cannabis; Cocaine; Heroin Dependence; Humans; Male; M | 1980 |
Follow-up of former clients of a large multimodality drug treatment program.
Topics: Adult; Crime; District of Columbia; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Her | 1980 |
Narcotics addiction treatment: behavioral methods concurrent with methadone maintenance.
Topics: Adult; Behavior Therapy; Humans; Illicit Drugs; Male; Methadone; Opioid-Related Disorders; Outcome a | 1980 |
Group therapy with methadone-maintained patients: structural problems and solutions.
Topics: Humans; Methadone; Opioid-Related Disorders; Psychotherapy, Group | 1980 |
Risk for alcoholism and methadone treatment. A longitudinal study.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Male; Methadone; Opioid-Related Disorders | 1980 |
DSM-III personality type and dose levels in methadone maintenance patients.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Male; Manuals as Topic | 1980 |
Clonidine for opiate detoxification: outpatient clinical trials.
Topics: Ambulatory Care; Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; | 1980 |
A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction.
Topics: Adult; Humans; Male; Methadone; Methadyl Acetate; Opioid-Related Disorders; Outcome and Process Asse | 1981 |
Treatment of iatrogenic drug dependence in the general hospital.
Topics: Aged; Female; Humans; Iatrogenic Disease; Inactivation, Metabolic; Male; Methadone; Middle Aged; Opi | 1980 |
Effects of psychiatric care for dual diagnosis patients treated in a drug dependence clinic.
Topics: Adult; Cocaine; Combined Modality Therapy; Diagnosis, Dual (Psychiatry); Humans; Illicit Drugs; Male | 1995 |
Suicidality in a sample of methadone maintenance clients.
Topics: Adult; Anxiety Disorders; Comorbidity; Depressive Disorder; Female; Humans; Male; Methadone; Opioid- | 1995 |
Conditioned responses to drug-related stimuli: is context crucial?
Topics: Adult; Conditioning, Classical; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Recurr | 1995 |
Psychological problems and client engagement in methadone treatment.
Topics: Adult; Alcohol Drinking; Comorbidity; Counseling; Female; Humans; Male; Mental Disorders; Methadone; | 1995 |
Methadone transition treatment: a treatment model for 180-day methadone detoxification.
Topics: Adult; Aftercare; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration S | 1995 |
Pilot study of behavioral and emotional disturbances in the high-risk children of parents with opioid dependence.
Topics: Adolescent; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior | 1995 |
Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Regression Analysis; Substance Wit | 1995 |
Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration response curves.
Topics: Adult; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 1995 |
[Abuse--of hospital services too].
Topics: Aged; Denmark; Drug Prescriptions; Humans; Male; Methadone; Munchausen Syndrome; Opioid-Related Diso | 1995 |
Gender differences in diagnosing antisocial personality disorder in methadone patients.
Topics: Antisocial Personality Disorder; Comorbidity; Female; Humans; Male; Methadone; Opioid-Related Disord | 1995 |
[Methadone treatment of narcotic addicts].
Topics: Humans; Methadone; Opioid-Related Disorders | 1995 |
[Results of urinary control analyses of narcotic addicts on methadone therapy. An evaluation in the county of ]rhus in 1993].
Topics: Adult; Amphetamine; Benzodiazepines; Cannabinoids; Denmark; Evaluation Studies as Topic; Female; Hum | 1995 |
Comparison of MMPI-2 and MMPI clinical scales and high-point scores among methadone maintenance clients.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; MMPI; Opioid-Related Disorders; Personality Dis | 1995 |
Fluoxetine treatment for dually diagnosed methadone maintained opioid addicts: a pilot study.
Topics: Adult; Cocaine; Combined Modality Therapy; Comorbidity; Depressive Disorder; Diagnosis, Dual (Psychi | 1994 |
Methadone maintenance treatment: coming of age in New Zealand.
Topics: Humans; Methadone; New Zealand; Opioid-Related Disorders; Program Evaluation | 1995 |
The impact on behavior of notifying methadone patients of their HIV serostatus.
Topics: Adult; Attitude to Health; Cocaine; Demography; Female; HIV Seronegativity; HIV Seropositivity; Huma | 1995 |
Another wall that crumbled--methadone maintenance treatment in Germany.
Topics: Acquired Immunodeficiency Syndrome; Crime; Germany; Health Policy; Humans; Methadone; Opioid-Related | 1995 |
Methadone maintenance treatment.
Topics: Humans; Methadone; Opioid-Related Disorders | 1995 |
Drug misusers in police custody.
Topics: England; Humans; Methadone; Opioid-Related Disorders; Police | 1994 |
[Methadone substitution in national public health care in Germany--patients, indications, physicians. Results of a survey of public health service facilities].
Topics: Ambulatory Care; Comorbidity; Cross-Sectional Studies; Germany; Humans; Incidence; Methadone; Nation | 1994 |
Suspected determinants of enrollment into detoxification and methadone maintenance treatment among injecting drug users.
Topics: Adolescent; Adult; Amphetamine; Baltimore; Cocaine; Cross-Sectional Studies; Female; Follow-Up Studi | 1994 |
Methadone withdrawal psychosis.
Topics: Adult; Female; Follow-Up Studies; Haloperidol; Humans; Male; Methadone; Middle Aged; Opioid-Related | 1995 |
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Topics: Adult; Buprenorphine; Humans; Male; Methadone; Middle Aged; Naloxone; Opioid-Related Disorders; Psyc | 1995 |
The effects of HIV infection on the development of methadone maintenance treatment in Spain.
Topics: HIV Infections; HIV Seroprevalence; Humans; Methadone; Opioid-Related Disorders; Spain; Substance Ab | 1994 |
Methadone maintenance treatment. Glasgow has an innovative scheme for encouraging GPs to manage drug misusers.
Topics: Family Practice; Humans; Methadone; Opioid-Related Disorders; Scotland | 1995 |
[Buprenorphine in the treatment of opiate dependence].
Topics: Administration, Sublingual; Buprenorphine; Drug Evaluation; France; Heroin Dependence; Humans; Metha | 1994 |
[Report on prescriptions of methadone at the Espace Murger, Hôpital F.-Widal (1984-1993)].
Topics: Adult; Benzodiazepines; Drug Prescriptions; Female; Heroin Dependence; Humans; Male; Methadone; Midd | 1994 |
[Treatment of heroin addiction by methadone. Specialized care].
Topics: Antidepressive Agents; Antipsychotic Agents; France; Heroin Dependence; Humans; Mental Disorders; Me | 1994 |
[Substitution treatment of drug-dependent patients].
Topics: Codeine; Drug and Narcotic Control; Germany; Health Policy; Heroin Dependence; Humans; Methadone; Na | 1995 |
The drugs in pregnancy service.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Behavior; HIV Infections; Humans; Infant, Newborn | 1995 |
[Long-term treatment with opioids and cognition disorders].
Topics: Analgesics, Opioid; Cognition Disorders; Humans; Methadone; Narcotics; Opioid-Related Disorders; Tim | 1994 |
[Diversified prescription of narcotics to heroin addicts. Basis, design, research plan].
Topics: Clinical Trials as Topic; Cocaine; Drug Prescriptions; Female; Heroin; Humans; Male; Methadone; Morp | 1994 |
Alcohol-abusing methadone patients.
Topics: Alcoholism; Combined Modality Therapy; Comorbidity; Disulfiram; Humans; Methadone; Opioid-Related Di | 1994 |
Condom use rates for specific sexual behaviors among opioid abusers entering treatment.
Topics: Adult; Ambulatory Care; Baltimore; Condoms; Cross-Sectional Studies; Female; Health Knowledge, Attit | 1994 |
Reporting of HIV risk behaviors by injection drug using heterosexual couples in methadone maintenance.
Topics: Adult; Condoms; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Methado | 1994 |
Plasma methadone monitoring with methadone maintenance treatment.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Methadone; Opioid-Related Di | 1994 |
Methadone maintenance outcome as a function of detoxification phobia.
Topics: Adult; Age Factors; Aged; Anxiety Disorders; Attitude to Health; Comorbidity; Depressive Disorder; E | 1994 |
Psychiatric distress in antisocial drug abusers: relation to other personality disorders.
Topics: Adult; Antisocial Personality Disorder; Anxiety Disorders; Combined Modality Therapy; Comorbidity; D | 1994 |
Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation.
Topics: Adaptation, Psychological; Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; O | 1994 |
Medical mismanagement in public methadone programs.
Topics: Adult; Community Mental Health Services; Dose-Response Relationship, Drug; Heroin Dependence; Humans | 1994 |
Predictors of outcome in methadone programs: effect of HIV counseling and testing.
Topics: Adult; AIDS Serodiagnosis; Connecticut; Female; HIV Infections; Humans; Male; Methadone; Opioid-Rela | 1994 |
Medical mismanagement in public methadone programs.
Topics: Attitude of Health Personnel; Community Mental Health Services; Humans; Methadone; Opioid-Related Di | 1994 |
Children of substance abusers: the life experiences of children of opiate addicts in methadone maintenance.
Topics: Adolescent; Adult; Antisocial Personality Disorder; Bipolar Disorder; Child; Child Abuse; Child Abus | 1994 |
Treatment process and relapse to opioid use during methadone maintenance.
Topics: Adult; Comorbidity; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; Ou | 1994 |
Development of the Leeds Dependence Questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package.
Topics: Adult; Alcoholism; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Pilot Pro | 1994 |
[Methadone substitution treatment. Results of an evaluation of 3 years implementation in an Austrian province].
Topics: Adult; Austria; Crime; Dose-Response Relationship, Drug; Female; Follow-Up Studies; HIV Infections; | 1994 |
Can you trust patient self-reports of drug use during treatment?
Topics: Adult; Cocaine; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-R | 1994 |
Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study.
Topics: Adolescent; Adult; Case-Control Studies; Cohort Studies; Dose-Response Relationship, Drug; Drug Admi | 1994 |
Relationships of personality disorders with problem severity in methadone patients.
Topics: Adolescent; Adult; Antisocial Personality Disorder; Comorbidity; Humans; Male; Methadone; Middle Age | 1994 |
Methadone therapy.
Topics: HIV Infections; Humans; Methadone; Opioid-Related Disorders; Pain | 1993 |
Benzodiazepine and sedative use/abuse by methadone maintenance clients.
Topics: Alprazolam; Anti-Anxiety Agents; Baltimore; Cross-Sectional Studies; Humans; Hypnotics and Sedatives | 1993 |
Descriptive analysis of cocaine use of methadone patients.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Baltimore; Benzodiazepines; Cocaine; Cross-Sectional Studies | 1993 |
A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients.
Topics: Adult; AIDS Dementia Complex; Ambulatory Care; Female; Follow-Up Studies; HIV Seronegativity; HIV Se | 1993 |
[Withdrawal treatment of drug dependent patients with the aim of achieving abstinence].
Topics: Adolescent; Adult; Ambulatory Care; Female; Heroin Dependence; Humans; Illicit Drugs; Length of Stay | 1994 |
[Substitution as a possibility for the treatment of opiate dependent patients].
Topics: Adult; Ambulatory Care; Female; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Opioid-R | 1994 |
Conversation with Vincent Dole.
Topics: Dose-Response Relationship, Drug; Heroin Dependence; Humans; Long-Term Care; Methadone; New York Cit | 1994 |
Distinctive features of the methadone treatment program of Victoria, Australia.
Topics: Cross-Cultural Comparison; Family Practice; Humans; Methadone; Opioid-Related Disorders; Patient Car | 1994 |
Probable metabolic interaction between methadone and fluvoxamine in addict patients.
Topics: Adult; Depressive Disorder; Drug Interactions; Female; Fluvoxamine; Humans; Male; Methadone; Opioid- | 1994 |
Predictors of injecting and injecting risk-taking behaviour among methadone-maintenance clients.
Topics: Adolescent; Adult; Female; Health Behavior; Heroin Dependence; HIV Infections; Humans; Male; Methado | 1994 |
Out-patient medical care in Edinburgh for IDU-related HIV.
Topics: Ambulatory Care; Appointments and Schedules; Combined Modality Therapy; Health Behavior; HIV Infecti | 1994 |
Review of the opiate dependence rehabilitation program in a rural community.
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Rural Health; Victori | 1994 |
Social networks and methadone treatment outcome: the costs and benefits of social ties.
Topics: Adult; Cost of Illness; Female; Humans; Illicit Drugs; Male; Methadone; Middle Aged; Opioid-Related | 1993 |
Cocaine abuse among methadone-maintained patients.
Topics: Buprenorphine; Cocaine; Comorbidity; Double-Blind Method; Humans; Methadone; Opioid-Related Disorder | 1993 |
Perfectionism in the therapeutic appraisal of methadone maintenance.
Topics: Evaluation Studies as Topic; Female; Humans; Male; Methadone; Opioid-Related Disorders; Research Des | 1993 |
Harm reduction--a common cause.
Topics: Cost of Illness; Health Priorities; Health Services Accessibility; Health Services Needs and Demand; | 1993 |
Study of 45 pregnant opiate addicts in Dublin.
Topics: Adult; Child Welfare; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Ireland; Life Styl | 1993 |
Poppy tea dependence.
Topics: Adult; Codeine; Dose-Response Relationship, Drug; Humans; Male; Methadone; Opioid-Related Disorders; | 1993 |
Risk dimensions of HIV-tested substance users.
Topics: Adult; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV Seroprevalence; Humans; Ma | 1993 |
Addiction Severity Index scores of four racial/ethnic and gender groups of methadone maintenance patients.
Topics: Adult; Alcoholism; Black or African American; Cocaine; Comorbidity; Cross-Cultural Comparison; Cross | 1993 |
A 24-year follow-up of California narcotics addicts.
Topics: Adult; California; Cause of Death; Drug Overdose; Employment; Follow-Up Studies; Health Status; Huma | 1993 |
[Fatal poisonings among drug addicts in Funen and South Jutland during the period 1989-1991].
Topics: Adolescent; Adult; Cause of Death; Denmark; Drug Overdose; Female; Humans; Male; Methadone; Middle A | 1993 |
[Methadone and drug addicts].
Topics: Adolescent; Adult; Cause of Death; Denmark; Drug Overdose; Female; Humans; Male; Methadone; Middle A | 1993 |
Correlates of alcohol use among methadone patients.
Topics: Adult; Alcoholism; Black or African American; Cocaine; Cohort Studies; Comorbidity; Cross-Sectional | 1993 |
The prescription of methadone for opiate dependence in Australia, 1985-1991.
Topics: Adolescent; Adult; Australia; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Methadone; | 1993 |
Serum methadone concentrations.
Topics: Humans; Methadone; Opioid-Related Disorders | 1993 |
The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity.
Topics: Ambulatory Care; Crime; Follow-Up Studies; Humans; Methadone; Opioid-Related Disorders; Prospective | 1993 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anorexia; Dronabinol; Humans; Methadone; Mollusca; Opio | 1993 |
Legality of methadone treatment.
Topics: Humans; Methadone; Opioid-Related Disorders; Primary Health Care; Substance Abuse Treatment Centers | 1993 |
The relationship of mean daily blood alcohol levels to admission MAST, clinic absenteeism and depression in alcoholic methadone patients.
Topics: Adult; Alcoholism; Breath Tests; Comorbidity; Depression; Ethanol; Female; Humans; Male; Methadone; | 1993 |
Organic mood syndrome associated with detoxification from methadone maintenance.
Topics: Adult; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Mo | 1993 |
Steady-state pharmacokinetics of methadone in opioid addicts.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Mal | 1993 |
Methadone maintenance. New research on a controversial treatment.
Topics: Humans; Methadone; Opioid-Related Disorders | 1993 |
Methadone dosage, cocaine and opiate abuse.
Topics: Cocaine; Comorbidity; Humans; Methadone; Opioid-Related Disorders; Substance Abuse, Intravenous; Sub | 1993 |
[Substitute drug treatments with methadone].
Topics: Adult; Ambulatory Care; Female; Follow-Up Studies; Hospitalization; Humans; Length of Stay; Male; Me | 1993 |
[EMG abnormalities in REM sleep of addicted patients].
Topics: Adolescent; Adult; Alcohol Withdrawal Delirium; Alcoholism; Electromyography; Female; Humans; Male; | 1993 |
Correlates of heavy drinking and alcohol related problems among men and women in drug treatment programs.
Topics: Adult; Alcohol Drinking; Alcoholism; Comorbidity; Female; Humans; Male; Methadone; Opioid-Related Di | 1993 |
Methadone maintenance and recovery.
Topics: Follow-Up Studies; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders; Outcome and Proce | 1993 |
Role reversals in families of substance misusers: a transgenerational phenomenon.
Topics: Adult; Aged; Alcoholism; Child of Impaired Parents; Cocaine; Family Therapy; Female; Gender Identity | 1993 |
Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Fluoxetine; Humans; Male; Meth | 1995 |
Personality disorders and treatment outcome in methadone maintenance patients.
Topics: Adult; Antisocial Personality Disorder; Comorbidity; Follow-Up Studies; Humans; Male; Methadone; Mid | 1996 |
[Ethical questions about methadone].
Topics: Chemical Engineering; Ethics, Professional; Humans; Methadone; Opioid-Related Disorders | 1995 |
Perception of AIDS risk and high-risk behaviors in African-American methadone-dependent women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Black or African American; Female; Health Knowledge, Atti | 1995 |
[Methadone substitution in public health management--results of a random day study sample].
Topics: Costs and Cost Analysis; Drug Utilization; Germany; Humans; Methadone; National Health Programs; Opi | 1996 |
Methadone treatment for opiate addicts.
Topics: Ambulatory Care; Humans; Methadone; Opioid-Related Disorders | 1996 |
Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies in England and Wales.
Topics: Administration, Oral; Ambulatory Care; Drug Prescriptions; Drug Utilization; England; Family Practic | 1996 |
Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antitubercular Agents; Comorbidity; Female; Humans; Male; | 1996 |
Problem drug users.
Topics: Australia; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1996 |
Enhancing the effectiveness of methadone using psychotherapeutic interventions.
Topics: Combined Modality Therapy; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Psy | 1995 |
Can psychotherapy rescue naltrexone treatment of opioid addiction?
Topics: Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Re | 1995 |
Management of opiate dependence.
Topics: Family Practice; Humans; Methadone; Opioid-Related Disorders; Physician-Patient Relations | 1996 |
Management of opiate dependence.
Topics: Attitude of Health Personnel; Humans; Methadone; Opioid-Related Disorders | 1995 |
Inadequate treatment of opioid dependence due to society's attitudes and beliefs.
Topics: Analgesics, Opioid; Behavior Therapy; Health Knowledge, Attitudes, Practice; Humans; Methadone; Opio | 1996 |
Buprenorphine for depression: the un-adoptable orphan.
Topics: Administration, Intranasal; Administration, Sublingual; Antidepressive Agents; Buprenorphine; Depres | 1996 |
Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance.
Topics: Adolescent; Adult; Cocaine; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; HIV In | 1996 |
Video techniques with chemically-dependent patients.
Topics: Adult; Affect; Cocaine; Cognitive Behavioral Therapy; Female; Humans; Male; Methadone; Middle Aged; | 1996 |
[Depressive disorders in management of drug dependent patients. Methadone maintenance].
Topics: Adult; Antidepressive Agents; Comorbidity; Depressive Disorder; Drug Interactions; Drug Therapy, Com | 1995 |
Treatment outcomes for methadone clients receiving lump-sum payments at initiation of disability benefits.
Topics: Adult; Ambulatory Care; Cocaine; Disability Evaluation; Eligibility Determination; Female; Financial | 1996 |
Craving despite extremely high methadone dosage.
Topics: Dose-Response Relationship, Drug; Humans; Male; Metabolic Clearance Rate; Methadone; Middle Aged; Mo | 1996 |
Methadone maintenance and tuberculosis treatment.
Topics: Adult; Antibiotics, Antitubercular; Female; Humans; Methadone; Opioid-Related Disorders; Rifampin; S | 1996 |
Does HIV test result influence methadone maintenance treatment retention?
Topics: Adult; AIDS Serodiagnosis; Feasibility Studies; Female; HIV Seronegativity; HIV Seropositivity; Huma | 1996 |
Patient retention in mobile and fixed-site methadone maintenance treatment.
Topics: Adult; Baltimore; Cocaine; Cross-Sectional Studies; Female; Heroin Dependence; Humans; Male; Methado | 1996 |
Concurrent validity of cocaine and sedative dependence diagnoses in opioid-dependent outpatients.
Topics: Adult; Ambulatory Care; Anti-Anxiety Agents; Benzodiazepines; Cocaine; Comorbidity; Diagnosis, Dual | 1996 |
Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease.
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Diagnosis, D | 1996 |
Conversation with John Ball.
Topics: Follow-Up Studies; Forecasting; Humans; Methadone; Narcotics; Opioid-Related Disorders; Outcome Asse | 1996 |
Effect of methadone on the biophysical profile.
Topics: Adult; Circadian Rhythm; Female; Fetal Movement; Heart Rate, Fetal; Humans; Methadone; Opioid-Relate | 1996 |
Response to methadone maintenance and counseling in antisocial patients with and without major depression.
Topics: Antisocial Personality Disorder; Comorbidity; Counseling; Depressive Disorder; Follow-Up Studies; Ho | 1996 |
Clomethiazole treatment of alcohol withdrawal delirium in a patient under methadone maintenance.
Topics: Adult; Alcohol Withdrawal Delirium; Chlormethiazole; Drug Interactions; Humans; Hypnotics and Sedati | 1996 |
Psychopathology and HIV risk behaviors among injection drug users in and out of treatment.
Topics: Adolescent; Adult; Antisocial Personality Disorder; Comorbidity; Female; Health Knowledge, Attitudes | 1996 |
Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users.
Topics: Adult; AIDS-Related Opportunistic Infections; Dose-Response Relationship, Drug; Drug Interactions; D | 1996 |
The induction and quantitation of methadone dependence in the rat.
Topics: Animals; Dose-Response Relationship, Drug; Drinking; Emulsions; Female; Methadone; Naloxone; Opioid- | 1996 |
Methadone treatment. Only half of patients store methadone in safe place.
Topics: Drug Storage; Female; Humans; Male; Methadone; Opioid-Related Disorders | 1996 |
The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1996 |
Nicotine dependence and depression among methadone maintenance patients.
Topics: Adult; Aged; Depression; Female; Humans; Logistic Models; Male; Methadone; Middle Aged; Nicotine; Od | 1996 |
[The methadone program is greatly reduced. Few addicts are referred to Uppsala].
Topics: Health Priorities; Humans; Methadone; Narcotics; Opioid-Related Disorders; Sweden | 1996 |
Psychiatric and substance use comorbidity among treatment-seeking opioid abusers.
Topics: Adolescent; Adult; Antisocial Personality Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Discr | 1997 |
Methadone and caries. Case reports.
Topics: Administration, Oral; Adult; Chemistry, Pharmaceutical; Dental Caries; Denture, Complete; Female; Hu | 1996 |
[Pregnancy and drug dependence].
Topics: Administration, Oral; Adult; Austria; Delayed-Action Preparations; Dose-Response Relationship, Drug; | 1996 |
Guanine nucleotide binding proteins in opioid-dependent patients.
Topics: Adenosine Diphosphate Ribose; Adult; Blood Platelets; Cell Membrane; Female; GTP-Binding Protein alp | 1997 |
Methadone vs naltrexone.
Topics: Connecticut; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorder | 1997 |
Integrating primary care and methadone maintenance treatment: implementation issues.
Topics: Adult; Combined Modality Therapy; Comorbidity; Delivery of Health Care, Integrated; Female; HIV Sero | 1997 |
[Does methadone lessen HIV risk behavior?].
Topics: Condoms; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related Disorders; Risk-Taking; Sexual | 1997 |
Validity of the psychopathy checklist-revised in male methadone patients.
Topics: Adolescent; Adult; Antisocial Personality Disorder; Comorbidity; Humans; Male; Mental Disorders; Met | 1997 |
Effect of methadone addiction on glucose metabolism in rats.
Topics: Animals; Blood Glucose; Female; Fructose-Bisphosphatase; Glucose Tolerance Test; Glucose-6-Phosphata | 1997 |
The effect of methadone prescribing in a clinic setting on the criminal activity of drug users.
Topics: Adult; Analgesics, Opioid; Crime; Drug Prescriptions; Female; Humans; Male; Methadone; Middle Aged; | 1996 |
Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use.
Topics: Adult; Alcoholism; Epilepsy, Generalized; Humans; Male; Methadone; Opioid-Related Disorders; Phenyto | 1997 |
Methadone and caries.
Topics: Cacao; Dental Caries; Dietary Sucrose; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pharm | 1997 |
Marked decrease of immunolabelled 68 kDa neurofilament (NF-L) proteins in brains of opiate addicts.
Topics: Adult; Blotting, Western; Cerebral Cortex; Drug Overdose; Female; Heroin; Humans; Male; Methadone; M | 1997 |
Interruption of methadone treatment by imprisonment.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Prisoners; Substance Abuse, Intravenous | 1997 |
Dependent opioid users assessed for methadone treatment in Otago: patterns of drug use.
Topics: Adolescent; Adult; Female; Humans; Male; Methadone; Narcotics; New Zealand; Opioid-Related Disorders | 1997 |
General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow.
Topics: Counseling; Drug Costs; Education, Medical, Continuing; Family Practice; Female; Humans; Inservice T | 1997 |
[Distribution of methadone by pharmacies--the Hamburg method].
Topics: Ambulatory Care; Germany; Humans; Methadone; Opioid-Related Disorders; Patient Acceptance of Health | 1997 |
Evaluation of a low-threshold clinic for opiate-dependent drug users.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; O | 1997 |
[Methadone maintenance treatment--no universal solution].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1997 |
The role of node-link maps in enhancing counseling efficiency.
Topics: Adult; Ambulatory Care; Attention; Cocaine; Communication; Counseling; Female; Humans; Male; Methado | 1997 |
Patterns of drug use in dependent opioid users in methadone treatment.
Topics: Humans; Methadone; New Zealand; Opioid-Related Disorders; Retrospective Studies | 1997 |
Natural classes of treatment response.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Clinical Trials as Topic; Cluster Analysis; Co | 1997 |
The relationship of methadone dose and other variables to outcomes of methadone maintenance.
Topics: Adult; Cocaine; Dose-Response Relationship, Drug; Female; Humans; Male; Methadone; Morphine Dependen | 1997 |
Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up.
Topics: Adolescent; Adult; Cocaine; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; HIV In | 1997 |
Treatment of opiate dependent drug misusers. Glasgow model should be replicated in other general practices.
Topics: Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1997 |
Treatment of opiate dependent drug misusers. Doctors in prison must be careful when prescribing methadone.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Prisoners | 1997 |
Treatment of opiate dependent drug misusers. More people die from methadone misuse than from heroin misuse.
Topics: Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 1997 |
Drug abuse treatment retention and process effects on follow-up outcomes.
Topics: Adult; Cocaine; Crime; Female; Follow-Up Studies; Humans; Male; Methadone; Motivation; Opioid-Relate | 1997 |
Subjective sleep-wake parameters in treatment-seeking opiate addicts.
Topics: Adult; Circadian Rhythm; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Pat | 1997 |
Harm reduction and decriminalization in the United States: a personal perspective.
Topics: Ethics, Medical; HIV Infections; Humans; Methadone; Opioid-Related Disorders; Patient Compliance; Re | 1997 |
Change in drug-using networks of injecting drug users during methadone treatment: a pilot study using snowball recruitment and intensive interviews.
Topics: Adult; Female; HIV Infections; Humans; Interview, Psychological; Male; Methadone; Middle Aged; Motiv | 1997 |
l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.
Topics: Analgesics, Opioid; Animals; Dogs; Dose-Response Relationship, Drug; Methadone; Methadyl Acetate; Mo | 1997 |
Methadone treatment increases in EU.
Topics: European Union; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1997 |
Enantioselective high-performance liquid chromatography determination of methadone enantiomers and its major metabolite in human biological fluids using a new derivatized cyclodextrin-bonded phase.
Topics: Analgesics, Opioid; Chromatography, High Pressure Liquid; Cyclodextrins; Humans; Methadone; Opioid-R | 1997 |
Reduction in use of temazepam is factor in deaths related to overdose.
Topics: Drug Overdose; Humans; Methadone; Narcotics; Opioid-Related Disorders; Scotland; Temazepam | 1997 |
High interindividual variability of methadone enantiomer blood levels to dose ratios.
Topics: Adult; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; | 1998 |
Consensus panel proposes sweeping changes to improve access to methadone maintenance treatment.
Topics: Consensus Development Conferences, NIH as Topic; Health Services Accessibility; Humans; Methadone; N | 1998 |
Patterns of symptom complaints in methadone maintenance patients.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Rela | 1997 |
Prediction of 7 months methadone maintenance treatment response by four measures of antisociality.
Topics: Adult; Antisocial Personality Disorder; Benzodiazepines; Cocaine; Conduct Disorder; Diagnosis, Dual | 1998 |
A naturalistic study of home detoxification from opiates using lofexidine.
Topics: Adult; Clonidine; Female; Heroin Dependence; Humans; Inactivation, Metabolic; Male; Methadone; Narco | 1998 |
Methadone treatment in the Scottish context: outcomes of a community-based service for drug users in Lothian.
Topics: Adolescent; Adult; Cohort Studies; Community Health Services; Cross-Sectional Studies; Female; Follo | 1998 |
Increasing employment of opioid dependent outpatients: an intensive behavioral intervention.
Topics: Adult; Analysis of Variance; Behavior Therapy; Cocaine; Cohort Studies; Critical Pathways; Drug Admi | 1998 |
Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure.
Topics: Adult; Discrimination Learning; Dose-Response Relationship, Drug; Female; Humans; Hydromorphone; Mal | 1998 |
Methadone treatment is widely accepted in prisons in New South Wales.
Topics: Humans; Methadone; Narcotics; New South Wales; Opioid-Related Disorders; Prisons | 1998 |
[Drug dependent patients in the methadone maintenance program: evaluation in primary care of psychosocial and organic severity].
Topics: Adult; Cross-Over Studies; Female; Health Status; Humans; Male; Methadone; Narcotics; Opioid-Related | 1998 |
GPs and methadone. Primum non nocere.
Topics: Attitude of Health Personnel; Family Practice; Female; Humans; Male; Methadone; Opioid-Related Disor | 1998 |
Treatment failure and methadone dose in a public methadone maintenance treatment programme in Geneva.
Topics: Adult; Chi-Square Distribution; Cohort Effect; Confidence Intervals; Depression; Female; Follow-Up S | 1998 |
Changing attitudes and beliefs of staff working in methadone maintenance programs.
Topics: Attitude of Health Personnel; Australia; Data Collection; Female; Health Knowledge, Attitudes, Pract | 1998 |
A psychometric evaluation of the Defense Style Questionnaire in methadone patients.
Topics: Adult; Defense Mechanisms; Factor Analysis, Statistical; Female; Humans; Male; Methadone; Narcotics; | 1998 |
Factor structure of psychopathy among methadone maintenance patients.
Topics: Adult; Antisocial Personality Disorder; Behavioral Symptoms; Chi-Square Distribution; Criminal Psych | 1998 |
MMPI profiles of opiate addicts: predicting response to treatment.
Topics: Analysis of Variance; Cluster Analysis; Female; Humans; Male; Methadone; MMPI; New Jersey; Opioid-Re | 1998 |
[Prevalence of psychiatric disorders in opiate dependent patients in contact with the drug treatment system].
Topics: Adolescent; Adult; Combined Modality Therapy; Comorbidity; Cross-Sectional Studies; Female; Follow-U | 1998 |
Methadone maintenance in pregnancy: a reappraisal.
Topics: Adult; Cocaine; Female; Fetus; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Com | 1998 |
Cocaine use early in treatment predicts outcome in a behavioral treatment program.
Topics: Adult; Behavior Therapy; Cocaine; Cocaine-Related Disorders; Female; Forecasting; Humans; Longitudin | 1998 |
Clinton administration plans to expand access to methadone.
Topics: Health Policy; Humans; Methadone; Narcotics; New York; Opioid-Related Disorders; United States | 1998 |
Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison.
Topics: Adult; Dextroamphetamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Female; Huma | 1998 |
Gender differences in psychiatric comorbidity among cocaine-using opiate addicts.
Topics: Adult; Alcoholism; Anxiety Disorders; Cocaine-Related Disorders; Comorbidity; Female; Humans; Male; | 1998 |
Opioid detoxification in pregnancy.
Topics: Adult; Analgesics; Analgesics, Opioid; Chi-Square Distribution; Clonidine; Drug Therapy, Combination | 1998 |
Gut motility and transit changes in patients receiving long-term methadone maintenance.
Topics: Adult; Breath Tests; Chromatography, Gas; Constipation; Female; Gastrointestinal Motility; Gastroint | 1998 |
A pilot study comparing severely and persistently mentally ill opiate-addicted patients in dual-diagnosis treatment with patients in methadone maintenance.
Topics: Adult; Comorbidity; Demography; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders | 1998 |
Treatment of depressed methadone maintenance patients with nefazodone. A case series.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Humans; Male; Methadon | 1998 |
Drug use predictors of partner violence in opiate-dependent women.
Topics: Adolescent; Adult; Alcohol Drinking; Battered Women; Child; Child, Preschool; Cocaine-Related Disord | 1998 |
[Ambulatory opiate withdrawal].
Topics: Ambulatory Care; Buprenorphine; Hospitalization; Humans; Methadone; Narcotics; Opioid-Related Disord | 1998 |
Maintenance treatment of opiate addicts in Germany with medications containing codeine--results of a follow-up study.
Topics: Adult; Codeine; Female; Follow-Up Studies; Germany; Humans; Male; Methadone; Narcotics; Opioid-Relat | 1998 |
Unilateral trigeminal and facial nerve palsies associated with epidural analgesia in labour.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anesthetics, Local; Anti-Inflammatory Agents, No | 1998 |
[Is methadone effective?].
Topics: Humans; Methadone; Opioid-Related Disorders | 1998 |
Medication adherence strategies for drug abusers with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Me | 1998 |
[Dogmatism on methadone].
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders; Randomized Controlled Trials as Top | 1998 |
Rapid determination of methadone and its major metabolite in biological fluids by gas-liquid chromatography with thermionic detection for maintenance treatment of opiate addicts.
Topics: Artifacts; Chromatography, Gas; Humans; Methadone; Opioid-Related Disorders; Pyrrolidines; Reproduci | 1998 |
Drug abuse treatment as HIV prevention: changes in social drug use patterns might also reduce risk.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-R | 1998 |
The impact of methadone on consumption of inpatient care and mortality, with special reference to HIV status.
Topics: Adult; Female; HIV Infections; HIV Seropositivity; Hospitalization; Humans; Length of Stay; Male; Me | 1998 |
Correlates of retention on the South Australian Methadone Program 1981-91.
Topics: HIV Seropositivity; Humans; Methadone; Opioid-Related Disorders; Patient Dropouts; Risk Factors; Sou | 1998 |
Long-term test-retest reliability of personality disorder diagnoses in opiate dependent patients.
Topics: Adult; Cluster Analysis; Female; Follow-Up Studies; Humans; Interview, Psychological; Male; Methadon | 1998 |
[Problems with maintenance therapy in opiate dependence and the clinical importance of methadone].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1998 |
Previous participation in outpatient methadone program and residential treatment outcome: a research note from Hong Kong.
Topics: Ambulatory Care; Follow-Up Studies; Hong Kong; Humans; Male; Methadone; Opioid-Related Disorders; Re | 1999 |
Attachment behavior and its antecedents in offspring born to methadone-maintained women.
Topics: Adult; Black or African American; Case-Control Studies; Chi-Square Distribution; Child of Impaired P | 1999 |
Early deviance and related risk factors in the children of narcotic addicts.
Topics: Adolescent; Adult; Alcoholism; Child; Child Behavior Disorders; Child of Impaired Parents; Developme | 1999 |
Safer sex strategies for women: the hierarchical model in methadone treatment clinics.
Topics: Acquired Immunodeficiency Syndrome; Adult; Attitude to Health; Condoms; Condoms, Female; Decision Ma | 1999 |
Methadone in maintenance treatment of narcotic addicts; joint revision of conditions for use; interim maintenance treatment; human immunodeficiency virus disease counseling--FDA and SAMHSA. Final rule.
Topics: Acquired Immunodeficiency Syndrome; Communicable Disease Control; Counseling; Humans; Methadone; Opi | 1993 |
Measuring program performance in methadone treatment using in-treatment outcomes: an illustration.
Topics: Demography; Diagnosis-Related Groups; Humans; Joint Commission on Accreditation of Healthcare Organi | 1995 |
Methadone maintenance. Does dose determine differences in outcome?
Topics: Adult; Aged; Analysis of Variance; Case-Control Studies; Chicago; Dose-Response Relationship, Drug; | 1999 |
Hyperphagia in neonates withdrawing from methadone.
Topics: Adult; Birth Weight; Body Weight; Female; Humans; Hyperphagia; Incidence; Infant, Newborn; Linear Mo | 1999 |
Methadone treatment practices.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
Allergic reactions from injectable methadone.
Topics: Humans; Injections, Intravenous; Methadone; Opioid-Related Disorders; Patient Dropouts; Urticaria | 1999 |
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
Topics: Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Middle A | 1999 |
Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
Topics: Adult; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Methadone; Narcotics; Nevirapine; | 1999 |
[Increasing drug abuse problems "down under"].
Topics: Alcohol-Related Disorders; Australia; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 1999 |
Orally delivered methadone as a reinforcer: Effects of the opioid antagonist naloxone.
Topics: Administration, Oral; Animals; Dose-Response Relationship, Drug; Macaca mulatta; Male; Methadone; Na | 1999 |
Program quality effects on patient outcomes during methadone maintenance: a study of 17 clinics.
Topics: Adult; Cocaine-Related Disorders; Female; Heroin Dependence; Humans; Male; Methadone; Narcotics; New | 1999 |
The 2-year test-retest reliability of the Psychopathy Checklist Revised in methadone patients.
Topics: Adult; Antisocial Personality Disorder; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related | 1999 |
Attention deficit hyperactivity disorder and treatment outcome in opioid abusers entering treatment.
Topics: Adult; Ambulatory Care; Attention; Attention Deficit Disorder with Hyperactivity; Clonidine; Cogniti | 1999 |
A study of methadone in fatalities in the Strathclyde Region, 1991-1996.
Topics: Adolescent; Adult; Cause of Death; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Diso | 1999 |
Cerebral phosphorus metabolite abnormalities in opiate-dependent polydrug abusers in methadone maintenance.
Topics: Adult; Brain; Case-Control Studies; Cerebrovascular Circulation; Female; Humans; Magnetic Resonance | 1999 |
HIV risk reduction in outpatient drug abuse treatment: individual and geographic differences.
Topics: Adult; Alcoholism; Antisocial Personality Disorder; Cities; Cocaine-Related Disorders; Female; HIV I | 1999 |
Injectable methadone prescribing in the United Kingdom--current practice and future policy guidelines.
Topics: Ethics, Medical; Health Policy; Humans; Injections, Intravenous; Methadone; Narcotics; Opioid-Relate | 1999 |
Methadone maintenance and state Medicaid managed care programs.
Topics: Humans; Insurance Coverage; Managed Care Programs; Medicaid; Methadone; Narcotics; Opioid-Related Di | 1999 |
Making residential treatment available to methadone clients.
Topics: Adult; California; Community Mental Health Services; Female; Humans; Interprofessional Relations; Ma | 1999 |
Changes in methadone treatment practices: results from a panel study, 1988-1995.
Topics: Adult; Clinical Trials as Topic; Environment; Female; Humans; Male; Methadone; Narcotics; Opioid-Rel | 1999 |
Methadone treatment.
Topics: Analgesics, Opioid; Chronic Disease; Humans; Methadone; Narcotics; Opioid-Related Disorders; Pain; P | 1999 |
Methadone treatment.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
Methadone treatment.
Topics: Drug Monitoring; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
Moderate- vs high-dose methadone for opioid dependence.
Topics: Drug Administration Schedule; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
Moderate- vs high-dose methadone for opioid dependence.
Topics: Drug Administration Schedule; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
Moderate- vs high-dose methadone for opioid dependence.
Topics: Clinical Trials as Topic; Humans; Methadone; Narcotics; Opioid-Related Disorders | 1999 |
[Management of opiate-dependent adolescents in the Vaud canton. Reflections on the indication for treatment with methadone].
Topics: Adolescent; Adolescent Health Services; Forecasting; Humans; Methadone; Narcotics; Opioid-Related Di | 1999 |
A therapeutic use of the methadone fluvoxamine drug interaction.
Topics: Adult; Drug Interactions; Female; Fluvoxamine; Humans; Methadone; Narcotics; Opioid-Related Disorder | 1999 |
Alterations in methadone metabolism during late pregnancy.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Me | 1999 |
Cocaine abuse sharply reduced in an effective methadone maintenance program.
Topics: Adult; Aged; Catchment Area, Health; Cocaine-Related Disorders; Drug Administration Schedule; Female | 1999 |
Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months.
Topics: Adolescent; Adult; Analysis of Variance; Chi-Square Distribution; Female; Follow-Up Studies; Humans; | 2000 |
The brief abstinence test: voucher-based reinforcement of cocaine abstinence.
Topics: Adult; Analysis of Variance; Behavior Therapy; Chi-Square Distribution; Cocaine-Related Disorders; F | 2000 |
Effects of opioid receptor agonists on cAMP second messenger system.
Topics: Adenylyl Cyclases; Analgesics, Opioid; Buprenorphine; Cyclic AMP; Etorphine; Glioma; Humans; Hybrid | 1999 |
Effects of low-pH treatment on cAMP second messenger system regulated by different opioid agonists.
Topics: Adenylyl Cyclases; Analgesics, Opioid; Buprenorphine; Cyclic AMP; Etorphine; Glioma; Humans; Hybrid | 1999 |
Methadone maintenance treatment: outcomes from the Otago methadone programme.
Topics: Adolescent; Adult; Analgesics, Opioid; Community Health Services; Female; Humans; Male; Methadone; N | 1999 |
Toxicology and pathology of deaths related to methadone: retrospective review.
Topics: Adult; Drug Overdose; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid-Related Disord | 2000 |
Use of methadone.
Topics: Analgesics, Opioid; Drug Interactions; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neonat | 2000 |
Decrease in methodone levels with nelfinavir mesylate.
Topics: Adult; Comorbidity; HIV Infections; HIV Protease Inhibitors; Humans; Male; Methadone; Nelfinavir; Op | 2000 |
[Initial effects of the 1998 revised narcotic law in substitute drug treatment of narcotic dependent patients--results of a physician survey].
Topics: Attitude of Health Personnel; Codeine; Drug and Narcotic Control; Germany; Humans; Methadone; Opioid | 2000 |
Comparison of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions.
Topics: Adult; Cocaine-Related Disorders; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Pa | 2000 |
Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance.
Topics: Antitubercular Agents; Cohort Studies; Drug Combinations; Female; Humans; Isoniazid; Male; Methadone | 1999 |
Treatment for opioid dependence: quality and access.
Topics: Delivery of Health Care; Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders; Sc | 2000 |
Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy.
Topics: Delivery of Health Care; Family Practice; Humans; Methadone; Narcotics; Opioid-Related Disorders; Ou | 2000 |
Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
Topics: Adult; Anesthesia, General; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Morphine De | 2000 |
[Nevirapine induces abstinence symptoms in patients on a methadone maintenance program with HIV infection].
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Chronic Disease; Drug Interactions; Drug Therapy, Comb | 2000 |
Alcohol consumption during methadone maintenance treatment.
Topics: Adult; Alcohol Drinking; Alcoholism; Austria; Comorbidity; Cross-Sectional Studies; Female; Humans; | 2000 |
On the usefulness of therapeutic drug monitoring of methadone.
Topics: Drug Monitoring; Humans; Metabolic Clearance Rate; Methadone; Narcotics; Opioid-Related Disorders; P | 2000 |
Treatment services received by supplemental security income drug and alcoholic clients.
Topics: Adult; Alcoholism; Cocaine-Related Disorders; Female; Health Services Needs and Demand; Humans; Male | 2000 |
Community reinforcement approach for combined opioid and cocaine dependence. Patterns of engagement in alternate activities.
Topics: Adult; Buprenorphine; Clinical Trials as Topic; Cocaine-Related Disorders; Community Networks; Couns | 2000 |
Health status of employed and unemployed methadone patients.
Topics: Adult; Disability Evaluation; Employment; Female; Health Status; Humans; Male; Methadone; Motivation | 2000 |
[Nutritional status of drug addicts in a methadone program].
Topics: Adult; Anthropometry; Blood Chemical Analysis; Female; Humans; Male; Methadone; Nutritional Status; | 1999 |
[New psychopharmacologic studies on methadone: implications for the treatment of opiate dependency].
Topics: Administration, Oral; Analgesics, Opioid; Biological Availability; Cytochrome P-450 Enzyme System; H | 2000 |
Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance.
Topics: Adult; Anti-HIV Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; HIV Infections | 2000 |
Implementation of the methadone treatment quality assurance system. findings from the feasibility study.
Topics: Feasibility Studies; Humans; Methadone; Opioid-Related Disorders; Outcome Assessment, Health Care; Q | 2000 |
[Methadone therapy in opiate dependency].
Topics: Analgesics, Opioid; Humans; Methadone; Opioid-Related Disorders | 2000 |
[Methadone treatment during pregnancy and its effect on the child. Better than continuing drug abuse, should be monitored by a specialized antenatal care center].
Topics: Adult; Embryonic and Fetal Development; Female; Heroin Dependence; Humans; Infant, Newborn; Maternal | 2000 |
Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use.
Topics: Antiretroviral Therapy, Highly Active; Comorbidity; HIV Infections; HIV Protease Inhibitors; Methado | 2000 |
Changes in Millon Clinical Multiaxial Inventory scores among opiate addicts as a function of retention in methadone maintenance treatment and recent drug use.
Topics: Adult; Antisocial Personality Disorder; Anxiety Disorders; Female; Follow-Up Studies; Humans; Male; | 2000 |
[Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction].
Topics: Adult; Buprenorphine; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Populati | 2000 |
Services provided during methadone treatment. A gender comparison.
Topics: Adult; Aged; Alcohol Drinking; Communication; Counseling; Crime; Female; Health Services Needs and D | 2000 |
Posttraumatic stress disorder and short-term outcome in early methadone treatment.
Topics: Adult; Analysis of Variance; Cocaine-Related Disorders; Diagnosis, Differential; Diagnosis, Dual (Ps | 2000 |
Patterns of drinking and drinking outcomes among drug misusers. 1-year follow-up results.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Female; Follow-Up Studies; Humans; Male; Methadone; Nar | 2000 |
Methadone maintenance for opioid dependence.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Self-Help Groups | 2000 |
Methadone maintenance for opioid dependence.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders | 2000 |
The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment.
Topics: Adult; Central Nervous System Stimulants; Cocaine-Related Disorders; Female; Follow-Up Studies; Huma | 2000 |
One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme.
Topics: Adult; Ambulatory Care; Cohort Studies; Family Practice; Female; Follow-Up Studies; Humans; Male; Me | 2000 |
The influence of coping and depression on abstinence from illicit drug use in methadone-maintained patients.
Topics: Adaptation, Psychological; Adult; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Mal | 2000 |
Methadone-related fatalities in Hamburg 1990-1999: implications for quality standards in maintenance treatment?
Topics: Analgesics, Opioid; Cause of Death; Drug and Narcotic Control; Germany; Humans; Methadone; Needs Ass | 2000 |
Comment: opiate withdrawal symptoms induced by antiretroviral drugs.
Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Humans; Methadone; Nevira | 2000 |
Methadone detoxification of tramadol dependence.
Topics: Acute Disease; Dose-Response Relationship, Drug; Female; Humans; Methadone; Middle Aged; Opioid-Rela | 2000 |
Dihydrocodeine: a useful tool in the detoxification of methadone-maintained patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Codeine; Cross-Over Studies; Dose-Response Relationship, Drug | 2000 |
[Postpartum risk factors in the development of children born to opiate-addicted mothers; comparison between mothers with and without methadone substitution].
Topics: Adult; Birth Weight; Case-Control Studies; Child Advocacy; Child Development; Female; Germany; Gesta | 2000 |
[Fatal intoxications among drug addicts in Denmark in 1997].
Topics: Adolescent; Adult; Analgesics, Opioid; Cause of Death; Denmark; Drug Overdose; Female; Forensic Medi | 2000 |
Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.
Topics: Adolescent; Adult; Aged; Enzyme Multiplied Immunoassay Technique; Enzyme-Linked Immunosorbent Assay; | 2000 |
The analysis of methadone in nail clippings from patients in a methadone-maintenance program.
Topics: Adult; Female; Gas Chromatography-Mass Spectrometry; Humans; Immunoenzyme Techniques; Male; Methadon | 2000 |
Women in treatment: within-gender differences in the clinical presentation of opioid-dependent women.
Topics: Adult; Cluster Analysis; Cohort Studies; Comorbidity; Ethnicity; Female; Health Status; Humans; Lang | 2000 |
Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.
Topics: Adult; Cluster Analysis; Cohort Studies; Crime; Female; Follow-Up Studies; Health Status; Humans; Il | 2000 |
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment.
Topics: Adult; Alleles; Analgesics, Opioid; Analysis of Variance; DNA; Female; Follow-Up Studies; Gene Frequ | 2000 |
Treating opioid dependence--new data and new opportunities.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Humans; Methadone; Methadyl Acetate | 2000 |
Variation between and within drug treatment modalities: data from the National Treatment Outcome Research Study (UK).
Topics: Ambulatory Care; Dose-Response Relationship, Drug; Drug Administration Schedule; England; Health Ser | 2000 |
Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.
Topics: Adult; Drug Administration Schedule; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Opioid | 2000 |
Comparison of [(3)H]Glyburide binding with opiate analgesia, tolerance, and dependence in ICR and Swiss-Webster mice.
Topics: Analgesics, Opioid; Animals; ATP-Binding Cassette Transporters; Drug Tolerance; Glyburide; Male; Met | 2000 |
Treatment of opioid dependence in pregnant women.
Topics: Adult; Female; HIV Infections; Humans; Infant, Newborn; Life Style; Methadone; Narcotics; Neonatal A | 2000 |
Influence of psychiatric comorbidity on HIV risk behaviors: changes during drug abuse treatment.
Topics: Adult; Comorbidity; Female; HIV Infections; Humans; Male; Maryland; Mental Disorders; Methadone; Nar | 2000 |
The processing of automatic thoughts of drug use and craving in opiate-dependent individuals.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Mental P | 2000 |
An alternative program for methadone maintenance dropouts: description and preliminary data.
Topics: Adult; Counseling; Humans; Methadone; Middle Aged; Narcotics; Opioid-Related Disorders; Patient Drop | 2001 |
A mandatory short-term methadone-to-abstinence program in New York City.
Topics: Adult; Humans; Methadone; Narcotics; New York City; Opioid-Related Disorders; Time Factors; Treatmen | 2001 |
Analysis of behavioral patterns in five cohorts of patients retained in methadone maintenance programs.
Topics: Adult; Behavior; Crime; Educational Status; Employment; Female; Health Services; Humans; Male; Metha | 2001 |
A naturalistic study on ending blind dosing in a methadone maintenance clinic in Israel.
Topics: Chi-Square Distribution; Confidentiality; Humans; Israel; Methadone; Narcotics; Opioid-Related Disor | 2001 |
[Unfounded prohibition of driving for chronic opioid users].
Topics: Automobile Driving; Humans; Methadone; Narcotics; Netherlands; Opioid-Related Disorders | 2000 |
The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients.
Topics: Adult; Analysis of Variance; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Humans; Male; | 2001 |
Recent evolution in opiate dependence in France during generalisation of maintenance treatments.
Topics: Adult; Buprenorphine; Chi-Square Distribution; Female; France; Humans; Male; Methadone; Narcotics; O | 2001 |
Chronic mu-opioid receptor stimulation in humans decreases muscle sympathetic nerve activity.
Topics: Adult; Blood Pressure; Electrophysiology; Epinephrine; Female; Heart Rate; Humans; Male; Methadone; | 2001 |
Getting to grips with heroin and other opioid use.
Topics: Australia; Evidence-Based Medicine; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 2000 |
Trends in licit opioid use in Australia, 1984-1998: comparative analysis of international and jurisdictional data.
Topics: Australia; Developed Countries; Drug Utilization; Humans; Meperidine; Methadone; Morphine; Narcotics | 2000 |
[Nutritional problems of persons qualified for the methadone treatment. Part I. Nutritional status of opiate addicts].
Topics: Adult; Anthropometry; Body Mass Index; Female; Humans; Male; Methadone; Middle Aged; Narcotics; Nutr | 2000 |
[Nutrition disorders in persons qualified for the methadone treatment. Part II. Food choice and intake in diets of opiate addicts].
Topics: Adult; Choice Behavior; Diet; Female; Food Preferences; Humans; Male; Methadone; Middle Aged; Narcot | 2000 |
Liver transplantation and opioid dependence.
Topics: Hepatitis C; Humans; Liver Transplantation; Methadone; Narcotics; Opioid-Related Disorders; Patient | 2001 |
[Evolution and update of detoxification techniques for opiate addicts].
Topics: Animals; Buprenorphine; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Relate | 2000 |
Treating opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders | 2001 |
Treating opioid dependence.
Topics: Analgesics, Opioid; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders | 2001 |
Addicted patients with personality disorders: traits, schemas, and presenting problems.
Topics: Adaptation, Psychological; Adjustment Disorders; Adult; Female; Humans; Male; Methadone; Narcotics; | 2001 |
Outbreak of multidrug-resistant tuberculosis at a methadone treatment program.
Topics: Adult; Ambulatory Care Facilities; Chi-Square Distribution; Contact Tracing; Cross Infection; Diseas | 2001 |
Re: prior history and its impact on criminal recidivism.
Topics: Crime; Humans; Male; Methadone; Opioid-Related Disorders | 2000 |
Hepatitis C in methadone maintenance patients: prevalence and public policy implications.
Topics: Adult; Aged; Asian; California; Comorbidity; Cross-Sectional Studies; Female; Health Policy; Hepatit | 2001 |
Methadone treatment: our vision for the future.
Topics: Drug and Narcotic Control; Forecasting; Health Policy; Humans; Methadone; Opioid-Related Disorders; | 2001 |
Injectable opiate maintenance in the UK: Is it good clinical practice?
Topics: Analgesics, Opioid; Ethics, Medical; Heroin; Humans; Injections; Methadone; Opioid-Related Disorders | 2001 |
Methadone prescribing to opiate addicts by private doctors: comparison with NHS practice in south east England.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Practice Patterns, Physicians'; Private Prac | 2001 |
Closure of an open drug scene--a case register-based analysis of the impact on the demand for methadone maintenance treatment.
Topics: Adult; Female; Health Services Needs and Demand; Humans; Illicit Drugs; Male; Methadone; Narcotics; | 2001 |
Myocardial Infarction associated with methadone and/or dihydrocodeine.
Topics: Adult; Analgesics, Opioid; Codeine; Humans; Hypercholesterolemia; Male; Methadone; Myocardial Infarc | 2001 |
Treatment of opioid addiction in physicians' offices: it's about time.
Topics: Buprenorphine; Humans; Methadone; Narcotics; Opioid-Related Disorders; Physicians' Offices | 2001 |
Qualitative screening for drugs of abuse in hair using GC-MS.
Topics: Gas Chromatography-Mass Spectrometry; Hair; Humans; Illicit Drugs; Methadone; Narcotics; Opioid-Rela | 2001 |
Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
Topics: Acoustic Stimulation; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Double-Blind Method | 2001 |
Drug czar seeks new emphasis on methadone treatment.
Topics: Health Policy; HIV Infections; Humans; Methadone; Opioid-Related Disorders; Politics; Substance Abus | 1997 |
Psychosis after ultrarapid opiate detoxification.
Topics: Alprazolam; Benzodiazepines; Drug Administration Schedule; Female; Humans; Hydrocodone; Methadone; M | 2001 |
The Supervised Methadone and Resettlement Team nurse: an effective approach with opiate-dependent, homeless people.
Topics: Community Mental Health Services; England; Humans; Ill-Housed Persons; Interinstitutional Relations; | 2001 |
Buprenorphine for opiate addiction: potential economic impact.
Topics: Buprenorphine; Cost-Benefit Analysis; Counseling; Drug Evaluation, Preclinical; Health Care Costs; H | 2001 |
A capture-recapture study of the prevalence and implications of opiate use in Dublin.
Topics: Adolescent; Adult; Age Distribution; Criminal Law; Female; Humans; Ireland; Linear Models; Male; Met | 2001 |
A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting.
Topics: Buprenorphine; Certification; Communicable Diseases; Family Practice; Humans; Information Services; | 2001 |
Methadone maintenance.
Topics: Drug Administration Schedule; Humans; Methadone; Narcotics; Opioid-Related Disorders | 2001 |
[Opiate dependent pregnant patients and mothers. What must be regarded in drug substitution and detoxification].
Topics: Ambulatory Care; Female; Germany; Humans; Infant, Newborn; Methadone; Neonatal Abstinence Syndrome; | 2001 |
Risk factors associated with noncompliance with methadone substitution therapy (MST) and relapse among chronic opiate users in an Outer London community.
Topics: Adult; England; Female; Humans; Male; Methadone; Middle Aged; Motivation; Opioid-Related Disorders; | 2001 |
[Evaluation of health status in participants from a methadone treatment program in Krakow after one year of maintenance treatment].
Topics: Adult; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Poland; Pregnancy; Pr | 2001 |
[Health status of individuals dependent on opiates before and after a year of treatment in a methadone maintenance program].
Topics: Adult; Female; Health Status; Humans; Infections; Liver Diseases; Male; Methadone; Opioid-Related Di | 2001 |
Determination of opiates in serum, saliva and hair addicted persons.
Topics: Adult; Codeine; Female; Gas Chromatography-Mass Spectrometry; Hair; Humans; Hydrogen-Ion Concentrati | 2001 |
Opioid drugs in maintenance and detoxification treatment of opiate addiction; Substance Abuse and Mental Health Services Administration, HHS. Final rule.
Topics: Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Rehabilitation; United States; Un | 2001 |
[Let the methadone patients in Stockholm tell--with the possibility to change their program].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Regional Medical Programs; Substance Abuse D | 2001 |
Relationships between counseling rapport and drug abuse treatment outcomes.
Topics: Adult; Analgesics, Opioid; Crime; Female; Follow-Up Studies; Humans; Logistic Models; Male; Methadon | 2001 |
Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients.
Topics: Adult; Cocaine; Combined Modality Therapy; Female; Germany; Heroin Dependence; Humans; Male; Methado | 2001 |
HIV risks of men in methadone maintenance treatment programs who abuse their intimate partners: a forgotten issue.
Topics: Adult; Female; HIV Infections; Humans; Logistic Models; Male; Methadone; Middle Aged; Needle Sharing | 2001 |
Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Feasibility Studies; Female; Hepatitis B; Hepatitis B V | 2001 |
Prevalence of psychiatric disorder in a methadone maintenance population.
Topics: Adolescent; Adult; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Mental Disorders | 2001 |
Reducing deaths among drug misusers. Standard of care in Britain was not addressed.
Topics: Analgesics, Opioid; Drug Administration Schedule; Humans; Methadone; Opioid-Related Disorders; Quali | 2001 |
Predictive validity of the Addiction Severity Index's composite scores in the assessment of 2-year outcomes in a methadone maintenance population.
Topics: Adult; Female; Humans; Interview, Psychological; Logistic Models; Male; Methadone; Opioid-Related Di | 2001 |
Sex trading and psychological distress among women on methadone.
Topics: Adult; Case-Control Studies; Female; Humans; Methadone; Middle Aged; Multivariate Analysis; New York | 2001 |
A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments.
Topics: Cross-Sectional Studies; Hepatitis C; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related D | 2001 |
[A national model for drug-supported rehabilitation of opiate addicts].
Topics: Adult; Buprenorphine; Community Health Services; Humans; Methadone; Models, Organizational; Narcotic | 2001 |
Narcotic withdrawal syndrome following gastric bypass--a difficult diagnosis.
Topics: Adult; Behavior, Addictive; Diagnosis, Differential; Female; Gastric Bypass; Humans; Methadone; Opio | 2001 |
Opioid therapy for chronic painful conditions.
Topics: Analgesics, Opioid; Chronic Disease; Clinical Trials as Topic; Fentanyl; Humans; Karnofsky Performan | 2001 |
Excessive alcohol consumption and drinking expectations among clients in methadone maintenance.
Topics: Adult; Alcohol Drinking; Alcoholism; Culture; Female; Humans; London; Male; Methadone; Narcotics; Op | 2001 |
[A methadone-patient's experiences with the Stockholm program].
Topics: Attitude of Health Personnel; Humans; Methadone; Opioid-Related Disorders; Regional Medical Programs | 2001 |
Less driving impairment on buprenorphine than methadone in drug-dependent patients?
Topics: Adult; Attention; Automobile Driving; Buprenorphine; Female; Humans; Male; Methadone; Opioid-Related | 2001 |
Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.
Topics: Buprenorphine; Electrocardiography; Heroin Dependence; Humans; Methadone; Methadyl Acetate; Naltrexo | 2001 |
Methadone: the question or the answer for US opioid therapy and pharmaco-economics?
Topics: Analgesics, Opioid; Humans; Methadone; Models, Theoretical; Neoplasms; Opioid-Related Disorders; Pai | 2001 |
The network of Centres for the Prevention and Treatment of Drug Addiction in the Republic of Slovenia.
Topics: Humans; Methadone; Opioid-Related Disorders; Slovenia; Substance Abuse Treatment Centers | 2001 |
[Comment to a contribution on methadone program in Stockholm].
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Satisfaction; Regional Medical Progr | 2001 |
[Cocaine abuse in maintenance therapy with methadone in narcotic dependent patients].
Topics: Adolescent; Adult; Ambulatory Care; Anti-Anxiety Agents; Austria; Benzodiazepines; Cocaine-Related D | 2001 |
Withdrawal from methadone maintenance treatment. Reasons for not trying to quit methadone.
Topics: Adult; Decision Making; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Subs | 2002 |
[Methadone and thyroid disorders].
Topics: Humans; Hypothyroidism; Methadone; Narcotics; Obesity; Opioid-Related Disorders; Weight Gain | 2001 |
Changing patient characteristics with increased methadone maintenance availability.
Topics: Adult; Analysis of Variance; Cohort Studies; Female; Health Services Accessibility; Humans; Male; Me | 2002 |
The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Combinations; Female; HIV Seropositivity; Humans; Lamivudin | 2002 |
[Documented effect of methadone, but not naltrexone].
Topics: Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Di | 2002 |
Opioid addiction changes cerebral blood flow symmetry.
Topics: Adult; Case-Control Studies; Cerebrovascular Circulation; Female; Functional Laterality; Heroin Depe | 2002 |
Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.
Topics: Adult; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Com | 2002 |
Utilization of preventive health services by HIV-seronegative injection drug users.
Topics: Adult; AIDS Serodiagnosis; Female; Health Behavior; Health Knowledge, Attitudes, Practice; Health Se | 2002 |
Slow metabolism and long half life of methadone in a patient with lung cancer and cirrhosis.
Topics: Adenocarcinoma; Adult; Analgesics, Opioid; Fibrosis; Half-Life; Humans; Lung Neoplasms; Male; Metabo | 2001 |
[Persistent injecting practices in subjects on methadone or buprenorphine maintenance therapy. A study of 600 cases].
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Methadone; Opioid-Related Disorders; | 2001 |
Methadone treatment and needle use prevention.
Topics: HIV Infections; Humans; Methadone; Needles; Opioid-Related Disorders; Social Conditions; Substance A | 2002 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Intravenous bolus or infusion of naloxone in opioid overdose.
Topics: Adult; Antidotes; Drug Overdose; Evidence-Based Medicine; Heroin Dependence; Humans; Infusions, Intr | 2002 |
Injecting drug use: implications for skin and wound management.
Topics: Abscess; Heroin Dependence; Humans; Ill-Housed Persons; Methadone; Opioid-Related Disorders; Skin; S | 2002 |
High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Meth | 2002 |
TX: did death result from methadone overdose?: Court finds failure to prove proximate cause.
Topics: Analgesics, Opioid; Drug Overdose; Fatal Outcome; Female; Humans; Malpractice; Methadone; Opioid-Rel | 2001 |
NAOMI--her time has come. North American Opiate Medication Initiative.
Topics: Canada; Cooperative Behavior; Humans; Methadone; Opioid-Related Disorders; Public Health; Randomized | 2002 |
Methadone dependence and its effects on consecutive pregnancies.
Topics: Adolescent; Adult; Birth Weight; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; | 2000 |
Policy progress for physician treatment of opiate addiction.
Topics: Buprenorphine; Humans; Methadone; Narcotic Antagonists; Opioid-Related Disorders; Physicians, Family | 2002 |
Neuropsychological deficits and opiate abuse.
Topics: Adult; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Narcoti | 2002 |
Methadone and heroin prescription: babies and bath water.
Topics: Attitude; Canada; Heroin; Humans; Methadone; Opioid-Related Disorders; Substance Abuse, Intravenous | 2002 |
Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study.
Topics: Adult; Attitude; Focus Groups; Heroin; Humans; Methadone; Middle Aged; North America; Opioid-Related | 2002 |
The role of consumers. Reflection on the possibilities and limits of user interviews in opiate addiction treatment.
Topics: Canada; Consumer Behavior; Humans; Interviews as Topic; Methadone; Opioid-Related Disorders | 2002 |
The search for a comprehensive strategy toward opiate addiction.
Topics: Canada; Focus Groups; Humans; Methadone; Opioid-Related Disorders; Therapeutic Community | 2002 |
Heroin maintenance and the United States.
Topics: Drug Prescriptions; Humans; Legislation, Drug; Methadone; Opioid-Related Disorders; United States | 2002 |
Appreciating the user's perspective: listening to the "methadonians".
Topics: Canada; Humans; Methadone; Opioid-Related Disorders; Patient Participation; Substance Abuse Treatmen | 2002 |
Which substitution pharmacotherapy is most effective in treating opioid dependence?
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Methadyl Acetate; Opioid-Related Disorders | 2002 |
[Regular prescription of narcotics and sedatives to drug-addicted patients in general practice].
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Family Practice; Female; Humans; Male; | 2002 |
Development of psychiatric illness in drug abusers. Possible role of drug preference.
Topics: Adult; Amphetamines; Anti-Anxiety Agents; Barbiturates; Benzodiazepines; Depression; Hallucinogens; | 1979 |
Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction.
Topics: Dextropropoxyphene; Dose-Response Relationship, Drug; Humans; Methadone; Opioid-Related Disorders | 1979 |
Conditioned drug responses to naturalistic stimuli.
Topics: Conditioning, Psychological; Heart Rate; Humans; Hydromorphone; Methadone; Naltrexone; Opioid-Relate | 1979 |
Decrease in serum prolactin by naloxone: evidence against antidopamine and antipsychotic effects.
Topics: Animals; Haloperidol; Haplorhini; Humans; Macaca; Male; Methadone; Morphine; Naloxone; Opioid-Relate | 1979 |
Reinforcement of drug abstinence: a behavioral approach to drug abuse treatment.
Topics: Adult; Alcoholism; Behavior Therapy; Diazepam; Heroin Dependence; Humans; Methadone; Opioid-Related | 1979 |
Additional metabolic correlates of 1-alpha-acetylmethadol (LAAM)-induced cellular tolerance and physical dependence: the role of the hepatic microsomal electron transport system.
Topics: Animals; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Tolerance; Electron | 1979 |
Effects of chronic treatment with morphine, methadone, and LAAM on the response to phencyclidine in rats.
Topics: Animals; Behavior, Animal; Drug Synergism; Humans; Male; Methadone; Methadyl Acetate; Morphine; Opio | 1979 |
Clonidine detoxification: a fourteen-day protocol for rapid opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome; Time Factors | 1979 |
Clonidine hydrochloride: a nonopiate treatment for opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1979 |
Effects of alcohol abuse on progression of liver disease in methadone-maintained patients.
Topics: Humans; Liver Diseases, Alcoholic; Liver Function Tests; Methadone; Opioid-Related Disorders | 1979 |
Overview: protracted effects of early exposure to drugs of abuse.
Topics: Animals; Female; Growth; Haplorhini; Heroin Dependence; Humans; Methadone; Opioid-Related Disorders; | 1979 |
A cognitive-behavioral versus nondirective group treatment program for opioid-addicted persons: an adjunct to methadone maintenance.
Topics: Adult; Behavior Therapy; Cognition; Humans; Internal-External Control; Methadone; Opioid-Related Dis | 1979 |
The relation of time spent in drug abuse treatment to posttreatment outcome.
Topics: Adolescent; Adult; Ambulatory Care; Ethnicity; Follow-Up Studies; Humans; Length of Stay; Male; Meth | 1979 |
Effectiveness of psychotherapeutic counseling in methadone maintenance.
Topics: Counseling; Double-Blind Method; Humans; Methadone; Methadyl Acetate; Narcotics; Opioid-Related Diso | 1979 |
Client evaluations of drug abuse treatment in relation to follow-up outcomes.
Topics: Adolescent; Adult; Ethnicity; Evaluation Studies as Topic; Hospitalization; Humans; Male; Methadone; | 1979 |
Outcomes of pregnancy for addicts receiving comprehensive care.
Topics: Adult; Bilirubin; Birth Weight; Comprehensive Health Care; Female; Gestational Age; Humans; Infant, | 1979 |
Sudden unexpected death in infants of narcotic-dependent mothers.
Topics: Adolescent; Adult; Female; Heroin Dependence; Humans; Infant; Infant, Newborn; Male; Maternal-Fetal | 1978 |
Development of cellular tolerance to lethality and analgesia concurrent with physical dependence following repeated oral administration of LAAM.
Topics: Administration, Oral; Animals; Drug Tolerance; Humans; Injections, Intraventricular; Lethal Dose 50; | 1979 |
[Drug-assisted treatment of substance dependence (Drug and Alcohol Symposium, Basel 1992)].
Topics: Acquired Immunodeficiency Syndrome; Alcoholism; Drug and Narcotic Control; Humans; Illicit Drugs; Me | 1992 |
Cocaine-associated panic attacks in methadone-maintained patients.
Topics: Adult; Agoraphobia; Cocaine; Female; Humans; Male; Methadone; Opioid-Related Disorders; Panic Disord | 1992 |
[Substance-controlled drug rehabilitation?].
Topics: Follow-Up Studies; Humans; Methadone; Opioid-Related Disorders; Social Environment; Substance Abuse | 1992 |
Patterns of substance use among methadone maintenance patients. Indicators of outcome.
Topics: Comorbidity; Follow-Up Studies; Humans; Illicit Drugs; Methadone; Opioid-Related Disorders; Psychotr | 1992 |
Baclofen-assisted detoxification from opiates. A pilot study.
Topics: Adult; Baclofen; Female; Humans; Male; Methadone; Neurologic Examination; Opioid-Related Disorders; | 1992 |
Establishment of a liaison service for pregnant opiate-dependent women.
Topics: Adolescent; Adult; Behavior, Addictive; England; Female; Health Promotion; HIV Infections; Humans; I | 1992 |
Ten-year follow-up after admission to methadone maintenance.
Topics: Adult; Ethnicity; Female; Follow-Up Studies; Health Promotion; Humans; Male; Methadone; Middle Aged; | 1992 |
Mr R: a case study of withdrawal.
Topics: Alcoholism; Clonidine; Cocaine; Humans; Male; Methadone; Middle Aged; Neurologic Examination; Opioid | 1992 |
The consequences of a change in formulation of methadone prescribed in a drug clinic.
Topics: Adult; Attitude to Health; Crime; Dosage Forms; Female; Humans; Male; Methadone; Opioid-Related Diso | 1992 |
Deficits in initial feature registration of schizophrenics and substance abusers.
Topics: Adult; Antipsychotic Agents; Arousal; Attention; Chronic Disease; Discrimination Learning; Female; H | 1992 |
Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Female; Humans; Male; Methadone; Opioid-Related Disorde | 1992 |
Sub-chronic exposure to opiates in the rat: effects on brain levels of substance P and calcitonin gene-related peptide during dependence and withdrawal.
Topics: Animals; Brain Chemistry; Calcitonin Gene-Related Peptide; Female; Methadone; Morphine; Narcotics; O | 1992 |
The use of plasma levels to optimize methadone maintenance treatment.
Topics: Adult; Drug Monitoring; Female; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders; Substa | 1992 |
Factors associated with relapse among opiate addicts in an out-patient detoxification programme.
Topics: Adult; Ambulatory Care; Female; Heroin Dependence; Humans; Male; Methadone; Opioid-Related Disorders | 1992 |
Analysis of clinical trials for treatment of opiate dependence: what are the possibilities?
Topics: Buprenorphine; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Methadone; Narcot | 1992 |
Toward a dynamic analysis of disease-state transition monitored by serial clinical laboratory tests.
Topics: Buprenorphine; Cohort Studies; Data Interpretation, Statistical; Humans; Markov Chains; Methadone; M | 1992 |
A Markov model for NIDA data on treatment of opiate dependence.
Topics: Bayes Theorem; Buprenorphine; Data Interpretation, Statistical; Humans; Likelihood Functions; Markov | 1992 |
A Bayesian nonparametric approach to analysis of treatment for drug-dependence data.
Topics: Bayes Theorem; Buprenorphine; Data Interpretation, Statistical; Humans; Methadone; Narcotics; Opioid | 1992 |
Three estimators of the probability of opiate use from incomplete data.
Topics: Buprenorphine; Data Interpretation, Statistical; Humans; Methadone; Models, Statistical; Narcotics; | 1992 |
Issues in the analysis of clinical trials for opiate dependence.
Topics: Bias; Buprenorphine; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Methadone; | 1992 |
[4 years' methadone substitution therapy in Austria].
Topics: Administration, Oral; Adult; Austria; Cross-Sectional Studies; Female; Follow-Up Studies; HIV Infect | 1992 |
Harm minimisation for drug misusers.
Topics: Humans; Methadone; Opioid-Related Disorders; Opium | 1992 |
Crack cocaine use in a cohort of methadone maintenance patients.
Topics: Adult; Cohort Studies; Comorbidity; Crack Cocaine; Female; Follow-Up Studies; HIV Infections; Humans | 1992 |
Auditory event-related potentials in HIV-1 infection: a study in the drug-user risk group.
Topics: Adult; AIDS Dementia Complex; Brain Stem; Evoked Potentials, Auditory, Brain Stem; HIV Seropositivit | 1992 |
[Critical comments on the contribution by N. Scherbaum and N. Gaspar. Substitution with methadone as a therapeutic approach in the treatment of drug dependent patients].
Topics: Follow-Up Studies; Heroin Dependence; Humans; Long-Term Care; Methadone; Opioid-Related Disorders; R | 1992 |
Maintenance treatment with methadone.
Topics: Humans; Methadone; Opioid-Related Disorders; Professional Practice | 1992 |
Morphine dispensing to long term problematic injectors.
Topics: Cause of Death; Drug Therapy, Combination; Follow-Up Studies; Humans; Methadone; Morphine; Netherlan | 1992 |
Plasma methadone measurements and their role in methadone detoxification programs.
Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Methadone; Opioid-R | 1992 |
[Methadone treatment of narcotic addicts--can it be defended?].
Topics: Ethics, Medical; Humans; Methadone; Norway; Opioid-Related Disorders | 1992 |
[Methadone treatment?].
Topics: Humans; Methadone; Norway; Opioid-Related Disorders | 1992 |
[Methadone treatment of narcotic addicts].
Topics: Humans; Methadone; Opioid-Related Disorders | 1992 |
[Methadone treatment--for whom?].
Topics: Ethics, Medical; Humans; Methadone; Norway; Opioid-Related Disorders | 1992 |
Cutting their coat according to their cloth: economic behavior of Amsterdam opiate users.
Topics: Age Factors; Crime; Economics; Female; Humans; Income; Male; Methadone; Netherlands; Opioid-Related | 1992 |
[Methadone therapy--for whom?].
Topics: Humans; Methadone; Norway; Opioid-Related Disorders | 1992 |
[Methadone treatment--for whom?].
Topics: Evaluation Studies as Topic; Humans; Methadone; Norway; Opioid-Related Disorders | 1992 |
The perceptions of program directors and clients regarding the efficacy of methadone treatment.
Topics: Attitude of Health Personnel; Combined Modality Therapy; Follow-Up Studies; Humans; Methadone; Opioi | 1991 |
Social support and relapse: commonalities among alcoholics, opiate users, and cigarette smokers.
Topics: Adult; Alcoholism; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opioid-Related D | 1991 |
Methadone patients' opinions on legalization of drugs.
Topics: Adult; Attitude; Drug and Narcotic Control; Female; Humans; Male; Methadone; Opioid-Related Disorder | 1991 |
Methadone maintenance and clonidine detoxification in the treatment of opiate addicts in Israel: suggesting evidence for cultural differences in the effectiveness of treatment modalities for opiate addiction.
Topics: Antidepressive Agents; Clonidine; Combined Modality Therapy; Cross-Cultural Comparison; Culture; Emp | 1991 |
The effects of buprenorphine in methadone-dependent volunteers.
Topics: Buprenorphine; Double-Blind Method; Humans; Hydromorphone; Male; Methadone; Naloxone; Opioid-Related | 1990 |
A scale for estimating the health status of opioid users.
Topics: Adolescent; Adult; Female; Health Status; Health Status Indicators; Humans; Male; Methadone; Narcoti | 1991 |
Withdrawal from heroin and methadone.
Topics: Heroin; Heroin Dependence; Hospitalization; Humans; Methadone; Neurologic Examination; Opioid-Relate | 1991 |
Outcomes of an AIDS prevention program for methadone patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Contraceptive Devices, Male; Counseling; Female; Health E | 1991 |
[Nicotine--drug addiction--AIDS. Drug use habits of Vienna addicts].
Topics: Adolescent; Adult; Austria; Cross-Sectional Studies; Female; HIV Seroprevalence; Humans; Incidence; | 1991 |
[Methadone treatment of narcotic addicts--can it be defended?].
Topics: Alcoholism; Ethics, Medical; Humans; Methadone; Norway; Opioid-Related Disorders | 1991 |
[Methadone treatment of narcotic addicts--can it be defended?].
Topics: Ethics, Medical; Humans; Methadone; Opioid-Related Disorders | 1991 |
Treatment predictors of tenure in methadone maintenance.
Topics: Black or African American; Episode of Care; Follow-Up Studies; Heroin Dependence; Humans; Length of | 1991 |
A comparison of the withdrawal responses of heroin and methadone addicts during detoxification.
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heroin; Heroin Depend | 1991 |
Methadone treatment in the pediatric intensive care unit.
Topics: Child; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome; Substance-Related | 1991 |
Marijuana use by methadone maintenance patients.
Topics: Adult; Humans; Marijuana Smoking; Methadone; Middle Aged; Opioid-Related Disorders | 1990 |
A treatment crisis: cocaine use by clients in methadone maintenance programs.
Topics: Cocaine; Humans; Methadone; Opioid-Related Disorders; Substance-Related Disorders | 1990 |
Metyrapone-induced withdrawal symptoms: symptoms in methadone-maintained patients.
Topics: Female; Humans; Male; Methadone; Metyrapone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1990 |
Double blind assessment of buprenorphine withdrawal in opiate-addicts.
Topics: Buprenorphine; Double-Blind Method; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawa | 1990 |
Opening the "black box" of drug abuse treatment-measurement and evaluation of the treatment domain.
Topics: Humans; Methadone; Opioid-Related Disorders; Substance-Related Disorders | 1990 |
Psychiatric symptoms, high risk behaviors and HIV positivity among methadone patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Behavior; Female; Humans; Male; Mental Disorders; Methado | 1990 |
Mazindol treatment of cocaine abuse. A double-blind investigation.
Topics: Adult; Cocaine; Double-Blind Method; Female; Humans; Mazindol; Methadone; Opioid-Related Disorders; | 1990 |
Medical methadone/interim report.
Topics: Adult; Consumer Behavior; Humans; Methadone; Middle Aged; Opioid-Related Disorders | 1990 |
Outpatient comparison of buprenorphine and methadone maintenance. I. Effects on opiate use and self-reported adverse effects and withdrawal symptomatology.
Topics: Adult; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Middle Aged; Naloxone; O | 1990 |
Outpatient comparison of buprenorphine and methadone maintenance. II. Effects on cocaine usage, retention time in study and missed clinic visits.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorder | 1990 |
Methadone maintenance outcome as a function of detoxification fear: preliminary findings.
Topics: Alabama; California; Fear; Humans; Methadone; Opioid-Related Disorders; Philadelphia | 1990 |
Methadone dose for cocaine abuse.
Topics: Adult; Cocaine; Drug Administration Schedule; Humans; Methadone; Opioid-Related Disorders; Substance | 1991 |
A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fetal Movement; Humans; Infa | 1991 |
Opiate system in self-injurious behavior.
Topics: Adult; Child; Child Abuse; Endorphins; Humans; Methadone; Opioid-Related Disorders; Self Mutilation | 1991 |
An open pilot study of bupropion and psychotherapy for the treatment of cocaine abuse in methadone-maintained patients.
Topics: Antidepressive Agents; Bupropion; Cocaine; Humans; Methadone; Opioid-Related Disorders; Propiophenon | 1990 |
Predictors of opiate drug abuse during a 90-day methadone detoxification.
Topics: Adult; Ambulatory Care; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders | 1991 |
Similar efficacy of abrupt and gradual opiate detoxification.
Topics: Adult; Anesthesia, General; Female; Humans; Length of Stay; Male; Methadone; Methohexital; Naloxone; | 1991 |
[Methadone treatment of narcotic addicts--can it be justified?].
Topics: HIV Seropositivity; Humans; Methadone; Opioid-Related Disorders | 1991 |
[Pro and contra: maintaining drug dependent patients on methadone].
Topics: Drug and Narcotic Control; Germany; Health Policy; Humans; Methadone; Opioid-Related Disorders; Subs | 1991 |
Methadone and schizophrenia.
Topics: Adult; Dose-Response Relationship, Drug; Humans; Infant; Male; Methadone; Opioid-Related Disorders; | 1991 |
Sexual behavior, attitudes toward safer sex, and gender among a cohort of 244 recovering i.v. drug users.
Topics: Adult; Attitude; Cohort Studies; Contraceptive Devices, Male; Female; Gender Identity; Health Knowle | 1991 |
A psychoeducational approach to methadone maintenance treatment: a survey of client reactions.
Topics: Activities of Daily Living; Adult; Behavior Therapy; Combined Modality Therapy; Consumer Behavior; F | 1991 |
Combined naloxone/methadone preparations for opiate substitution therapy.
Topics: Administration, Oral; Adult; Drug Combinations; Humans; Infusions, Intravenous; Methadone; Naloxone; | 1991 |
Chronic pain and substance abuse: a pilot study of opioid maintenance.
Topics: Adult; Analgesics, Opioid; Combined Modality Therapy; Female; Humans; Long-Term Care; Male; Methadon | 1990 |
Methadone concentrations in plasma and their relationship to drug dosage.
Topics: Chromatography, High Pressure Liquid; Humans; Methadone; Opioid-Related Disorders | 1991 |
Early treatment time course of depressive symptoms in opiate addicts.
Topics: Adult; Black or African American; Depression; Depressive Disorder; Female; Follow-Up Studies; Humans | 1991 |
Carbamazepine for high-dose diazepam withdrawal in opiate users.
Topics: Adult; Carbamazepine; Diazepam; Female; Humans; Male; Methadone; Opioid-Related Disorders; Substance | 1991 |
Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Dose-Response Relationship, Drug; | 1991 |
From science to social policy: an uncertain road.
Topics: Genetic Testing; Health Policy; Humans; Insurance Benefits; Methadone; Opioid-Related Disorders; Pat | 1991 |
[HIV-infected drug addicts in a clinic for infectious diseases are dissatisfied and desire more treatment].
Topics: Adult; Female; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Opioid-Related Disorders; | 1991 |
[Detoxification from opiates through hospitalization: the long-term results. A longitudinal study of 104 admissions in 1982-1986].
Topics: Follow-Up Studies; Heroin; Heroin Dependence; Hospitalization; Humans; Italy; Longitudinal Studies; | 1991 |
The sharing of injecting equipment among drug users attending prescribing clinics and those using needle-exchanges.
Topics: Adolescent; Adult; Female; Health Behavior; HIV Infections; Humans; Male; Methadone; Needles; Opioid | 1991 |
Alcohol abuse by patients undergoing methadone treatment programmes.
Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Methadone; Opioid-Related Disorders; Pers | 1991 |
[New organization shortens the waiting list for methadone therapy].
Topics: Health Services Administration; Humans; Methadone; Opioid-Related Disorders; Sweden; Waiting Lists | 1991 |
Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methadone; Mid | 1991 |
Clustering of multiple substance use and psychiatric diagnoses in opiate addicts.
Topics: Adult; Antisocial Personality Disorder; Anxiety Disorders; Cluster Analysis; Cross-Sectional Studies | 1991 |
Unmet service needs in methadone maintenance.
Topics: Combined Modality Therapy; Community Mental Health Services; Consumer Behavior; Follow-Up Studies; H | 1991 |
Narcotic addiction: the expectant mother and her baby.
Topics: Adolescent; Adult; Diseases in Twins; Female; Heroin Dependence; Humans; Infant, Newborn; Infant, Pr | 1990 |
[Prenatal development and postnatal morbidity of newborn infants of HIV positive mothers].
Topics: Birth Weight; Female; Fetal Growth Retardation; Gestational Age; HIV Seropositivity; Humans; Infant, | 1990 |
Availability of drugs and psychological proneness in opioid addiction.
Topics: Adult; Ambulatory Care; Female; Follow-Up Studies; Heroin; Heroin Dependence; Hospitalization; Human | 1990 |
Psychotherapy and counseling for methadone-maintained opiate addicts: results of research studies.
Topics: Antisocial Personality Disorder; Community Health Services; Counseling; Female; Follow-Up Studies; H | 1990 |
[Methadone treatment: experience and progress].
Topics: Acquired Immunodeficiency Syndrome; Cross-Sectional Studies; Humans; Incidence; Methadone; New York | 1990 |
[Drug-assisted rehabilitation of long-term intravenous drug abusers in North Rhine-Westphalia].
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Follow-Up Studies; Germany; Heroin Dependence; Hu | 1990 |
[Drug-assisted rehabilitation of HIV-infected drug-dependent prostitutes].
Topics: Adult; Female; Follow-Up Studies; HIV Infections; Humans; Male; Methadone; Opioid-Related Disorders; | 1990 |
[Drug substitution program in Zurich].
Topics: Acquired Immunodeficiency Syndrome; Humans; Methadone; Opioid-Related Disorders; Risk Factors; Subst | 1990 |
The influence of prolonged stable methadone maintenance treatment on mortality and employment: an 8-year follow-up.
Topics: Adult; Cause of Death; Cohort Studies; Denmark; Female; Follow-Up Studies; Humans; Long-Term Care; M | 1990 |
[Substitute drug-assisted treatment of drug dependent patients in general practice].
Topics: Ambulatory Care; Codeine; Combined Modality Therapy; Follow-Up Studies; Humans; Long-Term Care; Meth | 1990 |
Social and drug-taking behaviour of 'maintained' opiate addicts.
Topics: Adult; Cohort Studies; Cross-Sectional Studies; Drug Prescriptions; England; Female; Follow-Up Studi | 1990 |
Static and dynamic pupillometry for determination of the course of gradual detoxification of opiate-addicted patients.
Topics: Adult; Arousal; Dose-Response Relationship, Drug; Female; Heroin Dependence; Humans; Image Processin | 1990 |
Report of the Expert Advisory Committee on the Use of Drugs in the Treatment of Abuse and Dependence to Narcotic and Controlled Drugs.
Topics: Canada; Drug and Narcotic Control; Female; Humans; Inactivation, Metabolic; Methadone; Opioid-Relate | 1990 |
[Rational control analysis within the scope of a methadone program].
Topics: Adult; Austria; Female; Follow-Up Studies; Gas Chromatography-Mass Spectrometry; Heroin Dependence; | 1990 |
Habituation of skin conductance response in a methadone population.
Topics: Adult; Arousal; Female; Galvanic Skin Response; Habituation, Psychophysiologic; Humans; Male; Methad | 1990 |
Rifampin-induced methadone withdrawal in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Methadone; Mycobacterium avium-intr | 1990 |
Trends in criminal activity and drug use over an addiction career.
Topics: Adult; Aged; Baltimore; Crime; Cross-Sectional Studies; Fraud; Humans; Incidence; Male; Methadone; M | 1990 |
Drug dependency units.
Topics: Ambulatory Care; England; Humans; Methadone; Opioid-Related Disorders; Psychiatric Department, Hospi | 1990 |
Difficulties in a clinical application of methadone-dose contingency contracting.
Topics: Adult; Behavior Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hum | 1990 |
Methadone and edema.
Topics: Adult; Edema; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders | 1990 |
Depressive symptoms during buprenorphine treatment of opioid abusers.
Topics: Adult; Buprenorphine; Cocaine; Combined Modality Therapy; Depressive Disorder; Female; Follow-Up Stu | 1990 |
Detoxification with phenobarbital of alprazolam-dependent polysubstance abusers.
Topics: Adult; Alprazolam; Combined Modality Therapy; Follow-Up Studies; Humans; Illicit Drugs; Male; Methad | 1990 |
Politicians and scientists in the combat against drug abuse.
Topics: Community Mental Health Services; Drug and Narcotic Control; Follow-Up Studies; Humans; Methadone; O | 1990 |
Opiate maintenance and abstinence--attitudes, treatment modalities and outcome.
Topics: Attitude of Health Personnel; Combined Modality Therapy; Follow-Up Studies; Humans; Methadone; Narco | 1990 |
[Narcotic abuse in Jylland. A study based on narcotics and deaths of addicts examined at the Institute of Forensic Medicine, University of Aarhus during the period 1981-1988. 2. Deaths among addicts].
Topics: Adolescent; Adult; Alcoholic Intoxication; Amphetamine; Denmark; Dextropropoxyphene; Female; Heroin | 1990 |
Methadone treatment in medical private practice: outcome according to the number of courses followed.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; Private Practic | 1990 |
Some reflections on dynamics and dilemmas in a DDU.
Topics: Acquired Immunodeficiency Syndrome; Combined Modality Therapy; Hospitals, Teaching; Humans; London; | 1990 |
Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy.
Topics: Adult; Birth Weight; Embryonic and Fetal Development; Female; Humans; Infant, Newborn; Maternal-Feta | 1990 |
Corrections and revised analyses for psychotherapy in methadone maintenance patients.
Topics: Humans; Methadone; Opioid-Related Disorders; Psychotherapy; Research Design; Statistics as Topic | 1990 |
[Organization and implementation of the Austrian methadone program and initial results].
Topics: Adult; Austria; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Methadone | 1990 |
Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone.
Topics: Desipramine; Drug Interactions; Humans; Hydroxylation; Methadone; Opioid-Related Disorders | 1990 |
Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification.
Topics: Adult; Clonidine; Drug Administration Schedule; Humans; Hydromorphone; Male; Methadone; Opioid-Relat | 1985 |
Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
Topics: Adult; Discrimination Learning; Dose-Response Relationship, Drug; Generalization, Psychological; Hum | 1987 |
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
Topics: Butorphanol; Heart Rate; Humans; Hydromorphone; Male; Methadone; Morphinans; Naloxone; Opioid-Relate | 1987 |
Evidence of single dose opioid dependence in 12- to 14-day-old chicken embryos.
Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamid | 1989 |
Evaluation of an AIDS prevention education program for health service providers working with i.v. drug users.
Topics: Acquired Immunodeficiency Syndrome; Adult; Curriculum; Female; Health Knowledge, Attitudes, Practice | 1989 |
Increase in desipramine serum levels associated with methadone treatment.
Topics: Adult; Cocaine; Desipramine; Drug Interactions; Drug Therapy, Combination; Humans; Male; Methadone; | 1989 |
Methadone and theories of addiction.
Topics: Humans; Methadone; Opioid-Related Disorders; Physician Impairment; Receptors, Opioid | 1989 |
From the Food and Drug Administration.
Topics: Acyclovir; Anilides; Cytomegalovirus Infections; Flutamide; Ganciclovir; Humans; Ifosfamide; Male; M | 1989 |
Psychoneuroendocrine effects of methadone maintenance.
Topics: Adrenocorticotropic Hormone; Adult; Energy Intake; Growth Hormone; Humans; Hydrocortisone; Insulin; | 1989 |
From theory to practice: the planned treatment of drug users. Interview by Stanley Einstein.
Topics: Aftercare; Combined Modality Therapy; Humans; Methadone; Motivation; Naltrexone; Opioid-Related Diso | 1989 |
Naloxone applied to conjunctiva as a test for physical opiate dependence.
Topics: Administration, Topical; Adult; Conjunctiva; Evaluation Studies as Topic; Female; Humans; Male; Meth | 1989 |
Relative abuse liability of benzodiazepines in methadone maintained populations in three cities.
Topics: Adult; Anti-Anxiety Agents; Baltimore; Benzodiazepines; Cross-Sectional Studies; Female; Humans; Ill | 1989 |
Can buspirone substitute for benzodiazepines in all anxious patients?
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Humans; Male; | 1989 |
Naloxone challenge as a biological predictor of treatment outcome in opiate addicts.
Topics: Arousal; Depressive Disorder; Humans; Methadone; Naloxone; Opioid-Related Disorders; Personality Tes | 1989 |
Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study.
Topics: Adolescent; Adult; England; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; O | 1989 |
Circumstances surrounding the initial lapse to opiate use following detoxification.
Topics: Adolescent; Adult; Cues; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Methadone; Opio | 1989 |
Types of opiate addiction and notification to the home office.
Topics: Adult; Commitment of Mentally Ill; Drug and Narcotic Control; Follow-Up Studies; Humans; Methadone; | 1989 |
Management of cocaine abuse in methadone maintenance programs.
Topics: Cocaine; Humans; Maryland; Methadone; Opioid-Related Disorders; Substance Abuse Detection; Substance | 1989 |
Detoxification of the chemically dependent patient.
Topics: Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Syndrome; Substance-Related Disord | 1989 |
[Proposal of a detoxication program for drug dependency in pregnancy].
Topics: Female; Humans; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Complications | 1989 |
Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction.
Topics: Carbamazepine; Cocaine; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Methado | 1989 |
Outpatient maintenance/detoxification comparison of methadone and buprenorphine.
Topics: Adult; Ambulatory Care; Buprenorphine; Drug Evaluation; Female; Humans; Male; Methadone; Middle Aged | 1989 |
HIV risk behavior: antisocial personality disorder, drug use patterns, and sexual behavior among methadone maintenance admissions.
Topics: Antisocial Personality Disorder; Health Behavior; HIV Infections; Humans; Methadone; Opioid-Related | 1989 |
Psychiatric symptoms in HIV test consenters and refusers.
Topics: AIDS Serodiagnosis; HIV Infections; Humans; Methadone; Opioid-Related Disorders; Patient Compliance; | 1989 |
Methadone maintenance: high rate of other substance use disorders and relationship to psychiatric comorbidity.
Topics: Humans; Mental Disorders; Methadone; Opioid-Related Disorders; Prognosis; Psychotropic Drugs; Substa | 1989 |
Use predicts treatment outcome, not opiate dependence or withdrawal.
Topics: Adult; Cocaine; Follow-Up Studies; Humans; Male; Methadone; Naloxone; Opioid-Related Disorders; Subs | 1989 |
Buprenorphine treatment of cocaine abuse.
Topics: Buprenorphine; Cocaine; Humans; Methadone; Opioid-Related Disorders; Substance Abuse Detection; Subs | 1989 |
The effect of methadone in vitro on natural killer (NK) activity.
Topics: Adult; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Female; Humans; Immune Tolerance | 1989 |
Treatment of drug abuse in veterans.
Topics: Humans; Male; Methadone; Opioid-Related Disorders; Substance-Related Disorders; Texas; Veterans; Vie | 1989 |
Differences in organization of psychological needs between inpatient and outpatient opiate addicts.
Topics: Adult; Follow-Up Studies; Humans; Male; Methadone; Opioid-Related Disorders; Patient Dropouts; Perso | 1989 |
Naltrexone treatment--the problem of patient acceptance.
Topics: Adult; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Dis | 1989 |
Methadone maintenance program for AIDS-affected opiate addicts.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; California; Combined Modality Thera | 1989 |
The effects of methadone treatment on the reactivity of the nonstress test.
Topics: Female; Fetal Movement; Heart Rate, Fetal; Humans; Methadone; Opioid-Related Disorders; Pregnancy; P | 1989 |
Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria.
Topics: Adult; Female; Humans; Male; Methadone; Naloxone; Opioid-Related Disorders; Psychiatric Status Ratin | 1989 |
Cyclizine abuse among a group of opiate dependents receiving methadone.
Topics: Adult; Cyclizine; Dose-Response Relationship, Drug; England; Female; Humans; Infusions, Intravenous; | 1989 |
Consequences and costs of shutting off methadone.
Topics: Adult; California; Community Mental Health Services; Cost Control; Crime; Cross-Sectional Studies; F | 1989 |
Neuro-electric therapy: criticisms of the 1984 Bethlem Study.
Topics: Electric Stimulation Therapy; Humans; Methadone; Opioid-Related Disorders; Substance Withdrawal Synd | 1989 |
Patients successfully maintained with methadone escaped human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Cocaine; HIV Antibodies; HIV-1; Humans; Methadone; Opioid-Relate | 1989 |
[Study of the motor and sensory neuron conduction velocity and of the H reflex in subjects with chronic opiate poisoning].
Topics: Adult; Chronic Disease; Female; H-Reflex; Heroin Dependence; Humans; Male; Methadone; Motor Neurons; | 1989 |
Prevalence of movement disorder in a methadone-maintained population.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Methadone; Opioid-Relat | 1985 |
Chronic use of opioid analgesics in non-malignant pain: report of 38 cases.
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Levorphanol; Male; Methadone; Middle Aged; Opioid-R | 1986 |
Extinguishing conditioned responses during opiate dependence treatment turning laboratory findings into clinical procedures.
Topics: Behavior Therapy; Combined Modality Therapy; Conditioning, Psychological; Desensitization, Psycholog | 1986 |
The role of drugs in the treatment of opioid addicts.
Topics: Alcoholism; Anxiety; Clonidine; Dextropropoxyphene; Heroin; Humans; Inactivation, Metabolic; Kinetic | 1986 |
Medical services provided to 2,394 patients at methadone programs in three states.
Topics: Ambulatory Care Facilities; Humans; Methadone; Nurse Practitioners; Nurses; Opioid-Related Disorders | 1986 |
Divided dose for methadone maintenance patients.
Topics: Adrenergic alpha-Agonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methadon | 1988 |
Determination of methadone in human hair by radioimmunoassay.
Topics: Hair; Humans; Methadone; Opioid-Related Disorders; Radioimmunoassay | 1989 |
Role of opioid antagonists in treating intravenous cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Injections, Intravenous; Male; Methadone; Naltrexone; | 1989 |
Human immunodeficiency virus seropositivity in intravenous drug users in Ohio.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; HIV Seropositivity; Humans; Male; Methadone; Ohio | 1989 |
Reduced estriol and dehydroepiandrosterone sulphate plasma levels in methadone-addicted pregnant women.
Topics: Adult; Circadian Rhythm; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estriol; Female; Ge | 1986 |
Opiate addiction and plasma beta-endorphin-like immunoreactivity: methadone maintained, recently detoxified and early naltrexone treated ex-addicts.
Topics: Adult; beta-Endorphin; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related | 1987 |
Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations.
Topics: Acquired Immunodeficiency Syndrome; Adult; B-Lymphocytes; Female; HIV Seropositivity; Humans; Inject | 1987 |
Drug abuse treatment process: a review of the literature.
Topics: Aftercare; Ambulatory Care; Combined Modality Therapy; Community Mental Health Services; Counseling; | 1985 |
Naltrexone.
Topics: Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Pituitary Gland; Receptors, Opioid; S | 1985 |
Source of income as a predictor in opioid addicts: 2.5 year follow-up.
Topics: Adult; Crime; Employment; Female; Humans; Income; Male; Methadone; Opioid-Related Disorders; Public | 1987 |
The use of tricyclic antidepressants in methadone maintained pregnant women and infant outcome.
Topics: Adult; Antidepressive Agents, Tricyclic; Apgar Score; Birth Weight; Demography; Female; Heroin Depen | 1988 |
The criminal justice system and opiate addiction: a historical perspective.
Topics: Criminal Law; History, 20th Century; Humans; Jurisprudence; Methadone; New York City; Opioid-Related | 1988 |
The efficacy of civil commitment in treating narcotic addiction.
Topics: California; Commitment of Mentally Ill; Crime; Criminal Law; Humans; Longitudinal Studies; Methadone | 1988 |
Classically conditioned responses in opioid and cocaine dependence: a role in relapse?
Topics: Cocaine; Conditioning, Classical; Humans; Methadone; Opioid-Related Disorders; Random Allocation; Re | 1988 |
Metabolism of methadone by chicken embryos prevents induction of chronic opioid-type dependence after a single injection: use of osmotic pumps for continuous infusion.
Topics: Animals; Chick Embryo; Infusion Pumps; Methadone; Opioid-Related Disorders | 1988 |
Methadone maintenance.
Topics: Counseling; Family Practice; Humans; Methadone; Opioid-Related Disorders; Physician-Patient Relation | 1988 |
Psychological symptoms in methadone maintenance patients: prevalence and change over treatment.
Topics: Adult; Humans; Longitudinal Studies; Male; Methadone; Opioid-Related Disorders | 1988 |
Differences among treatment clinic types in attitudes toward narcotic addiction.
Topics: Attitude; Attitude of Health Personnel; Black or African American; Combined Modality Therapy; Counse | 1988 |
Psychopathology of opiate addiction: comparative data from the MMPI and MCMI.
Topics: Adult; Female; Humans; Male; Methadone; MMPI; Opioid-Related Disorders; Psychological Tests; Psychom | 1988 |
Group psychotherapy with methadone-maintained pregnant women.
Topics: Adult; Attitude of Health Personnel; Female; Humans; Methadone; Opioid-Related Disorders; Patient Ed | 1988 |
Impaired glucose metabolism in heroin and methadone users.
Topics: Adult; Blood Glucose; Glucose Tolerance Test; Heroin Dependence; Humans; Insulin; Male; Methadone; O | 1987 |
Methadone treatment in Canada: the clinical questions continue.
Topics: Counseling; Humans; Methadone; Opioid-Related Disorders; Psychotherapy | 1988 |
Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up.
Topics: Adult; Cocaine; Criminal Psychology; Employment; Female; Follow-Up Studies; Humans; Male; Methadone; | 1988 |
Changes in methadone withdrawal doses over a five year period: (1982 to 1986).
Topics: Adult; Drug Administration Schedule; Female; Humans; Male; Methadone; Opioid-Related Disorders | 1988 |
Assessment of opioid dependence with naloxone.
Topics: Adult; Female; Humans; Male; Methadone; Naloxone; Opioid-Related Disorders | 1988 |
Drug treatment of opioid dependence.
Topics: Humans; Methadone; Opioid-Related Disorders; Patient Compliance | 1988 |
Eleven year follow-up of 300 young opioid addicts.
Topics: Adolescent; Adult; Combined Modality Therapy; Denmark; Female; Humans; Male; Methadone; Opioid-Relat | 1988 |
Amantadine for treatment of cocaine dependence in methadone-maintained patients.
Topics: Adult; Amantadine; Cocaine; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; | 1988 |
MMPI-168 profiles of male narcotic addicts by ethnic group and city.
Topics: Ethnicity; Humans; Male; Maryland; Methadone; MMPI; New York City; Opioid-Related Disorders; Urban P | 1988 |
Tapering from methadone maintenance: attitudes of clients and staff.
Topics: Adult; Attitude of Health Personnel; Attitude to Health; Drug Administration Schedule; Female; Human | 1988 |
Gonadal function in male heroin and methadone addicts.
Topics: Adolescent; Adult; Gonadotropins, Pituitary; Heroin Dependence; Humans; Male; Methadone; Opioid-Rela | 1988 |
[Serum methadone monitoring in addicts on methadone maintenance treatment].
Topics: Adult; Blood Specimen Collection; Female; Humans; Male; Methadone; Opioid-Related Disorders | 1988 |
Propranolol and clonidine in detoxification.
Topics: Clonidine; Humans; Lorazepam; Methadone; Opioid-Related Disorders; Propranolol; Psychomotor Agitatio | 1988 |
Valium use and abuse by methadone maintenance clients.
Topics: Adult; Diazepam; Drug Synergism; Humans; Male; Methadone; Opioid-Related Disorders; Self Medication; | 1987 |
Differential modification of morphine and methadone dependence by interferon alpha.
Topics: Animals; Behavior, Animal; Interferon Type I; Male; Methadone; Morphine Dependence; Opioid-Related D | 1987 |
Bridges and barriers to recovery: clinical observations from an opiate recovery project.
Topics: Adult; Female; Humans; Male; Methadone; Opioid-Related Disorders; Social Isolation | 1987 |
Ophthalmic naloxone elicits abstinence in opioid-dependent subjects.
Topics: Humans; Methadone; Naloxone; Ophthalmic Solutions; Opioid-Related Disorders; Pupil; Substance Withdr | 1987 |
Identification and treatment of alcoholics who use opiates.
Topics: Adult; Aged; Alcoholism; Female; Heroin Dependence; Humans; Male; Methadone; Middle Aged; Opioid-Rel | 1986 |
Alcohol use and psychopathology in opioid addicts on methadone maintenance.
Topics: Adult; Alcoholism; Humans; Male; Marriage; Methadone; Opioid-Related Disorders; Personality Tests; S | 1986 |
Role of conditioning factors in the development of drug dependence.
Topics: Affect; Behavior Therapy; Cognition; Conditioning, Classical; Counseling; Extinction, Psychological; | 1986 |
Survival analysis in drug program evaluation. Part II. Partitioning treatment effects.
Topics: Crime; Humans; Methadone; Opioid-Related Disorders; Patient Compliance; Prognosis; Recurrence; Stati | 1987 |
Characterization of N-terminal fragment of proopiomelanocortin in cerebrospinal fluid.
Topics: Adolescent; Adult; Chromatography, Affinity; Chromatography, Gel; Female; Humans; Hydrocephalus; Mal | 1987 |
Alprazolam abuse during methadone maintenance therapy.
Topics: Alprazolam; Humans; Methadone; Opioid-Related Disorders; Substance-Related Disorders | 1987 |
A system for uniform application of contingencies for illicit drug use.
Topics: Humans; Methadone; Narcotics; Opioid-Related Disorders; Patient Compliance; Retrospective Studies | 1987 |
Methadone treatment. Defining and evaluating success.
Topics: Acquired Immunodeficiency Syndrome; Health Policy; Humans; Methadone; Opioid-Related Disorders; Unit | 1987 |
Management of narcotic dependent pregnancy.
Topics: Female; Heroin Dependence; Humans; Infant, Newborn; Methadone; Narcotics; Opioid-Related Disorders; | 1986 |
Assessing pathological detoxification fear among methadone maintenance patients: the DFSS.
Topics: Adult; Fear; Female; Humans; Inactivation, Metabolic; Male; Methadone; Opioid-Related Disorders; Psy | 1987 |
Impact of maternal drug dependency on birth weight and head circumference of offspring.
Topics: Adult; Birth Weight; Female; Fetal Growth Retardation; Fetus; Head; Humans; Infant, Newborn; Methado | 1987 |
What is the most effective way to treat opiate addiction?
Topics: Humans; Methadone; Opioid-Related Disorders; Prognosis | 1987 |
Approval need in self-reports of addicts and family members.
Topics: Adult; Family; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Psychological | 1987 |
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients.
Topics: Adult; Antisocial Personality Disorder; Black or African American; Cocaine; Desipramine; Female; Hum | 1987 |
Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income.
Topics: Adult; Crime; Employment; Female; Humans; Inactivation, Metabolic; Income; Male; Methadone; Opioid-R | 1987 |
The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study.
Topics: Adult; Combined Modality Therapy; Female; Follow-Up Studies; Hospitals, University; Humans; Male; Me | 1987 |
Depression in opioid users varies with substance use status.
Topics: Adult; Aged; Alcoholism; Depression; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Di | 1987 |
The nurse in a methadone maintenance clinic. Revisited.
Topics: Humans; Male; Methadone; Nurse-Patient Relations; Nurses; Opioid-Related Disorders; Patient Care Tea | 1987 |
Effect of maternal methadone administration on the development of multiple forms of monoamine oxidase in rat brain and liver.
Topics: Animals; Brain; Female; Isoenzymes; Liver; Methadone; Monoamine Oxidase; Opioid-Related Disorders; P | 1986 |
Prevalence and diagnostic reliability of methadone maintenance detoxification fear.
Topics: Adult; Fear; Female; Humans; Male; Methadone; Middle Aged; Opioid-Related Disorders; Substance Withd | 1986 |
Indicators of criminal involvement: crime rates versus qualitative classification of official records.
Topics: Adolescent; Adult; Age Factors; Crime; Denmark; Education; Female; Humans; Male; Methadone; Opioid-R | 1986 |
Methadone in pregnancy: clinical-toxicological aspects.
Topics: Female; Humans; Infant, Newborn; Methadone; Opioid-Related Disorders; Pregnancy; Pregnancy Complicat | 1986 |
Mother-infant interaction in multiproblem families: finding those at risk.
Topics: Adult; Child Development; Female; Humans; Infant; Methadone; Mother-Child Relations; Opioid-Related | 1986 |
Considerations on the psychotherapy of the substance abuser.
Topics: Adult; Alcoholics Anonymous; Alcoholism; Anxiety; Cocaine; Female; Humans; Male; Methadone; Middle A | 1986 |
The influence of psychological factors on the opiate withdrawal syndrome.
Topics: Adolescent; Adult; Female; Heroin Dependence; Humans; Male; Methadone; Narcotics; Neurotic Disorders | 1986 |
Alcohol use and abuse: heavy drinking among methadone clients.
Topics: Adult; Alcohol Drinking; Alcoholism; Crime; Female; Humans; Male; Methadone; Opioid-Related Disorder | 1986 |
Methadone treatment in British Columbia: bad medicine?
Topics: British Columbia; Humans; Methadone; Opioid-Related Disorders; Public Health Administration | 1987 |
Methadone dosage: patient characteristics and clinical correlates.
Topics: Adult; Humans; Male; Methadone; Middle Aged; MMPI; Neuropsychological Tests; Opioid-Related Disorder | 1986 |
[Dangers of intravenous use of peroral methadone solutions].
Topics: Acute Kidney Injury; Administration, Oral; Adult; Humans; Injections, Intravenous; Male; Methadone; | 1986 |
Clinical experiences with 959 opioid-dependent patients treated with levo-alpha-acetylmethadol (LAAM).
Topics: Adolescent; Adult; Female; Humans; Male; Methadone; Methadyl Acetate; Middle Aged; Opioid-Related Di | 1986 |
Psychoanalytically oriented psychotherapy of substance abuse (with observations on the Penn-VA Study).
Topics: Chronic Disease; Guilt; Hospitals, Veterans; Humans; Methadone; Opioid-Related Disorders; Profession | 1986 |
Sex differences in opioid addiction careers.
Topics: Adolescent; Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Opioid-Related D | 1986 |
Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related D | 1986 |
Fear of methadone maintenance.
Topics: Attitude to Health; Fear; Humans; Methadone; Opioid-Related Disorders; Outcome and Process Assessmen | 1987 |
A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped?
Topics: Adult; Cocaine; Connecticut; Depressive Disorder; Ethnicity; Female; Follow-Up Studies; Humans; Male | 1987 |
Methadone treatment of opiate dependence in Canada.
Topics: Canada; Health Services Accessibility; Humans; Legislation, Drug; Methadone; Opioid-Related Disorder | 1985 |
Electrostimulation and opiate withdrawal.
Topics: Electric Stimulation Therapy; Humans; Methadone; Opioid-Related Disorders | 1985 |
Behavior therapy in drug abuse treatment: review and evaluation.
Topics: Behavior Therapy; Combined Modality Therapy; Humans; Methadone; Opioid-Related Disorders; Reinforcem | 1985 |
Psychotherapy for opiate dependence.
Topics: Combined Modality Therapy; Humans; Methadone; Opioid-Related Disorders; Professional-Patient Relatio | 1985 |
Psychosocial factors in outcome in two opiate addiction treatments.
Topics: Adult; Family; Female; Humans; Life Change Events; Male; Methadone; Middle Aged; Motivation; Naltrex | 1986 |
Mydriatic response to topical naloxone in opiate abusers.
Topics: Adolescent; Adult; Dilatation; Female; Humans; Male; Methadone; Middle Aged; Naloxone; Opioid-Relate | 1986 |
Pyridoxine (Vit. B6) decreases opioids-induced hyperprolactinemia.
Topics: Adolescent; Adult; Growth Hormone; Heroin Dependence; Humans; Male; Methadone; Opioid-Related Disord | 1985 |
Use of guanabenz in methadone withdrawal.
Topics: Adult; Clonidine; Female; Guanabenz; Guanidines; Humans; Methadone; Opioid-Related Disorders; Substa | 1985 |
Contracting for treatment termination to reduce illicit drug use among methadone maintenance treatment failures.
Topics: Adult; Behavior Therapy; Follow-Up Studies; Humans; Illicit Drugs; Male; Methadone; Middle Aged; Opi | 1985 |
Prescribing methadone for the opiate addict: a problem of dosage conversion.
Topics: Adult; Female; Heroin; Humans; Male; Methadone; Narcotics; Opioid-Related Disorders | 1985 |
Client well-being in drug treatment: a social ecological analysis.
Topics: Community Mental Health Services; Consumer Behavior; Hospitalization; Humans; Methadone; Opioid-Rela | 1985 |
The personality and symptoms scales of the Millon Clinical Multiaxial Inventory: sensitivity to posttreatment outcomes.
Topics: Adult; Alcoholism; Behavior Therapy; Female; Humans; Male; Methadone; Opioid-Related Disorders; Pers | 1985 |
Narcotic addiction and methadone treatment in Hong Kong: lessons for the United States.
Topics: Hong Kong; Humans; Methadone; National Health Programs; Opioid-Related Disorders; United States | 1985 |